
<html lang="en"     class="pb-page"  data-request-id="b479840f-b6f6-4cc2-962c-9d8cb40ee6b5"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/jm100012m;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2010.53.issue-12"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Evolution of Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors. From Concept to Clinic" /></meta><meta name="dc.Creator" content="Dana V.  Ferraris" /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 5, 2010" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm100012m" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2010 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm100012m" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm100012m" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm100012m" /></link>
        
    
    

<title>Evolution of Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors. From Concept to Clinic | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm100012m" /></meta><meta property="og:title" content="Evolution of Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors. From Concept to Clinic" /></meta><meta property="og:image" content="https://pubs.acs.org/pb-assets/images/CoverImages_2by1Scaled/jmcmar-1595795902140.png" /></meta><meta property="og:description" content="" /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm100012m"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm100012m">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm100012m&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm100012m&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm100012m&amp;href=/doi/10.1021/jm100012m" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2010</span><span class="cit-fg-volume">, 53</span><span class="cit-fg-issue">, 12</span><span class="cit-fg-pageRange">, 4561-4584</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/53/12" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/jm100054f" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Evolution of Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors. From Concept to Clinic</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dana+V.++Ferraris">Dana V. Ferraris</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info"><span class="aff-text">Johns Hopkins University Brain Science Institute, 855 N. Wolfe Street, Baltimore, Maryland 21205</span></div><div class="corresp-info"><strong>*</strong>Contact information. Phone: (410) 614-1107. Fax: (410) 614-0659. E-mail: <a href="/cdn-cgi/l/email-protection#0c486a697e7e6d7e3e4c6664616522696879"><span class="__cf_email__" data-cfemail="12567477606073602052787a7f7b3c777667">[emailÂ protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm100012m&amp;href=/doi/10.1021%2Fjm100012m" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2010</span></span><span class="cit-volume">, 53</span><span class="cit-issue">, 12</span><span class="cit-pageRange">, 4561â4584</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 5, 2010</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>6 January 2010</li><li><span class="item_label"><b>Published</b> online</span>5 April 2010</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 June 2010</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm100012m" title="DOI URL">https://doi.org/10.1021/jm100012m</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2010 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4561%26pageCount%3D24%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DDana%2BV.%2BFerraris%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D53%26issueNum%3D12%26contentID%3Djm100012m%26title%3DEvolution%2Bof%2BPoly%2528ADP-ribose%2529%2BPolymerase-1%2B%2528PARP-1%2529%2BInhibitors.%2BFrom%2BConcept%2Bto%2BClinic%26numPages%3D24%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4584%26publicationDate%3DJune%2B2010">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm100012m"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">7049</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">231</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm100012m" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Evolution of Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors. From Concept to Clinic&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Dana&quot;,&quot;last_name&quot;:&quot;V. Ferraris&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2010&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;05&quot;,&quot;issue&quot;:&quot;12&quot;,&quot;volume&quot;:&quot;53&quot;,&quot;pages&quot;:&quot;4561-4584&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm100012m&quot;},&quot;abstract&quot;:&quot;&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm100012m&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm100012m" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm100012m&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm100012m" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm100012m&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm100012m" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm100012m&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm100012m&amp;href=/doi/10.1021/jm100012m" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm100012m" /></input><a href="/doi/pdf/10.1021/jm100012m" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm100012m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm100012m%26sid%3Dliteratum%253Aachs%26pmid%3D20364863%26genre%3Darticle%26aulast%3DFerraris%26date%3D2010%26atitle%3DEvolution%2Bof%2BPoly%2528ADP-ribose%2529%2BPolymerase-1%2B%2528PARP-1%2529%2BInhibitors.%2BFrom%2BConcept%2Bto%2BClinic%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D53%26issue%3D12%26spage%3D4561%26epage%3D4584%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290658" title="Amides">Amides</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/53/12" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45304" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45304" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Poly(ADP-ribose) polymerase-1 (PARP-1<a class="ref internalNav" href="#fnabbrev" aria-label="a">a</a>) <div class="NLM_fn" id="fnabbrev">a<p class="last">Abbreviations: PARP-1, poly(ADP-ribose)polymerase-1; PARG, poly(ADP-ribose)glycohydrolase; NAD<sup>+</sup>, nicotinamide adenine dinucleotide; BRCA, breast cancer associated genes; XRCC1, X-ray repair cross-complementing 1; LIG-IIIÎ±, deoxyribonucleic acid ligase III-Î±; 3-AB, 3-aminobenzamide; SSB, single strand breaks; DSB, double strand breaks; HR, homologous recombination; MTIC, 3-methyltriazen-1-yl)imidazole-4-carboxamide; MCAO, middle cerebral arterial occlusion; TMZ, temozolomide; TNBC, triple negative breast cancer; HER2, human epidermal growth factor receptor 2; MMS, methyl methane sulfonate; PBL, peripheral blood lymphocytes; PID, poly(ADP-ribose)polymerase inhibitory dose; PBMC, peripheral blood mononuclear cells; PSA, polar surface area; HBD, hydrogen bond donors; HBA, hydrogen bond acceptors; PTEN, phosphatase and tensin homologue.</p></div> has been an actively pursued drug discovery target for almost 3 decades. Often referred to as the âguardian angel of DNAâ,<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> this abundant nuclear enzyme has been the focus of over 20 medicinal chemistry programs in a wide range of therapeutic areas encompassing stroke, cardiac ischemia, cancer, inflammation, and diabetes (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>).<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Despite the great therapeutic potential for this target and the tremendous academic and industrial efforts dedicated to it, only recently have PARP-1 inhibitors made headway in clinical trials. Recent results from several PARP-1 inhibitors in phase II clinical trials for cancer therapy have attracted the attention of national media.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Of the several potential therapeutic indications for PARP-1 inhibitors, the two major areas that hold the most promise are ischemia and cancer. This review is structured to provide the readers with a brief summary of the rationale for PARP-1 as a therapeutic target, to explain the PARP-1 inhibitor pharmacophore, and to provide an update on the progress of the PARP-1 drug discovery programs. This Perspective will offer a historical account of the critical PARP-1 publications that instilled the interest of the biopharmaceutical industry in the late 1980s and early 1990s. Furthermore, I will discuss why PARP-1 received so much attention in the late 1990s and early 2000s followed by the slight decline in the medicinal chemistry efforts today (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). The major PARP-1 medicinal chemistry programs will be highlighted focusing on the lead generation, lead optimization, candidate selection, and clinical progress. Many aspects of the biological functions of PARP-1 fall outside the scope of this medicinal chemistry review. For this reason, the reader should refer to the following citations for a review of the PARP family of enzymes,<a onclick="showRef(event, 'ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6">(4-6)</a> the biological functions of poly(ADP-ribose),<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> PARP-1 and intracellular signaling,<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> PARP and DNA repair,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> PARP and epigenetics,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> PARP and angiogenesis,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> and the role of PARP-1 in inflammation.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11, 12)</a> The 30 years of medicinal chemistry on this topic have also afforded some excellent medicinal chemistry reviews, most of which predated the disclosure of clinical candidate structures and recent clinical trial results.<a onclick="showRef(event, 'ref13 ref14 ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15 ref16 ref17">(13-17)</a></div><figure id="fig1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0026.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Active PARP-1 drug discovery programs based on patent and publication records.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">PARP-1 Enzymatic Function</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02258" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02258" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Poly(ADP-ribose) polymerase-1 (aka PARP-1, ADPRT, PARS: EC 2.4.2.30) is one of the most abundant and well characterized members of the PARP family of nuclear enzymes.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> To date, 18 members of the PARP family have been identified and characterized, with PARP-1 being the most thoroughly studied and PARP-2 being its closest relative.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Despite the large number of enzymes in this family, PARP-1 accounts for >90% of the ADP-ribosylation within the cell and is highly evolutionarily conserved in all advanced eukaryotes.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17, 18)</a> PARP-2, the closest homologue to PARP-1, is the only other member of the PARP family with a DNA binding region indicating a potential functional redundancy within the genome. While PARP-1 knockout mice are viable, double PARP-1 and PARP-2 knockout mice are embryonically lethal<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> indicating the importance of these two family members in genomic integrity and cell survival. Because of the structural homology between PARP-1 and PARP-2, most PARP-1 inhibitors also inhibit PARP-2. One group has even described selective PARP-2 inhibitors as further tools to expound the role of this enzyme.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> PARP-1, however, has been a well studied enzyme for over 40 years, and despite the new and exciting roles for other members of the PARP family such as PARP-2, the focus of this review will be on PARP-1 as a therapeutic target.</div><div class="NLM_p">The PARP-1 enzyme is a 113 kDa protein with three major structural domains, a DNA binding domain with two zinc fingers, a 55 kDa catalytic domain, which utilizes nicotinamide adenine dinucleotide (NAD<sup>+</sup>, outlined in gray, Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>) as a substrate to construct polymers of ADP-ribose on histones<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> and other nuclear acceptor proteins including the automodification domain of PARP-1 itself. It is generally accepted that the catalytic activity of PARP-1 is stimulated by DNA damage caused by peroxidation,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> irradiation,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> and DNA-damaging chemicals, e.g., chemotherapeutic agents.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Toward this end, the 42 kDa DNA binding domain with two zinc fingers binds damaged DNA and stimulates polymerization of ADP-ribose resulting in the unwinding of DNA from histones and exposing the damaged DNA for repair. The synthesis of these polymers is illustrated in Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>. This cartoon represents the linear chain polymerization reaction that PARP-1 catalyzes. The 2â²-OH of an NAD<sup>+</sup> molecule binds to an intermediate oxonium ion that is generated by the dissociation of nicotinamide (blue, Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>) from the ribose ring. The critical amino acid residues (red, Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>) include Ser904 and Gly863 which form a hydrogen bonding network with the nicotinamide moiety. In addition, Tyr904 forms a planar surface which has a ÏâÏ-interaction with the nicotinamide group and stabilizes the oxonium ion. At the same time, Glu988 facilitates the proton transfer from the 2â²-OH group before the glycosidic bond is formed.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> PARP-1 can also catalyze the synthesis of branched polymers from the 2â²-OH of the nicotinamide ribose.</div><figure id="fig2" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0027.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Poly(ADP-ribosyl)ation catalyzed by PARP-1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">PARP-1 has long been associated with DNA repair and maintenance of the integrity of genomic function.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Experiments have elucidated the role of PARP-1 in DNA repair as illustrated in Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> The first step of this cycle is DNA damage (oxidative, chemical, or <i>h</i>Î½) and PARP activation. During this step several events occur:<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> (1) PARP-1 is recruited to the site of damage and binds DNA by means of its two zinc fingers; (2) PARP-1 enzymatic activity is stimulated up to 500-fold upon DNA binding;<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> (3) poly(ADP-ribosyl)ation occurs on histone glutamate residues and upon PARP-1 itself within the automodification region of the enzyme;<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> (4) NAD<sup>+</sup>, the substrate for PARP-1 is rapidly consumed in the generation of ADP-ribose polymers; (5) the negatively charged ADP-ribose chain results in a looser interaction between the histones and the DNA, making the site of damage more accessible for DNA repair enzymes; (6) PARP-1 upon being autopoly(ADPribosyl)ated becomes down-regulated. Simultaneously, poly(ADP-ribose)glycohydrolase (PARG) rapidly breaks down the ADP-ribose polymers, leaving the site of DNA damage even more accessible for the DNA repair enzymes. At this stage, PARP-1 is also inactivated and dissociated from the damaged DNA. Finally, DNA repair occurs as the DNA repair enzymes such as X-ray repair cross-complementing 1 (XRCC1)<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> and DNA ligase III-Î± (LIG-IIIÎ±) are recruited to the damaged site by (ADPribosyl)ated PARP-1.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> This repair cycle is a dynamic process, and the total time for this cycle from beginning to end can be measured in minutes.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">PARP-1 as a Target for Oncology</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00145" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00145" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The inhibition of PARP-1 has two potential therapeutic applications for drug discovery. The first application is as a chemopotentiator, since many anticancer therapeutics target DNA damage as a mechanism to destroy rapidly dividing cancer cells. Thus, the PARP-1 mediated repair pathway is one major mechanism for DNA repair by many cancerous cell types leading to drug resistance and continued tumor growth.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Hence, PARP-1 inhibition in combination with DNA damaging chemotherapeutics or radiation would compromise the cancer cell DNA repair mechanisms, resulting in genomic dysfunction and cell death.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> The second, a more recent discovery, is that PARP-1 can be used as a stand-alone therapy for tumor types that are already deficient in certain types of DNA repair mechanisms as discussed below.</div><figure id="fig3" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0001.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Role of PARP-1 in DNA repair.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Several pioneering publications vetting PARP-1 as a viable cancer target appeared in the 1980s. The earliest study demonstrated that 3-aminobenzamide (<b>2</b>, 3-AB, Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>),<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> first generation inhibitor of PARP-1 and close analogue of nicotinamide (<b>1</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>),<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> enhanced the cytotoxicity of DNA methylating agents in murine leukemia cells, providing a foreshadowing of PARP-1 inhibitors as chemopotentiators.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> By this time, there were several compelling reasons for evaluating PARP-1 as an attractive therapeutic target for oncology: (1) much was known about the role of PARP-1 in DNA repair, providing a mechanism of action for PARP-1 inhibitors as chemopotentiators; (2) the biochemistry of the enzyme was well characterized providing a reasonable screening tool for small molecule inhibitors; (3) small molecule PARP-1 prototype inhibitors were known and shown to enhance the cytotoxicity of DNA damaging agents in cells;<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> (4) rodent xenograft models were commonplace and hence provided an in vivo screening tool for PARP-1 inhibitors. These factors led to a reasonable optimization paradigm that many of the first medicinal chemistry programs followed to discover clinical candidates.</div><div class="NLM_p">The next major breakthrough in PARP-1 cancer research occurred in 2005 with two seminal <i>Nature</i> publications from independent groups regarding the sensitivity of BRCA1/2 deficient cell lines toward PARP-1 inhibitors.<a onclick="showRef(event, 'ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref35 ref36">(35, 36)</a> This research supported the hypothesis that PARP-1 inhibitors could be used as single agents in cancer cell types with deficient DNA repair mechanisms. Breast cancer associated genes BRCA1 and BRCA2 have long been characterized as tumor suppressor genes that play an integral role in the repair of double strand breaks (DSB) in DNA through a process called homologous recombination (HR).<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> While PARP-1 inhibition will lead to an increase in single strand breaks (SSB), the preponderance of these SSBs will eventually lead to DSBs via replication fork collapse (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>).<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> The increase of DSBs in the presence of HR deficient cell types leads to chromosomal aberrations and instability of the genome resulting in cell death. This phenomenon is referred to as synthetic lethality;<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> namely, the loss of one gene function will result in cell susceptibility (i.e., loss of PARP-1 <i>or</i> BRCA1/2), but the loss of both is lethal (i.e., BRCA1/2 deficient cells <i>and</i> a PARP-1 inhibitor).</div><figure id="fig4" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0002.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Synthetic lethality of cancer cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">This discovery that PARP-1 inhibitors could be used as a single agent provided a new opportunity for the drug discovery programs. Now the path to a PARP-1 clinical candidate involved testing the inhibitor in cell lines deficient in DNA repair mechanisms such as BRCA1/2 (â/â) cells. In vivo, these cell lines could then be utilized in xenograft models to test PARP-1 inhibitors. In addition, any cell lines that lacked the ability for HR could be tested for PARP-1 inhibitor sensitivity. This so-called âBRCAnessâ has been used to describe tumor types with inactivated HR pathways.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a></div><div class="NLM_p last">In addition to the changing research paradigms, now a promising new clinical pathway for PARP-1 inhibitors was apparent. Because of the substantial amount of evidence of BRCA1/2 mutations in hereditary breast and ovarian cancer, there was now a viable diagnostic screen to identify a patient population most likely to respond to PARP inhibition therapy. In addition, there seemed to be a significant overlap between BRCA1 mutation breast cancer and patients with so-called âtriple negativeâ breast cancer (TNBC), i.e., deficiencies in estrogen receptor Î± (ER), progesterone receptor (PR) expression, and the HER2 gene. In fact, more than half of BRCA1 carriers have TNBC. In addition, patients with TNBC account for â¼15% of the total breast cancer diagnoses and have a higher likelihood of recurrence and death.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Furthermore, the recent phase II clinical trials using a PARP-1 inhibitor<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> suggest that PARP-1 is up-regulated in TNBC patients (vide infra).</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">PARP-1 as a Therapeutic Target for Ischemia</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24230" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24230" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In the mid-1990s, evidence was mounting that PARP-1 played a significant role in ischemic damage of cells. The link was made between oxidative DNA damage, (e.g., nitric oxide or peroxynitrite) and single strand breaks.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> The hypothesis was that PARP-1 was overactivated under ischemiaâreperfusion conditions where excess DNA damage is occurring. This overactivation led to rapid consumption of NAD<sup>+</sup> to form ADP-ribose polymers. Because the biosynthesis of NAD<sup>+</sup> is an ATP consuming process, the cellular level of ATP would be subsequently depleted and the ischemic cells would die from necrosis. Therapeutic PARP-1 inhibition, however, would still leave the cell in a damaged state, bringing into question the viability of this strategy. Indeed, the involvement of drug discovery efforts in ischemia did not start in earnest until the therapeutic benefit of PARP-1 inhibitors was firmly established. In 1997, the laboratories of Dawson and Snyder at Johns Hopkins University and Moskowitz at Massachusetts General Hospital discovered that genetic disruption of PARP-1 resulted in significant protective effects against ischemic events in vivo.<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44, 45)</a> These groups demonstrated that PARP-1 knockout mice displayed profound protective effects (>60% reduction in damaged tissue) in an animal model of stroke, middle cerebral arterial occlusion (MCAO). Both papers provided compelling evidence that PARP-1 inhibitors could potentially provide a therapeutic benefit to stroke patients by reducing the amount of damaged brain tissue. At the same time, further evidence started accumulating to provide additional support for the role of PARP-1 in cardiac ischemia and other forms of ischemic injury.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Later evidence confirmed that inhibition of PARP-1 in ischemic conditions elicited protective effects in two ways: (1) by preservation of the cellular levels of NAD<sup>+</sup>, and consequently ATP, the peripheral damaged cells, e.g., the penumbra in the brain, could utilize the energy to repair the damaged DNA if not too extensive;<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> (2) PARP-1 inhibition prevented the activation of certain inflammation pathways that could have contributed to further cellular damage via an immune response.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></div><div class="NLM_p last">By the late 1990s, PARP-1 became a drug discovery target for ischemia for several reasons: (1) specific, low MW scaffolds with nanomolar potency were already known, providing good starting points for medicinal chemistry optimization;<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> (2) very few pharmaceutical companies had PARP-1 drug discovery programs, leaving plenty of competitive space in the area of ischemia; (3) ischemic animal models were available with proof-of-concept data from knockout mice; (4) the unmet medical needs and potential indication for an ischemia drug was vast (e.g., stroke, cardiac ischemia, cardiac bypass, and sepsis). As compelling PARP-1 related ischemia data increased, a 3-fold increase in drug discovery programs from 1995 to 2005 resulted (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). This culminated in an explosion of intellectual property in the early 2000s and a refined pharmacophore for the next generation of nicotinamide based PARP-1 inhibitors.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">PARP-1 Inhibitor Pharmacophore and Nicotinamide Binding Site</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04667" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04667" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a> outlines 30+ PARP-1 inhibitor scaffolds that have afforded thousands of analogues providing a solid pharmacophore for NAD<sup>+</sup> competitive inhibitors. In the 1980s, two inhibitors provided the starting point for this pharmacophore, namely, nicotinamide (<b>1</b>, IC<sub>50</sub> = 210 Î¼M) and 3-aminobenzamide (<b>2</b>, IC<sub>50</sub> = 30 Î¼M).<a onclick="showRef(event, 'ref15 ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref15 ref33 ref34">(15, 33, 34)</a> These two inhibitors played important roles as proof of concept PARP-1 inhibitors albeit with suboptimal inhibitory potencies.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> In an attempt to improve the potency of first generation PARP-1 inhibitors, Ueda and Banasik from Kyoto University screened over 100 compounds from several structural classes to discover multiple bicyclic and tricyclic lactams as submicromolar PARP-1 inhibitors. This work refined the PARP-1 pharmacophore by demonstrating that constraining the arylamide into another ring would restrict the degrees of freedom for the amide moiety, thus locking it into a geometry beneficial for PARP-1 inhibitory potency. The Banasik group introduced several bicyclic lactam derivatives with single digit micromolar potency such as the isoquinolinones (<b>3</b>),<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> dihydroisoquionlinones (<b>4</b>),<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> quinazoline diones (<b>5</b>), phthalazinones (<b>6</b>), quinazolinones (<b>7</b>), and phenanthridones (<b>8</b>, X = CH).<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> The groundbreaking work by Banasik and Ueda can be further appreciated by understanding the families of core structures that have evolved from, or bear close resemblance to, the basic scaffolds outlined in their publication (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>). For example, the isoindolinones (<b>12</b><a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> and <b>39</b>),<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> thienopyridinones (<b>17</b>),<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> tetracyclic isoquinolinones (<b>28</b>),<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> and pyrroloisoquinolinones (<b>49</b>)<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> are closely related to isoquinolinones (pink, Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>). Likewise, the tetrahydroquinazoline diones (<b>13</b> and <b>14</b>)<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> are closely related to the quinazoline diones (orange, Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>). Phthalazinone based inhibitors (yellow, Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>) evolved into tetrahydrophthalazinones (<b>15</b> and <b>16</b>)<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> and tri- and tetracyclic phthalazinones (<b>29</b> and <b>40</b>).<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Likewise, quinazolinone based inhibitors (light-green, Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>) developed into thienopyrimidinones (<b>18</b>),<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> pyrrazoloquinazolinones (<b>30</b>),<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> and indoloquinazolinones (<b>41</b>).<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Because of the inherent potency of the phenanthridone core (<b>8</b>, IC<sub>50</sub> â 300 nM),<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> many tricyclic and tetracyclic scaffolds evolved from it including the azaphenanthridones (<b>9</b>),<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> saturated phenanthridones (<b>19</b> and <b>20</b><a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> and <b>33</b><a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a>), bridged phenanthridones (<b>21</b>),<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> heterocyclic phenanthridones (<b>31</b> and <b>32</b>,<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a><b>42</b> and <b>43</b><a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a>), alkylquinolinones (<b>44</b>),<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> and indenoisoquinolinones (<b>50</b>).<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a></div><div class="NLM_p">Another family of scaffolds appeared in the early 1990s from the laboratories of Roger Griffin and Bernard Golding at the University of Newcastle (gray, Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>). This group first introduced the imidazole and benzoxazole carboxamides (<b>10</b> and <b>11</b>),<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> in which the imidazole nitrogen acts as an intramolecular hydrogen bond acceptor to the amide NH. This intramolecular hydrogen bond forms a âpseudoringâ, locking the primary amide in the geometry most beneficial to PARP-1 binding, similar to the bicyclic and tricyclic lactams. The benzimidazole carboxamides core is perhaps one of the most potent core structures for PARP-1 inhibitors (<i>K</i><sub>i</sub> = 95 nM).<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> This inherent potency for such a small core spawned multiple subseries of compounds from which several clinical candidates derived (vide infra). These series include the indole carboxamides (<b>22</b>),<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> the indazole and triazole carboxamides (<b>23</b> and <b>24</b>),<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> imidazopyridine carboxamides (<b>25</b>, <b>26</b>, and <b>27</b>),<a onclick="showRef(event, 'ref68 ref69'); return false;" href="javascript:void(0);" class="ref ref68 ref69">(68, 69)</a> quinoxaline carboxamides (<b>45</b> and <b>46</b>),<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> alkoxybenzamides (<b>47</b>)<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> as well as several tricyclic series such as diazepinoindolones (<b>34</b>)<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> and [5,6,6]- and [5,6,7]tricyclicindole lactams (<b>35</b> and <b>36</b>)<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> and [5,6,7]tricyclicimidazole lactams (<b>37</b> and <b>38</b>).<a onclick="showRef(event, 'ref74 ref75'); return false;" href="javascript:void(0);" class="ref ref74 ref75">(74, 75)</a> Even tricyclic benzimidazoles (<b>48</b>)<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> evolved from this family, a series without the characteristic lactam prevalent in so many NAD<sup>+</sup> competitive inhibitors.</div><figure id="fig5" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0003.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Evolution of PARP-1 Inhibitor Scaffolds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A distinct binding mode for several of these scaffolds was first established by Ruf and co-workers solving the first X-ray cocrystal studies with PARP-1 inhibitors and chicken PARP (cPARP), a close homologue (87%) of human PARP-1.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> The common thread for each of the inhibitors was a hydrogen bonding network between the amide functionality of the inhibitor core and Ser904 and Gly863 of PARP-1. Indeed, as outlined in Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>, this is the same network of H-bonds that bind the nicotinamide portion of NAD<sup>+</sup>. Lactam based inhibitors such as isoqunolinone NU1025 (<b>51</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>A) form three hydrogen bonds in the nicotinamide subsite of the NAD<sup>+</sup> pocket, two from Gly863 and one from Ser904. This network explained an improvement in potency observed with fused arylamides. This network of H-bonds also accounted for the fact that substituents close to the amide pharmacophore usually decrease enzymatic potency by disrupting these interactions. Other features of the nicotinamide pocket were the two aryl residues Tyr896 and Tyr907 forming a Ï-electron sandwich for the flat arylamide groups, explaining the improvement in potency often seen with arylamides versus saturated amides. The back wall of the nicotinamide subsite bordered by Ala898 and Lys903 formed a tight, small pocket just large enough for small substituents (e.g., CH<sub>3</sub>, F, Cl) on the benzamide-containing ring (A-ring). In some instances, Glu988 also formed a hydrogen bond with the inhibitor either with or without a conserved water molecule mediating the H-bond. This glutamate residue explains why heteroatoms in certain positions on the A-ring increase the potency of inhibitors. The last feature of the nicotinamide binding pocket is the large hydrophobic pocket adjacent to the nicotinamide binding site. This pocket is often referred to as the adenine-ribose binding site (AD site),<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> and most series of PARP-1 inhibitors take advantage of this spacious pocket to improve potency, solubility, and other pharmaceutical properties of the series. Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>B and Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>C diagram the binding modes for two other PARP-1 inhibitors. The Pfizer/Agouron/Newcastle group published a cocrystal of a indolobenzazepine (<b>52</b>)<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> with the catalytic domain of cPARP. This structure bears all of the hallmarks of the isoquinolinone first published by Ruf,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> indicating that this family of compounds shares the same binding mode as the bicyclic lactams. The Fujisawa group was one of the first groups to extensively study the X-ray cocrystal structures of their inhibitors with human PARP-1. The indolinedione (<b>53</b>)<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> formed the same network of hydrogen bonds within the nicotinamide pocket. Interestingly, however, the 4-phenyltetrahydropyridyl side chain depressed the back of the adenine diphosphate ribose binding pocket, forming a new hydrophobic subsite with residues Pro881, Ile879, Arg878, and Leu769. This tetrahydropyridyl nitrogen also forms a hydrogen bond with the carboxylate of Asp766, adding several orders of magnitude in binding potency. The Fujisawa compound exemplifies the increase in binding affinity with hydrophobic groups, 2Â° and 3Â° amines specifically, in the structures of many PARP-1 inhibitors.</div><figure id="fig6" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0004.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Binding modes of several PARP-1 inhibitors in the nicotinamide binding pocket: (A) dihydroisoquinolinone <b>51</b>; (B) indolobenzazepine, <b>52</b>; (C) indolinedione, <b>53</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The X-ray cocrystal studies from a multitude of scaffolds provide ample support for the PARP-1 pharmacophore outlined in Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>. The PARP-1 pharmacophore includes one or more of the following structural elements contributing to the inhibitory potency: (1) an amide moiety fused within a bicyclic ring system or âpseudo bicyclic ringâ (e.g., <b>10</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>) system as outlined in blue by rings A and B (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>); (2) hydrogen bond donors and acceptors on the opposite side of the A-ring from the amide (orange, Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>); (3) small hydrophobic substituents on the A-ring, adjacent to the amide (pink, Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>); (4) large hydrophobic groups in the southeast portion of the pharmacophore (green, Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>).</div><figure id="fig7" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0005.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. PARP-1 pharmacophore.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">PARP-1 Inhibitor Programs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10010" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10010" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> University of Bath (Threadgill Laboratories)</h3><div class="NLM_p">One of the earliest groups to explore PARP-1 as a therapeutic target was the laboratories of Michael Threadgill at the University of Bath in the early to mid-1990s. This group was the only one to specifically design mechanism based irreversible inhibitors,<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> mimicking the adenine based oxonium ion (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). Substituted benzamides and isoquinolin-1-ones with electrophilic groups were synthesized and tested for inhibition of PARP-1 at 10 Î¼M. One of the most potent compounds in this series was the 3-substituted oxirane (<b>54</b>),<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> a compound that situates an electrophilic carbon in a position similar to that of the ribose oxonium ion (Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>). The potency of this compound was reported as 88% inhibition at 9.2 Î¼M (IC<sub>50</sub> â 1 Î¼M). However, the Threadgill group reported no PARP inactivation upon preincubation with the potential irreversible inhibitors, suggesting that these compounds were not acting as time dependent irreversible inhibitors. In this case, the nucleophile reacting with the epoxide is most likely on an adjacent acceptor protein or the automodification region of PARP-1, not a critical residue in the active site.</div><figure id="fig8" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0006.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Mechanism based PARP-1 inhibitors designed by the Threadgill laboratories.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">This group was also the first to design micromolar PARP-1 inhibitors with a heterocyclic A ring, namely, thienopyridinones (<b>17</b>) and thienopyrimidinones (<b>18</b>), derived from isoquinolones (<b>3</b>) and quinazolinones (<b>7</b>), respectively (Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>).<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> 6-Methylpyridinone (<b>55</b>) and the analogous 2-methylpyrimidinone (<b>56</b>) exhibited almost complete PARP-1 inhibition at 10 Î¼M, demonstrating the feasibility of this core structure for optimization.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a></div><figure id="fig9" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0008.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Design of thienopyridinones and thienopyrimidinones.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">This group was also one of the first groups to attempt to design prodrugs of PARP-1 inhibitors. The prodrug consisted of a nitroimidazole group as in compound <b>57</b> (red, Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>), capping the most prevalent feature of PARP-1 inhibitors, the amide NH.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> Theoretically, this moiety will be reduced enzymatically under hypoxic conditions leading to the decomposition of the resultant aminoimidazole as outlined in Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>. This bioreductively triggered event would be most prevalent in areas with low oxygen such as hypoxic tumor tissue. The PARP-1 inhibitor, 5-bromoisoquinolinone (<b>58</b>, IC<sub>50</sub> = 270 nM)<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> in this example, would then be released predominantly in the desired tissue because of this physiological difference. Reductive conditions similar to that of the physiological hypoxia were used to demonstrate this point. The Threadgill laboratories were able to probe some of the lesser studied aspects of PARP-1 inhibition, namely, mechanism based inhibitors, A-ring heterocycles, and amide based prodrugs.</div><figure id="fig10" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0007.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Nitroimidazole prodrug of PARP-1 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> University of Newcastle/Agouron/Pfizer: AG014699 (<b>63</b>, PF-01367338)</h3><div class="NLM_p">One of the earliest groups dedicated to PARP-1 as a therapeutic target for cancer were the laboratories of Roger Griffin and Bernard Golding at the University of Newcastle in the early 1990s. At the time, a PARP-1 pharmacophore was starting to emerge from the bicyclic lactams (Figures <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a> and <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>). The focus of their efforts was on two core series, the quinazolinones (<b>7</b>, IC<sub>50</sub> = 15.8 Î¼M)<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> and, more importantly, benzimidazole carboxamides (<b>10</b>, <i>K</i><sub>i</sub> = 95 nM), a series that generated the clinical candidate several years later.</div><div class="NLM_p">The quinazolinone core, originally discovered by Banasik and Ueda, was optimized by the Newcastle group via derivatization at the 2 and 8 positions of the bicyclic ring system. This optimization culminated in the discovery of compound <b>51</b> (IC<sub>50</sub> = 0.44 Î¼M, Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a>), a quinazolinone based PARP-1 inhibitor 35 times more potent than the core structure. In addition, <b>51</b> was the subject of one of the first cPARP cocrystal structures (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>A), providing a clear binding mode from which extensive SAR studies were carried out to identify some of the most potent PARP-1 inhibitors at the time (100â300 nM).<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> This compound also displayed cellular activity by moderately potentiating the cytotoxicity of 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide (MTIC, an active metabolite of temozolomide, TMZ) in L1210 leukemia cells. Compound <b>51</b> enhanced 90% cell killing (EF<sub>90</sub>) of MTIC by 3.6-fold (EF<sub>90</sub> = (IC<sub>90</sub> of 200 mM MTIC)/(IC<sub>90</sub> of 200 mM MTIC + 200 Î¼M PARP-1 inhibitor)).<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> This result represented a 50-fold increase in potency over 3-AB in the same system. In vivo, <b>51</b> significantly enhanced the life span of tumor bearing mice (intracerebral neoplasias) when dosed intracerebrally (1 mg/mouse in PEG-400) in combination with 200 mg/kg TMZ.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> Despite these promising results, <b>51</b> did not proceed into human trials, presumably suffering from a lack of solubility, a problem that plagued many early PARP-1 inhibitors.</div><figure id="fig11" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0009.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Newcastleâs quinazolinone based PARP inhibitor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A collaboration between the Newcastle group and Agouron Pharmaceuticals in the late 1990s spawned several subseries of compounds and preclinical leads as outlined in Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a>. The benzimidazole carboxamides proved to be a strikingly potent core structure (<i>K</i><sub>i</sub> = 95 nM), the most potent core structure identified at the time.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Optimization of the benzimidazole carboxamides led to several 2-aryl derivatives with single digit nanomolar potency. Aryl groups substituted at the para position generally improved the potency of the core because of ÏâÏ interactions with Tyr889 and Tyr907 in the nicotinamide binding site of PARP-1. The first lead compound that emerged from this series was NU1085 (<b>59</b>, <i>K</i><sub>i</sub> = 6 nM, Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a>). In vitro, 10 Î¼M <b>59</b> was determined to be as effective as 50 Î¼M <b>51</b> at potentiating growth inhibition and cytotoxicity of TMZ and topotecan in several human cancer cell lines.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> However, this compound still suffered from poor aqueous solubility, prompting an optimization pathway focused on better physicochemical properties.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a></div><figure id="fig12" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0010.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Design of several lead PARP-1 inhibitors from Newcastle/Agouron/Pfizer.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Agouron and Newcastle designed several new subseries of compounds derived from benzimidazole carboxamides in order to address the solubility issues and at the same time improve the structural novelty of their PARP-1 inhibitors. These groups surmised that the free carboxamide of <b>10</b> could be constrained within a six- or seven-membered ring, effecting the same result as an intramolecular H-bond. Three lead series emerged from this concept as outlined in Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a>. One such series, the [5,6,7]tricyclicimidazole lactams (e.g., <b>38</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>) confirmed this hypothesis with several low nanomolar 2-substituted derivatives. Optimization of these tricyclic imidazoles led to the identification of AG014361 (<b>60</b>) as a lead PARP-1 inhibitor.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> Compound <b>60</b> had a notable feature that started to become commonplace in many of the PARP-1 inhibitors, namely, a secondary or tertiary amine (light-blue, Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a>) responsible for improving the aqueous solubility, inhibitory potency, and cell permeability of many of the arylamide cores. The high potency of <b>60</b> (<i>K</i><sub>i</sub> = 5.8 nM) led to increased antiproliferative activity of TMZ against LoVo cells (PF<sub>50</sub> = 5.5 when <b>60</b> was tested at 0.4 Î¼M). This lead PARP inhibitor also displayed in vivo efficacy by causing complete regression of SW620 xenograft tumors (ip daily at 5 or 15 mg/kg) in combination with TMZ (68 mg/kg po daily for 5 days).<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> Compound <b>60</b> served as the benchmark lead for the Agouron group as they designed other closely related series of PARP-1 inhibitors.</div><div class="NLM_p">In an effort to improve the biological activity and identify a clinical candidate as a chemosensitizer, Agouron probed two other series of compounds. One such series was the [5,6,7]tricyclic indole lactams which was optimized in a similar manner to afford AG014376 (<b>61</b>, <i>K</i><sub>i</sub> = 6.4 nM).<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> However, <b>61</b> and many other derivatives with this indole core did not retain the in vitro chemopotentiation of TMZ (PF<sub>50</sub> = 3.8 when tested at 0.4 Î¼M) as the [5,6,7]tricyclic imidazoles. Another such series, the [5,6,6]- and [5,6,7]-tricyclic indole lactams (e.g., <b>35</b> and <b>36</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>), emerged with several examples of single digit nanomolar PARP-1 inhibitors. Optimization of this series led to compounds such as AG014344 (<b>62</b>, IC<sub>50</sub> = 5.6 nM).<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> The binding mode for this series of inhibitors was confirmed by cocrystal data with cPARP (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>B). The constrained amide formed an H-bond network with Ser904 and Gly863 similar to many of the early PARP-1 inhibitors. In addition, the indole NH formed a water mediated H-bond with Glu988 (orange, Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a>), the aryl substituent formed a ÏâÏ interaction with Tyr889, and the dimethylamino group interacted with Asp766. In addition, <b>62</b> (PF<sub>50</sub> = 7.8 at 0.4 Î¼M) demonstrated the ability to potentiate temozolomide cytotoxicity in LoVo cells with a greater effectiveness than <b>60</b>.</div><div class="NLM_p">Agouron/Pfizerâs clinical candidate, <b>63</b>, emerged from the series of [5,6,7]-tricyclic indole lactams.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> The compound displayed better in vitro potency and in vivo efficacy than <b>60</b> and <b>62</b> (<i>K</i><sub>i</sub> = 1.4 nM and PF<sub>50</sub> = 8.1 in LoVo cells). Because many of the [5,6,7]-tricyclic lactam PARP-1 inhibitors had similar potency and potentiation factors, the selection strategy for the clinical candidate assessed the potency of lead inhibitors in rodent xenograft studies in the presence of TMZ.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> Compound <b>63</b>, when dosed at 0.15 (mg/kg)/day ip, exhibited a 50% increase in tumor growth delay as 1.5 (mg/kg)/day ip <b>60</b> in a 5 day xenograft study in conjunction with TMZ (68 (mg/kg)/day).<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> The clinical candidate (<b>63</b>) also displayed no toxicity alone or in combination with TMZ and no adverse effects on the PK of the coadministered anticancer agents. Gratifyingly, the group that had one of the oldest research interests in PARP-1 was the first group to test a PARP-1 inhibitor in human clinical trials as a chemopotentiator.</div><div class="NLM_p">Because the most consistent chemopotentiation results were obtained in combination with TMZ, the phase I study of <b>63</b> was conducted in conjunction with TMZ in adults with advanced solid tumors. This phase I study used pharmacodynamic analysis of PARP-1 activity in peripheral blood lymphocytes (PBLs) to assess the optimal PARP inhibitory dose (PID) for <b>63</b>. Patients then underwent a dose escalation of TMZ (up to 200 mg/m<sup>2</sup>, MTD) with the outcome being a well tolerated combination of 200 mg/m<sup>2</sup> TMZ with 12 mg/m<sup>2</sup><b>63</b> iv infusion. The drug possessed extensive tissue distribution (only 11% excreted in urine) and a terminal half-life of 9.5 h. These parameters translated into 74â97% PARP-1 inhibition in PBLs up to 24 h, indicating that PARP was inhibited throughout the treatment course of TMZ.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> In 2005, phase II studies were conducted with TMZ in patients with malignant melanoma. The end point of this study was to increase the response rate of patients treated with 200 mg/m<sup>2</sup> TMZ and 12 mg/m<sup>2</sup><b>63</b> iv infusion versus 200 mg/m<sup>2</sup> TMZ alone. Results from this phase II study indicated that the response rate for combination treatment was higher than TMZ alone, but <b>63</b> also enhanced the myelosuppression caused by TMZ more than what was expected from phase I data.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a></div><div class="NLM_p last">In 2005, the Newcastle group in collaboration with the University of Stockholm and the University of Sheffield demonstrated that BRCA deficient cell lines were sensitive to stand-alone treatment with PARP-1 inhibitors, in particular <b>60</b> and <b>51</b>.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> This seminal publication opened up a new avenue for the development of <b>63</b> and shifted the focus toward treating cancer patients with BRCA1/2 mutations. Currently, <b>63</b> (PF-01367338) is in a phase II trial in known carriers of BRCA1/2 with locally advanced metastatic breast cancer or advanced ovarian cancer (NCT 00664781).</div></div><div id="sec6_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> UCSF/Octamer/BiPar/Sanofi-Aventis: BSI-201 (<b>64</b>)</h3><div class="NLM_p">While the vast majority of PARP-1 drug discovery efforts focused on NAD<sup>+</sup> competitive inhibitors, a group from UCSF led by Ernest Kun in collaboration with Octamer Research Foundation identified two noncompetitive PARP-1 inhibitors (Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a>) that interact with the zinc binding site of PARP-1 <b>64</b> and BSI-401 (<b>65</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a>).<a onclick="showRef(event, 'ref89 ref90'); return false;" href="javascript:void(0);" class="ref ref89 ref90">(89, 90)</a> This unique interaction takes place on Arg34 as was determined by mutagenesis studies.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> By disrupting the PARP-1 zinc finger/DNA interaction, these compounds would theoretically prevent PARP-1 activation and enhancement,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> thus achieving a similar result as the NAD<sup>+</sup> competitive inhibitors. Clearly, these two compounds are unconventional PARP-1 inhibitors. The nitro group of <b>64</b> is known to be reduced in vivo to a nitroso group, the major metabolite that may covalently modify PARP-1 leading to inactivation even though this site has yet to be identified.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> This covalent modification is a characteristic often mentioned when describing this compound. Regardless of the mechanism of action of these compounds, both display efficacy in several cancer cell lines at micromolar concentrations (50â200 Î¼M) against Ovcar, Skov3, PC-3 cells as well as tumor reduction in xenograft models without signs of toxicity.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> Because of the relatively modest PARP-1 inhibition (estimated at â¼50â200 Î¼M based on analogous compounds),<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> it is quite possible that the these compounds interact with multiple targets, covalent or otherwise, the combination of which is necessary for anticancer activity. The UCSF/Octamer group provided the intellectual property for the BiPar Sciences PARP-1 program in the early to mid 2000s.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> The most recent patent filings from BiPar include other 6-substituted benzopyrones, indicating an interest in exploring this unique mechanism of inhibition by medicinal chemistry optimization.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a></div><figure id="fig13" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0011.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Lead PARP-1 inhibitors discovered by UCSF/Octamer/Bipar.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The lead clinical candidate that evolved from BiParâs PARP-1 program is <b>64</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a>).<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> This compound entered phase I human clinical trials in 2007 to assess the safety and tolerability of the drug when dosed iv in patients with advanced solid tumors. The dose levels were established using PARP inhibition in peripheral blood cell mononucleocytes (PBMCs). The drug inhibited PARP activity by greater than 50% at 2.8 mg/kg iv even though the compound was rapidly eliminated (<i>t</i><sub>1/2</sub> = 4 min), indicating the participation of an active metabolite in PARP inhibition, most likely the 4-iodo-3-nitrosobenzamide.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> Overall, the phase I study indicated that <b>64</b> was safe and well tolerated, and the pharmacodynamic end point established the relevant doses to achieve PARP inhibition. A phase IB study also established the safety and tolerability of iv <b>64</b> with topotecan, gemcitabine, carboplatin/paclitaxel, and TMZ.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a></div><div class="NLM_p last">In 2009, Sanofi-Aventis acquired BiPar, and with the acquisition, the company achieved the rights to develop their clinical candidate. With the support of big pharma, the clinical development for <b>64</b> began to accelerate. Several phase II studies are underway with this drug, the most impressive of which was in triple negative breast cancer patients.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> The iv administration of <b>64</b> in combination with gemcitabine/carboplatin (G/C) caused an increase in tumor response (48% patients with <b>64</b> + G/C vs 16% with G/C alone), progression free survival (211 days with <b>64</b> +G/C vs 87 days with G/C alone), and overall survival (>254 days with <b>64</b> + G/C vs 169 days with G/C alone).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> The phase III trial with <b>64</b> in patients with triple negative breast cancer started recruiting in July of 2009 (NCT00938652), preliminary results of which are expected in 2010 (estimated completion is June 2012). The story behind BiParâs clinical candidate is as intriguing and unconventional as its method of PARP-1 inhibition. All signs indicate that it will be one of the first PARP-1 inhibitors to seek approval by the FDA.</div></div><div id="sec6_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Inotek/Genentech: INO-1001 (<b>68</b>)</h3><div class="NLM_p">The Inotek group led by Jagtap and Southan was one of the first biotech medicinal chemistry programs to aggressively pursue PARP-1 as a therapeutic target for ischemia in the late 1990s. Some of their earliest patent applications outlined a series of 2-substituted phenanthridone derivatives (Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a>).<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> This series of phenanthridones was optimized by Inotek to improve the aqueous solubility of the core by addition of tertiary amines at the 2 position of the ring system. This optimization paradigm allowed the aqueous soluble salts of lead compounds to be tested iv in relevant models of ischemia. One such lead, PJ-34 (<b>66</b>, IC<sub>50</sub> = 20 nM, EC<sub>50</sub> = 35 nM),<a onclick="showRef(event, 'ref7 ref97'); return false;" href="javascript:void(0);" class="ref ref7 ref97">(7, 97)</a> so named for its inventor Prakash Jagtap, was used as a proof of concept compound for multiple indications.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Most notably, <b>66</b> demonstrated efficacy in multiple models of ischemic injury such as stroke,<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> cardiac ischemia,<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> and sepsis.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> This compound, despite a plethora of in vivo data, never entered into human clinical trials.</div><div class="NLM_p">The next series of inhibitors evolving from the phenanthridinones was the tetracyclic indenoisoquinolinones (<b>50</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a>).<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> The insertion of a five-membered ring in the phenanthridone core served to slightly disrupt the planarity of the molecule (light-green, Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a>), potentially alleviating the DNA intercalating ability of similar multicyclic ring systems.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> Taking advantage of the large hydrophobic pocket of PARP-1, the Inotek group designed an aminopropylmorpholine derivative to improve the aqueous solubility of the core structure and to improve the enzymatic and cellular potency in peroxynitrite induced cell stress assay<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> (<b>67</b>, IC<sub>50</sub> = 1 nM, EC<sub>50</sub> = 10 nM).</div><figure id="fig14" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0012.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. PARP-1 inhibitors designed by Inotek.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Inotek also pursued a series of isoindolinones (<b>12</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a>) and managed to take a rather weakly binding core and engineered the potency using an adenosine moiety in an attempt to bind the adenosine subsite of PARP-1. They achieved this goal with compound EB-47 (<b>69</b>),<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> which has an amidopiperazine linker joining the core and the adenosine. This derivative demonstrated good PARP-1 inhibitory potency (IC<sub>50</sub> = 45 nM, Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a>), a >600-fold improvement over the core structure. Extensive in vivo ischemia studies were performed with this compound. Compound <b>69</b> reduced the infarct volume in a rat transient MCAO model by 57% when dosed at 10 (mg/kg)/h prior to reperfusion. This compound also performed well in a cardiac reperfusion model by reducing the infarct size by 35% when dosing <b>69</b> at 20 mg/kg 10 min prior to reperfusion.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a></div><div class="NLM_p">Inotekâs clinical candidate was the first PARP-1 inhibitor to enter the clinic as a potential therapy for cardiac ischemia, particularly ST-elevation myocardial infarction (STEMI).<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> While the structure of Inotekâs clinical candidate (<b>68</b>) has not been disclosed, it is most likely a member of the indenoisoquinolinone family based on the known potency (<10 nM) of the compound.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> In a phase I trial, the safety, pharmacokinetics, and pharmacodynamics of <b>68</b> were evaluated in patients with STEMI undergoing primary percutaneous coronary intervention. The results indicated that <b>68</b> had a good terminal <i>t</i><sub>1/2</sub> (7.5 h) and inhibited >90% of PARP-1 activity in cultured cells from patients at all doses tested (200, 400, and 800 mg iv bolus).<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> In addition, <b>68</b> reduced the level of inflammation markers IL-6 and C-reactive protein, indicating a decrease in neutrophil recruitment, preservation of tissue ATP levels, improved myocardial contractility, and potential reduction in infarct size. In 2005, Inotek started a phase II trial in patients undergoing heart lung bypass surgery to potentially alleviate some of the ischemia related side effects from this procedure. However, this trial is no longer recruiting patients (NCT00271176), and interim results have not been published. The end of Inotekâs development of <b>68</b> for ischemia emphasizes the difficulty associated with this clinical path, a challenge that has faced many of the drug discovery groups in the PARP field to this day.</div><div class="NLM_p last">Like many lead PARP-1 inhibitors, however, <b>68</b> demonstrated the ability to be chemopotentiator preclinically by effectively prolonging life span and delaying tumor growth when dosed iv with TMZ in a glioma xenograft model.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> In 2006, Genentech signed a licensing agreement with Inotek to pursue cancer chemopotentiation with <b>68</b> in combination with TMZ in malignant melanoma.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> The results from this phase Ib trial were recently published indicating an increase in myelosuppression and liver enzymes at the dose limiting toxicities of <b>68.</b><a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> In March of 2009, Genentech terminated this phase Ib trial with <b>68</b>, returning all of the rights for this compound to Inotek. Currently, Inotek is pursuing treatment of retinal diseases for their PARP inhibitors and outlicensing opportunities for oncology indications with their more advanced PARP inhibitors such as <b>68</b> as indicated on the companyâs Web site.</div></div><div id="sec6_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Guilford/MGI/Eisai: GPI 21016 (<b>74</b>, E7016)</h3><div class="NLM_p">Guilford Pharmaceuticals started a PARP-1 inhibitor program targeting ischemic injuries in the mid-1990s. The primary focus of the Guilford PARP-1 program was the treatment of neurodegenerative diseases, mainly stroke. Focusing on treating PARP-1 related CNS diseases, Guilford emphasized the necessity of brain penetration when designing their inhibitors. Indeed, the Guilford group routinely included tertiary amines on several PARP-1 core structures to improve the solubility and brain penetrability of the inhibitors.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a></div><div class="NLM_p">One series of compounds from the Guilford group included several 3-substituted phenanthridones such as compound <b>70</b> (IC<sub>50</sub> = 14 nM, Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a>).<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> Despite the relative success at discovering several soluble, low nanomolar PARP-1 inhibitors from this series, the structural similarity to Inotekâs phenanthridone series led to a shift in compound design. One alternative series was the saturated phenanthridones, a notable example being compound <b>71</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a>)<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> with good inhibitory potency (IC<sub>50</sub> = 25 nM) and good cellular potency in a peroxide induced cytotoxicity assay developed by the group<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> (EC<sub>50</sub> = 30 nM). Despite achieving potency, solubility, and novelty within this series, the therapeutic limitation was a lack of brain penetrability.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> To address this issue, the Guilford group designed the azaphenanthridones (e.g., <b>9</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>). The lead compound from this series, GPI 16539 (<b>72</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a>), demonstrated comparable inhibitory potency to <b>71</b> as well as cellular potency in the same peroxide induced cytotoxicity assay (IC<sub>50</sub> = 45 nM, EC<sub>50</sub> = 125 nM).<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> The most important features of this compound, however, were high solubility in aqueous buffer and good brain penetration in rodents (<i>B</i>/<i>P</i> â 10). These two features of <b>72</b> allowed the compound to be dosed systemically for the treatment of stroke. In a transient MCAO model, <b>72</b> reduced infarct volume by 44% when dosed at 40 mg/kg prereperfusion, and in a permanent occlusion model it reduced infarct volume by 18% at the same dose level.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> This preclinical lead also displayed cardioprotective effects in a rat model of cardiac ischemia (25% reduction in infarct at 80 mg/kg).<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Despite the promising ischemia data and therapeutic potential for <b>72</b>, this preclinical lead never advanced into human clinical trials for ischemia.</div><figure id="fig15" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0013.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Lead series of phenanthridone based PARP-1 inhibitors designed by Guilford.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Another lead series designed by Guilford was the tetracyclic isoquinolones such as GPI-6150 (<b>28</b>, IC<sub>50</sub> = 60 nM, Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a>) derived from dihydroisoquinolinones.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> This compound, despite its poor solubility, served as a proof of concept compound for many of the in vitro cellular models of ischemia and in vivo models of inflammation, myocardial infarction, colitis, and stroke.<a onclick="showRef(event, 'ref7 ref111'); return false;" href="javascript:void(0);" class="ref ref7 ref111">(7, 111)</a> In an effort to further improve the structural novelty and solubility of this series, the Guilford group designed several tri- and tetracyclic cores related to <b>28</b> such as tri- and tetracyclic phthalazinones (<b>29</b> and <b>40</b>).<a onclick="showRef(event, 'ref55 ref112'); return false;" href="javascript:void(0);" class="ref ref55 ref112">(55, 112)</a> Once again, their optimization strategy involved attaching a solubilizing group on the southeast portion of the core structure to take advantage of the large hydrophobic adenosine binding pocket of PARP-1. This strategy led to the discovery of GPI 15427 (<b>73</b>, IC<sub>50</sub> = 31 nM), a tetracyclic phthalazinone (Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a>).<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Initially developed for ischemic reperfusion injury, <b>73</b> reduced total infarct volume in a rat transient MCAO model by 35% when dosed at 40 mg/kg iv prereperfusion. As seen from these in vivo results, the piperazine moiety conferred the aqueous solubility for this core as well as brain permeability. Leveraging this brain penetrability, this lead was also the first compound from Guilford to be used as a chemopotentiator with TMZ in brain cancer.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> In an intracranial mouse glioblastoma xenograft model, <b>73</b>, when dosed systemically 40 mg/kg iv with 100 mg/kg TMZ for 3 days, increased life span by 32% over TMZ alone.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> Despite the vast array of data and therapeutic potential for <b>73</b>, this preclinical lead never made it into human clinical trials for ischemia or cancer.</div><figure id="fig16" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0014.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Tetracyclic PARP-1 inhibitors designed by Guilford.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In late 2005, MGI Pharma, an oncology based company, acquired Guilford Pharmaceuticals. This acquisition provided the means and expertise to develop Guilfordâs latest preclinical lead (<b>74</b>) as a chemopotentiator with TMZ for brain cancer. Although the structure for this compound has not been disclosed, it is known to be structurally similar to <b>73</b>.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> Compound <b>74</b> displayed significant chemopotentiating activity in a murine leukemia model in combination with cisplatin. When dosed 15 min pre-, 3 h post-, and 6 h postcisplatin,<b>74</b> (40 mg/kg ip) increased the life span by 160% compared to cisplatin alone. In addition to this chemopotentiating ability, the compound demonstrated neuroprotective effects by restoring 82% of the nerve conduction velocity deficit caused by cisplatin.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> A recent publication demonstrated the ability of <b>74</b> to act as a chemo- and radiosensitizer in vivo in a glioblastoma xenograft model.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> Compound <b>74</b> (40 mg/kg po), when given in combination with radiation (4Gy) and TMZ (3 mg/kg), provided a 32% increase in life span over the TMZ/radiation group. This model verifies that <b>74</b> is effective in a system that is relevant to the current clinical standard of care for glioblastoma (i.e., TMZ plus radiation). These data indicate that the clinical direction for this compound will most likely be treatment of glioblastoma. In 2009, Eisai pharmaceuticals acquired MGI Pharma with plans to continue the development of <b>74</b>.</div></div><div id="sec6_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> BASF/Abbott: ABT-888 (<b>77</b>, Veliparib)</h3><div class="NLM_p">The BASF group, led by Wilfried Lubisch, entered into the PARP-1 field toward the end of the 1990s. This groupâs first PCT publications on PARP inhibitors were for the treatment of ischemic conditions covering a wide range of core structures including indole carboxamides (<b>22</b>),<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> phthalazines (<b>6</b>),<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> imidazopyridines (<b>25</b> and <b>26</b>),<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> and most importantly, 2-heteroaryl and 2-alkylamino benzimidazoles (<b>10</b>, X = NH),<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> the eventual series from which Abbottâs clinical candidate evolved several years later. The BASF group made several hundred compounds culminating in four series of PARP-1 inhibitors and presenting several examples with single digit nanomolar inhibitory potency. Despite not having disclosed a defined clinical candidate from their research efforts, BASF managed to build a solid PARP-1 intellectual property position from which Abbott Laboratories could expand after the acquisition of BASFâs pharmaceutical division in 2001.</div><figure id="fig17" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0015.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Discovery of Abbottâs clinical candidate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The Abbott group, led by Thomas Penning has been perhaps one of the most efficient PARP-1 medicinal chemistry groups over the past 5+ years with the filing of over a dozen composition of matter patents with several hundred analogues as potent PARP-1 inhibitors. Attracted by the size and potency of the benzimiazole carboxamide core (<b>10</b>, IC<sub>50</sub> = 240 nM, MW = 161), the Abbott group aggressively synthesized and characterized several hundred 2-alkylamino derivatives. Their screening paradigm selected compounds with <10 nM enzymatic potency and <10 nM cellular potency (C41 peroxide damaged cellular assay)<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> before advancing them into further in vivo studies. This strategy led to the identification of two closely related preclinical candidates <b>75</b> (<i>K</i><sub>i</sub> = 7 nM)<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> and A-620223 (<b>76</b>, <i>K</i><sub>i</sub> = 8 nM, Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a>).<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a></div><div class="NLM_p">The key discovery during the identification of <b>75</b> was that a tertiary carbon in the 2-position of the benzimidazole ring system was beneficial for both enzymatic potency and cellular efficacy. This feature would be utilized in the design of the clinical candidate. Compound <b>75</b> had a relatively short iv half-life across species (0.6 h in mice and monkeys to 2.8 h in dogs) and exhibited variable oral bioavailability over the same species (12.6% in monkeys to 82% in mice). Perhaps the variability in the PK parameters prevented this compound from advancing into human clinical trials, but the structural homology to the eventual clinical candidate is remarkable (Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a>). A similar optimization strategy led to the discovery of <b>76</b>. As several other PARP-1 medicinal chemistry groups discovered, having a secondary or tertiary amine provided adequate solubility for the core structure (>5 mg/mL for <b>76</b>), and in this case, it improved the cellular penetration and potency in a peroxide induced DNA damage cellular assay (EC<sub>50</sub> = 3 nM). Compound <b>76</b> displayed good oral bioavailability across species (32â82%) and terminal elimination half-lives of 1.2â2.7 h in the same species. This compound demonstrated chemopotentiation of TMZ (74â83% tumor growth inhibition vs 62% for TMZ alone) in a B16F10 melanoma model at 1 (mg/kg)/day over 14 days. In addition, this compound potentiated the effect of cisplatin in an MX-1 breast cancer tumor model albeit at higher doses.</div><div class="NLM_p">The structure of Abbottâs clinical candidate (<b>77</b>, <i>K</i><sub>i</sub> = 5 nM, EC<sub>50</sub> = 2 nM), was disclosed in early 2007<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> followed by the medicinal chemistry summary in early 2009.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> As this group discovered from previous series, the tertiary carbon adjacent to the benzimidazole ring was necessary for cellular efficacy and enzymatic potency. Consistently, compounds with this feature were 2â13 times more potent in the C41 cellular assay. While the enzymatic potency of <b>77</b> and its (<i>S</i>)-enantiomer were identical (<i>K</i><sub>i</sub> = 5 nM), stereochemistry played an important role in both the oral bioavailability and exposure of the compound leading to the selection of the (<i>R</i>)-enantiomer as the clinical candidate. This drug displayed excellent oral bioavailability across species (56â92%) and a comparable terminal half-life to their other preclinical leads <b>75</b> and <b>76</b> (1.2â2.7 h). In addition, <b>77</b> displayed moderate brain penetration (â¼1:3 brain/plasma ratio in rodents), a factor that influenced the eventual clinical path and its potential use in treating brain cancer. Compound <b>77</b> demonstrated excellent chemopotentiation in preclinical xenograft models. In a B16F10 melanoma model, <b>77</b>, administered orally in combination with TMZ, demonstrated a 43â64% tumor growth inhibition at 1, 5, and 12.5 (mg/kg)/day. Chemopotentiation was also observed in combination with carboplatin in an MX-1 breast cancer tumor model.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a></div><div class="NLM_p">In 2006, Abbott entered into the first ever phase 0 human clinical trial with <b>77</b>. Under the Exploratory Investigational New Drug Guidance of the FDA, a phase 0 study involves administering low, nontoxic doses for short periods to a limited numbers of patients. This type of trial requires less extensive toxicology and preclinical data than traditional phase I studies; hence, the first in human studies can be performed earlier than normal. The purpose of this study was to obtain biochemical, pharmacokinetic, and pharmacodynamic data to guide the design of subsequent phase I trials. The primary end point was inhibition of PARP in PBMCs and tumor biopsies. When dosed orally, <b>77</b> was rapidly absorbed (peak plasma levels at â¼1 h) and a large quantity of the drug was cleared unchanged in the urine (â¼70% in 24 h). However, the drug demonstrated good oral bioavailability, was well tolerated, and provided statistically significant inhibition of PAR levels for up to 24 h in tumor biopsies and peripheral blood mononuclear cells at the highest doses tested (25 and 50 mg).<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> The study was completed 5 months after initiation and supported a twice daily schedule for administration in further clinical studies.</div><div class="NLM_p">Abbott is currently involved in several phase I studies to assess the safety of <b>77</b> in combination with topotecan/carboplatin in leukemia (NCT00588991) and mitomycin C and cyclophosphamide in solid tumors (NCT00810966 and NCT 01017640). In addition, Abbott is supporting a phase I study assessing this lead PARP inhibitor in patients with BRCA1/2 mutations (NCT00892736). Leveraging the brain penetrability of this drug, Abbott is also currently supporting two phase I trials to treat brain cancer. One trial is testing the ability of TMZ/<b>77</b> combination to treat children with recurring brain tumors, and the other is testing the drug in combination with whole brain radiation therapy (NCT00994071) for patients with brain metastases (NCT00649207). In addition, <b>77</b> is in phase II studies with TMZ in metastatic breast cancer (NCT 01009788) and metastatic melanoma (NCT00804908, expected completion date of 2010).</div><div class="NLM_p">The Abbott medicinal chemistry group is still active in the PARP-1 field as noted from their recent publications (Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a>). A series of quinoxalinones (<b>31</b>, IC<sub>50</sub> = 238 nM)<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> demonstrated that the classic benzamide core of phenanthidones could be replaced with heterocyclic arylamides. This strategy was attempted with moderate success by Bayer, Fujisawa, and Guilford (vide infra). The Abbott group demonstrated that this series bound to the PARP-1 nicotinamide subsite through cocrystal studies. The lead compound from this series was compound <b>78</b><a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> which displayed excellent enzymatic potency (<i>K</i><sub>i</sub> = 5 nM) and cellular (EC<sub>50</sub> = 6 nM) potency due to an additional interaction between the pyrrolidine nitrogen and a water mediated hydrogen bond with Ser864 (green, Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a>) contributing to the binding potency. Although unique, saturated derivatives of the A ring such as <b>79</b> (IC<sub>50</sub> = 63 nM, EC<sub>50</sub> = 39 nM)<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> were not as potent as the aromatic pyrrole <b>78</b>, a trend that was noted in a similar series of saturated phenanthridones.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a></div><figure id="fig18" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0016.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Current PARP-1 inhibitors from Abbott.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec6_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> KuDOS/Maybridge/AstraZeneca: KU 59436 (<b>82</b>, AZD2281, Olaparib)</h3><div class="NLM_p">The KuDOS/Maybridge group started their fruitful PARP collaborations in the early 2000s. With Maybridgeâs extensive compound collections and KuDOS medicinal chemistry group, the two companies discovered several lead series via HTS. Not surprisingly, these hits consisted of many of the usual bicyclic amides (Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a>) discovered by Banasik in the early 90s. Many of these hits were validated by earlier work, and for this reason, KuDOS rapidly developed SAR by substitution on the positions most likely to lead to potent PARP-1 inhibitors. KuDOS/Maybridge filed a flurry of patents on 3- and 4-substituted isoquinolinones (<b>3</b>),<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> 4-substituted phthalazinones (<b>6</b>),<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> and 2-substituted quinazolinones (<b>7</b>),<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> from 2000 to 2003 (Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a>).</div><figure id="fig19" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0017.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Evolution of KuDOSâ clinical candidate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The bicyclic ring systems were distilled down into a focused medicinal chemistry optimization of phthalazinones. Initial attempts at optimization of phthalazinones resulted in compounds with good PARP-1 inhibitory potency but poor cellular activity. KuDOS was able to overcome this liability by optimization of benzyl substituted phthalazinones such as <b>80</b> with IC<sub>50</sub> = 770 nM.<a onclick="showRef(event, 'ref127 ref128'); return false;" href="javascript:void(0);" class="ref ref127 ref128">(127, 128)</a> Within this series KuDOS discovered compounds with the desired balance of physicochemical properties, potency (<10 nM), cytotoxicity potentiation in vitro (PF<sub>50</sub> >2), metabolic stability, pharmacokinetics (oral bioavailability), and the ability to potentiate the toxicity of various anticancer chemotherapies in vivo. All of these elements were addressed in the KuDOS screening paradigm over the course of their medicinal chemistry efforts. Initial improvement of this core was accomplished by addition of substituents in the 3 and 4 positions of the benzyl ring. The lead compound KU 58684 (<b>81</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a>)<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> was the result of early optimizations. Structural features of this molecule include the fluorine and imide groups which together contributed to improved enzymatic potency (IC<sub>50</sub> = 5 nM) and increased metabolic stability (human hepatic microsomes, Cl<sub>i</sub> < 1 mL min<sup>â1</sup> g<sup>â1</sup>). In addition, <b>81</b> potentiated methyl methane sulfonate cell, killing 5.6 times (i.e., PF<sub>50</sub> = 5.6 = (IC<sub>50</sub> growth curve for MMS)/(IC<sub>50</sub> growth curve of PARP-1 inhibitor plus MMS)).<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> As mentioned above, the KuDOS group was one of the first groups to establish the cytotoxic potential of PARP-1 inhibitors as single agents in cell lines that are deficient in certain DNA repair pathways. This preclinical candidate appeared in the seminal <i>Nature</i> paper describing the effects of PARP-1 inhibitors in cell lines deficient in BRCA1 and BRCA2.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> In a BRCA2 deficient xenograft model, <b>81</b>, when dosed twice a day ip at 15 mg/kg, dramatically blocked tumor growth. This compound acted as a stepping stone for what would eventually be the clinical candidate (<b>82</b>).<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a></div><div class="NLM_p">The necessity for oral bioavailability in the clinic took the medicinal chemistry efforts toward compounds that fit within âdruglikeâ parameters predictive of oral bioavailability (MW < 550, PSA < 140 Ã, rotatable bonds <7, HBD and HBA <10, solubility of >0.1 mg/kg).<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> After an extensive effort, optimization of the benzylphthalazinone series culminated in <b>82</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a>). The diacylpiperazine moiety of this molecule (light-blue) maintained the enzymatic potency (IC<sub>50</sub> = 5 nM) and improved the cell kill potentiation (PF<sub>50</sub> = 25.8) while improving the solubility over <b>81</b> (>0.1 mg/mL).<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> The cyclopropyl group (light-green) conferred oral bioavailability in mice, rats, and dogs greater than the methyl, ethyl, or isopropyl analogues. The cellular potency of <b>82</b> was established in several BRCA deficient cell lines, confirming this groupâs earlier work. In addition to the in vitro effects as a single agent, <b>82</b> displayed significant efficacy in vivo as a potentiating agent for TMZ in mice xenografts equating to over 80% tumor growth inhibition throughout the terminal phase of the study. The drug was well tolerated in vivo and advanced into clinical trials in 2005. In early 2006, AstraZeneca acquired KuDOS Pharmaceuticals to strengthen its portfolio of anticancer therapies and to further accelerate the development of <b>82</b>. The phase I results for <b>82</b> indicated that the drug when dosed orally was rapidly absorbed and eliminated but still inhibited PARP in samples of PBMCs and tumor tissue. More importantly, <sup>1</sup>/<sub>3</sub> of the patient population of this study were carriers of the BRCA mutation, and the majority of this subgroup (â¼60%) responded to treatment with this PARP inhibitor.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a>AstraZeneca has just completed two phase II studies for the treatment of BRCA positive advanced breast cancer (NCT00494234) and ovarian cancer (NCT00494442). The interim results from this phase II study indicate that there is a 33% response rate from BRCA1/2 carriers at the highest dose tested (400 mg/kg po). In addition, the clinical benefit rate (CBR = objective response rate and decline in CA-125 cancer biomarker) was determined to be 57.6% for this same group with mild toxicities. The results from these trials were recently reported at the latest ASCO meeting.<a onclick="showRef(event, 'ref3 ref132 ref133'); return false;" href="javascript:void(0);" class="ref ref3 ref132 ref133">(3, 132, 133)</a></div><div class="NLM_p">In addition to treating patients with BRCA mutations, the AstraZeneca group has established an aggressive clinical program to use <b>82</b> as a chemopotentiator. AstraZeneca either has recently finished or is currently testing <b>82</b> in multiple phase I trials to assess its safety profile when dosed orally with various anticancer agents such as doxorubicin (NCT00819221), carboplatin (NCT00516724), gemcitabine (NCT00678132), dacarbazine (NCT00516802), topotecan (NCT00516438), and irinotecan (NCT00535353).</div><div class="NLM_p last">The KuDOS/AstraZeneca medicinal chemistry group recently published a new series of 2-benzyloxybenzamides (<b>47</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a>) as a novel PARP-1 inhibitor scaffold.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> The intramolecular hydrogen bond formed between the benzyloxy group and the primary amide forms a âpseudocycleâ similar to benzimidazole carboxamides, locking the amide in the desired conformation for PARP-1 inhibition. Using knowledge accumulated from optimization of the phthalazinones, KuDOS conducted many of the same steps to arrive at their next lead compound. Compound <b>83</b> (IC<sub>50</sub> = 5 nM)<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> bears many of the same moieties as <b>81</b>, with a notable exception of the phenoxyalkyl group (green, Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a>). This group, however, was necessary to enhance the cellular potentiation factor (PF<sub>50</sub> = 3.7) over other alkyl groups (i.e., cyclopropyl) that were successful in the phthalazinone series. Despite the relatively low potentiation factors for this series, the inherent PARP-1 inhibitory potency is promising and bodes well for the next generation of KuDOS compounds.</div></div><div id="sec6_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Cephalon: CEP-9722 (<b>86</b>)</h3><div class="NLM_p">The first patent publications from Cephalon appeared in 2001. Similar to some of the earlier medicinal chemistry programs at the time (KuDOS/Maybridge, Fujisawa), this group conducted a high throughput screen to discover a structurally unique PARP-1 inhibitor core. The series of pyrrolocarbazole lactams (<b>39</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a>) incorporates an arylamide core but one that is heavily substituted, a characteristic not seen among many of the first prototypic PARP-1 inhibitors. Compound <b>39</b> was very potent (IC<sub>50</sub> = 36 nM, <i>K</i><sub>i</sub> = 5 nM) and much of the analoging actually diminished the enzymatic activity. Consequently, the size of the fused cyclopentane ring was critical for potency as the cyclohexyl, phenyl, and furyl groups caused a loss of inhibitory potency (pink, Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a>).<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> The proposed binding mode for this series included the standard conserved web of H-bonds from Ser904 and Gly863 with the lactam (light-blue, Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a>). In addition, the indole NâH formed an H-bond with Glu988 (light-orange, Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a>). Further optimization of this core was performed by addition of an aminomethyl group (light green) to the 3-position of the indole (<b>84</b>, CEP-6800, Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a>).<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> This substituent significantly improved the cellular potency in a PC12 cellular assay<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> as well as improved the aqueous solubility (0.1 mg/mL) of an otherwise insoluble core.</div><figure id="fig20" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0018.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Discovery of CEP-9722.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>84</b> was tested extensively in vitro displaying a robust ability to potentiate TMZ, irinotecan, and cisplatin against U251MG glioblastoma, HT29 colon carcinoma, and Calu-6 small cell lung carcinoma cell lines, respectively.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> The preclinical lead increased the amount and duration of DNA damage caused by these agents, further supporting the importance of PARP-1 in the DNA repair of these cell lines. This lead compound also performed well in vivo in xenograft models. The best results obtained were achieved by a combination of <b>84</b> (30 mg/kg sc, q.d., 5 days) and TMZ (34 mg/kg po, q.d., 5 days), displaying a 100% complete regression against U251MG tumors by day 28 versus 60% regression with TMZ alone. Despite the impressive package of preclinical data for this compound, <b>84</b> never made it to human clinical trials because of its myelotoxic effects.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a></div><div class="NLM_p last">Cephalon further optimized this series to produce <b>85</b>, a 20 nM PARP-1 inhibitor from the same series (Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a>).<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> The notable difference between <b>84</b> and <b>85</b> is the lack of solubilizing group, indicating the diminished aqueous solubility of <b>85</b>. Despite this fact, <b>85</b> was just as effective at sensitizing tumor cell lines (RG2, RH18, HT29, and NB1691) in vitro in combination with TMZ and camtothecin.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> More importantly, <b>85</b> did not display any myelosuppresive effects alone nor did this compound exacerbate the myelosuppression of TMZ and camptothecin in a human bone marrow cell assay. The limiting factor for this PARP-1 inhibitor was its aqueous solubility. Many of the first and second generation PARP-1 inhibitors suffered from a lack of solubility, as would be expected from compounds with extended, fused aryl ring systems. Despite this problem, Cephalon was the first group to successfully derivatize a PARP-1 inhibitor core to a soluble prodrug (<b>86</b>), the eventual clinical candidate and a prodrug of <b>85</b>. While the structure of this compound has not been disclosed, one can intuit from Cephalonâs latest patent filing that either the amide or the indole was modified with a methyldialkylamino group (Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a>, P = CH<sub>2</sub>NR<sub>2</sub>).<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> A compound of this nature could form an amine salt, solving the aqueous solubility issue, while at the same time, it would be labile enough to chemical hydrolysis upon dosing/dissolution. Compound <b>86</b> demonstrated significant tumor growth inhibition in vivo when dosed sc (136 mg/kg/dose, q.d.) with TMZ (68 mg/kg/dose, po, q.d.) versus TMZ alone.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> Unexpectedly however, <b>86</b> also showed some stand-alone efficacy against RG2 and HT29 tumors without TMZ. Cephalon hypothesized that <b>86</b> may interact with an angiogenesis pathway, accounting for the stand-alone efficacy. This antiangiogenesis effect has been noted with several other PARP-1 inhibitors including <b>66</b> and <b>77</b>.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> While the molecular mechanism by which PARP-1 inhibitors are affecting angiogenesis is unclear, PARP-1 activity has the ability to modulate the expression of genes that are involved in angiogenesis, particularly hypoxia inducible factor-Î± (HIF-Î±).<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> It is generally accepted that the PARP-1 pathway must be intact in order to have proper angiogenic network development. Regardless of the mechanism of action, Cephalon initiated a phase I clinical trial with <b>86</b> in May 2009 to evaluate the safety, pharmacokinetics, and pharmacodynamics as single-agent therapy and as combination therapy with TMZ in patients with advanced solid tumors (NCT00920595).</div></div><div id="sec6_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Yamanouchi/Fujisawa/Astellas</h3><div class="NLM_p">Since the early 2000s, the Fujisawa group has pursued the neuroprotective effects of PARP-1 inhibitors. Similar to Guilford, the focus of their medicinal chemistry optimization efforts was brain penetration. Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a> outlines the evolution of Fujisawaâs PARP-1 inhibitors starting with the chloroquinazolinone <b>87</b>, an HTS hit from their corporate library.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> This quinazolinone core, however, did not possess acceptable PARP-1 potency or brain/plasma ratio (IC<sub>50</sub> = 1.2 Î¼M, <i>B</i>/<i>P</i> = 0.82). Optimization of this series of quinazolinones was carried out by substitution at the 2-position to build in the desired pharmacological characteristics. Optimization efforts led to compound <b>88</b> with 65 nM potency and a <i>B</i>/<i>P</i> ratio of 5.8 by using the 4-phenyl-1,2,3,6-tetrahydropyridine moiety as a lipophilic tail. As it turned out, this lipophilic amine not only provided adequate brain permeability in rodents when ligated to other PARP cores<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> but also had unique binding properties in the adenosineâribose binding site similar to compound <b>53</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>C). The nitrogen atom in the tetrahydropyridine moiety forms a hydrogen bond to the carboxylate side chain of Asp766 within the AD site.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> Further optimizations such as fluorination of the side chain aryl ring and moving of the chlorine atom led to an orally available, brain penetrable lead PARP-1 inhibitor (<b>89</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a>). The side chain was further optimized to conformationally restrict the side chain and to improve the inhibitory potency while maintaining the <i>B</i>/<i>P</i> ratio (<b>90</b>, IC<sub>50</sub> = 8.7 nM, <i>B</i>/<i>P</i> â 2â3).<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a></div><figure id="fig21" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0019.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Lead PARP-1 inhibitors discovered by Fujisawa.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The Fujisawa group has also dedicated some medicinal chemistry efforts to the selective inhibition of PARP-2.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> As mentioned above, PARP-2 is the only other member of the PARP family with a DNA binding domain. The PARP-2 catalytic domain also has a high degree of homology with PARP-1. This fact implies that finding selective inhibitors for PARP-1 and PARP-2 is quite challenging. In fact, this group was the first to discover both selective PARP-1 and PARP-2 inhibtors with nanomolar potency and brain penetration as shown in Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a>. Compound <b>89</b> from their quinazolinone series displayed a 39-fold selectivity over PARP-2 due mainly to the side chain interaction within the adenosine binding site of PARP-2 (i.e., Leu769 in PARP-1 is replaced with Gly314 in PARP-2). Consequently, compound <b>91</b> from the quinoxaline series displayed â¼10-fold selectivity for PARP-2 over PARP-1.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> While this selectivity is modest, further optimization of these series will certainly be useful in determining the relevance of PARP-2 in various disease states.</div><figure id="fig22" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0020.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. PARP-1 and PARP-2 selective inhibitors by Fujisawa.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In 2005, Astellas Pharmaceuticals was formed by the union of Fujisawa and Yamanouchi Pharmaceuticals. This merger combined two companies with mature PARP-1 programs. Despite having several brain penetrable leads, Astellas has made no indication that they are developing a PARP-1 inhibitor nor does Astellas have any composition of matter patents or publications since 2007 on the subject.</div></div><div id="sec6_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Kyorin: KCL-440 (<b>93</b>)</h3><div class="NLM_p">In the early 2000s the Kyorin group designed a series of isoquinolinone based PARP-1 inhibitors for the potential treatment of cerebral ischemia. The lead compound from this series was optimized from a screening hit <b>92</b> (IC<sub>50</sub> = 890 nM) that was 10 times more potent than the isoquinolinone core. Similar to the Guilford and Fujisawa programs, optimization paradigms emphasized brain penetration and increased solubility of the core with a tertiary amine (light-blue, Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a>). Preclinical candidate <b>93</b> evolved from this series with an IC<sub>50</sub> value of 68 nM (<i>K</i><sub>i</sub> = 9.8 nM) against PARP-1 and an EC<sub>50</sub> of 73 nM in the peroxide induced cytotoxicity assay in cortical cultures.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> In rats, <b>93</b> displayed a brain/plasma ratio of 0.8 after a 6 h infusion of 10 (mg/kg)/h, an acceptable level to utilize in vivo. The Kyorin group designed their animal studies to replicate a realistic clinical scenario, paying particular attention to PARP activation over the course of the ischemic event. With this information the Kyorin group was able to obtain a therapeutic window for their lead candidate. In rats, the peak cerebral PARP activity was determined to be 6 h after the ischemic event, tapering off to control levels after 24 h as determined by immunostaining. In a transient MCAO model, <b>93</b> demonstrated protective effects similar to many of the lead candidates from other programs at the time (57% reduction at 3 (mg/kg)/h) when dosed preischemia. Reduction in infarct volume was also observed when <b>93</b> was dosed 2 h (50%) and 4 h (47%) after the ischemic event but not at 6 h.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> In a photothrombotic MCA model of stroke, a more stringent model, <b>93</b> showed a significant decrease (â¼10â15%) in infarct volume when dosed 1 h after the ischemic event at several dose levels (0.1â3 (mg/kg)/h) but failed to show efficacy when dosed 2 or 3 h after the occlusion.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> Despite having a brain penetrable preclinical lead showing efficacy in many relevant preclinical models, the Kyorin group never progressed into the clinic with their PARP program.</div><figure id="fig23" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0021.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Design of Kyorinâs preclinical candidate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec6_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Mitsubishi: MP-124 (<b>96</b>)</h3><div class="NLM_p">Along with Kyorin and Fujisawa, the Mitsubishi groupâs first PARP-1 patent applications appeared in the early mid-2000s. All of this groupâs medicinal chemistry focused on derivatives of isoquinolinones (Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a>). The hydrophobic substituents such as the pyrollidino alcohol in <b>94</b><a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> improved the enzymatic potency of the core by over 2 orders of magnitude (IC<sub>50</sub> = 29 nM). This group also discovered a series of pyrazoloisoquinolinones (<b>43</b>, X = N, Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a>) such as lead compound <b>95</b> (IC<sub>50</sub> = 25 nM).<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> After 7+ years of PARP-1 related research, Mitsubishi has one clinical candidate PARP-1 inhibitor (<b>96</b>, structure undisclosed) for cerebral ischemia. This compound has demonstrated efficacy in a primate model of MCAO (22â64% reduction in infarct volume when dosed iv at 0.3, 1, and 3 (mg/kg)/h). In addition, the primate study indicated that there is a significant therapeutic time window, as <b>96</b> displayed this reduction in infarct volume when dosed at 3 h and 6 h after the permanent occlusion. The lead PARP inhibitor also significantly improved many of the neurological deficits resulting from the ischemic event.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> The companyâs pipeline indicates that <b>96</b> is in phase I clinical development, but no trials have been registered within the U.S. Should this phase I trial commence, Mitsubishi would be the only pharmaceutical company with a PARP-1 inhibitor in the clinic for ischemic injury and would be the first to initiate a stroke clinical trial with a PARP inhibitor.</div><figure id="fig24" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0022.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Lead PARP inhibitors designed by Mitsubishi.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec6_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Merck: MK-4827 (<b>101</b>)</h3><div class="NLM_p">The first PARP patents and publications from Merck appeared in 2009. This group identified several novel series of PARP-1 inhibitors including the pyrrolodihydroisoquinolinones (<b>49</b>),<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> the pyrazoloquinazolinones (<b>30</b>),<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> and a series of indazole carboxamides (<b>23</b>) from which their clinical candidate (<b>101</b>) was derived.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> This clinical candidate evolved from a series of heterocyclic benzamides related to benzimidazole carboxamides (Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a>). An initial optimization paradigm selected the subseries with the best pharmacokinetics and enzymatic and cellular potency. Merck designed four closely related subseries from which to select: the triazolobenzimidazoles such as <b>97</b> (IC<sub>50</sub> = 71 nM), the imidazo- and triazolopyridine carboxamides <b>98</b> (IC<sub>50</sub> = 55 nM) and <b>99</b> (IC<sub>50</sub> = 270 nM), and the indazole carboxamides <b>100</b> (IC<sub>50</sub> = 24 nM).<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> Core compound <b>98</b> demonstrated better potency than any of the other series tested as well as cellular potency showing the ability to inhibit PAR polymers after induction of DNA damage by peroxide in HeLa cells (EC<sub>50</sub> = 3.7 Î¼M). In addition, <b>98</b> demonstrated moderate stability in rat and human microsomes and acceptable oral BA (41%) and terminal half-life (5.1 h) in rats. Optimization of the indazole core was accomplished by incorporating a solubilizing group on the para position of the aryl ring leading to general improvements in enzymatic and cellular potency. As part of Merckâs screening paradigm, cellular potency was evaluated in BRCA1 silenced HeLa cells for their ability to inhibit cell growth by 50% (CC<sub>50</sub>) versus BRCA1 wild type HeLa cells. The (<i>S</i>)-piperidine moiety of <b>101</b> afforded â¼28-fold selectivity against BRCA1 silenced cells (CC<sub>50</sub> = 33 nM) versus wild type (CC<sub>50</sub> = 860 nM) over the (<i>R</i>)-enantiomer (â¼11-fold). The PK profile of <b>101</b> was acceptable with a high volume of distribution (Vdss = 6.9 L/kg), long terminal half-life (<i>t</i><sub>1/2</sub> = 3.4 h), and excellent oral BA (65%) in rats. In vivo, <b>101</b> demonstrated tumor regression in a BRCA-1 mutant MDA-MB-436 xenograft model orally at 100 mg/kg q.d. or 50 mg/kg b.i.d. with no overt weight loss or signs of toxicity. Merck started a phase I study with oral <b>101</b> in 2008 to test the tolerability and PARP inhibitory activity in patients with advanced solid tumors (NCT00749502).</div><figure id="fig25" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0024.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Discovery Merckâs clinical candidate PARP inhibitor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec6_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Other PARP-1 Inhibitor Programs</h3><div class="NLM_p">Several other groups have contributed to the field of PARP-1 medicinal chemistry, and some of their lead structures are outlined in Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a>. In 2002, Novartis introduced indoloquinazolinone (<b>102</b>, IC<sub>50</sub> = 12 nM), a compound with efficacy in a rabbit stroke model (60% reduction in infarct volume when dosed iv prereperfusion).<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Ono Pharmaceuticals characterized a preclinical lead, ONO-1924H (<b>103</b>), a moderately potent PARP-1 inhibitor (IC<sub>50</sub> = 210 nM) that demonstrated neuroprotective effects by significantly reducing cerebral damage when dosed postocclusion at 10 and 30 (mg/kg)/h.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> Mochida introduced a series of tricyclic quinazolinones, one example of which is compound <b>104</b> with PARP-1 cocrystal data but little in vitro or in vivo data.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> The Icos/Deltagen group recently published a series of pyrazolopyridinones such as compound <b>105</b> (IC<sub>50</sub> = 7.3 nM) which displayed some submicromolar activity in a cell based chemosensitization assay.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> Jannsen has recently filed several patents based on ethylquinolinones (<b>44</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>). This series is a dramatic shift from the typical arylamide core. One such lead compound is derivative <b>106</b> (pIC<sub>50</sub> = 8.036, Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a>), presumably deriving much of its inhibitory effects from the side chain interactions rather than the ethylquinolinone core.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> The Bayer group discovered a series of saturated quinazoline diones from which the lead compound <b>107</b> (IC<sub>50</sub> = 20 nM) was derived.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Johnson & Johnson recently published a series of 2-substituted quinazolinones with elaborate side chains, the most potent of which was piperazine <b>108</b> (pIC<sub>50</sub> = 8.003, Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a>).<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a></div><figure id="fig26" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0023.jpeg" id="gr26" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. Lead structures from other PARP-1 inhibitor programs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec6_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Current Clinical Progress of PARP-1 Inhibitors and Future Directions</h3><div class="NLM_p">Of the â¼15 current PARP-1 medicinal chemistry programs (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>), most are focusing on optimization and development of PARP-1 inhibitors as anticancer agents. The slight decline in PARP-1 medicinal chemistry programs over the past few years can be explained by both corporate mergers (e.g., Astellas/Yamanouchi/Fujisawa and BiPar/Sanofi) and a waning interest in pursuing PARP-1 for ischemic injury or inflammation. Perhaps the most compelling reason that PARP inhibitors have not been pursued for inflammation is the potential long-term consequences of accumulation of double-strand DNA breaks in normal tissues of patients receiving chronic PARP-1 inhibitor therapy.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> For the most part, PARP inhibitors have not been tested clinically for ischemia either, despite several promising preclinical lead compounds. The only group to test a PARP-1 inhibitor in humans for ischemic injury was Inotek for cardiac ischemia. However, they are no longer actively pursuing this indication. This is a testament to the difficulty of this clinical path. There are several challenges associated with development of an ischemia drug: (1) Preclinical animal models often provide a snapshot of ischemic benefit by tissue staining after animal sacrifice. These results may not accurately represent the final extent of the ischemic damage but just a slowing of the damage. (2) Despite the improvement in identification and modulation of clinical biomarkers, the translation into clinical benefit (i.e., reduced mortality or improved function) is lacking. (3) Imaging technology is still not sensitive enough to measure the extent of cell death and smaller infarcts in patients. (4) The patient study population is already in a high risk category for adverse events, increasing the likelihood for drug side effects. (5) Identification of suitable patients that are most likely to benefit from such therapy is difficult. (6) Demonstrating the benefit of a new class of therapeutics requires large sample sizes, as noted with prior clinical attempts at ischemia treatment.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> These large sample sizes necessitate an enormous financial commitment and subsequently a lack of sponsors for late stage trials. The challenge associated with clinical design and outcome measurements make stroke and cardiac ischemia difficult pharmaceutical targets and account for the paucity of therapeutics available for such a debilitating conditions.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> This high risk clinical path played a major role in guiding the decision making and clinical indications for many PARP-1 inhibitors that were initially designed for ischemia. Of the several groups with initial interest in ischemia treatment many have either changed therapeutic focus (i.e., Inotek, Guilford) or failed to advance a clinical candidate (i.e., Ono, Kyorin, Astellas, Novartis). Perhaps the last hope for PARP-1 inhibitors to treat ischemia is the Mitsubishi group who seems determined to proceed with a PARP inhibitor in cerebral ischemia. Should the Mitsubishi group succeed in their endeavor, it is likely that many of the PARP-1 inhibitors already in the clinic (or potentially approved) would shortly follow.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Current Clinical Status of PARP-1 Inhibitors<a class="ref internalNav" href="#tbl1-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">company</th><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">IND</th><th class="colsep0 rowsep0" align="center">phase I</th><th class="colsep0 rowsep0" align="center">phase II</th><th class="colsep0 rowsep0" align="center">phase III</th><th class="colsep0 rowsep0" align="center">therapeutic indications</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BiPar/Sanofi</td><td class="colsep0 rowsep0" align="left">BSI-201</td><td class="colsep0 rowsep0" align="left">â</td><td class="colsep0 rowsep0" align="left">â</td><td class="colsep0 rowsep0" align="left">â</td><td class="colsep0 rowsep0" align="left">â</td><td class="colsep0 rowsep0" align="left">triple negative breast cancer</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">KuDOS/AstraZeneca</td><td class="colsep0 rowsep0" align="left">KU 59436 (AZD8821, olaparib)</td><td class="colsep0 rowsep0" align="left">â</td><td class="colsep0 rowsep0" align="left">â</td><td class="colsep0 rowsep0" align="left">â</td><td class="colsep0 rowsep0" align="left">â</td><td class="colsep0 rowsep0" align="left">metastatic breast cancer, advanced ovarian cancer</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Abbott</td><td class="colsep0 rowsep0" align="left">ABT-888</td><td class="colsep0 rowsep0" align="left">â</td><td class="colsep0 rowsep0" align="left">â</td><td class="colsep0 rowsep0" align="left">â</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">metastatic breast cancer, metastatic melanoma, brain cancer</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Pfizer</td><td class="colsep0 rowsep0" align="left">AG 14699 (PF-01367338)</td><td class="colsep0 rowsep0" align="left">â</td><td class="colsep0 rowsep0" align="left">â</td><td class="colsep0 rowsep0" align="left">â</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">metastatic breast cancer, advanced ovarian cancer</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Inotek</td><td class="colsep0 rowsep0" align="left">INO-1001</td><td class="colsep0 rowsep0" align="left">â</td><td class="colsep0 rowsep0" align="left">â</td><td class="colsep0 rowsep0" align="left">â</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">malignant melanoma, heart/lung bypass surgery</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cephalon</td><td class="colsep0 rowsep0" align="left">CEP-9722</td><td class="colsep0 rowsep0" align="left">â</td><td class="colsep0 rowsep0" align="left">â</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">advanced solid tumors</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Merck</td><td class="colsep0 rowsep0" align="left">MK-4827</td><td class="colsep0 rowsep0" align="left">â</td><td class="colsep0 rowsep0" align="left">â</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">advanced solid tumors</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Mitsubishi</td><td class="colsep0 rowsep0" align="left">MP-124</td><td class="colsep0 rowsep0" align="left">â</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">cerebral ischemia</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Guilford/MGI/Eisai</td><td class="colsep0 rowsep0" align="left">GPI 21016 (E7016)</td><td class="colsep0 rowsep0" align="left">â</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">glioblastoma</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl1-fn1"><div class="footnote" id="tbl1-fn1"><sup>a</sup><p class="last">The asterisk (â) indicates participation in the indicated stage.</p></div></div></div><div class="NLM_p">Currently, six groups have PARP-1 inhibitors in human clinical trials with two more on the verge of phase I studies (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>).<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> The most advanced of these programs are BiPar and KuDOS/Astrazeneca, both entering into phase III studies. Shortly following these groups will be Abbott and Pfizer with PARP-1 inhibitors in late phase II trials. Consequently, all of the current PARP-1 inhibitors are being tested as anticancer agents or chemopotentiators. In addition, the discovery that PARP-1 inhibitors have potential as single agents for tumors with compromised DNA repair machinery has provided a viable and exciting therapeutic course for patients with TNBC and BRCA carriers. This finding is especially important because effective therapy for TNBC patients is of paramount importance to the field.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a></div><div class="NLM_p last">As cancer treatment moves into the future, clinicians and oncologists are becoming more aware of the genetic components of each patient and specific tumor type. Successes such as Imatinib (BCR-Abl) are a testament to understanding the genetic component of cancer and applying it to the future of cancer chemotherapy.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> With more specific knowledge of the cancer genotypes, the doctors will be able to treat each patient accordingly. In the future, PARP-1 inhibitors may become the standard of care for patients who have identified tumor types deficient in DNA repair. Synthetic lethality would indicate that PARP-1 inhibitors will show efficacy against many tumors cell types with compromised DNA repair mechanisms, not just BRCA-1 and BRCA-2. While BRCA-1 and BRCA-2 are oncogenes most commonly associated with breast cancer, other tumor types have been described as displaying âBRCAnessâ as well.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Current research has identified the tumor suppressor gene PTEN (phosphatase and tensin homologue) as one of the most commonly mutated genes in cancer.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> PTEN deficiency causes HR defects in human tumor cell lines leading to sensitivity toward PARP inhibitors. Findings such as this could dramatically expand the therapeutic utility of PARP-1 inhibitors and provide a more selective therapy for this debilitating disease.</div></div></div><div class="NLM_back"><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38136" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38136" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dana V. Ferraris</span> - <span class="hlFld-Affiliation affiliation">Johns Hopkins University Brain Science Institute, 855 N. Wolfe Street, Baltimore, Maryland 21205</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#c480a2a1b6b6a5b6f684aeaca9adeaa1a0b1"><span class="__cf_email__" data-cfemail="541032312626352666143e3c393d7a313021">[emailÂ protected]</span></a></span></div></li></ul></li><li><ul></ul></li><li></li><li></li><li></li></ul></div><div class="testing" data-doi="10.1021/jm100012m" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="bio"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Biography</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67667" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67667" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="" data-index="" class="article__inlineFigure"><h2 class="fig-label"></h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id="><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Dana V. Ferraris</b> received his Ph.D. degree in Chemistry from Johns Hopkins University in 1999 and his M.B.A. from Carey Business School in 2009. Over the past 10 years, Dr. Ferraris has held a variety of leadership positions in the pharmaceutical industry at Guilford Pharmaceuticals, MGI Pharma, and Eisai Research Institute. Dr. Ferraris has extensive drug discovery experience in oncology and CNS disorders. His research efforts have resulted in two investigational drugs currently in development for the treatment of cancer. Dr. Ferraris joined Johns Hopkins University as a Principal Scientist in 2009. He oversees medicinal chemistry activities at the Brain Science Instituteâs NeuroTranslational program with a primary mission of translating discoveries in basic science into novel therapeutics.</p></figure></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81001" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81001" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 155 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Jeggo, P. A.</span><span> </span><span class="NLM_article-title">DNA repair: PARPâanother guardian angel?</span> <span class="citation_source-journal">Curr. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">R49</span><span class="NLM_x">â</span> <span class="NLM_lpage">R51</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1998&pages=R49-R51&author=P.+A.+Jeggo&title=DNA+repair%3A+PARP%E2%80%94another+guardian+angel%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJeggo%26aufirst%3DP.%2BA.%26atitle%3DDNA%2520repair%253A%2520PARP%25E2%2580%2594another%2520guardian%2520angel%253F%26jtitle%3DCurr.%2520Biol.%26date%3D1998%26volume%3D8%26spage%3DR49%26epage%3DR51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Virag, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabo, C.</span><span> </span><span class="NLM_article-title">The therapeutic potential of poly(ADP-ribose) polymerase inhibitors</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">375</span><span class="NLM_x">â</span> <span class="NLM_lpage">429</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2002&pages=375-429&author=L.+Viragauthor=C.+Szabo&title=The+therapeutic+potential+of+poly%28ADP-ribose%29+polymerase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVirag%26aufirst%3DL.%26aulast%3DSzabo%26aufirst%3DC.%26atitle%3DThe%2520therapeutic%2520potential%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitors%26jtitle%3DPharmacol.%2520Rev.%26date%3D2002%26volume%3D54%26spage%3D375%26epage%3D429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Winslow, R.</span><span> </span><span class="NLM_article-title">New class of drugs in early trials offers hope for breast cancer</span>.  <span class="citation_source-journal">Wall Street J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span><span class="NLM_issue">June 1</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&issue=June+1&author=R.+Winslow&title=New+class+of+drugs+in+early+trials+offers+hope+for+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWinslow%26aufirst%3DR.%26atitle%3DNew%2520class%2520of%2520drugs%2520in%2520early%2520trials%2520offers%2520hope%2520for%2520breast%2520cancer%26jtitle%3DWall%2520Street%2520J.%26date%3D2009%26issue%3DJune%25201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Hassa, P. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hottiger, M. O.</span><span> </span><span class="NLM_article-title">The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases</span> <span class="citation_source-journal">Front. Biosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">3046</span><span class="NLM_x">â</span> <span class="NLM_lpage">3082</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.2741%2F2909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=17981777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhs1Cntrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=3046-3082&author=P.+O.+Hassaauthor=M.+O.+Hottiger&title=The+diverse+biological+roles+of+mammalian+PARPS%2C+a+small+but+powerful+family+of+poly-ADP-ribose+polymerases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The diverse biological roles of mammalian PARPs, a small but powerful family of poly-ADP-ribose polymerases</span></div><div class="casAuthors">Hassa, Paul O.; Hottiger, Michael O.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Bioscience</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3046-3082</span>CODEN:
                <span class="NLM_cas:coden">FRBIF6</span>;
        ISSN:<span class="NLM_cas:issn">1093-4715</span>.
    
            (<span class="NLM_cas:orgname">Frontiers in Bioscience</span>)
        </div><div class="casAbstract">A review.  Poly-ADP-ribose metab. plays a mayor role in a wide range of biol. processes, such as maintenance of genomic stability, transcriptional regulation, energy metab., and cell death.  Poly-ADP-ribose polymerases (PARPs) are an ancient family of enzymes, as evidenced by the poly-ADP-ribosylating activities reported in dinoflagellates and archaebacteria and by the identification of Parp-like genes in eubacterial and archaeabacterial genomes.  Six genes encoding "bona fide" PARP enzymes have been identified in mammalians: PARP1, PARP2, PARP3, PARP4/vPARP, PARP5/Tankyrases-1, and PARP6/Tankyrases-2.  The best studied of these enzymes, PARP1, plays a primary role in the process of poly-ADP-ribosylation.  PARP1-mediated poly-ADP-ribosylation has been implicated in the pathogenesis of cancer, inflammatory, and neurodegenerative disorders.  Here, the authors summarize novel findings and concepts for PARP enzymes and their poly-ADP-ribosylation activity in the regulation of physiol. and pathophysiol. processes.  A special focus is placed on the proposed mol. mechanisms involved in these processes, such as signaling, regulation of telomere dynamics, remodeling of chromatin structure, and transcriptional regulation.  A potential functional cross-talk between PARP family members and other NAD-consuming enzymes is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoNyzgIk1gtrVg90H21EOLACvtfcHk0lhr6doV9q3EJA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhs1Cntrk%253D&md5=1e62c4597ec219b0797a29c1458b98b4</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.2741%2F2909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2741%252F2909%26sid%3Dliteratum%253Aachs%26aulast%3DHassa%26aufirst%3DP.%2BO.%26aulast%3DHottiger%26aufirst%3DM.%2BO.%26atitle%3DThe%2520diverse%2520biological%2520roles%2520of%2520mammalian%2520PARPS%252C%2520a%2520small%2520but%2520powerful%2520family%2520of%2520poly-ADP-ribose%2520polymerases%26jtitle%3DFront.%2520Biosci.%26date%3D2008%26volume%3D13%26spage%3D3046%26epage%3D3082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Miwa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masutani, M.</span><span> </span><span class="NLM_article-title">Poly(ADP-ribosyl)ation and cancer</span> <span class="citation_source-journal">Cancer Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">1528</span><span class="NLM_x">â</span> <span class="NLM_lpage">1535</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1111%2Fj.1349-7006.2007.00567.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=17645773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtF2qtb7L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2007&pages=1528-1535&author=M.+Miwaauthor=M.+Masutani&title=Poly%28ADP-ribosyl%29ation+and+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">PolyADP-ribosylation and cancer</span></div><div class="casAuthors">Miwa, Masanao; Masutani, Mitsuko</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1528-1535</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1347-9032</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Asia Pty Ltd.</span>)
        </div><div class="casAbstract">A review.  The polyADP-ribosylation reaction results in a unique posttranslational modification involved in various cellular processes and conditions, including DNA repair, transcriptional control, genomic stability, cell death and transformation.  The existence of 17 members of the poly(ADP-ribose) polymerase (PARP) family has so far been documented, with overlapping functional consequences.  PARP-1 is known to be involved in DNA base excision repair and this explains the susceptibility spectrum of PARP-1 knockout animals to genotoxic carcinogens.  The fact that centrosome amplification is induced by a non-genotoxic inhibitor of PARP and in PARP-1 knockout mouse cells, is in line with aneuploidy, which is frequent in cancers.  Genetically engineered animal models have revealed that PARP-1 and VPARP impact carcinogenesis.  Furthermore, accumulating exptl. evidence supports the utility of PARP and PARG inhibitors in cancer therapy and several clin. trials are now ongoing.  Increasing NAD+ levels by pharmacol. supplementation with niacin was also found to exert preventive effects against cancer.  In the present review, recent research progress on polyADP-ribosylation related to neoplasia is summarized and discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqohmHOW4JQ47Vg90H21EOLACvtfcHk0lhr6doV9q3EJA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtF2qtb7L&md5=ba468fe6fdae25fc6f41a9f1aea06b5f</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2007.00567.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2007.00567.x%26sid%3Dliteratum%253Aachs%26aulast%3DMiwa%26aufirst%3DM.%26aulast%3DMasutani%26aufirst%3DM.%26atitle%3DPoly%2528ADP-ribosyl%2529ation%2520and%2520cancer%26jtitle%3DCancer%2520Sci.%26date%3D2007%26volume%3D98%26spage%3D1528%26epage%3D1535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Schreiber, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dantzer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ame, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Murcia, G.</span><span> </span><span class="NLM_article-title">Poly(ADP-ribose): novel functions for an old molecule</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">517</span><span class="NLM_x">â</span> <span class="NLM_lpage">528</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1038%2Fnrm1963" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=16829982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD28Xms1Ohsb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=517-528&author=V.+Schreiberauthor=F.+Dantzerauthor=J.+C.+Ameauthor=G.+de+Murcia&title=Poly%28ADP-ribose%29%3A+novel+functions+for+an+old+molecule"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Poly(ADP-ribose): novel functions for an old molecule</span></div><div class="casAuthors">Schreiber, Valerie; Dantzer, Francoise; Ame, Jean-Christophe; de Murcia, Gilbert</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">517-528</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The addn. to proteins of the neg. charged polymer of ADP-ribose, which is synthesized by poly(ADP-ribose) polymerase (PARPs) from NAD, is a unique post-translational modification.  It regulates not only cell survival and cell-death programs, but also an increasing no. of other biol. functions with which novel members of the PARP family have been assocd.  These functions include transcriptional regulation, telomere cohesion and mitotic spindle formation during cell division, intracellular trafficking, and energy metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLsI4_BKfjdrVg90H21EOLACvtfcHk0liDkiHE2Hj9ww"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xms1Ohsb4%253D&md5=676e83755491500f3bf2137f348dfa1b</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrm1963&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm1963%26sid%3Dliteratum%253Aachs%26aulast%3DSchreiber%26aufirst%3DV.%26aulast%3DDantzer%26aufirst%3DF.%26aulast%3DAme%26aufirst%3DJ.%2BC.%26aulast%3Dde%2BMurcia%26aufirst%3DG.%26atitle%3DPoly%2528ADP-ribose%2529%253A%2520novel%2520functions%2520for%2520an%2520old%2520molecule%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2006%26volume%3D7%26spage%3D517%26epage%3D528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Jagtap, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabo, C.</span><span> </span><span class="NLM_article-title">Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">421</span><span class="NLM_x">â</span> <span class="NLM_lpage">440</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1038%2Fnrd1718" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=15864271" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjs1OktL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=421-440&author=P.+Jagtapauthor=C.+Szabo&title=Poly%28ADP-ribose%29+polymerase+and+the+therapeutic+effects+of+its+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors</span></div><div class="casAuthors">Jagtap, Prakash; Szabo, Csaba</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">421-440</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Poly(ADP-ribose) polymerases (PARPs) are involved in the regulation of many cellular functions.  Three consequences of the activation of PARP1, which is the main isoform of the PARP family, are particularly important for drug development: first, its role in DNA repair; second, its capacity to deplete cellular energetic pools, which culminates in cell dysfunction and necrosis; and third, its capacity to promote the transcription of pro-inflammatory genes.  Consequently, pharmacol. inhibitors of PARP have the potential to enhance the cytotoxicity of certain DNA-damaging anticancer drugs, reduce parenchymal cell necrosis (for example, in stroke or myocardial infarction) and downregulate multiple simultaneous pathways of inflammation and tissue injury (for example, in circulatory shock, colitis or diabetic complications).  The first ultrapotent novel PARP inhibitors have now entered human clin. trials.  This article presents an overview of the principal pathophysiol. pathways and mechanisms that are governed by PARP, followed by the main structures and therapeutic actions of various classes of novel PARP inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDsrfd_xv8g7Vg90H21EOLACvtfcHk0liDkiHE2Hj9ww"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjs1OktL8%253D&md5=1dfd177b8064b017efb5dd7779655d55</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrd1718&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1718%26sid%3Dliteratum%253Aachs%26aulast%3DJagtap%26aufirst%3DP.%26aulast%3DSzabo%26aufirst%3DC.%26atitle%3DPoly%2528ADP-ribose%2529%2520polymerase%2520and%2520the%2520therapeutic%2520effects%2520of%2520its%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2005%26volume%3D4%26spage%3D421%26epage%3D440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Ljungman, M.</span><span> </span><span class="NLM_article-title">Targeting the DNA damage response in cancer</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">2929</span><span class="NLM_x">â</span> <span class="NLM_lpage">2950</span></span><div class="citationLinks">[<a href="/doi/10.1021/cr900047g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnsFemtrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2009&pages=2929-2950&author=M.+Ljungman&title=Targeting+the+DNA+damage+response+in+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the DNA Damage Response in Cancer</span></div><div class="casAuthors">Ljungman, Mats</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2929-2950</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  We are in an exciting phase in cancer research with a rapid pace of discovery driven by new technologies.  Recent studies have shed light on the complexity of tumor biol., showing that tumors rarely have similar sets of mutations in common.  However, when placing the various tumor mutations into functional pathways, a more manageable picture emerges with about 12 core pathways abrogated in the majority of the tumors.  Thus, it may be possible after identifying the pathway(s) altered in a particular tumor to tailor therapies to specifically block that pathway(s).  The DNA damage response is one of these core pathways found to be frequently dysregulated in cancer.  Proteins participating in this pathway are expected to be important therapeutic targets for the sensitization of tumor cells to radiation or chemotherapy.  The targeting of the DNA damage response in cancer stem cells may be of particular importance, since these cells are often found to be more resistant to radiation and chemotherapy than other tumor cells.  The fact that many tumors have defects in DNA repair pathways and/or cell cycle checkpoints presents unique opportunities for therapeutic exploitation.  Likewise, oncogene-driven induction of "DNA damage" sets tumor cells apart from normal cells, and with a better understanding of the mechanisms involved in the repair of these lesions, tumor-selective therapies may be developed.  Aristotle once said: "We make war that we may live in peace".  By applying novel strategies involving inhibitors of the DNA damage response in combination with radiation or chemotherapy, we may improve the chances of peace by winning the war on cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopslYTMfDHnrVg90H21EOLACvtfcHk0liDkiHE2Hj9ww"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnsFemtrk%253D&md5=327ba938830918171b646fb2ad1754bc</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fcr900047g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr900047g%26sid%3Dliteratum%253Aachs%26aulast%3DLjungman%26aufirst%3DM.%26atitle%3DTargeting%2520the%2520DNA%2520damage%2520response%2520in%2520cancer%26jtitle%3DChem.%2520Rev.%26date%3D2009%26volume%3D109%26spage%3D2929%26epage%3D2950" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Caiafa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guastafierro, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zampieri, M.</span><span> </span><span class="NLM_article-title">Epigenetics: poly(ADP-ribosyl)ation of PARP-1 regulates genomic methylation patterns</span> <span class="citation_source-journal">FASEB J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">672</span><span class="NLM_x">â</span> <span class="NLM_lpage">678</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2009&pages=672-678&author=P.+Caiafaauthor=T.+Guastafierroauthor=M.+Zampieri&title=Epigenetics%3A+poly%28ADP-ribosyl%29ation+of+PARP-1+regulates+genomic+methylation+patterns"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCaiafa%26aufirst%3DP.%26aulast%3DGuastafierro%26aufirst%3DT.%26aulast%3DZampieri%26aufirst%3DM.%26atitle%3DEpigenetics%253A%2520poly%2528ADP-ribosyl%2529ation%2520of%2520PARP-1%2520regulates%2520genomic%2520methylation%2520patterns%26jtitle%3DFASEB%2520J.%26date%3D2009%26volume%3D23%26spage%3D672%26epage%3D678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Papeo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forte, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrera, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Posteri, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scolaro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montagnoli, A.</span><span> </span><span class="NLM_article-title">Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity?</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1377</span><span class="NLM_x">â</span> <span class="NLM_lpage">1400</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1517%2F13543770903215883" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFyhtLfN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1377-1400&author=G.+Papeoauthor=B.+Forteauthor=P.+Orsiniauthor=C.+Perreraauthor=H.+Posteriauthor=A.+Scolaroauthor=A.+Montagnoli&title=Poly%28ADP-ribose%29+polymerase+inhibition+in+cancer+therapy%3A+are+we+close+to+maturity%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity?</span></div><div class="casAuthors">Papeo, Gianluca; Forte, Barbara; Orsini, Paolo; Perrera, Claudia; Posteri, Helena; Scolaro, Alessandra; Montagnoli, Alessia</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1377-1400</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: During the last few years an increasing no. of poly(ADP-ribose) polymerase (PARP) inhibitors have been appearing in the context of cancer therapy.  This is mainly due to a better knowledge of the best-characterized member of the PARP family of enzymes, PARP-1, further reinforced by the recognition of the clin. benefits arising from its inhibition.  Objective/method: The aim of this review is to give the reader an update on PARP inhibition in cancer therapy, by covering both the scientific (SciFinder search) and the patent literature (Chem. Abstr./Derwent search) published recently (2005 - 2008).  Conclusions: More patient-compliant orally available PARP-1 inhibitor clin. candidates, along with their possible use as single agents in specific, molecularly defined cancer indications, increase the expectations for this therapeutic approach.  The growing understanding of the biol. role of other PARPs, such as Tankyrase 1, may be of interest as new potential targets.  Besides the classical NAD-mimicking pharmacophore, addnl. compds., which either do not resemble nicotinamide or exploit different binding sites, are emerging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIwGUDjN9gRbVg90H21EOLACvtfcHk0lh8ps6RD68iTw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFyhtLfN&md5=16cc23d941b16a80ff9d8da769f99a9b</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1517%2F13543770903215883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543770903215883%26sid%3Dliteratum%253Aachs%26aulast%3DPapeo%26aufirst%3DG.%26aulast%3DForte%26aufirst%3DB.%26aulast%3DOrsini%26aufirst%3DP.%26aulast%3DPerrera%26aufirst%3DC.%26aulast%3DPosteri%26aufirst%3DH.%26aulast%3DScolaro%26aufirst%3DA.%26aulast%3DMontagnoli%26aufirst%3DA.%26atitle%3DPoly%2528ADP-ribose%2529%2520polymerase%2520inhibition%2520in%2520cancer%2520therapy%253A%2520are%2520we%2520close%2520to%2520maturity%253F%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2009%26volume%3D19%26spage%3D1377%26epage%3D1400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Cuzzocrea, S.</span><span> </span><span class="NLM_article-title">Shock, inflammation and PARP</span> <span class="citation_source-journal">Pharmacol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">72</span><span class="NLM_x">â</span> <span class="NLM_lpage">82</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1016%2Fj.phrs.2005.02.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=15911335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1Wlt78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2005&pages=72-82&author=S.+Cuzzocrea&title=Shock%2C+inflammation+and+PARP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Shock, inflammation and PARP</span></div><div class="casAuthors">Cuzzocrea, Salvatore</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">72-82</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The activation of poly(ADP-ribose) polymerase (PARP) is well considered to play an important role in various patho-physiol. conditions like inflammation and shock.  A vast amt. of circumstantial evidence implicates oxygen-derived free radicals (esp., superoxide and hydroxyl radical) and high-energy oxidants (such as peroxynitrite) as mediators of inflammation and shock.  ROS (e.g., superoxide, peroxynitrite, hydroxyl radical and hydrogen peroxide) are all potential reactants capable of initiating DNA single strand breakage, with subsequent activation of the nuclear enzyme poly(ADP-ribose) synthetase (PARS), leading to eventual severe energy depletion of the cells, and necrotic-type cell death.  During the last years, numerous exptl. studies have clearly demonstrated the beneficial effects of PARP inhibition in cell cultures through rodent models and more recently in pre-clin. large animal models of acute and chronic inflammation.  The aim of this review is to describe recent exptl. evidence implicating PARP as a pathophysiol. modulator of acute and chronic inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4Exd627XiZbVg90H21EOLACvtfcHk0lh8ps6RD68iTw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1Wlt78%253D&md5=91556b95fcafc778639c4caf747c4675</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2005.02.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2005.02.016%26sid%3Dliteratum%253Aachs%26aulast%3DCuzzocrea%26aufirst%3DS.%26atitle%3DShock%252C%2520inflammation%2520and%2520PARP%26jtitle%3DPharmacol.%2520Res.%26date%3D2005%26volume%3D52%26spage%3D72%26epage%3D82" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Peralta-Leal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Vargas, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aguilar-Quesada, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linares, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Almodovar, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliver, F. J.</span><span> </span><span class="NLM_article-title">PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases</span> <span class="citation_source-journal">Free Radical Biol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">13</span><span class="NLM_x">â</span> <span class="NLM_lpage">26</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1016%2Fj.freeradbiomed.2009.04.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=19362586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD1MXms1yhsLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2009&pages=13-26&author=A.+Peralta-Lealauthor=J.+M.+Rodriguez-Vargasauthor=R.+Aguilar-Quesadaauthor=M.+I.+Rodriguezauthor=J.+L.+Linaresauthor=M.+R.+de+Almodovarauthor=F.+J.+Oliver&title=PARP+inhibitors%3A+new+partners+in+the+therapy+of+cancer+and+inflammatory+diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">PARP inhibitors: New partners in the therapy of cancer and inflammatory diseases</span></div><div class="casAuthors">Peralta-Leal, Andreina; Rodriguez-Vargas, Jose Manuel; Aguilar-Quesada, Rocio; Rodriguez, Maria Isabel; Linares, Jose Luis; Ruiz de Almodovar, Mariano; Oliver, F. Javier</div><div class="citationInfo"><span class="NLM_cas:title">Free Radical Biology & Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-26</span>CODEN:
                <span class="NLM_cas:coden">FRBMEH</span>;
        ISSN:<span class="NLM_cas:issn">0891-5849</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Poly(ADP-ribose) polymerases (PARPs) are defined as cell signaling enzymes that catalyze the transfer of ADP-ribose units from NAD+ to a no. of acceptor proteins.  PARP-1, the best characterized member of the PARP family, which currently comprises 18 members, is an abundant nuclear enzyme implicated in cellular responses to DNA injury provoked by genotoxic stress.  PARP is involved in DNA repair and transcriptional regulation and is now recognized as a key regulator of cell survival and cell death as well as a master component of a no. of transcription factors involved in tumor development and inflammation.  PARP-1 is essential to the repair of DNA single-strand breaks via the base excision repair pathway.  Inhibitors of PARP-1 have been shown to enhance the cytotoxic effects of ionizing radiation and DNA-damaging chemotherapy agents, such as the methylating agents and topoisomerase I inhibitors.  There are currently at least five PARP inhibitors in clin. trial development.  Recent in vitro and in vivo evidence suggests that PARP inhibitors could be used not only as chemo/radiotherapy sensitizers, but also as single agents to selectively kill cancers defective in DNA repair, specifically cancers with mutations in the breast cancer-assocd. genes (BRCA1 and BRCA2).  PARP becomes activated in response to oxidative DNA damage and depletes cellular energy pools, thus leading to cellular dysfunction in various tissues.  The activation of PARP may also induce various cell death processes and promotes an inflammatory response assocd. with multiple organ failure.  Inhibition of PARP activity is protective in a wide range of inflammatory and ischemia-reperfusion-assocd. diseases, including cardiovascular diseases, diabetes, rheumatoid arthritis, endotoxic shock, and stroke.  The aim of this review is to overview the emerging data in the literature showing the role of PARP in the pathogenesis of cancer and inflammatory diseases and unravel the solid body of literature that supports the view that PARP is an important target for therapeutic intervention in crit. illness.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoL1ahpR0DqBbVg90H21EOLACvtfcHk0lgdvf1kHwcYRA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXms1yhsLk%253D&md5=0c16682cb09319ecd32bf94586b151bf</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.freeradbiomed.2009.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.freeradbiomed.2009.04.008%26sid%3Dliteratum%253Aachs%26aulast%3DPeralta-Leal%26aufirst%3DA.%26aulast%3DRodriguez-Vargas%26aufirst%3DJ.%2BM.%26aulast%3DAguilar-Quesada%26aufirst%3DR.%26aulast%3DRodriguez%26aufirst%3DM.%2BI.%26aulast%3DLinares%26aufirst%3DJ.%2BL.%26aulast%3Dde%2BAlmodovar%26aufirst%3DM.%2BR.%26aulast%3DOliver%26aufirst%3DF.%2BJ.%26atitle%3DPARP%2520inhibitors%253A%2520new%2520partners%2520in%2520the%2520therapy%2520of%2520cancer%2520and%2520inflammatory%2520diseases%26jtitle%3DFree%2520Radical%2520Biol.%2520Med.%26date%3D2009%26volume%3D47%26spage%3D13%26epage%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Peukert, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwahn, U.</span><span> </span><span class="NLM_article-title">New inhibitors of poly(ADP-ribose) polymerase (PARP)</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1531</span><span class="NLM_x">â</span> <span class="NLM_lpage">1551</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1517%2F13543776.14.11.1531" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD2cXoslemu7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=1531-1551&author=S.+Peukertauthor=U.+Schwahn&title=New+inhibitors+of+poly%28ADP-ribose%29+polymerase+%28PARP%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">New inhibitors of poly(ADP-ribose) polymerase (PARP)</span></div><div class="casAuthors">Peukert, Stefan; Schwahn, Uwe</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1531-1551</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Poly(ADP-ribose) polymerase-1 (PARP-1), the most prominent member of the PARP family, is a DNA-binding protein that is activated by nicks in DNA occurring during inflammation, ischemia, neurodegeneration or cancer therapy.  Activated PARP-1 consumes NAD+ that is cleaved into nicotinamide and ADP-ribose and polymerizes the latter onto nuclear acceptor proteins.  This highly energy consuming process is pivotal for the maintenance of genomic stability although over-activation can culminate in cell dysfunction and necrosis.  Therefore, PARP-1 is regarded as a promising target for the development of drugs useful in various forms of inflammation, ischemia-reperfusion injury and as an adjunct in cancer therapy.  This review summarizes the structural classes of known PARP-1 inhibitors, with a focus on new inhibitors published for this target, between 2002 and July 2004.  The chem. and biol. data disclosed in these patent applications are discussed in light of new structural knowledge of the catalytic domain of the PARP family and recent work with potent inhibitors demonstrating the effects of PARP inhibition in various animal disease models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbTHYakSgCR7Vg90H21EOLACvtfcHk0lgdvf1kHwcYRA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXoslemu7k%253D&md5=56e768ccf3d5520f34e17b6886ba4405</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1517%2F13543776.14.11.1531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.14.11.1531%26sid%3Dliteratum%253Aachs%26aulast%3DPeukert%26aufirst%3DS.%26aulast%3DSchwahn%26aufirst%3DU.%26atitle%3DNew%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2004%26volume%3D14%26spage%3D1531%26epage%3D1551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Southan, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabo, C.</span><span> </span><span class="NLM_article-title">Poly(ADP-ribose) polymerase inhibitors</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">321</span><span class="NLM_x">â</span> <span class="NLM_lpage">340</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=12570705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlt1GhsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2003&pages=321-340&author=G.+J.+Southanauthor=C.+Szabo&title=Poly%28ADP-ribose%29+polymerase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Poly(ADP-ribose) polymerase inhibitors</span></div><div class="casAuthors">Southan, Garry J.; Szabo, Csaba</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">321-340</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers</span>)
        </div><div class="casAbstract">A review.  Poly(ADP-ribose) polymerase-1 (PARP-1) is the principal member of the PARP enzyme family consisting of PARP-1 and several recently identified novel poly(ADP-ribosyl)ating enzymes.  PARP-1 functions as a DNA damage sensor and signaling mol.  Upon binding to DNA breaks, activated PARP cleaves NAD+ into nicotinamide and ADP-ribose and polymerizes the latter onto nuclear acceptor proteins including histones, transcription factors and PARP itself.  This Poly(ADP-ribosyl)ation contributes to inflammatory signal transduction processes.  In addn., oxidative stress-induced overactivation of PARP consumes NAD+ and consequently ATP, culminating in cell dysfunction or necrosis.  Activation of PARP has been implicated in the pathogenesis of stroke, myocardial ischemia, diabetes, diabetes-assocd. cardiovascular dysfunction, shock, traumatic central nervous system injury, arthritis, colitis, allergic encephalomyelitis and various other forms of inflammation.  Therefore, inhibition of PARP by pharmacol. agents may prove useful for the therapy of these diseases, as has been shown in preclin. animal models.  Moreover, PARP inhibitors may have addnl., potential utility as anticancer agents, radiosensitizers and antiviral agents.  In the present article we overview the structures and pharmacol. actions of various pharmacol. classes of compds. which inhibit the catalytic activity of PARP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_QtUM117ipLVg90H21EOLACvtfcHk0likBw5wfEtG5g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlt1GhsQ%253D%253D&md5=43e29a697d0ead1c9d87c8336a83d43d</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSouthan%26aufirst%3DG.%2BJ.%26aulast%3DSzabo%26aufirst%3DC.%26atitle%3DPoly%2528ADP-ribose%2529%2520polymerase%2520inhibitors%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2003%26volume%3D10%26spage%3D321%26epage%3D340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Banasik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueda, K.</span><span> </span><span class="NLM_article-title">Inhibitors and activators of ADP-ribosylation reactions</span> <span class="citation_source-journal">Mol. Cell. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">138</span><span class="NLM_x">, </span> <span class="NLM_fpage">185</span><span class="NLM_x">â</span> <span class="NLM_lpage">197</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=1994&pages=185-197&author=M.+Banasikauthor=K.+Ueda&title=Inhibitors+and+activators+of+ADP-ribosylation+reactions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBanasik%26aufirst%3DM.%26aulast%3DUeda%26aufirst%3DK.%26atitle%3DInhibitors%2520and%2520activators%2520of%2520ADP-ribosylation%2520reactions%26jtitle%3DMol.%2520Cell.%2520Biochem.%26date%3D1994%26volume%3D138%26spage%3D185%26epage%3D197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Li, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span> </span><span class="NLM_article-title">PARP inhibitors</span> <span class="citation_source-journal">IDrugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">804</span><span class="NLM_x">â</span> <span class="NLM_lpage">812</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=15995937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlvVKht7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2001&pages=804-812&author=J.+H.+Liauthor=J.+Zhang&title=PARP+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">PARP inhibitors</span></div><div class="casAuthors">Li, Jia-He; Zhang, Jie</div><div class="citationInfo"><span class="NLM_cas:title">IDrugs</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">804-812</span>CODEN:
                <span class="NLM_cas:coden">IDRUFN</span>;
        ISSN:<span class="NLM_cas:issn">1369-7056</span>.
    
            (<span class="NLM_cas:orgname">Current Drugs Ltd.</span>)
        </div><div class="casAbstract">A review with refs.  Poly(ADP-ribose) polymerase (PARP) catalyzes the biochem. conversion of NAD (NAD+) to poly(ADP-ribose) and nicotinamide, which is a weak feedback inhibitor of the enzyme.  Early designs of PARP inhibitors were primarily based on mimicking the structure of nicotinamide and resulted in the identification and widespread use of benzamide analogs as PARP inhibitors.  Recent searches for more potent and specific PARP inhibitors, facilitated by the crystal structure of the catalytic domain of PARP, led to several families of amide and lactam derivs. with multiple ring systems.  New PARP inhibitors have shown efficacies in several animal disease models of cancer, ischemia and inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzuoUw68ISq7Vg90H21EOLACvtfcHk0likBw5wfEtG5g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlvVKht7k%253D&md5=8c5c04c7fcd5f4b1e752fcddad3d9df2</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%2BH.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DPARP%2520inhibitors%26jtitle%3DIDrugs%26date%3D2001%26volume%3D4%26spage%3D804%26epage%3D812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Zaremba, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span> </span><span class="NLM_article-title">PARP inhibitor development for systemic cancer targeting</span> <span class="citation_source-journal">Anti-Cancer Agents Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">515</span><span class="NLM_x">â</span> <span class="NLM_lpage">523</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=515-523&author=T.+Zarembaauthor=N.+J.+Curtin&title=PARP+inhibitor+development+for+systemic+cancer+targeting"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZaremba%26aufirst%3DT.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26atitle%3DPARP%2520inhibitor%2520development%2520for%2520systemic%2520cancer%2520targeting%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D515%26epage%3D523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Wang, Z. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stingl, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berghammer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haidacher, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schweiger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, E. F.</span><span> </span><span class="NLM_article-title">Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease</span> <span class="citation_source-journal">Genes Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">509</span><span class="NLM_x">â</span> <span class="NLM_lpage">520</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1995&pages=509-520&author=Z.+Q.+Wangauthor=B.+Auerauthor=L.+Stinglauthor=H.+Berghammerauthor=D.+Haidacherauthor=M.+Schweigerauthor=E.+F.+Wagner&title=Mice+lacking+ADPRT+and+poly%28ADP-ribosyl%29ation+develop+normally+but+are+susceptible+to+skin+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%2BQ.%26aulast%3DAuer%26aufirst%3DB.%26aulast%3DStingl%26aufirst%3DL.%26aulast%3DBerghammer%26aufirst%3DH.%26aulast%3DHaidacher%26aufirst%3DD.%26aulast%3DSchweiger%26aufirst%3DM.%26aulast%3DWagner%26aufirst%3DE.%2BF.%26atitle%3DMice%2520lacking%2520ADPRT%2520and%2520poly%2528ADP-ribosyl%2529ation%2520develop%2520normally%2520but%2520are%2520susceptible%2520to%2520skin%2520disease%26jtitle%3DGenes%2520Dev.%26date%3D1995%26volume%3D9%26spage%3D509%26epage%3D520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Huber, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Murcia, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Murcia, G.</span><span> </span><span class="NLM_article-title">PARP-1, PARP-2 and ATM in the DNA damage response: functional synergy in mouse development</span> <span class="citation_source-journal">DNA Repair</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1103</span><span class="NLM_x">â</span> <span class="NLM_lpage">1108</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=1103-1108&author=A.+Huberauthor=P.+Baiauthor=J.+M.+de+Murciaauthor=G.+de+Murcia&title=PARP-1%2C+PARP-2+and+ATM+in+the+DNA+damage+response%3A+functional+synergy+in+mouse+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHuber%26aufirst%3DA.%26aulast%3DBai%26aufirst%3DP.%26aulast%3Dde%2BMurcia%26aufirst%3DJ.%2BM.%26aulast%3Dde%2BMurcia%26aufirst%3DG.%26atitle%3DPARP-1%252C%2520PARP-2%2520and%2520ATM%2520in%2520the%2520DNA%2520damage%2520response%253A%2520functional%2520synergy%2520in%2520mouse%2520development%26jtitle%3DDNA%2520Repair%26date%3D2004%26volume%3D3%26spage%3D1103%26epage%3D1108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Ishida, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kido, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamijo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyake, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohkubo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinoshita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warizaya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwashita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mihara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuoka, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattori, K.</span><span> </span><span class="NLM_article-title">Discovery of potent and selective PARP-1 and PARP-2 inhibitors: SBDD analysis via a combination of X-ray structural study and homology modeling</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1378</span><span class="NLM_x">â</span> <span class="NLM_lpage">1390</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1016%2Fj.bmc.2005.09.061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=16288880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsVGjtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=1378-1390&author=J.+Ishidaauthor=H.+Yamamotoauthor=Y.+Kidoauthor=K.+Kamijoauthor=K.+Muranoauthor=H.+Miyakeauthor=M.+Ohkuboauthor=T.+Kinoshitaauthor=M.+Warizayaauthor=A.+Iwashitaauthor=K.+Miharaauthor=N.+Matsuokaauthor=K.+Hattori&title=Discovery+of+potent+and+selective+PARP-1+and+PARP-2+inhibitors%3A+SBDD+analysis+via+a+combination+of+X-ray+structural+study+and+homology+modeling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of potent and selective PARP-1 and PARP-2 inhibitors: SBDD analysis via a combination of X-ray structural study and homology modeling</span></div><div class="casAuthors">Ishida, Junya; Yamamoto, Hirofumi; Kido, Yoshiyuki; Kamijo, Kazunori; Murano, Kenji; Miyake, Hiroshi; Ohkubo, Mitsuru; Kinoshita, Takayoshi; Warizaya, Masaichi; Iwashita, Akinori; Mihara, Kayoko; Matsuoka, Nobuya; Hattori, Kouji</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1378-1390</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We disclose herein our efforts aimed at discovery of selective PARP-1 and PARP-2 inhibitors.  We have recently discovered several novel classes of quinazolinones, quinazolidinones, and quinoxalines as potent PARP-1 inhibitors, which may represent attractive therapeutic candidates.  In PARP enzyme assays using recombinant PARP-1 and PARP-2, the quinazolinone derivs. displayed relatively high selectivity for PARP-1 and quinoxaline derivs. showed superior selectivity for PARP-2, and the quinazolidinone derivs. did not have selectivity for PARP-1/2.  Structure-based drug design anal. via a combination of X-ray structural study utilizing the complexes of inhibitors and human PARP-1 catalytic domain, and homol. modeling using murine PARP-2 suggested distinct interactions of inhibitors with PARP-1 and PARP-2.  These findings provide a new structural framework for the design of selective inhibitors for PARP-1 and PARP-2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrukfYFsnRIEbVg90H21EOLACvtfcHk0liqFlVGW0u6Nw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsVGjtw%253D%253D&md5=9f72cd79428d0c006e2995c19a345c0f</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2005.09.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2005.09.061%26sid%3Dliteratum%253Aachs%26aulast%3DIshida%26aufirst%3DJ.%26aulast%3DYamamoto%26aufirst%3DH.%26aulast%3DKido%26aufirst%3DY.%26aulast%3DKamijo%26aufirst%3DK.%26aulast%3DMurano%26aufirst%3DK.%26aulast%3DMiyake%26aufirst%3DH.%26aulast%3DOhkubo%26aufirst%3DM.%26aulast%3DKinoshita%26aufirst%3DT.%26aulast%3DWarizaya%26aufirst%3DM.%26aulast%3DIwashita%26aufirst%3DA.%26aulast%3DMihara%26aufirst%3DK.%26aulast%3DMatsuoka%26aufirst%3DN.%26aulast%3DHattori%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520selective%2520PARP-1%2520and%2520PARP-2%2520inhibitors%253A%2520SBDD%2520analysis%2520via%2520a%2520combination%2520of%2520X-ray%2520structural%2520study%2520and%2520homology%2520modeling%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2006%26volume%3D14%26spage%3D1378%26epage%3D1390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Ogata, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kagamiyama, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayaishi, O.</span><span> </span><span class="NLM_article-title">ADP-ribosylation of histone H1. Identification of glutamic acid residues 2, 14, and the COOH-terminal lysine residue as modification sites</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1980</span><span class="NLM_x">, </span> <span class="NLM_volume">255</span><span class="NLM_x">, </span> <span class="NLM_fpage">7616</span><span class="NLM_x">â</span> <span class="NLM_lpage">7620</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=255&publication_year=1980&pages=7616-7620&author=N.+Ogataauthor=K.+Uedaauthor=H.+Kagamiyamaauthor=O.+Hayaishi&title=ADP-ribosylation+of+histone+H1.+Identification+of+glutamic+acid+residues+2%2C+14%2C+and+the+COOH-terminal+lysine+residue+as+modification+sites"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOgata%26aufirst%3DN.%26aulast%3DUeda%26aufirst%3DK.%26aulast%3DKagamiyama%26aufirst%3DH.%26aulast%3DHayaishi%26aufirst%3DO.%26atitle%3DADP-ribosylation%2520of%2520histone%2520H1.%2520Identification%2520of%2520glutamic%2520acid%2520residues%25202%252C%252014%252C%2520and%2520the%2520COOH-terminal%2520lysine%2520residue%2520as%2520modification%2520sites%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1980%26volume%3D255%26spage%3D7616%26epage%3D7620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Szabo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zingarelli, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâConnor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salzman, A. L.</span><span> </span><span class="NLM_article-title">DNA strand breakage, activation of poly (ADP-ribose) synthetase, and cellular energy depletion are involved in the cytotoxicity of macrophages and smooth muscle cells exposed to peroxynitrite</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">1753</span><span class="NLM_x">â</span> <span class="NLM_lpage">1758</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1996&pages=1753-1758&author=C.+Szaboauthor=B.+Zingarelliauthor=M.+O%E2%80%99Connorauthor=A.+L.+Salzman&title=DNA+strand+breakage%2C+activation+of+poly+%28ADP-ribose%29+synthetase%2C+and+cellular+energy+depletion+are+involved+in+the+cytotoxicity+of+macrophages+and+smooth+muscle+cells+exposed+to+peroxynitrite"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSzabo%26aufirst%3DC.%26aulast%3DZingarelli%26aufirst%3DB.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%26aulast%3DSalzman%26aufirst%3DA.%2BL.%26atitle%3DDNA%2520strand%2520breakage%252C%2520activation%2520of%2520poly%2520%2528ADP-ribose%2529%2520synthetase%252C%2520and%2520cellular%2520energy%2520depletion%2520are%2520involved%2520in%2520the%2520cytotoxicity%2520of%2520macrophages%2520and%2520smooth%2520muscle%2520cells%2520exposed%2520to%2520peroxynitrite%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1996%26volume%3D93%26spage%3D1753%26epage%3D1758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">de Murcia, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niedergang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trucco, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ricoul, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutrillaux, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mark, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliver, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dierich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LeMeur, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walztinger, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chambon, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Murcia, G.</span><span> </span><span class="NLM_article-title">Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">7303</span><span class="NLM_x">â</span> <span class="NLM_lpage">7307</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1073%2Fpnas.94.14.7303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=9207086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADyaK2sXksFOntb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1997&pages=7303-7307&author=J.+M.+de+Murciaauthor=C.+Niedergangauthor=C.+Truccoauthor=M.+Ricoulauthor=B.+Dutrillauxauthor=M.+Markauthor=F.+J.+Oliverauthor=M.+Massonauthor=A.+Dierichauthor=M.+LeMeurauthor=C.+Walztingerauthor=P.+Chambonauthor=G.+de+Murcia&title=Requirement+of+poly%28ADP-ribose%29+polymerase+in+recovery+from+DNA+damage+in+mice+and+in+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells</span></div><div class="casAuthors">Menissier de Murcia, Josiane; Niedergang, Claude; Trucco, Carlotta; Ricoul, Michele; Dutrillaux, Bernard; Mark, Manuel; Oliver, F. Javier; Masson, Murielle; Dierich, Andree; LeMeur, Marianne; Walztinger, Caroline; Chambon, Pierre; de Murcia, Gilbert</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">7303-7307</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase [PARP; NAD+ ADP-ribosyltransferase; NAD+:poly(adenosine-diphosphate-D-ribosyl)-acceptor ADP-D-ribosyltransferase, EC 2.4.2.30] is a zinc-finger DNA-binding protein that detects specifically DNA strand breaks generated by genotoxic agents.  To det. its biol. function, the authors have inactivated both alleles by gene targeting in mice.  Treatment of PARP-/- mice either by the alkylating agent N-methyl-N-nitrosourea (MNU) or by Î³-irradn. revealed an extreme sensitivity and a high genomic instability to both agents.  Following whole body Î³-irradn. (8 Gy) mutant mice died rapidly from acute radiation toxicity to the small intestine.  Mice-derived PARP-/- cells displayed a high sensitivity to MNU exposure: a G2/M arrest in mouse embryonic fibroblasts and a rapid apoptotic response and a p53 accumulation were obsd. in splenocytes.  Altogether these results demonstrate that PARP is a survival factor playing an essential and pos. role during DNA damage recovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlwmTBk-nHc7Vg90H21EOLACvtfcHk0li1y77kBubx1A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXksFOntb4%253D&md5=a652d7d877fa0c29ff1aeb9769fbd86f</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1073%2Fpnas.94.14.7303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.94.14.7303%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BMurcia%26aufirst%3DJ.%2BM.%26aulast%3DNiedergang%26aufirst%3DC.%26aulast%3DTrucco%26aufirst%3DC.%26aulast%3DRicoul%26aufirst%3DM.%26aulast%3DDutrillaux%26aufirst%3DB.%26aulast%3DMark%26aufirst%3DM.%26aulast%3DOliver%26aufirst%3DF.%2BJ.%26aulast%3DMasson%26aufirst%3DM.%26aulast%3DDierich%26aufirst%3DA.%26aulast%3DLeMeur%26aufirst%3DM.%26aulast%3DWalztinger%26aufirst%3DC.%26aulast%3DChambon%26aufirst%3DP.%26aulast%3Dde%2BMurcia%26aufirst%3DG.%26atitle%3DRequirement%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%2520in%2520recovery%2520from%2520DNA%2520damage%2520in%2520mice%2520and%2520in%2520cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1997%26volume%3D94%26spage%3D7303%26epage%3D7307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Bowman, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golding, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span> </span><span class="NLM_article-title">Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">78</span><span class="NLM_x">, </span> <span class="NLM_fpage">1269</span><span class="NLM_x">â</span> <span class="NLM_lpage">1277</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1038%2Fbjc.1998.670" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=9823965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADyaK1cXns1Wls7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=1998&pages=1269-1277&author=K.+J.+Bowmanauthor=A.+Whiteauthor=B.+T.+Goldingauthor=R.+J.+Griffinauthor=N.+J.+Curtin&title=Potentiation+of+anti-cancer+agent+cytotoxicity+by+the+potent+poly%28ADP-ribose%29+polymerase+inhibitors+NU1025+and+NU1064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064</span></div><div class="casAuthors">Bowman, K. J.; White, A.; Golding, B. T.; Griffin, R. J.; Curtin, N. J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1269-1277</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Churchill Livingstone</span>)
        </div><div class="casAbstract">The ability of the potent poly(ADP-ribose) polymerase (PARP) inhibitor, NU1025 (8-hydroxy-2-methyl-quinazolin-4-[3H]one) to potentiate the cytotoxicity of a panel of mechanistically diverse anti-cancer agents was evaluated in L1210 cells.  NU1025 enhanced the cytotoxicity of the DNA-methylating agent MTIC, Î³-irradn. and bleomycin 3.5-, 1.4- and 2-fold, resp.  The cytotoxicities of the thymidylate synthase inhibitor, nolatrexed, and the cytotoxic nucleoside, gemcitabine, were not increased.  Potentiation of MTIC cytotoxicity by a delayed exposure to NU1025 was equally effective as by a simultaneous exposure to NU1025, indicating that the effects of NU1025 were mediated by an inhibition of the cellular recovery.  The recovery from potentially lethal Î³-irradn. damage cytotoxicity in plateau-phase cells was also inhibited by NU1025.  Investigation of DNA strand breakage and repair in Î³-irradiated cells by alk. elution demonstrated that NU1025 caused a marked retardation of DNA repair.  A structurally different PARP inhibitor, NU1064 (2-methylbenzimidazole-4-carboxamide), also potentiated the cytotoxicity of MTIC, to a similar extent to NU1025.  NU1064 potentiated a sublethal concn. of a DNA methylating agent in a concn.-dependent manner.  Collectively, these data suggest that the most suitable cytotoxic agents for use in combination with PARP inhibitors are methylating agents, bleomycin and ionizing radiation, but not anti-metabolites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrck0a06VeTtLVg90H21EOLACvtfcHk0li1y77kBubx1A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXns1Wls7g%253D&md5=ff9df51529125a9117c195c491a440bf</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fbjc.1998.670&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.1998.670%26sid%3Dliteratum%253Aachs%26aulast%3DBowman%26aufirst%3DK.%2BJ.%26aulast%3DWhite%26aufirst%3DA.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26atitle%3DPotentiation%2520of%2520anti-cancer%2520agent%2520cytotoxicity%2520by%2520the%2520potent%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitors%2520NU1025%2520and%2520NU1064%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D1998%26volume%3D78%26spage%3D1269%26epage%3D1277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Ruf, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Murcia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulz, G. E.</span><span> </span><span class="NLM_article-title">Inhibitor and NAD+ binding to poly(ADP-ribose) polymerase as derived from crystal structures and homology modeling</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">3893</span><span class="NLM_x">â</span> <span class="NLM_lpage">3900</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi972383s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1998&pages=3893-3900&author=A.+Rufauthor=G.+de+Murciaauthor=G.+E.+Schulz&title=Inhibitor+and+NAD%2B+binding+to+poly%28ADP-ribose%29+polymerase+as+derived+from+crystal+structures+and+homology+modeling"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fbi972383s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi972383s%26sid%3Dliteratum%253Aachs%26aulast%3DRuf%26aufirst%3DA.%26aulast%3Dde%2BMurcia%26aufirst%3DG.%26aulast%3DSchulz%26aufirst%3DG.%2BE.%26atitle%3DInhibitor%2520and%2520NAD%252B%2520binding%2520to%2520poly%2528ADP-ribose%2529%2520polymerase%2520as%2520derived%2520from%2520crystal%2520structures%2520and%2520homology%2520modeling%26jtitle%3DBiochemistry%26date%3D1998%26volume%3D37%26spage%3D3893%26epage%3D3900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Cleaver, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borek, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milam, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, W. F.</span><span> </span><span class="NLM_article-title">The role of poly(ADP-ribose) synthesis in toxicity and repair of DNA damage</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">269</span><span class="NLM_x">â</span> <span class="NLM_lpage">293</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1016%2F0163-7258%2885%2990026-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=3939630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADyaL2sXhvFSnsLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1985&pages=269-293&author=J.+E.+Cleaverauthor=C.+Borekauthor=K.+Milamauthor=W.+F.+Morgan&title=The+role+of+poly%28ADP-ribose%29+synthesis+in+toxicity+and+repair+of+DNA+damage"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The role of poly(ADP-ribose) synthesis in toxicity and repair of DNA damage</span></div><div class="casAuthors">Cleaver, James E.; Borek, Carmia; Milam, Kathryn; Morgan, William F.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">269-93</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    </div><div class="casAbstract">A review with many refs. on the enzymic process of poly(ADP-ribose)  [26656-46-2] synthesis, poly(ADP-ribosyl)ation and protein function, inhibitors of poly(ADP-ribosyl)ation, poly(ADP-ribose) synthetase and the response of cells to DNA damage, inhibition of poly(ADP-ribose) synthesis and DNA repair, and the possible role for poly(ADP-ribose) synthesis in damaged cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfy4RC-q2OPLVg90H21EOLACvtfcHk0ljYf_v8oz3PZA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXhvFSnsLo%253D&md5=fa206bbb3f788dee30e06f3ce47faebf</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2F0163-7258%2885%2990026-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0163-7258%252885%252990026-9%26sid%3Dliteratum%253Aachs%26aulast%3DCleaver%26aufirst%3DJ.%2BE.%26aulast%3DBorek%26aufirst%3DC.%26aulast%3DMilam%26aufirst%3DK.%26aulast%3DMorgan%26aufirst%3DW.%2BF.%26atitle%3DThe%2520role%2520of%2520poly%2528ADP-ribose%2529%2520synthesis%2520in%2520toxicity%2520and%2520repair%2520of%2520DNA%2520damage%26jtitle%3DPharmacol.%2520Ther.%26date%3D1985%26volume%3D31%26spage%3D269%26epage%3D293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Dantzer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de La Rubia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menissier-De Murcia, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hostomsky, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Murcia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreiber, V.</span><span> </span><span class="NLM_article-title">Base excision repair is impaired in mammalian cells lacking Poly(ADP-ribose) polymerase-1</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">7559</span><span class="NLM_x">â</span> <span class="NLM_lpage">7569</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi0003442" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2000&pages=7559-7569&author=F.+Dantzerauthor=G.+de+La+Rubiaauthor=J.+Menissier-De+Murciaauthor=Z.+Hostomskyauthor=G.+de+Murciaauthor=V.+Schreiber&title=Base+excision+repair+is+impaired+in+mammalian+cells+lacking+Poly%28ADP-ribose%29+polymerase-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fbi0003442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi0003442%26sid%3Dliteratum%253Aachs%26aulast%3DDantzer%26aufirst%3DF.%26aulast%3Dde%2BLa%2BRubia%26aufirst%3DG.%26aulast%3DMenissier-De%2BMurcia%26aufirst%3DJ.%26aulast%3DHostomsky%26aufirst%3DZ.%26aulast%3Dde%2BMurcia%26aufirst%3DG.%26aulast%3DSchreiber%26aufirst%3DV.%26atitle%3DBase%2520excision%2520repair%2520is%2520impaired%2520in%2520mammalian%2520cells%2520lacking%2520Poly%2528ADP-ribose%2529%2520polymerase-1%26jtitle%3DBiochemistry%26date%3D2000%26volume%3D39%26spage%3D7559%26epage%3D7569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Durkacz, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Omidiji, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shall, S.</span><span> </span><span class="NLM_article-title">(ADP-ribose)n participates in DNA excision repair</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1980</span><span class="NLM_x">, </span> <span class="NLM_volume">283</span><span class="NLM_x">, </span> <span class="NLM_fpage">593</span><span class="NLM_x">â</span> <span class="NLM_lpage">596</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=1980&pages=593-596&author=B.+W.+Durkaczauthor=O.+Omidijiauthor=D.+A.+Grayauthor=S.+Shall&title=%28ADP-ribose%29n+participates+in+DNA+excision+repair"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDurkacz%26aufirst%3DB.%2BW.%26aulast%3DOmidiji%26aufirst%3DO.%26aulast%3DGray%26aufirst%3DD.%2BA.%26aulast%3DShall%26aufirst%3DS.%26atitle%3D%2528ADP-ribose%2529n%2520participates%2520in%2520DNA%2520excision%2520repair%26jtitle%3DNature%26date%3D1980%26volume%3D283%26spage%3D593%26epage%3D596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Caldecott, K. W.</span><span> </span><span class="NLM_article-title">XRCC1 and DNA strand break repair</span> <span class="citation_source-journal">DNA Repair</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">955</span><span class="NLM_x">â</span> <span class="NLM_lpage">969</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=955-969&author=K.+W.+Caldecott&title=XRCC1+and+DNA+strand+break+repair"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCaldecott%26aufirst%3DK.%2BW.%26atitle%3DXRCC1%2520and%2520DNA%2520strand%2520break%2520repair%26jtitle%3DDNA%2520Repair%26date%3D2003%26volume%3D2%26spage%3D955%26epage%3D969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Audebert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salles, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calsou, P.</span><span> </span><span class="NLM_article-title">Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x">, </span> <span class="NLM_fpage">55117</span><span class="NLM_x">â</span> <span class="NLM_lpage">55126</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=55117-55126&author=M.+Audebertauthor=B.+Sallesauthor=P.+Calsou&title=Involvement+of+poly%28ADP-ribose%29+polymerase-1+and+XRCC1%2FDNA+ligase+III+in+an+alternative+route+for+DNA+double-strand+breaks+rejoining"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAudebert%26aufirst%3DM.%26aulast%3DSalles%26aufirst%3DB.%26aulast%3DCalsou%26aufirst%3DP.%26atitle%3DInvolvement%2520of%2520poly%2528ADP-ribose%2529%2520polymerase-1%2520and%2520XRCC1%252FDNA%2520ligase%2520III%2520in%2520an%2520alternative%2520route%2520for%2520DNA%2520double-strand%2520breaks%2520rejoining%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D55117%26epage%3D55126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Affar, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirier, G. G.</span><span> </span><span class="NLM_article-title">Poly(ADP-ribose) turnover in quail myoblast cells: relation between the polymer level and its catabolism by glycohydrolase</span> <span class="citation_source-journal">Mol. Cell. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">193</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">â</span> <span class="NLM_lpage">135</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=193&publication_year=1999&pages=127-135&author=E.+B.+Affarauthor=R.+G.+Shahauthor=G.+G.+Poirier&title=Poly%28ADP-ribose%29+turnover+in+quail+myoblast+cells%3A+relation+between+the+polymer+level+and+its+catabolism+by+glycohydrolase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAffar%26aufirst%3DE.%2BB.%26aulast%3DShah%26aufirst%3DR.%2BG.%26aulast%3DPoirier%26aufirst%3DG.%2BG.%26atitle%3DPoly%2528ADP-ribose%2529%2520turnover%2520in%2520quail%2520myoblast%2520cells%253A%2520relation%2520between%2520the%2520polymer%2520level%2520and%2520its%2520catabolism%2520by%2520glycohydrolase%26jtitle%3DMol.%2520Cell.%2520Biochem.%26date%3D1999%26volume%3D193%26spage%3D127%26epage%3D135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Ljungman, M.</span><span> </span><span class="NLM_article-title">Targeting the DNA damage response in cancer</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">2929</span><span class="NLM_x">â</span> <span class="NLM_lpage">50</span></span><div class="citationLinks">[<a href="/doi/10.1021/cr900047g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnsFemtrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2009&pages=2929-50&author=M.+Ljungman&title=Targeting+the+DNA+damage+response+in+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the DNA Damage Response in Cancer</span></div><div class="casAuthors">Ljungman, Mats</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2929-2950</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  We are in an exciting phase in cancer research with a rapid pace of discovery driven by new technologies.  Recent studies have shed light on the complexity of tumor biol., showing that tumors rarely have similar sets of mutations in common.  However, when placing the various tumor mutations into functional pathways, a more manageable picture emerges with about 12 core pathways abrogated in the majority of the tumors.  Thus, it may be possible after identifying the pathway(s) altered in a particular tumor to tailor therapies to specifically block that pathway(s).  The DNA damage response is one of these core pathways found to be frequently dysregulated in cancer.  Proteins participating in this pathway are expected to be important therapeutic targets for the sensitization of tumor cells to radiation or chemotherapy.  The targeting of the DNA damage response in cancer stem cells may be of particular importance, since these cells are often found to be more resistant to radiation and chemotherapy than other tumor cells.  The fact that many tumors have defects in DNA repair pathways and/or cell cycle checkpoints presents unique opportunities for therapeutic exploitation.  Likewise, oncogene-driven induction of "DNA damage" sets tumor cells apart from normal cells, and with a better understanding of the mechanisms involved in the repair of these lesions, tumor-selective therapies may be developed.  Aristotle once said: "We make war that we may live in peace".  By applying novel strategies involving inhibitors of the DNA damage response in combination with radiation or chemotherapy, we may improve the chances of peace by winning the war on cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopslYTMfDHnrVg90H21EOLACvtfcHk0lhIghWkRaF2eg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnsFemtrk%253D&md5=327ba938830918171b646fb2ad1754bc</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fcr900047g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr900047g%26sid%3Dliteratum%253Aachs%26aulast%3DLjungman%26aufirst%3DM.%26atitle%3DTargeting%2520the%2520DNA%2520damage%2520response%2520in%2520cancer%26jtitle%3DChem.%2520Rev.%26date%3D2009%26volume%3D109%26spage%3D2929%26epage%3D50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Banasik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komura, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimoyama, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueda, K.</span><span> </span><span class="NLM_article-title">Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">267</span><span class="NLM_x">, </span> <span class="NLM_fpage">1569</span><span class="NLM_x">â</span> <span class="NLM_lpage">1575</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=1530940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADyaK38XitFSjtLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=1992&pages=1569-1575&author=M.+Banasikauthor=H.+Komuraauthor=M.+Shimoyamaauthor=K.+Ueda&title=Specific+inhibitors+of+poly%28ADP-ribose%29+synthetase+and+mono%28ADP-ribosyl%29transferase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase</span></div><div class="casAuthors">Banasik, Marek; Komura, Hajime; Shimoyama, Makoto; Ueda, Kunihiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">267</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1569-75</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Two classes of enzymes, poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferases, catalyze covalent attachment of multiple or single residues, resp., of the ADP-ribose moiety of NAD to various proteins.  In order to find good inhibitors of poly(ADP-ribose) synthetase free of side actions and applicable to in vivo studies, a large scale survey was made using an in vitro assay system, and many potent inhibitors were found.  The four strongest were 4-amino-1,8-naphthalimide, 6(5H)- and 2-nitro-6(5H)-phenanthridinones, and 1,5-dihydroxyisoquinoline.  Their 50% inhibitory concns., 0.18-0.39 Î¼M, were about two orders of magnitude lower than that of 3-aminobenzamide that is currently most popularly used.  A common structural feature among all potent inhibitors, including 1-hydroxyisoquinoline, chlorthenoxazin, 3-hydroxybenzamide, and 4-hydroxyquinazoline, in addn. to the four mentioned above, was the presence of a carbonyl group built in a polyarom. heterocyclic skeleton or a carbamoyl group attached to an arom. ring.  Most of the inhibitors exhibited mixed-type inhibition with respect to NAD.  Comparative studies of the effects on poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase from hen heterophils revealed high specificity of most of the potent inhibitors for poly(ADP-ribose) synthetase.  On the other hand, unsatd. long-chain fatty acids inhibited both enzymes, and satd. long-chain fatty acids and vitamin K1 acted selectively on mono(ADP-ribosyl)transferase.  The finding of many inhibitors of ADP-ribosyltransferases, esp. poly(ADP-ribose) synthetase, supports the view that ADP-ribosylation of proteins may be regulated by a variety of metabolites or structural constituents in the cell.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-Jh_eRCjHdbVg90H21EOLACvtfcHk0lgUcWe42FVVCg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XitFSjtLk%253D&md5=21bb51821a1caaeb30c42643a82116f4</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBanasik%26aufirst%3DM.%26aulast%3DKomura%26aufirst%3DH.%26aulast%3DShimoyama%26aufirst%3DM.%26aulast%3DUeda%26aufirst%3DK.%26atitle%3DSpecific%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529%2520synthetase%2520and%2520mono%2528ADP-ribosyl%2529transferase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1992%26volume%3D267%26spage%3D1569%26epage%3D1575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Purnell, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whish, W. J.</span><span> </span><span class="NLM_article-title">Novel inhibitors of poly(ADP-ribose) synthetase</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1980</span><span class="NLM_x">, </span> <span class="NLM_volume">185</span><span class="NLM_x">, </span> <span class="NLM_fpage">775</span><span class="NLM_x">â</span> <span class="NLM_lpage">777</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=185&publication_year=1980&pages=775-777&author=M.+R.+Purnellauthor=W.+J.+Whish&title=Novel+inhibitors+of+poly%28ADP-ribose%29+synthetase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPurnell%26aufirst%3DM.%2BR.%26aulast%3DWhish%26aufirst%3DW.%2BJ.%26atitle%3DNovel%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529%2520synthetase%26jtitle%3DBiochem.%2520J.%26date%3D1980%26volume%3D185%26spage%3D775%26epage%3D777" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Bryant, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flower, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kyle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helleday, T.</span><span> </span><span class="NLM_article-title">Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">434</span><span class="NLM_x">, </span> <span class="NLM_fpage">913</span><span class="NLM_x">â</span> <span class="NLM_lpage">917</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1038%2Fnature03443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=15829966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=434&publication_year=2005&pages=913-917&author=H.+E.+Bryantauthor=N.+Schultzauthor=H.+D.+Thomasauthor=K.+M.+Parkerauthor=D.+Flowerauthor=E.+Lopezauthor=S.+Kyleauthor=M.+Meuthauthor=N.+J.+Curtinauthor=T.+Helleday&title=Specific+killing+of+BRCA2-deficient+tumours+with+inhibitors+of+poly%28ADP-ribose%29+polymerase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Specific killing of BRCA2-deficient tumors with inhibitors of poly(ADP-ribose) polymerase</span></div><div class="casAuthors">Bryant, Helen E.; Schultz, Niklas; Thomas, Huw D.; Parker, Kayan M.; Flower, Dan; Lopez, Elena; Kyle, Suzanne; Meuth, Mark; Curtin, Nicola J.; Helleday, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">434</span>
        (<span class="NLM_cas:issue">7035</span>),
    <span class="NLM_cas:pages">913-917</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase (PARP1) facilitates DNA repair by binding to DNA breaks and attracting DNA repair proteins to the site of damage.  Nevertheless, PARP1-/- mice are viable, fertile and do not develop early onset tumors.  Here, the authors show that PARP inhibitors trigger Î³-H2AX and RAD51 foci formation.  The authors propose that, in the absence of PARP1, spontaneous single-strand breaks collapse replication forks and trigger homologous recombination for repair.  Furthermore, the authors show that BRCA2-deficient cells, as a result of their deficiency in homologous recombination, are acutely sensitive to PARP inhibitors, presumably because resultant collapsed replication forks are no longer repaired.  Thus, PARP1 activity is essential in homologous recombination-deficient BRCA2 mutant cells.  The authors exploit this requirement in order to kill BRCA2-deficient tumors by PARP inhibition alone.  Treatment with PARP inhibitors is likely to be highly tumor specific, because only the tumors (which are BRCA2-/-) in BRCA2+/- patients are defective in homologous recombination.  The use of an inhibitor of a DNA repair enzyme alone to selectively kill a tumor, in the absence of an exogenous DNA-damaging agent, represents a new concept in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZJ6B7d7dB77Vg90H21EOLACvtfcHk0lgUcWe42FVVCg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrY%253D&md5=44631eba667cf75ef99c31d011d6db44</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fnature03443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature03443%26sid%3Dliteratum%253Aachs%26aulast%3DBryant%26aufirst%3DH.%2BE.%26aulast%3DSchultz%26aufirst%3DN.%26aulast%3DThomas%26aufirst%3DH.%2BD.%26aulast%3DParker%26aufirst%3DK.%2BM.%26aulast%3DFlower%26aufirst%3DD.%26aulast%3DLopez%26aufirst%3DE.%26aulast%3DKyle%26aufirst%3DS.%26aulast%3DMeuth%26aufirst%3DM.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DHelleday%26aufirst%3DT.%26atitle%3DSpecific%2520killing%2520of%2520BRCA2-deficient%2520tumours%2520with%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%26jtitle%3DNature%26date%3D2005%26volume%3D434%26spage%3D913%26epage%3D917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Farmer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCabe, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tutt, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santarosa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dillon, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knights, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">434</span><span class="NLM_x">, </span> <span class="NLM_fpage">917</span><span class="NLM_x">â</span> <span class="NLM_lpage">921</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1038%2Fnature03445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=15829967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=434&publication_year=2005&pages=917-921&author=H.+Farmerauthor=N.+McCabeauthor=C.+J.+Lordauthor=A.+N.+Tuttauthor=D.+A.+Johnsonauthor=T.+B.+Richardsonauthor=M.+Santarosaauthor=K.+J.+Dillonauthor=I.+Hicksonauthor=C.+Knightsauthor=N.+M.+Martinauthor=S.+P.+Jacksonauthor=G.+C.+Smithauthor=A.+Ashworth&title=Targeting+the+DNA+repair+defect+in+BRCA+mutant+cells+as+a+therapeutic+strategy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy</span></div><div class="casAuthors">Farmer, Hannah; McCabe, Nuala; Lord, Christopher J.; Tutt, Andrew N. J.; Johnson, Damian A.; Richardson, Tobias B.; Santarosa, Manuela; Dillon, Krystyna J.; Hickson, Ian; Knights, Charlotte; Martin, Niall M. B.; Jackson, Stephen P.; Smith, Graeme C. M.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">434</span>
        (<span class="NLM_cas:issue">7035</span>),
    <span class="NLM_cas:pages">917-921</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">BRCA1 and BRCA2 are important for DNA double-strand break repair by homologous recombination, and mutations in these genes predispose to breast and other cancers.  Poly(ADP-ribose) polymerase (PARP) is an enzyme involved in base excision repair, a key pathway in the repair of DNA single-strand breaks.  The authors show here that BRCA1 or BRCA2 dysfunction unexpectedly and profoundly sensitizes cells to the inhibition of PARP enzymic activity, resulting in chromosomal instability, cell cycle arrest and subsequent apoptosis.  This seems to be because the inhibition of PARP leads to the persistence of DNA lesions normally repaired by homologous recombination.  These results illustrate how different pathways cooperate to repair damage, and suggest that the targeted inhibition of particular DNA repair pathways may allow the design of specific and less toxic therapies for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomVTKE4mFwfrVg90H21EOLACvtfcHk0liFypJUY22gXQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrc%253D&md5=03b5ba0adc21a5627fe17ae535f45078</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fnature03445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature03445%26sid%3Dliteratum%253Aachs%26aulast%3DFarmer%26aufirst%3DH.%26aulast%3DMcCabe%26aufirst%3DN.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DTutt%26aufirst%3DA.%2BN.%26aulast%3DJohnson%26aufirst%3DD.%2BA.%26aulast%3DRichardson%26aufirst%3DT.%2BB.%26aulast%3DSantarosa%26aufirst%3DM.%26aulast%3DDillon%26aufirst%3DK.%2BJ.%26aulast%3DHickson%26aufirst%3DI.%26aulast%3DKnights%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DN.%2BM.%26aulast%3DJackson%26aufirst%3DS.%2BP.%26aulast%3DSmith%26aufirst%3DG.%2BC.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DTargeting%2520the%2520DNA%2520repair%2520defect%2520in%2520BRCA%2520mutant%2520cells%2520as%2520a%2520therapeutic%2520strategy%26jtitle%3DNature%26date%3D2005%26volume%3D434%26spage%3D917%26epage%3D921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Lord, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">Targeted therapy for cancer using PARP inhibitors</span> <span class="citation_source-journal">Curr. Opin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">363</span><span class="NLM_x">â</span> <span class="NLM_lpage">369</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1016%2Fj.coph.2008.06.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=18644251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFCktL7I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=363-369&author=C.+J.+Lordauthor=A.+Ashworth&title=Targeted+therapy+for+cancer+using+PARP+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted therapy for cancer using PARP inhibitors</span></div><div class="casAuthors">Lord, Christopher J.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">363-369</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Poly (ADP-ribose) Polymerase (PARP) has a well-established role in DNA repair processes, and small mol. inhibitors of PARP have been developed as chemotherapy sensitizers for the treatment of cancer.  The subsequent demonstration that PARP inhibition is selective for BRCA1 or BRCA2 deficiency suggests that PARP inhibitors may be particularly useful for the treatment of cancer with BRCA mutations.  This would represent one of the first clin. implemented examples of a synthetic lethal approach for cancer treatment.  However, there are still unanswered questions surrounding PARP inhibitors, namely the levels of specificity and potency that are required to elicit BRCA selectivity.  The recent identification of mechanisms of cellular resistance to PARP inhibitors may provide indications as to how these drugs may be best used in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0-DMq21TzX7Vg90H21EOLACvtfcHk0liFypJUY22gXQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFCktL7I&md5=867dc1c878a3b1c36a981fe78dfb7d7d</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2008.06.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2008.06.016%26sid%3Dliteratum%253Aachs%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DTargeted%2520therapy%2520for%2520cancer%2520using%2520PARP%2520inhibitors%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2008%26volume%3D8%26spage%3D363%26epage%3D369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Saffhill, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ockey, C. H.</span><span> </span><span class="NLM_article-title">Strand breaks arising from the repair of the 5-bromodeoxyuridine-substituted template and methyl methanesulphonate-induced lesions can explain the formation of sister chromatid exchanges</span> <span class="citation_source-journal">Chromosoma</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">218</span><span class="NLM_x">â</span> <span class="NLM_lpage">224</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=1985&pages=218-224&author=R.+Saffhillauthor=C.+H.+Ockey&title=Strand+breaks+arising+from+the+repair+of+the+5-bromodeoxyuridine-substituted+template+and+methyl+methanesulphonate-induced+lesions+can+explain+the+formation+of+sister+chromatid+exchanges"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSaffhill%26aufirst%3DR.%26aulast%3DOckey%26aufirst%3DC.%2BH.%26atitle%3DStrand%2520breaks%2520arising%2520from%2520the%2520repair%2520of%2520the%25205-bromodeoxyuridine-substituted%2520template%2520and%2520methyl%2520methanesulphonate-induced%2520lesions%2520can%2520explain%2520the%2520formation%2520of%2520sister%2520chromatid%2520exchanges%26jtitle%3DChromosoma%26date%3D1985%26volume%3D92%26spage%3D218%26epage%3D224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Kaelin, W. G.,  Jr.</span><span> </span><span class="NLM_article-title">The concept of synthetic lethality in the context of anticancer therapy</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">689</span><span class="NLM_x">â</span> <span class="NLM_lpage">698</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1038%2Fnrc1691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=16110319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpsleks7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=689-698&author=W.+G.+Kaelin&title=The+concept+of+synthetic+lethality+in+the+context+of+anticancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The Concept of Synthetic Lethality in the Context of Anticancer Therapy</span></div><div class="casAuthors">Kaelin, William G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">689-698</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with refs.  Two genes are synthetic lethal if mutation of either alone is compatible with viability but mutation of both leads to death.  So, targeting a gene that is synthetic lethal to a cancer-relevant mutation should kill only cancer cells and spare normal cells.  Synthetic lethality therefore provides a conceptual framework for the development of cancer-specific cytotoxic agents.  This paradigm has not been exploited in the past because there were no robust methods for systematically identifying synthetic lethal genes.  This is changing as a result of the increased availability of chem. and genetic tools for perturbing gene function in somatic cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrf4V-KQ6I5ILVg90H21EOLACvtfcHk0lioI_IpmxzUCg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpsleks7c%253D&md5=4d5e38282cd8a3d2c3451d56ca88ac8b</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fnrc1691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1691%26sid%3Dliteratum%253Aachs%26aulast%3DKaelin%26aufirst%3DW.%2BG.%26atitle%3DThe%2520concept%2520of%2520synthetic%2520lethality%2520in%2520the%2520context%2520of%2520anticancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D689%26epage%3D698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Turner, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tutt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">Hallmarks of âBRCAnessâ in sporadic cancers</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">814</span><span class="NLM_x">â</span> <span class="NLM_lpage">819</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1038%2Fnrc1457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=15510162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD2cXos1ymu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=814-819&author=N.+Turnerauthor=A.+Tuttauthor=A.+Ashworth&title=Hallmarks+of+%E2%80%9CBRCAness%E2%80%9D+in+sporadic+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Hallmarks of 'BRCAness' in sporadic cancers</span></div><div class="casAuthors">Turner, Nicholas; Tutt, Andrew; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">814-819</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Germline mutations in the BRCA1, BRCA2 and Fanconi anemia genes confer cancer susceptibility, and the proteins encoded by these genes have distinct functions in related DNA-repair processes.  Emerging evidence indicates that these processes are disrupted by numerous mechanisms in sporadic cancers.  Collectively, there are properties that define 'BRCAness' - i.e., traits that some sporadic cancers share with those occurring in either BRCA1- or BRCA2-mutation carriers.  These common properties might have important implications for the clin. management of these cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSK5dEe3-aKLVg90H21EOLACvtfcHk0lioI_IpmxzUCg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXos1ymu7g%253D&md5=b2ec7c226f4ca388e2dc3a6c1d030e7d</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fnrc1457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1457%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DN.%26aulast%3DTutt%26aufirst%3DA.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DHallmarks%2520of%2520%25E2%2580%259CBRCAness%25E2%2580%259D%2520in%2520sporadic%2520cancers%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D814%26epage%3D819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Pal, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortimer, J.</span><span> </span><span class="NLM_article-title">Triple-negative breast cancer: novel therapies and new directions</span> <span class="citation_source-journal">Maturitas</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">269</span><span class="NLM_x">â</span> <span class="NLM_lpage">274</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2009&pages=269-274&author=S.+K.+Palauthor=J.+Mortimer&title=Triple-negative+breast+cancer%3A+novel+therapies+and+new+directions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPal%26aufirst%3DS.%2BK.%26aulast%3DMortimer%26aufirst%3DJ.%26atitle%3DTriple-negative%2520breast%2520cancer%253A%2520novel%2520therapies%2520and%2520new%2520directions%26jtitle%3DMaturitas%26date%3D2009%26volume%3D63%26spage%3D269%26epage%3D274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">OâShaughnessy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osborne, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pippen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoffe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patt, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monaghan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rocha, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ossovskaya, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, C.</span><span> </span><span class="NLM_article-title">Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1200%2FJCO.2009.22.0863" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=3&author=J.+O%E2%80%99Shaughnessyauthor=C.+Osborneauthor=J.+Pippenauthor=M.+Yoffeauthor=D.+Pattauthor=G.+Monaghanauthor=C.+Rochaauthor=V.+Ossovskayaauthor=B.+Shermanauthor=C.+Bradley&title=Efficacy+of+BSI-201%2C+a+poly+%28ADP-ribose%29+polymerase-1+%28PARP1%29+inhibitor%2C+in+combination+with+gemcitabine%2Fcarboplatin+%28G%2FC%29+in+patients+with+metastatic+triple-negative+breast+cancer+%28TNBC%29%3A+results+of+a+randomized+phase+II+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.22.0863&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.22.0863%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shaughnessy%26aufirst%3DJ.%26aulast%3DOsborne%26aufirst%3DC.%26aulast%3DPippen%26aufirst%3DJ.%26aulast%3DYoffe%26aufirst%3DM.%26aulast%3DPatt%26aufirst%3DD.%26aulast%3DMonaghan%26aufirst%3DG.%26aulast%3DRocha%26aufirst%3DC.%26aulast%3DOssovskaya%26aufirst%3DV.%26aulast%3DSherman%26aufirst%3DB.%26aulast%3DBradley%26aufirst%3DC.%26atitle%3DEfficacy%2520of%2520BSI-201%252C%2520a%2520poly%2520%2528ADP-ribose%2529%2520polymerase-1%2520%2528PARP1%2529%2520inhibitor%252C%2520in%2520combination%2520with%2520gemcitabine%252Fcarboplatin%2520%2528G%252FC%2529%2520in%2520patients%2520with%2520metastatic%2520triple-negative%2520breast%2520cancer%2520%2528TNBC%2529%253A%2520results%2520of%2520a%2520randomized%2520phase%2520II%2520trial%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, S. H.</span><span> </span><span class="NLM_article-title">Nitric oxide activation of poly(ADP-ribose) synthetase in neurotoxicity</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">263</span><span class="NLM_x">, </span> <span class="NLM_fpage">687</span><span class="NLM_x">â</span> <span class="NLM_lpage">689</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=1994&pages=687-689&author=J.+Zhangauthor=V.+L.+Dawsonauthor=T.+M.+Dawsonauthor=S.+H.+Snyder&title=Nitric+oxide+activation+of+poly%28ADP-ribose%29+synthetase+in+neurotoxicity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DDawson%26aufirst%3DV.%2BL.%26aulast%3DDawson%26aufirst%3DT.%2BM.%26aulast%3DSnyder%26aufirst%3DS.%2BH.%26atitle%3DNitric%2520oxide%2520activation%2520of%2520poly%2528ADP-ribose%2529%2520synthetase%2520in%2520neurotoxicity%26jtitle%3DScience%26date%3D1994%26volume%3D263%26spage%3D687%26epage%3D689" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Eliasson, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampei, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandir, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurn, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traystman, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pieper, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, V. L.</span><span> </span><span class="NLM_article-title">Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1089</span><span class="NLM_x">â</span> <span class="NLM_lpage">1095</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1038%2Fnm1097-1089" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=9334719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADyaK2sXmsFyqtb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1997&pages=1089-1095&author=M.+J.+Eliassonauthor=K.+Sampeiauthor=A.+S.+Mandirauthor=P.+D.+Hurnauthor=R.+J.+Traystmanauthor=J.+Baoauthor=A.+Pieperauthor=Z.+Q.+Wangauthor=T.+M.+Dawsonauthor=S.+H.+Snyderauthor=V.+L.+Dawson&title=Poly%28ADP-ribose%29+polymerase+gene+disruption+renders+mice+resistant+to+cerebral+ischemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia</span></div><div class="casAuthors">Eliasson, Mikael J. L.; Sampei, Kenji; Mandir, Allen S.; Hurn, Patricia D.; Traystman, Richard J.; Bao, Jun; Pieper, Andrew; Wang, Zhao-Qi; Dawson, Ted M.; Snyder, Solomon H.; Dawson, Valina L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1089-1095</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature America</span>)
        </div><div class="casAbstract">Nitric oxide (NO) and peroxynitrite, formed from NO and superoxide anion, have been implicated as mediators of neuronal damage following focal ischemia, but their mol. targets have not been defined.  One candidate pathway is DNA damage leading to activation of the nuclear enzyme, poly(ADP-ribose) polymerase (PARP), which catalyzes attachment of ADP ribose units from NAD to nuclear proteins following DNA damage.  Excessive activation of PARP can deplete NAD and ATP, which is consumed in regeneration of NAD, leading to cell death by energy depletion.  The authors show that genetic disruption of PARP provides profound protection against glutamate-NO-mediated ischemic insults in vitro and major decreases in infarct vol. after reversible middle cerebral artery occlusion.  These results provide compelling evidence for a primary involvement of PARP activation in neuronal damage following focal ischemia and suggest that therapies designed towards inhibiting PARP may provide benefit in the treatment of cerebrovascular disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLSq-7dMGKE7Vg90H21EOLACvtfcHk0lizW-WIr6Sbgw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmsFyqtb8%253D&md5=d83a2bb75e066d20b415119fb4452e21</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fnm1097-1089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1097-1089%26sid%3Dliteratum%253Aachs%26aulast%3DEliasson%26aufirst%3DM.%2BJ.%26aulast%3DSampei%26aufirst%3DK.%26aulast%3DMandir%26aufirst%3DA.%2BS.%26aulast%3DHurn%26aufirst%3DP.%2BD.%26aulast%3DTraystman%26aufirst%3DR.%2BJ.%26aulast%3DBao%26aufirst%3DJ.%26aulast%3DPieper%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DZ.%2BQ.%26aulast%3DDawson%26aufirst%3DT.%2BM.%26aulast%3DSnyder%26aufirst%3DS.%2BH.%26aulast%3DDawson%26aufirst%3DV.%2BL.%26atitle%3DPoly%2528ADP-ribose%2529%2520polymerase%2520gene%2520disruption%2520renders%2520mice%2520resistant%2520to%2520cerebral%2520ischemia%26jtitle%3DNat.%2520Med.%26date%3D1997%26volume%3D3%26spage%3D1089%26epage%3D1095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Endres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Namura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waeber, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moskowitz, M. A.</span><span> </span><span class="NLM_article-title">Ischemic brain injury is mediated by the activation of poly(ADP-ribose)polymerase</span> <span class="citation_source-journal">J. Cereb. Blood Flow Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1143</span><span class="NLM_x">â</span> <span class="NLM_lpage">1151</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1097%2F00004647-199711000-00002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=9390645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADyaK2sXotVShtbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1997&pages=1143-1151&author=M.+Endresauthor=Z.+Q.+Wangauthor=S.+Namuraauthor=C.+Waeberauthor=M.+A.+Moskowitz&title=Ischemic+brain+injury+is+mediated+by+the+activation+of+poly%28ADP-ribose%29polymerase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Ischemic brain injury is mediated by the activation of poly(ADP-ribose)polymerase</span></div><div class="casAuthors">Endres, Matthias; Wang, Zhao-Qi; Namura, Shobu; Waeber, Christian; Moskowitz, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cerebral Blood Flow and Metabolism</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1143-1151</span>CODEN:
                <span class="NLM_cas:coden">JCBMDN</span>;
        ISSN:<span class="NLM_cas:issn">0271-678X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott-Raven Publishers</span>)
        </div><div class="casAbstract">Poly(ADP-ribose)polymerase (PARP, EC 2.4.2.30), an abundant nuclear protein activated by DNA nicks, mediates cell death in vitro by NAD (NAD) depletion after exposure to nitric oxide.  The authors examd. whether genetic deletion of PARP (PARP null mice) or its pharmacol. inhibition by 3-aminobenzamide (3-AB) attenuates tissue injury after transient cerebral ischemia.  Twenty-two hours after reperfusion following 2 h of filamentous middle cerebral artery occlusion, ischemic injury was decreased in PARP-/- and PARP+/- mice compared with PARP+/+ litter mates, and also was attenuated in 129/SV wild-type mice after 3-AB treatment compared with controls.  Infarct sparing was accompanied by functional recovery in PARP-/- and 3-AB-treated mice.  Increased poly(ADP-ribose) immunostaining obsd. in ischemic cell nuclei 5 min after reperfusion was reduced by 3-AB treatment.  Levels of NAD-the substrate of PARP-were reduced 2 h after reperfusion and were 35% of contralateral levels at 24 h.  The decreases were attenuated in PARP-/- mice and in 3-AB-treated animals.  Poly(ADP-ribose)polymerase cleavage by caspase-3 (CPP-32) has been proposed as an important step in apoptotic cell death.  Markers of apoptosis, such as oligonucleosomal DNA damage, total DNA fragmentation, and the d. of terminal deoxy-nucleotidyl transferase dUTP nick-end-labeled (TUNEL +) cells, however, did not differ in ischemic brain tissue of PARP-/- mice or in 3-AB-treated animals vs. controls, although there were differences in the no. of TUNEL-stained cells reflecting the decrease in infarct size.  Thus, ischemic brain injury activates PARP and contributes to cell death most likely by NAD depletion and energy failure, although the authors have not excluded a role for PARP in apoptotic cell death at earlier or later stages in ischemic cell death.  Inhibitors of PARP activation could provide a potential therapy in acute stroke.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZgfj6WehsELVg90H21EOLACvtfcHk0liXb1mpgMW_zw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXotVShtbo%253D&md5=38ad29424df8e6f3613cab8c38b0dfcb</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1097%2F00004647-199711000-00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00004647-199711000-00002%26sid%3Dliteratum%253Aachs%26aulast%3DEndres%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DZ.%2BQ.%26aulast%3DNamura%26aufirst%3DS.%26aulast%3DWaeber%26aufirst%3DC.%26aulast%3DMoskowitz%26aufirst%3DM.%2BA.%26atitle%3DIschemic%2520brain%2520injury%2520is%2520mediated%2520by%2520the%2520activation%2520of%2520poly%2528ADP-ribose%2529polymerase%26jtitle%3DJ.%2520Cereb.%2520Blood%2520Flow%2520Metab.%26date%3D1997%26volume%3D17%26spage%3D1143%26epage%3D1151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Watson, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whish, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Threadgill, M. D.</span><span> </span><span class="NLM_article-title">Synthesis of 3-substituted benzamides and 5-substituted isoquinolin-1(2<i>H</i>)-ones and preliminary evaluation as inhibitors of poly(ADP-ribose)polymerase (PARP)</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">721</span><span class="NLM_x">â</span> <span class="NLM_lpage">734</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1998&pages=721-734&author=C.+Y.+Watsonauthor=W.+J.+Whishauthor=M.+D.+Threadgill&title=Synthesis+of+3-substituted+benzamides+and+5-substituted+isoquinolin-1%282H%29-ones+and+preliminary+evaluation+as+inhibitors+of+poly%28ADP-ribose%29polymerase+%28PARP%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWatson%26aufirst%3DC.%2BY.%26aulast%3DWhish%26aufirst%3DW.%2BJ.%26aulast%3DThreadgill%26aufirst%3DM.%2BD.%26atitle%3DSynthesis%2520of%25203-substituted%2520benzamides%2520and%25205-substituted%2520isoquinolin-1%25282H%2529-ones%2520and%2520preliminary%2520evaluation%2520as%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529polymerase%2520%2528PARP%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D1998%26volume%3D6%26spage%3D721%26epage%3D734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Suto, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arundel-Suto, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Werbel, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sebolt-Leopold, J. S.</span><span> </span><span class="NLM_article-title">Dihydroisoquinolinones: the design and synthesis of a new series of potent inhibitors of poly(ADP-ribose) polymerase</span> <span class="citation_source-journal">Anti-Cancer Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">107</span><span class="NLM_x">â</span> <span class="NLM_lpage">117</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1991&pages=107-117&author=M.+J.+Sutoauthor=W.+R.+Turnerauthor=C.+M.+Arundel-Sutoauthor=L.+M.+Werbelauthor=J.+S.+Sebolt-Leopold&title=Dihydroisoquinolinones%3A+the+design+and+synthesis+of+a+new+series+of+potent+inhibitors+of+poly%28ADP-ribose%29+polymerase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSuto%26aufirst%3DM.%2BJ.%26aulast%3DTurner%26aufirst%3DW.%2BR.%26aulast%3DArundel-Suto%26aufirst%3DC.%2BM.%26aulast%3DWerbel%26aufirst%3DL.%2BM.%26aulast%3DSebolt-Leopold%26aufirst%3DJ.%2BS.%26atitle%3DDihydroisoquinolinones%253A%2520the%2520design%2520and%2520synthesis%2520of%2520a%2520new%2520series%2520of%2520potent%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%26jtitle%3DAnti-Cancer%2520Drug%2520Des.%26date%3D1991%26volume%3D6%26spage%3D107%26epage%3D117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Jagtap, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Southan, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baloglu, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ram, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mabley, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marton, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salzman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabo, C.</span><span> </span><span class="NLM_article-title">The discovery and synthesis of novel adenosine substituted 2,3-dihydro-1<i>H</i>-isoindol-1-ones: potent inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1)</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">81</span><span class="NLM_x">â</span> <span class="NLM_lpage">85</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=81-85&author=P.+G.+Jagtapauthor=G.+J.+Southanauthor=E.+Balogluauthor=S.+Ramauthor=J.+G.+Mableyauthor=A.+Martonauthor=A.+Salzmanauthor=C.+Szabo&title=The+discovery+and+synthesis+of+novel+adenosine+substituted+2%2C3-dihydro-1H-isoindol-1-ones%3A+potent+inhibitors+of+poly%28ADP-ribose%29+polymerase-1+%28PARP-1%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJagtap%26aufirst%3DP.%2BG.%26aulast%3DSouthan%26aufirst%3DG.%2BJ.%26aulast%3DBaloglu%26aufirst%3DE.%26aulast%3DRam%26aufirst%3DS.%26aulast%3DMabley%26aufirst%3DJ.%2BG.%26aulast%3DMarton%26aufirst%3DA.%26aulast%3DSalzman%26aufirst%3DA.%26aulast%3DSzabo%26aufirst%3DC.%26atitle%3DThe%2520discovery%2520and%2520synthesis%2520of%2520novel%2520adenosine%2520substituted%25202%252C3-dihydro-1H-isoindol-1-ones%253A%2520potent%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529%2520polymerase-1%2520%2528PARP-1%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D81%26epage%3D85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Tao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bihovsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husten, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, R. L.</span><span> </span><span class="NLM_article-title">Synthesis and structureâactivity relationships of novel poly(ADP-ribose) polymerase-1 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">938</span><span class="NLM_x">â</span> <span class="NLM_lpage">942</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=938-942&author=M.+Taoauthor=C.+H.+Parkauthor=R.+Bihovskyauthor=G.+J.+Wellsauthor=J.+Hustenauthor=M.+A.+Atorauthor=R.+L.+Hudkins&title=Synthesis+and+structure%E2%88%92activity+relationships+of+novel+poly%28ADP-ribose%29+polymerase-1+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTao%26aufirst%3DM.%26aulast%3DPark%26aufirst%3DC.%2BH.%26aulast%3DBihovsky%26aufirst%3DR.%26aulast%3DWells%26aufirst%3DG.%2BJ.%26aulast%3DHusten%26aufirst%3DJ.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26atitle%3DSynthesis%2520and%2520structure%25E2%2588%2592activity%2520relationships%2520of%2520novel%2520poly%2528ADP-ribose%2529%2520polymerase-1%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D938%26epage%3D942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Shinkwin, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whish, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Threadgill, M. D.</span><span> </span><span class="NLM_article-title">Synthesis of thiophenecarboxamides, thieno[3,4-<i>c</i>]pyridin-4(5<i>H</i>)-ones and thieno[3,4-<i>d</i>]pyrimidin-4(3<i>H</i>)-ones and preliminary evaluation as inhibitors of poly(ADP-ribose)polymerase (PARP)</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">297</span><span class="NLM_x">â</span> <span class="NLM_lpage">308</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1999&pages=297-308&author=A.+E.+Shinkwinauthor=W.+J.+Whishauthor=M.+D.+Threadgill&title=Synthesis+of+thiophenecarboxamides%2C+thieno%5B3%2C4-c%5Dpyridin-4%285H%29-ones+and+thieno%5B3%2C4-d%5Dpyrimidin-4%283H%29-ones+and+preliminary+evaluation+as+inhibitors+of+poly%28ADP-ribose%29polymerase+%28PARP%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShinkwin%26aufirst%3DA.%2BE.%26aulast%3DWhish%26aufirst%3DW.%2BJ.%26aulast%3DThreadgill%26aufirst%3DM.%2BD.%26atitle%3DSynthesis%2520of%2520thiophenecarboxamides%252C%2520thieno%255B3%252C4-c%255Dpyridin-4%25285H%2529-ones%2520and%2520thieno%255B3%252C4-d%255Dpyrimidin-4%25283H%2529-ones%2520and%2520preliminary%2520evaluation%2520as%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529polymerase%2520%2528PARP%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D1999%26volume%3D7%26spage%3D297%26epage%3D308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Li, J.-h.; Zhang, J.; Jackson, P. F.; Maclin, K. M.</span><span> </span><span class="NLM_article-title">Compounds, Methods and Pharmaceutical Compositions for Treating Neural or Cardiovascular Tissue Damage</span>. U.S. Patent 6514983,<span class="NLM_x"> </span><span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=J.-h.+Li&author=J.+Zhang&author=P.+F.+Jackson&author=K.+M.+Maclin&title=Compounds%2C+Methods+and+Pharmaceutical+Compositions+for+Treating+Neural+or+Cardiovascular+Tissue+Damage"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.-h.%26atitle%3DCompounds%252C%2520Methods%2520and%2520Pharmaceutical%2520Compositions%2520for%2520Treating%2520Neural%2520or%2520Cardiovascular%2520Tissue%2520Damage%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Branca, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerretani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orvieto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palumbi, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toniatti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muraglia, E.</span><span> </span><span class="NLM_article-title">Identification of aminoethyl pyrrolo dihydroisoquinolinones as novel poly(ADP-ribose) polymerase-1 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">4042</span><span class="NLM_x">â</span> <span class="NLM_lpage">4045</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=4042-4045&author=D.+Brancaauthor=M.+Cerretaniauthor=P.+Jonesauthor=U.+Kochauthor=F.+Orvietoauthor=M.+C.+Palumbiauthor=M.+Rowleyauthor=C.+Toniattiauthor=E.+Muraglia&title=Identification+of+aminoethyl+pyrrolo+dihydroisoquinolinones+as+novel+poly%28ADP-ribose%29+polymerase-1+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBranca%26aufirst%3DD.%26aulast%3DCerretani%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DKoch%26aufirst%3DU.%26aulast%3DOrvieto%26aufirst%3DF.%26aulast%3DPalumbi%26aufirst%3DM.%2BC.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DToniatti%26aufirst%3DC.%26aulast%3DMuraglia%26aufirst%3DE.%26atitle%3DIdentification%2520of%2520aminoethyl%2520pyrrolo%2520dihydroisoquinolinones%2520as%2520novel%2520poly%2528ADP-ribose%2529%2520polymerase-1%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D4042%26epage%3D4045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Steinhagen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerisch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mittendorf, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlemmer, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, B.</span><span> </span><span class="NLM_article-title">Substituted uracil derivatives as potent inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1)</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">3187</span><span class="NLM_x">â</span> <span class="NLM_lpage">3190</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=3187-3190&author=H.+Steinhagenauthor=M.+Gerischauthor=J.+Mittendorfauthor=K.+H.+Schlemmerauthor=B.+Albrecht&title=Substituted+uracil+derivatives+as+potent+inhibitors+of+poly%28ADP-ribose%29polymerase-1+%28PARP-1%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSteinhagen%26aufirst%3DH.%26aulast%3DGerisch%26aufirst%3DM.%26aulast%3DMittendorf%26aufirst%3DJ.%26aulast%3DSchlemmer%26aufirst%3DK.%2BH.%26aulast%3DAlbrecht%26aufirst%3DB.%26atitle%3DSubstituted%2520uracil%2520derivatives%2520as%2520potent%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529polymerase-1%2520%2528PARP-1%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2002%26volume%3D12%26spage%3D3187%26epage%3D3190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Seko, T.; Takeuchi, J.; Takahashi, S.; Kamanaka, Y.; Kamoshima, W.</span><span> </span><span class="NLM_article-title">Fused Pyridazine Derivative Compounds and Drugs Containing These Compounds as the Active Ingredient</span>. U.S. Patent 7402580,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=T.+Seko&author=J.+Takeuchi&author=S.+Takahashi&author=Y.+Kamanaka&author=W.+Kamoshima&title=Fused+Pyridazine+Derivative+Compounds+and+Drugs+Containing+These+Compounds+as+the+Active+Ingredient"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSeko%26aufirst%3DT.%26atitle%3DFused%2520Pyridazine%2520Derivative%2520Compounds%2520and%2520Drugs%2520Containing%2520These%2520Compounds%2520as%2520the%2520Active%2520Ingredient%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Kalish, V.; Zhang, J.; Xu, W.; Li, J.-h.; Xing, A. D.; Liu, Q.</span><span> </span><span class="NLM_article-title">Compounds, Methods and Pharmaceutical Compositions for Inhibiting PARP</span>. U.S. Patent 7456178,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=V.+Kalish&author=J.+Zhang&author=W.+Xu&author=J.-h.+Li&author=A.+D.+Xing&author=Q.+Liu&title=Compounds%2C+Methods+and+Pharmaceutical+Compositions+for+Inhibiting+PARP"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKalish%26aufirst%3DV.%26atitle%3DCompounds%252C%2520Methods%2520and%2520Pharmaceutical%2520Compositions%2520for%2520Inhibiting%2520PARP%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Orvieto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Branca, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giomini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ontoria, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palumbi, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toniatti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muraglia, E.</span><span> </span><span class="NLM_article-title">Identification of substituted pyrazolo[1,5-<i>a</i>]quinazolin-5(4<i>H</i>)-one as potent poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">4196</span><span class="NLM_x">â</span> <span class="NLM_lpage">4200</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=4196-4200&author=F.+Orvietoauthor=D.+Brancaauthor=C.+Giominiauthor=P.+Jonesauthor=U.+Kochauthor=J.+M.+Ontoriaauthor=M.+C.+Palumbiauthor=M.+Rowleyauthor=C.+Toniattiauthor=E.+Muraglia&title=Identification+of+substituted+pyrazolo%5B1%2C5-a%5Dquinazolin-5%284H%29-one+as+potent+poly%28ADP-ribose%29polymerase-1+%28PARP-1%29+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOrvieto%26aufirst%3DF.%26aulast%3DBranca%26aufirst%3DD.%26aulast%3DGiomini%26aufirst%3DC.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DKoch%26aufirst%3DU.%26aulast%3DOntoria%26aufirst%3DJ.%2BM.%26aulast%3DPalumbi%26aufirst%3DM.%2BC.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DToniatti%26aufirst%3DC.%26aulast%3DMuraglia%26aufirst%3DE.%26atitle%3DIdentification%2520of%2520substituted%2520pyrazolo%255B1%252C5-a%255Dquinazolin-5%25284H%2529-one%2520as%2520potent%2520poly%2528ADP-ribose%2529polymerase-1%2520%2528PARP-1%2529%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D4196%26epage%3D4200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Zimmermann, K.; Portmann, R.; Rigel, D. F.</span><span> </span><span class="NLM_article-title">Indoloquinazolinones</span>. U.S. Patent 6964960,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=K.+Zimmermann&author=R.+Portmann&author=D.+F.+Rigel&title=Indoloquinazolinones"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZimmermann%26aufirst%3DK.%26atitle%3DIndoloquinazolinones%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Ferraris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pahutski, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ficco, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serdyuk, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alemu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradford, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoover, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lautar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooney, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Q. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalish, V.</span><span> </span><span class="NLM_article-title">Design and synthesis of poly ADP-ribose polymerase-1 inhibitors. 2. Biological evaluation of aza-5[H]-phenanthridin-6-ones as potent, aqueous-soluble compounds for the treatment of ischemic injuries</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">3138</span><span class="NLM_x">â</span> <span class="NLM_lpage">3151</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm030109s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=3138-3151&author=D.+Ferrarisauthor=Y.+S.+Koauthor=T.+Pahutskiauthor=R.+P.+Ficcoauthor=L.+Serdyukauthor=C.+Alemuauthor=C.+Bradfordauthor=T.+Chiouauthor=R.+Hooverauthor=S.+Huangauthor=S.+Lautarauthor=S.+Liangauthor=Q.+Linauthor=M.+X.+Luauthor=M.+Mooneyauthor=L.+Morganauthor=Y.+Qianauthor=S.+Tranauthor=L.+R.+Williamsauthor=Q.+Y.+Wuauthor=J.+Zhangauthor=Y.+Zouauthor=V.+Kalish&title=Design+and+synthesis+of+poly+ADP-ribose+polymerase-1+inhibitors.+2.+Biological+evaluation+of+aza-5%5BH%5D-phenanthridin-6-ones+as+potent%2C+aqueous-soluble+compounds+for+the+treatment+of+ischemic+injuries"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Fjm030109s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030109s%26sid%3Dliteratum%253Aachs%26aulast%3DFerraris%26aufirst%3DD.%26aulast%3DKo%26aufirst%3DY.%2BS.%26aulast%3DPahutski%26aufirst%3DT.%26aulast%3DFicco%26aufirst%3DR.%2BP.%26aulast%3DSerdyuk%26aufirst%3DL.%26aulast%3DAlemu%26aufirst%3DC.%26aulast%3DBradford%26aufirst%3DC.%26aulast%3DChiou%26aufirst%3DT.%26aulast%3DHoover%26aufirst%3DR.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DLautar%26aufirst%3DS.%26aulast%3DLiang%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DQ.%26aulast%3DLu%26aufirst%3DM.%2BX.%26aulast%3DMooney%26aufirst%3DM.%26aulast%3DMorgan%26aufirst%3DL.%26aulast%3DQian%26aufirst%3DY.%26aulast%3DTran%26aufirst%3DS.%26aulast%3DWilliams%26aufirst%3DL.%2BR.%26aulast%3DWu%26aufirst%3DQ.%2BY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DY.%26aulast%3DKalish%26aufirst%3DV.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520poly%2520ADP-ribose%2520polymerase-1%2520inhibitors.%25202.%2520Biological%2520evaluation%2520of%2520aza-5%255BH%255D-phenanthridin-6-ones%2520as%2520potent%252C%2520aqueous-soluble%2520compounds%2520for%2520the%2520treatment%2520of%2520ischemic%2520injuries%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D3138%26epage%3D3151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Ferraris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ficco, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pahutski, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lautar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalish, V.</span><span> </span><span class="NLM_article-title">Design and synthesis of poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors. Part 3: In vitro evaluation of 1,3,4,5-tetrahydro-benzo[<i>c</i>][1,6]- and [<i>c</i>][1,7]-naphthyridin-6-ones</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2513</span><span class="NLM_x">â</span> <span class="NLM_lpage">2518</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=2513-2518&author=D.+Ferrarisauthor=R.+P.+Ficcoauthor=T.+Pahutskiauthor=S.+Lautarauthor=S.+Huangauthor=J.+Zhangauthor=V.+Kalish&title=Design+and+synthesis+of+poly%28ADP-ribose%29polymerase-1+%28PARP-1%29+inhibitors.+Part+3%3A+In+vitro+evaluation+of+1%2C3%2C4%2C5-tetrahydro-benzo%5Bc%5D%5B1%2C6%5D-+and+%5Bc%5D%5B1%2C7%5D-naphthyridin-6-ones"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFerraris%26aufirst%3DD.%26aulast%3DFicco%26aufirst%3DR.%2BP.%26aulast%3DPahutski%26aufirst%3DT.%26aulast%3DLautar%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DKalish%26aufirst%3DV.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520poly%2528ADP-ribose%2529polymerase-1%2520%2528PARP-1%2529%2520inhibitors.%2520Part%25203%253A%2520In%2520vitro%2520evaluation%2520of%25201%252C3%252C4%252C5-tetrahydro-benzo%255Bc%255D%255B1%252C6%255D-%2520and%2520%255Bc%255D%255B1%252C7%255D-naphthyridin-6-ones%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D2513%26epage%3D2518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Miyashiro, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woods, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giranda, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penning, T. D.</span><span> </span><span class="NLM_article-title">Synthesis and SAR of novel tricyclic quinoxalinone inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1)</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">4050</span><span class="NLM_x">â</span> <span class="NLM_lpage">4054</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=4050-4054&author=J.+Miyashiroauthor=K.+W.+Woodsauthor=C.+H.+Parkauthor=X.+Liuauthor=Y.+Shiauthor=E.+F.+Johnsonauthor=J.+J.+Bouskaauthor=A.+M.+Olsonauthor=Y.+Luoauthor=E.+H.+Fryauthor=V.+L.+Girandaauthor=T.+D.+Penning&title=Synthesis+and+SAR+of+novel+tricyclic+quinoxalinone+inhibitors+of+poly%28ADP-ribose%29polymerase-1+%28PARP-1%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMiyashiro%26aufirst%3DJ.%26aulast%3DWoods%26aufirst%3DK.%2BW.%26aulast%3DPark%26aufirst%3DC.%2BH.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DOlson%26aufirst%3DA.%2BM.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DFry%26aufirst%3DE.%2BH.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26aulast%3DPenning%26aufirst%3DT.%2BD.%26atitle%3DSynthesis%2520and%2520SAR%2520of%2520novel%2520tricyclic%2520quinoxalinone%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529polymerase-1%2520%2528PARP-1%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D4050%26epage%3D4054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Li, J.-h.; Zhang, J.; Kalish, V.</span><span> </span><span class="NLM_article-title">Substituted 4,9-Dihydrocyclopenta{imn}phenanthridine-5-ones Derivatives Thereof and Their Uses</span>. U.S. Patent 7157452,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=J.-h.+Li&author=J.+Zhang&author=V.+Kalish&title=Substituted+4%2C9-Dihydrocyclopenta%7Bimn%7Dphenanthridine-5-ones+Derivatives+Thereof+and+Their+Uses"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.-h.%26atitle%3DSubstituted%25204%252C9-Dihydrocyclopenta%257Bimn%257Dphenanthridine-5-ones%2520Derivatives%2520Thereof%2520and%2520Their%2520Uses%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Fujio, M.; Satoh, H.; Inoue, S.; Matsumoto, T.; Egi, Y.; Takahashi, T.</span><span> </span><span class="NLM_article-title">Isoquinoline Compounds and Medicinal Use Thereof</span>. U.S. Patent 7501412,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=M.+Fujio&author=H.+Satoh&author=S.+Inoue&author=T.+Matsumoto&author=Y.+Egi&author=T.+Takahashi&title=Isoquinoline+Compounds+and+Medicinal+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFujio%26aufirst%3DM.%26atitle%3DIsoquinoline%2520Compounds%2520and%2520Medicinal%2520Use%2520Thereof%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Mabire, D. J.-p.; Guillemont, J. E. G.; Van Dun, J. A. J.; Somers, M. V. F.; Wouters, W. B. L.</span><span> </span><span class="NLM_article-title">6-Akenyl and 6-Phenylalkyl Substituted 2-Quinolinones and 2-Quinoxalinones as Poly(ADP-ribose) Polymerase Inhibitors</span> WO 2005054201,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=D.+J.-p.+Mabire&author=J.+E.+G.+Guillemont&author=J.+A.+J.+Van+Dun&author=M.+V.+F.+Somers&author=W.+B.+L.+Wouters&title=6-Akenyl+and+6-Phenylalkyl+Substituted+2-Quinolinones+and+2-Quinoxalinones+as+Poly%28ADP-ribose%29+Polymerase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMabire%26aufirst%3DD.%2BJ.-p.%26atitle%3D6-Akenyl%2520and%25206-Phenylalkyl%2520Substituted%25202-Quinolinones%2520and%25202-Quinoxalinones%2520as%2520Poly%2528ADP-ribose%2529%2520Polymerase%2520Inhibitors%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Jagtap, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baloglu, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Southan, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mabley, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Duzer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salzman, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabo, C.</span><span> </span><span class="NLM_article-title">Discovery of potent poly(ADP-ribose) polymerase-1 inhibitors from the modification of indeno[1,2-<i>c</i>]isoquinolinone</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">5100</span><span class="NLM_x">â</span> <span class="NLM_lpage">5103</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0502891" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=5100-5103&author=P.+G.+Jagtapauthor=E.+Balogluauthor=G.+J.+Southanauthor=J.+G.+Mableyauthor=H.+Liauthor=J.+Zhouauthor=J.+van+Duzerauthor=A.+L.+Salzmanauthor=C.+Szabo&title=Discovery+of+potent+poly%28ADP-ribose%29+polymerase-1+inhibitors+from+the+modification+of+indeno%5B1%2C2-c%5Disoquinolinone"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Fjm0502891&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0502891%26sid%3Dliteratum%253Aachs%26aulast%3DJagtap%26aufirst%3DP.%2BG.%26aulast%3DBaloglu%26aufirst%3DE.%26aulast%3DSouthan%26aufirst%3DG.%2BJ.%26aulast%3DMabley%26aufirst%3DJ.%2BG.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3Dvan%2BDuzer%26aufirst%3DJ.%26aulast%3DSalzman%26aufirst%3DA.%2BL.%26aulast%3DSzabo%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520potent%2520poly%2528ADP-ribose%2529%2520polymerase-1%2520inhibitors%2520from%2520the%2520modification%2520of%2520indeno%255B1%252C2-c%255Disoquinolinone%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D5100%26epage%3D5103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Griffin, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pemberton, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhodes, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bleasdale, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calvert, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durkacz, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newell, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porteous, J. K.</span><span> </span><span class="NLM_article-title">Novel potent inhibitors of the DNA repair enzyme poly(ADP-ribose)polymerase (PARP)</span> <span class="citation_source-journal">Anti-Cancer Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">507</span><span class="NLM_x">â</span> <span class="NLM_lpage">514</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1995&pages=507-514&author=R.+J.+Griffinauthor=L.+C.+Pembertonauthor=D.+Rhodesauthor=C.+Bleasdaleauthor=K.+Bowmanauthor=A.+H.+Calvertauthor=N.+J.+Curtinauthor=B.+W.+Durkaczauthor=D.+R.+Newellauthor=J.+K.+Porteous&title=Novel+potent+inhibitors+of+the+DNA+repair+enzyme+poly%28ADP-ribose%29polymerase+%28PARP%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DPemberton%26aufirst%3DL.%2BC.%26aulast%3DRhodes%26aufirst%3DD.%26aulast%3DBleasdale%26aufirst%3DC.%26aulast%3DBowman%26aufirst%3DK.%26aulast%3DCalvert%26aufirst%3DA.%2BH.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DDurkacz%26aufirst%3DB.%2BW.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DPorteous%26aufirst%3DJ.%2BK.%26atitle%3DNovel%2520potent%2520inhibitors%2520of%2520the%2520DNA%2520repair%2520enzyme%2520poly%2528ADP-ribose%2529polymerase%2520%2528PARP%2529%26jtitle%3DAnti-Cancer%2520Drug%2520Des.%26date%3D1995%26volume%3D10%26spage%3D507%26epage%3D514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group">White, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almassy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calvert, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hostomsky, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maegley, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newell, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srinivasan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golding, B. T.</span><span> </span><span class="NLM_article-title">Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">4084</span><span class="NLM_x">â</span> <span class="NLM_lpage">4097</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm000950v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=4084-4097&author=A.+W.+Whiteauthor=R.+Almassyauthor=A.+H.+Calvertauthor=N.+J.+Curtinauthor=R.+J.+Griffinauthor=Z.+Hostomskyauthor=K.+Maegleyauthor=D.+R.+Newellauthor=S.+Srinivasanauthor=B.+T.+Golding&title=Resistance-modifying+agents.+9.+Synthesis+and+biological+properties+of+benzimidazole+inhibitors+of+the+DNA+repair+enzyme+poly%28ADP-ribose%29+polymerase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1021%2Fjm000950v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000950v%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DA.%2BW.%26aulast%3DAlmassy%26aufirst%3DR.%26aulast%3DCalvert%26aufirst%3DA.%2BH.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DHostomsky%26aufirst%3DZ.%26aulast%3DMaegley%26aufirst%3DK.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DSrinivasan%26aufirst%3DS.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26atitle%3DResistance-modifying%2520agents.%25209.%2520Synthesis%2520and%2520biological%2520properties%2520of%2520benzimidazole%2520inhibitors%2520of%2520the%2520DNA%2520repair%2520enzyme%2520poly%2528ADP-ribose%2529%2520polymerase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D4084%26epage%3D4097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Grandel, R.; Lubisch, W.; Kock, M.; Hoger, T.; Muller, R.; Schult, S.; Holzenkamp, U.</span><span> </span><span class="NLM_article-title">Substituted Indoles Which Are PARP Inhibitors</span>. U.S. Patent 7087637,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=R.+Grandel&author=W.+Lubisch&author=M.+Kock&author=T.+Hoger&author=R.+Muller&author=S.+Schult&author=U.+Holzenkamp&title=Substituted+Indoles+Which+Are+PARP+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGrandel%26aufirst%3DR.%26atitle%3DSubstituted%2520Indoles%2520Which%2520Are%2520PARP%2520Inhibitors%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group">Jones, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boueres, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrigno, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fonsi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giomini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamartina, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monteagudo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ontoria, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsale, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palumbi, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesci, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roscilli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarpelli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz-Fademrecht, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toniatti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span> </span><span class="NLM_article-title">Discovery of 2-{4-[(3<i>S</i>)-piperidin-3-yl]phenyl}-2<i>H</i>-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">7170</span><span class="NLM_x">â</span> <span class="NLM_lpage">7185</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901188v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7170-7185&author=P.+Jonesauthor=S.+Altamuraauthor=J.+Boueresauthor=F.+Ferrignoauthor=M.+Fonsiauthor=C.+Giominiauthor=S.+Lamartinaauthor=E.+Monteagudoauthor=J.+M.+Ontoriaauthor=M.+V.+Orsaleauthor=M.+C.+Palumbiauthor=S.+Pesciauthor=G.+Roscilliauthor=R.+Scarpelliauthor=C.+Schultz-Fademrechtauthor=C.+Toniattiauthor=M.+Rowley&title=Discovery+of+2-%7B4-%5B%283S%29-piperidin-3-yl%5Dphenyl%7D-2H-indazole-7-carboxamide+%28MK-4827%29%3A+a+novel+oral+poly%28ADP-ribose%29polymerase+%28PARP%29+inhibitor+efficacious+in+BRCA-1+and+-2+mutant+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Fjm901188v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901188v%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DP.%26aulast%3DAltamura%26aufirst%3DS.%26aulast%3DBoueres%26aufirst%3DJ.%26aulast%3DFerrigno%26aufirst%3DF.%26aulast%3DFonsi%26aufirst%3DM.%26aulast%3DGiomini%26aufirst%3DC.%26aulast%3DLamartina%26aufirst%3DS.%26aulast%3DMonteagudo%26aufirst%3DE.%26aulast%3DOntoria%26aufirst%3DJ.%2BM.%26aulast%3DOrsale%26aufirst%3DM.%2BV.%26aulast%3DPalumbi%26aufirst%3DM.%2BC.%26aulast%3DPesci%26aufirst%3DS.%26aulast%3DRoscilli%26aufirst%3DG.%26aulast%3DScarpelli%26aufirst%3DR.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DToniatti%26aufirst%3DC.%26aulast%3DRowley%26aufirst%3DM.%26atitle%3DDiscovery%2520of%25202-%257B4-%255B%25283S%2529-piperidin-3-yl%255Dphenyl%257D-2H-indazole-7-carboxamide%2520%2528MK-4827%2529%253A%2520a%2520novel%2520oral%2520poly%2528ADP-ribose%2529polymerase%2520%2528PARP%2529%2520inhibitor%2520efficacious%2520in%2520BRCA-1%2520and%2520-2%2520mutant%2520tumors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7170%26epage%3D7185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group">Lubisch, W.; Kock, M.; Hoeger, T.; Grandel, R.; Mueller, R.; Schult, S.</span><span> </span><span class="NLM_article-title">Heterocyclic Compounds and Their Use as PARP Inhibitors</span>. U.S. Patent 7041675,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=W.+Lubisch&author=M.+Kock&author=T.+Hoeger&author=R.+Grandel&author=R.+Mueller&author=S.+Schult&title=Heterocyclic+Compounds+and+Their+Use+as+PARP+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLubisch%26aufirst%3DW.%26atitle%3DHeterocyclic%2520Compounds%2520and%2520Their%2520Use%2520as%2520PARP%2520Inhibitors%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group">Hattori, K.; Yamamoto, H.; Mukoyoshi, K.; Kuroda, S.</span><span> </span><span class="NLM_article-title">Quinoxaline Derivatives Which Have PARP Inhibitory Action</span>. WO/2003/007959,<span class="NLM_x"> </span><span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=K.+Hattori&author=H.+Yamamoto&author=K.+Mukoyoshi&author=S.+Kuroda&title=Quinoxaline+Derivatives+Which+Have+PARP+Inhibitory+Action"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHattori%26aufirst%3DK.%26atitle%3DQuinoxaline%2520Derivatives%2520Which%2520Have%2520PARP%2520Inhibitory%2520Action%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group">Menear, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adcock, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alonso, F. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackburn, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copsey, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drzewiecki, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fundo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Gall, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javaid, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lence, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mydlowski, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. C.</span><span> </span><span class="NLM_article-title">Novel alkoxybenzamide inhibitors of poly(ADP-ribose) polymerase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">3942</span><span class="NLM_x">â</span> <span class="NLM_lpage">3945</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=3942-3945&author=K.+A.+Menearauthor=C.+Adcockauthor=F.+C.+Alonsoauthor=K.+Blackburnauthor=L.+Copseyauthor=J.+Drzewieckiauthor=A.+Fundoauthor=A.+Le+Gallauthor=S.+Gomezauthor=H.+Javaidauthor=C.+F.+Lenceauthor=N.+M.+Martinauthor=C.+Mydlowskiauthor=G.+C.+Smith&title=Novel+alkoxybenzamide+inhibitors+of+poly%28ADP-ribose%29+polymerase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMenear%26aufirst%3DK.%2BA.%26aulast%3DAdcock%26aufirst%3DC.%26aulast%3DAlonso%26aufirst%3DF.%2BC.%26aulast%3DBlackburn%26aufirst%3DK.%26aulast%3DCopsey%26aufirst%3DL.%26aulast%3DDrzewiecki%26aufirst%3DJ.%26aulast%3DFundo%26aufirst%3DA.%26aulast%3DLe%2BGall%26aufirst%3DA.%26aulast%3DGomez%26aufirst%3DS.%26aulast%3DJavaid%26aufirst%3DH.%26aulast%3DLence%26aufirst%3DC.%2BF.%26aulast%3DMartin%26aufirst%3DN.%2BM.%26aulast%3DMydlowski%26aufirst%3DC.%26aulast%3DSmith%26aufirst%3DG.%2BC.%26atitle%3DNovel%2520alkoxybenzamide%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D3942%26epage%3D3945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group">Ferraris, D. V.; Li, J.-h.; Kalish, V.; Zhang, J.</span><span> </span><span class="NLM_article-title">Compounds and Their Uses</span>. U.S. Patent 7235557,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=D.+V.+Ferraris&author=J.-h.+Li&author=V.+Kalish&author=J.+Zhang&title=Compounds+and+Their+Uses"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFerraris%26aufirst%3DD.%2BV.%26atitle%3DCompounds%2520and%2520Their%2520Uses%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group">Canan Koch, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thoresen, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tikhe, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maegley, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almassy, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, X. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zook, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumpf, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boritzki, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansour, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ekker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calabrese, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kyle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calvert, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golding, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newell, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webber, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hostomsky, Z.</span><span> </span><span class="NLM_article-title">Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">4961</span><span class="NLM_x">â</span> <span class="NLM_lpage">4974</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm020259n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=4961-4974&author=S.+S.+Canan+Kochauthor=L.+H.+Thoresenauthor=J.+G.+Tikheauthor=K.+A.+Maegleyauthor=R.+J.+Almassyauthor=J.+Liauthor=X.+H.+Yuauthor=S.+E.+Zookauthor=R.+A.+Kumpfauthor=C.+Zhangauthor=T.+J.+Boritzkiauthor=R.+N.+Mansourauthor=K.+E.+Zhangauthor=A.+Ekkerauthor=C.+R.+Calabreseauthor=N.+J.+Curtinauthor=S.+Kyleauthor=H.+D.+Thomasauthor=L.+Z.+Wangauthor=A.+H.+Calvertauthor=B.+T.+Goldingauthor=R.+J.+Griffinauthor=D.+R.+Newellauthor=S.+E.+Webberauthor=Z.+Hostomsky&title=Novel+tricyclic+poly%28ADP-ribose%29+polymerase-1+inhibitors+with+potent+anticancer+chemopotentiating+activity%3A+design%2C+synthesis%2C+and+X-ray+cocrystal+structure"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Fjm020259n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020259n%26sid%3Dliteratum%253Aachs%26aulast%3DCanan%2BKoch%26aufirst%3DS.%2BS.%26aulast%3DThoresen%26aufirst%3DL.%2BH.%26aulast%3DTikhe%26aufirst%3DJ.%2BG.%26aulast%3DMaegley%26aufirst%3DK.%2BA.%26aulast%3DAlmassy%26aufirst%3DR.%2BJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DX.%2BH.%26aulast%3DZook%26aufirst%3DS.%2BE.%26aulast%3DKumpf%26aufirst%3DR.%2BA.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DBoritzki%26aufirst%3DT.%2BJ.%26aulast%3DMansour%26aufirst%3DR.%2BN.%26aulast%3DZhang%26aufirst%3DK.%2BE.%26aulast%3DEkker%26aufirst%3DA.%26aulast%3DCalabrese%26aufirst%3DC.%2BR.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DKyle%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DH.%2BD.%26aulast%3DWang%26aufirst%3DL.%2BZ.%26aulast%3DCalvert%26aufirst%3DA.%2BH.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DWebber%26aufirst%3DS.%2BE.%26aulast%3DHostomsky%26aufirst%3DZ.%26atitle%3DNovel%2520tricyclic%2520poly%2528ADP-ribose%2529%2520polymerase-1%2520inhibitors%2520with%2520potent%2520anticancer%2520chemopotentiating%2520activity%253A%2520design%252C%2520synthesis%252C%2520and%2520X-ray%2520cocrystal%2520structure%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D4961%26epage%3D4974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group">Skalitzky, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marakovits, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maegley, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ekker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, X. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hostomsky, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webber, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eastman, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almassy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newell, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calvert, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golding, B. T.</span><span> </span><span class="NLM_article-title">Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">210</span><span class="NLM_x">â</span> <span class="NLM_lpage">213</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0255769" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=210-213&author=D.+J.+Skalitzkyauthor=J.+T.+Marakovitsauthor=K.+A.+Maegleyauthor=A.+Ekkerauthor=X.+H.+Yuauthor=Z.+Hostomskyauthor=S.+E.+Webberauthor=B.+W.+Eastmanauthor=R.+Almassyauthor=J.+Liauthor=N.+J.+Curtinauthor=D.+R.+Newellauthor=A.+H.+Calvertauthor=R.+J.+Griffinauthor=B.+T.+Golding&title=Tricyclic+benzimidazoles+as+potent+poly%28ADP-ribose%29+polymerase-1+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1021%2Fjm0255769&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0255769%26sid%3Dliteratum%253Aachs%26aulast%3DSkalitzky%26aufirst%3DD.%2BJ.%26aulast%3DMarakovits%26aufirst%3DJ.%2BT.%26aulast%3DMaegley%26aufirst%3DK.%2BA.%26aulast%3DEkker%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DX.%2BH.%26aulast%3DHostomsky%26aufirst%3DZ.%26aulast%3DWebber%26aufirst%3DS.%2BE.%26aulast%3DEastman%26aufirst%3DB.%2BW.%26aulast%3DAlmassy%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DCalvert%26aufirst%3DA.%2BH.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26atitle%3DTricyclic%2520benzimidazoles%2520as%2520potent%2520poly%2528ADP-ribose%2529%2520polymerase-1%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D210%26epage%3D213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group">Ferraris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ficco, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dain, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ginski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lautar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee-Wisdom, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalish, V. J.</span><span> </span><span class="NLM_article-title">Design and synthesis of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. Part 4: Biological evaluation of imidazobenzodiazepines as potent PARP-1 inhibitors for treatment of ischemic injuries</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">3695</span><span class="NLM_x">â</span> <span class="NLM_lpage">3707</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2003&pages=3695-3707&author=D.+Ferrarisauthor=R.+P.+Ficcoauthor=D.+Dainauthor=M.+Ginskiauthor=S.+Lautarauthor=K.+Lee-Wisdomauthor=S.+Liangauthor=Q.+Linauthor=M.+X.+Luauthor=L.+Morganauthor=B.+Thomasauthor=L.+R.+Williamsauthor=J.+Zhangauthor=Y.+Zhouauthor=V.+J.+Kalish&title=Design+and+synthesis+of+poly%28ADP-ribose%29+polymerase-1+%28PARP-1%29+inhibitors.+Part+4%3A+Biological+evaluation+of+imidazobenzodiazepines+as+potent+PARP-1+inhibitors+for+treatment+of+ischemic+injuries"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFerraris%26aufirst%3DD.%26aulast%3DFicco%26aufirst%3DR.%2BP.%26aulast%3DDain%26aufirst%3DD.%26aulast%3DGinski%26aufirst%3DM.%26aulast%3DLautar%26aufirst%3DS.%26aulast%3DLee-Wisdom%26aufirst%3DK.%26aulast%3DLiang%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DQ.%26aulast%3DLu%26aufirst%3DM.%2BX.%26aulast%3DMorgan%26aufirst%3DL.%26aulast%3DThomas%26aufirst%3DB.%26aulast%3DWilliams%26aufirst%3DL.%2BR.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DKalish%26aufirst%3DV.%2BJ.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520poly%2528ADP-ribose%2529%2520polymerase-1%2520%2528PARP-1%2529%2520inhibitors.%2520Part%25204%253A%2520Biological%2520evaluation%2520of%2520imidazobenzodiazepines%2520as%2520potent%2520PARP-1%2520inhibitors%2520for%2520treatment%2520of%2520ischemic%2520injuries%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2003%26volume%3D11%26spage%3D3695%26epage%3D3707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group">Barth, F.; Bichon, D.; Bolkenius, F.; Van Dorsselaer, V.</span><span> </span><span class="NLM_article-title">Benzimidazole Derivatives, Preparation and Therapeutic Use Thereof</span>. U.S. Patent 6794382,<span class="NLM_x"> </span><span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=F.+Barth&author=D.+Bichon&author=F.+Bolkenius&author=V.+Van+Dorsselaer&title=Benzimidazole+Derivatives%2C+Preparation+and+Therapeutic+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBarth%26aufirst%3DF.%26atitle%3DBenzimidazole%2520Derivatives%252C%2520Preparation%2520and%2520Therapeutic%2520Use%2520Thereof%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group">Kinoshita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakanishi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warizaya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwashita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kido, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, T.</span><span> </span><span class="NLM_article-title">Inhibitor-induced structural change of the active site of human poly(ADP-ribose) polymerase</span> <span class="citation_source-journal">FEBS Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">556</span><span class="NLM_x">, </span> <span class="NLM_fpage">43</span><span class="NLM_x">â</span> <span class="NLM_lpage">46</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=556&publication_year=2004&pages=43-46&author=T.+Kinoshitaauthor=I.+Nakanishiauthor=M.+Warizayaauthor=A.+Iwashitaauthor=Y.+Kidoauthor=K.+Hattoriauthor=T.+Fujii&title=Inhibitor-induced+structural+change+of+the+active+site+of+human+poly%28ADP-ribose%29+polymerase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKinoshita%26aufirst%3DT.%26aulast%3DNakanishi%26aufirst%3DI.%26aulast%3DWarizaya%26aufirst%3DM.%26aulast%3DIwashita%26aufirst%3DA.%26aulast%3DKido%26aufirst%3DY.%26aulast%3DHattori%26aufirst%3DK.%26aulast%3DFujii%26aufirst%3DT.%26atitle%3DInhibitor-induced%2520structural%2520change%2520of%2520the%2520active%2520site%2520of%2520human%2520poly%2528ADP-ribose%2529%2520polymerase%26jtitle%3DFEBS%2520Lett.%26date%3D2004%26volume%3D556%26spage%3D43%26epage%3D46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group">Hattori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kido, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishida, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamijo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohkubo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinoshita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwashita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mihara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuoka, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teramura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyake, H.</span><span> </span><span class="NLM_article-title">Rational approaches to discovery of orally active and brain-penetrable quinazolinone inhibitors of poly(ADP-ribose)polymerase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">4151</span><span class="NLM_x">â</span> <span class="NLM_lpage">4154</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0499256" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD2cXls1Kqtr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=4151-4154&author=K.+Hattoriauthor=Y.+Kidoauthor=H.+Yamamotoauthor=J.+Ishidaauthor=K.+Kamijoauthor=K.+Muranoauthor=M.+Ohkuboauthor=T.+Kinoshitaauthor=A.+Iwashitaauthor=K.+Miharaauthor=S.+Yamazakiauthor=N.+Matsuokaauthor=Y.+Teramuraauthor=H.+Miyake&title=Rational+approaches+to+discovery+of+orally+active+and+brain-penetrable+quinazolinone+inhibitors+of+poly%28ADP-ribose%29polymerase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Approaches to Discovery of Orally Active and Brain-Penetrable Quinazolinone Inhibitors of Poly(ADP-ribose)polymerase</span></div><div class="casAuthors">Hattori, Kouji; Kido, Yoshiyuki; Yamamoto, Hirofumi; Ishida, Junya; Kamijo, Kazunori; Murano, Kenji; Ohkubo, Mitsuru; Kinoshita, Takayoshi; Iwashita, Akinori; Mihara, Kayoko; Yamazaki, Syunji; Matsuoka, Nobuya; Teramura, Yoshinori; Miyake, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4151-4154</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel class of quinazolinone derivs. as potent poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors has been discovered.  Key to success was application of a rational discovery strategy involving structure-based design, combinatorial chem., and classical SAR for improvement of potency and bioavailability.  The new inhibitors were shown to bind to the nicotinamide-ribose binding site (NI site) and the adenosine-ribose binding site (AD site) of NAD+.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnYt__YsYlRrVg90H21EOLACvtfcHk0lgqMwUr2FaMew"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXls1Kqtr4%253D&md5=710cbcd058d858e37c3ff6dcf8ba182d</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1021%2Fjm0499256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0499256%26sid%3Dliteratum%253Aachs%26aulast%3DHattori%26aufirst%3DK.%26aulast%3DKido%26aufirst%3DY.%26aulast%3DYamamoto%26aufirst%3DH.%26aulast%3DIshida%26aufirst%3DJ.%26aulast%3DKamijo%26aufirst%3DK.%26aulast%3DMurano%26aufirst%3DK.%26aulast%3DOhkubo%26aufirst%3DM.%26aulast%3DKinoshita%26aufirst%3DT.%26aulast%3DIwashita%26aufirst%3DA.%26aulast%3DMihara%26aufirst%3DK.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DMatsuoka%26aufirst%3DN.%26aulast%3DTeramura%26aufirst%3DY.%26aulast%3DMiyake%26aufirst%3DH.%26atitle%3DRational%2520approaches%2520to%2520discovery%2520of%2520orally%2520active%2520and%2520brain-penetrable%2520quinazolinone%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529polymerase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D4151%26epage%3D4154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group">Parveen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naughton, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whish, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Threadgill, M. D.</span><span> </span><span class="NLM_article-title">2-Nitroimidazol-5-ylmethyl as a potential bioreductively activated prodrug system: reductively triggered release of the PARP inhibitor 5-bromoisoquinolinone</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">2031</span><span class="NLM_x">â</span> <span class="NLM_lpage">2036</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1999&pages=2031-2036&author=I.+Parveenauthor=D.+P.+Naughtonauthor=W.+J.+Whishauthor=M.+D.+Threadgill&title=2-Nitroimidazol-5-ylmethyl+as+a+potential+bioreductively+activated+prodrug+system%3A+reductively+triggered+release+of+the+PARP+inhibitor+5-bromoisoquinolinone"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DParveen%26aufirst%3DI.%26aulast%3DNaughton%26aufirst%3DD.%2BP.%26aulast%3DWhish%26aufirst%3DW.%2BJ.%26aulast%3DThreadgill%26aufirst%3DM.%2BD.%26atitle%3D2-Nitroimidazol-5-ylmethyl%2520as%2520a%2520potential%2520bioreductively%2520activated%2520prodrug%2520system%253A%2520reductively%2520triggered%2520release%2520of%2520the%2520PARP%2520inhibitor%25205-bromoisoquinolinone%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1999%26volume%3D9%26spage%3D2031%26epage%3D2036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group">Griffin, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srinivasan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calvert, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newell, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pemberton, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golding, B. T.</span><span> </span><span class="NLM_article-title">Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">5247</span><span class="NLM_x">â</span> <span class="NLM_lpage">5256</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm980273t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=5247-5256&author=R.+J.+Griffinauthor=S.+Srinivasanauthor=K.+Bowmanauthor=A.+H.+Calvertauthor=N.+J.+Curtinauthor=D.+R.+Newellauthor=L.+C.+Pembertonauthor=B.+T.+Golding&title=Resistance-modifying+agents.+5.+Synthesis+and+biological+properties+of+quinazolinone+inhibitors+of+the+DNA+repair+enzyme+poly%28ADP-ribose%29+polymerase+%28PARP%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Fjm980273t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm980273t%26sid%3Dliteratum%253Aachs%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DSrinivasan%26aufirst%3DS.%26aulast%3DBowman%26aufirst%3DK.%26aulast%3DCalvert%26aufirst%3DA.%2BH.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DPemberton%26aufirst%3DL.%2BC.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26atitle%3DResistance-modifying%2520agents.%25205.%2520Synthesis%2520and%2520biological%2520properties%2520of%2520quinazolinone%2520inhibitors%2520of%2520the%2520DNA%2520repair%2520enzyme%2520poly%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D5247%26epage%3D5256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group">Boulton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pemberton, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porteous, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golding, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durkacz, B. W.</span><span> </span><span class="NLM_article-title">Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">849</span><span class="NLM_x">â</span> <span class="NLM_lpage">856</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1038%2Fbjc.1995.423" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=7547230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADyaK2MXptlKjtL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=1995&pages=849-856&author=S.+Boultonauthor=L.+C.+Pembertonauthor=J.+K.+Porteousauthor=N.+J.+Curtinauthor=R.+J.+Griffinauthor=B.+T.+Goldingauthor=B.+W.+Durkacz&title=Potentiation+of+temozolomide-induced+cytotoxicity%3A+a+comparative+study+of+the+biological+effects+of+poly%28ADP-ribose%29+polymerase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Potentiation of temozolomide-induced cytotoxicity: A comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors</span></div><div class="casAuthors">Boulton, S.; Pemberton, L C.; Porteous, J K.; Curtin, N J.; Griffin, R J.; Golding, B T.; Durkacz, B W.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">849-56</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Scientific & Medical Division</span>)
        </div><div class="casAbstract">Four poly(ADP-ribose) polymerase (PADPRP) inhibitors [3-aminobenzamide, benzamide, 3,4-dihydro-5-methoxyisoquinolin-1(2H)-one (PD 128763) and 8-hydroxy-2-methylquinazolin-4(3H)-one (NU1025)] were compared with respect to their effects on a no. of biol. end points.  The following parameters were assessed: their ability to inhibit the enzyme in permeabilized L1210 cells; their ability to potentiate the cytotoxicity of temozolomide (including the cytotoxicity of the compds. per se); their ability to increase net levels of temozolomide-induced DNA strand breaks and inhibit temozolomide-induced NAD depletion.  PD 128763 and NU1025 were equipotent as PADPRP inhibitors, and 40- and 50-fold more potent than benzamide and 3-aminobenzamide resp.  All the compds. acted in a concn.-dependent manner to potentiate the cytotoxicity and increase DNA strand break levels in cells treated with temozolomide.  There was an excellent correlation between the potency of the compds. as PADPRP inhibitors and their effects on cell survival and DNA repair.  Temozolomide treatment caused a decrease in cellular NAD levels, and this was abolished by the PADPRP inhibitors.  In conclusion, the new generation of PADPRP inhibitors are at least 50-fold more effective than 3-aminobenzamide as chemopotentiators, and can be used at micromolar rather than millimolar concns. in intact cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpO-XC_jBflmbVg90H21EOLACvtfcHk0lgqMwUr2FaMew"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXptlKjtL0%253D&md5=a383a8a3b9c4a748e8cb173b25e9d32a</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1038%2Fbjc.1995.423&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.1995.423%26sid%3Dliteratum%253Aachs%26aulast%3DBoulton%26aufirst%3DS.%26aulast%3DPemberton%26aufirst%3DL.%2BC.%26aulast%3DPorteous%26aufirst%3DJ.%2BK.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26aulast%3DDurkacz%26aufirst%3DB.%2BW.%26atitle%3DPotentiation%2520of%2520temozolomide-induced%2520cytotoxicity%253A%2520a%2520comparative%2520study%2520of%2520the%2520biological%2520effects%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitors%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D1995%26volume%3D72%26spage%3D849%26epage%3D856" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group">Tentori, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonetti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarsella, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">dâAmati, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Portarena, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zupi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonmassar, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graziani, G.</span><span> </span><span class="NLM_article-title">Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">2241</span><span class="NLM_x">â</span> <span class="NLM_lpage">2244</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=2241-2244&author=L.+Tentoriauthor=C.+Leonettiauthor=M.+Scarsellaauthor=G.+d%E2%80%99Amatiauthor=I.+Portarenaauthor=G.+Zupiauthor=E.+Bonmassarauthor=G.+Graziani&title=Combined+treatment+with+temozolomide+and+poly%28ADP-ribose%29+polymerase+inhibitor+enhances+survival+of+mice+bearing+hematologic+malignancy+at+the+central+nervous+system+site"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTentori%26aufirst%3DL.%26aulast%3DLeonetti%26aufirst%3DC.%26aulast%3DScarsella%26aufirst%3DM.%26aulast%3Dd%25E2%2580%2599Amati%26aufirst%3DG.%26aulast%3DPortarena%26aufirst%3DI.%26aulast%3DZupi%26aufirst%3DG.%26aulast%3DBonmassar%26aufirst%3DE.%26aulast%3DGraziani%26aufirst%3DG.%26atitle%3DCombined%2520treatment%2520with%2520temozolomide%2520and%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitor%2520enhances%2520survival%2520of%2520mice%2520bearing%2520hematologic%2520malignancy%2520at%2520the%2520central%2520nervous%2520system%2520site%26jtitle%3DBlood%26date%3D2002%26volume%3D99%26spage%3D2241%26epage%3D2244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group">Delaney, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kyle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calvert, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durkacz, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hostomsky, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newell, D. R.</span><span> </span><span class="NLM_article-title">Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">2860</span><span class="NLM_x">â</span> <span class="NLM_lpage">2867</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=10914735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlslentbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=2860-2867&author=C.+A.+Delaneyauthor=L.+Z.+Wangauthor=S.+Kyleauthor=A.+W.+Whiteauthor=A.+H.+Calvertauthor=N.+J.+Curtinauthor=B.+W.+Durkaczauthor=Z.+Hostomskyauthor=D.+R.+Newell&title=Potentiation+of+temozolomide+and+topotecan+growth+inhibition+and+cytotoxicity+by+novel+poly%28adenosine+diphosphoribose%29+polymerase+inhibitors+in+a+panel+of+human+tumor+cell+lines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines</span></div><div class="casAuthors">Delaney, Carol A.; Wang, Lan-Z.; Kyle, Suzanne; White, Alex W.; Calvert, A. Hilary; Curtin, Nicola J.; Durkacz, Barbara W.; Hostomsky, Zdenek; Newell, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2860-2867</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Potent poly(ADP-ribose) polymerase (PARP) inhibitors have been developed that potentiate the cytotoxicity of ionizing radiation and anticancer drugs.  The biol. effects of two novel PARP inhibitors, NU1025 (8-hydroxy-2-methylquinazolin-4-[3H]one, Ki = 48 nM) and NU1085 [2-(4-hydroxyphenyl)benzamidazole-4-carboxamide, Ki = 6 nM], in combination with temozolomide (TM) or topotecan (TP) have been studied in 12 human tumor cell lines (lung, colon, ovary, and breast cancer).  Cells were treated with increasing concns. of TM or TP Â± NU1025 (50, 200 Î¼M) or NU1085 (10 Î¼M) for 72 h.  The potentiation of growth inhibition by NU1025 and NU1085 varied between the cell lines from 1.5- to 4-fold for TM and 1- to 5-fold for TP and was unaffected by p53 status.  Clonogenic assays undertaken in two of the cell lines confirmed that the potentiation of growth inhibition reflected the potentiation of cytotoxicity.  NU1025 (50 Î¼M) was about as effective as 10 Î¼M NU1085 at potentiating growth inhibition and cytotoxicity, consistent with the relative potencies of the two mols. as PARP inhibitors.  Potentiation of cytotoxicity was obtained at concns. of NU1025 and NU1085 that were not toxic per se; however, NU1085 alone was 3-fold more cytotoxic (LC50 values ranged from 83 to 94 Î¼M) than NU1025 alone (LC50 > 900 Î¼M).  These data demonstrate that PARP inhibitors are effective resistance-modifying agents in human tumor cell lines and have provided a comprehensive assessment protocol for the selection of optimum combinations of anticancer drugs, PARP inhibitors, and cell lines for in vivo studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTctxg5iD_8rVg90H21EOLACvtfcHk0lhg-Y9VkaHihA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlslentbg%253D&md5=ba8603da91178e24aa914249946ca463</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDelaney%26aufirst%3DC.%2BA.%26aulast%3DWang%26aufirst%3DL.%2BZ.%26aulast%3DKyle%26aufirst%3DS.%26aulast%3DWhite%26aufirst%3DA.%2BW.%26aulast%3DCalvert%26aufirst%3DA.%2BH.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DDurkacz%26aufirst%3DB.%2BW.%26aulast%3DHostomsky%26aufirst%3DZ.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26atitle%3DPotentiation%2520of%2520temozolomide%2520and%2520topotecan%2520growth%2520inhibition%2520and%2520cytotoxicity%2520by%2520novel%2520poly%2528adenosine%2520diphosphoribose%2529%2520polymerase%2520inhibitors%2520in%2520a%2520panel%2520of%2520human%2520tumor%2520cell%2520lines%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2000%26volume%3D6%26spage%3D2860%26epage%3D2867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group">Calabrese, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almassy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batey, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calvert, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canan-Koch, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durkacz, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hostomsky, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumpf, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kyle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maegley, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newell, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Notarianni, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratford, I. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skalitzky, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webber, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span> </span><span class="NLM_article-title">Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">56</span><span class="NLM_x">â</span> <span class="NLM_lpage">67</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1093%2Fjnci%2Fdjh005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=14709739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD2cXislarsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2004&pages=56-67&author=C.+R.+Calabreseauthor=R.+Almassyauthor=S.+Bartonauthor=M.+A.+Bateyauthor=A.+H.+Calvertauthor=S.+Canan-Kochauthor=B.+W.+Durkaczauthor=Z.+Hostomskyauthor=R.+A.+Kumpfauthor=S.+Kyleauthor=J.+Liauthor=K.+Maegleyauthor=D.+R.+Newellauthor=E.+Notarianniauthor=I.+J.+Stratfordauthor=D.+Skalitzkyauthor=H.+D.+Thomasauthor=L.+Z.+Wangauthor=S.+E.+Webberauthor=K.+J.+Williamsauthor=N.+J.+Curtin&title=Anticancer+chemosensitization+and+radiosensitization+by+the+novel+poly%28ADP-ribose%29+polymerase-1+inhibitor+AG14361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Anticancer Chemosensitization and Radiosensitization by the Novel Poly(ADP-ribose) Polymerase-1 Inhibitor AG14361</span></div><div class="casAuthors">Calabrese, Christopher R.; Almassy, Robert; Barton, Stephanie; Batey, Michael A.; Calvert, A. Hilary; Canan-Koch, Stacie; Durkacz, Barbara W.; Hostomsky, Zdenek; Kumpf, Robert A.; Kyle, Suzanne; Li, Jianke; Maegley, Karen; Newell, David R.; Notarianni, Elena; Stratford, Ian J.; Skalitzky, Donald; Thomas, Huw D.; Wang, Lan-Zhen; Webber, Stephen E.; Williams, Kaye J.; Curtin, Nicola J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">56-67</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background: Poly(ADP-ribose) polymerase-1 (PARP-1) facilitates the repair of DNA strand breaks.  Inhibiting PARP-1 increases the cytotoxicity of DNA-damaging chemotherapy and radiation therapy in vitro.  Because classical PARP-1 inhibitors have limited clin. utility, we investigated whether AG14361, a novel potent PARP-1 inhibitor (inhibition const. <5 nM), enhances the effects of chemotherapy and radiation therapy in human cancer cell cultures and xenografts.  Methods: The effect of AG14361 on the antitumor activity of the DNA alkylating agent temozolomide, topoisomerase I poisons topotecan or irinotecan, or x-irradn. or Î³-radiation was investigated in human cancer cell lines A549, LoVo, and SW620 by proliferation and survival assays and in xenografts in mice by tumor vol. detn.  The specificity of AG14361 for PARP-1 was investigated by microarray anal. and by antiproliferation and acute toxicity assays in PARP-1-/- and PARP-1+/+ cells and mice.  After i.p. administration, the concn. of AG14361 was detd. in mouse plasma and tissues, and its effect on PARP-1 activity was detd. in tumor homogenates.  All statistical tests were two-sided.  Results: AG14361 at 0.4 Î¼M did not affect cancer cell gene expression or growth, but it did increase the antiproliferative activity of temozolomide (e.g., in LoVo cells by 5.5-fold, 95% confidence interval [CI] = 4.9-fold to 5.9-fold; P = .004) and topotecan (e.g., in LoVo cells by 1.6-fold, 95% CI = 1.3-fold to 1.9-fold; P = .002) and inhibited recovery from potentially lethal Î³-radiation damage in LoVo cells by 73% (95% CI = 48% to 98%).  In vivo, nontoxic doses of AG14361 increased the delay of LoVo xenograft growth induced by irinotecan, x-irradn., or temozolomide by two- to threefold.  The combination of AG14361 and temozolomide caused complete regression of SW620 xenograft tumors.  AG14361 was retained in xenografts in which PARP-1 activity was inhibited by more than 75% for at least 4 h.  Conclusion: AG14361 is, to our knowledge, the first high-potency PARP-1 inhibitor with the specificity and in vivo activity to enhance chemotherapy and radiation therapy of human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqorpwvo2sC6rVg90H21EOLACvtfcHk0lhg-Y9VkaHihA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXislarsw%253D%253D&md5=1b14488c625431de24ba11fad79ad9e5</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjh005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjh005%26sid%3Dliteratum%253Aachs%26aulast%3DCalabrese%26aufirst%3DC.%2BR.%26aulast%3DAlmassy%26aufirst%3DR.%26aulast%3DBarton%26aufirst%3DS.%26aulast%3DBatey%26aufirst%3DM.%2BA.%26aulast%3DCalvert%26aufirst%3DA.%2BH.%26aulast%3DCanan-Koch%26aufirst%3DS.%26aulast%3DDurkacz%26aufirst%3DB.%2BW.%26aulast%3DHostomsky%26aufirst%3DZ.%26aulast%3DKumpf%26aufirst%3DR.%2BA.%26aulast%3DKyle%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DMaegley%26aufirst%3DK.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DNotarianni%26aufirst%3DE.%26aulast%3DStratford%26aufirst%3DI.%2BJ.%26aulast%3DSkalitzky%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DH.%2BD.%26aulast%3DWang%26aufirst%3DL.%2BZ.%26aulast%3DWebber%26aufirst%3DS.%2BE.%26aulast%3DWilliams%26aufirst%3DK.%2BJ.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26atitle%3DAnticancer%2520chemosensitization%2520and%2520radiosensitization%2520by%2520the%2520novel%2520poly%2528ADP-ribose%2529%2520polymerase-1%2520inhibitor%2520AG14361%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2004%26volume%3D96%26spage%3D56%26epage%3D67" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group">Tikhe, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webber, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hostomsky, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maegley, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ekkers, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, X. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almassy, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumpf, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boritzki, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calabrese, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kyle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calvert, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golding, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newell, D. R.</span><span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of 3,4-dihydro-2<i>H</i>-[1,4]diazepino[6,7,1-<i>hi</i>]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">5467</span><span class="NLM_x">â</span> <span class="NLM_lpage">5481</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm030513r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=5467-5481&author=J.+G.+Tikheauthor=S.+E.+Webberauthor=Z.+Hostomskyauthor=K.+A.+Maegleyauthor=A.+Ekkersauthor=J.+Liauthor=X.+H.+Yuauthor=R.+J.+Almassyauthor=R.+A.+Kumpfauthor=T.+J.+Boritzkiauthor=C.+Zhangauthor=C.+R.+Calabreseauthor=N.+J.+Curtinauthor=S.+Kyleauthor=H.+D.+Thomasauthor=L.+Z.+Wangauthor=A.+H.+Calvertauthor=B.+T.+Goldingauthor=R.+J.+Griffinauthor=D.+R.+Newell&title=Design%2C+synthesis%2C+and+evaluation+of+3%2C4-dihydro-2H-%5B1%2C4%5Ddiazepino%5B6%2C7%2C1-hi%5Dindol-1-ones+as+inhibitors+of+poly%28ADP-ribose%29+polymerase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1021%2Fjm030513r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030513r%26sid%3Dliteratum%253Aachs%26aulast%3DTikhe%26aufirst%3DJ.%2BG.%26aulast%3DWebber%26aufirst%3DS.%2BE.%26aulast%3DHostomsky%26aufirst%3DZ.%26aulast%3DMaegley%26aufirst%3DK.%2BA.%26aulast%3DEkkers%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DX.%2BH.%26aulast%3DAlmassy%26aufirst%3DR.%2BJ.%26aulast%3DKumpf%26aufirst%3DR.%2BA.%26aulast%3DBoritzki%26aufirst%3DT.%2BJ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DCalabrese%26aufirst%3DC.%2BR.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DKyle%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DH.%2BD.%26aulast%3DWang%26aufirst%3DL.%2BZ.%26aulast%3DCalvert%26aufirst%3DA.%2BH.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%25203%252C4-dihydro-2H-%255B1%252C4%255Ddiazepino%255B6%252C7%252C1-hi%255Dindol-1-ones%2520as%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D5467%26epage%3D5481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group">Thomas, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calabrese, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batey, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hostomsky, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kyle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maegley, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newell, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skalitzky, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webber, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span> </span><span class="NLM_article-title">Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">945</span><span class="NLM_x">â</span> <span class="NLM_lpage">956</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1158%2F1535-7163.MCT-06-0552" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=17363489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivV2nurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=945-956&author=H.+D.+Thomasauthor=C.+R.+Calabreseauthor=M.+A.+Bateyauthor=S.+Cananauthor=Z.+Hostomskyauthor=S.+Kyleauthor=K.+A.+Maegleyauthor=D.+R.+Newellauthor=D.+Skalitzkyauthor=L.+Z.+Wangauthor=S.+E.+Webberauthor=N.+J.+Curtin&title=Preclinical+selection+of+a+novel+poly%28ADP-ribose%29+polymerase+inhibitor+for+clinical+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial</span></div><div class="casAuthors">Thomas, Huw D.; Calabrese, Christopher R.; Batey, Michael A.; Canan, Stacie; Hostomsky, Zdenek; Kyle, Suzanne; Maegley, Karen A.; Newell, David R.; Skalitzky, Donald; Wang, Lan-Zhen; Webber, Stephen E.; Curtin, Nicola J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">945-956</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase (PARP)-1 (EC 2.4.2.30) is a nuclear enzyme that promotes the base excision repair of DNA breaks.  Inhibition of PARP-1 enhances the efficacy of DNA alkylating agents, topoisomerase I poisons, and ionizing radiation.  Our aim was to identify a PARP inhibitor for clin. trial from a panel of 42 potent PARP inhibitors (Ki, 1.4-15.1 nmol/L) based on the quinazolinone, benzimidazole, tricyclic benzimidazole, tricyclic indole, and tricyclic indole-1-one core structures.  We evaluated chemosensitization of temozolomide and topotecan using LoVo and SW620 human colorectal cells; in vitro radiosensitization was measured using LoVo cells, and the enhancement of antitumor activity of temozolomide was evaluated in mice bearing SW620 xenografts.  Excellent chemopotentiation and radiopotentiation were obsd. in vitro, with 17 of the compds. causing a greater temozolomide and topotecan sensitization than the benchmark inhibitor AG14361 and 10 compds. were more potent radiosensitizers than AG14361.  In tumor-bearing mice, none of the compds. were toxic when given alone, and the antitumor activity of the PARP inhibitor-temozolomide combinations was unrelated to toxicity.  Compds. that were more potent chemosensitizers in vivo than AG14361 were also more potent in vitro, validating in vitro assays as a prescreen.  These studies have identified a compd., AG14447, as a PARP inhibitor with outstanding in vivo chemosensitization potency at tolerable doses, which is at least 10 times more potent than the initial lead, AG14361.  The phosphate salt of AG14447 (AG014699), which has improved aq. soly., has been selected for clin. trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk-3D2oL2giLVg90H21EOLACvtfcHk0lil1jWH-vy9Og"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivV2nurw%253D&md5=b451bf2c1fc836cc5a800c2799e5d211</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0552&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0552%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DH.%2BD.%26aulast%3DCalabrese%26aufirst%3DC.%2BR.%26aulast%3DBatey%26aufirst%3DM.%2BA.%26aulast%3DCanan%26aufirst%3DS.%26aulast%3DHostomsky%26aufirst%3DZ.%26aulast%3DKyle%26aufirst%3DS.%26aulast%3DMaegley%26aufirst%3DK.%2BA.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DSkalitzky%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DL.%2BZ.%26aulast%3DWebber%26aufirst%3DS.%2BE.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26atitle%3DPreclinical%2520selection%2520of%2520a%2520novel%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitor%2520for%2520clinical%2520trial%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D945%26epage%3D956" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group">Plummer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boddy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHugh, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinfeldt, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dewji, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calvert, H.</span><span> </span><span class="NLM_article-title">Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">7917</span><span class="NLM_x">â</span> <span class="NLM_lpage">7923</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1158%2F1078-0432.CCR-08-1223" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=19047122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVegt7%252FM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=7917-7923&author=R.+Plummerauthor=C.+Jonesauthor=M.+Middletonauthor=R.+Wilsonauthor=J.+Evansauthor=A.+Olsenauthor=N.+Curtinauthor=A.+Boddyauthor=P.+McHughauthor=D.+Newellauthor=A.+Harrisauthor=P.+Johnsonauthor=H.+Steinfeldtauthor=R.+Dewjiauthor=D.+Wangauthor=L.+Robsonauthor=H.+Calvert&title=Phase+I+study+of+the+poly%28ADP-ribose%29+polymerase+inhibitor%2C+AG014699%2C+in+combination+with+temozolomide+in+patients+with+advanced+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Plummer, Ruth; Jones, Christopher; Middleton, Mark; Wilson, Richard; Evans, Jeffrey; Olsen, Anna; Curtin, Nicola; Boddy, Alan; McHugh, Peter; Newell, David; Harris, Adrian; Johnson, Patrick; Steinfeldt, Heidi; Dewji, Raz; Wang, Diane; Robson, Lesley; Calvert, Hilary</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7917-7923</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: One mechanism of tumor resistance to cytotoxic therapy is repair of damaged DNA.  Poly(ADP-ribose) polymerase (PARP)-1 is a nuclear enzyme involved in base excision repair, one of the five major repair pathways.  PARP inhibitors are emerging as a new class of agents that can potentiate chemotherapy and radiotherapy.  The article reports safety, efficacy, pharmacokinetic, and pharmacodynamic results of the first-in-class trial of a PARP inhibitor, AG014699, combined with temozolomide in adults with advanced malignancy.  Exptl. Design: Initially, patients with solid tumors received escalating doses of AG014699 with 100 mg/m2/d temozolomide x 5 every 28 days to establish the PARP ID (PID).  Subsequently, AG014699 dose was fixed at PID and temozolomide escalated to max. tolerated dose or 200 mg/m2 in metastatic melanoma patients whose tumors were biopsied.  AG014699 and temozolomide pharmacokinetics, PARP activity, DNA strand single-strand breaks, response, and toxicity were evaluated.  RESULTS: Thirty-three patients were enrolled.  PARP inhibition was seen at all doses; PID was 12 mg/m2 based on 74% to 97% inhibition of peripheral blood lymphocyte PARP activity.  Recommended doses were 12 mg/m2 AG014699 and 200 mg/m2 temozolomide.  Mean tumor PARP inhibition at 5 h was 92% (range, 46-97%).  No toxicity attributable to AG014699 alone was obsd.  AG014699 showed linear pharmacokinetics with no interaction with temozolomide.  All patients treated at PID showed increases in DNA single-strand breaks and encouraging evidence of activity was seen.  CONCLUSIONS: The combination of AG014699 and temozolomide is well tolerated, pharmacodynamic assessments showing proof of principle of the mode of action of this new class of agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoh3DGcSbf45bVg90H21EOLACvtfcHk0lil1jWH-vy9Og"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVegt7%252FM&md5=76b77d0a31dcb652c31e049a7f6163c2</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-1223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-1223%26sid%3Dliteratum%253Aachs%26aulast%3DPlummer%26aufirst%3DR.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DMiddleton%26aufirst%3DM.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DEvans%26aufirst%3DJ.%26aulast%3DOlsen%26aufirst%3DA.%26aulast%3DCurtin%26aufirst%3DN.%26aulast%3DBoddy%26aufirst%3DA.%26aulast%3DMcHugh%26aufirst%3DP.%26aulast%3DNewell%26aufirst%3DD.%26aulast%3DHarris%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DP.%26aulast%3DSteinfeldt%26aufirst%3DH.%26aulast%3DDewji%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DRobson%26aufirst%3DL.%26aulast%3DCalvert%26aufirst%3DH.%26atitle%3DPhase%2520I%2520study%2520of%2520the%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitor%252C%2520AG014699%252C%2520in%2520combination%2520with%2520temozolomide%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D7917%26epage%3D7923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group">Plummer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorigan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steven, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snow, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dewji, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calvert, H.</span><span> </span><span class="NLM_article-title">First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM)</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">8013</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=8013&author=R.+Plummerauthor=P.+Loriganauthor=J.+Evansauthor=N.+Stevenauthor=M.+Middletonauthor=R.+Wilsonauthor=K.+Snowauthor=R.+Dewjiauthor=H.+Calvert&title=First+and+final+report+of+a+phase+II+study+of+the+poly%28ADP-ribose%29+polymerase+%28PARP%29+inhibitor%2C+AG014699%2C+in+combination+with+temozolomide+%28TMZ%29+in+patients+with+metastatic+malignant+melanoma+%28MM%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPlummer%26aufirst%3DR.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DEvans%26aufirst%3DJ.%26aulast%3DSteven%26aufirst%3DN.%26aulast%3DMiddleton%26aufirst%3DM.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DSnow%26aufirst%3DK.%26aulast%3DDewji%26aufirst%3DR.%26aulast%3DCalvert%26aufirst%3DH.%26atitle%3DFirst%2520and%2520final%2520report%2520of%2520a%2520phase%2520II%2520study%2520of%2520the%2520poly%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520inhibitor%252C%2520AG014699%252C%2520in%2520combination%2520with%2520temozolomide%2520%2528TMZ%2529%2520in%2520patients%2520with%2520metastatic%2520malignant%2520melanoma%2520%2528MM%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D8013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group">Buki, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, P. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendeleyev, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hakam, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kun, E.</span><span> </span><span class="NLM_article-title">Destabilization of Zn<sup>2+</sup> coordination in ADP-ribose transferase (polymerizing) by 6-nitroso-1,2-benzopyrone coincidental with inactivation of the polymerase but not the DNA binding function</span> <span class="citation_source-journal">FEBS Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">290</span><span class="NLM_x">, </span> <span class="NLM_fpage">181</span><span class="NLM_x">â</span> <span class="NLM_lpage">185</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=1991&pages=181-185&author=K.+G.+Bukiauthor=P.+I.+Bauerauthor=J.+Mendeleyevauthor=A.+Hakamauthor=E.+Kun&title=Destabilization+of+Zn2%2B+coordination+in+ADP-ribose+transferase+%28polymerizing%29+by+6-nitroso-1%2C2-benzopyrone+coincidental+with+inactivation+of+the+polymerase+but+not+the+DNA+binding+function"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBuki%26aufirst%3DK.%2BG.%26aulast%3DBauer%26aufirst%3DP.%2BI.%26aulast%3DMendeleyev%26aufirst%3DJ.%26aulast%3DHakam%26aufirst%3DA.%26aulast%3DKun%26aufirst%3DE.%26atitle%3DDestabilization%2520of%2520Zn2%252B%2520coordination%2520in%2520ADP-ribose%2520transferase%2520%2528polymerizing%2529%2520by%25206-nitroso-1%252C2-benzopyrone%2520coincidental%2520with%2520inactivation%2520of%2520the%2520polymerase%2520but%2520not%2520the%2520DNA%2520binding%2520function%26jtitle%3DFEBS%2520Lett.%26date%3D1991%26volume%3D290%26spage%3D181%26epage%3D185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group">Tseng, A.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakobovits, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirsten, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hakam, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kun, E.</span><span> </span><span class="NLM_article-title">Prevention of tumorigenesis of oncogene-transformed rat fibroblasts with DNA site inhibitors of poly(ADP ribose) polymerase</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">1107</span><span class="NLM_x">â</span> <span class="NLM_lpage">1111</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=1987&pages=1107-1111&author=A.+Tsengauthor=W.+M.+Leeauthor=E.+B.+Jakobovitsauthor=E.+Kirstenauthor=A.+Hakamauthor=J.+McLickauthor=K.+Bukiauthor=E.+Kun&title=Prevention+of+tumorigenesis+of+oncogene-transformed+rat+fibroblasts+with+DNA+site+inhibitors+of+poly%28ADP+ribose%29+polymerase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTseng%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DW.%2BM.%26aulast%3DJakobovits%26aufirst%3DE.%2BB.%26aulast%3DKirsten%26aufirst%3DE.%26aulast%3DHakam%26aufirst%3DA.%26aulast%3DMcLick%26aufirst%3DJ.%26aulast%3DBuki%26aufirst%3DK.%26aulast%3DKun%26aufirst%3DE.%26atitle%3DPrevention%2520of%2520tumorigenesis%2520of%2520oncogene-transformed%2520rat%2520fibroblasts%2520with%2520DNA%2520site%2520inhibitors%2520of%2520poly%2528ADP%2520ribose%2529%2520polymerase%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1987%26volume%3D84%26spage%3D1107%26epage%3D1111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group">Ossovskaya, V.; Sherman, B. M.</span><span> </span><span class="NLM_article-title">Methods and Compositions for the Treatment of Cancer Using Benzopyrone-Type PARP Inhibitors</span>. U.S. Patent Appl. 20090149417,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=V.+Ossovskaya&author=B.+M.+Sherman&title=Methods+and+Compositions+for+the+Treatment+of+Cancer+Using+Benzopyrone-Type+PARP+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DOssovskaya%26aufirst%3DV.%26atitle%3DMethods%2520and%2520Compositions%2520for%2520the%2520Treatment%2520of%2520Cancer%2520Using%2520Benzopyrone-Type%2520PARP%2520Inhibitors%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group">Mendeleyev, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirsten, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hakam, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buki, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kun, E.</span><span> </span><span class="NLM_article-title">Potential chemotherapeutic activity of 4-iodo-3-nitrobenzamide. Metabolic reduction to the 3-nitroso derivative and induction of cell death in tumor cells in culture</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">705</span><span class="NLM_x">â</span> <span class="NLM_lpage">714</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1995&pages=705-714&author=J.+Mendeleyevauthor=E.+Kirstenauthor=A.+Hakamauthor=K.+G.+Bukiauthor=E.+Kun&title=Potential+chemotherapeutic+activity+of+4-iodo-3-nitrobenzamide.+Metabolic+reduction+to+the+3-nitroso+derivative+and+induction+of+cell+death+in+tumor+cells+in+culture"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMendeleyev%26aufirst%3DJ.%26aulast%3DKirsten%26aufirst%3DE.%26aulast%3DHakam%26aufirst%3DA.%26aulast%3DBuki%26aufirst%3DK.%2BG.%26aulast%3DKun%26aufirst%3DE.%26atitle%3DPotential%2520chemotherapeutic%2520activity%2520of%25204-iodo-3-nitrobenzamide.%2520Metabolic%2520reduction%2520to%2520the%25203-nitroso%2520derivative%2520and%2520induction%2520of%2520cell%2520death%2520in%2520tumor%2520cells%2520in%2520culture%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1995%26volume%3D50%26spage%3D705%26epage%3D714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group">Kun, E.; Mendeleyev, J.; Basbaurn, C.; Lemjabbar-alaoui, H.; Ossovskaya, V.</span><span> </span><span class="NLM_article-title">Treatment of Cancer</span>. U.S. Patent 7405227,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=E.+Kun&author=J.+Mendeleyev&author=C.+Basbaurn&author=H.+Lemjabbar-alaoui&author=V.+Ossovskaya&title=Treatment+of+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKun%26aufirst%3DE.%26atitle%3DTreatment%2520of%2520Cancer%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group">Kopetz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mita, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sankhala, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moseley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolcher, A. W.</span><span> </span><span class="NLM_article-title">First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3577</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1200%2FJCO.2007.13.2407" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=3577&author=S.+Kopetzauthor=M.+M.+Mitaauthor=I.+Mokauthor=K.+K.+Sankhalaauthor=J.+Moseleyauthor=B.+M.+Shermanauthor=C.+R.+Bradleyauthor=A.+W.+Tolcher&title=First+in+human+phase+I+study+of+BSI-201%2C+a+small+molecule+inhibitor+of+poly+ADP-ribose+polymerase+%28PARP%29+in+subjects+with+advanced+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1200%2FJCO.2007.13.2407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2007.13.2407%26sid%3Dliteratum%253Aachs%26aulast%3DKopetz%26aufirst%3DS.%26aulast%3DMita%26aufirst%3DM.%2BM.%26aulast%3DMok%26aufirst%3DI.%26aulast%3DSankhala%26aufirst%3DK.%2BK.%26aulast%3DMoseley%26aufirst%3DJ.%26aulast%3DSherman%26aufirst%3DB.%2BM.%26aulast%3DBradley%26aufirst%3DC.%2BR.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26atitle%3DFirst%2520in%2520human%2520phase%2520I%2520study%2520of%2520BSI-201%252C%2520a%2520small%2520molecule%2520inhibitor%2520of%2520poly%2520ADP-ribose%2520polymerase%2520%2528PARP%2529%2520in%2520subjects%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D3577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group">Mahany, J. J.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heath, E. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoRusso, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mita, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolcher, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papadopoulos, K. P.</span><span> </span><span class="NLM_article-title">A phase IB study evaluating BSI-201 in combination with chemotherapy in subjects with advanced solid tumors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3579</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=3579&author=J.+J.+Mahanyauthor=N.+Lewisauthor=E.+I.+Heathauthor=P.+M.+LoRussoauthor=M.+M.+Mitaauthor=J.+Rodonauthor=A.+W.+Tolcherauthor=B.+M.+Shermanauthor=C.+R.+Bradleyauthor=K.+P.+Papadopoulos&title=A+phase+IB+study+evaluating+BSI-201+in+combination+with+chemotherapy+in+subjects+with+advanced+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMahany%26aufirst%3DJ.%2BJ.%26aulast%3DLewis%26aufirst%3DN.%26aulast%3DHeath%26aufirst%3DE.%2BI.%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26aulast%3DMita%26aufirst%3DM.%2BM.%26aulast%3DRodon%26aufirst%3DJ.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26aulast%3DSherman%26aufirst%3DB.%2BM.%26aulast%3DBradley%26aufirst%3DC.%2BR.%26aulast%3DPapadopoulos%26aufirst%3DK.%2BP.%26atitle%3DA%2520phase%2520IB%2520study%2520evaluating%2520BSI-201%2520in%2520combination%2520with%2520chemotherapy%2520in%2520subjects%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D3579" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group">Jagtap, P.; Southan, G.; Salzman, A.; Szabo, C.</span><span> </span><span class="NLM_article-title">Substituted Phenanthridinones and Methods of Use Thereof</span>. U.S. Patent 6277990,<span class="NLM_x"> </span><span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=P.+Jagtap&author=G.+Southan&author=A.+Salzman&author=C.+Szabo&title=Substituted+Phenanthridinones+and+Methods+of+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJagtap%26aufirst%3DP.%26atitle%3DSubstituted%2520Phenanthridinones%2520and%2520Methods%2520of%2520Use%2520Thereof%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group">Jagtap, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soriano, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Virag, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liaudet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mabley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasko, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marton, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorigados, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallyas, F.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sumegi, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoyt, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baloglu, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">VanDuzer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salzman, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Southan, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabo, C.</span><span> </span><span class="NLM_article-title">Novel phenanthridinone inhibitors of poly (adenosine 5â²-diphosphate-ribose) synthetase: potent cytoprotective and antishock agents</span> <span class="citation_source-journal">Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">1071</span><span class="NLM_x">â</span> <span class="NLM_lpage">1082</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1097%2F00003246-200205000-00019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=12006805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD38XktlWgur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2002&pages=1071-1082&author=P.+Jagtapauthor=F.+G.+Sorianoauthor=L.+Viragauthor=L.+Liaudetauthor=J.+Mableyauthor=E.+Szaboauthor=G.+Haskoauthor=A.+Martonauthor=C.+B.+Lorigadosauthor=F.+Gallyasauthor=B.+Sumegiauthor=D.+G.+Hoytauthor=E.+Balogluauthor=J.+VanDuzerauthor=A.+L.+Salzmanauthor=G.+J.+Southanauthor=C.+Szabo&title=Novel+phenanthridinone+inhibitors+of+poly+%28adenosine+5%E2%80%B2-diphosphate-ribose%29+synthetase%3A+potent+cytoprotective+and+antishock+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Novel phenanthridinone inhibitors of poly(adenosine 5'-diphosphateribose) synthetase: Potent cytoprotective and antishock agents</span></div><div class="casAuthors">Jagtap, Prakash; Garcia Soriano, Francisco; Virag, Laszlo; Liaudet, Lucas; Mabley, Jon; Szabo, Eva; Hasko, Gyorgy; Marton, Anita; Batista Lorigados, Clara; Gallyas, Fereno, Jr.; Sumegi, Balazs; Hoyt, Dale G.; Baloglu, Erkan; VanDuzer, John; Salzman, Andrew L.; Southan, Garry J.; Szabo, Csaba</div><div class="citationInfo"><span class="NLM_cas:title">Critical Care Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1071-1082</span>CODEN:
                <span class="NLM_cas:coden">CCMDC7</span>;
        ISSN:<span class="NLM_cas:issn">0090-3493</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Objective: To synthesize novel inhibitors of the nuclear enzyme poly(ADP [ADP]-ribose) synthetase (PARS), also known as poly(ADP-ribose) polymerase (PARP), and to test them in in vitro models of oxidant-induced cytotoxicity and in endotoxin and splanchnic occlusion-reperfusion-induced shock.  Design: Randomized, prospective lab. study.  Setting: Research lab.  Subjects: Murine macrophages, thymocytes, and endothelial cells; Balb/c mice and Wistar rats.  Interventions: Macrophages and endothelial cells were treated with peroxynitrite and bleomycin to induce PARS activation, and thymocytes were treated with peroxynitrite to induce cell necrosis.  Novel PARS inhibitors were synthesized and used to reduce PARS activation and to reverse cytotoxicity.  Balb/c mice were subjected to splanchnic occlusion and reperfusion and were pretreated with various doses (1-10 mg/kg i.p.) of PJ34, a selected, potent, water-sol. PARS inhibitor.  The passage of fluorescein isothiocyanate-conjugated dextran (4 kDa) was analyzed in everted gut ileal sacs incubated ex vivo as an index of gut permeability.  Wistar rats were subjected to Escherichia coli bacterial lipopolysaccharide (40 mg/kg i.p.).  PJ34 was also used at 10 mg/kg i.p., 1 h before lipopolysaccharide or at 25 mg/kg i.p. 1 h after lipopolysaccharide treatment.  Serum concns. of indicators or multiple organ injury, concns. of various proinflammatory mediators, and tissue concns. of myeloperoxidase and malondialdehyde were measured.  In addn., survival rates and vascular contractile and relaxant responses were recorded.  Measurements and Main Results: Appropriate modifications of the phenanthridinone core structure yielded significant increases in the potency of the compds., both as PARS inhibitors and as cytoprotective agents.  The compd. N-(6-oxo-5,6-dihydro-phenanthridin-2-yl) -N,N-dimethylacetamide (designated as PJ34) was one of the potent PARS inhibitors of the series, and it dose-dependently protected against thymocyte necrosis, with a half-maximal restoration of cell viability of 35 nM and complete protection at 200 nM.  PARS activation also was visualized by immunohistochem. and was dose-dependently suppressed by PJ34.  The effect of PJ34 was dose-dependently reversed by excess NAD (oxidized).  The PARS inhibitors dose-dependently suppressed proinflammatory cytokine and chemokine prodn. and restored viability in immunostimulated macrophages.  PJ34 was selected for the subsequent in vivo studies.  PJ34 significantly protected against splanchnic reperfusion-induced intestinal hyperpermeability in the mouse.  PJ34 reduced peak plasma concns. of tumor necrosis factor-Î±, interleukin-1Î², and nitrite/nitrate in the plasma of lipopolysaccharide-treated rats.  PJ34 ameliorated the lipopolysaccharide-induced increases in indexes of liver and kidney failure and concns. of myeloperoxidase and malondialdehyde in the lung and gut.  Lipopolysaccharide elicited vascular dysfunction, which was normalized by PJ34.  Lipopolysaccharide-induced mortality was reduced by PJ34 (both pre- and posttreatment).  Conclusions: The novel series of phenanthridinone PARS inhibitors have potent cytoprotective effects in vitro and significant protective effects in shock and reperfusion injury in rodent models in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoADiNMzYx8-bVg90H21EOLACvtfcHk0lgnsKXfsxEjXg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktlWgur4%253D&md5=90e3e6be7d7148c3f14486ffc35b216a</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1097%2F00003246-200205000-00019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00003246-200205000-00019%26sid%3Dliteratum%253Aachs%26aulast%3DJagtap%26aufirst%3DP.%26aulast%3DSoriano%26aufirst%3DF.%2BG.%26aulast%3DVirag%26aufirst%3DL.%26aulast%3DLiaudet%26aufirst%3DL.%26aulast%3DMabley%26aufirst%3DJ.%26aulast%3DSzabo%26aufirst%3DE.%26aulast%3DHasko%26aufirst%3DG.%26aulast%3DMarton%26aufirst%3DA.%26aulast%3DLorigados%26aufirst%3DC.%2BB.%26aulast%3DGallyas%26aufirst%3DF.%26aulast%3DSumegi%26aufirst%3DB.%26aulast%3DHoyt%26aufirst%3DD.%2BG.%26aulast%3DBaloglu%26aufirst%3DE.%26aulast%3DVanDuzer%26aufirst%3DJ.%26aulast%3DSalzman%26aufirst%3DA.%2BL.%26aulast%3DSouthan%26aufirst%3DG.%2BJ.%26aulast%3DSzabo%26aufirst%3DC.%26atitle%3DNovel%2520phenanthridinone%2520inhibitors%2520of%2520poly%2520%2528adenosine%25205%25E2%2580%25B2-diphosphate-ribose%2529%2520synthetase%253A%2520potent%2520cytoprotective%2520and%2520antishock%2520agents%26jtitle%3DCrit.%2520Care%2520Med.%26date%3D2002%26volume%3D30%26spage%3D1071%26epage%3D1082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group">Abdelkarim, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gertz, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harms, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katchanov, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dirnagl, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endres, M.</span><span> </span><span class="NLM_article-title">Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke</span> <span class="citation_source-journal">Int. J. Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">255</span><span class="NLM_x">â</span> <span class="NLM_lpage">260</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=11179503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhsFCrtrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=255-260&author=G.+E.+Abdelkarimauthor=K.+Gertzauthor=C.+Harmsauthor=J.+Katchanovauthor=U.+Dirnaglauthor=C.+Szaboauthor=M.+Endres&title=Protective+effects+of+PJ34%2C+a+novel%2C+potent+inhibitor+of+poly%28ADP-ribose%29+polymerase+%28PARP%29+in+in+vitro+and+in+vivo+models+of+stroke"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke</span></div><div class="casAuthors">Abdelkarim, Galaleldin E.; Gertz, Karen; Harms, Christoph; Katchanov, Juri; Dirnagl, Ulrich; Szabo, Csaba; Endres, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">255-260</span>CODEN:
                <span class="NLM_cas:coden">IJMMFG</span>;
        ISSN:<span class="NLM_cas:issn">1107-3756</span>.
    
            (<span class="NLM_cas:orgname">International Journal of Molecular Medicine</span>)
        </div><div class="casAbstract">Focal cerebral ischemia activates the nuclear protein poly(ADP-ribose) polymerase (PARP) by single DNA strand breaks which leads to energy depletion and cell necrosis.  Deletion or inhibition of PARP protects against ischemic brain injury.  Here the authors examd. the neuroprotective effect of PJ34, a novel potent inhibitor of PARP in vitro and in vivo.  Serumfree primary neuronal cultures derived from rat cortex (E15-17) and kept in culture for 10 days were exposed to oxygen glucose deprivation (OGD) in vitro.  Neuronal injury was quantified by LDH release after 24 h.  Pretreatment with 30-1000 nM PJ34 protected from OGD-induced cell injury in a dose-dependent manner.  For in vivo expts. SV/129 mice were treated with PJ34 (50 Î¼g) by i.p. injection 2 h before 1 h middle cerebral artery occlusion (MCAo) and again 6 h later.  23 H after reperfusion ischemic injury was decreased compared to vehicle-treated controls (infarct vol. redn. of 40%).  Similarly, in a rat model of MCAo (2 h occlusion followed by â¤ 22 h reperfusion), PJ34 administration (10 mg/kg i.v.) reduced infarct size, and the effect of the drug was maintained even if it was given as late as 10 min prior to reperfusion time.  PJ34 protected in a 4 h, but not in a 24 h permanent occlusion model.  In conclusion, PJ34, a novel, potent inhibitor of PARP exerts massive neuroprotective agents, with a therapeutic window of opportunity.  The present work strengthens the concept that pharmacol. PARP inhibition may be a suitable approach for the treatment of acute stroke in man.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfu3rYxVmP17Vg90H21EOLACvtfcHk0lgnsKXfsxEjXg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhsFCrtrs%253D&md5=d643efb37973db0e8704d9c921633620</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAbdelkarim%26aufirst%3DG.%2BE.%26aulast%3DGertz%26aufirst%3DK.%26aulast%3DHarms%26aufirst%3DC.%26aulast%3DKatchanov%26aufirst%3DJ.%26aulast%3DDirnagl%26aufirst%3DU.%26aulast%3DSzabo%26aufirst%3DC.%26aulast%3DEndres%26aufirst%3DM.%26atitle%3DProtective%2520effects%2520of%2520PJ34%252C%2520a%2520novel%252C%2520potent%2520inhibitor%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520in%2520in%2520vitro%2520and%2520in%2520vivo%2520models%2520of%2520stroke%26jtitle%3DInt.%2520J.%2520Mol.%2520Med.%26date%3D2001%26volume%3D7%26spage%3D255%26epage%3D260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group">Faro, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyoda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCully, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jagtap, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Virag, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bianchi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levitsky, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellke, F. W.</span><span> </span><span class="NLM_article-title">Myocardial protection by PJ34, a novel potent poly (ADP-ribose) synthetase inhibitor</span> <span class="citation_source-journal">Ann. Thorac. Surg.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">575</span><span class="NLM_x">â</span> <span class="NLM_lpage">581</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1016%2FS0003-4975%2801%2903329-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=11845877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A280%3ADC%252BD387htlyquw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2002&pages=575-581&author=R.+Faroauthor=Y.+Toyodaauthor=J.+D.+McCullyauthor=P.+Jagtapauthor=E.+Szaboauthor=L.+Viragauthor=C.+Bianchiauthor=S.+Levitskyauthor=C.+Szaboauthor=F.+W.+Sellke&title=Myocardial+protection+by+PJ34%2C+a+novel+potent+poly+%28ADP-ribose%29+synthetase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Myocardial protection by PJ34, a novel potent poly (ADP-ribose) synthetase inhibitor</span></div><div class="casAuthors">Faro Renato; Toyoda Yoshiya; McCully James D; Jagtap Prakash; Szabo Eva; Virag Laszlo; Bianchi Cesario; Levitsky Sidney; Szabo Csaba; Sellke Frank W</div><div class="citationInfo"><span class="NLM_cas:title">The Annals of thoracic surgery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">575-81</span>
        ISSN:<span class="NLM_cas:issn">0003-4975</span>.
    </div><div class="casAbstract">BACKGROUND:  The activation of poly (ADP-ribose) synthetase plays an important role in the pathogenesis leading to myocardial ischemia-reperfusion injury.  The aim of this study was to determine if a novel potent inhibitor of poly (ADP-ribose) synthetase, PJ34, provides myocardial protection.  METHODS:  Pigs were subjected to 60 minutes of regional ischemia followed by 180 minutes of reperfusion.  Ten mg/kg of PJ34 (PJ34; n = 6) was administrated intravenously (treated group) from 15 to 5 minutes before reperfusion followed by 3 mg/kg/hour of PJ34 from 5 minutes before reperfusion to the end of 180 minutes reperfusion.  Control pigs (n = 7) received vehicle only.  Arterial and left ventricular pressure and coronary flow were monitored.  RESULTS:  The PJ34 showed significant reduction on infarct size (37.5%+/-4.5% and 50.5%+/-4.8% of the area at risk) for PJ34 and control pigs groups, respectively, (p < 0.05).  Significant reduction in postsystolic shortening, as well as improvement on segment shortening, and positive first derivative of pressure over time (+dP/dt) maximum were also observed in PJ34 versus control pigs (p < 0.05).  CONCLUSIONS:  Our results suggest that PJ34 provides cardioprotection by decreasing myocardial infarct size and enhancing postischemic regional and global functional recovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSdW1W6ZTGLPsK3uFsUIZtkfW6udTcc2eaw1KDpw8ahxbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD387htlyquw%253D%253D&md5=7a0aa1cc2874deadb6c4885abcce82ba</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2FS0003-4975%2801%2903329-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0003-4975%252801%252903329-X%26sid%3Dliteratum%253Aachs%26aulast%3DFaro%26aufirst%3DR.%26aulast%3DToyoda%26aufirst%3DY.%26aulast%3DMcCully%26aufirst%3DJ.%2BD.%26aulast%3DJagtap%26aufirst%3DP.%26aulast%3DSzabo%26aufirst%3DE.%26aulast%3DVirag%26aufirst%3DL.%26aulast%3DBianchi%26aufirst%3DC.%26aulast%3DLevitsky%26aufirst%3DS.%26aulast%3DSzabo%26aufirst%3DC.%26aulast%3DSellke%26aufirst%3DF.%2BW.%26atitle%3DMyocardial%2520protection%2520by%2520PJ34%252C%2520a%2520novel%2520potent%2520poly%2520%2528ADP-ribose%2529%2520synthetase%2520inhibitor%26jtitle%3DAnn.%2520Thorac.%2520Surg.%26date%3D2002%26volume%3D73%26spage%3D575%26epage%3D581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group">Goldfarb, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marton, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Virag, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salzman, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glock, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akhter, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarthy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parrillo, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabo, C.</span><span> </span><span class="NLM_article-title">Protective effect of a novel, potent inhibitor of poly(adenosine 5â²-diphosphate-ribose) synthetase in a porcine model of severe bacterial sepsis</span> <span class="citation_source-journal">Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">974</span><span class="NLM_x">â</span> <span class="NLM_lpage">980</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1097%2F00003246-200205000-00004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=12006790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD38XktlWgtbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2002&pages=974-980&author=R.+D.+Goldfarbauthor=A.+Martonauthor=E.+Szaboauthor=L.+Viragauthor=A.+L.+Salzmanauthor=D.+Glockauthor=I.+Akhterauthor=R.+McCarthyauthor=J.+E.+Parrilloauthor=C.+Szabo&title=Protective+effect+of+a+novel%2C+potent+inhibitor+of+poly%28adenosine+5%E2%80%B2-diphosphate-ribose%29+synthetase+in+a+porcine+model+of+severe+bacterial+sepsis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Protective effect of a novel, potent inhibitor of poly(adenosine 5'-diphosphate-ribose) synthetase in a porcine model of severe bacterial sepsis</span></div><div class="casAuthors">Goldfarb, Roy D.; Marton, Anita; Szabo, Eva; Virag, Laszlo; Salzman, Andrew L.; Glock, Dana; Akhter, Imran; McCarthy, Robert; Parrillo, Joseph E.; Szabo, Csaba</div><div class="citationInfo"><span class="NLM_cas:title">Critical Care Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">974-980</span>CODEN:
                <span class="NLM_cas:coden">CCMDC7</span>;
        ISSN:<span class="NLM_cas:issn">0090-3493</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Objective: To det. whether activation of the nuclear enzyme poly(adenosine 5'diphosphate [ADP]-ribose) synthetase (PARS) contributes to mortality rate, myocardial dysfunction, and cardiovascular collapse in a porcine model of sepsis induced by implantation of an infected clot.  Design: Prospective, random animal study.  Setting: Research lab. at Rush Presbyterian St. Luke's Medical Center.  Subjects: Twenty pigs were chronically instrumented with intracardiac transducers to measure left ventricular pressure, sonomicrometer crystals in the left ventricle to measure short axis diam., an ultrasonic flow meter to measure cardiac output, and catheters in the pulmonary artery and aorta to measure blood pressure and collect samples.  Interventions: By using a randomized study design, the authors administered either the novel potent PARS inhibitor PJ34 (10 mg/kg for 1 h, 2 mgÂ·kg-1Â·hr-1 for 96 h) or vehicle to pigs immediately before i.p. implantation of Escherichia coli 0111.B4 (2.3Â±0.1 Ã 1010 colony-forming units/kg)-laden fibrin clots to produce peritonitis and bacteremia.  Measurements and Main Results: In vehicle-treated pigs, 12% survival was recorded at 24 h, whereas 83% and 66% survival was recorded in the PJ34-treated animals at 24 and 96 h, resp. (p <.05).  PJ34 treatment attenuated bacteremia-induced increases in systemic and pulmonary vascular resistances.  In controls, peritonitis induced rapid increase in plasma tumor necrosis factor-Î±.  PJ34 treatment significantly attenuated this cytokine response.  The formation of peroxynitrite and the activation of PARS were confirmed in hearts and lungs of the septic pigs by the immunohistochem. detection of nitrotyrosine and poly(ADP-ribose), resp.  Inhibition of PARS with PJ34 abolished poly(ADP-ribose) formation in septic animals.  Conclusions: Treatment with a potent PARS inhibitor improved survival and cardiovascular status and attenuated an important mediator component of the inflammatory response in a lethal porcine model of sepsis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo558Q_xOcHgbVg90H21EOLACvtfcHk0lhQLC0kdPFxMg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktlWgtbo%253D&md5=42c7329c08ed994a75d9c21cb5e7d095</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1097%2F00003246-200205000-00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00003246-200205000-00004%26sid%3Dliteratum%253Aachs%26aulast%3DGoldfarb%26aufirst%3DR.%2BD.%26aulast%3DMarton%26aufirst%3DA.%26aulast%3DSzabo%26aufirst%3DE.%26aulast%3DVirag%26aufirst%3DL.%26aulast%3DSalzman%26aufirst%3DA.%2BL.%26aulast%3DGlock%26aufirst%3DD.%26aulast%3DAkhter%26aufirst%3DI.%26aulast%3DMcCarthy%26aufirst%3DR.%26aulast%3DParrillo%26aufirst%3DJ.%2BE.%26aulast%3DSzabo%26aufirst%3DC.%26atitle%3DProtective%2520effect%2520of%2520a%2520novel%252C%2520potent%2520inhibitor%2520of%2520poly%2528adenosine%25205%25E2%2580%25B2-diphosphate-ribose%2529%2520synthetase%2520in%2520a%2520porcine%2520model%2520of%2520severe%2520bacterial%2520sepsis%26jtitle%3DCrit.%2520Care%2520Med.%26date%3D2002%26volume%3D30%26spage%3D974%26epage%3D980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group">Cushman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaraman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vroman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukunaga, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohlhagen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strumberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pommier, Y.</span><span> </span><span class="NLM_article-title">Synthesis of new indeno[1,2-<i>c</i>]isoquinolines: cytotoxic non-camptothecin topoisomerase I inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">3688</span><span class="NLM_x">â</span> <span class="NLM_lpage">3698</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm000029d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=3688-3698&author=M.+Cushmanauthor=M.+Jayaramanauthor=J.+A.+Vromanauthor=A.+K.+Fukunagaauthor=B.+M.+Foxauthor=G.+Kohlhagenauthor=D.+Strumbergauthor=Y.+Pommier&title=Synthesis+of+new+indeno%5B1%2C2-c%5Disoquinolines%3A+cytotoxic+non-camptothecin+topoisomerase+I+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1021%2Fjm000029d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000029d%26sid%3Dliteratum%253Aachs%26aulast%3DCushman%26aufirst%3DM.%26aulast%3DJayaraman%26aufirst%3DM.%26aulast%3DVroman%26aufirst%3DJ.%2BA.%26aulast%3DFukunaga%26aufirst%3DA.%2BK.%26aulast%3DFox%26aufirst%3DB.%2BM.%26aulast%3DKohlhagen%26aufirst%3DG.%26aulast%3DStrumberg%26aufirst%3DD.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DSynthesis%2520of%2520new%2520indeno%255B1%252C2-c%255Disoquinolines%253A%2520cytotoxic%2520non-camptothecin%2520topoisomerase%2520I%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D3688%26epage%3D3698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group">Jagtap, P.; Southan, G.; Salzman, A.; Szabo, C.; Ram, S.</span><span> </span><span class="NLM_article-title">7-Substituted Isoindolinone Inhibitors of Inflammation and Reperfusion Injury and Methods of Use Thereof</span>. U.S. Patent 6534651,<span class="NLM_x"> </span><span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=P.+Jagtap&author=G.+Southan&author=A.+Salzman&author=C.+Szabo&author=S.+Ram&title=7-Substituted+Isoindolinone+Inhibitors+of+Inflammation+and+Reperfusion+Injury+and+Methods+of+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJagtap%26aufirst%3DP.%26atitle%3D7-Substituted%2520Isoindolinone%2520Inhibitors%2520of%2520Inflammation%2520and%2520Reperfusion%2520Injury%2520and%2520Methods%2520of%2520Use%2520Thereof%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group">Morrow, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brickman, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baran, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krakover, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dauerman, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slomowitz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grip, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCabe, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salzman, A. L.</span><span> </span><span class="NLM_article-title">A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the TIMI 37 trial</span> <span class="citation_source-journal">J. Thromb. Thrombolysis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">359</span><span class="NLM_x">â</span> <span class="NLM_lpage">364</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1007%2Fs11239-008-0230-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=18535785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlslCis7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=359-364&author=D.+A.+Morrowauthor=C.+M.+Brickmanauthor=S.+A.+Murphyauthor=K.+Baranauthor=R.+Krakoverauthor=H.+Dauermanauthor=S.+Kumarauthor=N.+Slomowitzauthor=L.+Gripauthor=C.+H.+McCabeauthor=A.+L.+Salzman&title=A+randomized%2C+placebo-controlled+trial+to+evaluate+the+tolerability%2C+safety%2C+pharmacokinetics%2C+and+pharmacodynamics+of+a+potent+inhibitor+of+poly%28ADP-ribose%29+polymerase+%28INO-1001%29+in+patients+with+ST-elevation+myocardial+infarction+undergoing+primary+percutaneous+coronary+intervention%3A+results+of+the+TIMI+37+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the TIMI 37 trial</span></div><div class="casAuthors">Morrow, David A.; Brickman, Chaim M.; Murphy, Sabina A.; Baran, Kenneth; Krakover, Ricardo; Dauerman, Harold; Kumar, Sujatha; Slomowitz, Natanya; Grip, Laura; McCabe, Carolyn H.; Salzman, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thrombosis and Thrombolysis</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">359-364</span>CODEN:
                <span class="NLM_cas:coden">JTTHFF</span>;
        ISSN:<span class="NLM_cas:issn">0929-5305</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Reperfusion injury is a significant complication of the management of ST-elevation MI (STEMI).  INO-1001 is a potent inhibitor of poly(ADP-ribose) polymerase (PARP), a mediator of oxidant-induced myocyte dysfunction during reperfusion.  We assessed the safety and pharmacokinetics of INO-1001 in a randomized, placebo-controlled, single-blind, dose-escalating trial in 40 patients with STEMI undergoing primary percutaneous coronary intervention within 24 h of onset.  INO-1001 was well-tolerated.  A trend toward more frequent transaminitis was obsd. with 800 mg.  Plasma from INO1001-treated patients reduced in vitro PARP activity >90% at all doses.  Serial C-reactive protein and IL-6 levels showed a trend toward blunting of inflammation with INO-1001.  The apparent median terminal half-life (t1/2) of INO-1001 was 7.5 (25th, 75th: 5.9, 10.2) h.  The results from this first trial of INO-1001 in STEMI support future investigation of INO-1001 as a novel treatment for reperfusion injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKyTofr9_A1bVg90H21EOLACvtfcHk0lg2hV4PT-bSuQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlslCis7s%253D&md5=6400167cc4e96b6938f7f24e903a2a77</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1007%2Fs11239-008-0230-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11239-008-0230-1%26sid%3Dliteratum%253Aachs%26aulast%3DMorrow%26aufirst%3DD.%2BA.%26aulast%3DBrickman%26aufirst%3DC.%2BM.%26aulast%3DMurphy%26aufirst%3DS.%2BA.%26aulast%3DBaran%26aufirst%3DK.%26aulast%3DKrakover%26aufirst%3DR.%26aulast%3DDauerman%26aufirst%3DH.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DSlomowitz%26aufirst%3DN.%26aulast%3DGrip%26aufirst%3DL.%26aulast%3DMcCabe%26aufirst%3DC.%2BH.%26aulast%3DSalzman%26aufirst%3DA.%2BL.%26atitle%3DA%2520randomized%252C%2520placebo-controlled%2520trial%2520to%2520evaluate%2520the%2520tolerability%252C%2520safety%252C%2520pharmacokinetics%252C%2520and%2520pharmacodynamics%2520of%2520a%2520potent%2520inhibitor%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%2520%2528INO-1001%2529%2520in%2520patients%2520with%2520ST-elevation%2520myocardial%2520infarction%2520undergoing%2520primary%2520percutaneous%2520coronary%2520intervention%253A%2520results%2520of%2520the%2520TIMI%252037%2520trial%26jtitle%3DJ.%2520Thromb.%2520Thrombolysis%26date%3D2009%26volume%3D27%26spage%3D359%26epage%3D364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group">Mason, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valdecanas, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milas, L.</span><span> </span><span class="NLM_article-title">INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicin</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">â</span> <span class="NLM_lpage">5</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=1-5&author=K.+A.+Masonauthor=D.+Valdecanasauthor=N.+R.+Hunterauthor=L.+Milas&title=INO-1001%2C+a+novel+inhibitor+of+poly%28ADP-ribose%29+polymerase%2C+enhances+tumor+response+to+doxorubicin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMason%26aufirst%3DK.%2BA.%26aulast%3DValdecanas%26aufirst%3DD.%26aulast%3DHunter%26aufirst%3DN.%2BR.%26aulast%3DMilas%26aufirst%3DL.%26atitle%3DINO-1001%252C%2520a%2520novel%2520inhibitor%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%252C%2520enhances%2520tumor%2520response%2520to%2520doxorubicin%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2008%26volume%3D26%26spage%3D1%26epage%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group">Cheng, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keir, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali-Osman, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salzman, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dolan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modrich, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bigner, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, H. S.</span><span> </span><span class="NLM_article-title">Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1364</span><span class="NLM_x">â</span> <span class="NLM_lpage">1368</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1158%2F1535-7163.MCT-05-0128" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=16170028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVKnt7nP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=1364-1368&author=C.+L.+Chengauthor=S.+P.+Johnsonauthor=S.+T.+Keirauthor=J.+A.+Quinnauthor=F.+Ali-Osmanauthor=C.+Szaboauthor=H.+Liauthor=A.+L.+Salzmanauthor=M.+E.+Dolanauthor=P.+Modrichauthor=D.+D.+Bignerauthor=H.+S.+Friedman&title=Poly%28ADP-ribose%29+polymerase-1+inhibition+reverses+temozolomide+resistance+in+a+DNA+mismatch+repair-deficient+malignant+glioma+xenograft"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft</span></div><div class="casAuthors">Cheng, C. Lynn; Johnson, Stewart P.; Keir, Stephen T.; Quinn, Jennifer A.; Ali-Osman, Francis; Szabo, Csaba; Li, Hongshan; Salzman, Andrew L.; Dolan, M. Eileen; Modrich, Paul; Bigner, Darell D.; Friedman, Henry S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1364-1368</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Temozolomide is a DNA-methylating agent used in the treatment of malignant gliomas.  In this study, we have examd. if inhibition of poly(ADP-ribose) polymerase (PARP) could increase the cytotoxicity of temozolomide, particularly in cells deficient in DNA mismatch repair.  Athymic mice, transplanted with mismatch repair - proficient [D-245 MG] or deficient [D-245 MG (PR)] xenografts, were treated with a combination of temozolomide and the PARP inhibitor, INO-1001.  For the tumors deficient in mismatch repair, the most ED of INO-1001 was found to be 150 mg/kg, given i.p. thrice at 4-h intervals with the first injection in combination with 262.5 mg/kg temozolomide (0.75 LD10).  This dose of temozolomide by itself induced no partial regressions and a 4-day growth delay.  In two sep. expts., the combination therapy increased the growth delay by 21.6 and 9.7 days with partial regressions obsd. in four of eight and three of nine mice, resp.  The addn. of INO-1001 had a more modest, yet statistically significant, increase in tumor growth delay in the mismatch repair - proficient xenografts.  In these expts., mice were treated with a lower amt. of temozolomide (88 mg/kg), which resulted in growth delays of 43.1 and 39.2 days.  When the temozolomide treatment was in combination with 200 mg/kg INO-1001, there was an increase in growth delay to 48.9 and 45.7 days, resp.  These results suggest that inhibition of PARP may increase the efficacy of temozolomide in the treatment of malignant gliomas, particularly in tumors deficient in DNA mismatch repair.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoteU4bA489MrVg90H21EOLACvtfcHk0lg2hV4PT-bSuQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVKnt7nP&md5=ac1ce9ffbdb33d848bc961f35172b7f1</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-05-0128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-05-0128%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DC.%2BL.%26aulast%3DJohnson%26aufirst%3DS.%2BP.%26aulast%3DKeir%26aufirst%3DS.%2BT.%26aulast%3DQuinn%26aufirst%3DJ.%2BA.%26aulast%3DAli-Osman%26aufirst%3DF.%26aulast%3DSzabo%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DSalzman%26aufirst%3DA.%2BL.%26aulast%3DDolan%26aufirst%3DM.%2BE.%26aulast%3DModrich%26aufirst%3DP.%26aulast%3DBigner%26aufirst%3DD.%2BD.%26aulast%3DFriedman%26aufirst%3DH.%2BS.%26atitle%3DPoly%2528ADP-ribose%2529%2520polymerase-1%2520inhibition%2520reverses%2520temozolomide%2520resistance%2520in%2520a%2520DNA%2520mismatch%2520repair-deficient%2520malignant%2520glioma%2520xenograft%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2005%26volume%3D4%26spage%3D1364%26epage%3D1368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group">Wang, C.; Bedikian, A. Y.; Kim, K.; Papadopoulos, N. E.; Hwu, W.; Hwu, P.</span><span> </span><span class="NLM_article-title">Evaluation of Tolerability, Safety, and Pharmacokinetics of INO-1001 plus Temozolomide (TMZ) in Patients with Unresectable Stage III/IV Melanoma</span>.  <span class="citation_source-book">ASCO Meeting Abstracts</span>, 2006 ASCO Annual Meeting; <span class="NLM_publisher-name">American Society of Clinical Oncology</span>: <span class="NLM_publisher-loc">Alexandria, VA</span>,<span class="NLM_x"> </span><span class="NLM_year">2006</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">24</span>, p  <span class="NLM_fpage">12015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=12015&author=C.+Wang&author=A.+Y.+Bedikian&author=K.+Kim&author=N.+E.+Papadopoulos&author=W.+Hwu&author=P.+Hwu&title=ASCO+Meeting+Abstracts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DC.%26atitle%3DEvaluation%2520of%2520Tolerability%252C%2520Safety%252C%2520and%2520Pharmacokinetics%2520of%2520INO-1001%2520plus%2520Temozolomide%2520%2528TMZ%2529%2520in%2520Patients%2520with%2520Unresectable%2520Stage%2520III%252FIV%2520Melanoma%26btitle%3DASCO%2520Meeting%2520Abstracts%26pub%3DAmerican%2520Society%2520of%2520Clinical%2520Oncology%26date%3D2006%26volume%3D24%26spage%3D12015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group">Bedikian, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papadopoulos, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwu, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Homsi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glass, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cain, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudewicz, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vernillet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwu, P.</span><span> </span><span class="NLM_article-title">A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma</span> <span class="citation_source-journal">Cancer Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">756</span><span class="NLM_x">â</span> <span class="NLM_lpage">763</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=756-763&author=A.+Y.+Bedikianauthor=N.+E.+Papadopoulosauthor=K.+B.+Kimauthor=W.+J.+Hwuauthor=J.+Homsiauthor=M.+R.+Glassauthor=S.+Cainauthor=P.+Rudewiczauthor=L.+Vernilletauthor=P.+Hwu&title=A+phase+IB+trial+of+intravenous+INO-1001+plus+oral+temozolomide+in+subjects+with+unresectable+stage-III+or+IV+melanoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBedikian%26aufirst%3DA.%2BY.%26aulast%3DPapadopoulos%26aufirst%3DN.%2BE.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DHwu%26aufirst%3DW.%2BJ.%26aulast%3DHomsi%26aufirst%3DJ.%26aulast%3DGlass%26aufirst%3DM.%2BR.%26aulast%3DCain%26aufirst%3DS.%26aulast%3DRudewicz%26aufirst%3DP.%26aulast%3DVernillet%26aufirst%3DL.%26aulast%3DHwu%26aufirst%3DP.%26atitle%3DA%2520phase%2520IB%2520trial%2520of%2520intravenous%2520INO-1001%2520plus%2520oral%2520temozolomide%2520in%2520subjects%2520with%2520unresectable%2520stage-III%2520or%2520IV%2520melanoma%26jtitle%3DCancer%2520Invest.%26date%3D2009%26volume%3D27%26spage%3D756%26epage%3D763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group">Hitchcock, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennington, L. D.</span><span> </span><span class="NLM_article-title">Structureâbrain exposure relationships</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">7559</span><span class="NLM_x">â</span> <span class="NLM_lpage">7583</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm060642i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=7559-7583&author=S.+A.+Hitchcockauthor=L.+D.+Pennington&title=Structure%E2%88%92brain+exposure+relationships"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1021%2Fjm060642i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060642i%26sid%3Dliteratum%253Aachs%26aulast%3DHitchcock%26aufirst%3DS.%2BA.%26aulast%3DPennington%26aufirst%3DL.%2BD.%26atitle%3DStructure%25E2%2588%2592brain%2520exposure%2520relationships%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D7559%26epage%3D7583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group">Li, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serdyuk, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferraris, D. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tays, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kletzly, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lautar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalish, V. J.</span><span> </span><span class="NLM_article-title">Synthesis of substituted 5[H]phenanthridin-6-ones as potent poly(ADP-ribose)polymerase-1 (PARP1) inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1687</span><span class="NLM_x">â</span> <span class="NLM_lpage">1690</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=1687-1690&author=J.+H.+Liauthor=L.+Serdyukauthor=D.+V.+Ferrarisauthor=G.+Xiaoauthor=K.+L.+Taysauthor=P.+W.+Kletzlyauthor=W.+Liauthor=S.+Lautarauthor=J.+Zhangauthor=V.+J.+Kalish&title=Synthesis+of+substituted+5%5BH%5Dphenanthridin-6-ones+as+potent+poly%28ADP-ribose%29polymerase-1+%28PARP1%29+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%2BH.%26aulast%3DSerdyuk%26aufirst%3DL.%26aulast%3DFerraris%26aufirst%3DD.%2BV.%26aulast%3DXiao%26aufirst%3DG.%26aulast%3DTays%26aufirst%3DK.%2BL.%26aulast%3DKletzly%26aufirst%3DP.%2BW.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DLautar%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DKalish%26aufirst%3DV.%2BJ.%26atitle%3DSynthesis%2520of%2520substituted%25205%255BH%255Dphenanthridin-6-ones%2520as%2520potent%2520poly%2528ADP-ribose%2529polymerase-1%2520%2528PARP1%2529%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D1687%26epage%3D1690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lautar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramsey, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J. H.</span><span> </span><span class="NLM_article-title">GPI 6150 prevents H(2)O(2) cytotoxicity by inhibiting poly(ADP-ribose) polymerase</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">590</span><span class="NLM_x">â</span> <span class="NLM_lpage">598</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2000&pages=590-598&author=J.+Zhangauthor=S.+Lautarauthor=S.+Huangauthor=C.+Ramseyauthor=A.+Cheungauthor=J.+H.+Li&title=GPI+6150+prevents+H%282%29O%282%29+cytotoxicity+by+inhibiting+poly%28ADP-ribose%29+polymerase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLautar%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DRamsey%26aufirst%3DC.%26aulast%3DCheung%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DJ.%2BH.%26atitle%3DGPI%25206150%2520prevents%2520H%25282%2529O%25282%2529%2520cytotoxicity%2520by%2520inhibiting%2520poly%2528ADP-ribose%2529%2520polymerase%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2000%26volume%3D278%26spage%3D590%26epage%3D598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group">Zhang, J.</span><span> </span><span class="NLM_article-title">PARP inhibition: a novel approach to treat ischemia/reperfusion and inflammation-related injuries</span> <span class="citation_source-journal">Expert Opin. Emerging Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">209</span><span class="NLM_x">â</span> <span class="NLM_lpage">221</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1517%2F14728214.4.1.209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADyaK1MXislaqsL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1999&pages=209-221&author=J.+Zhang&title=PARP+inhibition%3A+a+novel+approach+to+treat+ischemia%2Freperfusion+and+inflammation-related+injuries"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">PARP inhibition: a novel approach to treat ischaemia/reperfusion and inflammation-related injuries</span></div><div class="casAuthors">Zhang, J.</div><div class="citationInfo"><span class="NLM_cas:title">Emerging Drugs</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">209-221</span>CODEN:
                <span class="NLM_cas:coden">EMDRFV</span>;
        ISSN:<span class="NLM_cas:issn">1361-9195</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications</span>)
        </div><div class="casAbstract">A review with 64 refs. and 3 website listings.  Poly(ADP-ribose) polymerase (PARP) is one of the most abundant nuclear enzymes.  When it is activated by DNA strand breaks, PARP synthesizes poly(ADP-ribose) by using NAD (NAD) as substrate.  Early PARP research focused primarily on its role in facilitating structural changes of chromosomal DNA, such as during DNA repair, gene expression, DNA replication, DNA rearrangement, sister chromatid exchange, differentiation and mutagenesis.  The recent discovery of PARP as a substrate for caspases has led to an intensive search for possible PARP involvement in the apoptosis pathway.  Although the exact physiol. functions of PARP still remain to be firmly established, it has long been known that PARP activation can cause a rapid depletion of cellular NAD and ATP.  This is mainly due to the high turnover rate of poly(ADP-ribose), which is degraded by poly(ADP-ribose) glycohydrolase.  Thus, it has been proposed as a "suicidal hypothesis" that PARP activation contributes to the energy failure that leads to cell death elicited by massive DNA damage.  Indeed, there is accumulating evidence to suggest that activation of PARP by free radical damaged DNA plays a pivotal role in mediating ischemia/reperfusion injuries.  PARP emerges as a novel target to treat such injuries.  The strategy of targeting PARP inhibition is validated by the findings that PARP deficient mice are extremely resistant to both cerebral and myocardial ischemia.  PARP inhibitors have demonstrated remarkable efficacy in reducing the infarct vols. of cerebral focal ischemia and regional heart ischemia.  They also exhibit strong anti-inflammatory activities in rodent models of inflammation related injuries, e.g., septic shock, arthritis and Type I diabetes.  Therefore, even at an early stage of drug discovery, PARP inhibitors have shown great potential for treating a broad spectrum of diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2cX7tJIsaebVg90H21EOLACvtfcHk0lhjGSBDnUGVsQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXislaqsL8%253D&md5=d59cce42244066534b1347b6b4f60d6a</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1517%2F14728214.4.1.209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728214.4.1.209%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DPARP%2520inhibition%253A%2520a%2520novel%2520approach%2520to%2520treat%2520ischemia%252Freperfusion%2520and%2520inflammation-related%2520injuries%26jtitle%3DExpert%2520Opin.%2520Emerging%2520Drugs%26date%3D1999%26volume%3D4%26spage%3D209%26epage%3D221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group">Kalish, V.; Zhang, J.; Xu, W.; Li, J.-h.; Xing, A. D.; Liu, Q.</span><span> </span><span class="NLM_article-title">Compounds, Methods and Pharmaceutical Compositions for Inhibiting PARP</span>. U.S. Patent 7601719,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=V.+Kalish&author=J.+Zhang&author=W.+Xu&author=J.-h.+Li&author=A.+D.+Xing&author=Q.+Liu&title=Compounds%2C+Methods+and+Pharmaceutical+Compositions+for+Inhibiting+PARP"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKalish%26aufirst%3DV.%26atitle%3DCompounds%252C%2520Methods%2520and%2520Pharmaceutical%2520Compositions%2520for%2520Inhibiting%2520PARP%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group">Tentori, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonetti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarsella, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DâAmati, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vergati, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Portarena, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalish, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zupi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graziani, G.</span><span> </span><span class="NLM_article-title">Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">5370</span><span class="NLM_x">â</span> <span class="NLM_lpage">5379</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=14614022" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD3sXovVOnsrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=5370-5379&author=L.+Tentoriauthor=C.+Leonettiauthor=M.+Scarsellaauthor=G.+D%E2%80%99Amatiauthor=M.+Vergatiauthor=I.+Portarenaauthor=W.+Xuauthor=V.+Kalishauthor=G.+Zupiauthor=J.+Zhangauthor=G.+Graziani&title=Systemic+administration+of+GPI+15427%2C+a+novel+poly%28ADP-ribose%29+polymerase-1+inhibitor%2C+increases+the+antitumor+activity+of+temozolomide+against+intracranial+melanoma%2C+glioma%2C+lymphoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Systemic Administration of GPI 15427, a Novel Poly(ADP-Ribose) Polymerase-1 Inhibitor, Increases the Antitumor Activity of Temozolomide against Intracranial Melanoma, Glioma, Lymphoma</span></div><div class="casAuthors">Tentori, Lucio; Leonetti, Carlo; Scarsella, Marco; D'Amati, Giulia; Vergati, Matteo; Portarena, Ilaria; Xu, Weizheng; Kalish, Vincent; Zupi, Gabriella; Zhang, Jie; Graziani, Grazia</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5370-5379</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Temozolomide (TMZ) is a DNA methylating agent that has shown promising antitumor activity in recent clin. trials against high grade gliomas, metastatic melanoma, and brain lymphoma.  In this study, we tested whether systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase (PARP-1) inhibitor capable of crossing the blood-brain barrier, could enhance the efficacy of TMZ against metastatic melanoma, glioblastoma multiforme, and lymphoma growing in the brain.  Murine B16 melanoma or L5178Y lymphoma cells were injected intracranially in syngeneic mice.  An orthotopic xenograft of the human SJGBM2 glioblastoma multiforme was implanted in nude mice.  Animals were treated with TMZ + GPI 15427 using a schedule of 40 mg/kg/i.v. GPI 15427 + 100 mg/kg/i.p. TMZ for 3 days.  The efficacy of drug treatment was assessed by: (a) the increase of mouse survival and life span; and (b) the suppression of melanoma metastases to lung after i.v. injection of B16 cells.  In all models, systemic administration of GPI 15427 shortly before TMZ significantly increased life span of tumor-bearing mice with respect to untreated controls or to groups treated with either GPI 15427 or TMZ only.  Moreover, GPI 15427 increased the antimetastatic effect of TMZ.  These data indicate that systemic administration of the poly(ADP-ribose) polymerase-1 inhibitor GPI 15427 significantly enhances TMZ antitumor efficacy against solid or hematol. neoplasias even when located at the central nervous system site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJYH9LbPZeJLVg90H21EOLACvtfcHk0lhJlK5nVsxxOQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXovVOnsrY%253D&md5=5f50132c0d4610520363360abedcc9e5</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTentori%26aufirst%3DL.%26aulast%3DLeonetti%26aufirst%3DC.%26aulast%3DScarsella%26aufirst%3DM.%26aulast%3DD%25E2%2580%2599Amati%26aufirst%3DG.%26aulast%3DVergati%26aufirst%3DM.%26aulast%3DPortarena%26aufirst%3DI.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DKalish%26aufirst%3DV.%26aulast%3DZupi%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DGraziani%26aufirst%3DG.%26atitle%3DSystemic%2520administration%2520of%2520GPI%252015427%252C%2520a%2520novel%2520poly%2528ADP-ribose%2529%2520polymerase-1%2520inhibitor%252C%2520increases%2520the%2520antitumor%2520activity%2520of%2520temozolomide%2520against%2520intracranial%2520melanoma%252C%2520glioma%252C%2520lymphoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2003%26volume%3D9%26spage%3D5370%26epage%3D5379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group">Russo, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwon, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgan, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beam, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weizheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slusher, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakravarti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tofilon, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camphausen, K.</span><span> </span><span class="NLM_article-title">In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">607</span><span class="NLM_x">â</span> <span class="NLM_lpage">612</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1158%2F1078-0432.CCR-08-2079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=19147766" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlvFeqsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=607-612&author=A.+L.+Russoauthor=H.+C.+Kwonauthor=W.+E.+Burganauthor=D.+Carterauthor=K.+Beamauthor=X.+Weizhengauthor=J.+Zhangauthor=B.+S.+Slusherauthor=A.+Chakravartiauthor=P.+J.+Tofilonauthor=K.+Camphausen&title=In+vitro+and+in+vivo+radiosensitization+of+glioblastoma+cells+by+the+poly+%28ADP-ribose%29+polymerase+inhibitor+E7016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and In vivo Radiosensitization of Glioblastoma Cells by the Poly (ADP-Ribose) Polymerase Inhibitor E7016</span></div><div class="casAuthors">Russo, Andrea L.; Kwon, Hyuk-Chan; Burgan, William E.; Carter, Donna; Beam, Katie; Weizheng, Xu; Zhang, Jie; Slusher, Barbara S.; Chakravarti, Arnab; Tofilon, Philip J.; Camphausen, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">607-612</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Poly (ADP-ribose) polymerase (PARP) inhibitors are undergoing clin. evaluation for cancer therapy.  Because PARP inhibition has been shown to enhance tumor cell sensitivity to radiation, we investigated the in vitro and in vivo effects of the novel PARP inhibitor E7016.  Exptl. Design: The effect of E7016 on the in vitro radiosensitivity of tumor cell lines was evaluated using clonogenic survival.  DNA damage and repair were measured using Î³H2AX foci and neutral comet assay.  Mitotic catastrophe was detd. by immunostaining. Tumor growth delay was evaluated in mice for the effect of E7016 on in vivo (U251) tumor radiosensitivity.  Results: Cell lines exposed to E7016 preirradn. yielded an increase in radiosensitivity with dose enhancement factors at a surviving fraction of 0.1 from 1.4 to 1.7.  To assess DNA double-strand breaks repair, Î³H2AX measured at 24 h postirradn. had significantly more foci per cell in the E7016/irradn. group vs. irradn. alone.  Neutral comet assay further suggested unrepaired double-strand breaks with significantly greater DNA damage at 6 h postirradn. in the combination group vs. irradn. alone.  Mitotic catastrophe staining revealed a significantly greater no. of cells staining pos. at 24 h postirradn. in the combination group.  In vivo, mice treated with E7016/irradn./temozolomide had an addnl. growth delay of six days compared with the combination of temozolomide and irradn.  Conclusions: These results indicate that E7016 can enhance tumor cell radiosensitivity in vitro and in vivo through the inhibition of DNA repair.  Moreover, enhanced growth delay with the addn. of E7016 to temozolomide and radiotherapy in a glioma mouse model suggests a potential role for this drug in the treatment of glioblastoma multiforme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwKbKGkXjVd7Vg90H21EOLACvtfcHk0lhJlK5nVsxxOQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlvFeqsg%253D%253D&md5=6b7d2b4cc62ff752d8402788fae07d71</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-2079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-2079%26sid%3Dliteratum%253Aachs%26aulast%3DRusso%26aufirst%3DA.%2BL.%26aulast%3DKwon%26aufirst%3DH.%2BC.%26aulast%3DBurgan%26aufirst%3DW.%2BE.%26aulast%3DCarter%26aufirst%3DD.%26aulast%3DBeam%26aufirst%3DK.%26aulast%3DWeizheng%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DChakravarti%26aufirst%3DA.%26aulast%3DTofilon%26aufirst%3DP.%2BJ.%26aulast%3DCamphausen%26aufirst%3DK.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520radiosensitization%2520of%2520glioblastoma%2520cells%2520by%2520the%2520poly%2520%2528ADP-ribose%2529%2520polymerase%2520inhibitor%2520E7016%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D607%26epage%3D612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group">Lapidus, R. G.; Xu, W.; Spicer, E.; Hoover, R.; Zhang, J.</span><span> </span><span class="NLM_article-title">PARP Inhibitors Enhance the Effect of Cisplatin against Tumors and Ameliorate Cisplatin-Induced Neuropathy</span>.  <span class="citation_source-book">AACR Meeting Abstracts</span>, 97th Annual Meeting of the American Association for Cancer Research, Washington, DC, April 1â5, 2006; <span class="NLM_publisher-name">American Association for Cancer Research</span>: <span class="NLM_publisher-loc">Philadelphia, PA</span>,<span class="NLM_x"> </span><span class="NLM_year">2006</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">2006</span>, p  <span class="NLM_fpage">506</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=506&author=R.+G.+Lapidus&author=W.+Xu&author=E.+Spicer&author=R.+Hoover&author=J.+Zhang&title=AACR+Meeting+Abstracts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DLapidus%26aufirst%3DR.%2BG.%26atitle%3DPARP%2520Inhibitors%2520Enhance%2520the%2520Effect%2520of%2520Cisplatin%2520against%2520Tumors%2520and%2520Ameliorate%2520Cisplatin-Induced%2520Neuropathy%26btitle%3DAACR%2520Meeting%2520Abstracts%26pub%3DAmerican%2520Association%2520for%2520Cancer%2520Research%26date%3D2006%26volume%3D2006%26spage%3D506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group">Lubisch, W.; Sadowski, J.; Kock, M.; Hoger, T.</span><span> </span><span class="NLM_article-title">Use of Phthalazine Derivatives</span>. WO 2000067734,<span class="NLM_x"> </span><span class="NLM_year">2000</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&author=W.+Lubisch&author=J.+Sadowski&author=M.+Kock&author=T.+Hoger&title=Use+of+Phthalazine+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLubisch%26aufirst%3DW.%26atitle%3DUse%2520of%2520Phthalazine%2520Derivatives%26date%3D2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group">Lubisch, W.; Kock, M.; Hoger, T.; Grandel, R.; Schult, S.</span><span> </span><span class="NLM_article-title">Heterocyclic Compounds and Their Use as PARP Inhibitors</span>. WO 2001057038,<span class="NLM_x"> </span><span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=W.+Lubisch&author=M.+Kock&author=T.+Hoger&author=R.+Grandel&author=S.+Schult&title=Heterocyclic+Compounds+and+Their+Use+as+PARP+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLubisch%26aufirst%3DW.%26atitle%3DHeterocyclic%2520Compounds%2520and%2520Their%2520Use%2520as%2520PARP%2520Inhibitors%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group">Lubisch, W.; Kock, M.; Hoger, T.; Schult, S.; Grandel, R.; Muller, R.</span><span> </span><span class="NLM_article-title">Substituted Benzimidazoles and Their Use as PARP Inhibitors</span>. U.S. Patent 6448271,<span class="NLM_x"> </span><span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=W.+Lubisch&author=M.+Kock&author=T.+Hoger&author=S.+Schult&author=R.+Grandel&author=R.+Muller&title=Substituted+Benzimidazoles+and+Their+Use+as+PARP+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLubisch%26aufirst%3DW.%26atitle%3DSubstituted%2520Benzimidazoles%2520and%2520Their%2520Use%2520as%2520PARP%2520Inhibitors%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group">Penning, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubisch, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grandel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wernet, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinghofer, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donawho, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bontcheva-Diaz, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giranda, V. L.</span><span> </span><span class="NLM_article-title">Discovery and SAR of 2-(1-propylpiperidin-4-yl)-1<i>H</i>-benzimidazole-4-carboxamide: a potent inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">6965</span><span class="NLM_x">â</span> <span class="NLM_lpage">6975</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2008&pages=6965-6975&author=T.+D.+Penningauthor=G.+D.+Zhuauthor=V.+B.+Gandhiauthor=J.+Gongauthor=S.+Thomasauthor=W.+Lubischauthor=R.+Grandelauthor=W.+Wernetauthor=C.+H.+Parkauthor=E.+H.+Fryauthor=X.+Liuauthor=Y.+Shiauthor=V.+Klinghoferauthor=E.+F.+Johnsonauthor=C.+K.+Donawhoauthor=D.+J.+Frostauthor=V.+Bontcheva-Diazauthor=J.+J.+Bouskaauthor=A.+M.+Olsonauthor=K.+C.+Marshauthor=Y.+Luoauthor=S.+H.+Rosenbergauthor=V.+L.+Giranda&title=Discovery+and+SAR+of+2-%281-propylpiperidin-4-yl%29-1H-benzimidazole-4-carboxamide%3A+a+potent+inhibitor+of+poly%28ADP-ribose%29+polymerase+%28PARP%29+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPenning%26aufirst%3DT.%2BD.%26aulast%3DZhu%26aufirst%3DG.%2BD.%26aulast%3DGandhi%26aufirst%3DV.%2BB.%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DS.%26aulast%3DLubisch%26aufirst%3DW.%26aulast%3DGrandel%26aufirst%3DR.%26aulast%3DWernet%26aufirst%3DW.%26aulast%3DPark%26aufirst%3DC.%2BH.%26aulast%3DFry%26aufirst%3DE.%2BH.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DKlinghofer%26aufirst%3DV.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DDonawho%26aufirst%3DC.%2BK.%26aulast%3DFrost%26aufirst%3DD.%2BJ.%26aulast%3DBontcheva-Diaz%26aufirst%3DV.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DOlson%26aufirst%3DA.%2BM.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DRosenberg%26aufirst%3DS.%2BH.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26atitle%3DDiscovery%2520and%2520SAR%2520of%25202-%25281-propylpiperidin-4-yl%2529-1H-benzimidazole-4-carboxamide%253A%2520a%2520potent%2520inhibitor%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2008%26volume%3D16%26spage%3D6965%26epage%3D6975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group">Zhu, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinghofer, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donawho, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarvis, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giranda, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penning, T. D.</span><span> </span><span class="NLM_article-title">Synthesis and SAR of novel, potent and orally bioavailable benzimidazole inhibitors of poly(ADP-ribose) polymerase (PARP) with a quaternary methylene-amino substituent</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">3955</span><span class="NLM_x">â</span> <span class="NLM_lpage">3958</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=3955-3958&author=G.+D.+Zhuauthor=V.+B.+Gandhiauthor=J.+Gongauthor=S.+Thomasauthor=Y.+Luoauthor=X.+Liuauthor=Y.+Shiauthor=V.+Klinghoferauthor=E.+F.+Johnsonauthor=D.+Frostauthor=C.+Donawhoauthor=K.+Jarvisauthor=J.+Bouskaauthor=K.+C.+Marshauthor=S.+H.+Rosenbergauthor=V.+L.+Girandaauthor=T.+D.+Penning&title=Synthesis+and+SAR+of+novel%2C+potent+and+orally+bioavailable+benzimidazole+inhibitors+of+poly%28ADP-ribose%29+polymerase+%28PARP%29+with+a+quaternary+methylene-amino+substituent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DG.%2BD.%26aulast%3DGandhi%26aufirst%3DV.%2BB.%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DKlinghofer%26aufirst%3DV.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DFrost%26aufirst%3DD.%26aulast%3DDonawho%26aufirst%3DC.%26aulast%3DJarvis%26aufirst%3DK.%26aulast%3DBouska%26aufirst%3DJ.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DRosenberg%26aufirst%3DS.%2BH.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26aulast%3DPenning%26aufirst%3DT.%2BD.%26atitle%3DSynthesis%2520and%2520SAR%2520of%2520novel%252C%2520potent%2520and%2520orally%2520bioavailable%2520benzimidazole%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520with%2520a%2520quaternary%2520methylene-amino%2520substituent%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D3955%26epage%3D3958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group">Donawho, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penning, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauch, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bontcheva-Diaz, V. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeWeese, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dillehay, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghoreishi-Haack, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimm, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holley-Shanks, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hristov, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Idler, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarvis, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleinberg, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinghofer, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasko, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGonigal, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meulbroek, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palma, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stavropoulos, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsurutani, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giranda, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, D. J.</span><span> </span><span class="NLM_article-title">ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2728</span><span class="NLM_x">â</span> <span class="NLM_lpage">2737</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1158%2F1078-0432.CCR-06-3039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=17473206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkslOhurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=2728-2737&author=C.+K.+Donawhoauthor=Y.+Luoauthor=T.+D.+Penningauthor=J.+L.+Bauchauthor=J.+J.+Bouskaauthor=V.+D.+Bontcheva-Diazauthor=B.+F.+Coxauthor=T.+L.+DeWeeseauthor=L.+E.+Dillehayauthor=D.+C.+Fergusonauthor=N.+S.+Ghoreishi-Haackauthor=D.+R.+Grimmauthor=R.+Guanauthor=E.+K.+Hanauthor=R.+R.+Holley-Shanksauthor=B.+Hristovauthor=K.+B.+Idlerauthor=K.+Jarvisauthor=E.+F.+Johnsonauthor=L.+R.+Kleinbergauthor=V.+Klinghoferauthor=L.+M.+Laskoauthor=X.+Liuauthor=K.+C.+Marshauthor=T.+P.+McGonigalauthor=J.+A.+Meulbroekauthor=A.+M.+Olsonauthor=J.+P.+Palmaauthor=L.+E.+Rodriguezauthor=Y.+Shiauthor=J.+A.+Stavropoulosauthor=A.+C.+Tsurutaniauthor=G.+D.+Zhuauthor=S.+H.+Rosenbergauthor=V.+L.+Girandaauthor=D.+J.+Frost&title=ABT-888%2C+an+orally+active+poly%28ADP-ribose%29+polymerase+inhibitor+that+potentiates+DNA-damaging+agents+in+preclinical+tumor+models"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models</span></div><div class="casAuthors">Donawho, Cherrie K.; Luo, Yan; Luo, Yanping; Penning, Thomas D.; Bauch, Joy L.; Bouska, Jennifer J.; Bontcheva-Diaz, Velitchka D.; Cox, Bryan F.; DeWeese, Theodore L.; Dillehay, Larry E.; Ferguson, Debra C.; Ghoreishi-Haack, Nayereh S.; Grimm, David R.; Guan, Ran; Han, Edward K.; Holley-Shanks, Rhonda R.; Hristov, Boris; Idler, Kenneth B.; Jarvis, Ken; Johnson, Eric F.; Kleinberg, Lawrence R.; Klinghofer, Vered; Lasko, Loren M.; Liu, Xuesong; Marsh, Kennan C.; McGonigal, Thomas P.; Meulbroek, Jonathan A.; Olson, Amanda M.; Palma, Joann P.; Rodriguez, Luis E.; Shi, Yan; Stavropoulos, Jason A.; Tsurutani, Alan C.; Zhu, Gui-Dong; Rosenberg, Saul H.; Giranda, Vincent L.; Frost, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2728-2737</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose is to evaluate the preclin. pharmacokinetics and antitumor efficacy of a novel orally bioavailable poly(ADP-ribose) polymerase (PARP) inhibitor, ABT-888.  In vitro potency was detd. in a PARP-1 and PARP-2 enzyme assay.  In vivo efficacy was evaluated in syngeneic and xenograft models in combination with temozolomide, platinums, cyclophosphamide, and ionizing radiation.  ABT-888 is a potent inhibitor of both PARP-1 and PARP-2 with Kis of 5.2 and 2.9 nmol/L, resp.  The compd. has good oral bioavailability and crosses the blood-brain barrier.  ABT-888 strongly potentiated temozolomide in the B16F10 s.c. murine melanoma model.  PARP inhibition dramatically increased the efficacy of temozolomide at ABT-888 doses as low as 3.1 mg/kg/d and a maximal efficacy achieved at 25 mg/kg/d.  In the 9L orthotopic rat glioma model, temozolomide alone exhibited minimal efficacy, whereas ABT-888, when combined with temozolomide, significantly slowed tumor progression.  In the MX-1 breast xenograft model (BRCA1 deletion and BRCA2 mutation), ABT-888 potentiated cisplatin, carboplatin, and cyclophosphamide, causing regression of established tumors, whereas with comparable doses of cytotoxic agents alone, only modest tumor inhibition was exhibited.  Finally, ABT-888 potentiated radiation (2 Gy/d Ã 10) in an HCT-116 colon carcinoma model.  In each model, ABT-888 did not display single-agent activity.  ABT-888 is a potent inhibitor of PARP, has good oral bioavailability, can cross the blood-brain barrier, and potentiates temozolomide, platinums, cyclophosphamide, and radiation in syngeneic and xenograft tumor models.  This broad spectrum of chemopotentiation and radiopotentiation makes this compd. an attractive candidate for clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2xiIRsPurHLVg90H21EOLACvtfcHk0lidxCj0KmLicA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkslOhurg%253D&md5=4769ee3eec82465993eb9e1443095894</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-3039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-3039%26sid%3Dliteratum%253Aachs%26aulast%3DDonawho%26aufirst%3DC.%2BK.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DPenning%26aufirst%3DT.%2BD.%26aulast%3DBauch%26aufirst%3DJ.%2BL.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DBontcheva-Diaz%26aufirst%3DV.%2BD.%26aulast%3DCox%26aufirst%3DB.%2BF.%26aulast%3DDeWeese%26aufirst%3DT.%2BL.%26aulast%3DDillehay%26aufirst%3DL.%2BE.%26aulast%3DFerguson%26aufirst%3DD.%2BC.%26aulast%3DGhoreishi-Haack%26aufirst%3DN.%2BS.%26aulast%3DGrimm%26aufirst%3DD.%2BR.%26aulast%3DGuan%26aufirst%3DR.%26aulast%3DHan%26aufirst%3DE.%2BK.%26aulast%3DHolley-Shanks%26aufirst%3DR.%2BR.%26aulast%3DHristov%26aufirst%3DB.%26aulast%3DIdler%26aufirst%3DK.%2BB.%26aulast%3DJarvis%26aufirst%3DK.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DKleinberg%26aufirst%3DL.%2BR.%26aulast%3DKlinghofer%26aufirst%3DV.%26aulast%3DLasko%26aufirst%3DL.%2BM.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DMcGonigal%26aufirst%3DT.%2BP.%26aulast%3DMeulbroek%26aufirst%3DJ.%2BA.%26aulast%3DOlson%26aufirst%3DA.%2BM.%26aulast%3DPalma%26aufirst%3DJ.%2BP.%26aulast%3DRodriguez%26aufirst%3DL.%2BE.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DStavropoulos%26aufirst%3DJ.%2BA.%26aulast%3DTsurutani%26aufirst%3DA.%2BC.%26aulast%3DZhu%26aufirst%3DG.%2BD.%26aulast%3DRosenberg%26aufirst%3DS.%2BH.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26aulast%3DFrost%26aufirst%3DD.%2BJ.%26atitle%3DABT-888%252C%2520an%2520orally%2520active%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitor%2520that%2520potentiates%2520DNA-damaging%2520agents%2520in%2520preclinical%2520tumor%2520models%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D2728%26epage%3D2737" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group">Penning, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinghofer, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donawho, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bontcheva-Diaz, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osterling, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giranda, V. L.</span><span> </span><span class="NLM_article-title">Discovery of the poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(<i>R</i>)-2-methylpyrrolidin-2-yl]-1<i>H</i>-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">514</span><span class="NLM_x">â</span> <span class="NLM_lpage">523</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm801171j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFals7bL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=514-523&author=T.+D.+Penningauthor=G.+D.+Zhuauthor=V.+B.+Gandhiauthor=J.+Gongauthor=X.+Liuauthor=Y.+Shiauthor=V.+Klinghoferauthor=E.+F.+Johnsonauthor=C.+K.+Donawhoauthor=D.+J.+Frostauthor=V.+Bontcheva-Diazauthor=J.+J.+Bouskaauthor=D.+J.+Osterlingauthor=A.+M.+Olsonauthor=K.+C.+Marshauthor=Y.+Luoauthor=V.+L.+Giranda&title=Discovery+of+the+poly%28ADP-ribose%29+polymerase+%28PARP%29+inhibitor+2-%5B%28R%29-2-methylpyrrolidin-2-yl%5D-1H-benzimidazole-4-carboxamide+%28ABT-888%29+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the Treatment of Cancer</span></div><div class="casAuthors">Penning, Thomas D.; Zhu, Gui-Dong; Gandhi, Viraj B.; Gong, Jianchun; Liu, Xuesong; Shi, Yan; Klinghofer, Vered; Johnson, Eric F.; Donawho, Cherrie K.; Frost, David J.; Bontcheva-Diaz, Velitchka; Bouska, Jennifer J.; Osterling, Donald J.; Olson, Amanda M.; Marsh, Kennan C.; Luo, Yan; Giranda, Vincent L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">514-523</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of cyclic amine-contg. benzimidazole carboxamide PARP inhibitors with a methyl-substituted quaternary center at the point of attachment to the benzimidazole ring system has been developed.  These compds. exhibit excellent PARP enzyme potency as well as single-digit nanomolar cellular potency.  These efforts led to the identification of (I)Â·2HCl (2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide, ABT-888), currently in human phase I clin. trials.  Compd. IÂ·2HCl displayed excellent potency against both the PARP-1 and PARP-2 enzymes with a Ki of 5 nM and in a C41 whole cell assay with an EC50 of 2 nM.  In addn., IÂ·2HCl is aq. sol., orally bioavailable across multiple species, and demonstrated good in vivo efficacy in a B16F10 s.c. murine melanoma model in combination with temozolomide (TMZ) and in an MX-1 breast cancer xenograft model in combination with either carboplatin or cyclophosphamide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaBVnNi7EZcbVg90H21EOLACvtfcHk0ljoYIcbfRh3zw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFals7bL&md5=283eddd2e8220740c48865e4e8269a95</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1021%2Fjm801171j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801171j%26sid%3Dliteratum%253Aachs%26aulast%3DPenning%26aufirst%3DT.%2BD.%26aulast%3DZhu%26aufirst%3DG.%2BD.%26aulast%3DGandhi%26aufirst%3DV.%2BB.%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DKlinghofer%26aufirst%3DV.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DDonawho%26aufirst%3DC.%2BK.%26aulast%3DFrost%26aufirst%3DD.%2BJ.%26aulast%3DBontcheva-Diaz%26aufirst%3DV.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DOsterling%26aufirst%3DD.%2BJ.%26aulast%3DOlson%26aufirst%3DA.%2BM.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26atitle%3DDiscovery%2520of%2520the%2520poly%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520inhibitor%25202-%255B%2528R%2529-2-methylpyrrolidin-2-yl%255D-1H-benzimidazole-4-carboxamide%2520%2528ABT-888%2529%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D514%26epage%3D523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group">Kummar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinders, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutierrez, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubinstein, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parchment, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monks, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Low, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murgo, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinberg, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eliopoulos, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giranda, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiltrout, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomaszewski, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doroshow, J. H.</span><span> </span><span class="NLM_article-title">Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">2705</span><span class="NLM_x">â</span> <span class="NLM_lpage">2711</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1200%2FJCO.2008.19.7681" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=19364967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnslWitLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=2705-2711&author=S.+Kummarauthor=R.+Kindersauthor=M.+E.+Gutierrezauthor=L.+Rubinsteinauthor=R.+E.+Parchmentauthor=L.+R.+Phillipsauthor=J.+Jiauthor=A.+Monksauthor=J.+A.+Lowauthor=A.+Chenauthor=A.+J.+Murgoauthor=J.+Collinsauthor=S.+M.+Steinbergauthor=H.+Eliopoulosauthor=V.+L.+Girandaauthor=G.+Gordonauthor=L.+Helmanauthor=R.+Wiltroutauthor=J.+E.+Tomaszewskiauthor=J.+H.+Doroshow&title=Phase+0+clinical+trial+of+the+poly+%28ADP-ribose%29+polymerase+inhibitor+ABT-888+in+patients+with+advanced+malignancies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies</span></div><div class="casAuthors">Kummar, Shivaani; Kinders, Robert; Gutierrez, Martin E.; Rubinstein, Larry; Parchment, Ralph E.; Phillips, Lawrence R.; Ji, Jiuping; Monks, Anne; Low, Jennifer A.; Chen, Alice; Murgo, Anthony J.; Collins, Jerry; Steinberg, Seth M.; Eliopoulos, Helen; Giranda, Vincent L.; Gordon, Gary; Helman, Lee; Wiltrout, Robert; Tomaszewski, Joseph E.; Doroshow, James H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2705-2711</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">We conducted the first phase 0 clin. trial in oncol. of a therapeutic agent under the Exploratory Investigational New Drug Guidance of the US Food and Drug Administration.  It was a first-in-human study of the poly (ADP-ribose) polymerase (PARP) inhibitor ABT-888 in patients with advanced malignancies.  ABT-888 was administered as a single oral dose of 10, 25, or 50 mg to det. the dose range and time course over which ABT-888 inhibits PARP activity in tumor samples and peripheral blood mononuclear cells, and to evaluate ABT-888 pharmacokinetics.  Blood samples and tumor biopsies were obtained pre- and postdrug administration for evaluation of PARP activity and pharmacokinetics.  A novel statistical approach was developed and utilized to study pharmacodynamic modulation as the primary end point for trials of limited sample size.  Thirteen patients with advanced malignancies received the study drug; nine patients underwent paired tumor biopsies.  ABT-888 demonstrated good oral bioavailability and was well tolerated.  Statistically significant inhibition of poly (ADP-ribose) levels was obsd. in tumor biopsies and peripheral blood mononuclear cells at the 25-mg and 50-mg dose levels.  Within 5 mo of study activation, we obtained pivotal biochem. and pharmacokinetic data that have guided the design of subsequent phase I trials of ABT-888 in combination with DNA-damaging agents.  In addn. to accelerating the development of ABT-888, the rapid conclusion of this trial demonstrates the feasibility of conducting proof-of-principle phase 0 trials as part of an alternative paradigm for early drug development in oncol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtTZJu529qYbVg90H21EOLACvtfcHk0ljoYIcbfRh3zw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnslWitLs%253D&md5=29b206795ad0d6195cb6ac3279ebda48</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1200%2FJCO.2008.19.7681&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2008.19.7681%26sid%3Dliteratum%253Aachs%26aulast%3DKummar%26aufirst%3DS.%26aulast%3DKinders%26aufirst%3DR.%26aulast%3DGutierrez%26aufirst%3DM.%2BE.%26aulast%3DRubinstein%26aufirst%3DL.%26aulast%3DParchment%26aufirst%3DR.%2BE.%26aulast%3DPhillips%26aufirst%3DL.%2BR.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DMonks%26aufirst%3DA.%26aulast%3DLow%26aufirst%3DJ.%2BA.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DMurgo%26aufirst%3DA.%2BJ.%26aulast%3DCollins%26aufirst%3DJ.%26aulast%3DSteinberg%26aufirst%3DS.%2BM.%26aulast%3DEliopoulos%26aufirst%3DH.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26aulast%3DGordon%26aufirst%3DG.%26aulast%3DHelman%26aufirst%3DL.%26aulast%3DWiltrout%26aufirst%3DR.%26aulast%3DTomaszewski%26aufirst%3DJ.%2BE.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26atitle%3DPhase%25200%2520clinical%2520trial%2520of%2520the%2520poly%2520%2528ADP-ribose%2529%2520polymerase%2520inhibitor%2520ABT-888%2520in%2520patients%2520with%2520advanced%2520malignancies%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D2705%26epage%3D2711" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group">Martin, N. M. B.; Smith, G. C. M.; White, C. R.; Newton, R. F.; Douglas, D. G.; Eversley, P. J.; Whittle, A. J.</span><span> </span><span class="NLM_article-title">Isoquinolinone Derivatives</span>. U.S. Patent 6664269,<span class="NLM_x"> </span><span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=N.+M.+B.+Martin&author=G.+C.+M.+Smith&author=C.+R.+White&author=R.+F.+Newton&author=D.+G.+Douglas&author=P.+J.+Eversley&author=A.+J.+Whittle&title=Isoquinolinone+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DN.%2BM.%2BB.%26atitle%3DIsoquinolinone%2520Derivatives%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group">Martin, N. M. B.; Smith, G. C. M.; Eversley, P. J.; Cockcroft, X.-l.; Kerrigan, F.; Hoare, J.; Dixon, L.</span><span> </span><span class="NLM_article-title">Phthalazinone Derivatives</span>. U.S. Patent 7196085,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=N.+M.+B.+Martin&author=G.+C.+M.+Smith&author=P.+J.+Eversley&author=X.-l.+Cockcroft&author=F.+Kerrigan&author=J.+Hoare&author=L.+Dixon&title=Phthalazinone+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DN.%2BM.%2BB.%26atitle%3DPhthalazinone%2520Derivatives%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group">Jacobs, R. T.; Folmer, J. J.; Simpson, T. R.; Chaudhari, B.; Frazee, W. J.; Davenport, T. W.; Sundarababu, G.</span><span> </span><span class="NLM_article-title">Therapeutic Heterocycles</span>. U.S. Patent 6399603,<span class="NLM_x"> </span><span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=R.+T.+Jacobs&author=J.+J.+Folmer&author=T.+R.+Simpson&author=B.+Chaudhari&author=W.+J.+Frazee&author=T.+W.+Davenport&author=G.+Sundarababu&title=Therapeutic+Heterocycles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJacobs%26aufirst%3DR.%2BT.%26atitle%3DTherapeutic%2520Heterocycles%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group">Loh, V. M.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockcroft, X. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dillon, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dixon, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drzewiecki, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eversley, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoare, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerrigan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, I. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menear, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paul, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vile, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittle, A. J.</span><span> </span><span class="NLM_article-title">Phthalazinones. Part 1: The design and synthesis of a novel series of potent inhibitors of poly(ADP-ribose)polymerase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">2235</span><span class="NLM_x">â</span> <span class="NLM_lpage">2238</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=2235-2238&author=V.+M.+Lohauthor=X.+L.+Cockcroftauthor=K.+J.+Dillonauthor=L.+Dixonauthor=J.+Drzewieckiauthor=P.+J.+Eversleyauthor=S.+Gomezauthor=J.+Hoareauthor=F.+Kerriganauthor=I.+T.+Matthewsauthor=K.+A.+Menearauthor=N.+M.+Martinauthor=R.+F.+Newtonauthor=J.+Paulauthor=G.+C.+Smithauthor=J.+Vileauthor=A.+J.+Whittle&title=Phthalazinones.+Part+1%3A+The+design+and+synthesis+of+a+novel+series+of+potent+inhibitors+of+poly%28ADP-ribose%29polymerase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLoh%26aufirst%3DV.%2BM.%26aulast%3DCockcroft%26aufirst%3DX.%2BL.%26aulast%3DDillon%26aufirst%3DK.%2BJ.%26aulast%3DDixon%26aufirst%3DL.%26aulast%3DDrzewiecki%26aufirst%3DJ.%26aulast%3DEversley%26aufirst%3DP.%2BJ.%26aulast%3DGomez%26aufirst%3DS.%26aulast%3DHoare%26aufirst%3DJ.%26aulast%3DKerrigan%26aufirst%3DF.%26aulast%3DMatthews%26aufirst%3DI.%2BT.%26aulast%3DMenear%26aufirst%3DK.%2BA.%26aulast%3DMartin%26aufirst%3DN.%2BM.%26aulast%3DNewton%26aufirst%3DR.%2BF.%26aulast%3DPaul%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DG.%2BC.%26aulast%3DVile%26aufirst%3DJ.%26aulast%3DWhittle%26aufirst%3DA.%2BJ.%26atitle%3DPhthalazinones.%2520Part%25201%253A%2520The%2520design%2520and%2520synthesis%2520of%2520a%2520novel%2520series%2520of%2520potent%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529polymerase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D2235%26epage%3D2238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group">Cockcroft, X. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dillon, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dixon, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drzewiecki, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerrigan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loh, V. M.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menear, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. C.</span><span> </span><span class="NLM_article-title">Phthalazinones 2: optimisation and synthesis of novel potent inhibitors of poly(ADP-ribose)polymerase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1040</span><span class="NLM_x">â</span> <span class="NLM_lpage">1044</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=1040-1044&author=X.+L.+Cockcroftauthor=K.+J.+Dillonauthor=L.+Dixonauthor=J.+Drzewieckiauthor=F.+Kerriganauthor=V.+M.+Lohauthor=N.+M.+Martinauthor=K.+A.+Menearauthor=G.+C.+Smith&title=Phthalazinones+2%3A+optimisation+and+synthesis+of+novel+potent+inhibitors+of+poly%28ADP-ribose%29polymerase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCockcroft%26aufirst%3DX.%2BL.%26aulast%3DDillon%26aufirst%3DK.%2BJ.%26aulast%3DDixon%26aufirst%3DL.%26aulast%3DDrzewiecki%26aufirst%3DJ.%26aulast%3DKerrigan%26aufirst%3DF.%26aulast%3DLoh%26aufirst%3DV.%2BM.%26aulast%3DMartin%26aufirst%3DN.%2BM.%26aulast%3DMenear%26aufirst%3DK.%2BA.%26aulast%3DSmith%26aufirst%3DG.%2BC.%26atitle%3DPhthalazinones%25202%253A%2520optimisation%2520and%2520synthesis%2520of%2520novel%2520potent%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529polymerase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D1040%26epage%3D1044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group">Menear, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adcock, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulter, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockcroft, X. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copsey, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cranston, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dillon, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drzewiecki, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javaid, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerrigan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knights, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loh, V. M.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, I. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâConnor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N. M.</span><span> </span><span class="NLM_article-title">4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2<i>H</i>-phth alazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">6581</span><span class="NLM_x">â</span> <span class="NLM_lpage">6591</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8001263" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=6581-6591&author=K.+A.+Menearauthor=C.+Adcockauthor=R.+Boulterauthor=X.+L.+Cockcroftauthor=L.+Copseyauthor=A.+Cranstonauthor=K.+J.+Dillonauthor=J.+Drzewieckiauthor=S.+Garmanauthor=S.+Gomezauthor=H.+Javaidauthor=F.+Kerriganauthor=C.+Knightsauthor=A.+Lauauthor=V.+M.+Lohauthor=I.+T.+Matthewsauthor=S.+Mooreauthor=M.+J.+O%E2%80%99Connorauthor=G.+C.+Smithauthor=N.+M.+Martin&title=4-%5B3-%284-Cyclopropanecarbonylpiperazine-1-carbonyl%29-4-fluorobenzyl%5D-2H-phth+alazin-1-one%3A+a+novel+bioavailable+inhibitor+of+poly%28ADP-ribose%29+polymerase-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1021%2Fjm8001263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8001263%26sid%3Dliteratum%253Aachs%26aulast%3DMenear%26aufirst%3DK.%2BA.%26aulast%3DAdcock%26aufirst%3DC.%26aulast%3DBoulter%26aufirst%3DR.%26aulast%3DCockcroft%26aufirst%3DX.%2BL.%26aulast%3DCopsey%26aufirst%3DL.%26aulast%3DCranston%26aufirst%3DA.%26aulast%3DDillon%26aufirst%3DK.%2BJ.%26aulast%3DDrzewiecki%26aufirst%3DJ.%26aulast%3DGarman%26aufirst%3DS.%26aulast%3DGomez%26aufirst%3DS.%26aulast%3DJavaid%26aufirst%3DH.%26aulast%3DKerrigan%26aufirst%3DF.%26aulast%3DKnights%26aufirst%3DC.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DLoh%26aufirst%3DV.%2BM.%26aulast%3DMatthews%26aufirst%3DI.%2BT.%26aulast%3DMoore%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DSmith%26aufirst%3DG.%2BC.%26aulast%3DMartin%26aufirst%3DN.%2BM.%26atitle%3D4-%255B3-%25284-Cyclopropanecarbonylpiperazine-1-carbonyl%2529-4-fluorobenzyl%255D-2H-phth%2520alazin-1-one%253A%2520a%2520novel%2520bioavailable%2520inhibitor%2520of%2520poly%2528ADP-ribose%2529%2520polymerase-1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D6581%26epage%3D6591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group">Veber, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kopple, K. D.</span><span> </span><span class="NLM_article-title">Molecular properties that influence the oral bioavailability of drug candidates</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">2615</span><span class="NLM_x">â</span> <span class="NLM_lpage">2623</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm020017n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD38XjsFCmt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=2615-2623&author=D.+F.+Veberauthor=S.+R.+Johnsonauthor=H.+Y.+Chengauthor=B.+R.+Smithauthor=K.+W.+Wardauthor=K.+D.+Kopple&title=Molecular+properties+that+influence+the+oral+bioavailability+of+drug+candidates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Properties That Influence the Oral Bioavailability of Drug Candidates</span></div><div class="casAuthors">Veber, Daniel F.; Johnson, Stephen R.; Cheng, Hung-Yuan; Smith, Brian R.; Ward, Keith W.; Kopple, Kenneth D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2615-2623</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oral bioavailability measurements in rats for over 1100 drug candidates studied at Smith-Kline Beecham Pharmaceuticals (now Glaxo Smith-Kline) have allowed us to analyze the relative importance of mol. properties considered to influence that drug property.  Reduced mol. flexibility, as measured by the no. of rotatable bonds, and low polar surface area or total hydrogen bond count (sum of donors and acceptors) are found to be important predictors of good oral bioavailability, independent of mol. wt.  That on av. both the no. of rotatable bonds and polar surface area or hydrogen bond count tend to increase with mol. wt. may in part explain the success of the mol. wt. parameter in predicting oral bioavailability.  The commonly applied mol. wt. cutoff at 500 does not itself significantly sep. compds. with poor oral bioavailability from those with acceptable values in this extensive data set.  Our observations suggest that compds. which meet only the 2 criteria of (1) 10 or fewer rotatable bonds and (2) polar surface area â¤140 Ã2 (or 12 or fewer H-bond donors and acceptors) will have a high probability of good oral bioavailability in the rat.  Data sets for the artificial membrane permeation rate and for clearance in the rat were also examd.  Reduced polar surface area correlates better with increased permeation rate than does lipophilicity (C log P), and increased rotatable bond count has a neg. effect on the permeation rate.  A threshold permeation rate is a prerequisite of oral bioavailability.  The rotatable bond count does not correlate with the data examd. here for the in vivo clearance rate in the rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3JtJEkO7yVLVg90H21EOLACvtfcHk0ljgmHeJGX2dGA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjsFCmt7g%253D&md5=eaad26ed6a259de82ad65a8834fc397d</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1021%2Fjm020017n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020017n%26sid%3Dliteratum%253Aachs%26aulast%3DVeber%26aufirst%3DD.%2BF.%26aulast%3DJohnson%26aufirst%3DS.%2BR.%26aulast%3DCheng%26aufirst%3DH.%2BY.%26aulast%3DSmith%26aufirst%3DB.%2BR.%26aulast%3DWard%26aufirst%3DK.%2BW.%26aulast%3DKopple%26aufirst%3DK.%2BD.%26atitle%3DMolecular%2520properties%2520that%2520influence%2520the%2520oral%2520bioavailability%2520of%2520drug%2520candidates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D2615%26epage%3D2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group">Fong, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boss, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yap, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tutt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mergui-Roelvink, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortimer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swaisland, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâConnor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmichael, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schellens, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bono, J. S.</span><span> </span><span class="NLM_article-title">Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">361</span><span class="NLM_x">, </span> <span class="NLM_fpage">123</span><span class="NLM_x">â</span> <span class="NLM_lpage">134</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1056%2FNEJMoa0900212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=19553641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVKrtrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2009&pages=123-134&author=P.+C.+Fongauthor=D.+S.+Bossauthor=T.+A.+Yapauthor=A.+Tuttauthor=P.+Wuauthor=M.+Mergui-Roelvinkauthor=P.+Mortimerauthor=H.+Swaislandauthor=A.+Lauauthor=M.+J.+O%E2%80%99Connorauthor=A.+Ashworthauthor=J.+Carmichaelauthor=S.+B.+Kayeauthor=J.+H.+Schellensauthor=J.+S.+de+Bono&title=Inhibition+of+poly%28ADP-ribose%29+polymerase+in+tumors+from+BRCA+mutation+carriers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers</span></div><div class="casAuthors">Fong, Peter C.; Boss, David S.; Yap, Timothy A.; Tutt, Andrew; Wu, Peijun; Mergui-Roelvink, Marja; Mortimer, Peter; Swaisland, Helen; Lau, Alan; O'Connor, Mark J.; Ashworth, Alan; Carmichael, James; Kaye, Stan B.; Schellens, Jan H. M.; de Bono, Johann S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-134</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The inhibition of poly(ADP-ribose) polymerase (PARP) is a potential synthetic lethal therapeutic strategy for the treatment of cancers with specific DNA-repair defects, including those arising in carriers of a BRCA1 or BRCA2 mutation.  We conducted a clin. evaluation in humans of olaparib (AZD2281), a novel, potent, orally active PARP inhibitor.  This was a phase 1 trial that included the anal. of pharmacokinetic and pharmacodynamic characteristics of olaparib.  Selection was aimed at having a study population enriched in carriers of a BRCA1 or BRCA2 mutation.  We enrolled and treated 60 patients; 22 were carriers of a BRCA1 or BRCA2 mutation and 1 had a strong family history of BRCA-assocd. cancer but declined to undergo mutational testing.  The olaparib dose and schedule were increased from 10 mg daily for 2 of every 3 wk to 600 mg twice daily continuously.  Reversible dose-limiting toxicity was seen in one of eight patients receiving 400 mg twice daily (grade 3 mood alteration and fatigue) and two of five patients receiving 600 mg twice daily (grade 4 thrombocytopenia and grade 3 somnolence).  This led us to enroll another cohort, consisting only of carriers of a BRCA1 or BRCA2 mutation, to receive olaparib at a dose of 200 mg twice daily.  Other adverse effects included mild gastrointestinal symptoms.  There was no obvious increase in adverse effects seen in the mutation carriers.  Pharmacokinetic data indicated rapid absorption and elimination; pharmacodynamic studies confirmed PARP inhibition in surrogate samples (of peripheral-blood mononuclear cells and plucked eyebrow-hair follicles) and tumor tissue.  Objective antitumor activity was reported only in mutation carriers, all of whom had ovarian, breast, or prostate cancer and had received multiple treatment regimens.  Olaparib has few of the adverse effects of conventional chemotherapy, inhibits PARP, and has antitumor activity in cancer assocd. with the BRCA1 or BRCA2 mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCT49Hz0HbW7Vg90H21EOLACvtfcHk0ljgmHeJGX2dGA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVKrtrw%253D&md5=aec7dcffe3d3cf614362a4f38bbb369a</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0900212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0900212%26sid%3Dliteratum%253Aachs%26aulast%3DFong%26aufirst%3DP.%2BC.%26aulast%3DBoss%26aufirst%3DD.%2BS.%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DTutt%26aufirst%3DA.%26aulast%3DWu%26aufirst%3DP.%26aulast%3DMergui-Roelvink%26aufirst%3DM.%26aulast%3DMortimer%26aufirst%3DP.%26aulast%3DSwaisland%26aufirst%3DH.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DAshworth%26aufirst%3DA.%26aulast%3DCarmichael%26aufirst%3DJ.%26aulast%3DKaye%26aufirst%3DS.%2BB.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26atitle%3DInhibition%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%2520in%2520tumors%2520from%2520BRCA%2520mutation%2520carriers%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D361%26spage%3D123%26epage%3D134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group">Tutt, A.; Robson, M.; Garber, J. E.; Domchek, S.; Audeh, M. W.; Weitzel, J. N.; Friedlander, M.; Carmichael, J.</span><span> </span><span class="NLM_article-title">Phase II Trial of the Oral PARP Inhibitor Olaparib in BRCA-Deficient Advanced Breast Cancer</span>.  <span class="citation_source-book">ASCO Meeting Abstracts</span>, 2009 ASCO Annual Meeting; <span class="NLM_publisher-name">American Society of Clinical Oncology</span>: <span class="NLM_publisher-loc">Alexandria, VA</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">27</span>, CRA501.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=A.+Tutt&author=M.+Robson&author=J.+E.+Garber&author=S.+Domchek&author=M.+W.+Audeh&author=J.+N.+Weitzel&author=M.+Friedlander&author=J.+Carmichael&title=ASCO+Meeting+Abstracts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DTutt%26aufirst%3DA.%26atitle%3DPhase%2520II%2520Trial%2520of%2520the%2520Oral%2520PARP%2520Inhibitor%2520Olaparib%2520in%2520BRCA-Deficient%2520Advanced%2520Breast%2520Cancer%26btitle%3DASCO%2520Meeting%2520Abstracts%26pub%3DAmerican%2520Society%2520of%2520Clinical%2520Oncology%26date%3D2009%26volume%3D27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group">Audeh, M. W.; Penson, R. T.; Friedlander, M.; Powell, B.; Bell-McGuinn, K. M.; Scott, C.; Weitzel, J. N.; Carmichael, J.; Tutt, A.</span><span> </span><span class="NLM_article-title">Phase II Trial of the Oral PARP Inhibitor Olaparib (AZD2281) in BRCA-Deficient Advanced Ovarian Cancer</span>.  <span class="citation_source-book">ASCO Meeting Abstracts</span>, 2009 ASCO Annual Meeting; <span class="NLM_publisher-name">American Society of Clinical Oncology</span>: <span class="NLM_publisher-loc">Alexandria, VA</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">27</span>, p  <span class="NLM_fpage">5500</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&pages=5500&author=M.+W.+Audeh&author=R.+T.+Penson&author=M.+Friedlander&author=B.+Powell&author=K.+M.+Bell-McGuinn&author=C.+Scott&author=J.+N.+Weitzel&author=J.+Carmichael&author=A.+Tutt&title=ASCO+Meeting+Abstracts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DAudeh%26aufirst%3DM.%2BW.%26atitle%3DPhase%2520II%2520Trial%2520of%2520the%2520Oral%2520PARP%2520Inhibitor%2520Olaparib%2520%2528AZD2281%2529%2520in%2520BRCA-Deficient%2520Advanced%2520Ovarian%2520Cancer%26btitle%3DASCO%2520Meeting%2520Abstracts%26pub%3DAmerican%2520Society%2520of%2520Clinical%2520Oncology%26date%3D2009%26volume%3D27%26spage%3D5500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group">Wells, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bihovsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husten, J.</span><span> </span><span class="NLM_article-title">Synthesis and structureâactivity relationships of novel pyrrolocarbazole lactam analogs as potent and cell-permeable inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1)</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1151</span><span class="NLM_x">â</span> <span class="NLM_lpage">1155</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=1151-1155&author=G.+J.+Wellsauthor=R.+Bihovskyauthor=R.+L.+Hudkinsauthor=M.+A.+Atorauthor=J.+Husten&title=Synthesis+and+structure%E2%88%92activity+relationships+of+novel+pyrrolocarbazole+lactam+analogs+as+potent+and+cell-permeable+inhibitors+of+poly%28ADP-ribose%29polymerase-1+%28PARP-1%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWells%26aufirst%3DG.%2BJ.%26aulast%3DBihovsky%26aufirst%3DR.%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DHusten%26aufirst%3DJ.%26atitle%3DSynthesis%2520and%2520structure%25E2%2588%2592activity%2520relationships%2520of%2520novel%2520pyrrolocarbazole%2520lactam%2520analogs%2520as%2520potent%2520and%2520cell-permeable%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529polymerase-1%2520%2528PARP-1%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D1151%26epage%3D1155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group">Shah, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirier, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duchaine, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brochu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desnoyers, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lagueux, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verreault, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoflack, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkland, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirier, G. G.</span><span> </span><span class="NLM_article-title">Methods for biochemical study of poly(ADP-ribose) metabolism in vitro and in vivo</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">227</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">â</span> <span class="NLM_lpage">13</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=227&publication_year=1995&pages=1-13&author=G.+M.+Shahauthor=D.+Poirierauthor=C.+Duchaineauthor=G.+Brochuauthor=S.+Desnoyersauthor=J.+Lagueuxauthor=A.+Verreaultauthor=J.+C.+Hoflackauthor=J.+B.+Kirklandauthor=G.+G.+Poirier&title=Methods+for+biochemical+study+of+poly%28ADP-ribose%29+metabolism+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DG.%2BM.%26aulast%3DPoirier%26aufirst%3DD.%26aulast%3DDuchaine%26aufirst%3DC.%26aulast%3DBrochu%26aufirst%3DG.%26aulast%3DDesnoyers%26aufirst%3DS.%26aulast%3DLagueux%26aufirst%3DJ.%26aulast%3DVerreault%26aufirst%3DA.%26aulast%3DHoflack%26aufirst%3DJ.%2BC.%26aulast%3DKirkland%26aufirst%3DJ.%2BB.%26aulast%3DPoirier%26aufirst%3DG.%2BG.%26atitle%3DMethods%2520for%2520biochemical%2520study%2520of%2520poly%2528ADP-ribose%2529%2520metabolism%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DAnal.%2520Biochem.%26date%3D1995%26volume%3D227%26spage%3D1%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group">Miknyoczki, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones-Bolin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bihovsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chatterjee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein-Szanto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dionne, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B.</span><span> </span><span class="NLM_article-title">Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">371</span><span class="NLM_x">â</span> <span class="NLM_lpage">382</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.4161%2Fcbt.2.4.460" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=12700281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjvVyktbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=371-382&author=S.+J.+Miknyoczkiauthor=S.+Jones-Bolinauthor=S.+Pritchardauthor=K.+Hunterauthor=H.+Zhaoauthor=W.+Wanauthor=M.+Atorauthor=R.+Bihovskyauthor=R.+Hudkinsauthor=S.+Chatterjeeauthor=A.+Klein-Szantoauthor=C.+Dionneauthor=B.+Ruggeri&title=Chemopotentiation+of+temozolomide%2C+irinotecan%2C+and+cisplatin+activity+by+CEP-6800%2C+a+poly%28ADP-ribose%29+polymerase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor</span></div><div class="casAuthors">Miknyoczki, Sheila J.; Jones-Bolin, Susan; Pritchard, Sonya; Hunter, Kathryn; Zhao, Hugh; Wan, Weihua; Ator, Mark; Bihovsky, Ronald; Hudkins, Robert; Chatterjee, Sankar; Klein-Szanto, Andres; Dionne, Craig; Ruggeri, Bruce</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">371-382</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase 1 (PARP-1) is a nuclear zinc finger DNA-binding protein that is implicated in the repair of DNA damage.  Inhibition of PARP-1 through genetic knockouts causes cells to become hypersensitive to various chemotherapeutic agents.  We tested the chemopotentiating ability of the PARP-1 inhibitor, CEP-6800, when used in combination with temozolomide (TMZ), irinotecan (camptothecin or SN38), and cisplatin against U251MG glioblastoma, HT29 colon carcinoma, and Calu-6 non-small cell lung carcinoma xenografts and cell lines, resp.  Exposure of tumor cells to TMZ, camptothecin (or SN38), and cisplatin before, or in the presence of, CEP-6800 significantly increased the onset and the magnitude of DNA damage, the duration for cells to effect repair, and the onset, duration, or fraction of cells arrested at the G2/M boundary.  In addn., in vivo biochem. efficacy studies with CEP-6800 showed that it was able to attenuate irinotecan- and TMZ-induced poly(ADP-ribose) accumulation in LoVo and HT29 xenografts, resp.  Treatment of CEP 6800 (30 mg/kg) with TMZ (17 and 34 mg/kg) resulted in 100% complete regression of U251MG tumors by day 28 vs. 60% complete regression caused by TMZ alone.  CEP-6800 (30 mg/kg) in combination with irinotecan (10 mg/kg) resulted in a 60% inhibition of HT29 tumor growth vs. irinotecan alone by day 33.  The combination therapy of cisplatin (5 mg/kg) with CEP-6800 (30 mg/kg) caused a 35% redn. in Calu-6 tumor growth vs. cisplatin alone by day 28.  These data suggest that CEP-6800 could be used as a chemopotentiating agent with a variety of clin. effective chemotherapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaiwSIo74c1LVg90H21EOLACvtfcHk0lg5rhS6Q7DMmg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjvVyktbY%253D&md5=2c4b1eb96a1b16c44ad15760f5c1f73c</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.4161%2Fcbt.2.4.460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.2.4.460%26sid%3Dliteratum%253Aachs%26aulast%3DMiknyoczki%26aufirst%3DS.%2BJ.%26aulast%3DJones-Bolin%26aufirst%3DS.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DHunter%26aufirst%3DK.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DAtor%26aufirst%3DM.%26aulast%3DBihovsky%26aufirst%3DR.%26aulast%3DHudkins%26aufirst%3DR.%26aulast%3DChatterjee%26aufirst%3DS.%26aulast%3DKlein-Szanto%26aufirst%3DA.%26aulast%3DDionne%26aufirst%3DC.%26aulast%3DRuggeri%26aufirst%3DB.%26atitle%3DChemopotentiation%2520of%2520temozolomide%252C%2520irinotecan%252C%2520and%2520cisplatin%2520activity%2520by%2520CEP-6800%252C%2520a%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2003%26volume%3D2%26spage%3D371%26epage%3D382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group">Miknyoczki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grobelny, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worrell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husten, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deibold, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zulli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parchment, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B.</span><span> </span><span class="NLM_article-title">The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">2290</span><span class="NLM_x">â</span> <span class="NLM_lpage">2302</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1158%2F1535-7163.MCT-07-0062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=17699724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD2sXptVGltbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=2290-2302&author=S.+Miknyoczkiauthor=H.+Changauthor=J.+Grobelnyauthor=S.+Pritchardauthor=C.+Worrellauthor=N.+McGannauthor=M.+Atorauthor=J.+Hustenauthor=J.+Deiboldauthor=R.+Hudkinsauthor=A.+Zulliauthor=R.+Parchmentauthor=B.+Ruggeri&title=The+selective+poly%28ADP-ribose%29+polymerase-1%282%29+inhibitor%2C+CEP-8983%2C+increases+the+sensitivity+of+chemoresistant+tumor+cells+to+temozolomide+and+irinotecan+but+does+not+potentiate+myelotoxicity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity</span></div><div class="casAuthors">Miknyoczki, Sheila; Chang, Hong; Grobelny, Jennifer; Pritchard, Sonya; Worrell, Candace; McGann, Natalie; Ator, Mark; Husten, Jean; Deibold, James; Hudkins, Robert; Zulli, Allison; Parchment, Ralph; Ruggeri, Bruce</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2290-2302</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The effect of the potent and selective poly(ADP-ribose) (PAR) polymerase-1 [and PAR polymerase-2] inhibitor CEP-8983 on the ability to sensitize chemoresistant glioblastoma (RG2), rhabdomyosarcoma (RH18), neuroblastoma (NB1691), and colon carcinoma (HT29) tumor cells to temozolomide- and camptothecin-induced cytotoxicity, DNA damage, and G2-M arrest and on the potentiation of chemotherapy-induced myelotoxicity was evaluated using in vitro assays.  In addn., the effect of the prodrug CEP-9722 in combination with temozolomide and/or irinotecan on PAR accumulation and tumor growth was also detd. using glioblastoma and/or colon carcinoma xenografts relative to chemotherapy alone.  CEP-8983 sensitized carcinoma cells to the growth-inhibitory effects of temozolomide and/or SN38 increased the fraction of and/or lengthened duration of time tumor cells accumulated in chemotherapy-induced G2-M arrest and sensitized tumor cells to chemotherapy-induced DNA damage and apoptosis.  A granulocyte-macrophage colony-forming unit colony formation assay showed that coincubation of CEP-8983 with temozolomide or topotecan did not potentiate chemotherapy-assocd. myelotoxicity.  CEP-9722 (136 mg/kg) administered with temozolomide (68 mg/kg for 5 days) or irinotecan (10 mg/kg for 5 days) inhibited significantly the growth of RG2 tumors (60%) or HT29 tumors (80%) compared with temozolomide or irinotecan monotherapy, resp.  In addn., CEP-9722 showed "stand alone" antitumor efficacy in these preclin. xenografts.  In vivo biochem. efficacy studies showed that CEP-9722 attenuated PAR accumulation in glioma xenografts in a dose- and time-related manner.  These data indicate that CEP-8983 and its prodrug are effective chemosensitizing agents when administered in combination with select chemotherapeutic agents against chemoresistant tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr870nJ_ojOQbVg90H21EOLACvtfcHk0lgGleayr9DwLg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXptVGltbc%253D&md5=eef1600ec2ce56e71ca6045dca135bf4</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0062%26sid%3Dliteratum%253Aachs%26aulast%3DMiknyoczki%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DH.%26aulast%3DGrobelny%26aufirst%3DJ.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWorrell%26aufirst%3DC.%26aulast%3DMcGann%26aufirst%3DN.%26aulast%3DAtor%26aufirst%3DM.%26aulast%3DHusten%26aufirst%3DJ.%26aulast%3DDeibold%26aufirst%3DJ.%26aulast%3DHudkins%26aufirst%3DR.%26aulast%3DZulli%26aufirst%3DA.%26aulast%3DParchment%26aufirst%3DR.%26aulast%3DRuggeri%26aufirst%3DB.%26atitle%3DThe%2520selective%2520poly%2528ADP-ribose%2529%2520polymerase-1%25282%2529%2520inhibitor%252C%2520CEP-8983%252C%2520increases%2520the%2520sensitivity%2520of%2520chemoresistant%2520tumor%2520cells%2520to%2520temozolomide%2520and%2520irinotecan%2520but%2520does%2520not%2520potentiate%2520myelotoxicity%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D2290%26epage%3D2302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group">Chatterjee, S.; Diebold, J. L.; Dunn, D.; Hudkins, R. L.; Dandu, R.; Wells, G. J.; Zulli, A. L.</span><span> </span><span class="NLM_article-title">Cycloalkanopyrrolocarbazole Derivatives and the Use Thereof as PARP, VEGFR2 and MLK3 Inhibitors</span>. WO 2007149451,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=S.+Chatterjee&author=J.+L.+Diebold&author=D.+Dunn&author=R.+L.+Hudkins&author=R.+Dandu&author=G.+J.+Wells&author=A.+L.+Zulli&title=Cycloalkanopyrrolocarbazole+Derivatives+and+the+Use+Thereof+as+PARP%2C+VEGFR2+and+MLK3+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChatterjee%26aufirst%3DS.%26atitle%3DCycloalkanopyrrolocarbazole%2520Derivatives%2520and%2520the%2520Use%2520Thereof%2520as%2520PARP%252C%2520VEGFR2%2520and%2520MLK3%2520Inhibitors%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group">Martinez-Romero, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez-Lara, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aguilar-Quesada, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peralta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliver, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siles, E.</span><span> </span><span class="NLM_article-title">PARP-1 modulates deferoxamine-induced HIF-1alpha accumulation through the regulation of nitric oxide and oxidative stress</span> <span class="citation_source-journal">J. Cell. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">2248</span><span class="NLM_x">â</span> <span class="NLM_lpage">2260</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2008&pages=2248-2260&author=R.+Martinez-Romeroauthor=E.+Martinez-Laraauthor=R.+Aguilar-Quesadaauthor=A.+Peraltaauthor=F.+J.+Oliverauthor=E.+Siles&title=PARP-1+modulates+deferoxamine-induced+HIF-1alpha+accumulation+through+the+regulation+of+nitric+oxide+and+oxidative+stress"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez-Romero%26aufirst%3DR.%26aulast%3DMartinez-Lara%26aufirst%3DE.%26aulast%3DAguilar-Quesada%26aufirst%3DR.%26aulast%3DPeralta%26aufirst%3DA.%26aulast%3DOliver%26aufirst%3DF.%2BJ.%26aulast%3DSiles%26aufirst%3DE.%26atitle%3DPARP-1%2520modulates%2520deferoxamine-induced%2520HIF-1alpha%2520accumulation%2520through%2520the%2520regulation%2520of%2520nitric%2520oxide%2520and%2520oxidative%2520stress%26jtitle%3DJ.%2520Cell.%2520Biochem.%26date%3D2008%26volume%3D104%26spage%3D2248%26epage%3D2260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group">Ishida, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwashita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mihara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuoka, N.</span><span> </span><span class="NLM_article-title">4-Phenyl-1,2,3,6-tetrahydropyridine, an excellent fragment to improve the potency of PARP-1 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">4221</span><span class="NLM_x">â</span> <span class="NLM_lpage">4225</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=4221-4225&author=J.+Ishidaauthor=K.+Hattoriauthor=H.+Yamamotoauthor=A.+Iwashitaauthor=K.+Miharaauthor=N.+Matsuoka&title=4-Phenyl-1%2C2%2C3%2C6-tetrahydropyridine%2C+an+excellent+fragment+to+improve+the+potency+of+PARP-1+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIshida%26aufirst%3DJ.%26aulast%3DHattori%26aufirst%3DK.%26aulast%3DYamamoto%26aufirst%3DH.%26aulast%3DIwashita%26aufirst%3DA.%26aulast%3DMihara%26aufirst%3DK.%26aulast%3DMatsuoka%26aufirst%3DN.%26atitle%3D4-Phenyl-1%252C2%252C3%252C6-tetrahydropyridine%252C%2520an%2520excellent%2520fragment%2520to%2520improve%2520the%2520potency%2520of%2520PARP-1%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D4221%26epage%3D4225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group">Hattori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kido, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishida, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwashita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mihara, K.</span><span> </span><span class="NLM_article-title">Rational design of conformationally restricted quinazolinone inhibitors of poly(ADP-ribose)polymerase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">5577</span><span class="NLM_x">â</span> <span class="NLM_lpage">5581</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1016%2Fj.bmcl.2007.07.091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=17804225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVGisLfK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=5577-5581&author=K.+Hattoriauthor=Y.+Kidoauthor=H.+Yamamotoauthor=J.+Ishidaauthor=A.+Iwashitaauthor=K.+Mihara&title=Rational+design+of+conformationally+restricted+quinazolinone+inhibitors+of+poly%28ADP-ribose%29polymerase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design of conformationally restricted quinazolinone inhibitors of poly(ADP-ribose)polymerase</span></div><div class="casAuthors">Hattori, Kouji; Kido, Yoshiyuki; Yamamoto, Hirofumi; Ishida, Junya; Iwashita, Akinori; Mihara, Kayoko</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5577-5581</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A successful design of conformationally restricted novel quinazolinone derivs. linked via a cyclopentene moiety as potent poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors has been developed.  One selected member of the new series, 8-chloro-2-[(3S)-3-(4-phenylpiperidin-1-yl)cyclopent-1-en-1-yl]quinazolin-4(3H)-one (S-16d, I), was found to be highly potent with IC50 = 8.7 nM and good brain penetration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosvYPS7NANArVg90H21EOLACvtfcHk0lgGleayr9DwLg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVGisLfK&md5=3ff78c0d7dbce0960a07274207348330</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.07.091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.07.091%26sid%3Dliteratum%253Aachs%26aulast%3DHattori%26aufirst%3DK.%26aulast%3DKido%26aufirst%3DY.%26aulast%3DYamamoto%26aufirst%3DH.%26aulast%3DIshida%26aufirst%3DJ.%26aulast%3DIwashita%26aufirst%3DA.%26aulast%3DMihara%26aufirst%3DK.%26atitle%3DRational%2520design%2520of%2520conformationally%2520restricted%2520quinazolinone%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529polymerase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D5577%26epage%3D5581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group">Iwashita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishida, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kido, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamijo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyake, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinoshita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warizaya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohkubo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuoka, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mutoh, S.</span><span> </span><span class="NLM_article-title">Discovery of quinazolinone and quinoxaline derivatives as potent and selective poly(ADP-ribose) polymerase-1/2 inhibitors</span> <span class="citation_source-journal">FEBS Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">579</span><span class="NLM_x">, </span> <span class="NLM_fpage">1389</span><span class="NLM_x">â</span> <span class="NLM_lpage">1393</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1016%2Fj.febslet.2005.01.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=15733846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhslCju7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=579&publication_year=2005&pages=1389-1393&author=A.+Iwashitaauthor=K.+Hattoriauthor=H.+Yamamotoauthor=J.+Ishidaauthor=Y.+Kidoauthor=K.+Kamijoauthor=K.+Muranoauthor=H.+Miyakeauthor=T.+Kinoshitaauthor=M.+Warizayaauthor=M.+Ohkuboauthor=N.+Matsuokaauthor=S.+Mutoh&title=Discovery+of+quinazolinone+and+quinoxaline+derivatives+as+potent+and+selective+poly%28ADP-ribose%29+polymerase-1%2F2+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of quinazolinone and quinoxaline derivatives as potent and selective poly(ADP-ribose) polymerase-1/2 inhibitors</span></div><div class="casAuthors">Iwashita, Akinori; Hattori, Kouji; Yamamoto, Hirofumi; Ishida, Junya; Kido, Yoshiyuki; Kamijo, Kazunori; Murano, Kenji; Miyake, Hiroshi; Kinoshita, Takayoshi; Warizaya, Masaichi; Ohkubo, Mitsuru; Matsuoka, Nobuya; Mutoh, Seitaro</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">579</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1389-1393</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Two classes of quinazolinone derivs. and quinoxaline derivs. were identified as potent and selective poly(ADP-ribose) polymerase-1 and 2 (PARP-1) and (PARP-2) inhibitors, resp.  In PARP enzyme assays using recombinant PARP-1 and PARP-2, quinazolinone derivs. displayed relatively high selectivity for PARP-1 and quinoxaline derivs. showed superior selectivity for PARP-2.  SBDD anal. via a combination of x-ray structural study and homol. modeling suggested distinct interactions of inhibitors with PARP-1 and PARP-2.  These findings provide a new structural framework for the design of selective inhibitors for PARP-1 and PARP-2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7D1Y5QxX8xbVg90H21EOLACvtfcHk0lgxjYmfkz1OIw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhslCju7o%253D&md5=13b0b7ea2e960c6e2734176c71754afc</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1016%2Fj.febslet.2005.01.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.febslet.2005.01.036%26sid%3Dliteratum%253Aachs%26aulast%3DIwashita%26aufirst%3DA.%26aulast%3DHattori%26aufirst%3DK.%26aulast%3DYamamoto%26aufirst%3DH.%26aulast%3DIshida%26aufirst%3DJ.%26aulast%3DKido%26aufirst%3DY.%26aulast%3DKamijo%26aufirst%3DK.%26aulast%3DMurano%26aufirst%3DK.%26aulast%3DMiyake%26aufirst%3DH.%26aulast%3DKinoshita%26aufirst%3DT.%26aulast%3DWarizaya%26aufirst%3DM.%26aulast%3DOhkubo%26aufirst%3DM.%26aulast%3DMatsuoka%26aufirst%3DN.%26aulast%3DMutoh%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520quinazolinone%2520and%2520quinoxaline%2520derivatives%2520as%2520potent%2520and%2520selective%2520poly%2528ADP-ribose%2529%2520polymerase-1%252F2%2520inhibitors%26jtitle%3DFEBS%2520Lett.%26date%3D2005%26volume%3D579%26spage%3D1389%26epage%3D1393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group">Ikeda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hokamura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishiyama, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anraku, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Umemura, K.</span><span> </span><span class="NLM_article-title">Neuroprotective effects of KCL-440, a new poly(ADP-ribose) polymerase inhibitor, in the rat middle cerebral artery occlusion model</span> <span class="citation_source-journal">Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">1060</span><span class="NLM_x">, </span> <span class="NLM_fpage">73</span><span class="NLM_x">â</span> <span class="NLM_lpage">80</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1016%2Fj.brainres.2005.08.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=16202986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFeku73E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1060&publication_year=2005&pages=73-80&author=Y.+Ikedaauthor=K.+Hokamuraauthor=T.+Kawaiauthor=J.+Ishiyamaauthor=K.+Ishikawaauthor=T.+Anrakuauthor=T.+Unoauthor=K.+Umemura&title=Neuroprotective+effects+of+KCL-440%2C+a+new+poly%28ADP-ribose%29+polymerase+inhibitor%2C+in+the+rat+middle+cerebral+artery+occlusion+model"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroprotective effects of KCL-440, a new poly(ADP-ribose) polymerase inhibitor, in the rat middle cerebral artery occlusion model</span></div><div class="casAuthors">Ikeda, Yasuhiko; Hokamura, Kazuya; Kawai, Tomoyuki; Ishiyama, Junichi; Ishikawa, Kumi; Anraku, Tsuyoshi; Uno, Takashi; Umemura, Kazuo</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1060</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">73-80</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">It is reported that ischemic brain injury is mediated by the activation of poly(ADP-ribose) polymerase (PARP).  In this study, we examd. the pharmacol. profile of KCL-440, a new PARP inhibitor, and its neuroprotective effects in the rat acute cerebral infarction model induced by photothrombotic middle cerebral artery (MCA) occlusion.  In an in vitro study, KCL-440 exhibited potency with regard to inhibition of PARP activity, with an IC50 value of 68 nM.  An in vivo pharmacokinetic study showed that the brain concn. of KCL-440 was sufficient to inhibit PARP activity during the i.v. infusion of KCL-440 at the rate of 1 mg/kg/h.  KCL-440 at various doses or saline was administered for 24 h immediately after the MCA occlusion.  Administration of KCL-440 led to a dose-dependent redn. in the infarct size at 24 h after MCA occlusion.  Infarct sizes were 44.8% Â± 3.0% (n = 8), 40.5% Â± 1.1% (n = 8), 38.2% Â± 1.4% (n = 8), 35.1% Â± 2.1% (n = 8), 34.2% Â± 2.3% (n = 7), 32.6% Â± 1.9% (n = 8), and 31.0% Â± 2.1% (n = 5) at doses of 0, 0.01, 0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg/h.  When compared to the control group, a statistically significant difference was obsd. in the doses that were higher than 0.03 mg/kg/h.  When the infusion of KCL-440 (1 mg/kg/h, n = 8) was started at 1 h after the MCA occlusion, a significant redn. in infarct size was obsd.; this was not obsd. when KCL-440 infusion was started 2 or 3 h after the MCA occlusion.  Furthermore, increased poly(ADP-ribose) immunostaining was confirmed at the ischemic border zone 2 h after the MCA occlusion, and it was reduced by KCL-440 treatment.  These results suggest that KCL-440 is a possible neuroprotective agent with high blood-brain barrier permeability and high PARP inhibitory activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0K8evVssB7rVg90H21EOLACvtfcHk0lgxjYmfkz1OIw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFeku73E&md5=959f94631a188a1112606d17b68d1220</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1016%2Fj.brainres.2005.08.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainres.2005.08.046%26sid%3Dliteratum%253Aachs%26aulast%3DIkeda%26aufirst%3DY.%26aulast%3DHokamura%26aufirst%3DK.%26aulast%3DKawai%26aufirst%3DT.%26aulast%3DIshiyama%26aufirst%3DJ.%26aulast%3DIshikawa%26aufirst%3DK.%26aulast%3DAnraku%26aufirst%3DT.%26aulast%3DUno%26aufirst%3DT.%26aulast%3DUmemura%26aufirst%3DK.%26atitle%3DNeuroprotective%2520effects%2520of%2520KCL-440%252C%2520a%2520new%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitor%252C%2520in%2520the%2520rat%2520middle%2520cerebral%2520artery%2520occlusion%2520model%26jtitle%3DBrain%2520Res.%26date%3D2005%26volume%3D1060%26spage%3D73%26epage%3D80" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group">Anraku, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishiyama, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uno, T.</span><span> </span><span class="NLM_article-title">The broad therapeutic time window of KCL-440 bases on delayed activation of poly(ADP-ribose)polymerase after transient ischemic insults in rats</span> <span class="citation_source-journal">Stroke</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">P393</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2005&pages=P393&author=T.+Anrakuauthor=T.+Kawaiauthor=K.+Ishikawaauthor=J.+Ishiyamaauthor=T.+Uno&title=The+broad+therapeutic+time+window+of+KCL-440+bases+on+delayed+activation+of+poly%28ADP-ribose%29polymerase+after+transient+ischemic+insults+in+rats"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAnraku%26aufirst%3DT.%26aulast%3DKawai%26aufirst%3DT.%26aulast%3DIshikawa%26aufirst%3DK.%26aulast%3DIshiyama%26aufirst%3DJ.%26aulast%3DUno%26aufirst%3DT.%26atitle%3DThe%2520broad%2520therapeutic%2520time%2520window%2520of%2520KCL-440%2520bases%2520on%2520delayed%2520activation%2520of%2520poly%2528ADP-ribose%2529polymerase%2520after%2520transient%2520ischemic%2520insults%2520in%2520rats%26jtitle%3DStroke%26date%3D2005%26volume%3D36%26spage%3DP393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group">Fujio, M.; Satoh, H.; Numata, A.; Takanashi, S.; Egi, Y.; Tatsumi, R.</span><span> </span><span class="NLM_article-title">Fused Heterocyclic Compound and Medicinal Use Thereof</span>. WO 2002094790,<span class="NLM_x"> </span><span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=M.+Fujio&author=H.+Satoh&author=A.+Numata&author=S.+Takanashi&author=Y.+Egi&author=R.+Tatsumi&title=Fused+Heterocyclic+Compound+and+Medicinal+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFujio%26aufirst%3DM.%26atitle%3DFused%2520Heterocyclic%2520Compound%2520and%2520Medicinal%2520Use%2520Thereof%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group">Matsuura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasuhiro, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiroyuki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toshiaki, A.</span><span> </span><span class="NLM_article-title">Abstracts from the 2009 International Stroke Conference</span> <span class="citation_source-journal">Stroke</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">e105</span><span class="NLM_x">â</span> <span class="NLM_lpage">e276</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2009&pages=e105-e276&author=S.+Matsuuraauthor=S.+Yukiauthor=M.+Fujioauthor=E.+Yasuhiroauthor=S.+Hiroyukiauthor=A.+Toshiaki&title=Abstracts+from+the+2009+International+Stroke+Conference"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMatsuura%26aufirst%3DS.%26aulast%3DYuki%26aufirst%3DS.%26aulast%3DFujio%26aufirst%3DM.%26aulast%3DYasuhiro%26aufirst%3DE.%26aulast%3DHiroyuki%26aufirst%3DS.%26aulast%3DToshiaki%26aufirst%3DA.%26atitle%3DAbstracts%2520from%2520the%25202009%2520International%2520Stroke%2520Conference%26jtitle%3DStroke%26date%3D2009%26volume%3D40%26spage%3De105%26epage%3De276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group">Kamanaka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamoshima, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitajima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Umemura, K.</span><span> </span><span class="NLM_article-title">Neuroprotective effects of ONO-1924H, an inhibitor of poly ADP-ribose polymerase (PARP), on cytotoxicity of PC12 cells and ischemic cerebral damage</span> <span class="citation_source-journal">Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">151</span><span class="NLM_x">â</span> <span class="NLM_lpage">162</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2004&pages=151-162&author=Y.+Kamanakaauthor=K.+Kondoauthor=Y.+Ikedaauthor=W.+Kamoshimaauthor=T.+Kitajimaauthor=Y.+Suzukiauthor=Y.+Nakamuraauthor=K.+Umemura&title=Neuroprotective+effects+of+ONO-1924H%2C+an+inhibitor+of+poly+ADP-ribose+polymerase+%28PARP%29%2C+on+cytotoxicity+of+PC12+cells+and+ischemic+cerebral+damage"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKamanaka%26aufirst%3DY.%26aulast%3DKondo%26aufirst%3DK.%26aulast%3DIkeda%26aufirst%3DY.%26aulast%3DKamoshima%26aufirst%3DW.%26aulast%3DKitajima%26aufirst%3DT.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DNakamura%26aufirst%3DY.%26aulast%3DUmemura%26aufirst%3DK.%26atitle%3DNeuroprotective%2520effects%2520of%2520ONO-1924H%252C%2520an%2520inhibitor%2520of%2520poly%2520ADP-ribose%2520polymerase%2520%2528PARP%2529%252C%2520on%2520cytotoxicity%2520of%2520PC12%2520cells%2520and%2520ischemic%2520cerebral%2520damage%26jtitle%3DLife%2520Sci.%26date%3D2004%26volume%3D76%26spage%3D151%26epage%3D162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group">Shiromizu, I.; Kato, K.; Yamamoto, I.; Hamamoto, H.</span><span> </span><span class="NLM_article-title">Novel PARP Inhibitor</span>. WO 20060004028,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=I.+Shiromizu&author=K.+Kato&author=I.+Yamamoto&author=H.+Hamamoto&title=Novel+PARP+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DShiromizu%26aufirst%3DI.%26atitle%3DNovel%2520PARP%2520Inhibitor%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group">Moree, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demaggio, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christenson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herendeen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eksterowicz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kesicki, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McElligott, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaton, G.</span><span> </span><span class="NLM_article-title">Identification of ring-fused pyrazolo pyridin-2-ones as novel poly(ADP-ribose)polymerase-1 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">5126</span><span class="NLM_x">â</span> <span class="NLM_lpage">5129</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=5126-5129&author=W.+J.+Moreeauthor=P.+Goldmanauthor=A.+J.+Demaggioauthor=E.+Christensonauthor=D.+Herendeenauthor=J.+Eksterowiczauthor=E.+A.+Kesickiauthor=D.+L.+McElligottauthor=G.+Beaton&title=Identification+of+ring-fused+pyrazolo+pyridin-2-ones+as+novel+poly%28ADP-ribose%29polymerase-1+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoree%26aufirst%3DW.%2BJ.%26aulast%3DGoldman%26aufirst%3DP.%26aulast%3DDemaggio%26aufirst%3DA.%2BJ.%26aulast%3DChristenson%26aufirst%3DE.%26aulast%3DHerendeen%26aufirst%3DD.%26aulast%3DEksterowicz%26aufirst%3DJ.%26aulast%3DKesicki%26aufirst%3DE.%2BA.%26aulast%3DMcElligott%26aufirst%3DD.%2BL.%26aulast%3DBeaton%26aufirst%3DG.%26atitle%3DIdentification%2520of%2520ring-fused%2520pyrazolo%2520pyridin-2-ones%2520as%2520novel%2520poly%2528ADP-ribose%2529polymerase-1%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D5126%26epage%3D5129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group">Guillemont, J. E. G.; Kennis, L. E. J.; Mertens, J. C.; Van Dun, J. A. J.; Somers, M. V. F.; Wouters, W. B. L.</span><span> </span><span class="NLM_article-title">Quinazoline Derivatives as PARP Inhibitors</span>. WO 20080070915,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=J.+E.+G.+Guillemont&author=L.+E.+J.+Kennis&author=J.+C.+Mertens&author=J.+A.+J.+Van+Dun&author=M.+V.+F.+Somers&author=W.+B.+L.+Wouters&title=Quinazoline+Derivatives+as+PARP+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGuillemont%26aufirst%3DJ.%2BE.%2BG.%26atitle%3DQuinazoline%2520Derivatives%2520as%2520PARP%2520Inhibitors%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group">Bolli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mentzer, R.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balshaw, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lathrop, D. A.</span><span> </span><span class="NLM_article-title">Myocardial protection at a crossroads: the need for translation into clinical therapy</span> <span class="citation_source-journal">Circ. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">125</span><span class="NLM_x">â</span> <span class="NLM_lpage">134</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2004&pages=125-134&author=R.+Bolliauthor=L.+Beckerauthor=G.+Grossauthor=R.+Mentzerauthor=D.+Balshawauthor=D.+A.+Lathrop&title=Myocardial+protection+at+a+crossroads%3A+the+need+for+translation+into+clinical+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBolli%26aufirst%3DR.%26aulast%3DBecker%26aufirst%3DL.%26aulast%3DGross%26aufirst%3DG.%26aulast%3DMentzer%26aufirst%3DR.%26aulast%3DBalshaw%26aufirst%3DD.%26aulast%3DLathrop%26aufirst%3DD.%2BA.%26atitle%3DMyocardial%2520protection%2520at%2520a%2520crossroads%253A%2520the%2520need%2520for%2520translation%2520into%2520clinical%2520therapy%26jtitle%3DCirc.%2520Res.%26date%3D2004%26volume%3D95%26spage%3D125%26epage%3D134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group">Opie, L. H.</span><span> </span><span class="NLM_article-title">Anti-Ischemic Drugs</span>. In  <span class="citation_source-book">Evidence-Based Cardiology</span>, <span class="NLM_edition">2</span>nd ed.; <span class="NLM_contrib-group">Yusuf, S.; Cairns, J. A.; Camm, J.; Fallen, E. L.; Gersh, B. J.</span>, Eds.; <span class="NLM_publisher-name">Wiley-Interscience</span>: <span class="NLM_publisher-loc">Malden, MA</span>,<span class="NLM_x"> </span><span class="NLM_year">2007</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">329</span>â <span class="NLM_lpage">338</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&pages=329-338&author=L.+H.+Opieauthor=S.+Yusuf&author=J.+A.+Cairns&author=J.+Camm&author=E.+L.+Fallen&author=B.+J.+Gersh&title=Evidence-Based+Cardiology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DOpie%26aufirst%3DL.%2BH.%26atitle%3DAnti-Ischemic%2520Drugs%26btitle%3DEvidence-Based%2520Cardiology%26aulast%3DYusuf%26aufirst%3DS.%26pub%3DWiley-Interscience%26date%3D2007%26spage%3D329%26epage%3D338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group">Drew, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plummer, R.</span><span> </span><span class="NLM_article-title">PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications</span> <span class="citation_source-journal">Drug Resist. Updates</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">â</span> <span class="NLM_lpage">156</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1016%2Fj.drup.2009.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=19939726" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFagtLvN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2009&pages=153-156&author=Y.+Drewauthor=R.+Plummer&title=PARP+inhibitors+in+cancer+therapy%3A+two+modes+of+attack+on+the+cancer+cell+widening+the+clinical+applications"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">PARP inhibitors in cancer therapy: Two modes of attack on the cancer cell widening the clinical applications</span></div><div class="casAuthors">Drew, Yvette; Plummer, Ruth</div><div class="citationInfo"><span class="NLM_cas:title">Drug Resistance Updates</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">153-156</span>CODEN:
                <span class="NLM_cas:coden">DRUPFW</span>;
        ISSN:<span class="NLM_cas:issn">1368-7646</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The abundant nuclear enzyme poly(ADP-ribose)polymerase-1 (PARP-1) represents an important novel target in cancer therapy.  PARP-1 is essential to the repair of single strand DNA breaks via the base excision repair pathway.  Inhibitors of PARP-1 have been shown to enhance the cytotoxic effects of ionizing radiation and DNA damaging chemotherapy agents such as the methylating agents and topoisomerase-I inhibitors.  There are currently at least eight PARP inhibitors in clin. trial development.  In vitro data, in vivo preclin. data and most recently early clin. trial data suggests that PARP inhibitors could be used not only as chemo/radiotherapy sensitizers but also as single agents to selectively kill cancers defective in DNA repair, specifically cancers with mutations in the breast cancer assocd. (BRCA)1 and BRCA2 genes.  This theory of selectively exploiting cells defective in one DNA repair pathway by inhibiting another is a major breakthrough in the treatment of cancer.  The current clin. data are discussed within this review with ref. to the preclin. models which predicted activity and also future directions and the possible dangers/pitfalls of this clin. strategy are explored.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKkKkEObuiarVg90H21EOLACvtfcHk0lgIdL0oBKD93w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFagtLvN&md5=bee59a3756fbac7e82faffa72cdb7e4f</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1016%2Fj.drup.2009.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drup.2009.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DDrew%26aufirst%3DY.%26aulast%3DPlummer%26aufirst%3DR.%26atitle%3DPARP%2520inhibitors%2520in%2520cancer%2520therapy%253A%2520two%2520modes%2520of%2520attack%2520on%2520the%2520cancer%2520cell%2520widening%2520the%2520clinical%2520applications%26jtitle%3DDrug%2520Resist.%2520Updates%26date%3D2009%26volume%3D12%26spage%3D153%26epage%3D156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group">Vasella, D.; Slater, R.</span> <span class="citation_source-book">Magic Cancer Bullet: How a Tiny Orange Pill May Rewrite Medical History</span>; <span class="NLM_publisher-name">HarperCollins</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=D.+Vasella&author=R.+Slater&title=Magic+Cancer+Bullet%3A+How+a+Tiny+Orange+Pill+May+Rewrite+Medical+History"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DVasella%26aufirst%3DD.%26btitle%3DMagic%2520Cancer%2520Bullet%253A%2520How%2520a%2520Tiny%2520Orange%2520Pill%2520May%2520Rewrite%2520Medical%2520History%26pub%3DHarperCollins%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group">Mendes-Pereira, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brough, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarthy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waldman, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors</span> <span class="citation_source-journal">EMBO Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">315</span><span class="NLM_x">â</span> <span class="NLM_lpage">322</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1002%2Femmm.200900041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=20049735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVSltL%252FK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2009&pages=315-322&author=A.+M.+Mendes-Pereiraauthor=S.+A.+Martinauthor=R.+Broughauthor=A.+McCarthyauthor=J.+R.+Taylorauthor=J.+S.+Kimauthor=T.+Waldmanauthor=C.+J.+Lordauthor=A.+Ashworth&title=Synthetic+lethal+targeting+of+PTEN+mutant+cells+with+PARP+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors</span></div><div class="casAuthors">Mendes-Pereira, Ana M.; Martin, Sarah A.; Brough, Rachel; McCarthy, Afshan; Taylor, Jessica R.; Kim, Jung-Sik; Waldman, Todd; Lord, Christopher J.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Molecular Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6-7</span>),
    <span class="NLM_cas:pages">315-322</span>CODEN:
                <span class="NLM_cas:coden">EMMMAM</span>;
        ISSN:<span class="NLM_cas:issn">1757-4684</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The tumor suppressor gene, phosphatase and tensin homolog (PTEN), is one of the most commonly mutated genes in human cancers.  Recent evidence suggests that PTEN is important for the maintenance of genome stability.  Here, we show that PTEN deficiency causes a homologous recombination (HR) defect in human tumor cells.  The HR deficiency caused by PTEN deficiency, sensitizes tumor cells to potent inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP), both in vitro and in vivo.  PARP inhibitors are now showing considerable promise in the clinic, specifically in patients with mutations in either of the breast cancer susceptibility genes BRCA1 or BRCA2.  The data we present here now suggests that the clin. assessment of PARP inhibitors should be extended beyond those with BRCA mutations to a larger group of patients with PTEN mutant tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPqq6kbXT_l7Vg90H21EOLACvtfcHk0ligpk2I3lguwg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVSltL%252FK&md5=c14c7e0d1ae6a753deabbfb125dcc5a2</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1002%2Femmm.200900041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Femmm.200900041%26sid%3Dliteratum%253Aachs%26aulast%3DMendes-Pereira%26aufirst%3DA.%2BM.%26aulast%3DMartin%26aufirst%3DS.%2BA.%26aulast%3DBrough%26aufirst%3DR.%26aulast%3DMcCarthy%26aufirst%3DA.%26aulast%3DTaylor%26aufirst%3DJ.%2BR.%26aulast%3DKim%26aufirst%3DJ.%2BS.%26aulast%3DWaldman%26aufirst%3DT.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DSynthetic%2520lethal%2520targeting%2520of%2520PTEN%2520mutant%2520cells%2520with%2520PARP%2520inhibitors%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2009%26volume%3D1%26spage%3D315%26epage%3D322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 231 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Stefano Tomassi, Julian Pfahler, Nicola Mautone, Annarita Rovere, Chiara Esposito, Daniela Passeri, Roberto Pellicciari, Ettore Novellino, Martin Pannek, Clemens Steegborn, Alessandro Paiardini, Antonello Mai, <span class="NLM_string-name hlFld-ContribAuthor">Dante Rotili</span>. </span><span class="cited-content_cbyCitation_article-title">From PARP1 to TNKS2 Inhibition: A Structure-Based Approach. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (5)
                                     , 862-868. <a href="https://doi.org/10.1021/acsmedchemlett.9b00654" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00654</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00654%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DFrom%252BPARP1%252Bto%252BTNKS2%252BInhibition%25253A%252BA%252BStructure-Based%252BApproach%26aulast%3DTomassi%26aufirst%3DStefano%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D26122019%26date%3D03022020%26date%3D11022020%26date%3D03022020%26volume%3D11%26issue%3D5%26spage%3D862%26epage%3D868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Junwei Wang, Hui Li, Guangchao He, Zhaoxing Chu, Kewen Peng, Yiran Ge, Qihua Zhu, <span class="NLM_string-name hlFld-ContribAuthor">Yungen Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Dual Poly(ADP-ribose)polymerase and Phosphoinositide 3-Kinase Inhibitors as a Promising Strategy for Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (1)
                                     , 122-139. <a href="https://doi.org/10.1021/acs.jmedchem.9b00622" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00622</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00622%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%252BDual%252BPoly%252528ADP-ribose%252529polymerase%252Band%252BPhosphoinositide%252B3-Kinase%252BInhibitors%252Bas%252Ba%252BPromising%252BStrategy%252Bfor%252BCancer%252BTherapy%26aulast%3DWang%26aufirst%3DJunwei%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D11042019%26date%3D27122019%26date%3D17122019%26volume%3D63%26issue%3D1%26spage%3D122%26epage%3D139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Sergei A. Shipilovskikh, <span class="NLM_string-name hlFld-ContribAuthor">Aleksandr E. Rubtsov</span>. </span><span class="cited-content_cbyCitation_article-title">One-Pot Synthesis of Thieno[3,2-e]pyrrolo[1,2-a]pyrimidine Derivative Scaffold: A Valuable Source of PARP-1 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>84 </em>
                                    (24)
                                     , 15788-15796. <a href="https://doi.org/10.1021/acs.joc.9b00711" title="DOI URL">https://doi.org/10.1021/acs.joc.9b00711</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.9b00711&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.9b00711%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DOne-Pot%252BSynthesis%252Bof%252BThieno%25255B3%25252C2-e%25255Dpyrrolo%25255B1%25252C2-a%25255Dpyrimidine%252BDerivative%252BScaffold%25253A%252BA%252BValuable%252BSource%252Bof%252BPARP-1%252BInhibitors%26aulast%3DShipilovskikh%26aufirst%3DSergei%2BA.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D13032019%26date%3D04122019%26date%3D26112019%26volume%3D84%26issue%3D24%26spage%3D15788%26epage%3D15796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zoufeng Xu, Cai Li, Qiyuan Zhou, Zhiqin Deng, Zixuan Tong, Man-Kit Tse, <span class="NLM_string-name hlFld-ContribAuthor">Guangyu Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, Cytotoxicity, and Mechanistic Investigation of Platinum(IV) Anticancer Complexes Conjugated with Poly(ADP-ribose) Polymerase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Inorganic Chemistry</span><span> <strong>2019,</strong> <em>58 </em>
                                    (23)
                                     , 16279-16291. <a href="https://doi.org/10.1021/acs.inorgchem.9b02839" title="DOI URL">https://doi.org/10.1021/acs.inorgchem.9b02839</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.inorgchem.9b02839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.inorgchem.9b02839%26sid%3Dliteratum%253Aachs%26jtitle%3DInorganic%2520Chemistry%26atitle%3DSynthesis%25252C%252BCytotoxicity%25252C%252Band%252BMechanistic%252BInvestigation%252Bof%252BPlatinum%252528IV%252529%252BAnticancer%252BComplexes%252BConjugated%252Bwith%252BPoly%252528ADP-ribose%252529%252BPolymerase%252BInhibitors%26aulast%3DXu%26aufirst%3DZoufeng%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D23092019%26date%3D18112019%26volume%3D58%26issue%3D23%26spage%3D16279%26epage%3D16291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Lik Hang Yuen, Srikanta Dana, Yu Liu, Samuel I. Bloom, Ann-Gerd Thorsell, Dario Neri, Anthony J. Donato, Dmitri Kireev, Herwig SchÃ¼ler, <span class="NLM_string-name hlFld-ContribAuthor">Raphael M. Franzini</span>. </span><span class="cited-content_cbyCitation_article-title">A Focused DNA-Encoded Chemical Library for the Discovery of Inhibitors of NAD+-Dependent Enzymes. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2019,</strong> <em>141 </em>
                                    (13)
                                     , 5169-5181. <a href="https://doi.org/10.1021/jacs.8b08039" title="DOI URL">https://doi.org/10.1021/jacs.8b08039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.8b08039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.8b08039%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DA%252BFocused%252BDNA-Encoded%252BChemical%252BLibrary%252Bfor%252Bthe%252BDiscovery%252Bof%252BInhibitors%252Bof%252BNAD%25252B-Dependent%252BEnzymes%26aulast%3DYuen%26aufirst%3DLik%2BHang%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D28072018%26date%3D19032019%26date%3D11032019%26volume%3D141%26issue%3D13%26spage%3D5169%26epage%3D5181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Rory K. Morgan, Ilsa T. Kirby, Anke Vermehren-Schmaedick, Kelsie Rodriguez, <span class="NLM_string-name hlFld-ContribAuthor">Michael S. Cohen</span>. </span><span class="cited-content_cbyCitation_article-title">Rational Design of Cell-Active Inhibitors of PARP10. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (1)
                                     , 74-79. <a href="https://doi.org/10.1021/acsmedchemlett.8b00429" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00429</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00429&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00429%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DRational%252BDesign%252Bof%252BCell-Active%252BInhibitors%252Bof%252BPARP10%26aulast%3DMorgan%26aufirst%3DRory%2BK.%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D25092018%26date%3D29112018%26date%3D10122018%26date%3D29112018%26volume%3D10%26issue%3D1%26spage%3D74%26epage%3D79" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Albert A. AntolÃ­n, <span class="NLM_string-name hlFld-ContribAuthor">Jordi Mestres</span>. </span><span class="cited-content_cbyCitation_article-title">Dual Inhibitors of PARPs and ROCKs. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2018,</strong> <em>3 </em>
                                    (10)
                                     , 12707-12712. <a href="https://doi.org/10.1021/acsomega.8b02337" title="DOI URL">https://doi.org/10.1021/acsomega.8b02337</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.8b02337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.8b02337%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DDual%252BInhibitors%252Bof%252BPARPs%252Band%252BROCKs%26aulast%3DAntol%25C3%25ADn%26aufirst%3DAlbert%2BA.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D10092018%26date%3D24092018%26volume%3D3%26issue%3D10%26spage%3D12707%26epage%3D12712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Sean W. Reilly, Laura N. Puentes, Khadija Wilson, Chia-Ju Hsieh, Chi-Chang Weng, Mehran Makvandi, <span class="NLM_string-name hlFld-ContribAuthor">Robert H. Mach</span>. </span><span class="cited-content_cbyCitation_article-title">Examination of Diazaspiro Cores as Piperazine Bioisosteres in the Olaparib Framework Shows Reduced DNA Damage and Cytotoxicity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (12)
                                     , 5367-5379. <a href="https://doi.org/10.1021/acs.jmedchem.8b00576" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00576</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00576%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DExamination%252Bof%252BDiazaspiro%252BCores%252Bas%252BPiperazine%252BBioisosteres%252Bin%252Bthe%252BOlaparib%252BFramework%252BShows%252BReduced%252BDNA%252BDamage%252Band%252BCytotoxicity%26aulast%3DReilly%26aufirst%3DSean%2BW.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D12042018%26date%3D14062018%26date%3D01062018%26volume%3D61%26issue%3D12%26spage%3D5367%26epage%3D5379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tzuen-Yang  Ye</span>, <span class="hlFld-ContribAuthor ">Manikandan  Selvaraju</span>, and <span class="hlFld-ContribAuthor ">Chung-Ming  Sun</span>  . </span><span class="cited-content_cbyCitation_article-title">Cascade Synthesis of Benzimidazole-Linked Pyrroles via Copper Catalyzed Oxidative Cyclization and Ketonization. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2017,</strong> <em>19 </em>
                                    (12)
                                     , 3103-3106. <a href="https://doi.org/10.1021/acs.orglett.7b01224" title="DOI URL">https://doi.org/10.1021/acs.orglett.7b01224</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.7b01224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.7b01224%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DCascade%252BSynthesis%252Bof%252BBenzimidazole-Linked%252BPyrroles%252Bvia%252BCopper%252BCatalyzed%252BOxidative%252BCyclization%252Band%252BKetonization%26aulast%3DYe%26aufirst%3DTzuen-Yang%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D23042017%26date%3D05062017%26date%3D16062017%26volume%3D19%26issue%3D12%26spage%3D3103%26epage%3D3106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ann-Gerd  Thorsell</span>, <span class="hlFld-ContribAuthor ">Torun  Ekblad</span>, <span class="hlFld-ContribAuthor ">Tobias  Karlberg</span>, <span class="hlFld-ContribAuthor ">Mirjam  LÃ¶w</span>, <span class="hlFld-ContribAuthor ">Ana Filipa  Pinto</span>, <span class="hlFld-ContribAuthor ">Lionel  TrÃ©saugues</span>, <span class="hlFld-ContribAuthor ">Martin  Moche</span>, <span class="hlFld-ContribAuthor ">Michael S.  Cohen</span>, and <span class="hlFld-ContribAuthor ">Herwig  SchÃ¼ler</span>  . </span><span class="cited-content_cbyCitation_article-title">Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (4)
                                     , 1262-1271. <a href="https://doi.org/10.1021/acs.jmedchem.6b00990" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00990</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00990%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructural%252BBasis%252Bfor%252BPotency%252Band%252BPromiscuity%252Bin%252BPoly%252528ADP-ribose%252529%252BPolymerase%252B%252528PARP%252529%252Band%252BTankyrase%252BInhibitors%26aulast%3DThorsell%26aufirst%3DAnn-Gerd%26date%3D2017%26date%3D2016%26date%3D2016%26date%3D13072016%26date%3D21122016%26date%3D23022017%26date%3D02122016%26volume%3D60%26issue%3D4%26spage%3D1262%26epage%3D1271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amit  Nathubhai</span>, <span class="hlFld-ContribAuthor ">Teemu  Haikarainen</span>, <span class="hlFld-ContribAuthor ">Jarkko  Koivunen</span>, <span class="hlFld-ContribAuthor ">Sudarshan  Murthy</span>, <span class="hlFld-ContribAuthor ">FranÃ§oise  Koumanov</span>, <span class="hlFld-ContribAuthor ">Matthew D.  Lloyd</span>, <span class="hlFld-ContribAuthor ">Geoffrey D.  Holman</span>, <span class="hlFld-ContribAuthor ">Taina  Pihlajaniemi</span>, <span class="hlFld-ContribAuthor ">David  Tosh</span>, <span class="hlFld-ContribAuthor ">Lari  LehtiÃ¶</span>, and <span class="hlFld-ContribAuthor ">Michael D.  Threadgill</span>  . </span><span class="cited-content_cbyCitation_article-title">Highly Potent and Isoform Selective Dual Site Binding Tankyrase/Wnt Signaling Inhibitors That Increase Cellular Glucose Uptake and Have Antiproliferative Activity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (2)
                                     , 814-820. <a href="https://doi.org/10.1021/acs.jmedchem.6b01574" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01574</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01574%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHighly%252BPotent%252Band%252BIsoform%252BSelective%252BDual%252BSite%252BBinding%252BTankyrase%25252FWnt%252BSignaling%252BInhibitors%252BThat%252BIncrease%252BCellular%252BGlucose%252BUptake%252Band%252BHave%252BAntiproliferative%252BActivity%26aulast%3DNathubhai%26aufirst%3DAmit%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D28102016%26date%3D09012017%26date%3D26012017%26date%3D16122016%26volume%3D60%26issue%3D2%26spage%3D814%26epage%3D820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ying-Qing  Wang</span>, <span class="hlFld-ContribAuthor ">Ping-Yuan  Wang</span>, <span class="hlFld-ContribAuthor ">Yu-Ting  Wang</span>, <span class="hlFld-ContribAuthor ">Guang-Fu  Yang</span>, <span class="hlFld-ContribAuthor ">Ao  Zhang</span>, and <span class="hlFld-ContribAuthor ">Ze-Hong  Miao</span>  . </span><span class="cited-content_cbyCitation_article-title">An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (21)
                                     , 9575-9598. <a href="https://doi.org/10.1021/acs.jmedchem.6b00055" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00055</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00055%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAn%252BUpdate%252Bon%252BPoly%252528ADP-ribose%252529polymerase-1%252B%252528PARP-1%252529%252BInhibitors%25253A%252BOpportunities%252Band%252BChallenges%252Bin%252BCancer%252BTherapy%26aulast%3DWang%26aufirst%3DYing-Qing%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D13012016%26date%3D27072016%26date%3D10112016%26date%3D14072016%26volume%3D59%26issue%3D21%26spage%3D9575%26epage%3D9598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Huanfeng  Jiang</span>, <span class="hlFld-ContribAuthor ">Jidan  Yang</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Tang</span>, and <span class="hlFld-ContribAuthor ">Wanqing  Wu</span>  . </span><span class="cited-content_cbyCitation_article-title">Divergent Syntheses of Isoquinolines and Indolo[1,2-a]quinazolines by Copper-Catalyzed Cascade Annulation from 2-Haloaryloxime Acetates with Active Methylene Compounds and Indoles. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2016,</strong> <em>81 </em>
                                    (5)
                                     , 2053-2061. <a href="https://doi.org/10.1021/acs.joc.5b02914" title="DOI URL">https://doi.org/10.1021/acs.joc.5b02914</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.5b02914&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.5b02914%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DDivergent%252BSyntheses%252Bof%252BIsoquinolines%252Band%252BIndolo%25255B1%25252C2-a%25255Dquinazolines%252Bby%252BCopper-Catalyzed%252BCascade%252BAnnulation%252Bfrom%252B2-Haloaryloxime%252BAcetates%252Bwith%252BActive%252BMethylene%252BCompounds%252Band%252BIndoles%26aulast%3DJiang%26aufirst%3DHuanfeng%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D30122015%26date%3D11022016%26date%3D04032016%26date%3D01022016%26volume%3D81%26issue%3D5%26spage%3D2053%26epage%3D2061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bing  Wang</span>, <span class="hlFld-ContribAuthor ">Daniel  Chu</span>, <span class="hlFld-ContribAuthor ">Ying  Feng</span>, <span class="hlFld-ContribAuthor ">Yuqiao  Shen</span>, <span class="hlFld-ContribAuthor ">Mika  Aoyagi-Scharber</span>, and <span class="hlFld-ContribAuthor ">Leonard E.  Post</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (1)
                                     , 335-357. <a href="https://doi.org/10.1021/acs.jmedchem.5b01498" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01498</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01498%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BCharacterization%252Bof%252B%2525288S%25252C9R%252529-5-Fluoro-8-%2525284-fluorophenyl%252529-9-%2525281-methyl-1H-1%25252C2%25252C4-triazol-5-yl%252529-2%25252C7%25252C8%25252C9-tetrahydro-3H-pyrido%25255B4%25252C3%25252C2-de%25255Dphthalazin-3-one%252B%252528BMN%252B673%25252C%252BTalazoparib%252529%25252C%252Ba%252BNovel%25252C%252BHighly%252BPotent%25252C%252Band%252BOrally%252BEfficacious%252BPoly%252528ADP-ribose%252529%252BPolymerase-1%25252F2%252BInhibitor%25252C%252Bas%252Ban%252BAnticancer%252BAgent%26aulast%3DWang%26aufirst%3DBing%26date%3D2016%26date%3D2015%26date%3D2015%26date%3D27092015%26date%3D23122015%26date%3D14012016%26date%3D10122015%26volume%3D59%26issue%3D1%26spage%3D335%26epage%3D357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Filip  Zmuda</span>, <span class="hlFld-ContribAuthor ">Gaurav  Malviya</span>, <span class="hlFld-ContribAuthor ">Adele  Blair</span>, <span class="hlFld-ContribAuthor ">Marie  Boyd</span>, <span class="hlFld-ContribAuthor ">Anthony J.  Chalmers</span>, <span class="hlFld-ContribAuthor ">Andrew  Sutherland</span>, and <span class="hlFld-ContribAuthor ">Sally L.  Pimlott</span>  . </span><span class="cited-content_cbyCitation_article-title">Synthesis and Evaluation of a Radioiodinated Tracer with Specificity for Poly(ADP-ribose) Polymerase-1 (PARP-1) in Vivo. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (21)
                                     , 8683-8693. <a href="https://doi.org/10.1021/acs.jmedchem.5b01324" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01324</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01324%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252BEvaluation%252Bof%252Ba%252BRadioiodinated%252BTracer%252Bwith%252BSpecificity%252Bfor%252BPoly%252528ADP-ribose%252529%252BPolymerase-1%252B%252528PARP-1%252529%252Bin%252BVivo%26aulast%3DZmuda%26aufirst%3DFilip%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D27082015%26date%3D27102015%26date%3D12112015%26date%3D15102015%26volume%3D58%26issue%3D21%26spage%3D8683%26epage%3D8693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gianluca  Papeo</span>, <span class="hlFld-ContribAuthor ">Helena  Posteri</span>, <span class="hlFld-ContribAuthor ">Daniela  Borghi</span>, <span class="hlFld-ContribAuthor ">Alina A.  Busel</span>, <span class="hlFld-ContribAuthor ">Francesco  Caprera</span>, <span class="hlFld-ContribAuthor ">Elena  Casale</span>, <span class="hlFld-ContribAuthor ">Marina  Ciomei</span>, <span class="hlFld-ContribAuthor ">Alessandra  Cirla</span>, <span class="hlFld-ContribAuthor ">Emiliana  Corti</span>, <span class="hlFld-ContribAuthor ">Matteo  DâAnello</span>, <span class="hlFld-ContribAuthor ">Marina  Fasolini</span>, <span class="hlFld-ContribAuthor ">Barbara  Forte</span>, <span class="hlFld-ContribAuthor ">Arturo  Galvani</span>, <span class="hlFld-ContribAuthor ">Antonella  Isacchi</span>, <span class="hlFld-ContribAuthor ">Alexander  Khvat</span>, <span class="hlFld-ContribAuthor ">Mikhail Y.  Krasavin</span>, <span class="hlFld-ContribAuthor ">Rosita  Lupi</span>, <span class="hlFld-ContribAuthor ">Paolo  Orsini</span>, <span class="hlFld-ContribAuthor ">Rita  Perego</span>, <span class="hlFld-ContribAuthor ">Enrico  Pesenti</span>, <span class="hlFld-ContribAuthor ">Daniele  Pezzetta</span>, <span class="hlFld-ContribAuthor ">Sonia  Rainoldi</span>, <span class="hlFld-ContribAuthor ">Federico  Riccardi-Sirtori</span>, <span class="hlFld-ContribAuthor ">Alessandra  Scolaro</span>, <span class="hlFld-ContribAuthor ">Francesco  Sola</span>, <span class="hlFld-ContribAuthor ">Fabio  Zuccotto</span>, <span class="hlFld-ContribAuthor ">Eduard R.  Felder</span>, <span class="hlFld-ContribAuthor ">Daniele  Donati</span>, and <span class="hlFld-ContribAuthor ">Alessia  Montagnoli</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (17)
                                     , 6875-6898. <a href="https://doi.org/10.1021/acs.jmedchem.5b00680" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00680</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b00680%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B2-%25255B1-%2525284%25252C4-Difluorocyclohexyl%252529piperidin-4-yl%25255D-6-fluoro-3-oxo-2%25252C3-dihydro-1H-isoindole-4-carboxamide%252B%252528NMS-P118%252529%25253A%252BA%252BPotent%25252C%252BOrally%252BAvailable%25252C%252Band%252BHighly%252BSelective%252BPARP-1%252BInhibitor%252Bfor%252BCancer%252BTherapy%26aulast%3DPapeo%26aufirst%3DGianluca%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D04052015%26date%3D26082015%26date%3D10092015%26date%3D29072015%26volume%3D58%26issue%3D17%26spage%3D6875%26epage%3D6898" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sandip  Dhole</span>, <span class="hlFld-ContribAuthor ">Manikandan  Selvaraju</span>, <span class="hlFld-ContribAuthor ">Barnali  Maiti</span>, <span class="hlFld-ContribAuthor ">Kaushik  Chanda</span>, and <span class="hlFld-ContribAuthor ">Chung-Ming  Sun</span>  . </span><span class="cited-content_cbyCitation_article-title">Microwave Controlled Reductive Cyclization: A Selective Synthesis of Novel Benzimidazole-alkyloxypyrrolo[1,2-a]quinoxalinones. </span><span class="cited-content_cbyCitation_journal-name">ACS Combinatorial Science</span><span> <strong>2015,</strong> <em>17 </em>
                                    (5)
                                     , 310-316. <a href="https://doi.org/10.1021/acscombsci.5b00010" title="DOI URL">https://doi.org/10.1021/acscombsci.5b00010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscombsci.5b00010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscombsci.5b00010%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Combinatorial%2520Science%26atitle%3DMicrowave%252BControlled%252BReductive%252BCyclization%25253A%252BA%252BSelective%252BSynthesis%252Bof%252BNovel%252BBenzimidazole-alkyloxypyrrolo%25255B1%25252C2-a%25255Dquinoxalinones%26aulast%3DDhole%26aufirst%3DSandip%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D2015%26date%3D15042014%26date%3D12042015%26date%3D21042015%26date%3D11052015%26volume%3D17%26issue%3D5%26spage%3D310%26epage%3D316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Philip  Jones</span>, <span class="hlFld-ContribAuthor ">Keith  Wilcoxen</span>, <span class="hlFld-ContribAuthor ">Michael  Rowley</span>, and <span class="hlFld-ContribAuthor ">Carlo  Toniatti</span>  . </span><span class="cited-content_cbyCitation_article-title">Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (8)
                                     , 3302-3314. <a href="https://doi.org/10.1021/jm5018237" title="DOI URL">https://doi.org/10.1021/jm5018237</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm5018237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm5018237%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNiraparib%25253A%252BA%252BPoly%252528ADP-ribose%252529%252BPolymerase%252B%252528PARP%252529%252BInhibitor%252Bfor%252Bthe%252BTreatment%252Bof%252BTumors%252Bwith%252BDefective%252BHomologous%252BRecombination%26aulast%3DJones%26aufirst%3DPhilip%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D25112014%26date%3D11032015%26date%3D23042015%26volume%3D58%26issue%3D8%26spage%3D3302%26epage%3D3314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bingliang  Fang</span>  . </span><span class="cited-content_cbyCitation_article-title">Development of Synthetic Lethality Anticancer Therapeutics. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (19)
                                     , 7859-7873. <a href="https://doi.org/10.1021/jm500415t" title="DOI URL">https://doi.org/10.1021/jm500415t</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm500415t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm500415t%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Bof%252BSynthetic%252BLethality%252BAnticancer%252BTherapeutics%26aulast%3DFang%26aufirst%3DBingliang%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D17032014%26date%3D13062014%26date%3D09102014%26date%3D03062014%26volume%3D57%26issue%3D19%26spage%3D7859%26epage%3D7873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maulik R.  Patel</span>, <span class="hlFld-ContribAuthor ">Aaditya  Bhatt</span>, <span class="hlFld-ContribAuthor ">Jamin D.  Steffen</span>, <span class="hlFld-ContribAuthor ">Adel  Chergui</span>, <span class="hlFld-ContribAuthor ">Junko  Murai</span>, <span class="hlFld-ContribAuthor ">Yves  Pommier</span>, <span class="hlFld-ContribAuthor ">John M.  Pascal</span>, <span class="hlFld-ContribAuthor ">Louis D.  Trombetta</span>, <span class="hlFld-ContribAuthor ">Frank R.  Fronczek</span>, and <span class="hlFld-ContribAuthor ">Tanaji T.  Talele</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery and StructureâActivity Relationship of Novel 2,3-Dihydrobenzofuran-7-carboxamide and 2,3-Dihydrobenzofuran-3(2H)-one-7-carboxamide Derivatives as Poly(ADP-ribose)polymerase-1 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (13)
                                     , 5579-5601. <a href="https://doi.org/10.1021/jm5002502" title="DOI URL">https://doi.org/10.1021/jm5002502</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm5002502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm5002502%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BStructure%2525E2%252580%252593Activity%252BRelationship%252Bof%252BNovel%252B2%25252C3-Dihydrobenzofuran-7-carboxamide%252Band%252B2%25252C3-Dihydrobenzofuran-3%2525282H%252529-one-7-carboxamide%252BDerivatives%252Bas%252BPoly%252528ADP-ribose%252529polymerase-1%252BInhibitors%26aulast%3DPatel%26aufirst%3DMaulik%2BR.%26date%3D2014%26date%3D2014%26date%3D2013%26date%3D31122013%26date%3D25062014%26date%3D10072014%26date%3D12062014%26volume%3D57%26issue%3D13%26spage%3D5579%26epage%3D5601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rachel C.  Botham</span>, <span class="hlFld-ContribAuthor ">Timothy M.  Fan</span>, <span class="hlFld-ContribAuthor ">Isak  Im</span>, <span class="hlFld-ContribAuthor ">Luke B.  Borst</span>, <span class="hlFld-ContribAuthor ">Levent  Dirikolu</span>, and <span class="hlFld-ContribAuthor ">Paul J.  Hergenrother</span>  . </span><span class="cited-content_cbyCitation_article-title">Dual Small-Molecule Targeting of Procaspase-3 Dramatically Enhances Zymogen Activation and Anticancer Activity. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2014,</strong> <em>136 </em>
                                    (4)
                                     , 1312-1319. <a href="https://doi.org/10.1021/ja4124303" title="DOI URL">https://doi.org/10.1021/ja4124303</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ja4124303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fja4124303%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DDual%252BSmall-Molecule%252BTargeting%252Bof%252BProcaspase-3%252BDramatically%252BEnhances%252BZymogen%252BActivation%252Band%252BAnticancer%252BActivity%26aulast%3DBotham%26aufirst%3DRachel%2BC.%26date%3D2014%26date%3D2014%26date%3D2013%26date%3D01062013%26date%3D16012014%26date%3D29012014%26date%3D02012014%26volume%3D136%26issue%3D4%26spage%3D1312%26epage%3D1319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zihao  Hua</span>, <span class="hlFld-ContribAuthor ">Howard  Bregman</span>, <span class="hlFld-ContribAuthor ">John L.  Buchanan</span>, <span class="hlFld-ContribAuthor ">Nagasree  Chakka</span>, <span class="hlFld-ContribAuthor ">Angel  Guzman-Perez</span>, <span class="hlFld-ContribAuthor ">Hakan  Gunaydin</span>, <span class="hlFld-ContribAuthor ">Xin  Huang</span>, <span class="hlFld-ContribAuthor ">Yan  Gu</span>, <span class="hlFld-ContribAuthor ">Virginia  Berry</span>, <span class="hlFld-ContribAuthor ">Jingzhou  Liu</span>, <span class="hlFld-ContribAuthor ">Yohannes  Teffera</span>, <span class="hlFld-ContribAuthor ">Liyue  Huang</span>, <span class="hlFld-ContribAuthor ">Bryan  Egge</span>, <span class="hlFld-ContribAuthor ">Renee  Emkey</span>, <span class="hlFld-ContribAuthor ">Erin L.  Mullady</span>, <span class="hlFld-ContribAuthor ">Steve  Schneider</span>, <span class="hlFld-ContribAuthor ">Paul S.  Andrews</span>, <span class="hlFld-ContribAuthor ">Lisa  Acquaviva</span>, <span class="hlFld-ContribAuthor ">Jennifer  Dovey</span>, <span class="hlFld-ContribAuthor ">Ankita  Mishra</span>, <span class="hlFld-ContribAuthor ">John  Newcomb</span>, <span class="hlFld-ContribAuthor ">Douglas  Saffran</span>, <span class="hlFld-ContribAuthor ">Randy  Serafino</span>, <span class="hlFld-ContribAuthor ">Craig A.  Strathdee</span>, <span class="hlFld-ContribAuthor ">Susan M.  Turci</span>, <span class="hlFld-ContribAuthor ">Mary  Stanton</span>, <span class="hlFld-ContribAuthor ">Cindy  Wilson</span>, and <span class="hlFld-ContribAuthor ">Erin F.  DiMauro</span>  . </span><span class="cited-content_cbyCitation_article-title">Development of Novel Dual Binders as Potent, Selective, and Orally Bioavailable Tankyrase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (24)
                                     , 10003-10015. <a href="https://doi.org/10.1021/jm401317z" title="DOI URL">https://doi.org/10.1021/jm401317z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm401317z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm401317z%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Bof%252BNovel%252BDual%252BBinders%252Bas%252BPotent%25252C%252BSelective%25252C%252Band%252BOrally%252BBioavailable%252BTankyrase%252BInhibitors%26aulast%3DHua%26aufirst%3DZihao%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D26082013%26date%3D11122013%26date%3D27122013%26date%3D02122013%26volume%3D56%26issue%3D24%26spage%3D10003%26epage%3D10015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alexander  Kornienko</span>, <span class="hlFld-ContribAuthor ">VÃ©ronique  Mathieu</span>, <span class="hlFld-ContribAuthor ">Shiva K.  Rastogi</span>, <span class="hlFld-ContribAuthor ">Florence  Lefranc</span>, and <span class="hlFld-ContribAuthor ">Robert  Kiss</span>  . </span><span class="cited-content_cbyCitation_article-title">Therapeutic Agents Triggering Nonapoptotic Cancer Cell Death. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (12)
                                     , 4823-4839. <a href="https://doi.org/10.1021/jm400136m" title="DOI URL">https://doi.org/10.1021/jm400136m</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm400136m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm400136m%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTherapeutic%252BAgents%252BTriggering%252BNonapoptotic%252BCancer%252BCell%252BDeath%26aulast%3DKornienko%26aufirst%3DAlexander%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D28012013%26date%3D05042013%26date%3D27062013%26date%3D21032013%26volume%3D56%26issue%3D12%26spage%3D4823%26epage%3D4839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">E. Andreas  Larsson</span>, <span class="hlFld-ContribAuthor ">Anna  Jansson</span>, <span class="hlFld-ContribAuthor ">Fui Mee  Ng</span>, <span class="hlFld-ContribAuthor ">Siew Wen  Then</span>, <span class="hlFld-ContribAuthor ">Resmi  Panicker</span>, <span class="hlFld-ContribAuthor ">Boping  Liu</span>, <span class="hlFld-ContribAuthor ">Kanda  Sangthongpitag</span>, <span class="hlFld-ContribAuthor ">Vishal  Pendharkar</span>, <span class="hlFld-ContribAuthor ">Shi Jing  Tai</span>, <span class="hlFld-ContribAuthor ">Jeffrey  Hill</span>, <span class="hlFld-ContribAuthor ">Chen  Dan</span>, <span class="hlFld-ContribAuthor ">Soo Yei  Ho</span>, <span class="hlFld-ContribAuthor ">Wei Wen  Cheong</span>, <span class="hlFld-ContribAuthor ">Anders  Poulsen</span>, <span class="hlFld-ContribAuthor ">Stephanie  Blanchard</span>, <span class="hlFld-ContribAuthor ">Grace Ruiting  Lin</span>, <span class="hlFld-ContribAuthor ">Jenefer  Alam</span>, <span class="hlFld-ContribAuthor ">Thomas H.  Keller</span>, and <span class="hlFld-ContribAuthor ">PÃ¤r  Nordlund</span>  . </span><span class="cited-content_cbyCitation_article-title">Fragment-Based Ligand Design of Novel Potent Inhibitors of Tankyrases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (11)
                                     , 4497-4508. <a href="https://doi.org/10.1021/jm400211f" title="DOI URL">https://doi.org/10.1021/jm400211f</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm400211f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm400211f%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFragment-Based%252BLigand%252BDesign%252Bof%252BNovel%252BPotent%252BInhibitors%252Bof%252BTankyrases%26aulast%3DLarsson%26aufirst%3DE.%2BAndreas%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D09022013%26date%3D04062013%26date%3D13062013%26date%3D14052013%26volume%3D56%26issue%3D11%26spage%3D4497%26epage%3D4508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mohit  Narwal</span>, <span class="hlFld-ContribAuthor ">Teemu  Haikarainen</span>, <span class="hlFld-ContribAuthor ">Adyary  Fallarero</span>, <span class="hlFld-ContribAuthor ">Pia M.  Vuorela</span>, and <span class="hlFld-ContribAuthor ">Lari  LehtiÃ¶</span>  . </span><span class="cited-content_cbyCitation_article-title">Screening and Structural Analysis of Flavones Inhibiting Tankyrases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (9)
                                     , 3507-3517. <a href="https://doi.org/10.1021/jm3018783" title="DOI URL">https://doi.org/10.1021/jm3018783</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm3018783&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm3018783%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DScreening%252Band%252BStructural%252BAnalysis%252Bof%252BFlavones%252BInhibiting%252BTankyrases%26aulast%3DNarwal%26aufirst%3DMohit%26date%3D2013%26date%3D2013%26date%3D2012%26date%3D20122012%26date%3D24042013%26date%3D09052013%26date%3D10042013%26volume%3D56%26issue%3D9%26spage%3D3507%26epage%3D3517" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Na  Ye</span>, <span class="hlFld-ContribAuthor ">Chuan-Huizi  Chen</span>, <span class="hlFld-ContribAuthor ">TianTian  Chen</span>, <span class="hlFld-ContribAuthor ">Zilan  Song</span>, <span class="hlFld-ContribAuthor ">Jin-Xue  He</span>, <span class="hlFld-ContribAuthor ">Xia-Juan  Huan</span>, <span class="hlFld-ContribAuthor ">Shan-Shan  Song</span>, <span class="hlFld-ContribAuthor ">Qiufeng  Liu</span>, <span class="hlFld-ContribAuthor ">Yi  Chen</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Yechun  Xu</span>, <span class="hlFld-ContribAuthor ">Ze-Hong  Miao</span>, and <span class="hlFld-ContribAuthor ">Ao  Zhang</span>  . </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of a Series of Benzo[de][1,7]naphthyridin-7(8H)-ones Bearing a Functionalized Longer Chain Appendage as Novel PARP1 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (7)
                                     , 2885-2903. <a href="https://doi.org/10.1021/jm301825t" title="DOI URL">https://doi.org/10.1021/jm301825t</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm301825t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm301825t%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252Ba%252BSeries%252Bof%252BBenzo%25255Bde%25255D%25255B1%25252C7%25255Dnaphthyridin-7%2525288H%252529-ones%252BBearing%252Ba%252BFunctionalized%252BLonger%252BChain%252BAppendage%252Bas%252BNovel%252BPARP1%252BInhibitors%26aulast%3DYe%26aufirst%3DNa%26date%3D2013%26date%3D2013%26date%3D2012%26date%3D11122012%26date%3D21032013%26date%3D11042013%26date%3D08032013%26volume%3D56%26issue%3D7%26spage%3D2885%26epage%3D2903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mohit  Narwal</span>, <span class="hlFld-ContribAuthor ">Harikanth  Venkannagari</span>, and <span class="hlFld-ContribAuthor ">Lari  LehtiÃ¶</span>  . </span><span class="cited-content_cbyCitation_article-title">Structural Basis of Selective Inhibition of Human Tankyrases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2012,</strong> <em>55 </em>
                                    (3)
                                     , 1360-1367. <a href="https://doi.org/10.1021/jm201510p" title="DOI URL">https://doi.org/10.1021/jm201510p</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm201510p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm201510p%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructural%252BBasis%252Bof%252BSelective%252BInhibition%252Bof%252BHuman%252BTankyrases%26aulast%3DNarwal%26aufirst%3DMohit%26date%3D2012%26date%3D2012%26date%3D2011%26date%3D08112011%26date%3D25012012%26date%3D09022012%26date%3D10012012%26volume%3D55%26issue%3D3%26spage%3D1360%26epage%3D1367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adeeti V.  Ullal</span>, <span class="hlFld-ContribAuthor ">Thomas  Reiner</span>, <span class="hlFld-ContribAuthor ">Katherine S.  Yang</span>, <span class="hlFld-ContribAuthor ">Rostic  Gorbatov</span>, <span class="hlFld-ContribAuthor ">Changwook  Min</span>, <span class="hlFld-ContribAuthor ">David  Issadore</span>, <span class="hlFld-ContribAuthor ">Hakho  Lee</span>, and <span class="hlFld-ContribAuthor ">Ralph  Weissleder</span>  . </span><span class="cited-content_cbyCitation_article-title">Nanoparticle-Mediated Measurement of TargetâDrug Binding in Cancer Cells. </span><span class="cited-content_cbyCitation_journal-name">ACS Nano</span><span> <strong>2011,</strong> <em>5 </em>
                                    (11)
                                     , 9216-9224. <a href="https://doi.org/10.1021/nn203450p" title="DOI URL">https://doi.org/10.1021/nn203450p</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/nn203450p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fnn203450p%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Nano%26atitle%3DNanoparticle-Mediated%252BMeasurement%252Bof%252BTarget%2525E2%252580%252593Drug%252BBinding%252Bin%252BCancer%252BCells%26aulast%3DUllal%26aufirst%3DAdeeti%2BV.%26date%3D2011%26date%3D2011%26date%3D2011%26date%3D2011%26date%3D07092011%26date%3D01102011%26date%3D13102011%26date%3D22112011%26date%3D01102011%26volume%3D5%26issue%3D11%26spage%3D9216%26epage%3D9224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jamin D.  Steffen</span>, <span class="hlFld-ContribAuthor ">Donna L.  Coyle</span>, <span class="hlFld-ContribAuthor ">Komath  Damodaran</span>, <span class="hlFld-ContribAuthor ">Paul  Beroza</span>, and <span class="hlFld-ContribAuthor ">Myron K.  Jacobson</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery and StructureâActivity Relationships of Modified Salicylanilides as Cell Permeable Inhibitors of Poly(ADP-ribose) Glycohydrolase (PARG). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2011,</strong> <em>54 </em>
                                    (15)
                                     , 5403-5413. <a href="https://doi.org/10.1021/jm200325s" title="DOI URL">https://doi.org/10.1021/jm200325s</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm200325s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm200325s%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BStructure%2525E2%252580%252593Activity%252BRelationships%252Bof%252BModified%252BSalicylanilides%252Bas%252BCell%252BPermeable%252BInhibitors%252Bof%252BPoly%252528ADP-ribose%252529%252BGlycohydrolase%252B%252528PARG%252529%26aulast%3DSteffen%26aufirst%3DJamin%2BD.%26date%3D2011%26date%3D2011%26date%3D2011%26date%3D21032011%26date%3D08072011%26date%3D11082011%26date%3D21062011%26volume%3D54%26issue%3D15%26spage%3D5403%26epage%3D5413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thomas  Pesnot</span>, <span class="hlFld-ContribAuthor ">Julia  Kempter</span>, <span class="hlFld-ContribAuthor ">JÃ¶rg  Schemies</span>, <span class="hlFld-ContribAuthor ">Giulia  Pergolizzi</span>, <span class="hlFld-ContribAuthor ">Urszula  Uciechowska</span>, <span class="hlFld-ContribAuthor ">Tobias  Rumpf</span>, <span class="hlFld-ContribAuthor ">Wolfgang  Sippl</span>, <span class="hlFld-ContribAuthor ">Manfred  Jung</span>, and <span class="hlFld-ContribAuthor ">Gerd K.  Wagner</span>  . </span><span class="cited-content_cbyCitation_article-title">Two-Step Synthesis of Novel, Bioactive Derivatives of the Ubiquitous Cofactor Nicotinamide Adenine Dinucleotide (NAD). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2011,</strong> <em>54 </em>
                                    (10)
                                     , 3492-3499. <a href="https://doi.org/10.1021/jm1013852" title="DOI URL">https://doi.org/10.1021/jm1013852</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm1013852&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm1013852%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTwo-Step%252BSynthesis%252Bof%252BNovel%25252C%252BBioactive%252BDerivatives%252Bof%252Bthe%252BUbiquitous%252BCofactor%252BNicotinamide%252BAdenine%252BDinucleotide%252B%252528NAD%252529%26aulast%3DPesnot%26aufirst%3DThomas%26date%3D2011%26date%3D2011%26date%3D2010%26date%3D25102010%26date%3D29042011%26date%3D26052011%26volume%3D54%26issue%3D10%26spage%3D3492%26epage%3D3499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Uday Kiran  Velagapudi</span>, <span class="hlFld-ContribAuthor ">Bhargav A.  Patel</span>, <span class="hlFld-ContribAuthor ">Xuwei  Shao</span>, <span class="hlFld-ContribAuthor ">Sanjai Kumar  Pathak</span>, <span class="hlFld-ContribAuthor ">Dana V.  Ferraris</span>, <span class="hlFld-ContribAuthor ">Tanaji T.  Talele</span>. </span><span class="cited-content_cbyCitation_article-title">Recent development in the discovery of PARP inhibitors as anticancer agents: a patent update (2016-2020). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2021,</strong> <em>31 </em>
                                    (7)
                                     , 609-623. <a href="https://doi.org/10.1080/13543776.2021.1886275" title="DOI URL">https://doi.org/10.1080/13543776.2021.1886275</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2021.1886275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2021.1886275%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DRecent%252Bdevelopment%252Bin%252Bthe%252Bdiscovery%252Bof%252BPARP%252Binhibitors%252Bas%252Banticancer%252Bagents%25253A%252Ba%252Bpatent%252Bupdate%252B%2525282016-2020%252529%26aulast%3DVelagapudi%26aufirst%3DUday%2BKiran%26date%3D2021%26date%3D2021%26volume%3D31%26issue%3D7%26spage%3D609%26epage%3D623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jacob O.  Spiegel</span>, <span class="hlFld-ContribAuthor ">Bennett  Van Houten</span>, <span class="hlFld-ContribAuthor ">Jacob D.  Durrant</span>. </span><span class="cited-content_cbyCitation_article-title">PARP1: Structural insights and pharmacological targets for inhibition. </span><span class="cited-content_cbyCitation_journal-name">DNA Repair</span><span> <strong>2021,</strong> <em>103 </em>, 103125. <a href="https://doi.org/10.1016/j.dnarep.2021.103125" title="DOI URL">https://doi.org/10.1016/j.dnarep.2021.103125</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.dnarep.2021.103125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.dnarep.2021.103125%26sid%3Dliteratum%253Aachs%26jtitle%3DDNA%2520Repair%26atitle%3DPARP1%25253A%252BStructural%252Binsights%252Band%252Bpharmacological%252Btargets%252Bfor%252Binhibition%26aulast%3DSpiegel%26aufirst%3DJacob%2BO.%26date%3D2021%26volume%3D103%26spage%3D103125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mingqi  Huang</span>, <span class="hlFld-ContribAuthor ">Jinghui  Ren</span>, <span class="hlFld-ContribAuthor ">Yuhong  Wang</span>, <span class="hlFld-ContribAuthor ">Xixi  Chen</span>, <span class="hlFld-ContribAuthor ">Jia  Yang</span>, <span class="hlFld-ContribAuthor ">Tu  Tang</span>, <span class="hlFld-ContribAuthor ">Zhenyong  Yang</span>, <span class="hlFld-ContribAuthor ">Xiaojing  Li</span>, <span class="hlFld-ContribAuthor ">Min  Ji</span>, <span class="hlFld-ContribAuthor ">Jin  Cai</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis and Activity Evaluation of New Phthalazinone PARP Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chemical and Pharmaceutical Bulletin</span><span> <strong>2021,</strong> <em>69 </em>
                                    (7)
                                     , 620-629. <a href="https://doi.org/10.1248/cpb.c20-01018" title="DOI URL">https://doi.org/10.1248/cpb.c20-01018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1248/cpb.c20-01018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1248%2Fcpb.c20-01018%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520and%2520Pharmaceutical%2520Bulletin%26atitle%3DDesign%25252C%252BSynthesis%252Band%252BActivity%252BEvaluation%252Bof%252BNew%252BPhthalazinone%252BPARP%252BInhibitors%26aulast%3DHuang%26aufirst%3DMingqi%26date%3D2021%26volume%3D69%26issue%3D7%26spage%3D620%26epage%3D629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Miaojia  Chen</span>, <span class="hlFld-ContribAuthor ">Honglin  Huang</span>, <span class="hlFld-ContribAuthor ">Kaiyue  Wu</span>, <span class="hlFld-ContribAuthor ">Yunfan  Liu</span>, <span class="hlFld-ContribAuthor ">Lizhi  Jiang</span>, <span class="hlFld-ContribAuthor ">Yang  Li</span>, <span class="hlFld-ContribAuthor ">Guotao  Tang</span>, <span class="hlFld-ContribAuthor ">Junmei  Peng</span>, <span class="hlFld-ContribAuthor ">Xuan  Cao</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and evaluation of 2â(4â[4âacetylpiperazineâ1âcarbonyl] phenyl)â
              1H
              âbenzo[d]imidazoleâ4âcarboxamide derivatives as potential
              PARP
              â1 inhibitors and preliminary study on structureâactivity relationship. </span><span class="cited-content_cbyCitation_journal-name">Drug Development Research</span><span> <strong>2021,</strong> <em>18 </em><a href="https://doi.org/10.1002/ddr.21843" title="DOI URL">https://doi.org/10.1002/ddr.21843</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ddr.21843&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fddr.21843%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Development%2520Research%26atitle%3DSynthesis%252Band%252Bevaluation%252Bof%252B2%2525E2%252580%252590%2525284%2525E2%252580%252590%25255B4%2525E2%252580%252590acetylpiperazine%2525E2%252580%2525901%2525E2%252580%252590carbonyl%25255D%252Bphenyl%252529%2525E2%252580%252590%252B1H%252B%2525E2%252580%252590benzo%25255Bd%25255Dimidazole%2525E2%252580%2525904%2525E2%252580%252590carboxamide%252Bderivatives%252Bas%252Bpotential%252BPARP%252B%2525E2%252580%2525901%252Binhibitors%252Band%252Bpreliminary%252Bstudy%252Bon%252Bstructure%2525E2%252580%252590activity%252Brelationship%26aulast%3DChen%26aufirst%3DMiaojia%26date%3D2021%26date%3D2021%26volume%3D18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Patricia  Korn</span>, <span class="hlFld-ContribAuthor ">Arno  Classen</span>, <span class="hlFld-ContribAuthor ">Sudarshan  Murthy</span>, <span class="hlFld-ContribAuthor ">Riccardo  Guareschi</span>, <span class="hlFld-ContribAuthor ">Mirko M.  Maksimainen</span>, <span class="hlFld-ContribAuthor ">Barbara E.  Lippok</span>, <span class="hlFld-ContribAuthor ">Albert  GaleraâPrat</span>, <span class="hlFld-ContribAuthor ">Sven T.  Sowa</span>, <span class="hlFld-ContribAuthor ">Catharina  Voigt</span>, <span class="hlFld-ContribAuthor ">Giulia  Rossetti</span>, <span class="hlFld-ContribAuthor ">Lari  LehtiÃ¶</span>, <span class="hlFld-ContribAuthor ">Carsten  Bolm</span>, <span class="hlFld-ContribAuthor ">Bernhard  LÃ¼scher</span>. </span><span class="cited-content_cbyCitation_article-title">Evaluation of 3â and 4âPhenoxybenzamides as Selective Inhibitors of the MonoâADPâRibosyltransferase PARP10. </span><span class="cited-content_cbyCitation_journal-name">ChemistryOpen</span><span> <strong>2021,</strong> <em>384 </em><a href="https://doi.org/10.1002/open.202100087" title="DOI URL">https://doi.org/10.1002/open.202100087</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/open.202100087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fopen.202100087%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistryOpen%26atitle%3DEvaluation%252Bof%252B3%2525E2%252580%252590%252Band%252B4%2525E2%252580%252590Phenoxybenzamides%252Bas%252BSelective%252BInhibitors%252Bof%252Bthe%252BMono%2525E2%252580%252590ADP%2525E2%252580%252590Ribosyltransferase%252BPARP10%26aulast%3DKorn%26aufirst%3DPatricia%26date%3D2021%26date%3D2021%26volume%3D384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maninder  Singh</span>, <span class="hlFld-ContribAuthor ">Jyotika  Rajawat</span>, <span class="hlFld-ContribAuthor ">Jitendra  Kuldeep</span>, <span class="hlFld-ContribAuthor ">Nidhi  Shukla</span>, <span class="hlFld-ContribAuthor ">Durga Prasad  Mishra</span>, <span class="hlFld-ContribAuthor ">Mohammad Imran  Siddiqi</span>. </span><span class="cited-content_cbyCitation_article-title">Integrated support vector machine and pharmacophore based virtual screening driven identification of thiophene carboxamide scaffold containing compound as potential PARP1 inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2021,</strong> <em>45 </em>, 1-14. <a href="https://doi.org/10.1080/07391102.2021.1913229" title="DOI URL">https://doi.org/10.1080/07391102.2021.1913229</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2021.1913229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2021.1913229%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DIntegrated%252Bsupport%252Bvector%252Bmachine%252Band%252Bpharmacophore%252Bbased%252Bvirtual%252Bscreening%252Bdriven%252Bidentification%252Bof%252Bthiophene%252Bcarboxamide%252Bscaffold%252Bcontaining%252Bcompound%252Bas%252Bpotential%252BPARP1%252Binhibitor%26aulast%3DSingh%26aufirst%3DManinder%26date%3D2021%26date%3D2021%26volume%3D45%26spage%3D1%26epage%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dong  Zhou</span>, <span class="hlFld-ContribAuthor ">Huaping  Chen</span>, <span class="hlFld-ContribAuthor ">Cedric  Mpoy</span>, <span class="hlFld-ContribAuthor ">Sadia  Afrin</span>, <span class="hlFld-ContribAuthor ">Buck E.  Rogers</span>, <span class="hlFld-ContribAuthor ">Joel R.  Garbow</span>, <span class="hlFld-ContribAuthor ">John A.  Katzenellenbogen</span>, <span class="hlFld-ContribAuthor ">Jinbin  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Radiosynthesis and Evaluation of Talazoparib and Its Derivatives as PARP-1-Targeting Agents. </span><span class="cited-content_cbyCitation_journal-name">Biomedicines</span><span> <strong>2021,</strong> <em>9 </em>
                                    (5)
                                     , 565. <a href="https://doi.org/10.3390/biomedicines9050565" title="DOI URL">https://doi.org/10.3390/biomedicines9050565</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/biomedicines9050565&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fbiomedicines9050565%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomedicines%26atitle%3DRadiosynthesis%252Band%252BEvaluation%252Bof%252BTalazoparib%252Band%252BIts%252BDerivatives%252Bas%252BPARP-1-Targeting%252BAgents%26aulast%3DZhou%26aufirst%3DDong%26date%3D2021%26date%3D2021%26volume%3D9%26issue%3D5%26spage%3D565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Asha  Sinha</span>, <span class="hlFld-ContribAuthor ">Sachin  Katyal</span>, <span class="hlFld-ContribAuthor ">Tiina M.  Kauppinen</span>. </span><span class="cited-content_cbyCitation_article-title">PARP-DNA trapping ability of PARP inhibitors jeopardizes astrocyte viability: Implications for CNS disease therapeutics. </span><span class="cited-content_cbyCitation_journal-name">Neuropharmacology</span><span> <strong>2021,</strong> <em>187 </em>, 108502. <a href="https://doi.org/10.1016/j.neuropharm.2021.108502" title="DOI URL">https://doi.org/10.1016/j.neuropharm.2021.108502</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.neuropharm.2021.108502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.neuropharm.2021.108502%26sid%3Dliteratum%253Aachs%26jtitle%3DNeuropharmacology%26atitle%3DPARP-DNA%252Btrapping%252Bability%252Bof%252BPARP%252Binhibitors%252Bjeopardizes%252Bastrocyte%252Bviability%25253A%252BImplications%252Bfor%252BCNS%252Bdisease%252Btherapeutics%26aulast%3DSinha%26aufirst%3DAsha%26date%3D2021%26volume%3D187%26spage%3D108502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Homood  Alharbi</span>, <span class="hlFld-ContribAuthor ">Abdualrahman Saeed  Alshehri</span>, <span class="hlFld-ContribAuthor ">Mohammad  Ahmad</span>, <span class="hlFld-ContribAuthor ">Wang Wen  Guo</span>. </span><span class="cited-content_cbyCitation_article-title">Promising anti- cervical carcinoma and inflammatory agent, Resveratrol targets poly (ADP-ribose) polymerase 1 (PARP-1) induced premature ovarian failure with a potent enzymatic modulatory activity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Reproductive Immunology</span><span> <strong>2021,</strong> <em>144 </em>, 103272. <a href="https://doi.org/10.1016/j.jri.2021.103272" title="DOI URL">https://doi.org/10.1016/j.jri.2021.103272</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jri.2021.103272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jri.2021.103272%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Reproductive%2520Immunology%26atitle%3DPromising%252Banti-%252Bcervical%252Bcarcinoma%252Band%252Binflammatory%252Bagent%25252C%252BResveratrol%252Btargets%252Bpoly%252B%252528ADP-ribose%252529%252Bpolymerase%252B1%252B%252528PARP-1%252529%252Binduced%252Bpremature%252Bovarian%252Bfailure%252Bwith%252Ba%252Bpotent%252Benzymatic%252Bmodulatory%252Bactivity%26aulast%3DAlharbi%26aufirst%3DHomood%26date%3D2021%26volume%3D144%26spage%3D103272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Garri  Manasaryan</span>, <span class="hlFld-ContribAuthor ">Dmitry  Suplatov</span>, <span class="hlFld-ContribAuthor ">Sergey  Pushkarev</span>, <span class="hlFld-ContribAuthor ">Viktor  Drobot</span>, <span class="hlFld-ContribAuthor ">Alexander  Kuimov</span>, <span class="hlFld-ContribAuthor ">Vytas  Å vedas</span>, <span class="hlFld-ContribAuthor ">Dmitry  Nilov</span>. </span><span class="cited-content_cbyCitation_article-title">Bioinformatic Analysis of the Nicotinamide Binding Site in Poly(ADP-Ribose) Polymerase Family Proteins. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (6)
                                     , 1201. <a href="https://doi.org/10.3390/cancers13061201" title="DOI URL">https://doi.org/10.3390/cancers13061201</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13061201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13061201%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DBioinformatic%252BAnalysis%252Bof%252Bthe%252BNicotinamide%252BBinding%252BSite%252Bin%252BPoly%252528ADP-Ribose%252529%252BPolymerase%252BFamily%252BProteins%26aulast%3DManasaryan%26aufirst%3DGarri%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D6%26spage%3D1201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kongkona  Gogoi</span>, <span class="hlFld-ContribAuthor ">Bidisha R.  Bora</span>, <span class="hlFld-ContribAuthor ">Geetika  Borah</span>, <span class="hlFld-ContribAuthor ">Bipul  Sarma</span>, <span class="hlFld-ContribAuthor ">Sanjib  Gogoi</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of quaternary carbon-centered indolo[1,2-
              a
              ]quinazolinones and indazolo[1,2-
              a
              ]indazolones
              via
              CâH functionalization. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2021,</strong> <em>57 </em>
                                    (11)
                                     , 1388-1391. <a href="https://doi.org/10.1039/D0CC07419E" title="DOI URL">https://doi.org/10.1039/D0CC07419E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0CC07419E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0CC07419E%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DSynthesis%252Bof%252Bquaternary%252Bcarbon-centered%252Bindolo%25255B1%25252C2-%252Ba%252B%25255Dquinazolinones%252Band%252Bindazolo%25255B1%25252C2-%252Ba%252B%25255Dindazolones%252Bvia%252BC%2525E2%252580%252593H%252Bfunctionalization%26aulast%3DGogoi%26aufirst%3DKongkona%26date%3D2021%26date%3D2021%26volume%3D57%26issue%3D11%26spage%3D1388%26epage%3D1391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Samridhi  Lal</span>, <span class="hlFld-ContribAuthor ">Timothy J.  Snape</span>. </span><span class="cited-content_cbyCitation_article-title">A therapeutic update on PARP inhibitors: implications in the treatment of glioma. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2021,</strong> <em>26 </em>
                                    (2)
                                     , 532-541. <a href="https://doi.org/10.1016/j.drudis.2020.10.029" title="DOI URL">https://doi.org/10.1016/j.drudis.2020.10.029</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2020.10.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2020.10.029%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DA%252Btherapeutic%252Bupdate%252Bon%252BPARP%252Binhibitors%25253A%252Bimplications%252Bin%252Bthe%252Btreatment%252Bof%252Bglioma%26aulast%3DLal%26aufirst%3DSamridhi%26date%3D2021%26volume%3D26%26issue%3D2%26spage%3D532%26epage%3D541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nour E. A.  Abd El-sattar</span>, <span class="hlFld-ContribAuthor ">Eman H. K.  Badawy</span>, <span class="hlFld-ContribAuthor ">Eman Z.  Elrazaz</span>, <span class="hlFld-ContribAuthor ">Nasser S. M.  Ismail</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of pyrano[2,3-
              d
              ]pyrimidine-2,4-dione derivatives as novel PARP-1 inhibitors: design, synthesis and antitumor activity. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2021,</strong> <em>11 </em>
                                    (8)
                                     , 4454-4464. <a href="https://doi.org/10.1039/D0RA10321G" title="DOI URL">https://doi.org/10.1039/D0RA10321G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0RA10321G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0RA10321G%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DDiscovery%252Bof%252Bpyrano%25255B2%25252C3-%252Bd%252B%25255Dpyrimidine-2%25252C4-dione%252Bderivatives%252Bas%252Bnovel%252BPARP-1%252Binhibitors%25253A%252Bdesign%25252C%252Bsynthesis%252Band%252Bantitumor%252Bactivity%26aulast%3DAbd%2BEl-sattar%26aufirst%3DNour%2BE.%2BA.%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D8%26spage%3D4454%26epage%3D4464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hao-Yue  Xiang</span>, <span class="hlFld-ContribAuthor ">Jian-Yang  Chen</span>, <span class="hlFld-ContribAuthor ">Xia-Juan  Huan</span>, <span class="hlFld-ContribAuthor ">Yi  Chen</span>, <span class="hlFld-ContribAuthor ">Zhao-bing  Gao</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Ze-Hong  Miao</span>, <span class="hlFld-ContribAuthor ">Chun-Hao  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of 2-substituted pyrrolo[1,2-b]pyridazine derivatives as new PARP-1 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>31 </em>, 127710. <a href="https://doi.org/10.1016/j.bmcl.2020.127710" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127710</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127710%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DIdentification%252Bof%252B2-substituted%252Bpyrrolo%25255B1%25252C2-b%25255Dpyridazine%252Bderivatives%252Bas%252Bnew%252BPARP-1%252Binhibitors%26aulast%3DXiang%26aufirst%3DHao-Yue%26date%3D2021%26volume%3D31%26spage%3D127710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhang-Xu  He</span>, <span class="hlFld-ContribAuthor ">Yun-Peng  Gong</span>, <span class="hlFld-ContribAuthor ">Xin  Zhang</span>, <span class="hlFld-ContribAuthor ">Li-Ying  Ma</span>, <span class="hlFld-ContribAuthor ">Wen  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Pyridazine as a privileged structure: An updated review on anticancer activity of pyridazine containing bioactive molecules. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>209 </em>, 112946. <a href="https://doi.org/10.1016/j.ejmech.2020.112946" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112946</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112946&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112946%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPyridazine%252Bas%252Ba%252Bprivileged%252Bstructure%25253A%252BAn%252Bupdated%252Breview%252Bon%252Banticancer%252Bactivity%252Bof%252Bpyridazine%252Bcontaining%252Bbioactive%252Bmolecules%26aulast%3DHe%26aufirst%3DZhang-Xu%26date%3D2021%26volume%3D209%26spage%3D112946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Albert A.  Antolin</span>, <span class="hlFld-ContribAuthor ">Malaka  Ameratunga</span>, <span class="hlFld-ContribAuthor ">Udai  Banerji</span>, <span class="hlFld-ContribAuthor ">Paul A.  Clarke</span>, <span class="hlFld-ContribAuthor ">Paul  Workman</span>, <span class="hlFld-ContribAuthor ">Bissan  Al-Lazikani</span>. </span><span class="cited-content_cbyCitation_article-title">The kinase polypharmacology landscape of clinical PARP inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2020,</strong> <em>10 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-020-59074-4" title="DOI URL">https://doi.org/10.1038/s41598-020-59074-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-020-59074-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-020-59074-4%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DThe%252Bkinase%252Bpolypharmacology%252Blandscape%252Bof%252Bclinical%252BPARP%252Binhibitors%26aulast%3DAntolin%26aufirst%3DAlbert%2BA.%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yexiaoxu  wang</span>, <span class="hlFld-ContribAuthor ">Yi  Liu</span>, <span class="hlFld-ContribAuthor ">Qin  Yang</span>, <span class="hlFld-ContribAuthor ">Xuechun  Mao</span>, <span class="hlFld-ContribAuthor ">Wei-Ming  Chai</span>, <span class="hlFld-ContribAuthor ">Yiyuan  Peng</span>. </span><span class="cited-content_cbyCitation_article-title">Study on the interaction between 4-(1H-indol-3-yl)-2-(p-tolyl)quinazoline-3-oxide and human serum albumin. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2020,</strong> <em>28 </em>
                                    (21)
                                     , 115720. <a href="https://doi.org/10.1016/j.bmc.2020.115720" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115720</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115720&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115720%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DStudy%252Bon%252Bthe%252Binteraction%252Bbetween%252B4-%2525281H-indol-3-yl%252529-2-%252528p-tolyl%252529quinazoline-3-oxide%252Band%252Bhuman%252Bserum%252Balbumin%26aulast%3Dwang%26aufirst%3DYexiaoxu%26date%3D2020%26volume%3D28%26issue%3D21%26spage%3D115720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yue  Zhao</span>, <span class="hlFld-ContribAuthor ">Liu-Xia  Zhang</span>, <span class="hlFld-ContribAuthor ">Ting  Jiang</span>, <span class="hlFld-ContribAuthor ">Jing  Long</span>, <span class="hlFld-ContribAuthor ">Zhong-Ye  Ma</span>, <span class="hlFld-ContribAuthor ">Ai-Ping  Lu</span>, <span class="hlFld-ContribAuthor ">Yan  Cheng</span>, <span class="hlFld-ContribAuthor ">Dong-Sheng  Cao</span>. </span><span class="cited-content_cbyCitation_article-title">The ups and downs of Poly(ADP-ribose) Polymerase-1 inhibitors in cancer therapyâCurrent progress and future direction. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>203 </em>, 112570. <a href="https://doi.org/10.1016/j.ejmech.2020.112570" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112570</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112570&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112570%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252Bups%252Band%252Bdowns%252Bof%252BPoly%252528ADP-ribose%252529%252BPolymerase-1%252Binhibitors%252Bin%252Bcancer%252Btherapy%2525E2%252580%252593Current%252Bprogress%252Band%252Bfuture%252Bdirection%26aulast%3DZhao%26aufirst%3DYue%26date%3D2020%26volume%3D203%26spage%3D112570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicola J.  Curtin</span>, <span class="hlFld-ContribAuthor ">Csaba  Szabo</span>. </span><span class="cited-content_cbyCitation_article-title">Poly(ADP-ribose) polymerase inhibition: past, present and future. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Drug Discovery</span><span> <strong>2020,</strong> <em>19 </em>
                                    (10)
                                     , 711-736. <a href="https://doi.org/10.1038/s41573-020-0076-6" title="DOI URL">https://doi.org/10.1038/s41573-020-0076-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41573-020-0076-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41573-020-0076-6%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Drug%2520Discovery%26atitle%3DPoly%252528ADP-ribose%252529%252Bpolymerase%252Binhibition%25253A%252Bpast%25252C%252Bpresent%252Band%252Bfuture%26aulast%3DCurtin%26aufirst%3DNicola%2BJ.%26date%3D2020%26date%3D2020%26volume%3D19%26issue%3D10%26spage%3D711%26epage%3D736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xuwei  Shao</span>, <span class="hlFld-ContribAuthor ">Steven  Pak</span>, <span class="hlFld-ContribAuthor ">Uday Kiran  Velagapudi</span>, <span class="hlFld-ContribAuthor ">Shruthi  Gobbooru</span>, <span class="hlFld-ContribAuthor ">Sai Shilpa  Kommaraju</span>, <span class="hlFld-ContribAuthor ">Woon-Kai  Low</span>, <span class="hlFld-ContribAuthor ">Gopal  Subramaniam</span>, <span class="hlFld-ContribAuthor ">Sanjai Kumar  Pathak</span>, <span class="hlFld-ContribAuthor ">Tanaji T.  Talele</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of 2,3-dihydrobenzo[b][1,4]dioxine-5-carboxamide and 3-oxo-3,4-dihydrobenzo[b][1,4]oxazine-8-carboxamide derivatives as PARP1 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>102 </em>, 104075. <a href="https://doi.org/10.1016/j.bioorg.2020.104075" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.104075</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.104075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.104075%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DSynthesis%252Bof%252B2%25252C3-dihydrobenzo%25255Bb%25255D%25255B1%25252C4%25255Ddioxine-5-carboxamide%252Band%252B3-oxo-3%25252C4-dihydrobenzo%25255Bb%25255D%25255B1%25252C4%25255Doxazine-8-carboxamide%252Bderivatives%252Bas%252BPARP1%252Binhibitors%26aulast%3DShao%26aufirst%3DXuwei%26date%3D2020%26volume%3D102%26spage%3D104075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Asma  Siavashpour</span>, <span class="hlFld-ContribAuthor ">Bahman  Khalvati</span>, <span class="hlFld-ContribAuthor ">Negar  Azarpira</span>, <span class="hlFld-ContribAuthor ">Hamidreza  Mohammadi</span>, <span class="hlFld-ContribAuthor ">Hossein  Niknahad</span>, <span class="hlFld-ContribAuthor ">Reza  Heidari</span>. </span><span class="cited-content_cbyCitation_article-title">Poly (ADP-Ribose) polymerase-1 (PARP-1) overactivity plays a pathogenic role in bile acids-induced nephrotoxicity in cholestatic rats. </span><span class="cited-content_cbyCitation_journal-name">Toxicology Letters</span><span> <strong>2020,</strong> <em>330 </em>, 144-158. <a href="https://doi.org/10.1016/j.toxlet.2020.05.012" title="DOI URL">https://doi.org/10.1016/j.toxlet.2020.05.012</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.toxlet.2020.05.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.toxlet.2020.05.012%26sid%3Dliteratum%253Aachs%26jtitle%3DToxicology%2520Letters%26atitle%3DPoly%252B%252528ADP-Ribose%252529%252Bpolymerase-1%252B%252528PARP-1%252529%252Boveractivity%252Bplays%252Ba%252Bpathogenic%252Brole%252Bin%252Bbile%252Bacids-induced%252Bnephrotoxicity%252Bin%252Bcholestatic%252Brats%26aulast%3DSiavashpour%26aufirst%3DAsma%26date%3D2020%26volume%3D330%26spage%3D144%26epage%3D158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel  Harrision</span>, <span class="hlFld-ContribAuthor ">Polly  Gravells</span>, <span class="hlFld-ContribAuthor ">Ruth  Thompson</span>, <span class="hlFld-ContribAuthor ">Helen E.  Bryant</span>. </span><span class="cited-content_cbyCitation_article-title">Poly(ADP-Ribose) Glycohydrolase (PARG) vs. Poly(ADP-Ribose) Polymerase (PARP) â Function in Genome Maintenance and Relevance of Inhibitors for Anti-cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Molecular Biosciences</span><span> <strong>2020,</strong> <em>7 </em><a href="https://doi.org/10.3389/fmolb.2020.00191" title="DOI URL">https://doi.org/10.3389/fmolb.2020.00191</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fmolb.2020.00191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffmolb.2020.00191%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Molecular%2520Biosciences%26atitle%3DPoly%252528ADP-Ribose%252529%252BGlycohydrolase%252B%252528PARG%252529%252Bvs.%252BPoly%252528ADP-Ribose%252529%252BPolymerase%252B%252528PARP%252529%252B%2525E2%252580%252593%252BFunction%252Bin%252BGenome%252BMaintenance%252Band%252BRelevance%252Bof%252BInhibitors%252Bfor%252BAnti-cancer%252BTherapy%26aulast%3DHarrision%26aufirst%3DDaniel%26date%3D2020%26date%3D2020%26volume%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tania  Di Raimo</span>, <span class="hlFld-ContribAuthor ">Francesco  Angelini</span>. </span><span class="cited-content_cbyCitation_article-title">Enhance PARPi Application beyond BRCA-Mutant Breast Cancer (BC): Facts Are Facts. </span><span class="cited-content_cbyCitation_journal-name">Journal of Clinical Medicine</span><span> <strong>2020,</strong> <em>9 </em>
                                    (8)
                                     , 2377. <a href="https://doi.org/10.3390/jcm9082377" title="DOI URL">https://doi.org/10.3390/jcm9082377</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/jcm9082377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fjcm9082377%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Clinical%2520Medicine%26atitle%3DEnhance%252BPARPi%252BApplication%252Bbeyond%252BBRCA-Mutant%252BBreast%252BCancer%252B%252528BC%252529%25253A%252BFacts%252BAre%252BFacts%26aulast%3DDi%2BRaimo%26aufirst%3DTania%26date%3D2020%26date%3D2020%26volume%3D9%26issue%3D8%26spage%3D2377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alexandra L.  Zakharenko</span>, <span class="hlFld-ContribAuthor ">Mikhail S.  Drenichev</span>, <span class="hlFld-ContribAuthor ">Nadezhda S.  Dyrkheeva</span>, <span class="hlFld-ContribAuthor ">Georgy A.  Ivanov</span>, <span class="hlFld-ContribAuthor ">Vladimir E.  Oslovsky</span>, <span class="hlFld-ContribAuthor ">Ekaterina S.  Ilina</span>, <span class="hlFld-ContribAuthor ">Irina A.  Chernyshova</span>, <span class="hlFld-ContribAuthor ">Olga I.  Lavrik</span>, <span class="hlFld-ContribAuthor ">Sergey N.  Mikhailov</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibition of Tyrosyl-DNA Phosphodiesterase 1 by Lipophilic Pyrimidine Nucleosides. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (16)
                                     , 3694. <a href="https://doi.org/10.3390/molecules25163694" title="DOI URL">https://doi.org/10.3390/molecules25163694</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25163694&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25163694%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DInhibition%252Bof%252BTyrosyl-DNA%252BPhosphodiesterase%252B1%252Bby%252BLipophilic%252BPyrimidine%252BNucleosides%26aulast%3DZakharenko%26aufirst%3DAlexandra%2BL.%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D16%26spage%3D3694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thomas C.  Wilson</span>, <span class="hlFld-ContribAuthor ">Nagavarakishore  Pillarsetty</span>, <span class="hlFld-ContribAuthor ">Thomas  Reiner</span>. </span><span class="cited-content_cbyCitation_article-title">A one-pot radiosynthesis of [
              18
              F]PARPi. </span><span class="cited-content_cbyCitation_journal-name">Journal of Labelled Compounds and Radiopharmaceuticals</span><span> <strong>2020,</strong> <em>63 </em>
                                    (9)
                                     , 419-425. <a href="https://doi.org/10.1002/jlcr.3847" title="DOI URL">https://doi.org/10.1002/jlcr.3847</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jlcr.3847&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjlcr.3847%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Labelled%2520Compounds%2520and%2520Radiopharmaceuticals%26atitle%3DA%252Bone-pot%252Bradiosynthesis%252Bof%252B%25255B%252B18%252BF%25255DPARPi%26aulast%3DWilson%26aufirst%3DThomas%2BC.%26date%3D2020%26date%3D2020%26volume%3D63%26issue%3D9%26spage%3D419%26epage%3D425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicolas  Malaquin</span>, <span class="hlFld-ContribAuthor ">Arthur  Vancayseele</span>, <span class="hlFld-ContribAuthor ">Sophie  Gilbert</span>, <span class="hlFld-ContribAuthor ">Laureen  Antenor-Habazac</span>, <span class="hlFld-ContribAuthor ">Marc-Alexandre  Olivier</span>, <span class="hlFld-ContribAuthor ">Zakia  Ait Ali Brahem</span>, <span class="hlFld-ContribAuthor ">Fred  Saad</span>, <span class="hlFld-ContribAuthor ">Guila  Delouya</span>, <span class="hlFld-ContribAuthor ">Francis  Rodier</span>. </span><span class="cited-content_cbyCitation_article-title">DNA Damage- But Not Enzalutamide-Induced Senescence in Prostate Cancer Promotes Senolytic Bcl-xL Inhibitor Sensitivity. </span><span class="cited-content_cbyCitation_journal-name">Cells</span><span> <strong>2020,</strong> <em>9 </em>
                                    (7)
                                     , 1593. <a href="https://doi.org/10.3390/cells9071593" title="DOI URL">https://doi.org/10.3390/cells9071593</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cells9071593&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcells9071593%26sid%3Dliteratum%253Aachs%26jtitle%3DCells%26atitle%3DDNA%252BDamage-%252BBut%252BNot%252BEnzalutamide-Induced%252BSenescence%252Bin%252BProstate%252BCancer%252BPromotes%252BSenolytic%252BBcl-xL%252BInhibitor%252BSensitivity%26aulast%3DMalaquin%26aufirst%3DNicolas%26date%3D2020%26date%3D2020%26volume%3D9%26issue%3D7%26spage%3D1593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kaviarasan  Lakshmanan</span>, <span class="hlFld-ContribAuthor ">Gowramma  Byran</span>, <span class="hlFld-ContribAuthor ">Manal  Mohammed</span>. </span><span class="cited-content_cbyCitation_article-title">A Brief Review on Dual Target of PARP1 and STAT3 for Cancer Therapy: A Novel Perception. </span><span class="cited-content_cbyCitation_journal-name">Current Enzyme Inhibition</span><span> <strong>2020,</strong> <em>16 </em>
                                    (2)
                                     , 115-134. <a href="https://doi.org/10.2174/1573408016666200316114209" title="DOI URL">https://doi.org/10.2174/1573408016666200316114209</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1573408016666200316114209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1573408016666200316114209%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Enzyme%2520Inhibition%26atitle%3DA%252BBrief%252BReview%252Bon%252BDual%252BTarget%252Bof%252BPARP1%252Band%252BSTAT3%252Bfor%252BCancer%252BTherapy%25253A%252BA%252BNovel%252BPerception%26aulast%3DLakshmanan%26aufirst%3DKaviarasan%26date%3D2020%26volume%3D16%26issue%3D2%26spage%3D115%26epage%3D134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maria Giovanna  Scioli</span>, <span class="hlFld-ContribAuthor ">Gabriele  Storti</span>, <span class="hlFld-ContribAuthor ">Federico  DâAmico</span>, <span class="hlFld-ContribAuthor ">Roger  RodrÃ­guez GuzmÃ¡n</span>, <span class="hlFld-ContribAuthor ">Federica  Centofanti</span>, <span class="hlFld-ContribAuthor ">Elena  Doldo</span>, <span class="hlFld-ContribAuthor ">Ela MarÃ­a  CÃ©spedes Miranda</span>, <span class="hlFld-ContribAuthor ">Augusto  Orlandi</span>. </span><span class="cited-content_cbyCitation_article-title">Oxidative Stress and New Pathogenetic Mechanisms in Endothelial Dysfunction: Potential Diagnostic Biomarkers and Therapeutic Targets. </span><span class="cited-content_cbyCitation_journal-name">Journal of Clinical Medicine</span><span> <strong>2020,</strong> <em>9 </em>
                                    (6)
                                     , 1995. <a href="https://doi.org/10.3390/jcm9061995" title="DOI URL">https://doi.org/10.3390/jcm9061995</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/jcm9061995&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fjcm9061995%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Clinical%2520Medicine%26atitle%3DOxidative%252BStress%252Band%252BNew%252BPathogenetic%252BMechanisms%252Bin%252BEndothelial%252BDysfunction%25253A%252BPotential%252BDiagnostic%252BBiomarkers%252Band%252BTherapeutic%252BTargets%26aulast%3DScioli%26aufirst%3DMaria%2BGiovanna%26date%3D2020%26date%3D2020%26volume%3D9%26issue%3D6%26spage%3D1995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shanshan  Lin</span>, <span class="hlFld-ContribAuthor ">LingYu  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiao  Zhang</span>, <span class="hlFld-ContribAuthor ">Zelei  Yu</span>, <span class="hlFld-ContribAuthor ">Xiuwang  Huang</span>, <span class="hlFld-ContribAuthor ">Jianhua  Xu</span>, <span class="hlFld-ContribAuthor ">Yang  Liu</span>, <span class="hlFld-ContribAuthor ">Limin  Chen</span>, <span class="hlFld-ContribAuthor ">Lixian  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of novel dual target inhibitors of PARP and HSP90 and their antitumor activities. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2020,</strong> <em>28 </em>
                                    (9)
                                     , 115434. <a href="https://doi.org/10.1016/j.bmc.2020.115434" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115434</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115434%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Bof%252Bnovel%252Bdual%252Btarget%252Binhibitors%252Bof%252BPARP%252Band%252BHSP90%252Band%252Btheir%252Bantitumor%252Bactivities%26aulast%3DLin%26aufirst%3DShanshan%26date%3D2020%26volume%3D28%26issue%3D9%26spage%3D115434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dea  Slade</span>. </span><span class="cited-content_cbyCitation_article-title">PARP and PARG inhibitors in cancer treatment. </span><span class="cited-content_cbyCitation_journal-name">Genes & Development</span><span> <strong>2020,</strong> <em>34 </em>
                                    (5-6)
                                     , 360-394. <a href="https://doi.org/10.1101/gad.334516.119" title="DOI URL">https://doi.org/10.1101/gad.334516.119</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1101/gad.334516.119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1101%2Fgad.334516.119%26sid%3Dliteratum%253Aachs%26jtitle%3DGenes%2520%2526%2520Development%26atitle%3DPARP%252Band%252BPARG%252Binhibitors%252Bin%252Bcancer%252Btreatment%26aulast%3DSlade%26aufirst%3DDea%26date%3D2020%26date%3D2020%26volume%3D34%26issue%3D5-6%26spage%3D360%26epage%3D394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dmitry  Nilov</span>, <span class="hlFld-ContribAuthor ">Natalya  Maluchenko</span>, <span class="hlFld-ContribAuthor ">Tatyana  Kurgina</span>, <span class="hlFld-ContribAuthor ">Sergey  Pushkarev</span>, <span class="hlFld-ContribAuthor ">Alexandra  Lys</span>, <span class="hlFld-ContribAuthor ">Mikhail  Kutuzov</span>, <span class="hlFld-ContribAuthor ">Nadezhda  Gerasimova</span>, <span class="hlFld-ContribAuthor ">Alexey  Feofanov</span>, <span class="hlFld-ContribAuthor ">Vytas  Å vedas</span>, <span class="hlFld-ContribAuthor ">Olga  Lavrik</span>, <span class="hlFld-ContribAuthor ">Vasily M.  Studitsky</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular Mechanisms of PARP-1 Inhibitor 7-Methylguanine. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (6)
                                     , 2159. <a href="https://doi.org/10.3390/ijms21062159" title="DOI URL">https://doi.org/10.3390/ijms21062159</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21062159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21062159%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DMolecular%252BMechanisms%252Bof%252BPARP-1%252BInhibitor%252B7-Methylguanine%26aulast%3DNilov%26aufirst%3DDmitry%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D6%26spage%3D2159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">D. K.  Nilov</span>, <span class="hlFld-ContribAuthor ">S. V.  Pushkarev</span>, <span class="hlFld-ContribAuthor ">I. V.  Gushchina</span>, <span class="hlFld-ContribAuthor ">G. A.  Manasaryan</span>, <span class="hlFld-ContribAuthor ">K. I.  Kirsanov</span>, <span class="hlFld-ContribAuthor ">V. K.  Å vedas</span>. </span><span class="cited-content_cbyCitation_article-title">Modeling of the EnzymeâSubstrate Complexes of Human Poly(ADP-Ribose) Polymerase 1. </span><span class="cited-content_cbyCitation_journal-name">Biochemistry (Moscow)</span><span> <strong>2020,</strong> <em>85 </em>
                                    (1)
                                     , 99-107. <a href="https://doi.org/10.1134/S0006297920010095" title="DOI URL">https://doi.org/10.1134/S0006297920010095</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1134/S0006297920010095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1134%2FS0006297920010095%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemistry%2520%2528Moscow%2529%26atitle%3DModeling%252Bof%252Bthe%252BEnzyme%2525E2%252580%252594Substrate%252BComplexes%252Bof%252BHuman%252BPoly%252528ADP-Ribose%252529%252BPolymerase%252B1%26aulast%3DNilov%26aufirst%3DD.%2BK.%26date%3D2020%26date%3D2020%26volume%3D85%26issue%3D1%26spage%3D99%26epage%3D107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuliya V.  Sherstyuk</span>, <span class="hlFld-ContribAuthor ">Nikita V.  Ivanisenko</span>, <span class="hlFld-ContribAuthor ">Alexandra L.  Zakharenko</span>, <span class="hlFld-ContribAuthor ">Maria V.  Sukhanova</span>, <span class="hlFld-ContribAuthor ">Roman Y.  Peshkov</span>, <span class="hlFld-ContribAuthor ">Ilia V.  Eltsov</span>, <span class="hlFld-ContribAuthor ">Mikhail M.  Kutuzov</span>, <span class="hlFld-ContribAuthor ">Tatiana A.  Kurgina</span>, <span class="hlFld-ContribAuthor ">Ekaterina A.  Belousova</span>, <span class="hlFld-ContribAuthor ">Vladimir A.  Ivanisenko</span>, <span class="hlFld-ContribAuthor ">Olga I.  Lavrik</span>, <span class="hlFld-ContribAuthor ">Vladimir N.  Silnikov</span>, <span class="hlFld-ContribAuthor ">Tatyana V.  Abramova</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis and Molecular Modeling Study of Conjugates of ADP and Morpholino Nucleosides as A Novel Class of Inhibitors of PARP-1, PARP-2 and PARP-3. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (1)
                                     , 214. <a href="https://doi.org/10.3390/ijms21010214" title="DOI URL">https://doi.org/10.3390/ijms21010214</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21010214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21010214%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DDesign%25252C%252BSynthesis%252Band%252BMolecular%252BModeling%252BStudy%252Bof%252BConjugates%252Bof%252BADP%252Band%252BMorpholino%252BNucleosides%252Bas%252BA%252BNovel%252BClass%252Bof%252BInhibitors%252Bof%252BPARP-1%25252C%252BPARP-2%252Band%252BPARP-3%26aulast%3DSherstyuk%26aufirst%3DYuliya%2BV.%26date%3D2020%26date%3D2019%26volume%3D21%26issue%3D1%26spage%3D214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhimin  Zhang</span>, <span class="hlFld-ContribAuthor ">Xinyue  Chang</span>, <span class="hlFld-ContribAuthor ">Chixiao  Zhang</span>, <span class="hlFld-ContribAuthor ">Shenxin  Zeng</span>, <span class="hlFld-ContribAuthor ">Meihao  Liang</span>, <span class="hlFld-ContribAuthor ">Zhen  Ma</span>, <span class="hlFld-ContribAuthor ">Zunyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Wenhai  Huang</span>, <span class="hlFld-ContribAuthor ">Zhengrong  Shen</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1). </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2020,</strong> <em>35 </em>
                                    (1)
                                     , 1606-1615. <a href="https://doi.org/10.1080/14756366.2020.1804382" title="DOI URL">https://doi.org/10.1080/14756366.2020.1804382</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14756366.2020.1804382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14756366.2020.1804382%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252Bprobe-quality%252Bdegraders%252Bfor%252BPoly%252528ADP-ribose%252529%252Bpolymerase-1%252B%252528PARP-1%252529%26aulast%3DZhang%26aufirst%3DZhimin%26date%3D2020%26date%3D2020%26volume%3D35%26issue%3D1%26spage%3D1606%26epage%3D1615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuai  Wang</span>, <span class="hlFld-ContribAuthor ">Lei  Han</span>, <span class="hlFld-ContribAuthor ">Jungsoo  Han</span>, <span class="hlFld-ContribAuthor ">Peng  Li</span>, <span class="hlFld-ContribAuthor ">Qing  Ding</span>, <span class="hlFld-ContribAuthor ">Qing-Jun  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhi-Ping  Liu</span>, <span class="hlFld-ContribAuthor ">Chuo  Chen</span>, <span class="hlFld-ContribAuthor ">Yonghao  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">Uncoupling of PARP1 trapping and inhibition using selective PARP1 degradation. </span><span class="cited-content_cbyCitation_journal-name">Nature Chemical Biology</span><span> <strong>2019,</strong> <em>15 </em>
                                    (12)
                                     , 1223-1231. <a href="https://doi.org/10.1038/s41589-019-0379-2" title="DOI URL">https://doi.org/10.1038/s41589-019-0379-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41589-019-0379-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41589-019-0379-2%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Chemical%2520Biology%26atitle%3DUncoupling%252Bof%252BPARP1%252Btrapping%252Band%252Binhibition%252Busing%252Bselective%252BPARP1%252Bdegradation%26aulast%3DWang%26aufirst%3DShuai%26date%3D2019%26date%3D2019%26volume%3D15%26issue%3D12%26spage%3D1223%26epage%3D1231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bernard T.  Golding</span>. </span><span class="cited-content_cbyCitation_article-title">The Story of Rucaparib (Rubraca). </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 201-223. <a href="https://doi.org/10.1002/9783527814695.ch8" title="DOI URL">https://doi.org/10.1002/9783527814695.ch8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9783527814695.ch8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9783527814695.ch8%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BStory%252Bof%252BRucaparib%252B%252528Rubraca%252529%26aulast%3DGolding%26aufirst%3DBernard%2BT.%26date%3D2019%26date%3D2019%26spage%3D201%26epage%3D223%26pub%3DWiley%26atitle%3DSuccessful%252BDrug%252BDiscovery%26aulast%3DFischer%26aufirst%3DJ%25C3%25A1nos%26date%3D2019%26date%3D2019%26volume%3D242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yi  Zhong</span>, <span class="hlFld-ContribAuthor ">Ying  Meng</span>, <span class="hlFld-ContribAuthor ">Xi  Xu</span>, <span class="hlFld-ContribAuthor ">Lulu  Zhao</span>, <span class="hlFld-ContribAuthor ">Zhiyu  Li</span>, <span class="hlFld-ContribAuthor ">Qidong  You</span>, <span class="hlFld-ContribAuthor ">Jinlei  Bian</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and evaluation of phthalazinone thiohydantoin-based derivative as potent PARP-1 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2019,</strong> <em>91 </em>, 103181. <a href="https://doi.org/10.1016/j.bioorg.2019.103181" title="DOI URL">https://doi.org/10.1016/j.bioorg.2019.103181</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2019.103181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2019.103181%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bevaluation%252Bof%252Bphthalazinone%252Bthiohydantoin-based%252Bderivative%252Bas%252Bpotent%252BPARP-1%252Binhibitors%26aulast%3DZhong%26aufirst%3DYi%26date%3D2019%26volume%3D91%26spage%3D103181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sergey N.  Mikhailov</span>, <span class="hlFld-ContribAuthor ">Mikhail S.  Drenichev</span>, <span class="hlFld-ContribAuthor ">Vladimir E.  Oslovsky</span>, <span class="hlFld-ContribAuthor ">Irina V.  Kulikova</span>, <span class="hlFld-ContribAuthor ">Piet  Herdewijn</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Poly(ADPâribose) Monomer Containing 2â²â
              O
              âÎ±â
              D
              âRibofuranosyl Adenosine. </span><span class="cited-content_cbyCitation_journal-name">Current Protocols in Nucleic Acid Chemistry</span><span> <strong>2019,</strong> <em>78 </em>
                                    (1)
                                     <a href="https://doi.org/10.1002/cpnc.92" title="DOI URL">https://doi.org/10.1002/cpnc.92</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cpnc.92&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcpnc.92%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Protocols%2520in%2520Nucleic%2520Acid%2520Chemistry%26atitle%3DSynthesis%252Bof%252BPoly%252528ADP%2525E2%252580%252590ribose%252529%252BMonomer%252BContaining%252B2%2525E2%252580%2525B2%2525E2%252580%252590%252BO%252B%2525E2%252580%252590%2525CE%2525B1%2525E2%252580%252590%252BD%252B%2525E2%252580%252590Ribofuranosyl%252BAdenosine%26aulast%3DMikhailov%26aufirst%3DSergey%2BN.%26date%3D2019%26date%3D2019%26volume%3D78%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haiying  Lu</span>, <span class="hlFld-ContribAuthor ">Lan  Bai</span>, <span class="hlFld-ContribAuthor ">Yanping  Zhou</span>, <span class="hlFld-ContribAuthor ">Yongping  Lu</span>, <span class="hlFld-ContribAuthor ">Zhongliang  Jiang</span>, <span class="hlFld-ContribAuthor ">Jianyou  Shi</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Study of Dual HDAC/PARP Inhibitor for the Treatment of Tumor. </span><span class="cited-content_cbyCitation_journal-name">Current Topics in Medicinal Chemistry</span><span> <strong>2019,</strong> <em>19 </em>
                                    (12)
                                     , 1041-1050. <a href="https://doi.org/10.2174/1568026619666190603092407" title="DOI URL">https://doi.org/10.2174/1568026619666190603092407</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1568026619666190603092407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1568026619666190603092407%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Topics%2520in%2520Medicinal%2520Chemistry%26atitle%3DRecent%252BStudy%252Bof%252BDual%252BHDAC%25252FPARP%252BInhibitor%252Bfor%252Bthe%252BTreatment%252Bof%252BTumor%26aulast%3DLu%26aufirst%3DHaiying%26date%3D2019%26volume%3D19%26issue%3D12%26spage%3D1041%26epage%3D1050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ghada F.  Elmasry</span>, <span class="hlFld-ContribAuthor ">Enayat E.  Aly</span>, <span class="hlFld-ContribAuthor ">Fadi M.  Awadallah</span>, <span class="hlFld-ContribAuthor ">Samir M.  El-Moghazy</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of novel PARP-1 inhibitors based on pyridopyridazinone scaffold. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2019,</strong> <em>87 </em>, 655-666. <a href="https://doi.org/10.1016/j.bioorg.2019.03.068" title="DOI URL">https://doi.org/10.1016/j.bioorg.2019.03.068</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2019.03.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2019.03.068%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bnovel%252BPARP-1%252Binhibitors%252Bbased%252Bon%252Bpyridopyridazinone%252Bscaffold%26aulast%3DElmasry%26aufirst%3DGhada%2BF.%26date%3D2019%26volume%3D87%26spage%3D655%26epage%3D666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chandan  Kumar</span>, <span class="hlFld-ContribAuthor ">Lakshmi  P.T.V.</span>, <span class="hlFld-ContribAuthor ">Annamalai  Arunachalam</span>. </span><span class="cited-content_cbyCitation_article-title">Structure based pharmacophore study to identify possible natural selective PARP-1 trapper as anti-cancer agent. </span><span class="cited-content_cbyCitation_journal-name">Computational Biology and Chemistry</span><span> <strong>2019,</strong> <em>80 </em>, 314-323. <a href="https://doi.org/10.1016/j.compbiolchem.2019.04.018" title="DOI URL">https://doi.org/10.1016/j.compbiolchem.2019.04.018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.compbiolchem.2019.04.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.compbiolchem.2019.04.018%26sid%3Dliteratum%253Aachs%26jtitle%3DComputational%2520Biology%2520and%2520Chemistry%26atitle%3DStructure%252Bbased%252Bpharmacophore%252Bstudy%252Bto%252Bidentify%252Bpossible%252Bnatural%252Bselective%252BPARP-1%252Btrapper%252Bas%252Banti-cancer%252Bagent%26aulast%3DKumar%26aufirst%3DChandan%26date%3D2019%26volume%3D80%26spage%3D314%26epage%3D323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Neha  Sharma</span>, <span class="hlFld-ContribAuthor ">Anurag</span>. </span><span class="cited-content_cbyCitation_article-title">7-Azaindole Analogues as Bioactive Agents and Recent Results. </span><span class="cited-content_cbyCitation_journal-name">Mini-Reviews in Medicinal Chemistry</span><span> <strong>2019,</strong> <em>19 </em>
                                    (9)
                                     , 727-736. <a href="https://doi.org/10.2174/1389557518666180928154004" title="DOI URL">https://doi.org/10.2174/1389557518666180928154004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1389557518666180928154004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1389557518666180928154004%26sid%3Dliteratum%253Aachs%26jtitle%3DMini-Reviews%2520in%2520Medicinal%2520Chemistry%26atitle%3D7-Azaindole%252BAnalogues%252Bas%252BBioactive%252BAgents%252Band%252BRecent%252BResults%26aulast%3DSharma%26aufirst%3DNeha%26date%3D2019%26volume%3D19%26issue%3D9%26spage%3D727%26epage%3D736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Benjamin D.  Dickson</span>, <span class="hlFld-ContribAuthor ">Way Wua  Wong</span>, <span class="hlFld-ContribAuthor ">William R.  Wilson</span>, <span class="hlFld-ContribAuthor ">Michael P.  Hay</span>. </span><span class="cited-content_cbyCitation_article-title">Studies Towards Hypoxia-Activated Prodrugs of PARP Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2019,</strong> <em>24 </em>
                                    (8)
                                     , 1559. <a href="https://doi.org/10.3390/molecules24081559" title="DOI URL">https://doi.org/10.3390/molecules24081559</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules24081559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules24081559%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DStudies%252BTowards%252BHypoxia-Activated%252BProdrugs%252Bof%252BPARP%252BInhibitors%26aulast%3DDickson%26aufirst%3DBenjamin%2BD.%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D8%26spage%3D1559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaolong  Guo</span>, <span class="hlFld-ContribAuthor ">Jing  Hu</span>, <span class="hlFld-ContribAuthor ">Mengmeng  Zhang</span>, <span class="hlFld-ContribAuthor ">Luyao  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Palladium-Catalyzed C(
              sp
              2
              )âH Activation for the Formation of CâN Bonds: Rapid Access to Benzimidazoquinazolines. </span><span class="cited-content_cbyCitation_journal-name">Asian Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>8 </em>
                                    (3)
                                     , 417-421. <a href="https://doi.org/10.1002/ajoc.201800710" title="DOI URL">https://doi.org/10.1002/ajoc.201800710</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ajoc.201800710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fajoc.201800710%26sid%3Dliteratum%253Aachs%26jtitle%3DAsian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DPalladium-Catalyzed%252BC%252528%252Bsp%252B2%252B%252529%2525E2%252588%252592H%252BActivation%252Bfor%252Bthe%252BFormation%252Bof%252BC%2525E2%252588%252592N%252BBonds%25253A%252BRapid%252BAccess%252Bto%252BBenzimidazoquinazolines%26aulast%3DGuo%26aufirst%3DXiaolong%26date%3D2019%26date%3D2019%26volume%3D8%26issue%3D3%26spage%3D417%26epage%3D421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qin  Yang</span>, <span class="hlFld-ContribAuthor ">Zhijian  Yin</span>, <span class="hlFld-ContribAuthor ">Lifang  Zheng</span>, <span class="hlFld-ContribAuthor ">Jianjun  Yuan</span>, <span class="hlFld-ContribAuthor ">Song  Wei</span>, <span class="hlFld-ContribAuthor ">Qiuping  Ding</span>, <span class="hlFld-ContribAuthor ">Yiyuan  Peng</span>. </span><span class="cited-content_cbyCitation_article-title">Copper-catalyzed cross-dehydrogenative coupling between quinazoline-3-oxides and indoles. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2019,</strong> <em>9 </em>
                                    (11)
                                     , 5870-5877. <a href="https://doi.org/10.1039/C8RA09864F" title="DOI URL">https://doi.org/10.1039/C8RA09864F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8RA09864F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8RA09864F%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DCopper-catalyzed%252Bcross-dehydrogenative%252Bcoupling%252Bbetween%252Bquinazoline-3-oxides%252Band%252Bindoles%26aulast%3DYang%26aufirst%3DQin%26date%3D2019%26date%3D2019%26volume%3D9%26issue%3D11%26spage%3D5870%26epage%3D5877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pamlea N.  Brady</span>, <span class="hlFld-ContribAuthor ">Anupam  Goel</span>, <span class="hlFld-ContribAuthor ">Margaret A.  Johnson</span>. </span><span class="cited-content_cbyCitation_article-title">Poly(ADP-Ribose) Polymerases in Host-Pathogen Interactions, Inflammation, and Immunity. </span><span class="cited-content_cbyCitation_journal-name">Microbiology and Molecular Biology Reviews</span><span> <strong>2019,</strong> <em>83 </em>
                                    (1)
                                     <a href="https://doi.org/10.1128/MMBR.00038-18" title="DOI URL">https://doi.org/10.1128/MMBR.00038-18</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1128/MMBR.00038-18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1128%2FMMBR.00038-18%26sid%3Dliteratum%253Aachs%26jtitle%3DMicrobiology%2520and%2520Molecular%2520Biology%2520Reviews%26atitle%3DPoly%252528ADP-Ribose%252529%252BPolymerases%252Bin%252BHost-Pathogen%252BInteractions%25252C%252BInflammation%25252C%252Band%252BImmunity%26aulast%3DBrady%26aufirst%3DPamlea%2BN.%26date%3D2019%26volume%3D83%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Monika  Pospisilova</span>, <span class="hlFld-ContribAuthor ">Martin  Andrs</span>, <span class="hlFld-ContribAuthor ">Martina  Seifrtova</span>, <span class="hlFld-ContribAuthor ">Radim  Havelek</span>, <span class="hlFld-ContribAuthor ">Daniel  Jun</span>, <span class="hlFld-ContribAuthor ">Pavel  Tomsik</span>, <span class="hlFld-ContribAuthor ">Lukas  Prchal</span>, <span class="hlFld-ContribAuthor ">Rafael  Dolezal</span>, <span class="hlFld-ContribAuthor ">Ales  Tichy</span>, <span class="hlFld-ContribAuthor ">Tomas  Kucera</span>, <span class="hlFld-ContribAuthor ">Jan  Korabecny</span>, <span class="hlFld-ContribAuthor ">Martina  Rezacova</span>. </span><span class="cited-content_cbyCitation_article-title">Novel quinazolin-4-one derivatives as potentiating agents of doxorubicin cytotoxicity. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2019,</strong> <em>82 </em>, 204-210. <a href="https://doi.org/10.1016/j.bioorg.2018.10.001" title="DOI URL">https://doi.org/10.1016/j.bioorg.2018.10.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2018.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2018.10.001%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DNovel%252Bquinazolin-4-one%252Bderivatives%252Bas%252Bpotentiating%252Bagents%252Bof%252Bdoxorubicin%252Bcytotoxicity%26aulast%3DPospisilova%26aufirst%3DMonika%26date%3D2019%26volume%3D82%26spage%3D204%26epage%3D210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shengxiao  Li</span>, <span class="hlFld-ContribAuthor ">Xin-Xing  Wu</span>, <span class="hlFld-ContribAuthor ">Shufeng  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Base-promoted direct synthesis of functionalized
              N
              -arylindoles
              via
              the cascade reactions of allenic ketones with indoles. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2019,</strong> <em>17 </em>
                                    (4)
                                     , 789-793. <a href="https://doi.org/10.1039/C8OB02921K" title="DOI URL">https://doi.org/10.1039/C8OB02921K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8OB02921K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8OB02921K%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DBase-promoted%252Bdirect%252Bsynthesis%252Bof%252Bfunctionalized%252BN%252B-arylindoles%252Bvia%252Bthe%252Bcascade%252Breactions%252Bof%252Ballenic%252Bketones%252Bwith%252Bindoles%26aulast%3DLi%26aufirst%3DShengxiao%26date%3D2019%26date%3D2019%26volume%3D17%26issue%3D4%26spage%3D789%26epage%3D793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cheng-Zhi  Gao</span>, <span class="hlFld-ContribAuthor ">Wei  Dong</span>, <span class="hlFld-ContribAuthor ">Zhi-Wen  Cui</span>, <span class="hlFld-ContribAuthor ">Qiong  Yuan</span>, <span class="hlFld-ContribAuthor ">Xia-Min  Hu</span>, <span class="hlFld-ContribAuthor ">Qing-Ming  Wu</span>, <span class="hlFld-ContribAuthor ">Xianlin  Han</span>, <span class="hlFld-ContribAuthor ">Yao  Xu</span>, <span class="hlFld-ContribAuthor ">Zhen-Li  Min</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, preliminarily biological evaluation and molecular docking study of new Olaparib analogues as multifunctional PARP-1 and cholinesterase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2019,</strong> <em>34 </em>
                                    (1)
                                     , 150-162. <a href="https://doi.org/10.1080/14756366.2018.1530224" title="DOI URL">https://doi.org/10.1080/14756366.2018.1530224</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14756366.2018.1530224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14756366.2018.1530224%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%25252C%252Bpreliminarily%252Bbiological%252Bevaluation%252Band%252Bmolecular%252Bdocking%252Bstudy%252Bof%252Bnew%252BOlaparib%252Banalogues%252Bas%252Bmultifunctional%252BPARP-1%252Band%252Bcholinesterase%252Binhibitors%26aulast%3DGao%26aufirst%3DCheng-Zhi%26date%3D2019%26date%3D2018%26volume%3D34%26issue%3D1%26spage%3D150%26epage%3D162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Meng  Zheng</span>, <span class="hlFld-ContribAuthor ">Martin  Mex</span>, <span class="hlFld-ContribAuthor ">Kathrin H.  GÃ¶tz</span>, <span class="hlFld-ContribAuthor ">Andreas  Marx</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of disaccharide nucleoside analogues as potential poly(ADP-ribose) polymerase-1 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2018,</strong> <em>16 </em>
                                    (46)
                                     , 8904-8907. <a href="https://doi.org/10.1039/C8OB01894D" title="DOI URL">https://doi.org/10.1039/C8OB01894D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8OB01894D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8OB01894D%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DSynthesis%252Bof%252Bdisaccharide%252Bnucleoside%252Banalogues%252Bas%252Bpotential%252Bpoly%252528ADP-ribose%252529%252Bpolymerase-1%252Binhibitors%26aulast%3DZheng%26aufirst%3DMeng%26date%3D2018%26date%3D2018%26volume%3D16%26issue%3D46%26spage%3D8904%26epage%3D8907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Olga Ð.  Vysokova</span>, <span class="hlFld-ContribAuthor ">Tatiana A.  Kalinina</span>, <span class="hlFld-ContribAuthor ">Pavel Ð.  Slepukhin</span>, <span class="hlFld-ContribAuthor ">Tatiana Ð.  Pospelova</span>, <span class="hlFld-ContribAuthor ">Konstantin L.  Obydennov</span>, <span class="hlFld-ContribAuthor ">Tatiana V.  Glukhareva</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of 5-(5-amino-1H-pyrazol-1-yl)-1,2,3-thiadiazole-4-carboxylic acid ethyl esters and their cyclization into pyrazolo[1,5-a][1,2,3]thiadiazolo[4,5-e]pyrimidin-4(5H)-ones. </span><span class="cited-content_cbyCitation_journal-name">Chemistry of Heterocyclic Compounds</span><span> <strong>2018,</strong> <em>54 </em>
                                    (11)
                                     , 1079-1082. <a href="https://doi.org/10.1007/s10593-018-2396-6" title="DOI URL">https://doi.org/10.1007/s10593-018-2396-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10593-018-2396-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10593-018-2396-6%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520of%2520Heterocyclic%2520Compounds%26atitle%3DSynthesis%252Bof%252B5-%2525285-amino-1H-pyrazol-1-yl%252529-1%25252C2%25252C3-thiadiazole-4-carboxylic%252Bacid%252Bethyl%252Besters%252Band%252Btheir%252Bcyclization%252Binto%252Bpyrazolo%25255B1%25252C5-a%25255D%25255B1%25252C2%25252C3%25255Dthiadiazolo%25255B4%25252C5-e%25255Dpyrimidin-4%2525285H%252529-ones%26aulast%3DVysokova%26aufirst%3DOlga%2B%25D0%2590.%26date%3D2018%26date%3D2018%26volume%3D54%26issue%3D11%26spage%3D1079%26epage%3D1082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dong  Zhou</span>, <span class="hlFld-ContribAuthor ">Jinbin  Xu</span>, <span class="hlFld-ContribAuthor ">Cedric  Mpoy</span>, <span class="hlFld-ContribAuthor ">Wenhua  Chu</span>, <span class="hlFld-ContribAuthor ">Sung Hoon  Kim</span>, <span class="hlFld-ContribAuthor ">Huifangjie  Li</span>, <span class="hlFld-ContribAuthor ">Buck E.  Rogers</span>, <span class="hlFld-ContribAuthor ">John A.  Katzenellenbogen</span>. </span><span class="cited-content_cbyCitation_article-title">Preliminary evaluation of a novel 18F-labeled PARP-1 ligand for PET imaging of PARP-1 expression in prostate cancer. </span><span class="cited-content_cbyCitation_journal-name">Nuclear Medicine and Biology</span><span> <strong>2018,</strong> <em>66 </em>, 26-31. <a href="https://doi.org/10.1016/j.nucmedbio.2018.08.003" title="DOI URL">https://doi.org/10.1016/j.nucmedbio.2018.08.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.nucmedbio.2018.08.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.nucmedbio.2018.08.003%26sid%3Dliteratum%253Aachs%26jtitle%3DNuclear%2520Medicine%2520and%2520Biology%26atitle%3DPreliminary%252Bevaluation%252Bof%252Ba%252Bnovel%252B18F-labeled%252BPARP-1%252Bligand%252Bfor%252BPET%252Bimaging%252Bof%252BPARP-1%252Bexpression%252Bin%252Bprostate%252Bcancer%26aulast%3DZhou%26aufirst%3DDong%26date%3D2018%26volume%3D66%26spage%3D26%26epage%3D31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiao-Long  Hu</span>, <span class="hlFld-ContribAuthor ">Jia-Hao  Feng</span>, <span class="hlFld-ContribAuthor ">Thi-Anh  Pham</span>, <span class="hlFld-ContribAuthor ">Hai-Yan  Ma</span>, <span class="hlFld-ContribAuthor ">Ming-Xi  Ma</span>, <span class="hlFld-ContribAuthor ">Rui  Song</span>, <span class="hlFld-ContribAuthor ">Wei  Shen</span>, <span class="hlFld-ContribAuthor ">Fei  Xiong</span>, <span class="hlFld-ContribAuthor ">Xiao-Qi  Zhang</span>, <span class="hlFld-ContribAuthor ">Wen-Cai  Ye</span>, <span class="hlFld-ContribAuthor ">Hao  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of amentoflavone as a potent highly selective PARP-1 inhibitor and its potentiation on carboplatin in human non-small cell lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Phytomedicine</span><span> <strong>2018,</strong> <em>50 </em>, 88-98. <a href="https://doi.org/10.1016/j.phymed.2018.09.012" title="DOI URL">https://doi.org/10.1016/j.phymed.2018.09.012</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phymed.2018.09.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phymed.2018.09.012%26sid%3Dliteratum%253Aachs%26jtitle%3DPhytomedicine%26atitle%3DIdentification%252Bof%252Bamentoflavone%252Bas%252Ba%252Bpotent%252Bhighly%252Bselective%252BPARP-1%252Binhibitor%252Band%252Bits%252Bpotentiation%252Bon%252Bcarboplatin%252Bin%252Bhuman%252Bnon-small%252Bcell%252Blung%252Bcancer%26aulast%3DHu%26aufirst%3DXiao-Long%26date%3D2018%26volume%3D50%26spage%3D88%26epage%3D98" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuangshuang  Wu</span>, <span class="hlFld-ContribAuthor ">Changhui  Chen</span>, <span class="hlFld-ContribAuthor ">Haitang  Yang</span>, <span class="hlFld-ContribAuthor ">Wei  Wei</span>, <span class="hlFld-ContribAuthor ">Min  Wei</span>, <span class="hlFld-ContribAuthor ">Yuanjian  Zhang</span>, <span class="hlFld-ContribAuthor ">Songqin  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">A sensitive fluorescence âturn-off-onâ biosensor for poly(ADP-ribose) polymerase-1 detection based on cationic conjugated polymer-MnO2 nanosheets. </span><span class="cited-content_cbyCitation_journal-name">Sensors and Actuators B: Chemical</span><span> <strong>2018,</strong> <em>273 </em>, 1047-1053. <a href="https://doi.org/10.1016/j.snb.2018.07.013" title="DOI URL">https://doi.org/10.1016/j.snb.2018.07.013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.snb.2018.07.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.snb.2018.07.013%26sid%3Dliteratum%253Aachs%26jtitle%3DSensors%2520and%2520Actuators%2520B%253A%2520Chemical%26atitle%3DA%252Bsensitive%252Bfluorescence%252B%2525E2%252580%25259Cturn-off-on%2525E2%252580%25259D%252Bbiosensor%252Bfor%252Bpoly%252528ADP-ribose%252529%252Bpolymerase-1%252Bdetection%252Bbased%252Bon%252Bcationic%252Bconjugated%252Bpolymer-MnO2%252Bnanosheets%26aulast%3DWu%26aufirst%3DShuangshuang%26date%3D2018%26volume%3D273%26spage%3D1047%26epage%3D1053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dan  Li</span>, <span class="hlFld-ContribAuthor ">Jun  Liu</span>, <span class="hlFld-ContribAuthor ">Xin  Wang</span>, <span class="hlFld-ContribAuthor ">Di  Kong</span>, <span class="hlFld-ContribAuthor ">Wei  Du</span>, <span class="hlFld-ContribAuthor ">Hongbo  Li</span>, <span class="hlFld-ContribAuthor ">Chung-Yun  Hse</span>, <span class="hlFld-ContribAuthor ">Todd  Shupe</span>, <span class="hlFld-ContribAuthor ">Dongpo  Zhou</span>, <span class="hlFld-ContribAuthor ">Kai  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Biological Potential and Mechanism of Prodigiosin from Serratia marcescens Subsp. lawsoniana in Human Choriocarcinoma and Prostate Cancer Cell Lines. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2018,</strong> <em>19 </em>
                                    (11)
                                     , 3465. <a href="https://doi.org/10.3390/ijms19113465" title="DOI URL">https://doi.org/10.3390/ijms19113465</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms19113465&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms19113465%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DBiological%252BPotential%252Band%252BMechanism%252Bof%252BProdigiosin%252Bfrom%252BSerratia%252Bmarcescens%252BSubsp.%252Blawsoniana%252Bin%252BHuman%252BChoriocarcinoma%252Band%252BProstate%252BCancer%252BCell%252BLines%26aulast%3DLi%26aufirst%3DDan%26date%3D2018%26date%3D2018%26volume%3D19%26issue%3D11%26spage%3D3465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giulia  Boscutti</span>, <span class="hlFld-ContribAuthor ">Chiara  Nardon</span>, <span class="hlFld-ContribAuthor ">Luciano  MarchiÃ²</span>, <span class="hlFld-ContribAuthor ">Marco  Crisma</span>, <span class="hlFld-ContribAuthor ">Barbara  Biondi</span>, <span class="hlFld-ContribAuthor ">Daniele  Dalzoppo</span>, <span class="hlFld-ContribAuthor ">Lisa  DallaâVia</span>, <span class="hlFld-ContribAuthor ">Fernando  Formaggio</span>, <span class="hlFld-ContribAuthor ">Angela  Casini</span>, <span class="hlFld-ContribAuthor ">Dolores  Fregona</span>. </span><span class="cited-content_cbyCitation_article-title">Anticancer Gold(III) Peptidomimetics: From Synthesis to in vitro and ex vivo Biological Evaluations. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2018,</strong> <em>13 </em>
                                    (11)
                                     , 1131-1145. <a href="https://doi.org/10.1002/cmdc.201800098" title="DOI URL">https://doi.org/10.1002/cmdc.201800098</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201800098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201800098%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DAnticancer%252BGold%252528III%252529%252BPeptidomimetics%25253A%252BFrom%252BSynthesis%252Bto%252Bin%252Bvitro%252Band%252Bex%252Bvivo%252BBiological%252BEvaluations%26aulast%3DBoscutti%26aufirst%3DGiulia%26date%3D2018%26date%3D2018%26volume%3D13%26issue%3D11%26spage%3D1131%26epage%3D1145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jacob  Holechek</span>, <span class="hlFld-ContribAuthor ">Robert  Lease</span>, <span class="hlFld-ContribAuthor ">Ann-Gerd  Thorsell</span>, <span class="hlFld-ContribAuthor ">Tobias  Karlberg</span>, <span class="hlFld-ContribAuthor ">Caitlin  McCadden</span>, <span class="hlFld-ContribAuthor ">Ryan  Grant</span>, <span class="hlFld-ContribAuthor ">Abby  Keen</span>, <span class="hlFld-ContribAuthor ">Evan  Callahan</span>, <span class="hlFld-ContribAuthor ">Herwig  SchÃ¼ler</span>, <span class="hlFld-ContribAuthor ">Dana  Ferraris</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and evaluation of potent and selective inhibitors of mono-(ADP-ribosyl)transferases PARP10 and PARP14. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>28 </em>
                                    (11)
                                     , 2050-2054. <a href="https://doi.org/10.1016/j.bmcl.2018.04.056" title="DOI URL">https://doi.org/10.1016/j.bmcl.2018.04.056</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2018.04.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2018.04.056%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bevaluation%252Bof%252Bpotent%252Band%252Bselective%252Binhibitors%252Bof%252Bmono-%252528ADP-ribosyl%252529transferases%252BPARP10%252Band%252BPARP14%26aulast%3DHolechek%26aufirst%3DJacob%26date%3D2018%26volume%3D28%26issue%3D11%26spage%3D2050%26epage%3D2054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bo  Peng</span>, <span class="hlFld-ContribAuthor ">Changmin  Yu</span>, <span class="hlFld-ContribAuthor ">Shubo  Du</span>, <span class="hlFld-ContribAuthor ">Si S.  Liew</span>, <span class="hlFld-ContribAuthor ">Xin  Mao</span>, <span class="hlFld-ContribAuthor ">Peiyan  Yuan</span>, <span class="hlFld-ContribAuthor ">Zhenkun  Na</span>, <span class="hlFld-ContribAuthor ">Shao Q.  Yao</span>. </span><span class="cited-content_cbyCitation_article-title">MSN-on-a-Chip: Cell-Based Screenings Made Possible on a Small-Molecule Microarray of Native Natural Products. </span><span class="cited-content_cbyCitation_journal-name">ChemBioChem</span><span> <strong>2018,</strong> <em>19 </em>
                                    (9)
                                     , 986-996. <a href="https://doi.org/10.1002/cbic.201800101" title="DOI URL">https://doi.org/10.1002/cbic.201800101</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cbic.201800101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcbic.201800101%26sid%3Dliteratum%253Aachs%26jtitle%3DChemBioChem%26atitle%3DMSN-on-a-Chip%25253A%252BCell-Based%252BScreenings%252BMade%252BPossible%252Bon%252Ba%252BSmall-Molecule%252BMicroarray%252Bof%252BNative%252BNatural%252BProducts%26aulast%3DPeng%26aufirst%3DBo%26date%3D2018%26date%3D2018%26volume%3D19%26issue%3D9%26spage%3D986%26epage%3D996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hadia  Almahli</span>, <span class="hlFld-ContribAuthor ">Elie  Hadchity</span>, <span class="hlFld-ContribAuthor ">Maiy Y.  Jaballah</span>, <span class="hlFld-ContribAuthor ">Racha  Daher</span>, <span class="hlFld-ContribAuthor ">Hazem A.  Ghabbour</span>, <span class="hlFld-ContribAuthor ">Maha M.  Kabil</span>, <span class="hlFld-ContribAuthor ">Nasser S.  Al-shakliah</span>, <span class="hlFld-ContribAuthor ">Wagdy M.  Eldehna</span>. </span><span class="cited-content_cbyCitation_article-title">Development of novel synthesized phthalazinone-based PARP-1 inhibitors with apoptosis inducing mechanism in lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2018,</strong> <em>77 </em>, 443-456. <a href="https://doi.org/10.1016/j.bioorg.2018.01.034" title="DOI URL">https://doi.org/10.1016/j.bioorg.2018.01.034</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2018.01.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2018.01.034%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDevelopment%252Bof%252Bnovel%252Bsynthesized%252Bphthalazinone-based%252BPARP-1%252Binhibitors%252Bwith%252Bapoptosis%252Binducing%252Bmechanism%252Bin%252Blung%252Bcancer%26aulast%3DAlmahli%26aufirst%3DHadia%26date%3D2018%26volume%3D77%26spage%3D443%26epage%3D456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pierre  Daumar</span>, <span class="hlFld-ContribAuthor ">Robin  Dufour</span>, <span class="hlFld-ContribAuthor ">ClÃ©mence  Dubois</span>, <span class="hlFld-ContribAuthor ">FrÃ©dÃ©rique  Penault-Llorca</span>, <span class="hlFld-ContribAuthor ">Mahchid  Bamdad</span>, <span class="hlFld-ContribAuthor ">Emmanuelle  Mounetou</span>. </span><span class="cited-content_cbyCitation_article-title">Development and validation of a high-performance liquid chromatography method for the quantitation of intracellular PARP inhibitor Olaparib in cancer cells. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmaceutical and Biomedical Analysis</span><span> <strong>2018,</strong> <em>152 </em>, 74-80. <a href="https://doi.org/10.1016/j.jpba.2018.01.036" title="DOI URL">https://doi.org/10.1016/j.jpba.2018.01.036</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jpba.2018.01.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jpba.2018.01.036%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmaceutical%2520and%2520Biomedical%2520Analysis%26atitle%3DDevelopment%252Band%252Bvalidation%252Bof%252Ba%252Bhigh-performance%252Bliquid%252Bchromatography%252Bmethod%252Bfor%252Bthe%252Bquantitation%252Bof%252Bintracellular%252BPARP%252Binhibitor%252BOlaparib%252Bin%252Bcancer%252Bcells%26aulast%3DDaumar%26aufirst%3DPierre%26date%3D2018%26volume%3D152%26spage%3D74%26epage%3D80" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuangshuang  Wu</span>, <span class="hlFld-ContribAuthor ">Min  Wei</span>, <span class="hlFld-ContribAuthor ">Haitang  Yang</span>, <span class="hlFld-ContribAuthor ">Jiahui  Fan</span>, <span class="hlFld-ContribAuthor ">Wei  Wei</span>, <span class="hlFld-ContribAuthor ">Yuanjian  Zhang</span>, <span class="hlFld-ContribAuthor ">Songqin  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Counterions-mediated gold nanorods-based sensor for label-free detection of poly(ADP-ribose) polymerase-1 activity and its inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Sensors and Actuators B: Chemical</span><span> <strong>2018,</strong> <em>259 </em>, 565-572. <a href="https://doi.org/10.1016/j.snb.2017.12.076" title="DOI URL">https://doi.org/10.1016/j.snb.2017.12.076</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.snb.2017.12.076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.snb.2017.12.076%26sid%3Dliteratum%253Aachs%26jtitle%3DSensors%2520and%2520Actuators%2520B%253A%2520Chemical%26atitle%3DCounterions-mediated%252Bgold%252Bnanorods-based%252Bsensor%252Bfor%252Blabel-free%252Bdetection%252Bof%252Bpoly%252528ADP-ribose%252529%252Bpolymerase-1%252Bactivity%252Band%252Bits%252Binhibitor%26aulast%3DWu%26aufirst%3DShuangshuang%26date%3D2018%26volume%3D259%26spage%3D565%26epage%3D572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xuxing  Chen</span>, <span class="hlFld-ContribAuthor ">Xiajuan  Huan</span>, <span class="hlFld-ContribAuthor ">Qiufeng  Liu</span>, <span class="hlFld-ContribAuthor ">Yuqin  Wang</span>, <span class="hlFld-ContribAuthor ">Qian  He</span>, <span class="hlFld-ContribAuthor ">Cun  Tan</span>, <span class="hlFld-ContribAuthor ">Yi  Chen</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Yechun  Xu</span>, <span class="hlFld-ContribAuthor ">Zehong  Miao</span>, <span class="hlFld-ContribAuthor ">Chunhao  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of 2-(4,5,6,7-tetrahydrothienopyridin-2-yl)-benzoimidazole carboxamides as novel orally efficacious Poly(ADP-ribose)polymerase (PARP) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>145 </em>, 389-403. <a href="https://doi.org/10.1016/j.ejmech.2018.01.018" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.01.018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.01.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.01.018%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252B2-%2525284%25252C5%25252C6%25252C7-tetrahydrothienopyridin-2-yl%252529-benzoimidazole%252Bcarboxamides%252Bas%252Bnovel%252Borally%252Befficacious%252BPoly%252528ADP-ribose%252529polymerase%252B%252528PARP%252529%252Binhibitors%26aulast%3DChen%26aufirst%3DXuxing%26date%3D2018%26volume%3D145%26spage%3D389%26epage%3D403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">D. K.  Nilov</span>, <span class="hlFld-ContribAuthor ">K. I.  Yashina</span>, <span class="hlFld-ContribAuthor ">I. V.  Gushchina</span>, <span class="hlFld-ContribAuthor ">A. L.  Zakharenko</span>, <span class="hlFld-ContribAuthor ">M. V.  Sukhanova</span>, <span class="hlFld-ContribAuthor ">O. I.  Lavrik</span>, <span class="hlFld-ContribAuthor ">V. K.  Å vedas</span>. </span><span class="cited-content_cbyCitation_article-title">2,5-Diketopiperazines: A New Class of Poly(ADP-ribose)polymerase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Biochemistry (Moscow)</span><span> <strong>2018,</strong> <em>83 </em>
                                    (2)
                                     , 152-158. <a href="https://doi.org/10.1134/S0006297918020074" title="DOI URL">https://doi.org/10.1134/S0006297918020074</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1134/S0006297918020074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1134%2FS0006297918020074%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemistry%2520%2528Moscow%2529%26atitle%3D2%25252C5-Diketopiperazines%25253A%252BA%252BNew%252BClass%252Bof%252BPoly%252528ADP-ribose%252529polymerase%252BInhibitors%26aulast%3DNilov%26aufirst%3DD.%2BK.%26date%3D2018%26date%3D2018%26volume%3D83%26issue%3D2%26spage%3D152%26epage%3D158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ilsa T.  Kirby</span>, <span class="hlFld-ContribAuthor ">Michael S.  Cohen</span>. </span><span class="cited-content_cbyCitation_article-title">Small-Molecule Inhibitors of PARPs: From Tools for Investigating ADP-Ribosylation to Therapeutics. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 211-231. <a href="https://doi.org/10.1007/82_2018_137" title="DOI URL">https://doi.org/10.1007/82_2018_137</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/82_2018_137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F82_2018_137%26sid%3Dliteratum%253Aachs%26atitle%3DSmall-Molecule%252BInhibitors%252Bof%252BPARPs%25253A%252BFrom%252BTools%252Bfor%252BInvestigating%252BADP-Ribosylation%252Bto%252BTherapeutics%26aulast%3DKirby%26aufirst%3DIlsa%2BT.%26date%3D2018%26date%3D2018%26spage%3D211%26epage%3D231%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DActivity-Based%252BProtein%252BProfiling%26aulast%3DCravatt%26aufirst%3DBenjamin%2BF.%26date%3D2019%26volume%3D420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael  Saleeb</span>, <span class="hlFld-ContribAuthor ">Charlotta  Sundin</span>, <span class="hlFld-ContribAuthor ">Ãznur  Aglar</span>, <span class="hlFld-ContribAuthor ">Ana Filipa  Pinto</span>, <span class="hlFld-ContribAuthor ">Mahsa  Ebrahimi</span>, <span class="hlFld-ContribAuthor ">Ãke  Forsberg</span>, <span class="hlFld-ContribAuthor ">Herwig  SchÃ¼ler</span>, <span class="hlFld-ContribAuthor ">Mikael  Elofsson</span>. </span><span class="cited-content_cbyCitation_article-title">Structureâactivity relationships for inhibitors of Pseudomonas aeruginosa exoenzyme S ADP-ribosyltransferase activity. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>143 </em>, 568-576. <a href="https://doi.org/10.1016/j.ejmech.2017.11.036" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.11.036</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.11.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.11.036%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure%2525E2%252580%252593activity%252Brelationships%252Bfor%252Binhibitors%252Bof%252BPseudomonas%252Baeruginosa%252Bexoenzyme%252BS%252BADP-ribosyltransferase%252Bactivity%26aulast%3DSaleeb%26aufirst%3DMichael%26date%3D2018%26volume%3D143%26spage%3D568%26epage%3D576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ki-Hong  Jang</span>, <span class="hlFld-ContribAuthor ">Yun-Ju  Do</span>, <span class="hlFld-ContribAuthor ">Dongwon  Son</span>, <span class="hlFld-ContribAuthor ">Eunji  Son</span>, <span class="hlFld-ContribAuthor ">Jun-Sub  Choi</span>, <span class="hlFld-ContribAuthor ">Eunhee  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">AIF-independent parthanatos in the pathogenesis of dry age-related macular degeneration. </span><span class="cited-content_cbyCitation_journal-name">Cell Death & Disease</span><span> <strong>2018,</strong> <em>8 </em>
                                    (1)
                                     , e2526-e2526. <a href="https://doi.org/10.1038/cddis.2016.437" title="DOI URL">https://doi.org/10.1038/cddis.2016.437</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/cddis.2016.437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fcddis.2016.437%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Death%2520%2526%2520Disease%26atitle%3DAIF-independent%252Bparthanatos%252Bin%252Bthe%252Bpathogenesis%252Bof%252Bdry%252Bage-related%252Bmacular%252Bdegeneration%26aulast%3DJang%26aufirst%3DKi-Hong%26date%3D2018%26date%3D2017%26volume%3D8%26issue%3D1%26spage%3De2526%26epage%3De2526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhonghe  Tang</span>, <span class="hlFld-ContribAuthor ">Shaoyu  Mai</span>, <span class="hlFld-ContribAuthor ">Yao  Zhou</span>, <span class="hlFld-ContribAuthor ">Qiuling  Song</span>. </span><span class="cited-content_cbyCitation_article-title">Divergent synthesis of Î±-aryl ketones/esters
              via
              rhodium-catalyzed selective deesterification and decarbonylation of diazo compounds. </span><span class="cited-content_cbyCitation_journal-name">Organic Chemistry Frontiers</span><span> <strong>2018,</strong> <em>5 </em>
                                    (17)
                                     , 2583-2587. <a href="https://doi.org/10.1039/C8QO00619A" title="DOI URL">https://doi.org/10.1039/C8QO00619A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8QO00619A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8QO00619A%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Chemistry%2520Frontiers%26atitle%3DDivergent%252Bsynthesis%252Bof%252B%2525CE%2525B1-aryl%252Bketones%25252Festers%252Bvia%252Brhodium-catalyzed%252Bselective%252Bdeesterification%252Band%252Bdecarbonylation%252Bof%252Bdiazo%252Bcompounds%26aulast%3DTang%26aufirst%3DZhonghe%26date%3D2018%26date%3D2018%26volume%3D5%26issue%3D17%26spage%3D2583%26epage%3D2587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaolong  Guo</span>, <span class="hlFld-ContribAuthor ">Luyao  Wang</span>, <span class="hlFld-ContribAuthor ">Jing  Hu</span>, <span class="hlFld-ContribAuthor ">Mengmeng  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">CuI nanoparticle-catalyzed synthesis of tetracyclic benzo[
              e
              ]benzo[4,5]imidazo[1,2-
              c
              ][1,3]thiazin-6-imine heterocycles by S
              N
              Ar-type CâS, CâN bond formation from isothiocyanatobenzenes and benzimidazoles. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2018,</strong> <em>8 </em>
                                    (39)
                                     , 22259-22267. <a href="https://doi.org/10.1039/C8RA02552E" title="DOI URL">https://doi.org/10.1039/C8RA02552E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8RA02552E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8RA02552E%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DCuI%252Bnanoparticle-catalyzed%252Bsynthesis%252Bof%252Btetracyclic%252Bbenzo%25255B%252Be%252B%25255Dbenzo%25255B4%25252C5%25255Dimidazo%25255B1%25252C2-%252Bc%252B%25255D%25255B1%25252C3%25255Dthiazin-6-imine%252Bheterocycles%252Bby%252BS%252BN%252BAr-type%252BC%2525E2%252580%252593S%25252C%252BC%2525E2%252580%252593N%252Bbond%252Bformation%252Bfrom%252Bisothiocyanatobenzenes%252Band%252Bbenzimidazoles%26aulast%3DGuo%26aufirst%3DXiaolong%26date%3D2018%26date%3D2018%26volume%3D8%26issue%3D39%26spage%3D22259%26epage%3D22267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A. L.  Zakharenko</span>, <span class="hlFld-ContribAuthor ">N. A.  Lebedeva</span>, <span class="hlFld-ContribAuthor ">O. I.  Lavrik</span>. </span><span class="cited-content_cbyCitation_article-title">DNA Repair Enzymes as Promising Targets in Oncotherapy. </span><span class="cited-content_cbyCitation_journal-name">Russian Journal of Bioorganic Chemistry</span><span> <strong>2018,</strong> <em>44 </em>
                                    (1)
                                     , 1-18. <a href="https://doi.org/10.1134/S1068162017060140" title="DOI URL">https://doi.org/10.1134/S1068162017060140</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1134/S1068162017060140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1134%2FS1068162017060140%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Journal%2520of%2520Bioorganic%2520Chemistry%26atitle%3DDNA%252BRepair%252BEnzymes%252Bas%252BPromising%252BTargets%252Bin%252BOncotherapy%26aulast%3DZakharenko%26aufirst%3DA.%2BL.%26date%3D2018%26date%3D2018%26volume%3D44%26issue%3D1%26spage%3D1%26epage%3D18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wen-hua  Chen</span>, <span class="hlFld-ContribAuthor ">Shan-shan  Song</span>, <span class="hlFld-ContribAuthor ">Ming-hui  Qi</span>, <span class="hlFld-ContribAuthor ">Xia-juan  Huan</span>, <span class="hlFld-ContribAuthor ">Ying-qing  Wang</span>, <span class="hlFld-ContribAuthor ">Hualiang  Jiang</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Guo-bin  Ren</span>, <span class="hlFld-ContribAuthor ">Ze-hong  Miao</span>, <span class="hlFld-ContribAuthor ">Jian  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of potent 2,4-difluoro-linker poly(ADP-ribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmacologica Sinica</span><span> <strong>2017,</strong> <em>38 </em>
                                    (11)
                                     , 1521-1532. <a href="https://doi.org/10.1038/aps.2017.104" title="DOI URL">https://doi.org/10.1038/aps.2017.104</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/aps.2017.104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Faps.2017.104%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmacologica%2520Sinica%26atitle%3DDiscovery%252Bof%252Bpotent%252B2%25252C4-difluoro-linker%252Bpoly%252528ADP-ribose%252529%252Bpolymerase%252B1%252Binhibitors%252Bwith%252Benhanced%252Bwater%252Bsolubility%252Band%252Bin%252Bvivo%252Banticancer%252Befficacy%26aulast%3DChen%26aufirst%3DWen-hua%26date%3D2017%26date%3D2017%26volume%3D38%26issue%3D11%26spage%3D1521%26epage%3D1532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div><a href="#" data-source="/pb/widgets/cited-by?doi=10.1021%2Fjm100012m&amp;widgetId=9cf770f4-a9a2-46e0-bd29-3da15bcf4ae0&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Fjm100012m%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2010.53.issue-12&amp;citedByCount=231&amp;pagesCount=3&amp;pageNumber=2" title="Load more citations" class="button_primary float-right cited-by__see-more mb-5"><i aria-hidden="âtrueâ" class="icon-angle-double-down"></i><span>Load more citations</span></a></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="fig1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0026.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Active PARP-1 drug discovery programs based on patent and publication records.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0027.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Poly(ADP-ribosyl)ation catalyzed by PARP-1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0001.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Role of PARP-1 in DNA repair.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0002.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Synthetic lethality of cancer cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0003.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Evolution of PARP-1 Inhibitor Scaffolds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0004.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Binding modes of several PARP-1 inhibitors in the nicotinamide binding pocket: (A) dihydroisoquinolinone <b>51</b>; (B) indolobenzazepine, <b>52</b>; (C) indolinedione, <b>53</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0005.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. PARP-1 pharmacophore.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0006.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Mechanism based PARP-1 inhibitors designed by the Threadgill laboratories.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0008.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Design of thienopyridinones and thienopyrimidinones.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0007.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Nitroimidazole prodrug of PARP-1 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0009.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Newcastleâs quinazolinone based PARP inhibitor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0010.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Design of several lead PARP-1 inhibitors from Newcastle/Agouron/Pfizer.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0011.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Lead PARP-1 inhibitors discovered by UCSF/Octamer/Bipar.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0012.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. PARP-1 inhibitors designed by Inotek.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0013.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Lead series of phenanthridone based PARP-1 inhibitors designed by Guilford.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0014.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Tetracyclic PARP-1 inhibitors designed by Guilford.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0015.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Discovery of Abbottâs clinical candidate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0016.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Current PARP-1 inhibitors from Abbott.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0017.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Evolution of KuDOSâ clinical candidate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0018.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Discovery of CEP-9722.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig21" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0019.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Lead PARP-1 inhibitors discovered by Fujisawa.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig22" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0020.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. PARP-1 and PARP-2 selective inhibitors by Fujisawa.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig23" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0021.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Design of Kyorinâs preclinical candidate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig24" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0022.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Lead PARP inhibitors designed by Mitsubishi.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig25" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0024.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Discovery Merckâs clinical candidate PARP inhibitor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig26" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/medium/jm-2010-00012m_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0023.jpeg" id="rightTab-gr26" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. Lead structures from other PARP-1 inhibitor programs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100012m/production/images/large/jm-2010-00012m_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100012m&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i23">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00524" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00524" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 155 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Jeggo, P. A.</span><span> </span><span class="NLM_article-title">DNA repair: PARPâanother guardian angel?</span> <span class="citation_source-journal">Curr. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">R49</span><span class="NLM_x">â</span> <span class="NLM_lpage">R51</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1998&pages=R49-R51&author=P.+A.+Jeggo&title=DNA+repair%3A+PARP%E2%80%94another+guardian+angel%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJeggo%26aufirst%3DP.%2BA.%26atitle%3DDNA%2520repair%253A%2520PARP%25E2%2580%2594another%2520guardian%2520angel%253F%26jtitle%3DCurr.%2520Biol.%26date%3D1998%26volume%3D8%26spage%3DR49%26epage%3DR51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Virag, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabo, C.</span><span> </span><span class="NLM_article-title">The therapeutic potential of poly(ADP-ribose) polymerase inhibitors</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">375</span><span class="NLM_x">â</span> <span class="NLM_lpage">429</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2002&pages=375-429&author=L.+Viragauthor=C.+Szabo&title=The+therapeutic+potential+of+poly%28ADP-ribose%29+polymerase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVirag%26aufirst%3DL.%26aulast%3DSzabo%26aufirst%3DC.%26atitle%3DThe%2520therapeutic%2520potential%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitors%26jtitle%3DPharmacol.%2520Rev.%26date%3D2002%26volume%3D54%26spage%3D375%26epage%3D429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Winslow, R.</span><span> </span><span class="NLM_article-title">New class of drugs in early trials offers hope for breast cancer</span>.  <span class="citation_source-journal">Wall Street J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span><span class="NLM_issue">June 1</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&issue=June+1&author=R.+Winslow&title=New+class+of+drugs+in+early+trials+offers+hope+for+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWinslow%26aufirst%3DR.%26atitle%3DNew%2520class%2520of%2520drugs%2520in%2520early%2520trials%2520offers%2520hope%2520for%2520breast%2520cancer%26jtitle%3DWall%2520Street%2520J.%26date%3D2009%26issue%3DJune%25201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Hassa, P. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hottiger, M. O.</span><span> </span><span class="NLM_article-title">The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases</span> <span class="citation_source-journal">Front. Biosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">3046</span><span class="NLM_x">â</span> <span class="NLM_lpage">3082</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.2741%2F2909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=17981777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhs1Cntrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=3046-3082&author=P.+O.+Hassaauthor=M.+O.+Hottiger&title=The+diverse+biological+roles+of+mammalian+PARPS%2C+a+small+but+powerful+family+of+poly-ADP-ribose+polymerases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The diverse biological roles of mammalian PARPs, a small but powerful family of poly-ADP-ribose polymerases</span></div><div class="casAuthors">Hassa, Paul O.; Hottiger, Michael O.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Bioscience</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3046-3082</span>CODEN:
                <span class="NLM_cas:coden">FRBIF6</span>;
        ISSN:<span class="NLM_cas:issn">1093-4715</span>.
    
            (<span class="NLM_cas:orgname">Frontiers in Bioscience</span>)
        </div><div class="casAbstract">A review.  Poly-ADP-ribose metab. plays a mayor role in a wide range of biol. processes, such as maintenance of genomic stability, transcriptional regulation, energy metab., and cell death.  Poly-ADP-ribose polymerases (PARPs) are an ancient family of enzymes, as evidenced by the poly-ADP-ribosylating activities reported in dinoflagellates and archaebacteria and by the identification of Parp-like genes in eubacterial and archaeabacterial genomes.  Six genes encoding "bona fide" PARP enzymes have been identified in mammalians: PARP1, PARP2, PARP3, PARP4/vPARP, PARP5/Tankyrases-1, and PARP6/Tankyrases-2.  The best studied of these enzymes, PARP1, plays a primary role in the process of poly-ADP-ribosylation.  PARP1-mediated poly-ADP-ribosylation has been implicated in the pathogenesis of cancer, inflammatory, and neurodegenerative disorders.  Here, the authors summarize novel findings and concepts for PARP enzymes and their poly-ADP-ribosylation activity in the regulation of physiol. and pathophysiol. processes.  A special focus is placed on the proposed mol. mechanisms involved in these processes, such as signaling, regulation of telomere dynamics, remodeling of chromatin structure, and transcriptional regulation.  A potential functional cross-talk between PARP family members and other NAD-consuming enzymes is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoNyzgIk1gtrVg90H21EOLACvtfcHk0lgrmkPFohsqNw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhs1Cntrk%253D&md5=1e62c4597ec219b0797a29c1458b98b4</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.2741%2F2909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2741%252F2909%26sid%3Dliteratum%253Aachs%26aulast%3DHassa%26aufirst%3DP.%2BO.%26aulast%3DHottiger%26aufirst%3DM.%2BO.%26atitle%3DThe%2520diverse%2520biological%2520roles%2520of%2520mammalian%2520PARPS%252C%2520a%2520small%2520but%2520powerful%2520family%2520of%2520poly-ADP-ribose%2520polymerases%26jtitle%3DFront.%2520Biosci.%26date%3D2008%26volume%3D13%26spage%3D3046%26epage%3D3082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Miwa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masutani, M.</span><span> </span><span class="NLM_article-title">Poly(ADP-ribosyl)ation and cancer</span> <span class="citation_source-journal">Cancer Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">1528</span><span class="NLM_x">â</span> <span class="NLM_lpage">1535</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1111%2Fj.1349-7006.2007.00567.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=17645773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtF2qtb7L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2007&pages=1528-1535&author=M.+Miwaauthor=M.+Masutani&title=Poly%28ADP-ribosyl%29ation+and+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">PolyADP-ribosylation and cancer</span></div><div class="casAuthors">Miwa, Masanao; Masutani, Mitsuko</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1528-1535</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1347-9032</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Asia Pty Ltd.</span>)
        </div><div class="casAbstract">A review.  The polyADP-ribosylation reaction results in a unique posttranslational modification involved in various cellular processes and conditions, including DNA repair, transcriptional control, genomic stability, cell death and transformation.  The existence of 17 members of the poly(ADP-ribose) polymerase (PARP) family has so far been documented, with overlapping functional consequences.  PARP-1 is known to be involved in DNA base excision repair and this explains the susceptibility spectrum of PARP-1 knockout animals to genotoxic carcinogens.  The fact that centrosome amplification is induced by a non-genotoxic inhibitor of PARP and in PARP-1 knockout mouse cells, is in line with aneuploidy, which is frequent in cancers.  Genetically engineered animal models have revealed that PARP-1 and VPARP impact carcinogenesis.  Furthermore, accumulating exptl. evidence supports the utility of PARP and PARG inhibitors in cancer therapy and several clin. trials are now ongoing.  Increasing NAD+ levels by pharmacol. supplementation with niacin was also found to exert preventive effects against cancer.  In the present review, recent research progress on polyADP-ribosylation related to neoplasia is summarized and discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqohmHOW4JQ47Vg90H21EOLACvtfcHk0lhTlhIybdoHcg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtF2qtb7L&md5=ba468fe6fdae25fc6f41a9f1aea06b5f</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2007.00567.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2007.00567.x%26sid%3Dliteratum%253Aachs%26aulast%3DMiwa%26aufirst%3DM.%26aulast%3DMasutani%26aufirst%3DM.%26atitle%3DPoly%2528ADP-ribosyl%2529ation%2520and%2520cancer%26jtitle%3DCancer%2520Sci.%26date%3D2007%26volume%3D98%26spage%3D1528%26epage%3D1535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Schreiber, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dantzer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ame, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Murcia, G.</span><span> </span><span class="NLM_article-title">Poly(ADP-ribose): novel functions for an old molecule</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">517</span><span class="NLM_x">â</span> <span class="NLM_lpage">528</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1038%2Fnrm1963" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=16829982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD28Xms1Ohsb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=517-528&author=V.+Schreiberauthor=F.+Dantzerauthor=J.+C.+Ameauthor=G.+de+Murcia&title=Poly%28ADP-ribose%29%3A+novel+functions+for+an+old+molecule"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Poly(ADP-ribose): novel functions for an old molecule</span></div><div class="casAuthors">Schreiber, Valerie; Dantzer, Francoise; Ame, Jean-Christophe; de Murcia, Gilbert</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">517-528</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The addn. to proteins of the neg. charged polymer of ADP-ribose, which is synthesized by poly(ADP-ribose) polymerase (PARPs) from NAD, is a unique post-translational modification.  It regulates not only cell survival and cell-death programs, but also an increasing no. of other biol. functions with which novel members of the PARP family have been assocd.  These functions include transcriptional regulation, telomere cohesion and mitotic spindle formation during cell division, intracellular trafficking, and energy metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLsI4_BKfjdrVg90H21EOLACvtfcHk0lhTlhIybdoHcg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xms1Ohsb4%253D&md5=676e83755491500f3bf2137f348dfa1b</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrm1963&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm1963%26sid%3Dliteratum%253Aachs%26aulast%3DSchreiber%26aufirst%3DV.%26aulast%3DDantzer%26aufirst%3DF.%26aulast%3DAme%26aufirst%3DJ.%2BC.%26aulast%3Dde%2BMurcia%26aufirst%3DG.%26atitle%3DPoly%2528ADP-ribose%2529%253A%2520novel%2520functions%2520for%2520an%2520old%2520molecule%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2006%26volume%3D7%26spage%3D517%26epage%3D528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Jagtap, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabo, C.</span><span> </span><span class="NLM_article-title">Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">421</span><span class="NLM_x">â</span> <span class="NLM_lpage">440</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1038%2Fnrd1718" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=15864271" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjs1OktL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=421-440&author=P.+Jagtapauthor=C.+Szabo&title=Poly%28ADP-ribose%29+polymerase+and+the+therapeutic+effects+of+its+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors</span></div><div class="casAuthors">Jagtap, Prakash; Szabo, Csaba</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">421-440</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Poly(ADP-ribose) polymerases (PARPs) are involved in the regulation of many cellular functions.  Three consequences of the activation of PARP1, which is the main isoform of the PARP family, are particularly important for drug development: first, its role in DNA repair; second, its capacity to deplete cellular energetic pools, which culminates in cell dysfunction and necrosis; and third, its capacity to promote the transcription of pro-inflammatory genes.  Consequently, pharmacol. inhibitors of PARP have the potential to enhance the cytotoxicity of certain DNA-damaging anticancer drugs, reduce parenchymal cell necrosis (for example, in stroke or myocardial infarction) and downregulate multiple simultaneous pathways of inflammation and tissue injury (for example, in circulatory shock, colitis or diabetic complications).  The first ultrapotent novel PARP inhibitors have now entered human clin. trials.  This article presents an overview of the principal pathophysiol. pathways and mechanisms that are governed by PARP, followed by the main structures and therapeutic actions of various classes of novel PARP inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDsrfd_xv8g7Vg90H21EOLACvtfcHk0li33E9mPY2SJw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjs1OktL8%253D&md5=1dfd177b8064b017efb5dd7779655d55</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrd1718&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1718%26sid%3Dliteratum%253Aachs%26aulast%3DJagtap%26aufirst%3DP.%26aulast%3DSzabo%26aufirst%3DC.%26atitle%3DPoly%2528ADP-ribose%2529%2520polymerase%2520and%2520the%2520therapeutic%2520effects%2520of%2520its%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2005%26volume%3D4%26spage%3D421%26epage%3D440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Ljungman, M.</span><span> </span><span class="NLM_article-title">Targeting the DNA damage response in cancer</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">2929</span><span class="NLM_x">â</span> <span class="NLM_lpage">2950</span></span><div class="citationLinks">[<a href="/doi/10.1021/cr900047g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnsFemtrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2009&pages=2929-2950&author=M.+Ljungman&title=Targeting+the+DNA+damage+response+in+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the DNA Damage Response in Cancer</span></div><div class="casAuthors">Ljungman, Mats</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2929-2950</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  We are in an exciting phase in cancer research with a rapid pace of discovery driven by new technologies.  Recent studies have shed light on the complexity of tumor biol., showing that tumors rarely have similar sets of mutations in common.  However, when placing the various tumor mutations into functional pathways, a more manageable picture emerges with about 12 core pathways abrogated in the majority of the tumors.  Thus, it may be possible after identifying the pathway(s) altered in a particular tumor to tailor therapies to specifically block that pathway(s).  The DNA damage response is one of these core pathways found to be frequently dysregulated in cancer.  Proteins participating in this pathway are expected to be important therapeutic targets for the sensitization of tumor cells to radiation or chemotherapy.  The targeting of the DNA damage response in cancer stem cells may be of particular importance, since these cells are often found to be more resistant to radiation and chemotherapy than other tumor cells.  The fact that many tumors have defects in DNA repair pathways and/or cell cycle checkpoints presents unique opportunities for therapeutic exploitation.  Likewise, oncogene-driven induction of "DNA damage" sets tumor cells apart from normal cells, and with a better understanding of the mechanisms involved in the repair of these lesions, tumor-selective therapies may be developed.  Aristotle once said: "We make war that we may live in peace".  By applying novel strategies involving inhibitors of the DNA damage response in combination with radiation or chemotherapy, we may improve the chances of peace by winning the war on cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopslYTMfDHnrVg90H21EOLACvtfcHk0li33E9mPY2SJw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnsFemtrk%253D&md5=327ba938830918171b646fb2ad1754bc</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fcr900047g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr900047g%26sid%3Dliteratum%253Aachs%26aulast%3DLjungman%26aufirst%3DM.%26atitle%3DTargeting%2520the%2520DNA%2520damage%2520response%2520in%2520cancer%26jtitle%3DChem.%2520Rev.%26date%3D2009%26volume%3D109%26spage%3D2929%26epage%3D2950" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Caiafa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guastafierro, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zampieri, M.</span><span> </span><span class="NLM_article-title">Epigenetics: poly(ADP-ribosyl)ation of PARP-1 regulates genomic methylation patterns</span> <span class="citation_source-journal">FASEB J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">672</span><span class="NLM_x">â</span> <span class="NLM_lpage">678</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2009&pages=672-678&author=P.+Caiafaauthor=T.+Guastafierroauthor=M.+Zampieri&title=Epigenetics%3A+poly%28ADP-ribosyl%29ation+of+PARP-1+regulates+genomic+methylation+patterns"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCaiafa%26aufirst%3DP.%26aulast%3DGuastafierro%26aufirst%3DT.%26aulast%3DZampieri%26aufirst%3DM.%26atitle%3DEpigenetics%253A%2520poly%2528ADP-ribosyl%2529ation%2520of%2520PARP-1%2520regulates%2520genomic%2520methylation%2520patterns%26jtitle%3DFASEB%2520J.%26date%3D2009%26volume%3D23%26spage%3D672%26epage%3D678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Papeo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forte, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrera, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Posteri, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scolaro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montagnoli, A.</span><span> </span><span class="NLM_article-title">Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity?</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1377</span><span class="NLM_x">â</span> <span class="NLM_lpage">1400</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1517%2F13543770903215883" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFyhtLfN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1377-1400&author=G.+Papeoauthor=B.+Forteauthor=P.+Orsiniauthor=C.+Perreraauthor=H.+Posteriauthor=A.+Scolaroauthor=A.+Montagnoli&title=Poly%28ADP-ribose%29+polymerase+inhibition+in+cancer+therapy%3A+are+we+close+to+maturity%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity?</span></div><div class="casAuthors">Papeo, Gianluca; Forte, Barbara; Orsini, Paolo; Perrera, Claudia; Posteri, Helena; Scolaro, Alessandra; Montagnoli, Alessia</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1377-1400</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: During the last few years an increasing no. of poly(ADP-ribose) polymerase (PARP) inhibitors have been appearing in the context of cancer therapy.  This is mainly due to a better knowledge of the best-characterized member of the PARP family of enzymes, PARP-1, further reinforced by the recognition of the clin. benefits arising from its inhibition.  Objective/method: The aim of this review is to give the reader an update on PARP inhibition in cancer therapy, by covering both the scientific (SciFinder search) and the patent literature (Chem. Abstr./Derwent search) published recently (2005 - 2008).  Conclusions: More patient-compliant orally available PARP-1 inhibitor clin. candidates, along with their possible use as single agents in specific, molecularly defined cancer indications, increase the expectations for this therapeutic approach.  The growing understanding of the biol. role of other PARPs, such as Tankyrase 1, may be of interest as new potential targets.  Besides the classical NAD-mimicking pharmacophore, addnl. compds., which either do not resemble nicotinamide or exploit different binding sites, are emerging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIwGUDjN9gRbVg90H21EOLACvtfcHk0lgmfOgFZeFT8A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFyhtLfN&md5=16cc23d941b16a80ff9d8da769f99a9b</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1517%2F13543770903215883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543770903215883%26sid%3Dliteratum%253Aachs%26aulast%3DPapeo%26aufirst%3DG.%26aulast%3DForte%26aufirst%3DB.%26aulast%3DOrsini%26aufirst%3DP.%26aulast%3DPerrera%26aufirst%3DC.%26aulast%3DPosteri%26aufirst%3DH.%26aulast%3DScolaro%26aufirst%3DA.%26aulast%3DMontagnoli%26aufirst%3DA.%26atitle%3DPoly%2528ADP-ribose%2529%2520polymerase%2520inhibition%2520in%2520cancer%2520therapy%253A%2520are%2520we%2520close%2520to%2520maturity%253F%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2009%26volume%3D19%26spage%3D1377%26epage%3D1400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Cuzzocrea, S.</span><span> </span><span class="NLM_article-title">Shock, inflammation and PARP</span> <span class="citation_source-journal">Pharmacol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">72</span><span class="NLM_x">â</span> <span class="NLM_lpage">82</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1016%2Fj.phrs.2005.02.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=15911335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1Wlt78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2005&pages=72-82&author=S.+Cuzzocrea&title=Shock%2C+inflammation+and+PARP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Shock, inflammation and PARP</span></div><div class="casAuthors">Cuzzocrea, Salvatore</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">72-82</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The activation of poly(ADP-ribose) polymerase (PARP) is well considered to play an important role in various patho-physiol. conditions like inflammation and shock.  A vast amt. of circumstantial evidence implicates oxygen-derived free radicals (esp., superoxide and hydroxyl radical) and high-energy oxidants (such as peroxynitrite) as mediators of inflammation and shock.  ROS (e.g., superoxide, peroxynitrite, hydroxyl radical and hydrogen peroxide) are all potential reactants capable of initiating DNA single strand breakage, with subsequent activation of the nuclear enzyme poly(ADP-ribose) synthetase (PARS), leading to eventual severe energy depletion of the cells, and necrotic-type cell death.  During the last years, numerous exptl. studies have clearly demonstrated the beneficial effects of PARP inhibition in cell cultures through rodent models and more recently in pre-clin. large animal models of acute and chronic inflammation.  The aim of this review is to describe recent exptl. evidence implicating PARP as a pathophysiol. modulator of acute and chronic inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4Exd627XiZbVg90H21EOLACvtfcHk0lgmfOgFZeFT8A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1Wlt78%253D&md5=91556b95fcafc778639c4caf747c4675</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2005.02.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2005.02.016%26sid%3Dliteratum%253Aachs%26aulast%3DCuzzocrea%26aufirst%3DS.%26atitle%3DShock%252C%2520inflammation%2520and%2520PARP%26jtitle%3DPharmacol.%2520Res.%26date%3D2005%26volume%3D52%26spage%3D72%26epage%3D82" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Peralta-Leal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Vargas, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aguilar-Quesada, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linares, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Almodovar, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliver, F. J.</span><span> </span><span class="NLM_article-title">PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases</span> <span class="citation_source-journal">Free Radical Biol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">13</span><span class="NLM_x">â</span> <span class="NLM_lpage">26</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1016%2Fj.freeradbiomed.2009.04.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=19362586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD1MXms1yhsLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2009&pages=13-26&author=A.+Peralta-Lealauthor=J.+M.+Rodriguez-Vargasauthor=R.+Aguilar-Quesadaauthor=M.+I.+Rodriguezauthor=J.+L.+Linaresauthor=M.+R.+de+Almodovarauthor=F.+J.+Oliver&title=PARP+inhibitors%3A+new+partners+in+the+therapy+of+cancer+and+inflammatory+diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">PARP inhibitors: New partners in the therapy of cancer and inflammatory diseases</span></div><div class="casAuthors">Peralta-Leal, Andreina; Rodriguez-Vargas, Jose Manuel; Aguilar-Quesada, Rocio; Rodriguez, Maria Isabel; Linares, Jose Luis; Ruiz de Almodovar, Mariano; Oliver, F. Javier</div><div class="citationInfo"><span class="NLM_cas:title">Free Radical Biology & Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-26</span>CODEN:
                <span class="NLM_cas:coden">FRBMEH</span>;
        ISSN:<span class="NLM_cas:issn">0891-5849</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Poly(ADP-ribose) polymerases (PARPs) are defined as cell signaling enzymes that catalyze the transfer of ADP-ribose units from NAD+ to a no. of acceptor proteins.  PARP-1, the best characterized member of the PARP family, which currently comprises 18 members, is an abundant nuclear enzyme implicated in cellular responses to DNA injury provoked by genotoxic stress.  PARP is involved in DNA repair and transcriptional regulation and is now recognized as a key regulator of cell survival and cell death as well as a master component of a no. of transcription factors involved in tumor development and inflammation.  PARP-1 is essential to the repair of DNA single-strand breaks via the base excision repair pathway.  Inhibitors of PARP-1 have been shown to enhance the cytotoxic effects of ionizing radiation and DNA-damaging chemotherapy agents, such as the methylating agents and topoisomerase I inhibitors.  There are currently at least five PARP inhibitors in clin. trial development.  Recent in vitro and in vivo evidence suggests that PARP inhibitors could be used not only as chemo/radiotherapy sensitizers, but also as single agents to selectively kill cancers defective in DNA repair, specifically cancers with mutations in the breast cancer-assocd. genes (BRCA1 and BRCA2).  PARP becomes activated in response to oxidative DNA damage and depletes cellular energy pools, thus leading to cellular dysfunction in various tissues.  The activation of PARP may also induce various cell death processes and promotes an inflammatory response assocd. with multiple organ failure.  Inhibition of PARP activity is protective in a wide range of inflammatory and ischemia-reperfusion-assocd. diseases, including cardiovascular diseases, diabetes, rheumatoid arthritis, endotoxic shock, and stroke.  The aim of this review is to overview the emerging data in the literature showing the role of PARP in the pathogenesis of cancer and inflammatory diseases and unravel the solid body of literature that supports the view that PARP is an important target for therapeutic intervention in crit. illness.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoL1ahpR0DqBbVg90H21EOLACvtfcHk0lgmfOgFZeFT8A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXms1yhsLk%253D&md5=0c16682cb09319ecd32bf94586b151bf</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.freeradbiomed.2009.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.freeradbiomed.2009.04.008%26sid%3Dliteratum%253Aachs%26aulast%3DPeralta-Leal%26aufirst%3DA.%26aulast%3DRodriguez-Vargas%26aufirst%3DJ.%2BM.%26aulast%3DAguilar-Quesada%26aufirst%3DR.%26aulast%3DRodriguez%26aufirst%3DM.%2BI.%26aulast%3DLinares%26aufirst%3DJ.%2BL.%26aulast%3Dde%2BAlmodovar%26aufirst%3DM.%2BR.%26aulast%3DOliver%26aufirst%3DF.%2BJ.%26atitle%3DPARP%2520inhibitors%253A%2520new%2520partners%2520in%2520the%2520therapy%2520of%2520cancer%2520and%2520inflammatory%2520diseases%26jtitle%3DFree%2520Radical%2520Biol.%2520Med.%26date%3D2009%26volume%3D47%26spage%3D13%26epage%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Peukert, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwahn, U.</span><span> </span><span class="NLM_article-title">New inhibitors of poly(ADP-ribose) polymerase (PARP)</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1531</span><span class="NLM_x">â</span> <span class="NLM_lpage">1551</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1517%2F13543776.14.11.1531" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD2cXoslemu7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=1531-1551&author=S.+Peukertauthor=U.+Schwahn&title=New+inhibitors+of+poly%28ADP-ribose%29+polymerase+%28PARP%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">New inhibitors of poly(ADP-ribose) polymerase (PARP)</span></div><div class="casAuthors">Peukert, Stefan; Schwahn, Uwe</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1531-1551</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Poly(ADP-ribose) polymerase-1 (PARP-1), the most prominent member of the PARP family, is a DNA-binding protein that is activated by nicks in DNA occurring during inflammation, ischemia, neurodegeneration or cancer therapy.  Activated PARP-1 consumes NAD+ that is cleaved into nicotinamide and ADP-ribose and polymerizes the latter onto nuclear acceptor proteins.  This highly energy consuming process is pivotal for the maintenance of genomic stability although over-activation can culminate in cell dysfunction and necrosis.  Therefore, PARP-1 is regarded as a promising target for the development of drugs useful in various forms of inflammation, ischemia-reperfusion injury and as an adjunct in cancer therapy.  This review summarizes the structural classes of known PARP-1 inhibitors, with a focus on new inhibitors published for this target, between 2002 and July 2004.  The chem. and biol. data disclosed in these patent applications are discussed in light of new structural knowledge of the catalytic domain of the PARP family and recent work with potent inhibitors demonstrating the effects of PARP inhibition in various animal disease models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbTHYakSgCR7Vg90H21EOLACvtfcHk0lieJOZdMrbp4w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXoslemu7k%253D&md5=56e768ccf3d5520f34e17b6886ba4405</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1517%2F13543776.14.11.1531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.14.11.1531%26sid%3Dliteratum%253Aachs%26aulast%3DPeukert%26aufirst%3DS.%26aulast%3DSchwahn%26aufirst%3DU.%26atitle%3DNew%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2004%26volume%3D14%26spage%3D1531%26epage%3D1551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Southan, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabo, C.</span><span> </span><span class="NLM_article-title">Poly(ADP-ribose) polymerase inhibitors</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">321</span><span class="NLM_x">â</span> <span class="NLM_lpage">340</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=12570705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlt1GhsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2003&pages=321-340&author=G.+J.+Southanauthor=C.+Szabo&title=Poly%28ADP-ribose%29+polymerase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Poly(ADP-ribose) polymerase inhibitors</span></div><div class="casAuthors">Southan, Garry J.; Szabo, Csaba</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">321-340</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers</span>)
        </div><div class="casAbstract">A review.  Poly(ADP-ribose) polymerase-1 (PARP-1) is the principal member of the PARP enzyme family consisting of PARP-1 and several recently identified novel poly(ADP-ribosyl)ating enzymes.  PARP-1 functions as a DNA damage sensor and signaling mol.  Upon binding to DNA breaks, activated PARP cleaves NAD+ into nicotinamide and ADP-ribose and polymerizes the latter onto nuclear acceptor proteins including histones, transcription factors and PARP itself.  This Poly(ADP-ribosyl)ation contributes to inflammatory signal transduction processes.  In addn., oxidative stress-induced overactivation of PARP consumes NAD+ and consequently ATP, culminating in cell dysfunction or necrosis.  Activation of PARP has been implicated in the pathogenesis of stroke, myocardial ischemia, diabetes, diabetes-assocd. cardiovascular dysfunction, shock, traumatic central nervous system injury, arthritis, colitis, allergic encephalomyelitis and various other forms of inflammation.  Therefore, inhibition of PARP by pharmacol. agents may prove useful for the therapy of these diseases, as has been shown in preclin. animal models.  Moreover, PARP inhibitors may have addnl., potential utility as anticancer agents, radiosensitizers and antiviral agents.  In the present article we overview the structures and pharmacol. actions of various pharmacol. classes of compds. which inhibit the catalytic activity of PARP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_QtUM117ipLVg90H21EOLACvtfcHk0lieJOZdMrbp4w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlt1GhsQ%253D%253D&md5=43e29a697d0ead1c9d87c8336a83d43d</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSouthan%26aufirst%3DG.%2BJ.%26aulast%3DSzabo%26aufirst%3DC.%26atitle%3DPoly%2528ADP-ribose%2529%2520polymerase%2520inhibitors%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2003%26volume%3D10%26spage%3D321%26epage%3D340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Banasik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueda, K.</span><span> </span><span class="NLM_article-title">Inhibitors and activators of ADP-ribosylation reactions</span> <span class="citation_source-journal">Mol. Cell. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">138</span><span class="NLM_x">, </span> <span class="NLM_fpage">185</span><span class="NLM_x">â</span> <span class="NLM_lpage">197</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=1994&pages=185-197&author=M.+Banasikauthor=K.+Ueda&title=Inhibitors+and+activators+of+ADP-ribosylation+reactions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBanasik%26aufirst%3DM.%26aulast%3DUeda%26aufirst%3DK.%26atitle%3DInhibitors%2520and%2520activators%2520of%2520ADP-ribosylation%2520reactions%26jtitle%3DMol.%2520Cell.%2520Biochem.%26date%3D1994%26volume%3D138%26spage%3D185%26epage%3D197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Li, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span> </span><span class="NLM_article-title">PARP inhibitors</span> <span class="citation_source-journal">IDrugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">804</span><span class="NLM_x">â</span> <span class="NLM_lpage">812</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=15995937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlvVKht7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2001&pages=804-812&author=J.+H.+Liauthor=J.+Zhang&title=PARP+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">PARP inhibitors</span></div><div class="casAuthors">Li, Jia-He; Zhang, Jie</div><div class="citationInfo"><span class="NLM_cas:title">IDrugs</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">804-812</span>CODEN:
                <span class="NLM_cas:coden">IDRUFN</span>;
        ISSN:<span class="NLM_cas:issn">1369-7056</span>.
    
            (<span class="NLM_cas:orgname">Current Drugs Ltd.</span>)
        </div><div class="casAbstract">A review with refs.  Poly(ADP-ribose) polymerase (PARP) catalyzes the biochem. conversion of NAD (NAD+) to poly(ADP-ribose) and nicotinamide, which is a weak feedback inhibitor of the enzyme.  Early designs of PARP inhibitors were primarily based on mimicking the structure of nicotinamide and resulted in the identification and widespread use of benzamide analogs as PARP inhibitors.  Recent searches for more potent and specific PARP inhibitors, facilitated by the crystal structure of the catalytic domain of PARP, led to several families of amide and lactam derivs. with multiple ring systems.  New PARP inhibitors have shown efficacies in several animal disease models of cancer, ischemia and inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzuoUw68ISq7Vg90H21EOLACvtfcHk0lhx02mBbAdnpQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlvVKht7k%253D&md5=8c5c04c7fcd5f4b1e752fcddad3d9df2</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%2BH.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DPARP%2520inhibitors%26jtitle%3DIDrugs%26date%3D2001%26volume%3D4%26spage%3D804%26epage%3D812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Zaremba, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span> </span><span class="NLM_article-title">PARP inhibitor development for systemic cancer targeting</span> <span class="citation_source-journal">Anti-Cancer Agents Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">515</span><span class="NLM_x">â</span> <span class="NLM_lpage">523</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=515-523&author=T.+Zarembaauthor=N.+J.+Curtin&title=PARP+inhibitor+development+for+systemic+cancer+targeting"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZaremba%26aufirst%3DT.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26atitle%3DPARP%2520inhibitor%2520development%2520for%2520systemic%2520cancer%2520targeting%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D515%26epage%3D523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Wang, Z. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stingl, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berghammer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haidacher, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schweiger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, E. F.</span><span> </span><span class="NLM_article-title">Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease</span> <span class="citation_source-journal">Genes Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">509</span><span class="NLM_x">â</span> <span class="NLM_lpage">520</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1995&pages=509-520&author=Z.+Q.+Wangauthor=B.+Auerauthor=L.+Stinglauthor=H.+Berghammerauthor=D.+Haidacherauthor=M.+Schweigerauthor=E.+F.+Wagner&title=Mice+lacking+ADPRT+and+poly%28ADP-ribosyl%29ation+develop+normally+but+are+susceptible+to+skin+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%2BQ.%26aulast%3DAuer%26aufirst%3DB.%26aulast%3DStingl%26aufirst%3DL.%26aulast%3DBerghammer%26aufirst%3DH.%26aulast%3DHaidacher%26aufirst%3DD.%26aulast%3DSchweiger%26aufirst%3DM.%26aulast%3DWagner%26aufirst%3DE.%2BF.%26atitle%3DMice%2520lacking%2520ADPRT%2520and%2520poly%2528ADP-ribosyl%2529ation%2520develop%2520normally%2520but%2520are%2520susceptible%2520to%2520skin%2520disease%26jtitle%3DGenes%2520Dev.%26date%3D1995%26volume%3D9%26spage%3D509%26epage%3D520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Huber, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Murcia, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Murcia, G.</span><span> </span><span class="NLM_article-title">PARP-1, PARP-2 and ATM in the DNA damage response: functional synergy in mouse development</span> <span class="citation_source-journal">DNA Repair</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1103</span><span class="NLM_x">â</span> <span class="NLM_lpage">1108</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=1103-1108&author=A.+Huberauthor=P.+Baiauthor=J.+M.+de+Murciaauthor=G.+de+Murcia&title=PARP-1%2C+PARP-2+and+ATM+in+the+DNA+damage+response%3A+functional+synergy+in+mouse+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHuber%26aufirst%3DA.%26aulast%3DBai%26aufirst%3DP.%26aulast%3Dde%2BMurcia%26aufirst%3DJ.%2BM.%26aulast%3Dde%2BMurcia%26aufirst%3DG.%26atitle%3DPARP-1%252C%2520PARP-2%2520and%2520ATM%2520in%2520the%2520DNA%2520damage%2520response%253A%2520functional%2520synergy%2520in%2520mouse%2520development%26jtitle%3DDNA%2520Repair%26date%3D2004%26volume%3D3%26spage%3D1103%26epage%3D1108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Ishida, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kido, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamijo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyake, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohkubo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinoshita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warizaya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwashita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mihara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuoka, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattori, K.</span><span> </span><span class="NLM_article-title">Discovery of potent and selective PARP-1 and PARP-2 inhibitors: SBDD analysis via a combination of X-ray structural study and homology modeling</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1378</span><span class="NLM_x">â</span> <span class="NLM_lpage">1390</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1016%2Fj.bmc.2005.09.061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=16288880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsVGjtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=1378-1390&author=J.+Ishidaauthor=H.+Yamamotoauthor=Y.+Kidoauthor=K.+Kamijoauthor=K.+Muranoauthor=H.+Miyakeauthor=M.+Ohkuboauthor=T.+Kinoshitaauthor=M.+Warizayaauthor=A.+Iwashitaauthor=K.+Miharaauthor=N.+Matsuokaauthor=K.+Hattori&title=Discovery+of+potent+and+selective+PARP-1+and+PARP-2+inhibitors%3A+SBDD+analysis+via+a+combination+of+X-ray+structural+study+and+homology+modeling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of potent and selective PARP-1 and PARP-2 inhibitors: SBDD analysis via a combination of X-ray structural study and homology modeling</span></div><div class="casAuthors">Ishida, Junya; Yamamoto, Hirofumi; Kido, Yoshiyuki; Kamijo, Kazunori; Murano, Kenji; Miyake, Hiroshi; Ohkubo, Mitsuru; Kinoshita, Takayoshi; Warizaya, Masaichi; Iwashita, Akinori; Mihara, Kayoko; Matsuoka, Nobuya; Hattori, Kouji</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1378-1390</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We disclose herein our efforts aimed at discovery of selective PARP-1 and PARP-2 inhibitors.  We have recently discovered several novel classes of quinazolinones, quinazolidinones, and quinoxalines as potent PARP-1 inhibitors, which may represent attractive therapeutic candidates.  In PARP enzyme assays using recombinant PARP-1 and PARP-2, the quinazolinone derivs. displayed relatively high selectivity for PARP-1 and quinoxaline derivs. showed superior selectivity for PARP-2, and the quinazolidinone derivs. did not have selectivity for PARP-1/2.  Structure-based drug design anal. via a combination of X-ray structural study utilizing the complexes of inhibitors and human PARP-1 catalytic domain, and homol. modeling using murine PARP-2 suggested distinct interactions of inhibitors with PARP-1 and PARP-2.  These findings provide a new structural framework for the design of selective inhibitors for PARP-1 and PARP-2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrukfYFsnRIEbVg90H21EOLACvtfcHk0lhp0xKFRtrBjA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsVGjtw%253D%253D&md5=9f72cd79428d0c006e2995c19a345c0f</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2005.09.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2005.09.061%26sid%3Dliteratum%253Aachs%26aulast%3DIshida%26aufirst%3DJ.%26aulast%3DYamamoto%26aufirst%3DH.%26aulast%3DKido%26aufirst%3DY.%26aulast%3DKamijo%26aufirst%3DK.%26aulast%3DMurano%26aufirst%3DK.%26aulast%3DMiyake%26aufirst%3DH.%26aulast%3DOhkubo%26aufirst%3DM.%26aulast%3DKinoshita%26aufirst%3DT.%26aulast%3DWarizaya%26aufirst%3DM.%26aulast%3DIwashita%26aufirst%3DA.%26aulast%3DMihara%26aufirst%3DK.%26aulast%3DMatsuoka%26aufirst%3DN.%26aulast%3DHattori%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520selective%2520PARP-1%2520and%2520PARP-2%2520inhibitors%253A%2520SBDD%2520analysis%2520via%2520a%2520combination%2520of%2520X-ray%2520structural%2520study%2520and%2520homology%2520modeling%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2006%26volume%3D14%26spage%3D1378%26epage%3D1390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Ogata, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kagamiyama, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayaishi, O.</span><span> </span><span class="NLM_article-title">ADP-ribosylation of histone H1. Identification of glutamic acid residues 2, 14, and the COOH-terminal lysine residue as modification sites</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1980</span><span class="NLM_x">, </span> <span class="NLM_volume">255</span><span class="NLM_x">, </span> <span class="NLM_fpage">7616</span><span class="NLM_x">â</span> <span class="NLM_lpage">7620</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=255&publication_year=1980&pages=7616-7620&author=N.+Ogataauthor=K.+Uedaauthor=H.+Kagamiyamaauthor=O.+Hayaishi&title=ADP-ribosylation+of+histone+H1.+Identification+of+glutamic+acid+residues+2%2C+14%2C+and+the+COOH-terminal+lysine+residue+as+modification+sites"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOgata%26aufirst%3DN.%26aulast%3DUeda%26aufirst%3DK.%26aulast%3DKagamiyama%26aufirst%3DH.%26aulast%3DHayaishi%26aufirst%3DO.%26atitle%3DADP-ribosylation%2520of%2520histone%2520H1.%2520Identification%2520of%2520glutamic%2520acid%2520residues%25202%252C%252014%252C%2520and%2520the%2520COOH-terminal%2520lysine%2520residue%2520as%2520modification%2520sites%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1980%26volume%3D255%26spage%3D7616%26epage%3D7620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Szabo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zingarelli, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâConnor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salzman, A. L.</span><span> </span><span class="NLM_article-title">DNA strand breakage, activation of poly (ADP-ribose) synthetase, and cellular energy depletion are involved in the cytotoxicity of macrophages and smooth muscle cells exposed to peroxynitrite</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">1753</span><span class="NLM_x">â</span> <span class="NLM_lpage">1758</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1996&pages=1753-1758&author=C.+Szaboauthor=B.+Zingarelliauthor=M.+O%E2%80%99Connorauthor=A.+L.+Salzman&title=DNA+strand+breakage%2C+activation+of+poly+%28ADP-ribose%29+synthetase%2C+and+cellular+energy+depletion+are+involved+in+the+cytotoxicity+of+macrophages+and+smooth+muscle+cells+exposed+to+peroxynitrite"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSzabo%26aufirst%3DC.%26aulast%3DZingarelli%26aufirst%3DB.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%26aulast%3DSalzman%26aufirst%3DA.%2BL.%26atitle%3DDNA%2520strand%2520breakage%252C%2520activation%2520of%2520poly%2520%2528ADP-ribose%2529%2520synthetase%252C%2520and%2520cellular%2520energy%2520depletion%2520are%2520involved%2520in%2520the%2520cytotoxicity%2520of%2520macrophages%2520and%2520smooth%2520muscle%2520cells%2520exposed%2520to%2520peroxynitrite%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1996%26volume%3D93%26spage%3D1753%26epage%3D1758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">de Murcia, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niedergang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trucco, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ricoul, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutrillaux, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mark, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliver, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dierich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LeMeur, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walztinger, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chambon, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Murcia, G.</span><span> </span><span class="NLM_article-title">Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">7303</span><span class="NLM_x">â</span> <span class="NLM_lpage">7307</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1073%2Fpnas.94.14.7303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=9207086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADyaK2sXksFOntb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1997&pages=7303-7307&author=J.+M.+de+Murciaauthor=C.+Niedergangauthor=C.+Truccoauthor=M.+Ricoulauthor=B.+Dutrillauxauthor=M.+Markauthor=F.+J.+Oliverauthor=M.+Massonauthor=A.+Dierichauthor=M.+LeMeurauthor=C.+Walztingerauthor=P.+Chambonauthor=G.+de+Murcia&title=Requirement+of+poly%28ADP-ribose%29+polymerase+in+recovery+from+DNA+damage+in+mice+and+in+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells</span></div><div class="casAuthors">Menissier de Murcia, Josiane; Niedergang, Claude; Trucco, Carlotta; Ricoul, Michele; Dutrillaux, Bernard; Mark, Manuel; Oliver, F. Javier; Masson, Murielle; Dierich, Andree; LeMeur, Marianne; Walztinger, Caroline; Chambon, Pierre; de Murcia, Gilbert</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">7303-7307</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase [PARP; NAD+ ADP-ribosyltransferase; NAD+:poly(adenosine-diphosphate-D-ribosyl)-acceptor ADP-D-ribosyltransferase, EC 2.4.2.30] is a zinc-finger DNA-binding protein that detects specifically DNA strand breaks generated by genotoxic agents.  To det. its biol. function, the authors have inactivated both alleles by gene targeting in mice.  Treatment of PARP-/- mice either by the alkylating agent N-methyl-N-nitrosourea (MNU) or by Î³-irradn. revealed an extreme sensitivity and a high genomic instability to both agents.  Following whole body Î³-irradn. (8 Gy) mutant mice died rapidly from acute radiation toxicity to the small intestine.  Mice-derived PARP-/- cells displayed a high sensitivity to MNU exposure: a G2/M arrest in mouse embryonic fibroblasts and a rapid apoptotic response and a p53 accumulation were obsd. in splenocytes.  Altogether these results demonstrate that PARP is a survival factor playing an essential and pos. role during DNA damage recovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlwmTBk-nHc7Vg90H21EOLACvtfcHk0lhp0xKFRtrBjA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXksFOntb4%253D&md5=a652d7d877fa0c29ff1aeb9769fbd86f</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1073%2Fpnas.94.14.7303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.94.14.7303%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BMurcia%26aufirst%3DJ.%2BM.%26aulast%3DNiedergang%26aufirst%3DC.%26aulast%3DTrucco%26aufirst%3DC.%26aulast%3DRicoul%26aufirst%3DM.%26aulast%3DDutrillaux%26aufirst%3DB.%26aulast%3DMark%26aufirst%3DM.%26aulast%3DOliver%26aufirst%3DF.%2BJ.%26aulast%3DMasson%26aufirst%3DM.%26aulast%3DDierich%26aufirst%3DA.%26aulast%3DLeMeur%26aufirst%3DM.%26aulast%3DWalztinger%26aufirst%3DC.%26aulast%3DChambon%26aufirst%3DP.%26aulast%3Dde%2BMurcia%26aufirst%3DG.%26atitle%3DRequirement%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%2520in%2520recovery%2520from%2520DNA%2520damage%2520in%2520mice%2520and%2520in%2520cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1997%26volume%3D94%26spage%3D7303%26epage%3D7307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Bowman, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golding, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span> </span><span class="NLM_article-title">Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">78</span><span class="NLM_x">, </span> <span class="NLM_fpage">1269</span><span class="NLM_x">â</span> <span class="NLM_lpage">1277</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1038%2Fbjc.1998.670" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=9823965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADyaK1cXns1Wls7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=1998&pages=1269-1277&author=K.+J.+Bowmanauthor=A.+Whiteauthor=B.+T.+Goldingauthor=R.+J.+Griffinauthor=N.+J.+Curtin&title=Potentiation+of+anti-cancer+agent+cytotoxicity+by+the+potent+poly%28ADP-ribose%29+polymerase+inhibitors+NU1025+and+NU1064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064</span></div><div class="casAuthors">Bowman, K. J.; White, A.; Golding, B. T.; Griffin, R. J.; Curtin, N. J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1269-1277</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Churchill Livingstone</span>)
        </div><div class="casAbstract">The ability of the potent poly(ADP-ribose) polymerase (PARP) inhibitor, NU1025 (8-hydroxy-2-methyl-quinazolin-4-[3H]one) to potentiate the cytotoxicity of a panel of mechanistically diverse anti-cancer agents was evaluated in L1210 cells.  NU1025 enhanced the cytotoxicity of the DNA-methylating agent MTIC, Î³-irradn. and bleomycin 3.5-, 1.4- and 2-fold, resp.  The cytotoxicities of the thymidylate synthase inhibitor, nolatrexed, and the cytotoxic nucleoside, gemcitabine, were not increased.  Potentiation of MTIC cytotoxicity by a delayed exposure to NU1025 was equally effective as by a simultaneous exposure to NU1025, indicating that the effects of NU1025 were mediated by an inhibition of the cellular recovery.  The recovery from potentially lethal Î³-irradn. damage cytotoxicity in plateau-phase cells was also inhibited by NU1025.  Investigation of DNA strand breakage and repair in Î³-irradiated cells by alk. elution demonstrated that NU1025 caused a marked retardation of DNA repair.  A structurally different PARP inhibitor, NU1064 (2-methylbenzimidazole-4-carboxamide), also potentiated the cytotoxicity of MTIC, to a similar extent to NU1025.  NU1064 potentiated a sublethal concn. of a DNA methylating agent in a concn.-dependent manner.  Collectively, these data suggest that the most suitable cytotoxic agents for use in combination with PARP inhibitors are methylating agents, bleomycin and ionizing radiation, but not anti-metabolites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrck0a06VeTtLVg90H21EOLACvtfcHk0ljhBdtLvCzeqA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXns1Wls7g%253D&md5=ff9df51529125a9117c195c491a440bf</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fbjc.1998.670&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.1998.670%26sid%3Dliteratum%253Aachs%26aulast%3DBowman%26aufirst%3DK.%2BJ.%26aulast%3DWhite%26aufirst%3DA.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26atitle%3DPotentiation%2520of%2520anti-cancer%2520agent%2520cytotoxicity%2520by%2520the%2520potent%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitors%2520NU1025%2520and%2520NU1064%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D1998%26volume%3D78%26spage%3D1269%26epage%3D1277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Ruf, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Murcia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulz, G. E.</span><span> </span><span class="NLM_article-title">Inhibitor and NAD+ binding to poly(ADP-ribose) polymerase as derived from crystal structures and homology modeling</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">3893</span><span class="NLM_x">â</span> <span class="NLM_lpage">3900</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi972383s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1998&pages=3893-3900&author=A.+Rufauthor=G.+de+Murciaauthor=G.+E.+Schulz&title=Inhibitor+and+NAD%2B+binding+to+poly%28ADP-ribose%29+polymerase+as+derived+from+crystal+structures+and+homology+modeling"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fbi972383s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi972383s%26sid%3Dliteratum%253Aachs%26aulast%3DRuf%26aufirst%3DA.%26aulast%3Dde%2BMurcia%26aufirst%3DG.%26aulast%3DSchulz%26aufirst%3DG.%2BE.%26atitle%3DInhibitor%2520and%2520NAD%252B%2520binding%2520to%2520poly%2528ADP-ribose%2529%2520polymerase%2520as%2520derived%2520from%2520crystal%2520structures%2520and%2520homology%2520modeling%26jtitle%3DBiochemistry%26date%3D1998%26volume%3D37%26spage%3D3893%26epage%3D3900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Cleaver, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borek, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milam, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, W. F.</span><span> </span><span class="NLM_article-title">The role of poly(ADP-ribose) synthesis in toxicity and repair of DNA damage</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">269</span><span class="NLM_x">â</span> <span class="NLM_lpage">293</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1016%2F0163-7258%2885%2990026-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=3939630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADyaL2sXhvFSnsLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1985&pages=269-293&author=J.+E.+Cleaverauthor=C.+Borekauthor=K.+Milamauthor=W.+F.+Morgan&title=The+role+of+poly%28ADP-ribose%29+synthesis+in+toxicity+and+repair+of+DNA+damage"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The role of poly(ADP-ribose) synthesis in toxicity and repair of DNA damage</span></div><div class="casAuthors">Cleaver, James E.; Borek, Carmia; Milam, Kathryn; Morgan, William F.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">269-93</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    </div><div class="casAbstract">A review with many refs. on the enzymic process of poly(ADP-ribose)  [26656-46-2] synthesis, poly(ADP-ribosyl)ation and protein function, inhibitors of poly(ADP-ribosyl)ation, poly(ADP-ribose) synthetase and the response of cells to DNA damage, inhibition of poly(ADP-ribose) synthesis and DNA repair, and the possible role for poly(ADP-ribose) synthesis in damaged cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfy4RC-q2OPLVg90H21EOLACvtfcHk0lhSmcYjDcTwOg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXhvFSnsLo%253D&md5=fa206bbb3f788dee30e06f3ce47faebf</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2F0163-7258%2885%2990026-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0163-7258%252885%252990026-9%26sid%3Dliteratum%253Aachs%26aulast%3DCleaver%26aufirst%3DJ.%2BE.%26aulast%3DBorek%26aufirst%3DC.%26aulast%3DMilam%26aufirst%3DK.%26aulast%3DMorgan%26aufirst%3DW.%2BF.%26atitle%3DThe%2520role%2520of%2520poly%2528ADP-ribose%2529%2520synthesis%2520in%2520toxicity%2520and%2520repair%2520of%2520DNA%2520damage%26jtitle%3DPharmacol.%2520Ther.%26date%3D1985%26volume%3D31%26spage%3D269%26epage%3D293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Dantzer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de La Rubia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menissier-De Murcia, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hostomsky, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Murcia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreiber, V.</span><span> </span><span class="NLM_article-title">Base excision repair is impaired in mammalian cells lacking Poly(ADP-ribose) polymerase-1</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">7559</span><span class="NLM_x">â</span> <span class="NLM_lpage">7569</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi0003442" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2000&pages=7559-7569&author=F.+Dantzerauthor=G.+de+La+Rubiaauthor=J.+Menissier-De+Murciaauthor=Z.+Hostomskyauthor=G.+de+Murciaauthor=V.+Schreiber&title=Base+excision+repair+is+impaired+in+mammalian+cells+lacking+Poly%28ADP-ribose%29+polymerase-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fbi0003442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi0003442%26sid%3Dliteratum%253Aachs%26aulast%3DDantzer%26aufirst%3DF.%26aulast%3Dde%2BLa%2BRubia%26aufirst%3DG.%26aulast%3DMenissier-De%2BMurcia%26aufirst%3DJ.%26aulast%3DHostomsky%26aufirst%3DZ.%26aulast%3Dde%2BMurcia%26aufirst%3DG.%26aulast%3DSchreiber%26aufirst%3DV.%26atitle%3DBase%2520excision%2520repair%2520is%2520impaired%2520in%2520mammalian%2520cells%2520lacking%2520Poly%2528ADP-ribose%2529%2520polymerase-1%26jtitle%3DBiochemistry%26date%3D2000%26volume%3D39%26spage%3D7559%26epage%3D7569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Durkacz, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Omidiji, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shall, S.</span><span> </span><span class="NLM_article-title">(ADP-ribose)n participates in DNA excision repair</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1980</span><span class="NLM_x">, </span> <span class="NLM_volume">283</span><span class="NLM_x">, </span> <span class="NLM_fpage">593</span><span class="NLM_x">â</span> <span class="NLM_lpage">596</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=1980&pages=593-596&author=B.+W.+Durkaczauthor=O.+Omidijiauthor=D.+A.+Grayauthor=S.+Shall&title=%28ADP-ribose%29n+participates+in+DNA+excision+repair"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDurkacz%26aufirst%3DB.%2BW.%26aulast%3DOmidiji%26aufirst%3DO.%26aulast%3DGray%26aufirst%3DD.%2BA.%26aulast%3DShall%26aufirst%3DS.%26atitle%3D%2528ADP-ribose%2529n%2520participates%2520in%2520DNA%2520excision%2520repair%26jtitle%3DNature%26date%3D1980%26volume%3D283%26spage%3D593%26epage%3D596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Caldecott, K. W.</span><span> </span><span class="NLM_article-title">XRCC1 and DNA strand break repair</span> <span class="citation_source-journal">DNA Repair</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">955</span><span class="NLM_x">â</span> <span class="NLM_lpage">969</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=955-969&author=K.+W.+Caldecott&title=XRCC1+and+DNA+strand+break+repair"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCaldecott%26aufirst%3DK.%2BW.%26atitle%3DXRCC1%2520and%2520DNA%2520strand%2520break%2520repair%26jtitle%3DDNA%2520Repair%26date%3D2003%26volume%3D2%26spage%3D955%26epage%3D969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Audebert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salles, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calsou, P.</span><span> </span><span class="NLM_article-title">Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x">, </span> <span class="NLM_fpage">55117</span><span class="NLM_x">â</span> <span class="NLM_lpage">55126</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=55117-55126&author=M.+Audebertauthor=B.+Sallesauthor=P.+Calsou&title=Involvement+of+poly%28ADP-ribose%29+polymerase-1+and+XRCC1%2FDNA+ligase+III+in+an+alternative+route+for+DNA+double-strand+breaks+rejoining"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAudebert%26aufirst%3DM.%26aulast%3DSalles%26aufirst%3DB.%26aulast%3DCalsou%26aufirst%3DP.%26atitle%3DInvolvement%2520of%2520poly%2528ADP-ribose%2529%2520polymerase-1%2520and%2520XRCC1%252FDNA%2520ligase%2520III%2520in%2520an%2520alternative%2520route%2520for%2520DNA%2520double-strand%2520breaks%2520rejoining%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D55117%26epage%3D55126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Affar, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirier, G. G.</span><span> </span><span class="NLM_article-title">Poly(ADP-ribose) turnover in quail myoblast cells: relation between the polymer level and its catabolism by glycohydrolase</span> <span class="citation_source-journal">Mol. Cell. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">193</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">â</span> <span class="NLM_lpage">135</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=193&publication_year=1999&pages=127-135&author=E.+B.+Affarauthor=R.+G.+Shahauthor=G.+G.+Poirier&title=Poly%28ADP-ribose%29+turnover+in+quail+myoblast+cells%3A+relation+between+the+polymer+level+and+its+catabolism+by+glycohydrolase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAffar%26aufirst%3DE.%2BB.%26aulast%3DShah%26aufirst%3DR.%2BG.%26aulast%3DPoirier%26aufirst%3DG.%2BG.%26atitle%3DPoly%2528ADP-ribose%2529%2520turnover%2520in%2520quail%2520myoblast%2520cells%253A%2520relation%2520between%2520the%2520polymer%2520level%2520and%2520its%2520catabolism%2520by%2520glycohydrolase%26jtitle%3DMol.%2520Cell.%2520Biochem.%26date%3D1999%26volume%3D193%26spage%3D127%26epage%3D135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Ljungman, M.</span><span> </span><span class="NLM_article-title">Targeting the DNA damage response in cancer</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">2929</span><span class="NLM_x">â</span> <span class="NLM_lpage">50</span></span><div class="citationLinks">[<a href="/doi/10.1021/cr900047g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnsFemtrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2009&pages=2929-50&author=M.+Ljungman&title=Targeting+the+DNA+damage+response+in+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the DNA Damage Response in Cancer</span></div><div class="casAuthors">Ljungman, Mats</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2929-2950</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  We are in an exciting phase in cancer research with a rapid pace of discovery driven by new technologies.  Recent studies have shed light on the complexity of tumor biol., showing that tumors rarely have similar sets of mutations in common.  However, when placing the various tumor mutations into functional pathways, a more manageable picture emerges with about 12 core pathways abrogated in the majority of the tumors.  Thus, it may be possible after identifying the pathway(s) altered in a particular tumor to tailor therapies to specifically block that pathway(s).  The DNA damage response is one of these core pathways found to be frequently dysregulated in cancer.  Proteins participating in this pathway are expected to be important therapeutic targets for the sensitization of tumor cells to radiation or chemotherapy.  The targeting of the DNA damage response in cancer stem cells may be of particular importance, since these cells are often found to be more resistant to radiation and chemotherapy than other tumor cells.  The fact that many tumors have defects in DNA repair pathways and/or cell cycle checkpoints presents unique opportunities for therapeutic exploitation.  Likewise, oncogene-driven induction of "DNA damage" sets tumor cells apart from normal cells, and with a better understanding of the mechanisms involved in the repair of these lesions, tumor-selective therapies may be developed.  Aristotle once said: "We make war that we may live in peace".  By applying novel strategies involving inhibitors of the DNA damage response in combination with radiation or chemotherapy, we may improve the chances of peace by winning the war on cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopslYTMfDHnrVg90H21EOLACvtfcHk0lheshflsNOD6Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnsFemtrk%253D&md5=327ba938830918171b646fb2ad1754bc</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fcr900047g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr900047g%26sid%3Dliteratum%253Aachs%26aulast%3DLjungman%26aufirst%3DM.%26atitle%3DTargeting%2520the%2520DNA%2520damage%2520response%2520in%2520cancer%26jtitle%3DChem.%2520Rev.%26date%3D2009%26volume%3D109%26spage%3D2929%26epage%3D50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Banasik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komura, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimoyama, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueda, K.</span><span> </span><span class="NLM_article-title">Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">267</span><span class="NLM_x">, </span> <span class="NLM_fpage">1569</span><span class="NLM_x">â</span> <span class="NLM_lpage">1575</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=1530940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADyaK38XitFSjtLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=1992&pages=1569-1575&author=M.+Banasikauthor=H.+Komuraauthor=M.+Shimoyamaauthor=K.+Ueda&title=Specific+inhibitors+of+poly%28ADP-ribose%29+synthetase+and+mono%28ADP-ribosyl%29transferase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase</span></div><div class="casAuthors">Banasik, Marek; Komura, Hajime; Shimoyama, Makoto; Ueda, Kunihiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">267</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1569-75</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Two classes of enzymes, poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferases, catalyze covalent attachment of multiple or single residues, resp., of the ADP-ribose moiety of NAD to various proteins.  In order to find good inhibitors of poly(ADP-ribose) synthetase free of side actions and applicable to in vivo studies, a large scale survey was made using an in vitro assay system, and many potent inhibitors were found.  The four strongest were 4-amino-1,8-naphthalimide, 6(5H)- and 2-nitro-6(5H)-phenanthridinones, and 1,5-dihydroxyisoquinoline.  Their 50% inhibitory concns., 0.18-0.39 Î¼M, were about two orders of magnitude lower than that of 3-aminobenzamide that is currently most popularly used.  A common structural feature among all potent inhibitors, including 1-hydroxyisoquinoline, chlorthenoxazin, 3-hydroxybenzamide, and 4-hydroxyquinazoline, in addn. to the four mentioned above, was the presence of a carbonyl group built in a polyarom. heterocyclic skeleton or a carbamoyl group attached to an arom. ring.  Most of the inhibitors exhibited mixed-type inhibition with respect to NAD.  Comparative studies of the effects on poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase from hen heterophils revealed high specificity of most of the potent inhibitors for poly(ADP-ribose) synthetase.  On the other hand, unsatd. long-chain fatty acids inhibited both enzymes, and satd. long-chain fatty acids and vitamin K1 acted selectively on mono(ADP-ribosyl)transferase.  The finding of many inhibitors of ADP-ribosyltransferases, esp. poly(ADP-ribose) synthetase, supports the view that ADP-ribosylation of proteins may be regulated by a variety of metabolites or structural constituents in the cell.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-Jh_eRCjHdbVg90H21EOLACvtfcHk0lheshflsNOD6Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XitFSjtLk%253D&md5=21bb51821a1caaeb30c42643a82116f4</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBanasik%26aufirst%3DM.%26aulast%3DKomura%26aufirst%3DH.%26aulast%3DShimoyama%26aufirst%3DM.%26aulast%3DUeda%26aufirst%3DK.%26atitle%3DSpecific%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529%2520synthetase%2520and%2520mono%2528ADP-ribosyl%2529transferase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1992%26volume%3D267%26spage%3D1569%26epage%3D1575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Purnell, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whish, W. J.</span><span> </span><span class="NLM_article-title">Novel inhibitors of poly(ADP-ribose) synthetase</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1980</span><span class="NLM_x">, </span> <span class="NLM_volume">185</span><span class="NLM_x">, </span> <span class="NLM_fpage">775</span><span class="NLM_x">â</span> <span class="NLM_lpage">777</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=185&publication_year=1980&pages=775-777&author=M.+R.+Purnellauthor=W.+J.+Whish&title=Novel+inhibitors+of+poly%28ADP-ribose%29+synthetase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPurnell%26aufirst%3DM.%2BR.%26aulast%3DWhish%26aufirst%3DW.%2BJ.%26atitle%3DNovel%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529%2520synthetase%26jtitle%3DBiochem.%2520J.%26date%3D1980%26volume%3D185%26spage%3D775%26epage%3D777" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Bryant, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flower, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kyle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helleday, T.</span><span> </span><span class="NLM_article-title">Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">434</span><span class="NLM_x">, </span> <span class="NLM_fpage">913</span><span class="NLM_x">â</span> <span class="NLM_lpage">917</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1038%2Fnature03443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=15829966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=434&publication_year=2005&pages=913-917&author=H.+E.+Bryantauthor=N.+Schultzauthor=H.+D.+Thomasauthor=K.+M.+Parkerauthor=D.+Flowerauthor=E.+Lopezauthor=S.+Kyleauthor=M.+Meuthauthor=N.+J.+Curtinauthor=T.+Helleday&title=Specific+killing+of+BRCA2-deficient+tumours+with+inhibitors+of+poly%28ADP-ribose%29+polymerase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Specific killing of BRCA2-deficient tumors with inhibitors of poly(ADP-ribose) polymerase</span></div><div class="casAuthors">Bryant, Helen E.; Schultz, Niklas; Thomas, Huw D.; Parker, Kayan M.; Flower, Dan; Lopez, Elena; Kyle, Suzanne; Meuth, Mark; Curtin, Nicola J.; Helleday, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">434</span>
        (<span class="NLM_cas:issue">7035</span>),
    <span class="NLM_cas:pages">913-917</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase (PARP1) facilitates DNA repair by binding to DNA breaks and attracting DNA repair proteins to the site of damage.  Nevertheless, PARP1-/- mice are viable, fertile and do not develop early onset tumors.  Here, the authors show that PARP inhibitors trigger Î³-H2AX and RAD51 foci formation.  The authors propose that, in the absence of PARP1, spontaneous single-strand breaks collapse replication forks and trigger homologous recombination for repair.  Furthermore, the authors show that BRCA2-deficient cells, as a result of their deficiency in homologous recombination, are acutely sensitive to PARP inhibitors, presumably because resultant collapsed replication forks are no longer repaired.  Thus, PARP1 activity is essential in homologous recombination-deficient BRCA2 mutant cells.  The authors exploit this requirement in order to kill BRCA2-deficient tumors by PARP inhibition alone.  Treatment with PARP inhibitors is likely to be highly tumor specific, because only the tumors (which are BRCA2-/-) in BRCA2+/- patients are defective in homologous recombination.  The use of an inhibitor of a DNA repair enzyme alone to selectively kill a tumor, in the absence of an exogenous DNA-damaging agent, represents a new concept in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZJ6B7d7dB77Vg90H21EOLACvtfcHk0liJwKs4hdbTmQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrY%253D&md5=44631eba667cf75ef99c31d011d6db44</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fnature03443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature03443%26sid%3Dliteratum%253Aachs%26aulast%3DBryant%26aufirst%3DH.%2BE.%26aulast%3DSchultz%26aufirst%3DN.%26aulast%3DThomas%26aufirst%3DH.%2BD.%26aulast%3DParker%26aufirst%3DK.%2BM.%26aulast%3DFlower%26aufirst%3DD.%26aulast%3DLopez%26aufirst%3DE.%26aulast%3DKyle%26aufirst%3DS.%26aulast%3DMeuth%26aufirst%3DM.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DHelleday%26aufirst%3DT.%26atitle%3DSpecific%2520killing%2520of%2520BRCA2-deficient%2520tumours%2520with%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%26jtitle%3DNature%26date%3D2005%26volume%3D434%26spage%3D913%26epage%3D917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Farmer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCabe, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tutt, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santarosa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dillon, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knights, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">434</span><span class="NLM_x">, </span> <span class="NLM_fpage">917</span><span class="NLM_x">â</span> <span class="NLM_lpage">921</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1038%2Fnature03445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=15829967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=434&publication_year=2005&pages=917-921&author=H.+Farmerauthor=N.+McCabeauthor=C.+J.+Lordauthor=A.+N.+Tuttauthor=D.+A.+Johnsonauthor=T.+B.+Richardsonauthor=M.+Santarosaauthor=K.+J.+Dillonauthor=I.+Hicksonauthor=C.+Knightsauthor=N.+M.+Martinauthor=S.+P.+Jacksonauthor=G.+C.+Smithauthor=A.+Ashworth&title=Targeting+the+DNA+repair+defect+in+BRCA+mutant+cells+as+a+therapeutic+strategy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy</span></div><div class="casAuthors">Farmer, Hannah; McCabe, Nuala; Lord, Christopher J.; Tutt, Andrew N. J.; Johnson, Damian A.; Richardson, Tobias B.; Santarosa, Manuela; Dillon, Krystyna J.; Hickson, Ian; Knights, Charlotte; Martin, Niall M. B.; Jackson, Stephen P.; Smith, Graeme C. M.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">434</span>
        (<span class="NLM_cas:issue">7035</span>),
    <span class="NLM_cas:pages">917-921</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">BRCA1 and BRCA2 are important for DNA double-strand break repair by homologous recombination, and mutations in these genes predispose to breast and other cancers.  Poly(ADP-ribose) polymerase (PARP) is an enzyme involved in base excision repair, a key pathway in the repair of DNA single-strand breaks.  The authors show here that BRCA1 or BRCA2 dysfunction unexpectedly and profoundly sensitizes cells to the inhibition of PARP enzymic activity, resulting in chromosomal instability, cell cycle arrest and subsequent apoptosis.  This seems to be because the inhibition of PARP leads to the persistence of DNA lesions normally repaired by homologous recombination.  These results illustrate how different pathways cooperate to repair damage, and suggest that the targeted inhibition of particular DNA repair pathways may allow the design of specific and less toxic therapies for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomVTKE4mFwfrVg90H21EOLACvtfcHk0liJwKs4hdbTmQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrc%253D&md5=03b5ba0adc21a5627fe17ae535f45078</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fnature03445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature03445%26sid%3Dliteratum%253Aachs%26aulast%3DFarmer%26aufirst%3DH.%26aulast%3DMcCabe%26aufirst%3DN.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DTutt%26aufirst%3DA.%2BN.%26aulast%3DJohnson%26aufirst%3DD.%2BA.%26aulast%3DRichardson%26aufirst%3DT.%2BB.%26aulast%3DSantarosa%26aufirst%3DM.%26aulast%3DDillon%26aufirst%3DK.%2BJ.%26aulast%3DHickson%26aufirst%3DI.%26aulast%3DKnights%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DN.%2BM.%26aulast%3DJackson%26aufirst%3DS.%2BP.%26aulast%3DSmith%26aufirst%3DG.%2BC.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DTargeting%2520the%2520DNA%2520repair%2520defect%2520in%2520BRCA%2520mutant%2520cells%2520as%2520a%2520therapeutic%2520strategy%26jtitle%3DNature%26date%3D2005%26volume%3D434%26spage%3D917%26epage%3D921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Lord, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">Targeted therapy for cancer using PARP inhibitors</span> <span class="citation_source-journal">Curr. Opin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">363</span><span class="NLM_x">â</span> <span class="NLM_lpage">369</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1016%2Fj.coph.2008.06.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=18644251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFCktL7I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=363-369&author=C.+J.+Lordauthor=A.+Ashworth&title=Targeted+therapy+for+cancer+using+PARP+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted therapy for cancer using PARP inhibitors</span></div><div class="casAuthors">Lord, Christopher J.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">363-369</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Poly (ADP-ribose) Polymerase (PARP) has a well-established role in DNA repair processes, and small mol. inhibitors of PARP have been developed as chemotherapy sensitizers for the treatment of cancer.  The subsequent demonstration that PARP inhibition is selective for BRCA1 or BRCA2 deficiency suggests that PARP inhibitors may be particularly useful for the treatment of cancer with BRCA mutations.  This would represent one of the first clin. implemented examples of a synthetic lethal approach for cancer treatment.  However, there are still unanswered questions surrounding PARP inhibitors, namely the levels of specificity and potency that are required to elicit BRCA selectivity.  The recent identification of mechanisms of cellular resistance to PARP inhibitors may provide indications as to how these drugs may be best used in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0-DMq21TzX7Vg90H21EOLACvtfcHk0lj9L-wsAPIPiQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFCktL7I&md5=867dc1c878a3b1c36a981fe78dfb7d7d</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2008.06.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2008.06.016%26sid%3Dliteratum%253Aachs%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DTargeted%2520therapy%2520for%2520cancer%2520using%2520PARP%2520inhibitors%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2008%26volume%3D8%26spage%3D363%26epage%3D369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Saffhill, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ockey, C. H.</span><span> </span><span class="NLM_article-title">Strand breaks arising from the repair of the 5-bromodeoxyuridine-substituted template and methyl methanesulphonate-induced lesions can explain the formation of sister chromatid exchanges</span> <span class="citation_source-journal">Chromosoma</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">218</span><span class="NLM_x">â</span> <span class="NLM_lpage">224</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=1985&pages=218-224&author=R.+Saffhillauthor=C.+H.+Ockey&title=Strand+breaks+arising+from+the+repair+of+the+5-bromodeoxyuridine-substituted+template+and+methyl+methanesulphonate-induced+lesions+can+explain+the+formation+of+sister+chromatid+exchanges"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSaffhill%26aufirst%3DR.%26aulast%3DOckey%26aufirst%3DC.%2BH.%26atitle%3DStrand%2520breaks%2520arising%2520from%2520the%2520repair%2520of%2520the%25205-bromodeoxyuridine-substituted%2520template%2520and%2520methyl%2520methanesulphonate-induced%2520lesions%2520can%2520explain%2520the%2520formation%2520of%2520sister%2520chromatid%2520exchanges%26jtitle%3DChromosoma%26date%3D1985%26volume%3D92%26spage%3D218%26epage%3D224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Kaelin, W. G.,  Jr.</span><span> </span><span class="NLM_article-title">The concept of synthetic lethality in the context of anticancer therapy</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">689</span><span class="NLM_x">â</span> <span class="NLM_lpage">698</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1038%2Fnrc1691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=16110319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpsleks7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=689-698&author=W.+G.+Kaelin&title=The+concept+of+synthetic+lethality+in+the+context+of+anticancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The Concept of Synthetic Lethality in the Context of Anticancer Therapy</span></div><div class="casAuthors">Kaelin, William G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">689-698</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with refs.  Two genes are synthetic lethal if mutation of either alone is compatible with viability but mutation of both leads to death.  So, targeting a gene that is synthetic lethal to a cancer-relevant mutation should kill only cancer cells and spare normal cells.  Synthetic lethality therefore provides a conceptual framework for the development of cancer-specific cytotoxic agents.  This paradigm has not been exploited in the past because there were no robust methods for systematically identifying synthetic lethal genes.  This is changing as a result of the increased availability of chem. and genetic tools for perturbing gene function in somatic cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrf4V-KQ6I5ILVg90H21EOLACvtfcHk0lj9L-wsAPIPiQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpsleks7c%253D&md5=4d5e38282cd8a3d2c3451d56ca88ac8b</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fnrc1691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1691%26sid%3Dliteratum%253Aachs%26aulast%3DKaelin%26aufirst%3DW.%2BG.%26atitle%3DThe%2520concept%2520of%2520synthetic%2520lethality%2520in%2520the%2520context%2520of%2520anticancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D689%26epage%3D698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Turner, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tutt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">Hallmarks of âBRCAnessâ in sporadic cancers</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">814</span><span class="NLM_x">â</span> <span class="NLM_lpage">819</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1038%2Fnrc1457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=15510162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD2cXos1ymu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=814-819&author=N.+Turnerauthor=A.+Tuttauthor=A.+Ashworth&title=Hallmarks+of+%E2%80%9CBRCAness%E2%80%9D+in+sporadic+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Hallmarks of 'BRCAness' in sporadic cancers</span></div><div class="casAuthors">Turner, Nicholas; Tutt, Andrew; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">814-819</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Germline mutations in the BRCA1, BRCA2 and Fanconi anemia genes confer cancer susceptibility, and the proteins encoded by these genes have distinct functions in related DNA-repair processes.  Emerging evidence indicates that these processes are disrupted by numerous mechanisms in sporadic cancers.  Collectively, there are properties that define 'BRCAness' - i.e., traits that some sporadic cancers share with those occurring in either BRCA1- or BRCA2-mutation carriers.  These common properties might have important implications for the clin. management of these cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSK5dEe3-aKLVg90H21EOLACvtfcHk0lhPqvbuyT8eMw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXos1ymu7g%253D&md5=b2ec7c226f4ca388e2dc3a6c1d030e7d</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fnrc1457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1457%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DN.%26aulast%3DTutt%26aufirst%3DA.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DHallmarks%2520of%2520%25E2%2580%259CBRCAness%25E2%2580%259D%2520in%2520sporadic%2520cancers%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D814%26epage%3D819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Pal, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortimer, J.</span><span> </span><span class="NLM_article-title">Triple-negative breast cancer: novel therapies and new directions</span> <span class="citation_source-journal">Maturitas</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">269</span><span class="NLM_x">â</span> <span class="NLM_lpage">274</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2009&pages=269-274&author=S.+K.+Palauthor=J.+Mortimer&title=Triple-negative+breast+cancer%3A+novel+therapies+and+new+directions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPal%26aufirst%3DS.%2BK.%26aulast%3DMortimer%26aufirst%3DJ.%26atitle%3DTriple-negative%2520breast%2520cancer%253A%2520novel%2520therapies%2520and%2520new%2520directions%26jtitle%3DMaturitas%26date%3D2009%26volume%3D63%26spage%3D269%26epage%3D274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">OâShaughnessy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osborne, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pippen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoffe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patt, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monaghan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rocha, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ossovskaya, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, C.</span><span> </span><span class="NLM_article-title">Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1200%2FJCO.2009.22.0863" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=3&author=J.+O%E2%80%99Shaughnessyauthor=C.+Osborneauthor=J.+Pippenauthor=M.+Yoffeauthor=D.+Pattauthor=G.+Monaghanauthor=C.+Rochaauthor=V.+Ossovskayaauthor=B.+Shermanauthor=C.+Bradley&title=Efficacy+of+BSI-201%2C+a+poly+%28ADP-ribose%29+polymerase-1+%28PARP1%29+inhibitor%2C+in+combination+with+gemcitabine%2Fcarboplatin+%28G%2FC%29+in+patients+with+metastatic+triple-negative+breast+cancer+%28TNBC%29%3A+results+of+a+randomized+phase+II+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.22.0863&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.22.0863%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shaughnessy%26aufirst%3DJ.%26aulast%3DOsborne%26aufirst%3DC.%26aulast%3DPippen%26aufirst%3DJ.%26aulast%3DYoffe%26aufirst%3DM.%26aulast%3DPatt%26aufirst%3DD.%26aulast%3DMonaghan%26aufirst%3DG.%26aulast%3DRocha%26aufirst%3DC.%26aulast%3DOssovskaya%26aufirst%3DV.%26aulast%3DSherman%26aufirst%3DB.%26aulast%3DBradley%26aufirst%3DC.%26atitle%3DEfficacy%2520of%2520BSI-201%252C%2520a%2520poly%2520%2528ADP-ribose%2529%2520polymerase-1%2520%2528PARP1%2529%2520inhibitor%252C%2520in%2520combination%2520with%2520gemcitabine%252Fcarboplatin%2520%2528G%252FC%2529%2520in%2520patients%2520with%2520metastatic%2520triple-negative%2520breast%2520cancer%2520%2528TNBC%2529%253A%2520results%2520of%2520a%2520randomized%2520phase%2520II%2520trial%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, S. H.</span><span> </span><span class="NLM_article-title">Nitric oxide activation of poly(ADP-ribose) synthetase in neurotoxicity</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">263</span><span class="NLM_x">, </span> <span class="NLM_fpage">687</span><span class="NLM_x">â</span> <span class="NLM_lpage">689</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=1994&pages=687-689&author=J.+Zhangauthor=V.+L.+Dawsonauthor=T.+M.+Dawsonauthor=S.+H.+Snyder&title=Nitric+oxide+activation+of+poly%28ADP-ribose%29+synthetase+in+neurotoxicity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DDawson%26aufirst%3DV.%2BL.%26aulast%3DDawson%26aufirst%3DT.%2BM.%26aulast%3DSnyder%26aufirst%3DS.%2BH.%26atitle%3DNitric%2520oxide%2520activation%2520of%2520poly%2528ADP-ribose%2529%2520synthetase%2520in%2520neurotoxicity%26jtitle%3DScience%26date%3D1994%26volume%3D263%26spage%3D687%26epage%3D689" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Eliasson, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampei, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandir, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurn, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traystman, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pieper, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, V. L.</span><span> </span><span class="NLM_article-title">Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1089</span><span class="NLM_x">â</span> <span class="NLM_lpage">1095</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1038%2Fnm1097-1089" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=9334719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADyaK2sXmsFyqtb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1997&pages=1089-1095&author=M.+J.+Eliassonauthor=K.+Sampeiauthor=A.+S.+Mandirauthor=P.+D.+Hurnauthor=R.+J.+Traystmanauthor=J.+Baoauthor=A.+Pieperauthor=Z.+Q.+Wangauthor=T.+M.+Dawsonauthor=S.+H.+Snyderauthor=V.+L.+Dawson&title=Poly%28ADP-ribose%29+polymerase+gene+disruption+renders+mice+resistant+to+cerebral+ischemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia</span></div><div class="casAuthors">Eliasson, Mikael J. L.; Sampei, Kenji; Mandir, Allen S.; Hurn, Patricia D.; Traystman, Richard J.; Bao, Jun; Pieper, Andrew; Wang, Zhao-Qi; Dawson, Ted M.; Snyder, Solomon H.; Dawson, Valina L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1089-1095</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature America</span>)
        </div><div class="casAbstract">Nitric oxide (NO) and peroxynitrite, formed from NO and superoxide anion, have been implicated as mediators of neuronal damage following focal ischemia, but their mol. targets have not been defined.  One candidate pathway is DNA damage leading to activation of the nuclear enzyme, poly(ADP-ribose) polymerase (PARP), which catalyzes attachment of ADP ribose units from NAD to nuclear proteins following DNA damage.  Excessive activation of PARP can deplete NAD and ATP, which is consumed in regeneration of NAD, leading to cell death by energy depletion.  The authors show that genetic disruption of PARP provides profound protection against glutamate-NO-mediated ischemic insults in vitro and major decreases in infarct vol. after reversible middle cerebral artery occlusion.  These results provide compelling evidence for a primary involvement of PARP activation in neuronal damage following focal ischemia and suggest that therapies designed towards inhibiting PARP may provide benefit in the treatment of cerebrovascular disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLSq-7dMGKE7Vg90H21EOLACvtfcHk0lj28tUP6oiA0w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmsFyqtb8%253D&md5=d83a2bb75e066d20b415119fb4452e21</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fnm1097-1089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1097-1089%26sid%3Dliteratum%253Aachs%26aulast%3DEliasson%26aufirst%3DM.%2BJ.%26aulast%3DSampei%26aufirst%3DK.%26aulast%3DMandir%26aufirst%3DA.%2BS.%26aulast%3DHurn%26aufirst%3DP.%2BD.%26aulast%3DTraystman%26aufirst%3DR.%2BJ.%26aulast%3DBao%26aufirst%3DJ.%26aulast%3DPieper%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DZ.%2BQ.%26aulast%3DDawson%26aufirst%3DT.%2BM.%26aulast%3DSnyder%26aufirst%3DS.%2BH.%26aulast%3DDawson%26aufirst%3DV.%2BL.%26atitle%3DPoly%2528ADP-ribose%2529%2520polymerase%2520gene%2520disruption%2520renders%2520mice%2520resistant%2520to%2520cerebral%2520ischemia%26jtitle%3DNat.%2520Med.%26date%3D1997%26volume%3D3%26spage%3D1089%26epage%3D1095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Endres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Namura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waeber, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moskowitz, M. A.</span><span> </span><span class="NLM_article-title">Ischemic brain injury is mediated by the activation of poly(ADP-ribose)polymerase</span> <span class="citation_source-journal">J. Cereb. Blood Flow Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1143</span><span class="NLM_x">â</span> <span class="NLM_lpage">1151</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1097%2F00004647-199711000-00002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=9390645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADyaK2sXotVShtbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1997&pages=1143-1151&author=M.+Endresauthor=Z.+Q.+Wangauthor=S.+Namuraauthor=C.+Waeberauthor=M.+A.+Moskowitz&title=Ischemic+brain+injury+is+mediated+by+the+activation+of+poly%28ADP-ribose%29polymerase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Ischemic brain injury is mediated by the activation of poly(ADP-ribose)polymerase</span></div><div class="casAuthors">Endres, Matthias; Wang, Zhao-Qi; Namura, Shobu; Waeber, Christian; Moskowitz, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cerebral Blood Flow and Metabolism</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1143-1151</span>CODEN:
                <span class="NLM_cas:coden">JCBMDN</span>;
        ISSN:<span class="NLM_cas:issn">0271-678X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott-Raven Publishers</span>)
        </div><div class="casAbstract">Poly(ADP-ribose)polymerase (PARP, EC 2.4.2.30), an abundant nuclear protein activated by DNA nicks, mediates cell death in vitro by NAD (NAD) depletion after exposure to nitric oxide.  The authors examd. whether genetic deletion of PARP (PARP null mice) or its pharmacol. inhibition by 3-aminobenzamide (3-AB) attenuates tissue injury after transient cerebral ischemia.  Twenty-two hours after reperfusion following 2 h of filamentous middle cerebral artery occlusion, ischemic injury was decreased in PARP-/- and PARP+/- mice compared with PARP+/+ litter mates, and also was attenuated in 129/SV wild-type mice after 3-AB treatment compared with controls.  Infarct sparing was accompanied by functional recovery in PARP-/- and 3-AB-treated mice.  Increased poly(ADP-ribose) immunostaining obsd. in ischemic cell nuclei 5 min after reperfusion was reduced by 3-AB treatment.  Levels of NAD-the substrate of PARP-were reduced 2 h after reperfusion and were 35% of contralateral levels at 24 h.  The decreases were attenuated in PARP-/- mice and in 3-AB-treated animals.  Poly(ADP-ribose)polymerase cleavage by caspase-3 (CPP-32) has been proposed as an important step in apoptotic cell death.  Markers of apoptosis, such as oligonucleosomal DNA damage, total DNA fragmentation, and the d. of terminal deoxy-nucleotidyl transferase dUTP nick-end-labeled (TUNEL +) cells, however, did not differ in ischemic brain tissue of PARP-/- mice or in 3-AB-treated animals vs. controls, although there were differences in the no. of TUNEL-stained cells reflecting the decrease in infarct size.  Thus, ischemic brain injury activates PARP and contributes to cell death most likely by NAD depletion and energy failure, although the authors have not excluded a role for PARP in apoptotic cell death at earlier or later stages in ischemic cell death.  Inhibitors of PARP activation could provide a potential therapy in acute stroke.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZgfj6WehsELVg90H21EOLACvtfcHk0lj28tUP6oiA0w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXotVShtbo%253D&md5=38ad29424df8e6f3613cab8c38b0dfcb</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1097%2F00004647-199711000-00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00004647-199711000-00002%26sid%3Dliteratum%253Aachs%26aulast%3DEndres%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DZ.%2BQ.%26aulast%3DNamura%26aufirst%3DS.%26aulast%3DWaeber%26aufirst%3DC.%26aulast%3DMoskowitz%26aufirst%3DM.%2BA.%26atitle%3DIschemic%2520brain%2520injury%2520is%2520mediated%2520by%2520the%2520activation%2520of%2520poly%2528ADP-ribose%2529polymerase%26jtitle%3DJ.%2520Cereb.%2520Blood%2520Flow%2520Metab.%26date%3D1997%26volume%3D17%26spage%3D1143%26epage%3D1151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Watson, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whish, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Threadgill, M. D.</span><span> </span><span class="NLM_article-title">Synthesis of 3-substituted benzamides and 5-substituted isoquinolin-1(2<i>H</i>)-ones and preliminary evaluation as inhibitors of poly(ADP-ribose)polymerase (PARP)</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">721</span><span class="NLM_x">â</span> <span class="NLM_lpage">734</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1998&pages=721-734&author=C.+Y.+Watsonauthor=W.+J.+Whishauthor=M.+D.+Threadgill&title=Synthesis+of+3-substituted+benzamides+and+5-substituted+isoquinolin-1%282H%29-ones+and+preliminary+evaluation+as+inhibitors+of+poly%28ADP-ribose%29polymerase+%28PARP%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWatson%26aufirst%3DC.%2BY.%26aulast%3DWhish%26aufirst%3DW.%2BJ.%26aulast%3DThreadgill%26aufirst%3DM.%2BD.%26atitle%3DSynthesis%2520of%25203-substituted%2520benzamides%2520and%25205-substituted%2520isoquinolin-1%25282H%2529-ones%2520and%2520preliminary%2520evaluation%2520as%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529polymerase%2520%2528PARP%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D1998%26volume%3D6%26spage%3D721%26epage%3D734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Suto, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arundel-Suto, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Werbel, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sebolt-Leopold, J. S.</span><span> </span><span class="NLM_article-title">Dihydroisoquinolinones: the design and synthesis of a new series of potent inhibitors of poly(ADP-ribose) polymerase</span> <span class="citation_source-journal">Anti-Cancer Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">107</span><span class="NLM_x">â</span> <span class="NLM_lpage">117</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1991&pages=107-117&author=M.+J.+Sutoauthor=W.+R.+Turnerauthor=C.+M.+Arundel-Sutoauthor=L.+M.+Werbelauthor=J.+S.+Sebolt-Leopold&title=Dihydroisoquinolinones%3A+the+design+and+synthesis+of+a+new+series+of+potent+inhibitors+of+poly%28ADP-ribose%29+polymerase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSuto%26aufirst%3DM.%2BJ.%26aulast%3DTurner%26aufirst%3DW.%2BR.%26aulast%3DArundel-Suto%26aufirst%3DC.%2BM.%26aulast%3DWerbel%26aufirst%3DL.%2BM.%26aulast%3DSebolt-Leopold%26aufirst%3DJ.%2BS.%26atitle%3DDihydroisoquinolinones%253A%2520the%2520design%2520and%2520synthesis%2520of%2520a%2520new%2520series%2520of%2520potent%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%26jtitle%3DAnti-Cancer%2520Drug%2520Des.%26date%3D1991%26volume%3D6%26spage%3D107%26epage%3D117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Jagtap, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Southan, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baloglu, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ram, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mabley, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marton, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salzman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabo, C.</span><span> </span><span class="NLM_article-title">The discovery and synthesis of novel adenosine substituted 2,3-dihydro-1<i>H</i>-isoindol-1-ones: potent inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1)</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">81</span><span class="NLM_x">â</span> <span class="NLM_lpage">85</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=81-85&author=P.+G.+Jagtapauthor=G.+J.+Southanauthor=E.+Balogluauthor=S.+Ramauthor=J.+G.+Mableyauthor=A.+Martonauthor=A.+Salzmanauthor=C.+Szabo&title=The+discovery+and+synthesis+of+novel+adenosine+substituted+2%2C3-dihydro-1H-isoindol-1-ones%3A+potent+inhibitors+of+poly%28ADP-ribose%29+polymerase-1+%28PARP-1%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJagtap%26aufirst%3DP.%2BG.%26aulast%3DSouthan%26aufirst%3DG.%2BJ.%26aulast%3DBaloglu%26aufirst%3DE.%26aulast%3DRam%26aufirst%3DS.%26aulast%3DMabley%26aufirst%3DJ.%2BG.%26aulast%3DMarton%26aufirst%3DA.%26aulast%3DSalzman%26aufirst%3DA.%26aulast%3DSzabo%26aufirst%3DC.%26atitle%3DThe%2520discovery%2520and%2520synthesis%2520of%2520novel%2520adenosine%2520substituted%25202%252C3-dihydro-1H-isoindol-1-ones%253A%2520potent%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529%2520polymerase-1%2520%2528PARP-1%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D81%26epage%3D85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Tao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bihovsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husten, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, R. L.</span><span> </span><span class="NLM_article-title">Synthesis and structureâactivity relationships of novel poly(ADP-ribose) polymerase-1 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">938</span><span class="NLM_x">â</span> <span class="NLM_lpage">942</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=938-942&author=M.+Taoauthor=C.+H.+Parkauthor=R.+Bihovskyauthor=G.+J.+Wellsauthor=J.+Hustenauthor=M.+A.+Atorauthor=R.+L.+Hudkins&title=Synthesis+and+structure%E2%88%92activity+relationships+of+novel+poly%28ADP-ribose%29+polymerase-1+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTao%26aufirst%3DM.%26aulast%3DPark%26aufirst%3DC.%2BH.%26aulast%3DBihovsky%26aufirst%3DR.%26aulast%3DWells%26aufirst%3DG.%2BJ.%26aulast%3DHusten%26aufirst%3DJ.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26atitle%3DSynthesis%2520and%2520structure%25E2%2588%2592activity%2520relationships%2520of%2520novel%2520poly%2528ADP-ribose%2529%2520polymerase-1%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D938%26epage%3D942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Shinkwin, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whish, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Threadgill, M. D.</span><span> </span><span class="NLM_article-title">Synthesis of thiophenecarboxamides, thieno[3,4-<i>c</i>]pyridin-4(5<i>H</i>)-ones and thieno[3,4-<i>d</i>]pyrimidin-4(3<i>H</i>)-ones and preliminary evaluation as inhibitors of poly(ADP-ribose)polymerase (PARP)</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">297</span><span class="NLM_x">â</span> <span class="NLM_lpage">308</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1999&pages=297-308&author=A.+E.+Shinkwinauthor=W.+J.+Whishauthor=M.+D.+Threadgill&title=Synthesis+of+thiophenecarboxamides%2C+thieno%5B3%2C4-c%5Dpyridin-4%285H%29-ones+and+thieno%5B3%2C4-d%5Dpyrimidin-4%283H%29-ones+and+preliminary+evaluation+as+inhibitors+of+poly%28ADP-ribose%29polymerase+%28PARP%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShinkwin%26aufirst%3DA.%2BE.%26aulast%3DWhish%26aufirst%3DW.%2BJ.%26aulast%3DThreadgill%26aufirst%3DM.%2BD.%26atitle%3DSynthesis%2520of%2520thiophenecarboxamides%252C%2520thieno%255B3%252C4-c%255Dpyridin-4%25285H%2529-ones%2520and%2520thieno%255B3%252C4-d%255Dpyrimidin-4%25283H%2529-ones%2520and%2520preliminary%2520evaluation%2520as%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529polymerase%2520%2528PARP%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D1999%26volume%3D7%26spage%3D297%26epage%3D308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Li, J.-h.; Zhang, J.; Jackson, P. F.; Maclin, K. M.</span><span> </span><span class="NLM_article-title">Compounds, Methods and Pharmaceutical Compositions for Treating Neural or Cardiovascular Tissue Damage</span>. U.S. Patent 6514983,<span class="NLM_x"> </span><span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=J.-h.+Li&author=J.+Zhang&author=P.+F.+Jackson&author=K.+M.+Maclin&title=Compounds%2C+Methods+and+Pharmaceutical+Compositions+for+Treating+Neural+or+Cardiovascular+Tissue+Damage"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.-h.%26atitle%3DCompounds%252C%2520Methods%2520and%2520Pharmaceutical%2520Compositions%2520for%2520Treating%2520Neural%2520or%2520Cardiovascular%2520Tissue%2520Damage%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Branca, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerretani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orvieto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palumbi, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toniatti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muraglia, E.</span><span> </span><span class="NLM_article-title">Identification of aminoethyl pyrrolo dihydroisoquinolinones as novel poly(ADP-ribose) polymerase-1 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">4042</span><span class="NLM_x">â</span> <span class="NLM_lpage">4045</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=4042-4045&author=D.+Brancaauthor=M.+Cerretaniauthor=P.+Jonesauthor=U.+Kochauthor=F.+Orvietoauthor=M.+C.+Palumbiauthor=M.+Rowleyauthor=C.+Toniattiauthor=E.+Muraglia&title=Identification+of+aminoethyl+pyrrolo+dihydroisoquinolinones+as+novel+poly%28ADP-ribose%29+polymerase-1+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBranca%26aufirst%3DD.%26aulast%3DCerretani%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DKoch%26aufirst%3DU.%26aulast%3DOrvieto%26aufirst%3DF.%26aulast%3DPalumbi%26aufirst%3DM.%2BC.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DToniatti%26aufirst%3DC.%26aulast%3DMuraglia%26aufirst%3DE.%26atitle%3DIdentification%2520of%2520aminoethyl%2520pyrrolo%2520dihydroisoquinolinones%2520as%2520novel%2520poly%2528ADP-ribose%2529%2520polymerase-1%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D4042%26epage%3D4045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Steinhagen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerisch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mittendorf, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlemmer, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, B.</span><span> </span><span class="NLM_article-title">Substituted uracil derivatives as potent inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1)</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">3187</span><span class="NLM_x">â</span> <span class="NLM_lpage">3190</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=3187-3190&author=H.+Steinhagenauthor=M.+Gerischauthor=J.+Mittendorfauthor=K.+H.+Schlemmerauthor=B.+Albrecht&title=Substituted+uracil+derivatives+as+potent+inhibitors+of+poly%28ADP-ribose%29polymerase-1+%28PARP-1%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSteinhagen%26aufirst%3DH.%26aulast%3DGerisch%26aufirst%3DM.%26aulast%3DMittendorf%26aufirst%3DJ.%26aulast%3DSchlemmer%26aufirst%3DK.%2BH.%26aulast%3DAlbrecht%26aufirst%3DB.%26atitle%3DSubstituted%2520uracil%2520derivatives%2520as%2520potent%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529polymerase-1%2520%2528PARP-1%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2002%26volume%3D12%26spage%3D3187%26epage%3D3190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Seko, T.; Takeuchi, J.; Takahashi, S.; Kamanaka, Y.; Kamoshima, W.</span><span> </span><span class="NLM_article-title">Fused Pyridazine Derivative Compounds and Drugs Containing These Compounds as the Active Ingredient</span>. U.S. Patent 7402580,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=T.+Seko&author=J.+Takeuchi&author=S.+Takahashi&author=Y.+Kamanaka&author=W.+Kamoshima&title=Fused+Pyridazine+Derivative+Compounds+and+Drugs+Containing+These+Compounds+as+the+Active+Ingredient"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSeko%26aufirst%3DT.%26atitle%3DFused%2520Pyridazine%2520Derivative%2520Compounds%2520and%2520Drugs%2520Containing%2520These%2520Compounds%2520as%2520the%2520Active%2520Ingredient%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Kalish, V.; Zhang, J.; Xu, W.; Li, J.-h.; Xing, A. D.; Liu, Q.</span><span> </span><span class="NLM_article-title">Compounds, Methods and Pharmaceutical Compositions for Inhibiting PARP</span>. U.S. Patent 7456178,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=V.+Kalish&author=J.+Zhang&author=W.+Xu&author=J.-h.+Li&author=A.+D.+Xing&author=Q.+Liu&title=Compounds%2C+Methods+and+Pharmaceutical+Compositions+for+Inhibiting+PARP"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKalish%26aufirst%3DV.%26atitle%3DCompounds%252C%2520Methods%2520and%2520Pharmaceutical%2520Compositions%2520for%2520Inhibiting%2520PARP%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Orvieto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Branca, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giomini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ontoria, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palumbi, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toniatti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muraglia, E.</span><span> </span><span class="NLM_article-title">Identification of substituted pyrazolo[1,5-<i>a</i>]quinazolin-5(4<i>H</i>)-one as potent poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">4196</span><span class="NLM_x">â</span> <span class="NLM_lpage">4200</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=4196-4200&author=F.+Orvietoauthor=D.+Brancaauthor=C.+Giominiauthor=P.+Jonesauthor=U.+Kochauthor=J.+M.+Ontoriaauthor=M.+C.+Palumbiauthor=M.+Rowleyauthor=C.+Toniattiauthor=E.+Muraglia&title=Identification+of+substituted+pyrazolo%5B1%2C5-a%5Dquinazolin-5%284H%29-one+as+potent+poly%28ADP-ribose%29polymerase-1+%28PARP-1%29+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOrvieto%26aufirst%3DF.%26aulast%3DBranca%26aufirst%3DD.%26aulast%3DGiomini%26aufirst%3DC.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DKoch%26aufirst%3DU.%26aulast%3DOntoria%26aufirst%3DJ.%2BM.%26aulast%3DPalumbi%26aufirst%3DM.%2BC.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DToniatti%26aufirst%3DC.%26aulast%3DMuraglia%26aufirst%3DE.%26atitle%3DIdentification%2520of%2520substituted%2520pyrazolo%255B1%252C5-a%255Dquinazolin-5%25284H%2529-one%2520as%2520potent%2520poly%2528ADP-ribose%2529polymerase-1%2520%2528PARP-1%2529%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D4196%26epage%3D4200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Zimmermann, K.; Portmann, R.; Rigel, D. F.</span><span> </span><span class="NLM_article-title">Indoloquinazolinones</span>. U.S. Patent 6964960,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=K.+Zimmermann&author=R.+Portmann&author=D.+F.+Rigel&title=Indoloquinazolinones"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZimmermann%26aufirst%3DK.%26atitle%3DIndoloquinazolinones%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Ferraris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pahutski, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ficco, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serdyuk, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alemu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradford, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoover, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lautar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooney, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Q. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalish, V.</span><span> </span><span class="NLM_article-title">Design and synthesis of poly ADP-ribose polymerase-1 inhibitors. 2. Biological evaluation of aza-5[H]-phenanthridin-6-ones as potent, aqueous-soluble compounds for the treatment of ischemic injuries</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">3138</span><span class="NLM_x">â</span> <span class="NLM_lpage">3151</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm030109s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=3138-3151&author=D.+Ferrarisauthor=Y.+S.+Koauthor=T.+Pahutskiauthor=R.+P.+Ficcoauthor=L.+Serdyukauthor=C.+Alemuauthor=C.+Bradfordauthor=T.+Chiouauthor=R.+Hooverauthor=S.+Huangauthor=S.+Lautarauthor=S.+Liangauthor=Q.+Linauthor=M.+X.+Luauthor=M.+Mooneyauthor=L.+Morganauthor=Y.+Qianauthor=S.+Tranauthor=L.+R.+Williamsauthor=Q.+Y.+Wuauthor=J.+Zhangauthor=Y.+Zouauthor=V.+Kalish&title=Design+and+synthesis+of+poly+ADP-ribose+polymerase-1+inhibitors.+2.+Biological+evaluation+of+aza-5%5BH%5D-phenanthridin-6-ones+as+potent%2C+aqueous-soluble+compounds+for+the+treatment+of+ischemic+injuries"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Fjm030109s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030109s%26sid%3Dliteratum%253Aachs%26aulast%3DFerraris%26aufirst%3DD.%26aulast%3DKo%26aufirst%3DY.%2BS.%26aulast%3DPahutski%26aufirst%3DT.%26aulast%3DFicco%26aufirst%3DR.%2BP.%26aulast%3DSerdyuk%26aufirst%3DL.%26aulast%3DAlemu%26aufirst%3DC.%26aulast%3DBradford%26aufirst%3DC.%26aulast%3DChiou%26aufirst%3DT.%26aulast%3DHoover%26aufirst%3DR.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DLautar%26aufirst%3DS.%26aulast%3DLiang%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DQ.%26aulast%3DLu%26aufirst%3DM.%2BX.%26aulast%3DMooney%26aufirst%3DM.%26aulast%3DMorgan%26aufirst%3DL.%26aulast%3DQian%26aufirst%3DY.%26aulast%3DTran%26aufirst%3DS.%26aulast%3DWilliams%26aufirst%3DL.%2BR.%26aulast%3DWu%26aufirst%3DQ.%2BY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DY.%26aulast%3DKalish%26aufirst%3DV.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520poly%2520ADP-ribose%2520polymerase-1%2520inhibitors.%25202.%2520Biological%2520evaluation%2520of%2520aza-5%255BH%255D-phenanthridin-6-ones%2520as%2520potent%252C%2520aqueous-soluble%2520compounds%2520for%2520the%2520treatment%2520of%2520ischemic%2520injuries%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D3138%26epage%3D3151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Ferraris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ficco, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pahutski, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lautar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalish, V.</span><span> </span><span class="NLM_article-title">Design and synthesis of poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors. Part 3: In vitro evaluation of 1,3,4,5-tetrahydro-benzo[<i>c</i>][1,6]- and [<i>c</i>][1,7]-naphthyridin-6-ones</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2513</span><span class="NLM_x">â</span> <span class="NLM_lpage">2518</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=2513-2518&author=D.+Ferrarisauthor=R.+P.+Ficcoauthor=T.+Pahutskiauthor=S.+Lautarauthor=S.+Huangauthor=J.+Zhangauthor=V.+Kalish&title=Design+and+synthesis+of+poly%28ADP-ribose%29polymerase-1+%28PARP-1%29+inhibitors.+Part+3%3A+In+vitro+evaluation+of+1%2C3%2C4%2C5-tetrahydro-benzo%5Bc%5D%5B1%2C6%5D-+and+%5Bc%5D%5B1%2C7%5D-naphthyridin-6-ones"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFerraris%26aufirst%3DD.%26aulast%3DFicco%26aufirst%3DR.%2BP.%26aulast%3DPahutski%26aufirst%3DT.%26aulast%3DLautar%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DKalish%26aufirst%3DV.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520poly%2528ADP-ribose%2529polymerase-1%2520%2528PARP-1%2529%2520inhibitors.%2520Part%25203%253A%2520In%2520vitro%2520evaluation%2520of%25201%252C3%252C4%252C5-tetrahydro-benzo%255Bc%255D%255B1%252C6%255D-%2520and%2520%255Bc%255D%255B1%252C7%255D-naphthyridin-6-ones%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D2513%26epage%3D2518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Miyashiro, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woods, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giranda, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penning, T. D.</span><span> </span><span class="NLM_article-title">Synthesis and SAR of novel tricyclic quinoxalinone inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1)</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">4050</span><span class="NLM_x">â</span> <span class="NLM_lpage">4054</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=4050-4054&author=J.+Miyashiroauthor=K.+W.+Woodsauthor=C.+H.+Parkauthor=X.+Liuauthor=Y.+Shiauthor=E.+F.+Johnsonauthor=J.+J.+Bouskaauthor=A.+M.+Olsonauthor=Y.+Luoauthor=E.+H.+Fryauthor=V.+L.+Girandaauthor=T.+D.+Penning&title=Synthesis+and+SAR+of+novel+tricyclic+quinoxalinone+inhibitors+of+poly%28ADP-ribose%29polymerase-1+%28PARP-1%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMiyashiro%26aufirst%3DJ.%26aulast%3DWoods%26aufirst%3DK.%2BW.%26aulast%3DPark%26aufirst%3DC.%2BH.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DOlson%26aufirst%3DA.%2BM.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DFry%26aufirst%3DE.%2BH.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26aulast%3DPenning%26aufirst%3DT.%2BD.%26atitle%3DSynthesis%2520and%2520SAR%2520of%2520novel%2520tricyclic%2520quinoxalinone%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529polymerase-1%2520%2528PARP-1%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D4050%26epage%3D4054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Li, J.-h.; Zhang, J.; Kalish, V.</span><span> </span><span class="NLM_article-title">Substituted 4,9-Dihydrocyclopenta{imn}phenanthridine-5-ones Derivatives Thereof and Their Uses</span>. U.S. Patent 7157452,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=J.-h.+Li&author=J.+Zhang&author=V.+Kalish&title=Substituted+4%2C9-Dihydrocyclopenta%7Bimn%7Dphenanthridine-5-ones+Derivatives+Thereof+and+Their+Uses"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.-h.%26atitle%3DSubstituted%25204%252C9-Dihydrocyclopenta%257Bimn%257Dphenanthridine-5-ones%2520Derivatives%2520Thereof%2520and%2520Their%2520Uses%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Fujio, M.; Satoh, H.; Inoue, S.; Matsumoto, T.; Egi, Y.; Takahashi, T.</span><span> </span><span class="NLM_article-title">Isoquinoline Compounds and Medicinal Use Thereof</span>. U.S. Patent 7501412,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=M.+Fujio&author=H.+Satoh&author=S.+Inoue&author=T.+Matsumoto&author=Y.+Egi&author=T.+Takahashi&title=Isoquinoline+Compounds+and+Medicinal+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFujio%26aufirst%3DM.%26atitle%3DIsoquinoline%2520Compounds%2520and%2520Medicinal%2520Use%2520Thereof%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Mabire, D. J.-p.; Guillemont, J. E. G.; Van Dun, J. A. J.; Somers, M. V. F.; Wouters, W. B. L.</span><span> </span><span class="NLM_article-title">6-Akenyl and 6-Phenylalkyl Substituted 2-Quinolinones and 2-Quinoxalinones as Poly(ADP-ribose) Polymerase Inhibitors</span> WO 2005054201,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=D.+J.-p.+Mabire&author=J.+E.+G.+Guillemont&author=J.+A.+J.+Van+Dun&author=M.+V.+F.+Somers&author=W.+B.+L.+Wouters&title=6-Akenyl+and+6-Phenylalkyl+Substituted+2-Quinolinones+and+2-Quinoxalinones+as+Poly%28ADP-ribose%29+Polymerase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMabire%26aufirst%3DD.%2BJ.-p.%26atitle%3D6-Akenyl%2520and%25206-Phenylalkyl%2520Substituted%25202-Quinolinones%2520and%25202-Quinoxalinones%2520as%2520Poly%2528ADP-ribose%2529%2520Polymerase%2520Inhibitors%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Jagtap, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baloglu, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Southan, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mabley, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Duzer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salzman, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabo, C.</span><span> </span><span class="NLM_article-title">Discovery of potent poly(ADP-ribose) polymerase-1 inhibitors from the modification of indeno[1,2-<i>c</i>]isoquinolinone</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">5100</span><span class="NLM_x">â</span> <span class="NLM_lpage">5103</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0502891" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=5100-5103&author=P.+G.+Jagtapauthor=E.+Balogluauthor=G.+J.+Southanauthor=J.+G.+Mableyauthor=H.+Liauthor=J.+Zhouauthor=J.+van+Duzerauthor=A.+L.+Salzmanauthor=C.+Szabo&title=Discovery+of+potent+poly%28ADP-ribose%29+polymerase-1+inhibitors+from+the+modification+of+indeno%5B1%2C2-c%5Disoquinolinone"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Fjm0502891&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0502891%26sid%3Dliteratum%253Aachs%26aulast%3DJagtap%26aufirst%3DP.%2BG.%26aulast%3DBaloglu%26aufirst%3DE.%26aulast%3DSouthan%26aufirst%3DG.%2BJ.%26aulast%3DMabley%26aufirst%3DJ.%2BG.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3Dvan%2BDuzer%26aufirst%3DJ.%26aulast%3DSalzman%26aufirst%3DA.%2BL.%26aulast%3DSzabo%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520potent%2520poly%2528ADP-ribose%2529%2520polymerase-1%2520inhibitors%2520from%2520the%2520modification%2520of%2520indeno%255B1%252C2-c%255Disoquinolinone%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D5100%26epage%3D5103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Griffin, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pemberton, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhodes, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bleasdale, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calvert, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durkacz, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newell, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porteous, J. K.</span><span> </span><span class="NLM_article-title">Novel potent inhibitors of the DNA repair enzyme poly(ADP-ribose)polymerase (PARP)</span> <span class="citation_source-journal">Anti-Cancer Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">507</span><span class="NLM_x">â</span> <span class="NLM_lpage">514</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1995&pages=507-514&author=R.+J.+Griffinauthor=L.+C.+Pembertonauthor=D.+Rhodesauthor=C.+Bleasdaleauthor=K.+Bowmanauthor=A.+H.+Calvertauthor=N.+J.+Curtinauthor=B.+W.+Durkaczauthor=D.+R.+Newellauthor=J.+K.+Porteous&title=Novel+potent+inhibitors+of+the+DNA+repair+enzyme+poly%28ADP-ribose%29polymerase+%28PARP%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DPemberton%26aufirst%3DL.%2BC.%26aulast%3DRhodes%26aufirst%3DD.%26aulast%3DBleasdale%26aufirst%3DC.%26aulast%3DBowman%26aufirst%3DK.%26aulast%3DCalvert%26aufirst%3DA.%2BH.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DDurkacz%26aufirst%3DB.%2BW.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DPorteous%26aufirst%3DJ.%2BK.%26atitle%3DNovel%2520potent%2520inhibitors%2520of%2520the%2520DNA%2520repair%2520enzyme%2520poly%2528ADP-ribose%2529polymerase%2520%2528PARP%2529%26jtitle%3DAnti-Cancer%2520Drug%2520Des.%26date%3D1995%26volume%3D10%26spage%3D507%26epage%3D514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group">White, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almassy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calvert, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hostomsky, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maegley, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newell, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srinivasan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golding, B. T.</span><span> </span><span class="NLM_article-title">Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">4084</span><span class="NLM_x">â</span> <span class="NLM_lpage">4097</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm000950v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=4084-4097&author=A.+W.+Whiteauthor=R.+Almassyauthor=A.+H.+Calvertauthor=N.+J.+Curtinauthor=R.+J.+Griffinauthor=Z.+Hostomskyauthor=K.+Maegleyauthor=D.+R.+Newellauthor=S.+Srinivasanauthor=B.+T.+Golding&title=Resistance-modifying+agents.+9.+Synthesis+and+biological+properties+of+benzimidazole+inhibitors+of+the+DNA+repair+enzyme+poly%28ADP-ribose%29+polymerase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1021%2Fjm000950v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000950v%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DA.%2BW.%26aulast%3DAlmassy%26aufirst%3DR.%26aulast%3DCalvert%26aufirst%3DA.%2BH.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DHostomsky%26aufirst%3DZ.%26aulast%3DMaegley%26aufirst%3DK.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DSrinivasan%26aufirst%3DS.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26atitle%3DResistance-modifying%2520agents.%25209.%2520Synthesis%2520and%2520biological%2520properties%2520of%2520benzimidazole%2520inhibitors%2520of%2520the%2520DNA%2520repair%2520enzyme%2520poly%2528ADP-ribose%2529%2520polymerase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D4084%26epage%3D4097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Grandel, R.; Lubisch, W.; Kock, M.; Hoger, T.; Muller, R.; Schult, S.; Holzenkamp, U.</span><span> </span><span class="NLM_article-title">Substituted Indoles Which Are PARP Inhibitors</span>. U.S. Patent 7087637,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=R.+Grandel&author=W.+Lubisch&author=M.+Kock&author=T.+Hoger&author=R.+Muller&author=S.+Schult&author=U.+Holzenkamp&title=Substituted+Indoles+Which+Are+PARP+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGrandel%26aufirst%3DR.%26atitle%3DSubstituted%2520Indoles%2520Which%2520Are%2520PARP%2520Inhibitors%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group">Jones, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boueres, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrigno, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fonsi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giomini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamartina, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monteagudo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ontoria, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsale, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palumbi, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesci, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roscilli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarpelli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz-Fademrecht, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toniatti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span> </span><span class="NLM_article-title">Discovery of 2-{4-[(3<i>S</i>)-piperidin-3-yl]phenyl}-2<i>H</i>-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">7170</span><span class="NLM_x">â</span> <span class="NLM_lpage">7185</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901188v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7170-7185&author=P.+Jonesauthor=S.+Altamuraauthor=J.+Boueresauthor=F.+Ferrignoauthor=M.+Fonsiauthor=C.+Giominiauthor=S.+Lamartinaauthor=E.+Monteagudoauthor=J.+M.+Ontoriaauthor=M.+V.+Orsaleauthor=M.+C.+Palumbiauthor=S.+Pesciauthor=G.+Roscilliauthor=R.+Scarpelliauthor=C.+Schultz-Fademrechtauthor=C.+Toniattiauthor=M.+Rowley&title=Discovery+of+2-%7B4-%5B%283S%29-piperidin-3-yl%5Dphenyl%7D-2H-indazole-7-carboxamide+%28MK-4827%29%3A+a+novel+oral+poly%28ADP-ribose%29polymerase+%28PARP%29+inhibitor+efficacious+in+BRCA-1+and+-2+mutant+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Fjm901188v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901188v%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DP.%26aulast%3DAltamura%26aufirst%3DS.%26aulast%3DBoueres%26aufirst%3DJ.%26aulast%3DFerrigno%26aufirst%3DF.%26aulast%3DFonsi%26aufirst%3DM.%26aulast%3DGiomini%26aufirst%3DC.%26aulast%3DLamartina%26aufirst%3DS.%26aulast%3DMonteagudo%26aufirst%3DE.%26aulast%3DOntoria%26aufirst%3DJ.%2BM.%26aulast%3DOrsale%26aufirst%3DM.%2BV.%26aulast%3DPalumbi%26aufirst%3DM.%2BC.%26aulast%3DPesci%26aufirst%3DS.%26aulast%3DRoscilli%26aufirst%3DG.%26aulast%3DScarpelli%26aufirst%3DR.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DToniatti%26aufirst%3DC.%26aulast%3DRowley%26aufirst%3DM.%26atitle%3DDiscovery%2520of%25202-%257B4-%255B%25283S%2529-piperidin-3-yl%255Dphenyl%257D-2H-indazole-7-carboxamide%2520%2528MK-4827%2529%253A%2520a%2520novel%2520oral%2520poly%2528ADP-ribose%2529polymerase%2520%2528PARP%2529%2520inhibitor%2520efficacious%2520in%2520BRCA-1%2520and%2520-2%2520mutant%2520tumors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7170%26epage%3D7185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group">Lubisch, W.; Kock, M.; Hoeger, T.; Grandel, R.; Mueller, R.; Schult, S.</span><span> </span><span class="NLM_article-title">Heterocyclic Compounds and Their Use as PARP Inhibitors</span>. U.S. Patent 7041675,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=W.+Lubisch&author=M.+Kock&author=T.+Hoeger&author=R.+Grandel&author=R.+Mueller&author=S.+Schult&title=Heterocyclic+Compounds+and+Their+Use+as+PARP+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLubisch%26aufirst%3DW.%26atitle%3DHeterocyclic%2520Compounds%2520and%2520Their%2520Use%2520as%2520PARP%2520Inhibitors%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group">Hattori, K.; Yamamoto, H.; Mukoyoshi, K.; Kuroda, S.</span><span> </span><span class="NLM_article-title">Quinoxaline Derivatives Which Have PARP Inhibitory Action</span>. WO/2003/007959,<span class="NLM_x"> </span><span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=K.+Hattori&author=H.+Yamamoto&author=K.+Mukoyoshi&author=S.+Kuroda&title=Quinoxaline+Derivatives+Which+Have+PARP+Inhibitory+Action"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHattori%26aufirst%3DK.%26atitle%3DQuinoxaline%2520Derivatives%2520Which%2520Have%2520PARP%2520Inhibitory%2520Action%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group">Menear, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adcock, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alonso, F. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackburn, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copsey, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drzewiecki, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fundo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Gall, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javaid, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lence, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mydlowski, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. C.</span><span> </span><span class="NLM_article-title">Novel alkoxybenzamide inhibitors of poly(ADP-ribose) polymerase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">3942</span><span class="NLM_x">â</span> <span class="NLM_lpage">3945</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=3942-3945&author=K.+A.+Menearauthor=C.+Adcockauthor=F.+C.+Alonsoauthor=K.+Blackburnauthor=L.+Copseyauthor=J.+Drzewieckiauthor=A.+Fundoauthor=A.+Le+Gallauthor=S.+Gomezauthor=H.+Javaidauthor=C.+F.+Lenceauthor=N.+M.+Martinauthor=C.+Mydlowskiauthor=G.+C.+Smith&title=Novel+alkoxybenzamide+inhibitors+of+poly%28ADP-ribose%29+polymerase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMenear%26aufirst%3DK.%2BA.%26aulast%3DAdcock%26aufirst%3DC.%26aulast%3DAlonso%26aufirst%3DF.%2BC.%26aulast%3DBlackburn%26aufirst%3DK.%26aulast%3DCopsey%26aufirst%3DL.%26aulast%3DDrzewiecki%26aufirst%3DJ.%26aulast%3DFundo%26aufirst%3DA.%26aulast%3DLe%2BGall%26aufirst%3DA.%26aulast%3DGomez%26aufirst%3DS.%26aulast%3DJavaid%26aufirst%3DH.%26aulast%3DLence%26aufirst%3DC.%2BF.%26aulast%3DMartin%26aufirst%3DN.%2BM.%26aulast%3DMydlowski%26aufirst%3DC.%26aulast%3DSmith%26aufirst%3DG.%2BC.%26atitle%3DNovel%2520alkoxybenzamide%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D3942%26epage%3D3945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group">Ferraris, D. V.; Li, J.-h.; Kalish, V.; Zhang, J.</span><span> </span><span class="NLM_article-title">Compounds and Their Uses</span>. U.S. Patent 7235557,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=D.+V.+Ferraris&author=J.-h.+Li&author=V.+Kalish&author=J.+Zhang&title=Compounds+and+Their+Uses"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFerraris%26aufirst%3DD.%2BV.%26atitle%3DCompounds%2520and%2520Their%2520Uses%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group">Canan Koch, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thoresen, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tikhe, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maegley, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almassy, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, X. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zook, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumpf, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boritzki, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansour, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ekker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calabrese, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kyle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calvert, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golding, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newell, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webber, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hostomsky, Z.</span><span> </span><span class="NLM_article-title">Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">4961</span><span class="NLM_x">â</span> <span class="NLM_lpage">4974</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm020259n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=4961-4974&author=S.+S.+Canan+Kochauthor=L.+H.+Thoresenauthor=J.+G.+Tikheauthor=K.+A.+Maegleyauthor=R.+J.+Almassyauthor=J.+Liauthor=X.+H.+Yuauthor=S.+E.+Zookauthor=R.+A.+Kumpfauthor=C.+Zhangauthor=T.+J.+Boritzkiauthor=R.+N.+Mansourauthor=K.+E.+Zhangauthor=A.+Ekkerauthor=C.+R.+Calabreseauthor=N.+J.+Curtinauthor=S.+Kyleauthor=H.+D.+Thomasauthor=L.+Z.+Wangauthor=A.+H.+Calvertauthor=B.+T.+Goldingauthor=R.+J.+Griffinauthor=D.+R.+Newellauthor=S.+E.+Webberauthor=Z.+Hostomsky&title=Novel+tricyclic+poly%28ADP-ribose%29+polymerase-1+inhibitors+with+potent+anticancer+chemopotentiating+activity%3A+design%2C+synthesis%2C+and+X-ray+cocrystal+structure"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Fjm020259n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020259n%26sid%3Dliteratum%253Aachs%26aulast%3DCanan%2BKoch%26aufirst%3DS.%2BS.%26aulast%3DThoresen%26aufirst%3DL.%2BH.%26aulast%3DTikhe%26aufirst%3DJ.%2BG.%26aulast%3DMaegley%26aufirst%3DK.%2BA.%26aulast%3DAlmassy%26aufirst%3DR.%2BJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DX.%2BH.%26aulast%3DZook%26aufirst%3DS.%2BE.%26aulast%3DKumpf%26aufirst%3DR.%2BA.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DBoritzki%26aufirst%3DT.%2BJ.%26aulast%3DMansour%26aufirst%3DR.%2BN.%26aulast%3DZhang%26aufirst%3DK.%2BE.%26aulast%3DEkker%26aufirst%3DA.%26aulast%3DCalabrese%26aufirst%3DC.%2BR.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DKyle%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DH.%2BD.%26aulast%3DWang%26aufirst%3DL.%2BZ.%26aulast%3DCalvert%26aufirst%3DA.%2BH.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DWebber%26aufirst%3DS.%2BE.%26aulast%3DHostomsky%26aufirst%3DZ.%26atitle%3DNovel%2520tricyclic%2520poly%2528ADP-ribose%2529%2520polymerase-1%2520inhibitors%2520with%2520potent%2520anticancer%2520chemopotentiating%2520activity%253A%2520design%252C%2520synthesis%252C%2520and%2520X-ray%2520cocrystal%2520structure%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D4961%26epage%3D4974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group">Skalitzky, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marakovits, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maegley, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ekker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, X. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hostomsky, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webber, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eastman, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almassy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newell, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calvert, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golding, B. T.</span><span> </span><span class="NLM_article-title">Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">210</span><span class="NLM_x">â</span> <span class="NLM_lpage">213</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0255769" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=210-213&author=D.+J.+Skalitzkyauthor=J.+T.+Marakovitsauthor=K.+A.+Maegleyauthor=A.+Ekkerauthor=X.+H.+Yuauthor=Z.+Hostomskyauthor=S.+E.+Webberauthor=B.+W.+Eastmanauthor=R.+Almassyauthor=J.+Liauthor=N.+J.+Curtinauthor=D.+R.+Newellauthor=A.+H.+Calvertauthor=R.+J.+Griffinauthor=B.+T.+Golding&title=Tricyclic+benzimidazoles+as+potent+poly%28ADP-ribose%29+polymerase-1+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1021%2Fjm0255769&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0255769%26sid%3Dliteratum%253Aachs%26aulast%3DSkalitzky%26aufirst%3DD.%2BJ.%26aulast%3DMarakovits%26aufirst%3DJ.%2BT.%26aulast%3DMaegley%26aufirst%3DK.%2BA.%26aulast%3DEkker%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DX.%2BH.%26aulast%3DHostomsky%26aufirst%3DZ.%26aulast%3DWebber%26aufirst%3DS.%2BE.%26aulast%3DEastman%26aufirst%3DB.%2BW.%26aulast%3DAlmassy%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DCalvert%26aufirst%3DA.%2BH.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26atitle%3DTricyclic%2520benzimidazoles%2520as%2520potent%2520poly%2528ADP-ribose%2529%2520polymerase-1%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D210%26epage%3D213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group">Ferraris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ficco, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dain, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ginski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lautar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee-Wisdom, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalish, V. J.</span><span> </span><span class="NLM_article-title">Design and synthesis of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. Part 4: Biological evaluation of imidazobenzodiazepines as potent PARP-1 inhibitors for treatment of ischemic injuries</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">3695</span><span class="NLM_x">â</span> <span class="NLM_lpage">3707</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2003&pages=3695-3707&author=D.+Ferrarisauthor=R.+P.+Ficcoauthor=D.+Dainauthor=M.+Ginskiauthor=S.+Lautarauthor=K.+Lee-Wisdomauthor=S.+Liangauthor=Q.+Linauthor=M.+X.+Luauthor=L.+Morganauthor=B.+Thomasauthor=L.+R.+Williamsauthor=J.+Zhangauthor=Y.+Zhouauthor=V.+J.+Kalish&title=Design+and+synthesis+of+poly%28ADP-ribose%29+polymerase-1+%28PARP-1%29+inhibitors.+Part+4%3A+Biological+evaluation+of+imidazobenzodiazepines+as+potent+PARP-1+inhibitors+for+treatment+of+ischemic+injuries"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFerraris%26aufirst%3DD.%26aulast%3DFicco%26aufirst%3DR.%2BP.%26aulast%3DDain%26aufirst%3DD.%26aulast%3DGinski%26aufirst%3DM.%26aulast%3DLautar%26aufirst%3DS.%26aulast%3DLee-Wisdom%26aufirst%3DK.%26aulast%3DLiang%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DQ.%26aulast%3DLu%26aufirst%3DM.%2BX.%26aulast%3DMorgan%26aufirst%3DL.%26aulast%3DThomas%26aufirst%3DB.%26aulast%3DWilliams%26aufirst%3DL.%2BR.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DKalish%26aufirst%3DV.%2BJ.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520poly%2528ADP-ribose%2529%2520polymerase-1%2520%2528PARP-1%2529%2520inhibitors.%2520Part%25204%253A%2520Biological%2520evaluation%2520of%2520imidazobenzodiazepines%2520as%2520potent%2520PARP-1%2520inhibitors%2520for%2520treatment%2520of%2520ischemic%2520injuries%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2003%26volume%3D11%26spage%3D3695%26epage%3D3707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group">Barth, F.; Bichon, D.; Bolkenius, F.; Van Dorsselaer, V.</span><span> </span><span class="NLM_article-title">Benzimidazole Derivatives, Preparation and Therapeutic Use Thereof</span>. U.S. Patent 6794382,<span class="NLM_x"> </span><span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=F.+Barth&author=D.+Bichon&author=F.+Bolkenius&author=V.+Van+Dorsselaer&title=Benzimidazole+Derivatives%2C+Preparation+and+Therapeutic+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBarth%26aufirst%3DF.%26atitle%3DBenzimidazole%2520Derivatives%252C%2520Preparation%2520and%2520Therapeutic%2520Use%2520Thereof%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group">Kinoshita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakanishi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warizaya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwashita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kido, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, T.</span><span> </span><span class="NLM_article-title">Inhibitor-induced structural change of the active site of human poly(ADP-ribose) polymerase</span> <span class="citation_source-journal">FEBS Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">556</span><span class="NLM_x">, </span> <span class="NLM_fpage">43</span><span class="NLM_x">â</span> <span class="NLM_lpage">46</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=556&publication_year=2004&pages=43-46&author=T.+Kinoshitaauthor=I.+Nakanishiauthor=M.+Warizayaauthor=A.+Iwashitaauthor=Y.+Kidoauthor=K.+Hattoriauthor=T.+Fujii&title=Inhibitor-induced+structural+change+of+the+active+site+of+human+poly%28ADP-ribose%29+polymerase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKinoshita%26aufirst%3DT.%26aulast%3DNakanishi%26aufirst%3DI.%26aulast%3DWarizaya%26aufirst%3DM.%26aulast%3DIwashita%26aufirst%3DA.%26aulast%3DKido%26aufirst%3DY.%26aulast%3DHattori%26aufirst%3DK.%26aulast%3DFujii%26aufirst%3DT.%26atitle%3DInhibitor-induced%2520structural%2520change%2520of%2520the%2520active%2520site%2520of%2520human%2520poly%2528ADP-ribose%2529%2520polymerase%26jtitle%3DFEBS%2520Lett.%26date%3D2004%26volume%3D556%26spage%3D43%26epage%3D46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group">Hattori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kido, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishida, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamijo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohkubo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinoshita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwashita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mihara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuoka, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teramura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyake, H.</span><span> </span><span class="NLM_article-title">Rational approaches to discovery of orally active and brain-penetrable quinazolinone inhibitors of poly(ADP-ribose)polymerase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">4151</span><span class="NLM_x">â</span> <span class="NLM_lpage">4154</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0499256" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD2cXls1Kqtr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=4151-4154&author=K.+Hattoriauthor=Y.+Kidoauthor=H.+Yamamotoauthor=J.+Ishidaauthor=K.+Kamijoauthor=K.+Muranoauthor=M.+Ohkuboauthor=T.+Kinoshitaauthor=A.+Iwashitaauthor=K.+Miharaauthor=S.+Yamazakiauthor=N.+Matsuokaauthor=Y.+Teramuraauthor=H.+Miyake&title=Rational+approaches+to+discovery+of+orally+active+and+brain-penetrable+quinazolinone+inhibitors+of+poly%28ADP-ribose%29polymerase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Approaches to Discovery of Orally Active and Brain-Penetrable Quinazolinone Inhibitors of Poly(ADP-ribose)polymerase</span></div><div class="casAuthors">Hattori, Kouji; Kido, Yoshiyuki; Yamamoto, Hirofumi; Ishida, Junya; Kamijo, Kazunori; Murano, Kenji; Ohkubo, Mitsuru; Kinoshita, Takayoshi; Iwashita, Akinori; Mihara, Kayoko; Yamazaki, Syunji; Matsuoka, Nobuya; Teramura, Yoshinori; Miyake, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4151-4154</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel class of quinazolinone derivs. as potent poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors has been discovered.  Key to success was application of a rational discovery strategy involving structure-based design, combinatorial chem., and classical SAR for improvement of potency and bioavailability.  The new inhibitors were shown to bind to the nicotinamide-ribose binding site (NI site) and the adenosine-ribose binding site (AD site) of NAD+.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnYt__YsYlRrVg90H21EOLACvtfcHk0liRIttAdLdliw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXls1Kqtr4%253D&md5=710cbcd058d858e37c3ff6dcf8ba182d</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1021%2Fjm0499256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0499256%26sid%3Dliteratum%253Aachs%26aulast%3DHattori%26aufirst%3DK.%26aulast%3DKido%26aufirst%3DY.%26aulast%3DYamamoto%26aufirst%3DH.%26aulast%3DIshida%26aufirst%3DJ.%26aulast%3DKamijo%26aufirst%3DK.%26aulast%3DMurano%26aufirst%3DK.%26aulast%3DOhkubo%26aufirst%3DM.%26aulast%3DKinoshita%26aufirst%3DT.%26aulast%3DIwashita%26aufirst%3DA.%26aulast%3DMihara%26aufirst%3DK.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DMatsuoka%26aufirst%3DN.%26aulast%3DTeramura%26aufirst%3DY.%26aulast%3DMiyake%26aufirst%3DH.%26atitle%3DRational%2520approaches%2520to%2520discovery%2520of%2520orally%2520active%2520and%2520brain-penetrable%2520quinazolinone%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529polymerase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D4151%26epage%3D4154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group">Parveen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naughton, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whish, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Threadgill, M. D.</span><span> </span><span class="NLM_article-title">2-Nitroimidazol-5-ylmethyl as a potential bioreductively activated prodrug system: reductively triggered release of the PARP inhibitor 5-bromoisoquinolinone</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">2031</span><span class="NLM_x">â</span> <span class="NLM_lpage">2036</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1999&pages=2031-2036&author=I.+Parveenauthor=D.+P.+Naughtonauthor=W.+J.+Whishauthor=M.+D.+Threadgill&title=2-Nitroimidazol-5-ylmethyl+as+a+potential+bioreductively+activated+prodrug+system%3A+reductively+triggered+release+of+the+PARP+inhibitor+5-bromoisoquinolinone"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DParveen%26aufirst%3DI.%26aulast%3DNaughton%26aufirst%3DD.%2BP.%26aulast%3DWhish%26aufirst%3DW.%2BJ.%26aulast%3DThreadgill%26aufirst%3DM.%2BD.%26atitle%3D2-Nitroimidazol-5-ylmethyl%2520as%2520a%2520potential%2520bioreductively%2520activated%2520prodrug%2520system%253A%2520reductively%2520triggered%2520release%2520of%2520the%2520PARP%2520inhibitor%25205-bromoisoquinolinone%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1999%26volume%3D9%26spage%3D2031%26epage%3D2036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group">Griffin, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srinivasan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calvert, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newell, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pemberton, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golding, B. T.</span><span> </span><span class="NLM_article-title">Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">5247</span><span class="NLM_x">â</span> <span class="NLM_lpage">5256</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm980273t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=5247-5256&author=R.+J.+Griffinauthor=S.+Srinivasanauthor=K.+Bowmanauthor=A.+H.+Calvertauthor=N.+J.+Curtinauthor=D.+R.+Newellauthor=L.+C.+Pembertonauthor=B.+T.+Golding&title=Resistance-modifying+agents.+5.+Synthesis+and+biological+properties+of+quinazolinone+inhibitors+of+the+DNA+repair+enzyme+poly%28ADP-ribose%29+polymerase+%28PARP%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Fjm980273t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm980273t%26sid%3Dliteratum%253Aachs%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DSrinivasan%26aufirst%3DS.%26aulast%3DBowman%26aufirst%3DK.%26aulast%3DCalvert%26aufirst%3DA.%2BH.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DPemberton%26aufirst%3DL.%2BC.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26atitle%3DResistance-modifying%2520agents.%25205.%2520Synthesis%2520and%2520biological%2520properties%2520of%2520quinazolinone%2520inhibitors%2520of%2520the%2520DNA%2520repair%2520enzyme%2520poly%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D5247%26epage%3D5256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group">Boulton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pemberton, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porteous, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golding, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durkacz, B. W.</span><span> </span><span class="NLM_article-title">Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">849</span><span class="NLM_x">â</span> <span class="NLM_lpage">856</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1038%2Fbjc.1995.423" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=7547230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADyaK2MXptlKjtL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=1995&pages=849-856&author=S.+Boultonauthor=L.+C.+Pembertonauthor=J.+K.+Porteousauthor=N.+J.+Curtinauthor=R.+J.+Griffinauthor=B.+T.+Goldingauthor=B.+W.+Durkacz&title=Potentiation+of+temozolomide-induced+cytotoxicity%3A+a+comparative+study+of+the+biological+effects+of+poly%28ADP-ribose%29+polymerase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Potentiation of temozolomide-induced cytotoxicity: A comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors</span></div><div class="casAuthors">Boulton, S.; Pemberton, L C.; Porteous, J K.; Curtin, N J.; Griffin, R J.; Golding, B T.; Durkacz, B W.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">849-56</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Scientific & Medical Division</span>)
        </div><div class="casAbstract">Four poly(ADP-ribose) polymerase (PADPRP) inhibitors [3-aminobenzamide, benzamide, 3,4-dihydro-5-methoxyisoquinolin-1(2H)-one (PD 128763) and 8-hydroxy-2-methylquinazolin-4(3H)-one (NU1025)] were compared with respect to their effects on a no. of biol. end points.  The following parameters were assessed: their ability to inhibit the enzyme in permeabilized L1210 cells; their ability to potentiate the cytotoxicity of temozolomide (including the cytotoxicity of the compds. per se); their ability to increase net levels of temozolomide-induced DNA strand breaks and inhibit temozolomide-induced NAD depletion.  PD 128763 and NU1025 were equipotent as PADPRP inhibitors, and 40- and 50-fold more potent than benzamide and 3-aminobenzamide resp.  All the compds. acted in a concn.-dependent manner to potentiate the cytotoxicity and increase DNA strand break levels in cells treated with temozolomide.  There was an excellent correlation between the potency of the compds. as PADPRP inhibitors and their effects on cell survival and DNA repair.  Temozolomide treatment caused a decrease in cellular NAD levels, and this was abolished by the PADPRP inhibitors.  In conclusion, the new generation of PADPRP inhibitors are at least 50-fold more effective than 3-aminobenzamide as chemopotentiators, and can be used at micromolar rather than millimolar concns. in intact cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpO-XC_jBflmbVg90H21EOLACvtfcHk0liKw76cf5caJA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXptlKjtL0%253D&md5=a383a8a3b9c4a748e8cb173b25e9d32a</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1038%2Fbjc.1995.423&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.1995.423%26sid%3Dliteratum%253Aachs%26aulast%3DBoulton%26aufirst%3DS.%26aulast%3DPemberton%26aufirst%3DL.%2BC.%26aulast%3DPorteous%26aufirst%3DJ.%2BK.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26aulast%3DDurkacz%26aufirst%3DB.%2BW.%26atitle%3DPotentiation%2520of%2520temozolomide-induced%2520cytotoxicity%253A%2520a%2520comparative%2520study%2520of%2520the%2520biological%2520effects%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitors%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D1995%26volume%3D72%26spage%3D849%26epage%3D856" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group">Tentori, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonetti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarsella, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">dâAmati, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Portarena, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zupi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonmassar, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graziani, G.</span><span> </span><span class="NLM_article-title">Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">2241</span><span class="NLM_x">â</span> <span class="NLM_lpage">2244</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=2241-2244&author=L.+Tentoriauthor=C.+Leonettiauthor=M.+Scarsellaauthor=G.+d%E2%80%99Amatiauthor=I.+Portarenaauthor=G.+Zupiauthor=E.+Bonmassarauthor=G.+Graziani&title=Combined+treatment+with+temozolomide+and+poly%28ADP-ribose%29+polymerase+inhibitor+enhances+survival+of+mice+bearing+hematologic+malignancy+at+the+central+nervous+system+site"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTentori%26aufirst%3DL.%26aulast%3DLeonetti%26aufirst%3DC.%26aulast%3DScarsella%26aufirst%3DM.%26aulast%3Dd%25E2%2580%2599Amati%26aufirst%3DG.%26aulast%3DPortarena%26aufirst%3DI.%26aulast%3DZupi%26aufirst%3DG.%26aulast%3DBonmassar%26aufirst%3DE.%26aulast%3DGraziani%26aufirst%3DG.%26atitle%3DCombined%2520treatment%2520with%2520temozolomide%2520and%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitor%2520enhances%2520survival%2520of%2520mice%2520bearing%2520hematologic%2520malignancy%2520at%2520the%2520central%2520nervous%2520system%2520site%26jtitle%3DBlood%26date%3D2002%26volume%3D99%26spage%3D2241%26epage%3D2244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group">Delaney, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kyle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calvert, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durkacz, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hostomsky, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newell, D. R.</span><span> </span><span class="NLM_article-title">Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">2860</span><span class="NLM_x">â</span> <span class="NLM_lpage">2867</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=10914735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlslentbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=2860-2867&author=C.+A.+Delaneyauthor=L.+Z.+Wangauthor=S.+Kyleauthor=A.+W.+Whiteauthor=A.+H.+Calvertauthor=N.+J.+Curtinauthor=B.+W.+Durkaczauthor=Z.+Hostomskyauthor=D.+R.+Newell&title=Potentiation+of+temozolomide+and+topotecan+growth+inhibition+and+cytotoxicity+by+novel+poly%28adenosine+diphosphoribose%29+polymerase+inhibitors+in+a+panel+of+human+tumor+cell+lines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines</span></div><div class="casAuthors">Delaney, Carol A.; Wang, Lan-Z.; Kyle, Suzanne; White, Alex W.; Calvert, A. Hilary; Curtin, Nicola J.; Durkacz, Barbara W.; Hostomsky, Zdenek; Newell, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2860-2867</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Potent poly(ADP-ribose) polymerase (PARP) inhibitors have been developed that potentiate the cytotoxicity of ionizing radiation and anticancer drugs.  The biol. effects of two novel PARP inhibitors, NU1025 (8-hydroxy-2-methylquinazolin-4-[3H]one, Ki = 48 nM) and NU1085 [2-(4-hydroxyphenyl)benzamidazole-4-carboxamide, Ki = 6 nM], in combination with temozolomide (TM) or topotecan (TP) have been studied in 12 human tumor cell lines (lung, colon, ovary, and breast cancer).  Cells were treated with increasing concns. of TM or TP Â± NU1025 (50, 200 Î¼M) or NU1085 (10 Î¼M) for 72 h.  The potentiation of growth inhibition by NU1025 and NU1085 varied between the cell lines from 1.5- to 4-fold for TM and 1- to 5-fold for TP and was unaffected by p53 status.  Clonogenic assays undertaken in two of the cell lines confirmed that the potentiation of growth inhibition reflected the potentiation of cytotoxicity.  NU1025 (50 Î¼M) was about as effective as 10 Î¼M NU1085 at potentiating growth inhibition and cytotoxicity, consistent with the relative potencies of the two mols. as PARP inhibitors.  Potentiation of cytotoxicity was obtained at concns. of NU1025 and NU1085 that were not toxic per se; however, NU1085 alone was 3-fold more cytotoxic (LC50 values ranged from 83 to 94 Î¼M) than NU1025 alone (LC50 > 900 Î¼M).  These data demonstrate that PARP inhibitors are effective resistance-modifying agents in human tumor cell lines and have provided a comprehensive assessment protocol for the selection of optimum combinations of anticancer drugs, PARP inhibitors, and cell lines for in vivo studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTctxg5iD_8rVg90H21EOLACvtfcHk0lh-31TZlTpn0A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlslentbg%253D&md5=ba8603da91178e24aa914249946ca463</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDelaney%26aufirst%3DC.%2BA.%26aulast%3DWang%26aufirst%3DL.%2BZ.%26aulast%3DKyle%26aufirst%3DS.%26aulast%3DWhite%26aufirst%3DA.%2BW.%26aulast%3DCalvert%26aufirst%3DA.%2BH.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DDurkacz%26aufirst%3DB.%2BW.%26aulast%3DHostomsky%26aufirst%3DZ.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26atitle%3DPotentiation%2520of%2520temozolomide%2520and%2520topotecan%2520growth%2520inhibition%2520and%2520cytotoxicity%2520by%2520novel%2520poly%2528adenosine%2520diphosphoribose%2529%2520polymerase%2520inhibitors%2520in%2520a%2520panel%2520of%2520human%2520tumor%2520cell%2520lines%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2000%26volume%3D6%26spage%3D2860%26epage%3D2867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group">Calabrese, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almassy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batey, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calvert, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canan-Koch, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durkacz, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hostomsky, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumpf, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kyle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maegley, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newell, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Notarianni, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratford, I. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skalitzky, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webber, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span> </span><span class="NLM_article-title">Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">56</span><span class="NLM_x">â</span> <span class="NLM_lpage">67</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1093%2Fjnci%2Fdjh005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=14709739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD2cXislarsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2004&pages=56-67&author=C.+R.+Calabreseauthor=R.+Almassyauthor=S.+Bartonauthor=M.+A.+Bateyauthor=A.+H.+Calvertauthor=S.+Canan-Kochauthor=B.+W.+Durkaczauthor=Z.+Hostomskyauthor=R.+A.+Kumpfauthor=S.+Kyleauthor=J.+Liauthor=K.+Maegleyauthor=D.+R.+Newellauthor=E.+Notarianniauthor=I.+J.+Stratfordauthor=D.+Skalitzkyauthor=H.+D.+Thomasauthor=L.+Z.+Wangauthor=S.+E.+Webberauthor=K.+J.+Williamsauthor=N.+J.+Curtin&title=Anticancer+chemosensitization+and+radiosensitization+by+the+novel+poly%28ADP-ribose%29+polymerase-1+inhibitor+AG14361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Anticancer Chemosensitization and Radiosensitization by the Novel Poly(ADP-ribose) Polymerase-1 Inhibitor AG14361</span></div><div class="casAuthors">Calabrese, Christopher R.; Almassy, Robert; Barton, Stephanie; Batey, Michael A.; Calvert, A. Hilary; Canan-Koch, Stacie; Durkacz, Barbara W.; Hostomsky, Zdenek; Kumpf, Robert A.; Kyle, Suzanne; Li, Jianke; Maegley, Karen; Newell, David R.; Notarianni, Elena; Stratford, Ian J.; Skalitzky, Donald; Thomas, Huw D.; Wang, Lan-Zhen; Webber, Stephen E.; Williams, Kaye J.; Curtin, Nicola J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">56-67</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background: Poly(ADP-ribose) polymerase-1 (PARP-1) facilitates the repair of DNA strand breaks.  Inhibiting PARP-1 increases the cytotoxicity of DNA-damaging chemotherapy and radiation therapy in vitro.  Because classical PARP-1 inhibitors have limited clin. utility, we investigated whether AG14361, a novel potent PARP-1 inhibitor (inhibition const. <5 nM), enhances the effects of chemotherapy and radiation therapy in human cancer cell cultures and xenografts.  Methods: The effect of AG14361 on the antitumor activity of the DNA alkylating agent temozolomide, topoisomerase I poisons topotecan or irinotecan, or x-irradn. or Î³-radiation was investigated in human cancer cell lines A549, LoVo, and SW620 by proliferation and survival assays and in xenografts in mice by tumor vol. detn.  The specificity of AG14361 for PARP-1 was investigated by microarray anal. and by antiproliferation and acute toxicity assays in PARP-1-/- and PARP-1+/+ cells and mice.  After i.p. administration, the concn. of AG14361 was detd. in mouse plasma and tissues, and its effect on PARP-1 activity was detd. in tumor homogenates.  All statistical tests were two-sided.  Results: AG14361 at 0.4 Î¼M did not affect cancer cell gene expression or growth, but it did increase the antiproliferative activity of temozolomide (e.g., in LoVo cells by 5.5-fold, 95% confidence interval [CI] = 4.9-fold to 5.9-fold; P = .004) and topotecan (e.g., in LoVo cells by 1.6-fold, 95% CI = 1.3-fold to 1.9-fold; P = .002) and inhibited recovery from potentially lethal Î³-radiation damage in LoVo cells by 73% (95% CI = 48% to 98%).  In vivo, nontoxic doses of AG14361 increased the delay of LoVo xenograft growth induced by irinotecan, x-irradn., or temozolomide by two- to threefold.  The combination of AG14361 and temozolomide caused complete regression of SW620 xenograft tumors.  AG14361 was retained in xenografts in which PARP-1 activity was inhibited by more than 75% for at least 4 h.  Conclusion: AG14361 is, to our knowledge, the first high-potency PARP-1 inhibitor with the specificity and in vivo activity to enhance chemotherapy and radiation therapy of human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqorpwvo2sC6rVg90H21EOLACvtfcHk0lh-31TZlTpn0A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXislarsw%253D%253D&md5=1b14488c625431de24ba11fad79ad9e5</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjh005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjh005%26sid%3Dliteratum%253Aachs%26aulast%3DCalabrese%26aufirst%3DC.%2BR.%26aulast%3DAlmassy%26aufirst%3DR.%26aulast%3DBarton%26aufirst%3DS.%26aulast%3DBatey%26aufirst%3DM.%2BA.%26aulast%3DCalvert%26aufirst%3DA.%2BH.%26aulast%3DCanan-Koch%26aufirst%3DS.%26aulast%3DDurkacz%26aufirst%3DB.%2BW.%26aulast%3DHostomsky%26aufirst%3DZ.%26aulast%3DKumpf%26aufirst%3DR.%2BA.%26aulast%3DKyle%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DMaegley%26aufirst%3DK.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DNotarianni%26aufirst%3DE.%26aulast%3DStratford%26aufirst%3DI.%2BJ.%26aulast%3DSkalitzky%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DH.%2BD.%26aulast%3DWang%26aufirst%3DL.%2BZ.%26aulast%3DWebber%26aufirst%3DS.%2BE.%26aulast%3DWilliams%26aufirst%3DK.%2BJ.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26atitle%3DAnticancer%2520chemosensitization%2520and%2520radiosensitization%2520by%2520the%2520novel%2520poly%2528ADP-ribose%2529%2520polymerase-1%2520inhibitor%2520AG14361%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2004%26volume%3D96%26spage%3D56%26epage%3D67" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group">Tikhe, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webber, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hostomsky, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maegley, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ekkers, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, X. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almassy, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumpf, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boritzki, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calabrese, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kyle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calvert, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golding, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newell, D. R.</span><span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of 3,4-dihydro-2<i>H</i>-[1,4]diazepino[6,7,1-<i>hi</i>]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">5467</span><span class="NLM_x">â</span> <span class="NLM_lpage">5481</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm030513r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=5467-5481&author=J.+G.+Tikheauthor=S.+E.+Webberauthor=Z.+Hostomskyauthor=K.+A.+Maegleyauthor=A.+Ekkersauthor=J.+Liauthor=X.+H.+Yuauthor=R.+J.+Almassyauthor=R.+A.+Kumpfauthor=T.+J.+Boritzkiauthor=C.+Zhangauthor=C.+R.+Calabreseauthor=N.+J.+Curtinauthor=S.+Kyleauthor=H.+D.+Thomasauthor=L.+Z.+Wangauthor=A.+H.+Calvertauthor=B.+T.+Goldingauthor=R.+J.+Griffinauthor=D.+R.+Newell&title=Design%2C+synthesis%2C+and+evaluation+of+3%2C4-dihydro-2H-%5B1%2C4%5Ddiazepino%5B6%2C7%2C1-hi%5Dindol-1-ones+as+inhibitors+of+poly%28ADP-ribose%29+polymerase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1021%2Fjm030513r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030513r%26sid%3Dliteratum%253Aachs%26aulast%3DTikhe%26aufirst%3DJ.%2BG.%26aulast%3DWebber%26aufirst%3DS.%2BE.%26aulast%3DHostomsky%26aufirst%3DZ.%26aulast%3DMaegley%26aufirst%3DK.%2BA.%26aulast%3DEkkers%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DX.%2BH.%26aulast%3DAlmassy%26aufirst%3DR.%2BJ.%26aulast%3DKumpf%26aufirst%3DR.%2BA.%26aulast%3DBoritzki%26aufirst%3DT.%2BJ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DCalabrese%26aufirst%3DC.%2BR.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DKyle%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DH.%2BD.%26aulast%3DWang%26aufirst%3DL.%2BZ.%26aulast%3DCalvert%26aufirst%3DA.%2BH.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%25203%252C4-dihydro-2H-%255B1%252C4%255Ddiazepino%255B6%252C7%252C1-hi%255Dindol-1-ones%2520as%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D5467%26epage%3D5481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group">Thomas, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calabrese, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batey, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hostomsky, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kyle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maegley, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newell, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skalitzky, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webber, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span> </span><span class="NLM_article-title">Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">945</span><span class="NLM_x">â</span> <span class="NLM_lpage">956</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1158%2F1535-7163.MCT-06-0552" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=17363489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivV2nurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=945-956&author=H.+D.+Thomasauthor=C.+R.+Calabreseauthor=M.+A.+Bateyauthor=S.+Cananauthor=Z.+Hostomskyauthor=S.+Kyleauthor=K.+A.+Maegleyauthor=D.+R.+Newellauthor=D.+Skalitzkyauthor=L.+Z.+Wangauthor=S.+E.+Webberauthor=N.+J.+Curtin&title=Preclinical+selection+of+a+novel+poly%28ADP-ribose%29+polymerase+inhibitor+for+clinical+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial</span></div><div class="casAuthors">Thomas, Huw D.; Calabrese, Christopher R.; Batey, Michael A.; Canan, Stacie; Hostomsky, Zdenek; Kyle, Suzanne; Maegley, Karen A.; Newell, David R.; Skalitzky, Donald; Wang, Lan-Zhen; Webber, Stephen E.; Curtin, Nicola J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">945-956</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase (PARP)-1 (EC 2.4.2.30) is a nuclear enzyme that promotes the base excision repair of DNA breaks.  Inhibition of PARP-1 enhances the efficacy of DNA alkylating agents, topoisomerase I poisons, and ionizing radiation.  Our aim was to identify a PARP inhibitor for clin. trial from a panel of 42 potent PARP inhibitors (Ki, 1.4-15.1 nmol/L) based on the quinazolinone, benzimidazole, tricyclic benzimidazole, tricyclic indole, and tricyclic indole-1-one core structures.  We evaluated chemosensitization of temozolomide and topotecan using LoVo and SW620 human colorectal cells; in vitro radiosensitization was measured using LoVo cells, and the enhancement of antitumor activity of temozolomide was evaluated in mice bearing SW620 xenografts.  Excellent chemopotentiation and radiopotentiation were obsd. in vitro, with 17 of the compds. causing a greater temozolomide and topotecan sensitization than the benchmark inhibitor AG14361 and 10 compds. were more potent radiosensitizers than AG14361.  In tumor-bearing mice, none of the compds. were toxic when given alone, and the antitumor activity of the PARP inhibitor-temozolomide combinations was unrelated to toxicity.  Compds. that were more potent chemosensitizers in vivo than AG14361 were also more potent in vitro, validating in vitro assays as a prescreen.  These studies have identified a compd., AG14447, as a PARP inhibitor with outstanding in vivo chemosensitization potency at tolerable doses, which is at least 10 times more potent than the initial lead, AG14361.  The phosphate salt of AG14447 (AG014699), which has improved aq. soly., has been selected for clin. trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk-3D2oL2giLVg90H21EOLACvtfcHk0ljtIU94AE-80Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivV2nurw%253D&md5=b451bf2c1fc836cc5a800c2799e5d211</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0552&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0552%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DH.%2BD.%26aulast%3DCalabrese%26aufirst%3DC.%2BR.%26aulast%3DBatey%26aufirst%3DM.%2BA.%26aulast%3DCanan%26aufirst%3DS.%26aulast%3DHostomsky%26aufirst%3DZ.%26aulast%3DKyle%26aufirst%3DS.%26aulast%3DMaegley%26aufirst%3DK.%2BA.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DSkalitzky%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DL.%2BZ.%26aulast%3DWebber%26aufirst%3DS.%2BE.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26atitle%3DPreclinical%2520selection%2520of%2520a%2520novel%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitor%2520for%2520clinical%2520trial%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D945%26epage%3D956" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group">Plummer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boddy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHugh, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinfeldt, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dewji, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calvert, H.</span><span> </span><span class="NLM_article-title">Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">7917</span><span class="NLM_x">â</span> <span class="NLM_lpage">7923</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1158%2F1078-0432.CCR-08-1223" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=19047122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVegt7%252FM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=7917-7923&author=R.+Plummerauthor=C.+Jonesauthor=M.+Middletonauthor=R.+Wilsonauthor=J.+Evansauthor=A.+Olsenauthor=N.+Curtinauthor=A.+Boddyauthor=P.+McHughauthor=D.+Newellauthor=A.+Harrisauthor=P.+Johnsonauthor=H.+Steinfeldtauthor=R.+Dewjiauthor=D.+Wangauthor=L.+Robsonauthor=H.+Calvert&title=Phase+I+study+of+the+poly%28ADP-ribose%29+polymerase+inhibitor%2C+AG014699%2C+in+combination+with+temozolomide+in+patients+with+advanced+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Plummer, Ruth; Jones, Christopher; Middleton, Mark; Wilson, Richard; Evans, Jeffrey; Olsen, Anna; Curtin, Nicola; Boddy, Alan; McHugh, Peter; Newell, David; Harris, Adrian; Johnson, Patrick; Steinfeldt, Heidi; Dewji, Raz; Wang, Diane; Robson, Lesley; Calvert, Hilary</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7917-7923</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: One mechanism of tumor resistance to cytotoxic therapy is repair of damaged DNA.  Poly(ADP-ribose) polymerase (PARP)-1 is a nuclear enzyme involved in base excision repair, one of the five major repair pathways.  PARP inhibitors are emerging as a new class of agents that can potentiate chemotherapy and radiotherapy.  The article reports safety, efficacy, pharmacokinetic, and pharmacodynamic results of the first-in-class trial of a PARP inhibitor, AG014699, combined with temozolomide in adults with advanced malignancy.  Exptl. Design: Initially, patients with solid tumors received escalating doses of AG014699 with 100 mg/m2/d temozolomide x 5 every 28 days to establish the PARP ID (PID).  Subsequently, AG014699 dose was fixed at PID and temozolomide escalated to max. tolerated dose or 200 mg/m2 in metastatic melanoma patients whose tumors were biopsied.  AG014699 and temozolomide pharmacokinetics, PARP activity, DNA strand single-strand breaks, response, and toxicity were evaluated.  RESULTS: Thirty-three patients were enrolled.  PARP inhibition was seen at all doses; PID was 12 mg/m2 based on 74% to 97% inhibition of peripheral blood lymphocyte PARP activity.  Recommended doses were 12 mg/m2 AG014699 and 200 mg/m2 temozolomide.  Mean tumor PARP inhibition at 5 h was 92% (range, 46-97%).  No toxicity attributable to AG014699 alone was obsd.  AG014699 showed linear pharmacokinetics with no interaction with temozolomide.  All patients treated at PID showed increases in DNA single-strand breaks and encouraging evidence of activity was seen.  CONCLUSIONS: The combination of AG014699 and temozolomide is well tolerated, pharmacodynamic assessments showing proof of principle of the mode of action of this new class of agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoh3DGcSbf45bVg90H21EOLACvtfcHk0liS3EzRp8vmgA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVegt7%252FM&md5=76b77d0a31dcb652c31e049a7f6163c2</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-1223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-1223%26sid%3Dliteratum%253Aachs%26aulast%3DPlummer%26aufirst%3DR.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DMiddleton%26aufirst%3DM.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DEvans%26aufirst%3DJ.%26aulast%3DOlsen%26aufirst%3DA.%26aulast%3DCurtin%26aufirst%3DN.%26aulast%3DBoddy%26aufirst%3DA.%26aulast%3DMcHugh%26aufirst%3DP.%26aulast%3DNewell%26aufirst%3DD.%26aulast%3DHarris%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DP.%26aulast%3DSteinfeldt%26aufirst%3DH.%26aulast%3DDewji%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DRobson%26aufirst%3DL.%26aulast%3DCalvert%26aufirst%3DH.%26atitle%3DPhase%2520I%2520study%2520of%2520the%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitor%252C%2520AG014699%252C%2520in%2520combination%2520with%2520temozolomide%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D7917%26epage%3D7923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group">Plummer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorigan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steven, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snow, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dewji, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calvert, H.</span><span> </span><span class="NLM_article-title">First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM)</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">8013</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=8013&author=R.+Plummerauthor=P.+Loriganauthor=J.+Evansauthor=N.+Stevenauthor=M.+Middletonauthor=R.+Wilsonauthor=K.+Snowauthor=R.+Dewjiauthor=H.+Calvert&title=First+and+final+report+of+a+phase+II+study+of+the+poly%28ADP-ribose%29+polymerase+%28PARP%29+inhibitor%2C+AG014699%2C+in+combination+with+temozolomide+%28TMZ%29+in+patients+with+metastatic+malignant+melanoma+%28MM%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPlummer%26aufirst%3DR.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DEvans%26aufirst%3DJ.%26aulast%3DSteven%26aufirst%3DN.%26aulast%3DMiddleton%26aufirst%3DM.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DSnow%26aufirst%3DK.%26aulast%3DDewji%26aufirst%3DR.%26aulast%3DCalvert%26aufirst%3DH.%26atitle%3DFirst%2520and%2520final%2520report%2520of%2520a%2520phase%2520II%2520study%2520of%2520the%2520poly%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520inhibitor%252C%2520AG014699%252C%2520in%2520combination%2520with%2520temozolomide%2520%2528TMZ%2529%2520in%2520patients%2520with%2520metastatic%2520malignant%2520melanoma%2520%2528MM%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D8013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group">Buki, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, P. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendeleyev, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hakam, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kun, E.</span><span> </span><span class="NLM_article-title">Destabilization of Zn<sup>2+</sup> coordination in ADP-ribose transferase (polymerizing) by 6-nitroso-1,2-benzopyrone coincidental with inactivation of the polymerase but not the DNA binding function</span> <span class="citation_source-journal">FEBS Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">290</span><span class="NLM_x">, </span> <span class="NLM_fpage">181</span><span class="NLM_x">â</span> <span class="NLM_lpage">185</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=1991&pages=181-185&author=K.+G.+Bukiauthor=P.+I.+Bauerauthor=J.+Mendeleyevauthor=A.+Hakamauthor=E.+Kun&title=Destabilization+of+Zn2%2B+coordination+in+ADP-ribose+transferase+%28polymerizing%29+by+6-nitroso-1%2C2-benzopyrone+coincidental+with+inactivation+of+the+polymerase+but+not+the+DNA+binding+function"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBuki%26aufirst%3DK.%2BG.%26aulast%3DBauer%26aufirst%3DP.%2BI.%26aulast%3DMendeleyev%26aufirst%3DJ.%26aulast%3DHakam%26aufirst%3DA.%26aulast%3DKun%26aufirst%3DE.%26atitle%3DDestabilization%2520of%2520Zn2%252B%2520coordination%2520in%2520ADP-ribose%2520transferase%2520%2528polymerizing%2529%2520by%25206-nitroso-1%252C2-benzopyrone%2520coincidental%2520with%2520inactivation%2520of%2520the%2520polymerase%2520but%2520not%2520the%2520DNA%2520binding%2520function%26jtitle%3DFEBS%2520Lett.%26date%3D1991%26volume%3D290%26spage%3D181%26epage%3D185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group">Tseng, A.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakobovits, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirsten, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hakam, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kun, E.</span><span> </span><span class="NLM_article-title">Prevention of tumorigenesis of oncogene-transformed rat fibroblasts with DNA site inhibitors of poly(ADP ribose) polymerase</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">1107</span><span class="NLM_x">â</span> <span class="NLM_lpage">1111</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=1987&pages=1107-1111&author=A.+Tsengauthor=W.+M.+Leeauthor=E.+B.+Jakobovitsauthor=E.+Kirstenauthor=A.+Hakamauthor=J.+McLickauthor=K.+Bukiauthor=E.+Kun&title=Prevention+of+tumorigenesis+of+oncogene-transformed+rat+fibroblasts+with+DNA+site+inhibitors+of+poly%28ADP+ribose%29+polymerase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTseng%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DW.%2BM.%26aulast%3DJakobovits%26aufirst%3DE.%2BB.%26aulast%3DKirsten%26aufirst%3DE.%26aulast%3DHakam%26aufirst%3DA.%26aulast%3DMcLick%26aufirst%3DJ.%26aulast%3DBuki%26aufirst%3DK.%26aulast%3DKun%26aufirst%3DE.%26atitle%3DPrevention%2520of%2520tumorigenesis%2520of%2520oncogene-transformed%2520rat%2520fibroblasts%2520with%2520DNA%2520site%2520inhibitors%2520of%2520poly%2528ADP%2520ribose%2529%2520polymerase%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1987%26volume%3D84%26spage%3D1107%26epage%3D1111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group">Ossovskaya, V.; Sherman, B. M.</span><span> </span><span class="NLM_article-title">Methods and Compositions for the Treatment of Cancer Using Benzopyrone-Type PARP Inhibitors</span>. U.S. Patent Appl. 20090149417,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=V.+Ossovskaya&author=B.+M.+Sherman&title=Methods+and+Compositions+for+the+Treatment+of+Cancer+Using+Benzopyrone-Type+PARP+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DOssovskaya%26aufirst%3DV.%26atitle%3DMethods%2520and%2520Compositions%2520for%2520the%2520Treatment%2520of%2520Cancer%2520Using%2520Benzopyrone-Type%2520PARP%2520Inhibitors%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group">Mendeleyev, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirsten, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hakam, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buki, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kun, E.</span><span> </span><span class="NLM_article-title">Potential chemotherapeutic activity of 4-iodo-3-nitrobenzamide. Metabolic reduction to the 3-nitroso derivative and induction of cell death in tumor cells in culture</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">705</span><span class="NLM_x">â</span> <span class="NLM_lpage">714</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1995&pages=705-714&author=J.+Mendeleyevauthor=E.+Kirstenauthor=A.+Hakamauthor=K.+G.+Bukiauthor=E.+Kun&title=Potential+chemotherapeutic+activity+of+4-iodo-3-nitrobenzamide.+Metabolic+reduction+to+the+3-nitroso+derivative+and+induction+of+cell+death+in+tumor+cells+in+culture"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMendeleyev%26aufirst%3DJ.%26aulast%3DKirsten%26aufirst%3DE.%26aulast%3DHakam%26aufirst%3DA.%26aulast%3DBuki%26aufirst%3DK.%2BG.%26aulast%3DKun%26aufirst%3DE.%26atitle%3DPotential%2520chemotherapeutic%2520activity%2520of%25204-iodo-3-nitrobenzamide.%2520Metabolic%2520reduction%2520to%2520the%25203-nitroso%2520derivative%2520and%2520induction%2520of%2520cell%2520death%2520in%2520tumor%2520cells%2520in%2520culture%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1995%26volume%3D50%26spage%3D705%26epage%3D714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group">Kun, E.; Mendeleyev, J.; Basbaurn, C.; Lemjabbar-alaoui, H.; Ossovskaya, V.</span><span> </span><span class="NLM_article-title">Treatment of Cancer</span>. U.S. Patent 7405227,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=E.+Kun&author=J.+Mendeleyev&author=C.+Basbaurn&author=H.+Lemjabbar-alaoui&author=V.+Ossovskaya&title=Treatment+of+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKun%26aufirst%3DE.%26atitle%3DTreatment%2520of%2520Cancer%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group">Kopetz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mita, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sankhala, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moseley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolcher, A. W.</span><span> </span><span class="NLM_article-title">First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3577</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1200%2FJCO.2007.13.2407" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=3577&author=S.+Kopetzauthor=M.+M.+Mitaauthor=I.+Mokauthor=K.+K.+Sankhalaauthor=J.+Moseleyauthor=B.+M.+Shermanauthor=C.+R.+Bradleyauthor=A.+W.+Tolcher&title=First+in+human+phase+I+study+of+BSI-201%2C+a+small+molecule+inhibitor+of+poly+ADP-ribose+polymerase+%28PARP%29+in+subjects+with+advanced+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1200%2FJCO.2007.13.2407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2007.13.2407%26sid%3Dliteratum%253Aachs%26aulast%3DKopetz%26aufirst%3DS.%26aulast%3DMita%26aufirst%3DM.%2BM.%26aulast%3DMok%26aufirst%3DI.%26aulast%3DSankhala%26aufirst%3DK.%2BK.%26aulast%3DMoseley%26aufirst%3DJ.%26aulast%3DSherman%26aufirst%3DB.%2BM.%26aulast%3DBradley%26aufirst%3DC.%2BR.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26atitle%3DFirst%2520in%2520human%2520phase%2520I%2520study%2520of%2520BSI-201%252C%2520a%2520small%2520molecule%2520inhibitor%2520of%2520poly%2520ADP-ribose%2520polymerase%2520%2528PARP%2529%2520in%2520subjects%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D3577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group">Mahany, J. J.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heath, E. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoRusso, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mita, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolcher, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papadopoulos, K. P.</span><span> </span><span class="NLM_article-title">A phase IB study evaluating BSI-201 in combination with chemotherapy in subjects with advanced solid tumors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3579</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=3579&author=J.+J.+Mahanyauthor=N.+Lewisauthor=E.+I.+Heathauthor=P.+M.+LoRussoauthor=M.+M.+Mitaauthor=J.+Rodonauthor=A.+W.+Tolcherauthor=B.+M.+Shermanauthor=C.+R.+Bradleyauthor=K.+P.+Papadopoulos&title=A+phase+IB+study+evaluating+BSI-201+in+combination+with+chemotherapy+in+subjects+with+advanced+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMahany%26aufirst%3DJ.%2BJ.%26aulast%3DLewis%26aufirst%3DN.%26aulast%3DHeath%26aufirst%3DE.%2BI.%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26aulast%3DMita%26aufirst%3DM.%2BM.%26aulast%3DRodon%26aufirst%3DJ.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26aulast%3DSherman%26aufirst%3DB.%2BM.%26aulast%3DBradley%26aufirst%3DC.%2BR.%26aulast%3DPapadopoulos%26aufirst%3DK.%2BP.%26atitle%3DA%2520phase%2520IB%2520study%2520evaluating%2520BSI-201%2520in%2520combination%2520with%2520chemotherapy%2520in%2520subjects%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D3579" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group">Jagtap, P.; Southan, G.; Salzman, A.; Szabo, C.</span><span> </span><span class="NLM_article-title">Substituted Phenanthridinones and Methods of Use Thereof</span>. U.S. Patent 6277990,<span class="NLM_x"> </span><span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=P.+Jagtap&author=G.+Southan&author=A.+Salzman&author=C.+Szabo&title=Substituted+Phenanthridinones+and+Methods+of+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJagtap%26aufirst%3DP.%26atitle%3DSubstituted%2520Phenanthridinones%2520and%2520Methods%2520of%2520Use%2520Thereof%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group">Jagtap, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soriano, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Virag, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liaudet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mabley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasko, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marton, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorigados, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallyas, F.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sumegi, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoyt, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baloglu, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">VanDuzer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salzman, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Southan, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabo, C.</span><span> </span><span class="NLM_article-title">Novel phenanthridinone inhibitors of poly (adenosine 5â²-diphosphate-ribose) synthetase: potent cytoprotective and antishock agents</span> <span class="citation_source-journal">Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">1071</span><span class="NLM_x">â</span> <span class="NLM_lpage">1082</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1097%2F00003246-200205000-00019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=12006805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD38XktlWgur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2002&pages=1071-1082&author=P.+Jagtapauthor=F.+G.+Sorianoauthor=L.+Viragauthor=L.+Liaudetauthor=J.+Mableyauthor=E.+Szaboauthor=G.+Haskoauthor=A.+Martonauthor=C.+B.+Lorigadosauthor=F.+Gallyasauthor=B.+Sumegiauthor=D.+G.+Hoytauthor=E.+Balogluauthor=J.+VanDuzerauthor=A.+L.+Salzmanauthor=G.+J.+Southanauthor=C.+Szabo&title=Novel+phenanthridinone+inhibitors+of+poly+%28adenosine+5%E2%80%B2-diphosphate-ribose%29+synthetase%3A+potent+cytoprotective+and+antishock+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Novel phenanthridinone inhibitors of poly(adenosine 5'-diphosphateribose) synthetase: Potent cytoprotective and antishock agents</span></div><div class="casAuthors">Jagtap, Prakash; Garcia Soriano, Francisco; Virag, Laszlo; Liaudet, Lucas; Mabley, Jon; Szabo, Eva; Hasko, Gyorgy; Marton, Anita; Batista Lorigados, Clara; Gallyas, Fereno, Jr.; Sumegi, Balazs; Hoyt, Dale G.; Baloglu, Erkan; VanDuzer, John; Salzman, Andrew L.; Southan, Garry J.; Szabo, Csaba</div><div class="citationInfo"><span class="NLM_cas:title">Critical Care Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1071-1082</span>CODEN:
                <span class="NLM_cas:coden">CCMDC7</span>;
        ISSN:<span class="NLM_cas:issn">0090-3493</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Objective: To synthesize novel inhibitors of the nuclear enzyme poly(ADP [ADP]-ribose) synthetase (PARS), also known as poly(ADP-ribose) polymerase (PARP), and to test them in in vitro models of oxidant-induced cytotoxicity and in endotoxin and splanchnic occlusion-reperfusion-induced shock.  Design: Randomized, prospective lab. study.  Setting: Research lab.  Subjects: Murine macrophages, thymocytes, and endothelial cells; Balb/c mice and Wistar rats.  Interventions: Macrophages and endothelial cells were treated with peroxynitrite and bleomycin to induce PARS activation, and thymocytes were treated with peroxynitrite to induce cell necrosis.  Novel PARS inhibitors were synthesized and used to reduce PARS activation and to reverse cytotoxicity.  Balb/c mice were subjected to splanchnic occlusion and reperfusion and were pretreated with various doses (1-10 mg/kg i.p.) of PJ34, a selected, potent, water-sol. PARS inhibitor.  The passage of fluorescein isothiocyanate-conjugated dextran (4 kDa) was analyzed in everted gut ileal sacs incubated ex vivo as an index of gut permeability.  Wistar rats were subjected to Escherichia coli bacterial lipopolysaccharide (40 mg/kg i.p.).  PJ34 was also used at 10 mg/kg i.p., 1 h before lipopolysaccharide or at 25 mg/kg i.p. 1 h after lipopolysaccharide treatment.  Serum concns. of indicators or multiple organ injury, concns. of various proinflammatory mediators, and tissue concns. of myeloperoxidase and malondialdehyde were measured.  In addn., survival rates and vascular contractile and relaxant responses were recorded.  Measurements and Main Results: Appropriate modifications of the phenanthridinone core structure yielded significant increases in the potency of the compds., both as PARS inhibitors and as cytoprotective agents.  The compd. N-(6-oxo-5,6-dihydro-phenanthridin-2-yl) -N,N-dimethylacetamide (designated as PJ34) was one of the potent PARS inhibitors of the series, and it dose-dependently protected against thymocyte necrosis, with a half-maximal restoration of cell viability of 35 nM and complete protection at 200 nM.  PARS activation also was visualized by immunohistochem. and was dose-dependently suppressed by PJ34.  The effect of PJ34 was dose-dependently reversed by excess NAD (oxidized).  The PARS inhibitors dose-dependently suppressed proinflammatory cytokine and chemokine prodn. and restored viability in immunostimulated macrophages.  PJ34 was selected for the subsequent in vivo studies.  PJ34 significantly protected against splanchnic reperfusion-induced intestinal hyperpermeability in the mouse.  PJ34 reduced peak plasma concns. of tumor necrosis factor-Î±, interleukin-1Î², and nitrite/nitrate in the plasma of lipopolysaccharide-treated rats.  PJ34 ameliorated the lipopolysaccharide-induced increases in indexes of liver and kidney failure and concns. of myeloperoxidase and malondialdehyde in the lung and gut.  Lipopolysaccharide elicited vascular dysfunction, which was normalized by PJ34.  Lipopolysaccharide-induced mortality was reduced by PJ34 (both pre- and posttreatment).  Conclusions: The novel series of phenanthridinone PARS inhibitors have potent cytoprotective effects in vitro and significant protective effects in shock and reperfusion injury in rodent models in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoADiNMzYx8-bVg90H21EOLACvtfcHk0liThYuYpiUemA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktlWgur4%253D&md5=90e3e6be7d7148c3f14486ffc35b216a</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1097%2F00003246-200205000-00019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00003246-200205000-00019%26sid%3Dliteratum%253Aachs%26aulast%3DJagtap%26aufirst%3DP.%26aulast%3DSoriano%26aufirst%3DF.%2BG.%26aulast%3DVirag%26aufirst%3DL.%26aulast%3DLiaudet%26aufirst%3DL.%26aulast%3DMabley%26aufirst%3DJ.%26aulast%3DSzabo%26aufirst%3DE.%26aulast%3DHasko%26aufirst%3DG.%26aulast%3DMarton%26aufirst%3DA.%26aulast%3DLorigados%26aufirst%3DC.%2BB.%26aulast%3DGallyas%26aufirst%3DF.%26aulast%3DSumegi%26aufirst%3DB.%26aulast%3DHoyt%26aufirst%3DD.%2BG.%26aulast%3DBaloglu%26aufirst%3DE.%26aulast%3DVanDuzer%26aufirst%3DJ.%26aulast%3DSalzman%26aufirst%3DA.%2BL.%26aulast%3DSouthan%26aufirst%3DG.%2BJ.%26aulast%3DSzabo%26aufirst%3DC.%26atitle%3DNovel%2520phenanthridinone%2520inhibitors%2520of%2520poly%2520%2528adenosine%25205%25E2%2580%25B2-diphosphate-ribose%2529%2520synthetase%253A%2520potent%2520cytoprotective%2520and%2520antishock%2520agents%26jtitle%3DCrit.%2520Care%2520Med.%26date%3D2002%26volume%3D30%26spage%3D1071%26epage%3D1082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group">Abdelkarim, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gertz, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harms, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katchanov, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dirnagl, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endres, M.</span><span> </span><span class="NLM_article-title">Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke</span> <span class="citation_source-journal">Int. J. Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">255</span><span class="NLM_x">â</span> <span class="NLM_lpage">260</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=11179503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhsFCrtrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=255-260&author=G.+E.+Abdelkarimauthor=K.+Gertzauthor=C.+Harmsauthor=J.+Katchanovauthor=U.+Dirnaglauthor=C.+Szaboauthor=M.+Endres&title=Protective+effects+of+PJ34%2C+a+novel%2C+potent+inhibitor+of+poly%28ADP-ribose%29+polymerase+%28PARP%29+in+in+vitro+and+in+vivo+models+of+stroke"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke</span></div><div class="casAuthors">Abdelkarim, Galaleldin E.; Gertz, Karen; Harms, Christoph; Katchanov, Juri; Dirnagl, Ulrich; Szabo, Csaba; Endres, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">255-260</span>CODEN:
                <span class="NLM_cas:coden">IJMMFG</span>;
        ISSN:<span class="NLM_cas:issn">1107-3756</span>.
    
            (<span class="NLM_cas:orgname">International Journal of Molecular Medicine</span>)
        </div><div class="casAbstract">Focal cerebral ischemia activates the nuclear protein poly(ADP-ribose) polymerase (PARP) by single DNA strand breaks which leads to energy depletion and cell necrosis.  Deletion or inhibition of PARP protects against ischemic brain injury.  Here the authors examd. the neuroprotective effect of PJ34, a novel potent inhibitor of PARP in vitro and in vivo.  Serumfree primary neuronal cultures derived from rat cortex (E15-17) and kept in culture for 10 days were exposed to oxygen glucose deprivation (OGD) in vitro.  Neuronal injury was quantified by LDH release after 24 h.  Pretreatment with 30-1000 nM PJ34 protected from OGD-induced cell injury in a dose-dependent manner.  For in vivo expts. SV/129 mice were treated with PJ34 (50 Î¼g) by i.p. injection 2 h before 1 h middle cerebral artery occlusion (MCAo) and again 6 h later.  23 H after reperfusion ischemic injury was decreased compared to vehicle-treated controls (infarct vol. redn. of 40%).  Similarly, in a rat model of MCAo (2 h occlusion followed by â¤ 22 h reperfusion), PJ34 administration (10 mg/kg i.v.) reduced infarct size, and the effect of the drug was maintained even if it was given as late as 10 min prior to reperfusion time.  PJ34 protected in a 4 h, but not in a 24 h permanent occlusion model.  In conclusion, PJ34, a novel, potent inhibitor of PARP exerts massive neuroprotective agents, with a therapeutic window of opportunity.  The present work strengthens the concept that pharmacol. PARP inhibition may be a suitable approach for the treatment of acute stroke in man.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfu3rYxVmP17Vg90H21EOLACvtfcHk0li9gntWHJvGjA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhsFCrtrs%253D&md5=d643efb37973db0e8704d9c921633620</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAbdelkarim%26aufirst%3DG.%2BE.%26aulast%3DGertz%26aufirst%3DK.%26aulast%3DHarms%26aufirst%3DC.%26aulast%3DKatchanov%26aufirst%3DJ.%26aulast%3DDirnagl%26aufirst%3DU.%26aulast%3DSzabo%26aufirst%3DC.%26aulast%3DEndres%26aufirst%3DM.%26atitle%3DProtective%2520effects%2520of%2520PJ34%252C%2520a%2520novel%252C%2520potent%2520inhibitor%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520in%2520in%2520vitro%2520and%2520in%2520vivo%2520models%2520of%2520stroke%26jtitle%3DInt.%2520J.%2520Mol.%2520Med.%26date%3D2001%26volume%3D7%26spage%3D255%26epage%3D260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group">Faro, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyoda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCully, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jagtap, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Virag, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bianchi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levitsky, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellke, F. W.</span><span> </span><span class="NLM_article-title">Myocardial protection by PJ34, a novel potent poly (ADP-ribose) synthetase inhibitor</span> <span class="citation_source-journal">Ann. Thorac. Surg.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">575</span><span class="NLM_x">â</span> <span class="NLM_lpage">581</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1016%2FS0003-4975%2801%2903329-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=11845877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A280%3ADC%252BD387htlyquw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2002&pages=575-581&author=R.+Faroauthor=Y.+Toyodaauthor=J.+D.+McCullyauthor=P.+Jagtapauthor=E.+Szaboauthor=L.+Viragauthor=C.+Bianchiauthor=S.+Levitskyauthor=C.+Szaboauthor=F.+W.+Sellke&title=Myocardial+protection+by+PJ34%2C+a+novel+potent+poly+%28ADP-ribose%29+synthetase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Myocardial protection by PJ34, a novel potent poly (ADP-ribose) synthetase inhibitor</span></div><div class="casAuthors">Faro Renato; Toyoda Yoshiya; McCully James D; Jagtap Prakash; Szabo Eva; Virag Laszlo; Bianchi Cesario; Levitsky Sidney; Szabo Csaba; Sellke Frank W</div><div class="citationInfo"><span class="NLM_cas:title">The Annals of thoracic surgery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">575-81</span>
        ISSN:<span class="NLM_cas:issn">0003-4975</span>.
    </div><div class="casAbstract">BACKGROUND:  The activation of poly (ADP-ribose) synthetase plays an important role in the pathogenesis leading to myocardial ischemia-reperfusion injury.  The aim of this study was to determine if a novel potent inhibitor of poly (ADP-ribose) synthetase, PJ34, provides myocardial protection.  METHODS:  Pigs were subjected to 60 minutes of regional ischemia followed by 180 minutes of reperfusion.  Ten mg/kg of PJ34 (PJ34; n = 6) was administrated intravenously (treated group) from 15 to 5 minutes before reperfusion followed by 3 mg/kg/hour of PJ34 from 5 minutes before reperfusion to the end of 180 minutes reperfusion.  Control pigs (n = 7) received vehicle only.  Arterial and left ventricular pressure and coronary flow were monitored.  RESULTS:  The PJ34 showed significant reduction on infarct size (37.5%+/-4.5% and 50.5%+/-4.8% of the area at risk) for PJ34 and control pigs groups, respectively, (p < 0.05).  Significant reduction in postsystolic shortening, as well as improvement on segment shortening, and positive first derivative of pressure over time (+dP/dt) maximum were also observed in PJ34 versus control pigs (p < 0.05).  CONCLUSIONS:  Our results suggest that PJ34 provides cardioprotection by decreasing myocardial infarct size and enhancing postischemic regional and global functional recovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSdW1W6ZTGLPsK3uFsUIZtkfW6udTcc2eZYrfwr2ixTXrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD387htlyquw%253D%253D&md5=7a0aa1cc2874deadb6c4885abcce82ba</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2FS0003-4975%2801%2903329-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0003-4975%252801%252903329-X%26sid%3Dliteratum%253Aachs%26aulast%3DFaro%26aufirst%3DR.%26aulast%3DToyoda%26aufirst%3DY.%26aulast%3DMcCully%26aufirst%3DJ.%2BD.%26aulast%3DJagtap%26aufirst%3DP.%26aulast%3DSzabo%26aufirst%3DE.%26aulast%3DVirag%26aufirst%3DL.%26aulast%3DBianchi%26aufirst%3DC.%26aulast%3DLevitsky%26aufirst%3DS.%26aulast%3DSzabo%26aufirst%3DC.%26aulast%3DSellke%26aufirst%3DF.%2BW.%26atitle%3DMyocardial%2520protection%2520by%2520PJ34%252C%2520a%2520novel%2520potent%2520poly%2520%2528ADP-ribose%2529%2520synthetase%2520inhibitor%26jtitle%3DAnn.%2520Thorac.%2520Surg.%26date%3D2002%26volume%3D73%26spage%3D575%26epage%3D581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group">Goldfarb, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marton, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Virag, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salzman, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glock, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akhter, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarthy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parrillo, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabo, C.</span><span> </span><span class="NLM_article-title">Protective effect of a novel, potent inhibitor of poly(adenosine 5â²-diphosphate-ribose) synthetase in a porcine model of severe bacterial sepsis</span> <span class="citation_source-journal">Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">974</span><span class="NLM_x">â</span> <span class="NLM_lpage">980</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1097%2F00003246-200205000-00004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=12006790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD38XktlWgtbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2002&pages=974-980&author=R.+D.+Goldfarbauthor=A.+Martonauthor=E.+Szaboauthor=L.+Viragauthor=A.+L.+Salzmanauthor=D.+Glockauthor=I.+Akhterauthor=R.+McCarthyauthor=J.+E.+Parrilloauthor=C.+Szabo&title=Protective+effect+of+a+novel%2C+potent+inhibitor+of+poly%28adenosine+5%E2%80%B2-diphosphate-ribose%29+synthetase+in+a+porcine+model+of+severe+bacterial+sepsis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Protective effect of a novel, potent inhibitor of poly(adenosine 5'-diphosphate-ribose) synthetase in a porcine model of severe bacterial sepsis</span></div><div class="casAuthors">Goldfarb, Roy D.; Marton, Anita; Szabo, Eva; Virag, Laszlo; Salzman, Andrew L.; Glock, Dana; Akhter, Imran; McCarthy, Robert; Parrillo, Joseph E.; Szabo, Csaba</div><div class="citationInfo"><span class="NLM_cas:title">Critical Care Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">974-980</span>CODEN:
                <span class="NLM_cas:coden">CCMDC7</span>;
        ISSN:<span class="NLM_cas:issn">0090-3493</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Objective: To det. whether activation of the nuclear enzyme poly(adenosine 5'diphosphate [ADP]-ribose) synthetase (PARS) contributes to mortality rate, myocardial dysfunction, and cardiovascular collapse in a porcine model of sepsis induced by implantation of an infected clot.  Design: Prospective, random animal study.  Setting: Research lab. at Rush Presbyterian St. Luke's Medical Center.  Subjects: Twenty pigs were chronically instrumented with intracardiac transducers to measure left ventricular pressure, sonomicrometer crystals in the left ventricle to measure short axis diam., an ultrasonic flow meter to measure cardiac output, and catheters in the pulmonary artery and aorta to measure blood pressure and collect samples.  Interventions: By using a randomized study design, the authors administered either the novel potent PARS inhibitor PJ34 (10 mg/kg for 1 h, 2 mgÂ·kg-1Â·hr-1 for 96 h) or vehicle to pigs immediately before i.p. implantation of Escherichia coli 0111.B4 (2.3Â±0.1 Ã 1010 colony-forming units/kg)-laden fibrin clots to produce peritonitis and bacteremia.  Measurements and Main Results: In vehicle-treated pigs, 12% survival was recorded at 24 h, whereas 83% and 66% survival was recorded in the PJ34-treated animals at 24 and 96 h, resp. (p <.05).  PJ34 treatment attenuated bacteremia-induced increases in systemic and pulmonary vascular resistances.  In controls, peritonitis induced rapid increase in plasma tumor necrosis factor-Î±.  PJ34 treatment significantly attenuated this cytokine response.  The formation of peroxynitrite and the activation of PARS were confirmed in hearts and lungs of the septic pigs by the immunohistochem. detection of nitrotyrosine and poly(ADP-ribose), resp.  Inhibition of PARS with PJ34 abolished poly(ADP-ribose) formation in septic animals.  Conclusions: Treatment with a potent PARS inhibitor improved survival and cardiovascular status and attenuated an important mediator component of the inflammatory response in a lethal porcine model of sepsis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo558Q_xOcHgbVg90H21EOLACvtfcHk0liVfppW-ZD5KA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktlWgtbo%253D&md5=42c7329c08ed994a75d9c21cb5e7d095</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1097%2F00003246-200205000-00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00003246-200205000-00004%26sid%3Dliteratum%253Aachs%26aulast%3DGoldfarb%26aufirst%3DR.%2BD.%26aulast%3DMarton%26aufirst%3DA.%26aulast%3DSzabo%26aufirst%3DE.%26aulast%3DVirag%26aufirst%3DL.%26aulast%3DSalzman%26aufirst%3DA.%2BL.%26aulast%3DGlock%26aufirst%3DD.%26aulast%3DAkhter%26aufirst%3DI.%26aulast%3DMcCarthy%26aufirst%3DR.%26aulast%3DParrillo%26aufirst%3DJ.%2BE.%26aulast%3DSzabo%26aufirst%3DC.%26atitle%3DProtective%2520effect%2520of%2520a%2520novel%252C%2520potent%2520inhibitor%2520of%2520poly%2528adenosine%25205%25E2%2580%25B2-diphosphate-ribose%2529%2520synthetase%2520in%2520a%2520porcine%2520model%2520of%2520severe%2520bacterial%2520sepsis%26jtitle%3DCrit.%2520Care%2520Med.%26date%3D2002%26volume%3D30%26spage%3D974%26epage%3D980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group">Cushman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaraman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vroman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukunaga, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohlhagen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strumberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pommier, Y.</span><span> </span><span class="NLM_article-title">Synthesis of new indeno[1,2-<i>c</i>]isoquinolines: cytotoxic non-camptothecin topoisomerase I inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">3688</span><span class="NLM_x">â</span> <span class="NLM_lpage">3698</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm000029d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=3688-3698&author=M.+Cushmanauthor=M.+Jayaramanauthor=J.+A.+Vromanauthor=A.+K.+Fukunagaauthor=B.+M.+Foxauthor=G.+Kohlhagenauthor=D.+Strumbergauthor=Y.+Pommier&title=Synthesis+of+new+indeno%5B1%2C2-c%5Disoquinolines%3A+cytotoxic+non-camptothecin+topoisomerase+I+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1021%2Fjm000029d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000029d%26sid%3Dliteratum%253Aachs%26aulast%3DCushman%26aufirst%3DM.%26aulast%3DJayaraman%26aufirst%3DM.%26aulast%3DVroman%26aufirst%3DJ.%2BA.%26aulast%3DFukunaga%26aufirst%3DA.%2BK.%26aulast%3DFox%26aufirst%3DB.%2BM.%26aulast%3DKohlhagen%26aufirst%3DG.%26aulast%3DStrumberg%26aufirst%3DD.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DSynthesis%2520of%2520new%2520indeno%255B1%252C2-c%255Disoquinolines%253A%2520cytotoxic%2520non-camptothecin%2520topoisomerase%2520I%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D3688%26epage%3D3698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group">Jagtap, P.; Southan, G.; Salzman, A.; Szabo, C.; Ram, S.</span><span> </span><span class="NLM_article-title">7-Substituted Isoindolinone Inhibitors of Inflammation and Reperfusion Injury and Methods of Use Thereof</span>. U.S. Patent 6534651,<span class="NLM_x"> </span><span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=P.+Jagtap&author=G.+Southan&author=A.+Salzman&author=C.+Szabo&author=S.+Ram&title=7-Substituted+Isoindolinone+Inhibitors+of+Inflammation+and+Reperfusion+Injury+and+Methods+of+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJagtap%26aufirst%3DP.%26atitle%3D7-Substituted%2520Isoindolinone%2520Inhibitors%2520of%2520Inflammation%2520and%2520Reperfusion%2520Injury%2520and%2520Methods%2520of%2520Use%2520Thereof%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group">Morrow, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brickman, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baran, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krakover, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dauerman, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slomowitz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grip, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCabe, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salzman, A. L.</span><span> </span><span class="NLM_article-title">A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the TIMI 37 trial</span> <span class="citation_source-journal">J. Thromb. Thrombolysis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">359</span><span class="NLM_x">â</span> <span class="NLM_lpage">364</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1007%2Fs11239-008-0230-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=18535785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlslCis7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=359-364&author=D.+A.+Morrowauthor=C.+M.+Brickmanauthor=S.+A.+Murphyauthor=K.+Baranauthor=R.+Krakoverauthor=H.+Dauermanauthor=S.+Kumarauthor=N.+Slomowitzauthor=L.+Gripauthor=C.+H.+McCabeauthor=A.+L.+Salzman&title=A+randomized%2C+placebo-controlled+trial+to+evaluate+the+tolerability%2C+safety%2C+pharmacokinetics%2C+and+pharmacodynamics+of+a+potent+inhibitor+of+poly%28ADP-ribose%29+polymerase+%28INO-1001%29+in+patients+with+ST-elevation+myocardial+infarction+undergoing+primary+percutaneous+coronary+intervention%3A+results+of+the+TIMI+37+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the TIMI 37 trial</span></div><div class="casAuthors">Morrow, David A.; Brickman, Chaim M.; Murphy, Sabina A.; Baran, Kenneth; Krakover, Ricardo; Dauerman, Harold; Kumar, Sujatha; Slomowitz, Natanya; Grip, Laura; McCabe, Carolyn H.; Salzman, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thrombosis and Thrombolysis</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">359-364</span>CODEN:
                <span class="NLM_cas:coden">JTTHFF</span>;
        ISSN:<span class="NLM_cas:issn">0929-5305</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Reperfusion injury is a significant complication of the management of ST-elevation MI (STEMI).  INO-1001 is a potent inhibitor of poly(ADP-ribose) polymerase (PARP), a mediator of oxidant-induced myocyte dysfunction during reperfusion.  We assessed the safety and pharmacokinetics of INO-1001 in a randomized, placebo-controlled, single-blind, dose-escalating trial in 40 patients with STEMI undergoing primary percutaneous coronary intervention within 24 h of onset.  INO-1001 was well-tolerated.  A trend toward more frequent transaminitis was obsd. with 800 mg.  Plasma from INO1001-treated patients reduced in vitro PARP activity >90% at all doses.  Serial C-reactive protein and IL-6 levels showed a trend toward blunting of inflammation with INO-1001.  The apparent median terminal half-life (t1/2) of INO-1001 was 7.5 (25th, 75th: 5.9, 10.2) h.  The results from this first trial of INO-1001 in STEMI support future investigation of INO-1001 as a novel treatment for reperfusion injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKyTofr9_A1bVg90H21EOLACvtfcHk0lgQPBjZ5eCP5w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlslCis7s%253D&md5=6400167cc4e96b6938f7f24e903a2a77</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1007%2Fs11239-008-0230-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11239-008-0230-1%26sid%3Dliteratum%253Aachs%26aulast%3DMorrow%26aufirst%3DD.%2BA.%26aulast%3DBrickman%26aufirst%3DC.%2BM.%26aulast%3DMurphy%26aufirst%3DS.%2BA.%26aulast%3DBaran%26aufirst%3DK.%26aulast%3DKrakover%26aufirst%3DR.%26aulast%3DDauerman%26aufirst%3DH.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DSlomowitz%26aufirst%3DN.%26aulast%3DGrip%26aufirst%3DL.%26aulast%3DMcCabe%26aufirst%3DC.%2BH.%26aulast%3DSalzman%26aufirst%3DA.%2BL.%26atitle%3DA%2520randomized%252C%2520placebo-controlled%2520trial%2520to%2520evaluate%2520the%2520tolerability%252C%2520safety%252C%2520pharmacokinetics%252C%2520and%2520pharmacodynamics%2520of%2520a%2520potent%2520inhibitor%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%2520%2528INO-1001%2529%2520in%2520patients%2520with%2520ST-elevation%2520myocardial%2520infarction%2520undergoing%2520primary%2520percutaneous%2520coronary%2520intervention%253A%2520results%2520of%2520the%2520TIMI%252037%2520trial%26jtitle%3DJ.%2520Thromb.%2520Thrombolysis%26date%3D2009%26volume%3D27%26spage%3D359%26epage%3D364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group">Mason, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valdecanas, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milas, L.</span><span> </span><span class="NLM_article-title">INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicin</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">â</span> <span class="NLM_lpage">5</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=1-5&author=K.+A.+Masonauthor=D.+Valdecanasauthor=N.+R.+Hunterauthor=L.+Milas&title=INO-1001%2C+a+novel+inhibitor+of+poly%28ADP-ribose%29+polymerase%2C+enhances+tumor+response+to+doxorubicin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMason%26aufirst%3DK.%2BA.%26aulast%3DValdecanas%26aufirst%3DD.%26aulast%3DHunter%26aufirst%3DN.%2BR.%26aulast%3DMilas%26aufirst%3DL.%26atitle%3DINO-1001%252C%2520a%2520novel%2520inhibitor%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%252C%2520enhances%2520tumor%2520response%2520to%2520doxorubicin%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2008%26volume%3D26%26spage%3D1%26epage%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group">Cheng, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keir, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali-Osman, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salzman, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dolan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modrich, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bigner, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, H. S.</span><span> </span><span class="NLM_article-title">Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1364</span><span class="NLM_x">â</span> <span class="NLM_lpage">1368</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1158%2F1535-7163.MCT-05-0128" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=16170028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVKnt7nP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=1364-1368&author=C.+L.+Chengauthor=S.+P.+Johnsonauthor=S.+T.+Keirauthor=J.+A.+Quinnauthor=F.+Ali-Osmanauthor=C.+Szaboauthor=H.+Liauthor=A.+L.+Salzmanauthor=M.+E.+Dolanauthor=P.+Modrichauthor=D.+D.+Bignerauthor=H.+S.+Friedman&title=Poly%28ADP-ribose%29+polymerase-1+inhibition+reverses+temozolomide+resistance+in+a+DNA+mismatch+repair-deficient+malignant+glioma+xenograft"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft</span></div><div class="casAuthors">Cheng, C. Lynn; Johnson, Stewart P.; Keir, Stephen T.; Quinn, Jennifer A.; Ali-Osman, Francis; Szabo, Csaba; Li, Hongshan; Salzman, Andrew L.; Dolan, M. Eileen; Modrich, Paul; Bigner, Darell D.; Friedman, Henry S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1364-1368</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Temozolomide is a DNA-methylating agent used in the treatment of malignant gliomas.  In this study, we have examd. if inhibition of poly(ADP-ribose) polymerase (PARP) could increase the cytotoxicity of temozolomide, particularly in cells deficient in DNA mismatch repair.  Athymic mice, transplanted with mismatch repair - proficient [D-245 MG] or deficient [D-245 MG (PR)] xenografts, were treated with a combination of temozolomide and the PARP inhibitor, INO-1001.  For the tumors deficient in mismatch repair, the most ED of INO-1001 was found to be 150 mg/kg, given i.p. thrice at 4-h intervals with the first injection in combination with 262.5 mg/kg temozolomide (0.75 LD10).  This dose of temozolomide by itself induced no partial regressions and a 4-day growth delay.  In two sep. expts., the combination therapy increased the growth delay by 21.6 and 9.7 days with partial regressions obsd. in four of eight and three of nine mice, resp.  The addn. of INO-1001 had a more modest, yet statistically significant, increase in tumor growth delay in the mismatch repair - proficient xenografts.  In these expts., mice were treated with a lower amt. of temozolomide (88 mg/kg), which resulted in growth delays of 43.1 and 39.2 days.  When the temozolomide treatment was in combination with 200 mg/kg INO-1001, there was an increase in growth delay to 48.9 and 45.7 days, resp.  These results suggest that inhibition of PARP may increase the efficacy of temozolomide in the treatment of malignant gliomas, particularly in tumors deficient in DNA mismatch repair.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoteU4bA489MrVg90H21EOLACvtfcHk0lgQPBjZ5eCP5w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVKnt7nP&md5=ac1ce9ffbdb33d848bc961f35172b7f1</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-05-0128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-05-0128%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DC.%2BL.%26aulast%3DJohnson%26aufirst%3DS.%2BP.%26aulast%3DKeir%26aufirst%3DS.%2BT.%26aulast%3DQuinn%26aufirst%3DJ.%2BA.%26aulast%3DAli-Osman%26aufirst%3DF.%26aulast%3DSzabo%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DSalzman%26aufirst%3DA.%2BL.%26aulast%3DDolan%26aufirst%3DM.%2BE.%26aulast%3DModrich%26aufirst%3DP.%26aulast%3DBigner%26aufirst%3DD.%2BD.%26aulast%3DFriedman%26aufirst%3DH.%2BS.%26atitle%3DPoly%2528ADP-ribose%2529%2520polymerase-1%2520inhibition%2520reverses%2520temozolomide%2520resistance%2520in%2520a%2520DNA%2520mismatch%2520repair-deficient%2520malignant%2520glioma%2520xenograft%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2005%26volume%3D4%26spage%3D1364%26epage%3D1368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group">Wang, C.; Bedikian, A. Y.; Kim, K.; Papadopoulos, N. E.; Hwu, W.; Hwu, P.</span><span> </span><span class="NLM_article-title">Evaluation of Tolerability, Safety, and Pharmacokinetics of INO-1001 plus Temozolomide (TMZ) in Patients with Unresectable Stage III/IV Melanoma</span>.  <span class="citation_source-book">ASCO Meeting Abstracts</span>, 2006 ASCO Annual Meeting; <span class="NLM_publisher-name">American Society of Clinical Oncology</span>: <span class="NLM_publisher-loc">Alexandria, VA</span>,<span class="NLM_x"> </span><span class="NLM_year">2006</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">24</span>, p  <span class="NLM_fpage">12015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=12015&author=C.+Wang&author=A.+Y.+Bedikian&author=K.+Kim&author=N.+E.+Papadopoulos&author=W.+Hwu&author=P.+Hwu&title=ASCO+Meeting+Abstracts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DC.%26atitle%3DEvaluation%2520of%2520Tolerability%252C%2520Safety%252C%2520and%2520Pharmacokinetics%2520of%2520INO-1001%2520plus%2520Temozolomide%2520%2528TMZ%2529%2520in%2520Patients%2520with%2520Unresectable%2520Stage%2520III%252FIV%2520Melanoma%26btitle%3DASCO%2520Meeting%2520Abstracts%26pub%3DAmerican%2520Society%2520of%2520Clinical%2520Oncology%26date%3D2006%26volume%3D24%26spage%3D12015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group">Bedikian, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papadopoulos, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwu, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Homsi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glass, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cain, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudewicz, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vernillet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwu, P.</span><span> </span><span class="NLM_article-title">A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma</span> <span class="citation_source-journal">Cancer Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">756</span><span class="NLM_x">â</span> <span class="NLM_lpage">763</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=756-763&author=A.+Y.+Bedikianauthor=N.+E.+Papadopoulosauthor=K.+B.+Kimauthor=W.+J.+Hwuauthor=J.+Homsiauthor=M.+R.+Glassauthor=S.+Cainauthor=P.+Rudewiczauthor=L.+Vernilletauthor=P.+Hwu&title=A+phase+IB+trial+of+intravenous+INO-1001+plus+oral+temozolomide+in+subjects+with+unresectable+stage-III+or+IV+melanoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBedikian%26aufirst%3DA.%2BY.%26aulast%3DPapadopoulos%26aufirst%3DN.%2BE.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DHwu%26aufirst%3DW.%2BJ.%26aulast%3DHomsi%26aufirst%3DJ.%26aulast%3DGlass%26aufirst%3DM.%2BR.%26aulast%3DCain%26aufirst%3DS.%26aulast%3DRudewicz%26aufirst%3DP.%26aulast%3DVernillet%26aufirst%3DL.%26aulast%3DHwu%26aufirst%3DP.%26atitle%3DA%2520phase%2520IB%2520trial%2520of%2520intravenous%2520INO-1001%2520plus%2520oral%2520temozolomide%2520in%2520subjects%2520with%2520unresectable%2520stage-III%2520or%2520IV%2520melanoma%26jtitle%3DCancer%2520Invest.%26date%3D2009%26volume%3D27%26spage%3D756%26epage%3D763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group">Hitchcock, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennington, L. D.</span><span> </span><span class="NLM_article-title">Structureâbrain exposure relationships</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">7559</span><span class="NLM_x">â</span> <span class="NLM_lpage">7583</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm060642i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=7559-7583&author=S.+A.+Hitchcockauthor=L.+D.+Pennington&title=Structure%E2%88%92brain+exposure+relationships"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1021%2Fjm060642i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060642i%26sid%3Dliteratum%253Aachs%26aulast%3DHitchcock%26aufirst%3DS.%2BA.%26aulast%3DPennington%26aufirst%3DL.%2BD.%26atitle%3DStructure%25E2%2588%2592brain%2520exposure%2520relationships%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D7559%26epage%3D7583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group">Li, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serdyuk, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferraris, D. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tays, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kletzly, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lautar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalish, V. J.</span><span> </span><span class="NLM_article-title">Synthesis of substituted 5[H]phenanthridin-6-ones as potent poly(ADP-ribose)polymerase-1 (PARP1) inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1687</span><span class="NLM_x">â</span> <span class="NLM_lpage">1690</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=1687-1690&author=J.+H.+Liauthor=L.+Serdyukauthor=D.+V.+Ferrarisauthor=G.+Xiaoauthor=K.+L.+Taysauthor=P.+W.+Kletzlyauthor=W.+Liauthor=S.+Lautarauthor=J.+Zhangauthor=V.+J.+Kalish&title=Synthesis+of+substituted+5%5BH%5Dphenanthridin-6-ones+as+potent+poly%28ADP-ribose%29polymerase-1+%28PARP1%29+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%2BH.%26aulast%3DSerdyuk%26aufirst%3DL.%26aulast%3DFerraris%26aufirst%3DD.%2BV.%26aulast%3DXiao%26aufirst%3DG.%26aulast%3DTays%26aufirst%3DK.%2BL.%26aulast%3DKletzly%26aufirst%3DP.%2BW.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DLautar%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DKalish%26aufirst%3DV.%2BJ.%26atitle%3DSynthesis%2520of%2520substituted%25205%255BH%255Dphenanthridin-6-ones%2520as%2520potent%2520poly%2528ADP-ribose%2529polymerase-1%2520%2528PARP1%2529%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D1687%26epage%3D1690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lautar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramsey, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J. H.</span><span> </span><span class="NLM_article-title">GPI 6150 prevents H(2)O(2) cytotoxicity by inhibiting poly(ADP-ribose) polymerase</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">590</span><span class="NLM_x">â</span> <span class="NLM_lpage">598</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2000&pages=590-598&author=J.+Zhangauthor=S.+Lautarauthor=S.+Huangauthor=C.+Ramseyauthor=A.+Cheungauthor=J.+H.+Li&title=GPI+6150+prevents+H%282%29O%282%29+cytotoxicity+by+inhibiting+poly%28ADP-ribose%29+polymerase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLautar%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DRamsey%26aufirst%3DC.%26aulast%3DCheung%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DJ.%2BH.%26atitle%3DGPI%25206150%2520prevents%2520H%25282%2529O%25282%2529%2520cytotoxicity%2520by%2520inhibiting%2520poly%2528ADP-ribose%2529%2520polymerase%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2000%26volume%3D278%26spage%3D590%26epage%3D598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group">Zhang, J.</span><span> </span><span class="NLM_article-title">PARP inhibition: a novel approach to treat ischemia/reperfusion and inflammation-related injuries</span> <span class="citation_source-journal">Expert Opin. Emerging Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">209</span><span class="NLM_x">â</span> <span class="NLM_lpage">221</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1517%2F14728214.4.1.209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADyaK1MXislaqsL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1999&pages=209-221&author=J.+Zhang&title=PARP+inhibition%3A+a+novel+approach+to+treat+ischemia%2Freperfusion+and+inflammation-related+injuries"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">PARP inhibition: a novel approach to treat ischaemia/reperfusion and inflammation-related injuries</span></div><div class="casAuthors">Zhang, J.</div><div class="citationInfo"><span class="NLM_cas:title">Emerging Drugs</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">209-221</span>CODEN:
                <span class="NLM_cas:coden">EMDRFV</span>;
        ISSN:<span class="NLM_cas:issn">1361-9195</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications</span>)
        </div><div class="casAbstract">A review with 64 refs. and 3 website listings.  Poly(ADP-ribose) polymerase (PARP) is one of the most abundant nuclear enzymes.  When it is activated by DNA strand breaks, PARP synthesizes poly(ADP-ribose) by using NAD (NAD) as substrate.  Early PARP research focused primarily on its role in facilitating structural changes of chromosomal DNA, such as during DNA repair, gene expression, DNA replication, DNA rearrangement, sister chromatid exchange, differentiation and mutagenesis.  The recent discovery of PARP as a substrate for caspases has led to an intensive search for possible PARP involvement in the apoptosis pathway.  Although the exact physiol. functions of PARP still remain to be firmly established, it has long been known that PARP activation can cause a rapid depletion of cellular NAD and ATP.  This is mainly due to the high turnover rate of poly(ADP-ribose), which is degraded by poly(ADP-ribose) glycohydrolase.  Thus, it has been proposed as a "suicidal hypothesis" that PARP activation contributes to the energy failure that leads to cell death elicited by massive DNA damage.  Indeed, there is accumulating evidence to suggest that activation of PARP by free radical damaged DNA plays a pivotal role in mediating ischemia/reperfusion injuries.  PARP emerges as a novel target to treat such injuries.  The strategy of targeting PARP inhibition is validated by the findings that PARP deficient mice are extremely resistant to both cerebral and myocardial ischemia.  PARP inhibitors have demonstrated remarkable efficacy in reducing the infarct vols. of cerebral focal ischemia and regional heart ischemia.  They also exhibit strong anti-inflammatory activities in rodent models of inflammation related injuries, e.g., septic shock, arthritis and Type I diabetes.  Therefore, even at an early stage of drug discovery, PARP inhibitors have shown great potential for treating a broad spectrum of diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2cX7tJIsaebVg90H21EOLACvtfcHk0lg23QXUC2hunw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXislaqsL8%253D&md5=d59cce42244066534b1347b6b4f60d6a</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1517%2F14728214.4.1.209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728214.4.1.209%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DPARP%2520inhibition%253A%2520a%2520novel%2520approach%2520to%2520treat%2520ischemia%252Freperfusion%2520and%2520inflammation-related%2520injuries%26jtitle%3DExpert%2520Opin.%2520Emerging%2520Drugs%26date%3D1999%26volume%3D4%26spage%3D209%26epage%3D221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group">Kalish, V.; Zhang, J.; Xu, W.; Li, J.-h.; Xing, A. D.; Liu, Q.</span><span> </span><span class="NLM_article-title">Compounds, Methods and Pharmaceutical Compositions for Inhibiting PARP</span>. U.S. Patent 7601719,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=V.+Kalish&author=J.+Zhang&author=W.+Xu&author=J.-h.+Li&author=A.+D.+Xing&author=Q.+Liu&title=Compounds%2C+Methods+and+Pharmaceutical+Compositions+for+Inhibiting+PARP"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKalish%26aufirst%3DV.%26atitle%3DCompounds%252C%2520Methods%2520and%2520Pharmaceutical%2520Compositions%2520for%2520Inhibiting%2520PARP%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group">Tentori, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonetti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarsella, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DâAmati, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vergati, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Portarena, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalish, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zupi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graziani, G.</span><span> </span><span class="NLM_article-title">Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">5370</span><span class="NLM_x">â</span> <span class="NLM_lpage">5379</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=14614022" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD3sXovVOnsrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=5370-5379&author=L.+Tentoriauthor=C.+Leonettiauthor=M.+Scarsellaauthor=G.+D%E2%80%99Amatiauthor=M.+Vergatiauthor=I.+Portarenaauthor=W.+Xuauthor=V.+Kalishauthor=G.+Zupiauthor=J.+Zhangauthor=G.+Graziani&title=Systemic+administration+of+GPI+15427%2C+a+novel+poly%28ADP-ribose%29+polymerase-1+inhibitor%2C+increases+the+antitumor+activity+of+temozolomide+against+intracranial+melanoma%2C+glioma%2C+lymphoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Systemic Administration of GPI 15427, a Novel Poly(ADP-Ribose) Polymerase-1 Inhibitor, Increases the Antitumor Activity of Temozolomide against Intracranial Melanoma, Glioma, Lymphoma</span></div><div class="casAuthors">Tentori, Lucio; Leonetti, Carlo; Scarsella, Marco; D'Amati, Giulia; Vergati, Matteo; Portarena, Ilaria; Xu, Weizheng; Kalish, Vincent; Zupi, Gabriella; Zhang, Jie; Graziani, Grazia</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5370-5379</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Temozolomide (TMZ) is a DNA methylating agent that has shown promising antitumor activity in recent clin. trials against high grade gliomas, metastatic melanoma, and brain lymphoma.  In this study, we tested whether systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase (PARP-1) inhibitor capable of crossing the blood-brain barrier, could enhance the efficacy of TMZ against metastatic melanoma, glioblastoma multiforme, and lymphoma growing in the brain.  Murine B16 melanoma or L5178Y lymphoma cells were injected intracranially in syngeneic mice.  An orthotopic xenograft of the human SJGBM2 glioblastoma multiforme was implanted in nude mice.  Animals were treated with TMZ + GPI 15427 using a schedule of 40 mg/kg/i.v. GPI 15427 + 100 mg/kg/i.p. TMZ for 3 days.  The efficacy of drug treatment was assessed by: (a) the increase of mouse survival and life span; and (b) the suppression of melanoma metastases to lung after i.v. injection of B16 cells.  In all models, systemic administration of GPI 15427 shortly before TMZ significantly increased life span of tumor-bearing mice with respect to untreated controls or to groups treated with either GPI 15427 or TMZ only.  Moreover, GPI 15427 increased the antimetastatic effect of TMZ.  These data indicate that systemic administration of the poly(ADP-ribose) polymerase-1 inhibitor GPI 15427 significantly enhances TMZ antitumor efficacy against solid or hematol. neoplasias even when located at the central nervous system site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJYH9LbPZeJLVg90H21EOLACvtfcHk0lg23QXUC2hunw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXovVOnsrY%253D&md5=5f50132c0d4610520363360abedcc9e5</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTentori%26aufirst%3DL.%26aulast%3DLeonetti%26aufirst%3DC.%26aulast%3DScarsella%26aufirst%3DM.%26aulast%3DD%25E2%2580%2599Amati%26aufirst%3DG.%26aulast%3DVergati%26aufirst%3DM.%26aulast%3DPortarena%26aufirst%3DI.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DKalish%26aufirst%3DV.%26aulast%3DZupi%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DGraziani%26aufirst%3DG.%26atitle%3DSystemic%2520administration%2520of%2520GPI%252015427%252C%2520a%2520novel%2520poly%2528ADP-ribose%2529%2520polymerase-1%2520inhibitor%252C%2520increases%2520the%2520antitumor%2520activity%2520of%2520temozolomide%2520against%2520intracranial%2520melanoma%252C%2520glioma%252C%2520lymphoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2003%26volume%3D9%26spage%3D5370%26epage%3D5379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group">Russo, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwon, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgan, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beam, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weizheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slusher, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakravarti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tofilon, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camphausen, K.</span><span> </span><span class="NLM_article-title">In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">607</span><span class="NLM_x">â</span> <span class="NLM_lpage">612</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1158%2F1078-0432.CCR-08-2079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=19147766" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlvFeqsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=607-612&author=A.+L.+Russoauthor=H.+C.+Kwonauthor=W.+E.+Burganauthor=D.+Carterauthor=K.+Beamauthor=X.+Weizhengauthor=J.+Zhangauthor=B.+S.+Slusherauthor=A.+Chakravartiauthor=P.+J.+Tofilonauthor=K.+Camphausen&title=In+vitro+and+in+vivo+radiosensitization+of+glioblastoma+cells+by+the+poly+%28ADP-ribose%29+polymerase+inhibitor+E7016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and In vivo Radiosensitization of Glioblastoma Cells by the Poly (ADP-Ribose) Polymerase Inhibitor E7016</span></div><div class="casAuthors">Russo, Andrea L.; Kwon, Hyuk-Chan; Burgan, William E.; Carter, Donna; Beam, Katie; Weizheng, Xu; Zhang, Jie; Slusher, Barbara S.; Chakravarti, Arnab; Tofilon, Philip J.; Camphausen, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">607-612</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Poly (ADP-ribose) polymerase (PARP) inhibitors are undergoing clin. evaluation for cancer therapy.  Because PARP inhibition has been shown to enhance tumor cell sensitivity to radiation, we investigated the in vitro and in vivo effects of the novel PARP inhibitor E7016.  Exptl. Design: The effect of E7016 on the in vitro radiosensitivity of tumor cell lines was evaluated using clonogenic survival.  DNA damage and repair were measured using Î³H2AX foci and neutral comet assay.  Mitotic catastrophe was detd. by immunostaining. Tumor growth delay was evaluated in mice for the effect of E7016 on in vivo (U251) tumor radiosensitivity.  Results: Cell lines exposed to E7016 preirradn. yielded an increase in radiosensitivity with dose enhancement factors at a surviving fraction of 0.1 from 1.4 to 1.7.  To assess DNA double-strand breaks repair, Î³H2AX measured at 24 h postirradn. had significantly more foci per cell in the E7016/irradn. group vs. irradn. alone.  Neutral comet assay further suggested unrepaired double-strand breaks with significantly greater DNA damage at 6 h postirradn. in the combination group vs. irradn. alone.  Mitotic catastrophe staining revealed a significantly greater no. of cells staining pos. at 24 h postirradn. in the combination group.  In vivo, mice treated with E7016/irradn./temozolomide had an addnl. growth delay of six days compared with the combination of temozolomide and irradn.  Conclusions: These results indicate that E7016 can enhance tumor cell radiosensitivity in vitro and in vivo through the inhibition of DNA repair.  Moreover, enhanced growth delay with the addn. of E7016 to temozolomide and radiotherapy in a glioma mouse model suggests a potential role for this drug in the treatment of glioblastoma multiforme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwKbKGkXjVd7Vg90H21EOLACvtfcHk0lgzCdUCUmgMuA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlvFeqsg%253D%253D&md5=6b7d2b4cc62ff752d8402788fae07d71</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-2079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-2079%26sid%3Dliteratum%253Aachs%26aulast%3DRusso%26aufirst%3DA.%2BL.%26aulast%3DKwon%26aufirst%3DH.%2BC.%26aulast%3DBurgan%26aufirst%3DW.%2BE.%26aulast%3DCarter%26aufirst%3DD.%26aulast%3DBeam%26aufirst%3DK.%26aulast%3DWeizheng%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DChakravarti%26aufirst%3DA.%26aulast%3DTofilon%26aufirst%3DP.%2BJ.%26aulast%3DCamphausen%26aufirst%3DK.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520radiosensitization%2520of%2520glioblastoma%2520cells%2520by%2520the%2520poly%2520%2528ADP-ribose%2529%2520polymerase%2520inhibitor%2520E7016%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D607%26epage%3D612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group">Lapidus, R. G.; Xu, W.; Spicer, E.; Hoover, R.; Zhang, J.</span><span> </span><span class="NLM_article-title">PARP Inhibitors Enhance the Effect of Cisplatin against Tumors and Ameliorate Cisplatin-Induced Neuropathy</span>.  <span class="citation_source-book">AACR Meeting Abstracts</span>, 97th Annual Meeting of the American Association for Cancer Research, Washington, DC, April 1â5, 2006; <span class="NLM_publisher-name">American Association for Cancer Research</span>: <span class="NLM_publisher-loc">Philadelphia, PA</span>,<span class="NLM_x"> </span><span class="NLM_year">2006</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">2006</span>, p  <span class="NLM_fpage">506</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=506&author=R.+G.+Lapidus&author=W.+Xu&author=E.+Spicer&author=R.+Hoover&author=J.+Zhang&title=AACR+Meeting+Abstracts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DLapidus%26aufirst%3DR.%2BG.%26atitle%3DPARP%2520Inhibitors%2520Enhance%2520the%2520Effect%2520of%2520Cisplatin%2520against%2520Tumors%2520and%2520Ameliorate%2520Cisplatin-Induced%2520Neuropathy%26btitle%3DAACR%2520Meeting%2520Abstracts%26pub%3DAmerican%2520Association%2520for%2520Cancer%2520Research%26date%3D2006%26volume%3D2006%26spage%3D506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group">Lubisch, W.; Sadowski, J.; Kock, M.; Hoger, T.</span><span> </span><span class="NLM_article-title">Use of Phthalazine Derivatives</span>. WO 2000067734,<span class="NLM_x"> </span><span class="NLM_year">2000</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&author=W.+Lubisch&author=J.+Sadowski&author=M.+Kock&author=T.+Hoger&title=Use+of+Phthalazine+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLubisch%26aufirst%3DW.%26atitle%3DUse%2520of%2520Phthalazine%2520Derivatives%26date%3D2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group">Lubisch, W.; Kock, M.; Hoger, T.; Grandel, R.; Schult, S.</span><span> </span><span class="NLM_article-title">Heterocyclic Compounds and Their Use as PARP Inhibitors</span>. WO 2001057038,<span class="NLM_x"> </span><span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=W.+Lubisch&author=M.+Kock&author=T.+Hoger&author=R.+Grandel&author=S.+Schult&title=Heterocyclic+Compounds+and+Their+Use+as+PARP+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLubisch%26aufirst%3DW.%26atitle%3DHeterocyclic%2520Compounds%2520and%2520Their%2520Use%2520as%2520PARP%2520Inhibitors%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group">Lubisch, W.; Kock, M.; Hoger, T.; Schult, S.; Grandel, R.; Muller, R.</span><span> </span><span class="NLM_article-title">Substituted Benzimidazoles and Their Use as PARP Inhibitors</span>. U.S. Patent 6448271,<span class="NLM_x"> </span><span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=W.+Lubisch&author=M.+Kock&author=T.+Hoger&author=S.+Schult&author=R.+Grandel&author=R.+Muller&title=Substituted+Benzimidazoles+and+Their+Use+as+PARP+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLubisch%26aufirst%3DW.%26atitle%3DSubstituted%2520Benzimidazoles%2520and%2520Their%2520Use%2520as%2520PARP%2520Inhibitors%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group">Penning, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubisch, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grandel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wernet, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinghofer, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donawho, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bontcheva-Diaz, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giranda, V. L.</span><span> </span><span class="NLM_article-title">Discovery and SAR of 2-(1-propylpiperidin-4-yl)-1<i>H</i>-benzimidazole-4-carboxamide: a potent inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">6965</span><span class="NLM_x">â</span> <span class="NLM_lpage">6975</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2008&pages=6965-6975&author=T.+D.+Penningauthor=G.+D.+Zhuauthor=V.+B.+Gandhiauthor=J.+Gongauthor=S.+Thomasauthor=W.+Lubischauthor=R.+Grandelauthor=W.+Wernetauthor=C.+H.+Parkauthor=E.+H.+Fryauthor=X.+Liuauthor=Y.+Shiauthor=V.+Klinghoferauthor=E.+F.+Johnsonauthor=C.+K.+Donawhoauthor=D.+J.+Frostauthor=V.+Bontcheva-Diazauthor=J.+J.+Bouskaauthor=A.+M.+Olsonauthor=K.+C.+Marshauthor=Y.+Luoauthor=S.+H.+Rosenbergauthor=V.+L.+Giranda&title=Discovery+and+SAR+of+2-%281-propylpiperidin-4-yl%29-1H-benzimidazole-4-carboxamide%3A+a+potent+inhibitor+of+poly%28ADP-ribose%29+polymerase+%28PARP%29+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPenning%26aufirst%3DT.%2BD.%26aulast%3DZhu%26aufirst%3DG.%2BD.%26aulast%3DGandhi%26aufirst%3DV.%2BB.%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DS.%26aulast%3DLubisch%26aufirst%3DW.%26aulast%3DGrandel%26aufirst%3DR.%26aulast%3DWernet%26aufirst%3DW.%26aulast%3DPark%26aufirst%3DC.%2BH.%26aulast%3DFry%26aufirst%3DE.%2BH.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DKlinghofer%26aufirst%3DV.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DDonawho%26aufirst%3DC.%2BK.%26aulast%3DFrost%26aufirst%3DD.%2BJ.%26aulast%3DBontcheva-Diaz%26aufirst%3DV.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DOlson%26aufirst%3DA.%2BM.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DRosenberg%26aufirst%3DS.%2BH.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26atitle%3DDiscovery%2520and%2520SAR%2520of%25202-%25281-propylpiperidin-4-yl%2529-1H-benzimidazole-4-carboxamide%253A%2520a%2520potent%2520inhibitor%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2008%26volume%3D16%26spage%3D6965%26epage%3D6975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group">Zhu, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinghofer, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donawho, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarvis, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giranda, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penning, T. D.</span><span> </span><span class="NLM_article-title">Synthesis and SAR of novel, potent and orally bioavailable benzimidazole inhibitors of poly(ADP-ribose) polymerase (PARP) with a quaternary methylene-amino substituent</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">3955</span><span class="NLM_x">â</span> <span class="NLM_lpage">3958</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=3955-3958&author=G.+D.+Zhuauthor=V.+B.+Gandhiauthor=J.+Gongauthor=S.+Thomasauthor=Y.+Luoauthor=X.+Liuauthor=Y.+Shiauthor=V.+Klinghoferauthor=E.+F.+Johnsonauthor=D.+Frostauthor=C.+Donawhoauthor=K.+Jarvisauthor=J.+Bouskaauthor=K.+C.+Marshauthor=S.+H.+Rosenbergauthor=V.+L.+Girandaauthor=T.+D.+Penning&title=Synthesis+and+SAR+of+novel%2C+potent+and+orally+bioavailable+benzimidazole+inhibitors+of+poly%28ADP-ribose%29+polymerase+%28PARP%29+with+a+quaternary+methylene-amino+substituent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DG.%2BD.%26aulast%3DGandhi%26aufirst%3DV.%2BB.%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DKlinghofer%26aufirst%3DV.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DFrost%26aufirst%3DD.%26aulast%3DDonawho%26aufirst%3DC.%26aulast%3DJarvis%26aufirst%3DK.%26aulast%3DBouska%26aufirst%3DJ.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DRosenberg%26aufirst%3DS.%2BH.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26aulast%3DPenning%26aufirst%3DT.%2BD.%26atitle%3DSynthesis%2520and%2520SAR%2520of%2520novel%252C%2520potent%2520and%2520orally%2520bioavailable%2520benzimidazole%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520with%2520a%2520quaternary%2520methylene-amino%2520substituent%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D3955%26epage%3D3958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group">Donawho, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penning, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauch, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bontcheva-Diaz, V. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeWeese, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dillehay, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghoreishi-Haack, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimm, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holley-Shanks, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hristov, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Idler, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarvis, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleinberg, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinghofer, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasko, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGonigal, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meulbroek, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palma, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stavropoulos, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsurutani, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giranda, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, D. J.</span><span> </span><span class="NLM_article-title">ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2728</span><span class="NLM_x">â</span> <span class="NLM_lpage">2737</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1158%2F1078-0432.CCR-06-3039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=17473206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkslOhurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=2728-2737&author=C.+K.+Donawhoauthor=Y.+Luoauthor=T.+D.+Penningauthor=J.+L.+Bauchauthor=J.+J.+Bouskaauthor=V.+D.+Bontcheva-Diazauthor=B.+F.+Coxauthor=T.+L.+DeWeeseauthor=L.+E.+Dillehayauthor=D.+C.+Fergusonauthor=N.+S.+Ghoreishi-Haackauthor=D.+R.+Grimmauthor=R.+Guanauthor=E.+K.+Hanauthor=R.+R.+Holley-Shanksauthor=B.+Hristovauthor=K.+B.+Idlerauthor=K.+Jarvisauthor=E.+F.+Johnsonauthor=L.+R.+Kleinbergauthor=V.+Klinghoferauthor=L.+M.+Laskoauthor=X.+Liuauthor=K.+C.+Marshauthor=T.+P.+McGonigalauthor=J.+A.+Meulbroekauthor=A.+M.+Olsonauthor=J.+P.+Palmaauthor=L.+E.+Rodriguezauthor=Y.+Shiauthor=J.+A.+Stavropoulosauthor=A.+C.+Tsurutaniauthor=G.+D.+Zhuauthor=S.+H.+Rosenbergauthor=V.+L.+Girandaauthor=D.+J.+Frost&title=ABT-888%2C+an+orally+active+poly%28ADP-ribose%29+polymerase+inhibitor+that+potentiates+DNA-damaging+agents+in+preclinical+tumor+models"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models</span></div><div class="casAuthors">Donawho, Cherrie K.; Luo, Yan; Luo, Yanping; Penning, Thomas D.; Bauch, Joy L.; Bouska, Jennifer J.; Bontcheva-Diaz, Velitchka D.; Cox, Bryan F.; DeWeese, Theodore L.; Dillehay, Larry E.; Ferguson, Debra C.; Ghoreishi-Haack, Nayereh S.; Grimm, David R.; Guan, Ran; Han, Edward K.; Holley-Shanks, Rhonda R.; Hristov, Boris; Idler, Kenneth B.; Jarvis, Ken; Johnson, Eric F.; Kleinberg, Lawrence R.; Klinghofer, Vered; Lasko, Loren M.; Liu, Xuesong; Marsh, Kennan C.; McGonigal, Thomas P.; Meulbroek, Jonathan A.; Olson, Amanda M.; Palma, Joann P.; Rodriguez, Luis E.; Shi, Yan; Stavropoulos, Jason A.; Tsurutani, Alan C.; Zhu, Gui-Dong; Rosenberg, Saul H.; Giranda, Vincent L.; Frost, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2728-2737</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose is to evaluate the preclin. pharmacokinetics and antitumor efficacy of a novel orally bioavailable poly(ADP-ribose) polymerase (PARP) inhibitor, ABT-888.  In vitro potency was detd. in a PARP-1 and PARP-2 enzyme assay.  In vivo efficacy was evaluated in syngeneic and xenograft models in combination with temozolomide, platinums, cyclophosphamide, and ionizing radiation.  ABT-888 is a potent inhibitor of both PARP-1 and PARP-2 with Kis of 5.2 and 2.9 nmol/L, resp.  The compd. has good oral bioavailability and crosses the blood-brain barrier.  ABT-888 strongly potentiated temozolomide in the B16F10 s.c. murine melanoma model.  PARP inhibition dramatically increased the efficacy of temozolomide at ABT-888 doses as low as 3.1 mg/kg/d and a maximal efficacy achieved at 25 mg/kg/d.  In the 9L orthotopic rat glioma model, temozolomide alone exhibited minimal efficacy, whereas ABT-888, when combined with temozolomide, significantly slowed tumor progression.  In the MX-1 breast xenograft model (BRCA1 deletion and BRCA2 mutation), ABT-888 potentiated cisplatin, carboplatin, and cyclophosphamide, causing regression of established tumors, whereas with comparable doses of cytotoxic agents alone, only modest tumor inhibition was exhibited.  Finally, ABT-888 potentiated radiation (2 Gy/d Ã 10) in an HCT-116 colon carcinoma model.  In each model, ABT-888 did not display single-agent activity.  ABT-888 is a potent inhibitor of PARP, has good oral bioavailability, can cross the blood-brain barrier, and potentiates temozolomide, platinums, cyclophosphamide, and radiation in syngeneic and xenograft tumor models.  This broad spectrum of chemopotentiation and radiopotentiation makes this compd. an attractive candidate for clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2xiIRsPurHLVg90H21EOLACvtfcHk0liIr-Vtriq6bg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkslOhurg%253D&md5=4769ee3eec82465993eb9e1443095894</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-3039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-3039%26sid%3Dliteratum%253Aachs%26aulast%3DDonawho%26aufirst%3DC.%2BK.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DPenning%26aufirst%3DT.%2BD.%26aulast%3DBauch%26aufirst%3DJ.%2BL.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DBontcheva-Diaz%26aufirst%3DV.%2BD.%26aulast%3DCox%26aufirst%3DB.%2BF.%26aulast%3DDeWeese%26aufirst%3DT.%2BL.%26aulast%3DDillehay%26aufirst%3DL.%2BE.%26aulast%3DFerguson%26aufirst%3DD.%2BC.%26aulast%3DGhoreishi-Haack%26aufirst%3DN.%2BS.%26aulast%3DGrimm%26aufirst%3DD.%2BR.%26aulast%3DGuan%26aufirst%3DR.%26aulast%3DHan%26aufirst%3DE.%2BK.%26aulast%3DHolley-Shanks%26aufirst%3DR.%2BR.%26aulast%3DHristov%26aufirst%3DB.%26aulast%3DIdler%26aufirst%3DK.%2BB.%26aulast%3DJarvis%26aufirst%3DK.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DKleinberg%26aufirst%3DL.%2BR.%26aulast%3DKlinghofer%26aufirst%3DV.%26aulast%3DLasko%26aufirst%3DL.%2BM.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DMcGonigal%26aufirst%3DT.%2BP.%26aulast%3DMeulbroek%26aufirst%3DJ.%2BA.%26aulast%3DOlson%26aufirst%3DA.%2BM.%26aulast%3DPalma%26aufirst%3DJ.%2BP.%26aulast%3DRodriguez%26aufirst%3DL.%2BE.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DStavropoulos%26aufirst%3DJ.%2BA.%26aulast%3DTsurutani%26aufirst%3DA.%2BC.%26aulast%3DZhu%26aufirst%3DG.%2BD.%26aulast%3DRosenberg%26aufirst%3DS.%2BH.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26aulast%3DFrost%26aufirst%3DD.%2BJ.%26atitle%3DABT-888%252C%2520an%2520orally%2520active%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitor%2520that%2520potentiates%2520DNA-damaging%2520agents%2520in%2520preclinical%2520tumor%2520models%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D2728%26epage%3D2737" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group">Penning, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinghofer, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donawho, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bontcheva-Diaz, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osterling, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giranda, V. L.</span><span> </span><span class="NLM_article-title">Discovery of the poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(<i>R</i>)-2-methylpyrrolidin-2-yl]-1<i>H</i>-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">514</span><span class="NLM_x">â</span> <span class="NLM_lpage">523</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm801171j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFals7bL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=514-523&author=T.+D.+Penningauthor=G.+D.+Zhuauthor=V.+B.+Gandhiauthor=J.+Gongauthor=X.+Liuauthor=Y.+Shiauthor=V.+Klinghoferauthor=E.+F.+Johnsonauthor=C.+K.+Donawhoauthor=D.+J.+Frostauthor=V.+Bontcheva-Diazauthor=J.+J.+Bouskaauthor=D.+J.+Osterlingauthor=A.+M.+Olsonauthor=K.+C.+Marshauthor=Y.+Luoauthor=V.+L.+Giranda&title=Discovery+of+the+poly%28ADP-ribose%29+polymerase+%28PARP%29+inhibitor+2-%5B%28R%29-2-methylpyrrolidin-2-yl%5D-1H-benzimidazole-4-carboxamide+%28ABT-888%29+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the Treatment of Cancer</span></div><div class="casAuthors">Penning, Thomas D.; Zhu, Gui-Dong; Gandhi, Viraj B.; Gong, Jianchun; Liu, Xuesong; Shi, Yan; Klinghofer, Vered; Johnson, Eric F.; Donawho, Cherrie K.; Frost, David J.; Bontcheva-Diaz, Velitchka; Bouska, Jennifer J.; Osterling, Donald J.; Olson, Amanda M.; Marsh, Kennan C.; Luo, Yan; Giranda, Vincent L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">514-523</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of cyclic amine-contg. benzimidazole carboxamide PARP inhibitors with a methyl-substituted quaternary center at the point of attachment to the benzimidazole ring system has been developed.  These compds. exhibit excellent PARP enzyme potency as well as single-digit nanomolar cellular potency.  These efforts led to the identification of (I)Â·2HCl (2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide, ABT-888), currently in human phase I clin. trials.  Compd. IÂ·2HCl displayed excellent potency against both the PARP-1 and PARP-2 enzymes with a Ki of 5 nM and in a C41 whole cell assay with an EC50 of 2 nM.  In addn., IÂ·2HCl is aq. sol., orally bioavailable across multiple species, and demonstrated good in vivo efficacy in a B16F10 s.c. murine melanoma model in combination with temozolomide (TMZ) and in an MX-1 breast cancer xenograft model in combination with either carboplatin or cyclophosphamide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaBVnNi7EZcbVg90H21EOLACvtfcHk0ljSH6EF-Htf-Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFals7bL&md5=283eddd2e8220740c48865e4e8269a95</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1021%2Fjm801171j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801171j%26sid%3Dliteratum%253Aachs%26aulast%3DPenning%26aufirst%3DT.%2BD.%26aulast%3DZhu%26aufirst%3DG.%2BD.%26aulast%3DGandhi%26aufirst%3DV.%2BB.%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DKlinghofer%26aufirst%3DV.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DDonawho%26aufirst%3DC.%2BK.%26aulast%3DFrost%26aufirst%3DD.%2BJ.%26aulast%3DBontcheva-Diaz%26aufirst%3DV.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DOsterling%26aufirst%3DD.%2BJ.%26aulast%3DOlson%26aufirst%3DA.%2BM.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26atitle%3DDiscovery%2520of%2520the%2520poly%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520inhibitor%25202-%255B%2528R%2529-2-methylpyrrolidin-2-yl%255D-1H-benzimidazole-4-carboxamide%2520%2528ABT-888%2529%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D514%26epage%3D523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group">Kummar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinders, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutierrez, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubinstein, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parchment, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monks, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Low, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murgo, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinberg, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eliopoulos, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giranda, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiltrout, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomaszewski, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doroshow, J. H.</span><span> </span><span class="NLM_article-title">Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">2705</span><span class="NLM_x">â</span> <span class="NLM_lpage">2711</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1200%2FJCO.2008.19.7681" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=19364967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnslWitLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=2705-2711&author=S.+Kummarauthor=R.+Kindersauthor=M.+E.+Gutierrezauthor=L.+Rubinsteinauthor=R.+E.+Parchmentauthor=L.+R.+Phillipsauthor=J.+Jiauthor=A.+Monksauthor=J.+A.+Lowauthor=A.+Chenauthor=A.+J.+Murgoauthor=J.+Collinsauthor=S.+M.+Steinbergauthor=H.+Eliopoulosauthor=V.+L.+Girandaauthor=G.+Gordonauthor=L.+Helmanauthor=R.+Wiltroutauthor=J.+E.+Tomaszewskiauthor=J.+H.+Doroshow&title=Phase+0+clinical+trial+of+the+poly+%28ADP-ribose%29+polymerase+inhibitor+ABT-888+in+patients+with+advanced+malignancies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies</span></div><div class="casAuthors">Kummar, Shivaani; Kinders, Robert; Gutierrez, Martin E.; Rubinstein, Larry; Parchment, Ralph E.; Phillips, Lawrence R.; Ji, Jiuping; Monks, Anne; Low, Jennifer A.; Chen, Alice; Murgo, Anthony J.; Collins, Jerry; Steinberg, Seth M.; Eliopoulos, Helen; Giranda, Vincent L.; Gordon, Gary; Helman, Lee; Wiltrout, Robert; Tomaszewski, Joseph E.; Doroshow, James H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2705-2711</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">We conducted the first phase 0 clin. trial in oncol. of a therapeutic agent under the Exploratory Investigational New Drug Guidance of the US Food and Drug Administration.  It was a first-in-human study of the poly (ADP-ribose) polymerase (PARP) inhibitor ABT-888 in patients with advanced malignancies.  ABT-888 was administered as a single oral dose of 10, 25, or 50 mg to det. the dose range and time course over which ABT-888 inhibits PARP activity in tumor samples and peripheral blood mononuclear cells, and to evaluate ABT-888 pharmacokinetics.  Blood samples and tumor biopsies were obtained pre- and postdrug administration for evaluation of PARP activity and pharmacokinetics.  A novel statistical approach was developed and utilized to study pharmacodynamic modulation as the primary end point for trials of limited sample size.  Thirteen patients with advanced malignancies received the study drug; nine patients underwent paired tumor biopsies.  ABT-888 demonstrated good oral bioavailability and was well tolerated.  Statistically significant inhibition of poly (ADP-ribose) levels was obsd. in tumor biopsies and peripheral blood mononuclear cells at the 25-mg and 50-mg dose levels.  Within 5 mo of study activation, we obtained pivotal biochem. and pharmacokinetic data that have guided the design of subsequent phase I trials of ABT-888 in combination with DNA-damaging agents.  In addn. to accelerating the development of ABT-888, the rapid conclusion of this trial demonstrates the feasibility of conducting proof-of-principle phase 0 trials as part of an alternative paradigm for early drug development in oncol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtTZJu529qYbVg90H21EOLACvtfcHk0ljSH6EF-Htf-Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnslWitLs%253D&md5=29b206795ad0d6195cb6ac3279ebda48</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1200%2FJCO.2008.19.7681&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2008.19.7681%26sid%3Dliteratum%253Aachs%26aulast%3DKummar%26aufirst%3DS.%26aulast%3DKinders%26aufirst%3DR.%26aulast%3DGutierrez%26aufirst%3DM.%2BE.%26aulast%3DRubinstein%26aufirst%3DL.%26aulast%3DParchment%26aufirst%3DR.%2BE.%26aulast%3DPhillips%26aufirst%3DL.%2BR.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DMonks%26aufirst%3DA.%26aulast%3DLow%26aufirst%3DJ.%2BA.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DMurgo%26aufirst%3DA.%2BJ.%26aulast%3DCollins%26aufirst%3DJ.%26aulast%3DSteinberg%26aufirst%3DS.%2BM.%26aulast%3DEliopoulos%26aufirst%3DH.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26aulast%3DGordon%26aufirst%3DG.%26aulast%3DHelman%26aufirst%3DL.%26aulast%3DWiltrout%26aufirst%3DR.%26aulast%3DTomaszewski%26aufirst%3DJ.%2BE.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26atitle%3DPhase%25200%2520clinical%2520trial%2520of%2520the%2520poly%2520%2528ADP-ribose%2529%2520polymerase%2520inhibitor%2520ABT-888%2520in%2520patients%2520with%2520advanced%2520malignancies%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D2705%26epage%3D2711" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group">Martin, N. M. B.; Smith, G. C. M.; White, C. R.; Newton, R. F.; Douglas, D. G.; Eversley, P. J.; Whittle, A. J.</span><span> </span><span class="NLM_article-title">Isoquinolinone Derivatives</span>. U.S. Patent 6664269,<span class="NLM_x"> </span><span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=N.+M.+B.+Martin&author=G.+C.+M.+Smith&author=C.+R.+White&author=R.+F.+Newton&author=D.+G.+Douglas&author=P.+J.+Eversley&author=A.+J.+Whittle&title=Isoquinolinone+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DN.%2BM.%2BB.%26atitle%3DIsoquinolinone%2520Derivatives%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group">Martin, N. M. B.; Smith, G. C. M.; Eversley, P. J.; Cockcroft, X.-l.; Kerrigan, F.; Hoare, J.; Dixon, L.</span><span> </span><span class="NLM_article-title">Phthalazinone Derivatives</span>. U.S. Patent 7196085,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=N.+M.+B.+Martin&author=G.+C.+M.+Smith&author=P.+J.+Eversley&author=X.-l.+Cockcroft&author=F.+Kerrigan&author=J.+Hoare&author=L.+Dixon&title=Phthalazinone+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DN.%2BM.%2BB.%26atitle%3DPhthalazinone%2520Derivatives%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group">Jacobs, R. T.; Folmer, J. J.; Simpson, T. R.; Chaudhari, B.; Frazee, W. J.; Davenport, T. W.; Sundarababu, G.</span><span> </span><span class="NLM_article-title">Therapeutic Heterocycles</span>. U.S. Patent 6399603,<span class="NLM_x"> </span><span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=R.+T.+Jacobs&author=J.+J.+Folmer&author=T.+R.+Simpson&author=B.+Chaudhari&author=W.+J.+Frazee&author=T.+W.+Davenport&author=G.+Sundarababu&title=Therapeutic+Heterocycles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJacobs%26aufirst%3DR.%2BT.%26atitle%3DTherapeutic%2520Heterocycles%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group">Loh, V. M.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockcroft, X. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dillon, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dixon, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drzewiecki, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eversley, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoare, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerrigan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, I. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menear, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paul, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vile, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittle, A. J.</span><span> </span><span class="NLM_article-title">Phthalazinones. Part 1: The design and synthesis of a novel series of potent inhibitors of poly(ADP-ribose)polymerase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">2235</span><span class="NLM_x">â</span> <span class="NLM_lpage">2238</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=2235-2238&author=V.+M.+Lohauthor=X.+L.+Cockcroftauthor=K.+J.+Dillonauthor=L.+Dixonauthor=J.+Drzewieckiauthor=P.+J.+Eversleyauthor=S.+Gomezauthor=J.+Hoareauthor=F.+Kerriganauthor=I.+T.+Matthewsauthor=K.+A.+Menearauthor=N.+M.+Martinauthor=R.+F.+Newtonauthor=J.+Paulauthor=G.+C.+Smithauthor=J.+Vileauthor=A.+J.+Whittle&title=Phthalazinones.+Part+1%3A+The+design+and+synthesis+of+a+novel+series+of+potent+inhibitors+of+poly%28ADP-ribose%29polymerase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLoh%26aufirst%3DV.%2BM.%26aulast%3DCockcroft%26aufirst%3DX.%2BL.%26aulast%3DDillon%26aufirst%3DK.%2BJ.%26aulast%3DDixon%26aufirst%3DL.%26aulast%3DDrzewiecki%26aufirst%3DJ.%26aulast%3DEversley%26aufirst%3DP.%2BJ.%26aulast%3DGomez%26aufirst%3DS.%26aulast%3DHoare%26aufirst%3DJ.%26aulast%3DKerrigan%26aufirst%3DF.%26aulast%3DMatthews%26aufirst%3DI.%2BT.%26aulast%3DMenear%26aufirst%3DK.%2BA.%26aulast%3DMartin%26aufirst%3DN.%2BM.%26aulast%3DNewton%26aufirst%3DR.%2BF.%26aulast%3DPaul%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DG.%2BC.%26aulast%3DVile%26aufirst%3DJ.%26aulast%3DWhittle%26aufirst%3DA.%2BJ.%26atitle%3DPhthalazinones.%2520Part%25201%253A%2520The%2520design%2520and%2520synthesis%2520of%2520a%2520novel%2520series%2520of%2520potent%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529polymerase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D2235%26epage%3D2238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group">Cockcroft, X. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dillon, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dixon, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drzewiecki, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerrigan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loh, V. M.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menear, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. C.</span><span> </span><span class="NLM_article-title">Phthalazinones 2: optimisation and synthesis of novel potent inhibitors of poly(ADP-ribose)polymerase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1040</span><span class="NLM_x">â</span> <span class="NLM_lpage">1044</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=1040-1044&author=X.+L.+Cockcroftauthor=K.+J.+Dillonauthor=L.+Dixonauthor=J.+Drzewieckiauthor=F.+Kerriganauthor=V.+M.+Lohauthor=N.+M.+Martinauthor=K.+A.+Menearauthor=G.+C.+Smith&title=Phthalazinones+2%3A+optimisation+and+synthesis+of+novel+potent+inhibitors+of+poly%28ADP-ribose%29polymerase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCockcroft%26aufirst%3DX.%2BL.%26aulast%3DDillon%26aufirst%3DK.%2BJ.%26aulast%3DDixon%26aufirst%3DL.%26aulast%3DDrzewiecki%26aufirst%3DJ.%26aulast%3DKerrigan%26aufirst%3DF.%26aulast%3DLoh%26aufirst%3DV.%2BM.%26aulast%3DMartin%26aufirst%3DN.%2BM.%26aulast%3DMenear%26aufirst%3DK.%2BA.%26aulast%3DSmith%26aufirst%3DG.%2BC.%26atitle%3DPhthalazinones%25202%253A%2520optimisation%2520and%2520synthesis%2520of%2520novel%2520potent%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529polymerase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D1040%26epage%3D1044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group">Menear, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adcock, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulter, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockcroft, X. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copsey, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cranston, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dillon, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drzewiecki, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javaid, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerrigan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knights, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loh, V. M.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, I. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâConnor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N. M.</span><span> </span><span class="NLM_article-title">4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2<i>H</i>-phth alazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">6581</span><span class="NLM_x">â</span> <span class="NLM_lpage">6591</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8001263" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=6581-6591&author=K.+A.+Menearauthor=C.+Adcockauthor=R.+Boulterauthor=X.+L.+Cockcroftauthor=L.+Copseyauthor=A.+Cranstonauthor=K.+J.+Dillonauthor=J.+Drzewieckiauthor=S.+Garmanauthor=S.+Gomezauthor=H.+Javaidauthor=F.+Kerriganauthor=C.+Knightsauthor=A.+Lauauthor=V.+M.+Lohauthor=I.+T.+Matthewsauthor=S.+Mooreauthor=M.+J.+O%E2%80%99Connorauthor=G.+C.+Smithauthor=N.+M.+Martin&title=4-%5B3-%284-Cyclopropanecarbonylpiperazine-1-carbonyl%29-4-fluorobenzyl%5D-2H-phth+alazin-1-one%3A+a+novel+bioavailable+inhibitor+of+poly%28ADP-ribose%29+polymerase-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1021%2Fjm8001263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8001263%26sid%3Dliteratum%253Aachs%26aulast%3DMenear%26aufirst%3DK.%2BA.%26aulast%3DAdcock%26aufirst%3DC.%26aulast%3DBoulter%26aufirst%3DR.%26aulast%3DCockcroft%26aufirst%3DX.%2BL.%26aulast%3DCopsey%26aufirst%3DL.%26aulast%3DCranston%26aufirst%3DA.%26aulast%3DDillon%26aufirst%3DK.%2BJ.%26aulast%3DDrzewiecki%26aufirst%3DJ.%26aulast%3DGarman%26aufirst%3DS.%26aulast%3DGomez%26aufirst%3DS.%26aulast%3DJavaid%26aufirst%3DH.%26aulast%3DKerrigan%26aufirst%3DF.%26aulast%3DKnights%26aufirst%3DC.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DLoh%26aufirst%3DV.%2BM.%26aulast%3DMatthews%26aufirst%3DI.%2BT.%26aulast%3DMoore%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DSmith%26aufirst%3DG.%2BC.%26aulast%3DMartin%26aufirst%3DN.%2BM.%26atitle%3D4-%255B3-%25284-Cyclopropanecarbonylpiperazine-1-carbonyl%2529-4-fluorobenzyl%255D-2H-phth%2520alazin-1-one%253A%2520a%2520novel%2520bioavailable%2520inhibitor%2520of%2520poly%2528ADP-ribose%2529%2520polymerase-1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D6581%26epage%3D6591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group">Veber, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kopple, K. D.</span><span> </span><span class="NLM_article-title">Molecular properties that influence the oral bioavailability of drug candidates</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">2615</span><span class="NLM_x">â</span> <span class="NLM_lpage">2623</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm020017n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD38XjsFCmt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=2615-2623&author=D.+F.+Veberauthor=S.+R.+Johnsonauthor=H.+Y.+Chengauthor=B.+R.+Smithauthor=K.+W.+Wardauthor=K.+D.+Kopple&title=Molecular+properties+that+influence+the+oral+bioavailability+of+drug+candidates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Properties That Influence the Oral Bioavailability of Drug Candidates</span></div><div class="casAuthors">Veber, Daniel F.; Johnson, Stephen R.; Cheng, Hung-Yuan; Smith, Brian R.; Ward, Keith W.; Kopple, Kenneth D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2615-2623</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oral bioavailability measurements in rats for over 1100 drug candidates studied at Smith-Kline Beecham Pharmaceuticals (now Glaxo Smith-Kline) have allowed us to analyze the relative importance of mol. properties considered to influence that drug property.  Reduced mol. flexibility, as measured by the no. of rotatable bonds, and low polar surface area or total hydrogen bond count (sum of donors and acceptors) are found to be important predictors of good oral bioavailability, independent of mol. wt.  That on av. both the no. of rotatable bonds and polar surface area or hydrogen bond count tend to increase with mol. wt. may in part explain the success of the mol. wt. parameter in predicting oral bioavailability.  The commonly applied mol. wt. cutoff at 500 does not itself significantly sep. compds. with poor oral bioavailability from those with acceptable values in this extensive data set.  Our observations suggest that compds. which meet only the 2 criteria of (1) 10 or fewer rotatable bonds and (2) polar surface area â¤140 Ã2 (or 12 or fewer H-bond donors and acceptors) will have a high probability of good oral bioavailability in the rat.  Data sets for the artificial membrane permeation rate and for clearance in the rat were also examd.  Reduced polar surface area correlates better with increased permeation rate than does lipophilicity (C log P), and increased rotatable bond count has a neg. effect on the permeation rate.  A threshold permeation rate is a prerequisite of oral bioavailability.  The rotatable bond count does not correlate with the data examd. here for the in vivo clearance rate in the rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3JtJEkO7yVLVg90H21EOLACvtfcHk0lgl-Ct40ArFhw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjsFCmt7g%253D&md5=eaad26ed6a259de82ad65a8834fc397d</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1021%2Fjm020017n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020017n%26sid%3Dliteratum%253Aachs%26aulast%3DVeber%26aufirst%3DD.%2BF.%26aulast%3DJohnson%26aufirst%3DS.%2BR.%26aulast%3DCheng%26aufirst%3DH.%2BY.%26aulast%3DSmith%26aufirst%3DB.%2BR.%26aulast%3DWard%26aufirst%3DK.%2BW.%26aulast%3DKopple%26aufirst%3DK.%2BD.%26atitle%3DMolecular%2520properties%2520that%2520influence%2520the%2520oral%2520bioavailability%2520of%2520drug%2520candidates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D2615%26epage%3D2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group">Fong, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boss, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yap, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tutt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mergui-Roelvink, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortimer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swaisland, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâConnor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmichael, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schellens, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bono, J. S.</span><span> </span><span class="NLM_article-title">Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">361</span><span class="NLM_x">, </span> <span class="NLM_fpage">123</span><span class="NLM_x">â</span> <span class="NLM_lpage">134</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1056%2FNEJMoa0900212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=19553641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVKrtrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2009&pages=123-134&author=P.+C.+Fongauthor=D.+S.+Bossauthor=T.+A.+Yapauthor=A.+Tuttauthor=P.+Wuauthor=M.+Mergui-Roelvinkauthor=P.+Mortimerauthor=H.+Swaislandauthor=A.+Lauauthor=M.+J.+O%E2%80%99Connorauthor=A.+Ashworthauthor=J.+Carmichaelauthor=S.+B.+Kayeauthor=J.+H.+Schellensauthor=J.+S.+de+Bono&title=Inhibition+of+poly%28ADP-ribose%29+polymerase+in+tumors+from+BRCA+mutation+carriers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers</span></div><div class="casAuthors">Fong, Peter C.; Boss, David S.; Yap, Timothy A.; Tutt, Andrew; Wu, Peijun; Mergui-Roelvink, Marja; Mortimer, Peter; Swaisland, Helen; Lau, Alan; O'Connor, Mark J.; Ashworth, Alan; Carmichael, James; Kaye, Stan B.; Schellens, Jan H. M.; de Bono, Johann S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-134</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The inhibition of poly(ADP-ribose) polymerase (PARP) is a potential synthetic lethal therapeutic strategy for the treatment of cancers with specific DNA-repair defects, including those arising in carriers of a BRCA1 or BRCA2 mutation.  We conducted a clin. evaluation in humans of olaparib (AZD2281), a novel, potent, orally active PARP inhibitor.  This was a phase 1 trial that included the anal. of pharmacokinetic and pharmacodynamic characteristics of olaparib.  Selection was aimed at having a study population enriched in carriers of a BRCA1 or BRCA2 mutation.  We enrolled and treated 60 patients; 22 were carriers of a BRCA1 or BRCA2 mutation and 1 had a strong family history of BRCA-assocd. cancer but declined to undergo mutational testing.  The olaparib dose and schedule were increased from 10 mg daily for 2 of every 3 wk to 600 mg twice daily continuously.  Reversible dose-limiting toxicity was seen in one of eight patients receiving 400 mg twice daily (grade 3 mood alteration and fatigue) and two of five patients receiving 600 mg twice daily (grade 4 thrombocytopenia and grade 3 somnolence).  This led us to enroll another cohort, consisting only of carriers of a BRCA1 or BRCA2 mutation, to receive olaparib at a dose of 200 mg twice daily.  Other adverse effects included mild gastrointestinal symptoms.  There was no obvious increase in adverse effects seen in the mutation carriers.  Pharmacokinetic data indicated rapid absorption and elimination; pharmacodynamic studies confirmed PARP inhibition in surrogate samples (of peripheral-blood mononuclear cells and plucked eyebrow-hair follicles) and tumor tissue.  Objective antitumor activity was reported only in mutation carriers, all of whom had ovarian, breast, or prostate cancer and had received multiple treatment regimens.  Olaparib has few of the adverse effects of conventional chemotherapy, inhibits PARP, and has antitumor activity in cancer assocd. with the BRCA1 or BRCA2 mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCT49Hz0HbW7Vg90H21EOLACvtfcHk0lgl-Ct40ArFhw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVKrtrw%253D&md5=aec7dcffe3d3cf614362a4f38bbb369a</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0900212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0900212%26sid%3Dliteratum%253Aachs%26aulast%3DFong%26aufirst%3DP.%2BC.%26aulast%3DBoss%26aufirst%3DD.%2BS.%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DTutt%26aufirst%3DA.%26aulast%3DWu%26aufirst%3DP.%26aulast%3DMergui-Roelvink%26aufirst%3DM.%26aulast%3DMortimer%26aufirst%3DP.%26aulast%3DSwaisland%26aufirst%3DH.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DAshworth%26aufirst%3DA.%26aulast%3DCarmichael%26aufirst%3DJ.%26aulast%3DKaye%26aufirst%3DS.%2BB.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26atitle%3DInhibition%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%2520in%2520tumors%2520from%2520BRCA%2520mutation%2520carriers%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D361%26spage%3D123%26epage%3D134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group">Tutt, A.; Robson, M.; Garber, J. E.; Domchek, S.; Audeh, M. W.; Weitzel, J. N.; Friedlander, M.; Carmichael, J.</span><span> </span><span class="NLM_article-title">Phase II Trial of the Oral PARP Inhibitor Olaparib in BRCA-Deficient Advanced Breast Cancer</span>.  <span class="citation_source-book">ASCO Meeting Abstracts</span>, 2009 ASCO Annual Meeting; <span class="NLM_publisher-name">American Society of Clinical Oncology</span>: <span class="NLM_publisher-loc">Alexandria, VA</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">27</span>, CRA501.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=A.+Tutt&author=M.+Robson&author=J.+E.+Garber&author=S.+Domchek&author=M.+W.+Audeh&author=J.+N.+Weitzel&author=M.+Friedlander&author=J.+Carmichael&title=ASCO+Meeting+Abstracts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DTutt%26aufirst%3DA.%26atitle%3DPhase%2520II%2520Trial%2520of%2520the%2520Oral%2520PARP%2520Inhibitor%2520Olaparib%2520in%2520BRCA-Deficient%2520Advanced%2520Breast%2520Cancer%26btitle%3DASCO%2520Meeting%2520Abstracts%26pub%3DAmerican%2520Society%2520of%2520Clinical%2520Oncology%26date%3D2009%26volume%3D27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group">Audeh, M. W.; Penson, R. T.; Friedlander, M.; Powell, B.; Bell-McGuinn, K. M.; Scott, C.; Weitzel, J. N.; Carmichael, J.; Tutt, A.</span><span> </span><span class="NLM_article-title">Phase II Trial of the Oral PARP Inhibitor Olaparib (AZD2281) in BRCA-Deficient Advanced Ovarian Cancer</span>.  <span class="citation_source-book">ASCO Meeting Abstracts</span>, 2009 ASCO Annual Meeting; <span class="NLM_publisher-name">American Society of Clinical Oncology</span>: <span class="NLM_publisher-loc">Alexandria, VA</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">27</span>, p  <span class="NLM_fpage">5500</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&pages=5500&author=M.+W.+Audeh&author=R.+T.+Penson&author=M.+Friedlander&author=B.+Powell&author=K.+M.+Bell-McGuinn&author=C.+Scott&author=J.+N.+Weitzel&author=J.+Carmichael&author=A.+Tutt&title=ASCO+Meeting+Abstracts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DAudeh%26aufirst%3DM.%2BW.%26atitle%3DPhase%2520II%2520Trial%2520of%2520the%2520Oral%2520PARP%2520Inhibitor%2520Olaparib%2520%2528AZD2281%2529%2520in%2520BRCA-Deficient%2520Advanced%2520Ovarian%2520Cancer%26btitle%3DASCO%2520Meeting%2520Abstracts%26pub%3DAmerican%2520Society%2520of%2520Clinical%2520Oncology%26date%3D2009%26volume%3D27%26spage%3D5500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group">Wells, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bihovsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husten, J.</span><span> </span><span class="NLM_article-title">Synthesis and structureâactivity relationships of novel pyrrolocarbazole lactam analogs as potent and cell-permeable inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1)</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1151</span><span class="NLM_x">â</span> <span class="NLM_lpage">1155</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=1151-1155&author=G.+J.+Wellsauthor=R.+Bihovskyauthor=R.+L.+Hudkinsauthor=M.+A.+Atorauthor=J.+Husten&title=Synthesis+and+structure%E2%88%92activity+relationships+of+novel+pyrrolocarbazole+lactam+analogs+as+potent+and+cell-permeable+inhibitors+of+poly%28ADP-ribose%29polymerase-1+%28PARP-1%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWells%26aufirst%3DG.%2BJ.%26aulast%3DBihovsky%26aufirst%3DR.%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DHusten%26aufirst%3DJ.%26atitle%3DSynthesis%2520and%2520structure%25E2%2588%2592activity%2520relationships%2520of%2520novel%2520pyrrolocarbazole%2520lactam%2520analogs%2520as%2520potent%2520and%2520cell-permeable%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529polymerase-1%2520%2528PARP-1%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D1151%26epage%3D1155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group">Shah, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirier, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duchaine, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brochu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desnoyers, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lagueux, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verreault, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoflack, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkland, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirier, G. G.</span><span> </span><span class="NLM_article-title">Methods for biochemical study of poly(ADP-ribose) metabolism in vitro and in vivo</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">227</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">â</span> <span class="NLM_lpage">13</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=227&publication_year=1995&pages=1-13&author=G.+M.+Shahauthor=D.+Poirierauthor=C.+Duchaineauthor=G.+Brochuauthor=S.+Desnoyersauthor=J.+Lagueuxauthor=A.+Verreaultauthor=J.+C.+Hoflackauthor=J.+B.+Kirklandauthor=G.+G.+Poirier&title=Methods+for+biochemical+study+of+poly%28ADP-ribose%29+metabolism+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DG.%2BM.%26aulast%3DPoirier%26aufirst%3DD.%26aulast%3DDuchaine%26aufirst%3DC.%26aulast%3DBrochu%26aufirst%3DG.%26aulast%3DDesnoyers%26aufirst%3DS.%26aulast%3DLagueux%26aufirst%3DJ.%26aulast%3DVerreault%26aufirst%3DA.%26aulast%3DHoflack%26aufirst%3DJ.%2BC.%26aulast%3DKirkland%26aufirst%3DJ.%2BB.%26aulast%3DPoirier%26aufirst%3DG.%2BG.%26atitle%3DMethods%2520for%2520biochemical%2520study%2520of%2520poly%2528ADP-ribose%2529%2520metabolism%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DAnal.%2520Biochem.%26date%3D1995%26volume%3D227%26spage%3D1%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group">Miknyoczki, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones-Bolin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bihovsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chatterjee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein-Szanto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dionne, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B.</span><span> </span><span class="NLM_article-title">Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">371</span><span class="NLM_x">â</span> <span class="NLM_lpage">382</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.4161%2Fcbt.2.4.460" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=12700281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjvVyktbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=371-382&author=S.+J.+Miknyoczkiauthor=S.+Jones-Bolinauthor=S.+Pritchardauthor=K.+Hunterauthor=H.+Zhaoauthor=W.+Wanauthor=M.+Atorauthor=R.+Bihovskyauthor=R.+Hudkinsauthor=S.+Chatterjeeauthor=A.+Klein-Szantoauthor=C.+Dionneauthor=B.+Ruggeri&title=Chemopotentiation+of+temozolomide%2C+irinotecan%2C+and+cisplatin+activity+by+CEP-6800%2C+a+poly%28ADP-ribose%29+polymerase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor</span></div><div class="casAuthors">Miknyoczki, Sheila J.; Jones-Bolin, Susan; Pritchard, Sonya; Hunter, Kathryn; Zhao, Hugh; Wan, Weihua; Ator, Mark; Bihovsky, Ronald; Hudkins, Robert; Chatterjee, Sankar; Klein-Szanto, Andres; Dionne, Craig; Ruggeri, Bruce</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">371-382</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase 1 (PARP-1) is a nuclear zinc finger DNA-binding protein that is implicated in the repair of DNA damage.  Inhibition of PARP-1 through genetic knockouts causes cells to become hypersensitive to various chemotherapeutic agents.  We tested the chemopotentiating ability of the PARP-1 inhibitor, CEP-6800, when used in combination with temozolomide (TMZ), irinotecan (camptothecin or SN38), and cisplatin against U251MG glioblastoma, HT29 colon carcinoma, and Calu-6 non-small cell lung carcinoma xenografts and cell lines, resp.  Exposure of tumor cells to TMZ, camptothecin (or SN38), and cisplatin before, or in the presence of, CEP-6800 significantly increased the onset and the magnitude of DNA damage, the duration for cells to effect repair, and the onset, duration, or fraction of cells arrested at the G2/M boundary.  In addn., in vivo biochem. efficacy studies with CEP-6800 showed that it was able to attenuate irinotecan- and TMZ-induced poly(ADP-ribose) accumulation in LoVo and HT29 xenografts, resp.  Treatment of CEP 6800 (30 mg/kg) with TMZ (17 and 34 mg/kg) resulted in 100% complete regression of U251MG tumors by day 28 vs. 60% complete regression caused by TMZ alone.  CEP-6800 (30 mg/kg) in combination with irinotecan (10 mg/kg) resulted in a 60% inhibition of HT29 tumor growth vs. irinotecan alone by day 33.  The combination therapy of cisplatin (5 mg/kg) with CEP-6800 (30 mg/kg) caused a 35% redn. in Calu-6 tumor growth vs. cisplatin alone by day 28.  These data suggest that CEP-6800 could be used as a chemopotentiating agent with a variety of clin. effective chemotherapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaiwSIo74c1LVg90H21EOLACvtfcHk0lhRUyzZ_YeOPQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjvVyktbY%253D&md5=2c4b1eb96a1b16c44ad15760f5c1f73c</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.4161%2Fcbt.2.4.460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.2.4.460%26sid%3Dliteratum%253Aachs%26aulast%3DMiknyoczki%26aufirst%3DS.%2BJ.%26aulast%3DJones-Bolin%26aufirst%3DS.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DHunter%26aufirst%3DK.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DAtor%26aufirst%3DM.%26aulast%3DBihovsky%26aufirst%3DR.%26aulast%3DHudkins%26aufirst%3DR.%26aulast%3DChatterjee%26aufirst%3DS.%26aulast%3DKlein-Szanto%26aufirst%3DA.%26aulast%3DDionne%26aufirst%3DC.%26aulast%3DRuggeri%26aufirst%3DB.%26atitle%3DChemopotentiation%2520of%2520temozolomide%252C%2520irinotecan%252C%2520and%2520cisplatin%2520activity%2520by%2520CEP-6800%252C%2520a%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2003%26volume%3D2%26spage%3D371%26epage%3D382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group">Miknyoczki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grobelny, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worrell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husten, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deibold, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zulli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parchment, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B.</span><span> </span><span class="NLM_article-title">The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">2290</span><span class="NLM_x">â</span> <span class="NLM_lpage">2302</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1158%2F1535-7163.MCT-07-0062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=17699724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD2sXptVGltbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=2290-2302&author=S.+Miknyoczkiauthor=H.+Changauthor=J.+Grobelnyauthor=S.+Pritchardauthor=C.+Worrellauthor=N.+McGannauthor=M.+Atorauthor=J.+Hustenauthor=J.+Deiboldauthor=R.+Hudkinsauthor=A.+Zulliauthor=R.+Parchmentauthor=B.+Ruggeri&title=The+selective+poly%28ADP-ribose%29+polymerase-1%282%29+inhibitor%2C+CEP-8983%2C+increases+the+sensitivity+of+chemoresistant+tumor+cells+to+temozolomide+and+irinotecan+but+does+not+potentiate+myelotoxicity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity</span></div><div class="casAuthors">Miknyoczki, Sheila; Chang, Hong; Grobelny, Jennifer; Pritchard, Sonya; Worrell, Candace; McGann, Natalie; Ator, Mark; Husten, Jean; Deibold, James; Hudkins, Robert; Zulli, Allison; Parchment, Ralph; Ruggeri, Bruce</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2290-2302</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The effect of the potent and selective poly(ADP-ribose) (PAR) polymerase-1 [and PAR polymerase-2] inhibitor CEP-8983 on the ability to sensitize chemoresistant glioblastoma (RG2), rhabdomyosarcoma (RH18), neuroblastoma (NB1691), and colon carcinoma (HT29) tumor cells to temozolomide- and camptothecin-induced cytotoxicity, DNA damage, and G2-M arrest and on the potentiation of chemotherapy-induced myelotoxicity was evaluated using in vitro assays.  In addn., the effect of the prodrug CEP-9722 in combination with temozolomide and/or irinotecan on PAR accumulation and tumor growth was also detd. using glioblastoma and/or colon carcinoma xenografts relative to chemotherapy alone.  CEP-8983 sensitized carcinoma cells to the growth-inhibitory effects of temozolomide and/or SN38 increased the fraction of and/or lengthened duration of time tumor cells accumulated in chemotherapy-induced G2-M arrest and sensitized tumor cells to chemotherapy-induced DNA damage and apoptosis.  A granulocyte-macrophage colony-forming unit colony formation assay showed that coincubation of CEP-8983 with temozolomide or topotecan did not potentiate chemotherapy-assocd. myelotoxicity.  CEP-9722 (136 mg/kg) administered with temozolomide (68 mg/kg for 5 days) or irinotecan (10 mg/kg for 5 days) inhibited significantly the growth of RG2 tumors (60%) or HT29 tumors (80%) compared with temozolomide or irinotecan monotherapy, resp.  In addn., CEP-9722 showed "stand alone" antitumor efficacy in these preclin. xenografts.  In vivo biochem. efficacy studies showed that CEP-9722 attenuated PAR accumulation in glioma xenografts in a dose- and time-related manner.  These data indicate that CEP-8983 and its prodrug are effective chemosensitizing agents when administered in combination with select chemotherapeutic agents against chemoresistant tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr870nJ_ojOQbVg90H21EOLACvtfcHk0lhRUyzZ_YeOPQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXptVGltbc%253D&md5=eef1600ec2ce56e71ca6045dca135bf4</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0062%26sid%3Dliteratum%253Aachs%26aulast%3DMiknyoczki%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DH.%26aulast%3DGrobelny%26aufirst%3DJ.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWorrell%26aufirst%3DC.%26aulast%3DMcGann%26aufirst%3DN.%26aulast%3DAtor%26aufirst%3DM.%26aulast%3DHusten%26aufirst%3DJ.%26aulast%3DDeibold%26aufirst%3DJ.%26aulast%3DHudkins%26aufirst%3DR.%26aulast%3DZulli%26aufirst%3DA.%26aulast%3DParchment%26aufirst%3DR.%26aulast%3DRuggeri%26aufirst%3DB.%26atitle%3DThe%2520selective%2520poly%2528ADP-ribose%2529%2520polymerase-1%25282%2529%2520inhibitor%252C%2520CEP-8983%252C%2520increases%2520the%2520sensitivity%2520of%2520chemoresistant%2520tumor%2520cells%2520to%2520temozolomide%2520and%2520irinotecan%2520but%2520does%2520not%2520potentiate%2520myelotoxicity%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D2290%26epage%3D2302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group">Chatterjee, S.; Diebold, J. L.; Dunn, D.; Hudkins, R. L.; Dandu, R.; Wells, G. J.; Zulli, A. L.</span><span> </span><span class="NLM_article-title">Cycloalkanopyrrolocarbazole Derivatives and the Use Thereof as PARP, VEGFR2 and MLK3 Inhibitors</span>. WO 2007149451,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=S.+Chatterjee&author=J.+L.+Diebold&author=D.+Dunn&author=R.+L.+Hudkins&author=R.+Dandu&author=G.+J.+Wells&author=A.+L.+Zulli&title=Cycloalkanopyrrolocarbazole+Derivatives+and+the+Use+Thereof+as+PARP%2C+VEGFR2+and+MLK3+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChatterjee%26aufirst%3DS.%26atitle%3DCycloalkanopyrrolocarbazole%2520Derivatives%2520and%2520the%2520Use%2520Thereof%2520as%2520PARP%252C%2520VEGFR2%2520and%2520MLK3%2520Inhibitors%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group">Martinez-Romero, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez-Lara, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aguilar-Quesada, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peralta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliver, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siles, E.</span><span> </span><span class="NLM_article-title">PARP-1 modulates deferoxamine-induced HIF-1alpha accumulation through the regulation of nitric oxide and oxidative stress</span> <span class="citation_source-journal">J. Cell. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">2248</span><span class="NLM_x">â</span> <span class="NLM_lpage">2260</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2008&pages=2248-2260&author=R.+Martinez-Romeroauthor=E.+Martinez-Laraauthor=R.+Aguilar-Quesadaauthor=A.+Peraltaauthor=F.+J.+Oliverauthor=E.+Siles&title=PARP-1+modulates+deferoxamine-induced+HIF-1alpha+accumulation+through+the+regulation+of+nitric+oxide+and+oxidative+stress"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez-Romero%26aufirst%3DR.%26aulast%3DMartinez-Lara%26aufirst%3DE.%26aulast%3DAguilar-Quesada%26aufirst%3DR.%26aulast%3DPeralta%26aufirst%3DA.%26aulast%3DOliver%26aufirst%3DF.%2BJ.%26aulast%3DSiles%26aufirst%3DE.%26atitle%3DPARP-1%2520modulates%2520deferoxamine-induced%2520HIF-1alpha%2520accumulation%2520through%2520the%2520regulation%2520of%2520nitric%2520oxide%2520and%2520oxidative%2520stress%26jtitle%3DJ.%2520Cell.%2520Biochem.%26date%3D2008%26volume%3D104%26spage%3D2248%26epage%3D2260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group">Ishida, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwashita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mihara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuoka, N.</span><span> </span><span class="NLM_article-title">4-Phenyl-1,2,3,6-tetrahydropyridine, an excellent fragment to improve the potency of PARP-1 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">4221</span><span class="NLM_x">â</span> <span class="NLM_lpage">4225</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=4221-4225&author=J.+Ishidaauthor=K.+Hattoriauthor=H.+Yamamotoauthor=A.+Iwashitaauthor=K.+Miharaauthor=N.+Matsuoka&title=4-Phenyl-1%2C2%2C3%2C6-tetrahydropyridine%2C+an+excellent+fragment+to+improve+the+potency+of+PARP-1+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIshida%26aufirst%3DJ.%26aulast%3DHattori%26aufirst%3DK.%26aulast%3DYamamoto%26aufirst%3DH.%26aulast%3DIwashita%26aufirst%3DA.%26aulast%3DMihara%26aufirst%3DK.%26aulast%3DMatsuoka%26aufirst%3DN.%26atitle%3D4-Phenyl-1%252C2%252C3%252C6-tetrahydropyridine%252C%2520an%2520excellent%2520fragment%2520to%2520improve%2520the%2520potency%2520of%2520PARP-1%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D4221%26epage%3D4225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group">Hattori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kido, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishida, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwashita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mihara, K.</span><span> </span><span class="NLM_article-title">Rational design of conformationally restricted quinazolinone inhibitors of poly(ADP-ribose)polymerase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">5577</span><span class="NLM_x">â</span> <span class="NLM_lpage">5581</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1016%2Fj.bmcl.2007.07.091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=17804225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVGisLfK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=5577-5581&author=K.+Hattoriauthor=Y.+Kidoauthor=H.+Yamamotoauthor=J.+Ishidaauthor=A.+Iwashitaauthor=K.+Mihara&title=Rational+design+of+conformationally+restricted+quinazolinone+inhibitors+of+poly%28ADP-ribose%29polymerase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design of conformationally restricted quinazolinone inhibitors of poly(ADP-ribose)polymerase</span></div><div class="casAuthors">Hattori, Kouji; Kido, Yoshiyuki; Yamamoto, Hirofumi; Ishida, Junya; Iwashita, Akinori; Mihara, Kayoko</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5577-5581</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A successful design of conformationally restricted novel quinazolinone derivs. linked via a cyclopentene moiety as potent poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors has been developed.  One selected member of the new series, 8-chloro-2-[(3S)-3-(4-phenylpiperidin-1-yl)cyclopent-1-en-1-yl]quinazolin-4(3H)-one (S-16d, I), was found to be highly potent with IC50 = 8.7 nM and good brain penetration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosvYPS7NANArVg90H21EOLACvtfcHk0li9mt8nWxN8NQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVGisLfK&md5=3ff78c0d7dbce0960a07274207348330</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.07.091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.07.091%26sid%3Dliteratum%253Aachs%26aulast%3DHattori%26aufirst%3DK.%26aulast%3DKido%26aufirst%3DY.%26aulast%3DYamamoto%26aufirst%3DH.%26aulast%3DIshida%26aufirst%3DJ.%26aulast%3DIwashita%26aufirst%3DA.%26aulast%3DMihara%26aufirst%3DK.%26atitle%3DRational%2520design%2520of%2520conformationally%2520restricted%2520quinazolinone%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529polymerase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D5577%26epage%3D5581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group">Iwashita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishida, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kido, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamijo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyake, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinoshita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warizaya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohkubo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuoka, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mutoh, S.</span><span> </span><span class="NLM_article-title">Discovery of quinazolinone and quinoxaline derivatives as potent and selective poly(ADP-ribose) polymerase-1/2 inhibitors</span> <span class="citation_source-journal">FEBS Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">579</span><span class="NLM_x">, </span> <span class="NLM_fpage">1389</span><span class="NLM_x">â</span> <span class="NLM_lpage">1393</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1016%2Fj.febslet.2005.01.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=15733846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhslCju7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=579&publication_year=2005&pages=1389-1393&author=A.+Iwashitaauthor=K.+Hattoriauthor=H.+Yamamotoauthor=J.+Ishidaauthor=Y.+Kidoauthor=K.+Kamijoauthor=K.+Muranoauthor=H.+Miyakeauthor=T.+Kinoshitaauthor=M.+Warizayaauthor=M.+Ohkuboauthor=N.+Matsuokaauthor=S.+Mutoh&title=Discovery+of+quinazolinone+and+quinoxaline+derivatives+as+potent+and+selective+poly%28ADP-ribose%29+polymerase-1%2F2+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of quinazolinone and quinoxaline derivatives as potent and selective poly(ADP-ribose) polymerase-1/2 inhibitors</span></div><div class="casAuthors">Iwashita, Akinori; Hattori, Kouji; Yamamoto, Hirofumi; Ishida, Junya; Kido, Yoshiyuki; Kamijo, Kazunori; Murano, Kenji; Miyake, Hiroshi; Kinoshita, Takayoshi; Warizaya, Masaichi; Ohkubo, Mitsuru; Matsuoka, Nobuya; Mutoh, Seitaro</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">579</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1389-1393</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Two classes of quinazolinone derivs. and quinoxaline derivs. were identified as potent and selective poly(ADP-ribose) polymerase-1 and 2 (PARP-1) and (PARP-2) inhibitors, resp.  In PARP enzyme assays using recombinant PARP-1 and PARP-2, quinazolinone derivs. displayed relatively high selectivity for PARP-1 and quinoxaline derivs. showed superior selectivity for PARP-2.  SBDD anal. via a combination of x-ray structural study and homol. modeling suggested distinct interactions of inhibitors with PARP-1 and PARP-2.  These findings provide a new structural framework for the design of selective inhibitors for PARP-1 and PARP-2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7D1Y5QxX8xbVg90H21EOLACvtfcHk0ljYPDe2Z6xwUQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhslCju7o%253D&md5=13b0b7ea2e960c6e2734176c71754afc</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1016%2Fj.febslet.2005.01.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.febslet.2005.01.036%26sid%3Dliteratum%253Aachs%26aulast%3DIwashita%26aufirst%3DA.%26aulast%3DHattori%26aufirst%3DK.%26aulast%3DYamamoto%26aufirst%3DH.%26aulast%3DIshida%26aufirst%3DJ.%26aulast%3DKido%26aufirst%3DY.%26aulast%3DKamijo%26aufirst%3DK.%26aulast%3DMurano%26aufirst%3DK.%26aulast%3DMiyake%26aufirst%3DH.%26aulast%3DKinoshita%26aufirst%3DT.%26aulast%3DWarizaya%26aufirst%3DM.%26aulast%3DOhkubo%26aufirst%3DM.%26aulast%3DMatsuoka%26aufirst%3DN.%26aulast%3DMutoh%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520quinazolinone%2520and%2520quinoxaline%2520derivatives%2520as%2520potent%2520and%2520selective%2520poly%2528ADP-ribose%2529%2520polymerase-1%252F2%2520inhibitors%26jtitle%3DFEBS%2520Lett.%26date%3D2005%26volume%3D579%26spage%3D1389%26epage%3D1393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group">Ikeda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hokamura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishiyama, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anraku, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Umemura, K.</span><span> </span><span class="NLM_article-title">Neuroprotective effects of KCL-440, a new poly(ADP-ribose) polymerase inhibitor, in the rat middle cerebral artery occlusion model</span> <span class="citation_source-journal">Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">1060</span><span class="NLM_x">, </span> <span class="NLM_fpage">73</span><span class="NLM_x">â</span> <span class="NLM_lpage">80</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1016%2Fj.brainres.2005.08.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=16202986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFeku73E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1060&publication_year=2005&pages=73-80&author=Y.+Ikedaauthor=K.+Hokamuraauthor=T.+Kawaiauthor=J.+Ishiyamaauthor=K.+Ishikawaauthor=T.+Anrakuauthor=T.+Unoauthor=K.+Umemura&title=Neuroprotective+effects+of+KCL-440%2C+a+new+poly%28ADP-ribose%29+polymerase+inhibitor%2C+in+the+rat+middle+cerebral+artery+occlusion+model"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroprotective effects of KCL-440, a new poly(ADP-ribose) polymerase inhibitor, in the rat middle cerebral artery occlusion model</span></div><div class="casAuthors">Ikeda, Yasuhiko; Hokamura, Kazuya; Kawai, Tomoyuki; Ishiyama, Junichi; Ishikawa, Kumi; Anraku, Tsuyoshi; Uno, Takashi; Umemura, Kazuo</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1060</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">73-80</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">It is reported that ischemic brain injury is mediated by the activation of poly(ADP-ribose) polymerase (PARP).  In this study, we examd. the pharmacol. profile of KCL-440, a new PARP inhibitor, and its neuroprotective effects in the rat acute cerebral infarction model induced by photothrombotic middle cerebral artery (MCA) occlusion.  In an in vitro study, KCL-440 exhibited potency with regard to inhibition of PARP activity, with an IC50 value of 68 nM.  An in vivo pharmacokinetic study showed that the brain concn. of KCL-440 was sufficient to inhibit PARP activity during the i.v. infusion of KCL-440 at the rate of 1 mg/kg/h.  KCL-440 at various doses or saline was administered for 24 h immediately after the MCA occlusion.  Administration of KCL-440 led to a dose-dependent redn. in the infarct size at 24 h after MCA occlusion.  Infarct sizes were 44.8% Â± 3.0% (n = 8), 40.5% Â± 1.1% (n = 8), 38.2% Â± 1.4% (n = 8), 35.1% Â± 2.1% (n = 8), 34.2% Â± 2.3% (n = 7), 32.6% Â± 1.9% (n = 8), and 31.0% Â± 2.1% (n = 5) at doses of 0, 0.01, 0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg/h.  When compared to the control group, a statistically significant difference was obsd. in the doses that were higher than 0.03 mg/kg/h.  When the infusion of KCL-440 (1 mg/kg/h, n = 8) was started at 1 h after the MCA occlusion, a significant redn. in infarct size was obsd.; this was not obsd. when KCL-440 infusion was started 2 or 3 h after the MCA occlusion.  Furthermore, increased poly(ADP-ribose) immunostaining was confirmed at the ischemic border zone 2 h after the MCA occlusion, and it was reduced by KCL-440 treatment.  These results suggest that KCL-440 is a possible neuroprotective agent with high blood-brain barrier permeability and high PARP inhibitory activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0K8evVssB7rVg90H21EOLACvtfcHk0ljYPDe2Z6xwUQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFeku73E&md5=959f94631a188a1112606d17b68d1220</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1016%2Fj.brainres.2005.08.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainres.2005.08.046%26sid%3Dliteratum%253Aachs%26aulast%3DIkeda%26aufirst%3DY.%26aulast%3DHokamura%26aufirst%3DK.%26aulast%3DKawai%26aufirst%3DT.%26aulast%3DIshiyama%26aufirst%3DJ.%26aulast%3DIshikawa%26aufirst%3DK.%26aulast%3DAnraku%26aufirst%3DT.%26aulast%3DUno%26aufirst%3DT.%26aulast%3DUmemura%26aufirst%3DK.%26atitle%3DNeuroprotective%2520effects%2520of%2520KCL-440%252C%2520a%2520new%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitor%252C%2520in%2520the%2520rat%2520middle%2520cerebral%2520artery%2520occlusion%2520model%26jtitle%3DBrain%2520Res.%26date%3D2005%26volume%3D1060%26spage%3D73%26epage%3D80" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group">Anraku, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishiyama, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uno, T.</span><span> </span><span class="NLM_article-title">The broad therapeutic time window of KCL-440 bases on delayed activation of poly(ADP-ribose)polymerase after transient ischemic insults in rats</span> <span class="citation_source-journal">Stroke</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">P393</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2005&pages=P393&author=T.+Anrakuauthor=T.+Kawaiauthor=K.+Ishikawaauthor=J.+Ishiyamaauthor=T.+Uno&title=The+broad+therapeutic+time+window+of+KCL-440+bases+on+delayed+activation+of+poly%28ADP-ribose%29polymerase+after+transient+ischemic+insults+in+rats"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAnraku%26aufirst%3DT.%26aulast%3DKawai%26aufirst%3DT.%26aulast%3DIshikawa%26aufirst%3DK.%26aulast%3DIshiyama%26aufirst%3DJ.%26aulast%3DUno%26aufirst%3DT.%26atitle%3DThe%2520broad%2520therapeutic%2520time%2520window%2520of%2520KCL-440%2520bases%2520on%2520delayed%2520activation%2520of%2520poly%2528ADP-ribose%2529polymerase%2520after%2520transient%2520ischemic%2520insults%2520in%2520rats%26jtitle%3DStroke%26date%3D2005%26volume%3D36%26spage%3DP393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group">Fujio, M.; Satoh, H.; Numata, A.; Takanashi, S.; Egi, Y.; Tatsumi, R.</span><span> </span><span class="NLM_article-title">Fused Heterocyclic Compound and Medicinal Use Thereof</span>. WO 2002094790,<span class="NLM_x"> </span><span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=M.+Fujio&author=H.+Satoh&author=A.+Numata&author=S.+Takanashi&author=Y.+Egi&author=R.+Tatsumi&title=Fused+Heterocyclic+Compound+and+Medicinal+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFujio%26aufirst%3DM.%26atitle%3DFused%2520Heterocyclic%2520Compound%2520and%2520Medicinal%2520Use%2520Thereof%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group">Matsuura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasuhiro, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiroyuki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toshiaki, A.</span><span> </span><span class="NLM_article-title">Abstracts from the 2009 International Stroke Conference</span> <span class="citation_source-journal">Stroke</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">e105</span><span class="NLM_x">â</span> <span class="NLM_lpage">e276</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2009&pages=e105-e276&author=S.+Matsuuraauthor=S.+Yukiauthor=M.+Fujioauthor=E.+Yasuhiroauthor=S.+Hiroyukiauthor=A.+Toshiaki&title=Abstracts+from+the+2009+International+Stroke+Conference"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMatsuura%26aufirst%3DS.%26aulast%3DYuki%26aufirst%3DS.%26aulast%3DFujio%26aufirst%3DM.%26aulast%3DYasuhiro%26aufirst%3DE.%26aulast%3DHiroyuki%26aufirst%3DS.%26aulast%3DToshiaki%26aufirst%3DA.%26atitle%3DAbstracts%2520from%2520the%25202009%2520International%2520Stroke%2520Conference%26jtitle%3DStroke%26date%3D2009%26volume%3D40%26spage%3De105%26epage%3De276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group">Kamanaka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamoshima, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitajima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Umemura, K.</span><span> </span><span class="NLM_article-title">Neuroprotective effects of ONO-1924H, an inhibitor of poly ADP-ribose polymerase (PARP), on cytotoxicity of PC12 cells and ischemic cerebral damage</span> <span class="citation_source-journal">Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">151</span><span class="NLM_x">â</span> <span class="NLM_lpage">162</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2004&pages=151-162&author=Y.+Kamanakaauthor=K.+Kondoauthor=Y.+Ikedaauthor=W.+Kamoshimaauthor=T.+Kitajimaauthor=Y.+Suzukiauthor=Y.+Nakamuraauthor=K.+Umemura&title=Neuroprotective+effects+of+ONO-1924H%2C+an+inhibitor+of+poly+ADP-ribose+polymerase+%28PARP%29%2C+on+cytotoxicity+of+PC12+cells+and+ischemic+cerebral+damage"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKamanaka%26aufirst%3DY.%26aulast%3DKondo%26aufirst%3DK.%26aulast%3DIkeda%26aufirst%3DY.%26aulast%3DKamoshima%26aufirst%3DW.%26aulast%3DKitajima%26aufirst%3DT.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DNakamura%26aufirst%3DY.%26aulast%3DUmemura%26aufirst%3DK.%26atitle%3DNeuroprotective%2520effects%2520of%2520ONO-1924H%252C%2520an%2520inhibitor%2520of%2520poly%2520ADP-ribose%2520polymerase%2520%2528PARP%2529%252C%2520on%2520cytotoxicity%2520of%2520PC12%2520cells%2520and%2520ischemic%2520cerebral%2520damage%26jtitle%3DLife%2520Sci.%26date%3D2004%26volume%3D76%26spage%3D151%26epage%3D162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group">Shiromizu, I.; Kato, K.; Yamamoto, I.; Hamamoto, H.</span><span> </span><span class="NLM_article-title">Novel PARP Inhibitor</span>. WO 20060004028,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=I.+Shiromizu&author=K.+Kato&author=I.+Yamamoto&author=H.+Hamamoto&title=Novel+PARP+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DShiromizu%26aufirst%3DI.%26atitle%3DNovel%2520PARP%2520Inhibitor%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group">Moree, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demaggio, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christenson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herendeen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eksterowicz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kesicki, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McElligott, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaton, G.</span><span> </span><span class="NLM_article-title">Identification of ring-fused pyrazolo pyridin-2-ones as novel poly(ADP-ribose)polymerase-1 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">5126</span><span class="NLM_x">â</span> <span class="NLM_lpage">5129</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=5126-5129&author=W.+J.+Moreeauthor=P.+Goldmanauthor=A.+J.+Demaggioauthor=E.+Christensonauthor=D.+Herendeenauthor=J.+Eksterowiczauthor=E.+A.+Kesickiauthor=D.+L.+McElligottauthor=G.+Beaton&title=Identification+of+ring-fused+pyrazolo+pyridin-2-ones+as+novel+poly%28ADP-ribose%29polymerase-1+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoree%26aufirst%3DW.%2BJ.%26aulast%3DGoldman%26aufirst%3DP.%26aulast%3DDemaggio%26aufirst%3DA.%2BJ.%26aulast%3DChristenson%26aufirst%3DE.%26aulast%3DHerendeen%26aufirst%3DD.%26aulast%3DEksterowicz%26aufirst%3DJ.%26aulast%3DKesicki%26aufirst%3DE.%2BA.%26aulast%3DMcElligott%26aufirst%3DD.%2BL.%26aulast%3DBeaton%26aufirst%3DG.%26atitle%3DIdentification%2520of%2520ring-fused%2520pyrazolo%2520pyridin-2-ones%2520as%2520novel%2520poly%2528ADP-ribose%2529polymerase-1%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D5126%26epage%3D5129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group">Guillemont, J. E. G.; Kennis, L. E. J.; Mertens, J. C.; Van Dun, J. A. J.; Somers, M. V. F.; Wouters, W. B. L.</span><span> </span><span class="NLM_article-title">Quinazoline Derivatives as PARP Inhibitors</span>. WO 20080070915,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=J.+E.+G.+Guillemont&author=L.+E.+J.+Kennis&author=J.+C.+Mertens&author=J.+A.+J.+Van+Dun&author=M.+V.+F.+Somers&author=W.+B.+L.+Wouters&title=Quinazoline+Derivatives+as+PARP+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGuillemont%26aufirst%3DJ.%2BE.%2BG.%26atitle%3DQuinazoline%2520Derivatives%2520as%2520PARP%2520Inhibitors%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group">Bolli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mentzer, R.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balshaw, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lathrop, D. A.</span><span> </span><span class="NLM_article-title">Myocardial protection at a crossroads: the need for translation into clinical therapy</span> <span class="citation_source-journal">Circ. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">125</span><span class="NLM_x">â</span> <span class="NLM_lpage">134</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2004&pages=125-134&author=R.+Bolliauthor=L.+Beckerauthor=G.+Grossauthor=R.+Mentzerauthor=D.+Balshawauthor=D.+A.+Lathrop&title=Myocardial+protection+at+a+crossroads%3A+the+need+for+translation+into+clinical+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBolli%26aufirst%3DR.%26aulast%3DBecker%26aufirst%3DL.%26aulast%3DGross%26aufirst%3DG.%26aulast%3DMentzer%26aufirst%3DR.%26aulast%3DBalshaw%26aufirst%3DD.%26aulast%3DLathrop%26aufirst%3DD.%2BA.%26atitle%3DMyocardial%2520protection%2520at%2520a%2520crossroads%253A%2520the%2520need%2520for%2520translation%2520into%2520clinical%2520therapy%26jtitle%3DCirc.%2520Res.%26date%3D2004%26volume%3D95%26spage%3D125%26epage%3D134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group">Opie, L. H.</span><span> </span><span class="NLM_article-title">Anti-Ischemic Drugs</span>. In  <span class="citation_source-book">Evidence-Based Cardiology</span>, <span class="NLM_edition">2</span>nd ed.; <span class="NLM_contrib-group">Yusuf, S.; Cairns, J. A.; Camm, J.; Fallen, E. L.; Gersh, B. J.</span>, Eds.; <span class="NLM_publisher-name">Wiley-Interscience</span>: <span class="NLM_publisher-loc">Malden, MA</span>,<span class="NLM_x"> </span><span class="NLM_year">2007</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">329</span>â <span class="NLM_lpage">338</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&pages=329-338&author=L.+H.+Opieauthor=S.+Yusuf&author=J.+A.+Cairns&author=J.+Camm&author=E.+L.+Fallen&author=B.+J.+Gersh&title=Evidence-Based+Cardiology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DOpie%26aufirst%3DL.%2BH.%26atitle%3DAnti-Ischemic%2520Drugs%26btitle%3DEvidence-Based%2520Cardiology%26aulast%3DYusuf%26aufirst%3DS.%26pub%3DWiley-Interscience%26date%3D2007%26spage%3D329%26epage%3D338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group">Drew, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plummer, R.</span><span> </span><span class="NLM_article-title">PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications</span> <span class="citation_source-journal">Drug Resist. Updates</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">â</span> <span class="NLM_lpage">156</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1016%2Fj.drup.2009.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=19939726" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFagtLvN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2009&pages=153-156&author=Y.+Drewauthor=R.+Plummer&title=PARP+inhibitors+in+cancer+therapy%3A+two+modes+of+attack+on+the+cancer+cell+widening+the+clinical+applications"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">PARP inhibitors in cancer therapy: Two modes of attack on the cancer cell widening the clinical applications</span></div><div class="casAuthors">Drew, Yvette; Plummer, Ruth</div><div class="citationInfo"><span class="NLM_cas:title">Drug Resistance Updates</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">153-156</span>CODEN:
                <span class="NLM_cas:coden">DRUPFW</span>;
        ISSN:<span class="NLM_cas:issn">1368-7646</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The abundant nuclear enzyme poly(ADP-ribose)polymerase-1 (PARP-1) represents an important novel target in cancer therapy.  PARP-1 is essential to the repair of single strand DNA breaks via the base excision repair pathway.  Inhibitors of PARP-1 have been shown to enhance the cytotoxic effects of ionizing radiation and DNA damaging chemotherapy agents such as the methylating agents and topoisomerase-I inhibitors.  There are currently at least eight PARP inhibitors in clin. trial development.  In vitro data, in vivo preclin. data and most recently early clin. trial data suggests that PARP inhibitors could be used not only as chemo/radiotherapy sensitizers but also as single agents to selectively kill cancers defective in DNA repair, specifically cancers with mutations in the breast cancer assocd. (BRCA)1 and BRCA2 genes.  This theory of selectively exploiting cells defective in one DNA repair pathway by inhibiting another is a major breakthrough in the treatment of cancer.  The current clin. data are discussed within this review with ref. to the preclin. models which predicted activity and also future directions and the possible dangers/pitfalls of this clin. strategy are explored.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKkKkEObuiarVg90H21EOLACvtfcHk0lhDKVFlE5sa2Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFagtLvN&md5=bee59a3756fbac7e82faffa72cdb7e4f</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1016%2Fj.drup.2009.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drup.2009.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DDrew%26aufirst%3DY.%26aulast%3DPlummer%26aufirst%3DR.%26atitle%3DPARP%2520inhibitors%2520in%2520cancer%2520therapy%253A%2520two%2520modes%2520of%2520attack%2520on%2520the%2520cancer%2520cell%2520widening%2520the%2520clinical%2520applications%26jtitle%3DDrug%2520Resist.%2520Updates%26date%3D2009%26volume%3D12%26spage%3D153%26epage%3D156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group">Vasella, D.; Slater, R.</span> <span class="citation_source-book">Magic Cancer Bullet: How a Tiny Orange Pill May Rewrite Medical History</span>; <span class="NLM_publisher-name">HarperCollins</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=D.+Vasella&author=R.+Slater&title=Magic+Cancer+Bullet%3A+How+a+Tiny+Orange+Pill+May+Rewrite+Medical+History"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DVasella%26aufirst%3DD.%26btitle%3DMagic%2520Cancer%2520Bullet%253A%2520How%2520a%2520Tiny%2520Orange%2520Pill%2520May%2520Rewrite%2520Medical%2520History%26pub%3DHarperCollins%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group">Mendes-Pereira, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brough, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarthy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waldman, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors</span> <span class="citation_source-journal">EMBO Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">315</span><span class="NLM_x">â</span> <span class="NLM_lpage">322</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Fjm100012m&amp;key=10.1002%2Femmm.200900041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Fjm100012m&amp;key=20049735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Fjm100012m&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVSltL%252FK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2009&pages=315-322&author=A.+M.+Mendes-Pereiraauthor=S.+A.+Martinauthor=R.+Broughauthor=A.+McCarthyauthor=J.+R.+Taylorauthor=J.+S.+Kimauthor=T.+Waldmanauthor=C.+J.+Lordauthor=A.+Ashworth&title=Synthetic+lethal+targeting+of+PTEN+mutant+cells+with+PARP+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors</span></div><div class="casAuthors">Mendes-Pereira, Ana M.; Martin, Sarah A.; Brough, Rachel; McCarthy, Afshan; Taylor, Jessica R.; Kim, Jung-Sik; Waldman, Todd; Lord, Christopher J.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Molecular Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6-7</span>),
    <span class="NLM_cas:pages">315-322</span>CODEN:
                <span class="NLM_cas:coden">EMMMAM</span>;
        ISSN:<span class="NLM_cas:issn">1757-4684</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The tumor suppressor gene, phosphatase and tensin homolog (PTEN), is one of the most commonly mutated genes in human cancers.  Recent evidence suggests that PTEN is important for the maintenance of genome stability.  Here, we show that PTEN deficiency causes a homologous recombination (HR) defect in human tumor cells.  The HR deficiency caused by PTEN deficiency, sensitizes tumor cells to potent inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP), both in vitro and in vivo.  PARP inhibitors are now showing considerable promise in the clinic, specifically in patients with mutations in either of the breast cancer susceptibility genes BRCA1 or BRCA2.  The data we present here now suggests that the clin. assessment of PARP inhibitors should be extended beyond those with BRCA mutations to a larger group of patients with PTEN mutant tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPqq6kbXT_l7Vg90H21EOLACvtfcHk0liqig_hSYHKrA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVSltL%252FK&md5=c14c7e0d1ae6a753deabbfb125dcc5a2</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1002%2Femmm.200900041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Femmm.200900041%26sid%3Dliteratum%253Aachs%26aulast%3DMendes-Pereira%26aufirst%3DA.%2BM.%26aulast%3DMartin%26aufirst%3DS.%2BA.%26aulast%3DBrough%26aufirst%3DR.%26aulast%3DMcCarthy%26aufirst%3DA.%26aulast%3DTaylor%26aufirst%3DJ.%2BR.%26aulast%3DKim%26aufirst%3DJ.%2BS.%26aulast%3DWaldman%26aufirst%3DT.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DSynthetic%2520lethal%2520targeting%2520of%2520PTEN%2520mutant%2520cells%2520with%2520PARP%2520inhibitors%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2009%26volume%3D1%26spage%3D315%26epage%3D322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm100012m&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Fjm100012m%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2010.53.issue-12" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm100012m" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67994aac8e6d2367","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
